<SEC-DOCUMENT>0001104659-12-085965.txt : 20121221
<SEC-HEADER>0001104659-12-085965.hdr.sgml : 20121221
<ACCEPTANCE-DATETIME>20121221163324
ACCESSION NUMBER:		0001104659-12-085965
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20121221
DATE AS OF CHANGE:		20121221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-185647
		FILM NUMBER:		121282299

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>a12-29921_1s3.htm
<DESCRIPTION>S-3
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">As filed with the Securities and Exchange Commission on December&nbsp;21, 2012</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Registration Statement No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="4" face="Times New Roman" style="font-size:15.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="4" face="Times New Roman" style="font-size:15.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="4" face="Times New Roman" style="font-size:15.0pt;font-weight:bold;">FORM&nbsp;S-3</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:9.0pt;font-weight:bold;">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="4" face="Times New Roman" style="font-size:15.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(Exact name of Registrant as Specified in Its Charter)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">13-3191702</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(State of Incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(I.R.S. Employer Identification Number)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">119 Fourth Avenue</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Needham, Massachusetts 02494</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">(781) 433-0771</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(Address, including zip code and telephone number, including area code, of Registrant&#146;s principal executive offices)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Avery W. Catlin</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Chief Financial Officer</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">119 Fourth Avenue</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Needham, Massachusetts 02494</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">(781) 433-0771</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(Name, address, including zip code and telephone number, including area code, of agent for service)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Copies to:</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Anthony O. Pergola,&nbsp;Esq.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Lowenstein Sandler PC</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">1251 Avenue of the Americas</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">New York, New York 10020</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(212) 262-6700</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Approximate Date of Commencement of Proposed Sale to the Public: From time to time after this Registration Statement becomes effective, as determined by the Registrant.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">If the only securities being registered on this Form&nbsp;are being offered pursuant to dividend or interest reinvestment plans, please check the following box. </font><font size="1" face="Wingdings" style="font-size:7.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">If any of the securities being registered on this Form&nbsp;are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. </font><font size="1" face="Wingdings" style="font-size:7.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">If this Form&nbsp;is used to register additional securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, please check the following box and list the Securities Act Registration Statement number of the earlier effective registration statement for the same offering. </font><font size="1" face="Wingdings" style="font-size:7.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">If this Form&nbsp;is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act Registration Statement number of the earlier effective registration statement for the same offering. </font><font size="1" face="Wingdings" style="font-size:7.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">If this Form&nbsp;is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&nbsp;462(e)&nbsp;under the Securities Act, check the following box. </font><font size="1" face="Wingdings" style="font-size:7.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">If this Form&nbsp;is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&nbsp;413(b)&nbsp;under the Securities Act, check the following box. </font><font size="1" face="Wingdings" style="font-size:7.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Indicate by check mark whether each registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Large accelerated filer<br>    </font><font size="1" face="Wingdings" style="font-size:7.0pt;">o</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.04%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Accelerated filer </font><font size="1" face="Wingdings" style="font-size:7.0pt;">x</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.04%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Non-accelerated filer </font><font size="1" face="Wingdings" style="font-size:7.0pt;">o</font><font size="1" style="font-size:7.0pt;"><br>   (Do not check if a smaller reporting<br>   company)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.04%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.46%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Smaller reporting company </font><font size="1" face="Wingdings" style="font-size:7.0pt;">o</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">CALCULATION OF REGISTRATION FEE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="62%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:double windowtext 1.5pt;padding:0in 0in 0in 0in;width:62.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:5.0pt;font-weight:bold;">Title&nbsp;of&nbsp;Each&nbsp;Class&nbsp;of<br>   Securities&nbsp;to&nbsp;be&nbsp;Registered</font></b></p>    </td>
<td width="2%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:double windowtext 1.5pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:double windowtext 1.5pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:5.0pt;font-weight:bold;">Proposed&nbsp;Maximum<br>   Aggregate&nbsp;Offering<br>   Price(1)(2)(3)</font></b></p>    </td>
<td width="2%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:double windowtext 1.5pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:double windowtext 1.5pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:5.0pt;font-weight:bold;">Amount&nbsp;of<br>   Registration&nbsp;Fee(2)</font></b></p>    </td>
<td width="2%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:double windowtext 1.5pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Common Stock, par value $0.001 per share (and   associated rights to purchase the registrant&#146;s Series&nbsp;C-1 Junior   Participating Cumulative Preferred Stock)</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Preferred Stock</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Warrants</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Depositary Shares</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Units(4)</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">Total:</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">200,000,000</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(4)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">23,652</font></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(5)</font></p>    </td>   </tr>
<tr height="0">
<td width="467" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="102" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="102" style="border:none;"></td>
<td width="19" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(1)</font></p>    </td>
<td width="96%" valign="top" style="padding:0in 0in 0in 0in;width:96.26%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">The amount to be registered and the proposed   maximum aggregate offering price per security are not specified as to each   class of securities to be registered pursuant to General Instruction II.D. of   Form S-3 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;).   The securities covered by this registration statement may be sold or   otherwise distributed separately or together with any other securities   covered by this registration statement.</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(2)</font></p>    </td>
<td width="96%" valign="top" style="padding:0in 0in 0in 0in;width:96.26%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">The registrant is hereby registering an   indeterminate amount of each identified class of securities up to a proposed   maximum aggregate offering price of $200,000,000, which may be offered from   time to time in unspecified amounts at unspecified prices. The registrant has   estimated the proposed maximum aggregate offering price solely for the   purpose of calculating the registration fee pursuant to Rule 457(o) under the   Securities Act. Securities registered hereunder may be sold separately,   together or as units with other securities registered hereunder. The   securities registered hereunder include securities that may be purchased by   underwriters to cover over-allotments, if any.</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(3)</font></p>    </td>
<td width="96%" valign="top" style="padding:0in 0in 0in 0in;width:96.26%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Pursuant to Rule 416 under the Securities Act,   this registration statement also covers any additional securities that may be   offered or issued in connection with any stock split, stock dividend or   similar transaction. Includes consideration to be received by the registrant,   if applicable, for registered securities that are issuable upon exercise,   conversion or exchange of other registered securities.</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(4)</font></p>    </td>
<td width="96%" valign="top" style="padding:0in 0in 0in 0in;width:96.26%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Consisting of some or all of the securities listed   above, in any combination, including common stock, preferred stock, warrants   and depositary shares.</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">(5)</font></p>    </td>
<td width="96%" valign="top" style="padding:0in 0in 0in 0in;width:96.26%;">
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:7.0pt;">Pursuant to Rule 415(a)(6) under the Securities   Act, the securities registered pursuant to the registration statement include   $26,600,000 of unsold securities previously registered on the registrant&#146;s   registration statement on Form S-3 filed on April 5, 2010 and declared   effective on April 22, 2010 (File No. 333-165899) (the &#147;Prior Registration   Statement&#148;). The Prior Registration Statement registered securities for a   proposed maximum aggregate offering price of $150,000,000, of which   $26,600,000 remain unsold. In connection with the filing of the Prior   Registration Statement, the registrant paid a registration fee of $1,897 in   respect of such unsold securities. In accordance with Question 212.24 of the   Securities and Exchange Commission, Division of Corporation Finance&#146;s   Compliance and Disclosure Interpretations regarding Securities Act Rules, the   registrant is not required to pay any additional fee with respect to the   $26,600,000 of unsold securities being included in this registration in   reliance on Rule 415(a)(6), because such unsold securities (and associated   fees) are being moved from the Prior Registration Statement to this   registration statement. Accordingly, the Amount of Registration Fee above   reflects only the registration fee attributable to the $173,400,000 of new   securities registered on this registration statement. Pursuant to Rule 415(a)(6)   of the Securities Act, the $1,897 registration fee previously paid by the   registrant relating to the unsold securities included on this registration   statement will continue to be applied to such unsold securities.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="1" face="Times New Roman" style="font-size:7.0pt;font-weight:bold;">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:6.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105342\12-29921-1\task5718412\29921-1-ba-01.htm',USER='105342',CD='Dec 21 01:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXPLANANTORY NOTE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This registration statement contains two prospectuses:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a base prospectus that covers the offering, issuance and sale by the registrant of its common stock, preferred stock, warrants, depositary shares and/or units up to a maximum aggregate offering price of $200,000,000; and</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an at-the-market offering prospectus covering the offering, issuance and sale by the registrant of shares of the registrant&#146;s common stock up to a maximum aggregate offering price of $26,600,000 from time to time through Cantor Fitzgerald &amp; Co. acting as agent pursuant to the terms of a sales agreement, as amended, between the registrant and Cantor Fitzgerald &amp; Co.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The base prospectus immediately follows this explanatory note.&#160; The at-the-market offering prospectus, or ATM prospectus, immediately follows the base prospectus.&#160; The common stock that may be offered, issued and sold under the ATM prospectus is included in the $200,000,000 of securities that may be offered, issued and sold by the registrant under the base prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105342\12-29921-1\task5718412\29921-1-ba-01.htm',USER='105342',CD='Dec 21 01:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;font-weight:bold;">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;font-weight:bold;">Subject to Completion, dated December&nbsp;21, 2012</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROSPECTUS</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX THERAPEUTICS, INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$200,000,000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common Stock</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Preferred Stock</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Warrants</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Depositary Shares</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Units</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics, Inc. may offer, issue and sell from time to time, together or separately, in one or more offerings, any combination of:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our common stock,</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our preferred stock, which we may issue in one or more series,</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">warrants,</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">depositary shares, and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">units,</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">up to a maximum aggregate offering price of $200,000,000.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus provides a general description of the securities we may offer.&#160; Each time we sell securities, we will provide specific terms of the securities offered in a supplement to this prospectus (which includes an at-the-market offering prospectus). The prospectus supplement may also add, update or change information contained in this prospectus.&#160; You should read this prospectus and the accompanying prospectus supplement, as well as the documents incorporated or deemed incorporated by reference in this prospectus, carefully before you make your investment decision. Our common stock is traded on the NASDAQ Global Market under the symbol &#147;CLDX.&#148; On December 18, 2012, the last reported sale price of our common stock on the NASDAQ Global Market was $6.64 per share. You are urged to obtain current market quotations of the common stock. Each prospectus supplement will indicate if the securities offered thereby will be listed on any securities exchange.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus may not be used to sell securities unless accompanied by a prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may offer to sell these securities on a continuous or delayed basis, through agents, dealers or underwriters, or directly to purchasers. The prospectus supplement for each offering of securities will describe in detail the plan of distribution for that offering. If our agents or any dealers or underwriters are involved in the sale of the securities, the applicable prospectus supplement will set forth the names of the agents, dealers or underwriters and any applicable commissions or discounts. Our net proceeds from the sale of securities will also be set forth in the applicable prospectus supplement. For general information about the distribution of securities offered, please see &#147;Plan of Distribution&#148; in this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Investing in our securities involves risks. Before making an investment decisions, you should carefully review the information contained in this prospectus under the heading &#147;Risk Factors&#148; beginning on page 4 of this prospectus.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105342\12-29921-1\task5718412\29921-1-ba-01.htm',USER='105342',CD='Dec 21 01:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION OR REGULATORY BODY HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105342\12-29921-1\task5718412\29921-1-ba-01.htm',USER='105342',CD='Dec 21 01:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="TableOfContents"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AboutThisProspectus_002616">ABOUT   THIS PROSPECTUS</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ProspectusSummary_002618">PROSPECTUS   SUMMARY</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#SpecialNoteRegardingForwardlookin_002657">SPECIAL   NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RiskFactors_002704">RISK FACTORS</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RatiosOfCombinedFixedChargesAndPr_002707">RATIOS OF   COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS TO EARNINGS</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#UseOfProceeds_002919">USE OF   PROCEEDS</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DescriptionsOfSecuritiesWeMayoffe_002921">DESCRIPTIONS   OF SECURITIES WE MAY&nbsp;OFFER</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DescriptionOfCommonStock_002923">DESCRIPTION   OF COMMON STOCK</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DescriptionOfPreferredStock_002933">DESCRIPTION OF   PREFERRED STOCK</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DescriptionOfWarrants_003101">DESCRIPTION   OF WARRANTS</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DescriptionOfDepositaryShares_002819">DESCRIPTION OF   DEPOSITARY SHARES</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#DescriptionOfUnits_002825">DESCRIPTION   OF UNITS</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PlanOfDistribution_002839">PLAN   OF DISTRIBUTION</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#LegalMatters_002914">LEGAL   MATTERS</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Experts_002916">EXPERTS</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#WhereYouCanFindMoreInformation_002918">WHERE YOU CAN   FIND MORE INFORMATION</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>
<tr>
<td width="94%" valign="top" style="padding:0in 0in 0in 0in;width:94.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#IncorporationOfCertainDocumentsBy_002920">INCORPORATION   OF CERTAIN DOCUMENTS BY REFERENCE</a></font></p>    </td>
<td width="5%" valign="bottom" style="padding:0in 0in 0in 0in;width:5.44%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105342\12-29921-1\task5718412\29921-1-ba-01.htm',USER='105342',CD='Dec 21 01:50 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABOUT THIS PROSPECTUS</font></b><a name="AboutThisProspectus_002616"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus is a part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under this prospectus. You should read the registration statement and the accompanying exhibits for further information.&#160; The registration statement, including the exhibits and the documents incorporated or deemed incorporated herein by reference, can be read and are available to the public over the Internet at the SEC&#146;s website at <i>http://www.sec.gov</i> as described under the heading &#147;Where You Can Find More Information.&#148;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus provides you with a general description of the securities we may offer. Each time we sell securities pursuant to this prospectus, we will provide a prospectus supplement (which term includes, as applicable, the at-the-market offering prospectus filed with the registration statement of which this prospectus forms a part) containing specific information about the terms of a particular offering by us. That prospectus supplement may include a discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement may add, update or change information in this prospectus. If the information in the prospectus is inconsistent with a prospectus supplement, you should rely on the information in that prospectus supplement. You should read both this prospectus and, if applicable, any prospectus supplement. See &#147;Where You Can Find More Information&#148; for more information.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any prospectus supplement. This prospectus and any prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus or any prospectus supplement is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any prospectus supplement is delivered or securities are sold on a later date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Unless this prospectus indicates otherwise or the context otherwise requires, the terms &#147;we,&#148; &#147;our,&#148; &#147;us,&#148; &#147;Celldex&#148; or the &#147;Company&#148; as used in this prospectus refer to Celldex Therapeutics, Inc. and its subsidiaries, except that such terms refer to only Celldex Therapeutics, Inc. and not its subsidiaries in the sections entitled &#147;Description of Common Stock,&#148; &#147;Description of Preferred Stock,&#148; &#147;Description of Warrants,&#148; &#147;Description of Depositary Shares,&#148; and &#147;Description of Units.&#148;</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROSPECTUS SUMMARY</font></b><a name="ProspectusSummary_002618"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Company Overview</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Our lead drug candidates include rindopepimut (CDX-110), an immunotherapeutic vaccine in a pivotal Phase 3 study for the treatment of front-line glioblastoma and a Phase 2 study for the treatment of recurrent glioblastoma, CDX-011, an antibody-drug conjugate which recently completed a randomized Phase 2b study for the treatment of advanced breast cancer and CDX-1127, a therapeutic human antibody in a Phase 1 study for cancer indications. We have additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology&#153; program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. Our drug candidates address market opportunities for which we believe current therapies are inadequate or non-existent.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_002622_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\106466\12-29921-1\task5718210\29921-1-ba-03.htm',USER='106466',CD='Dec 21 00:31 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Generally our strategy is to develop and demonstrate proof-of-concept for our drug candidates before leveraging their value through partnerships or, in appropriate situations, continuing late stage development through commercialization ourselves. Demonstrating proof-of-concept for a drug candidate generally involves bringing it through Phase 1 clinical trials and one or more Phase 2 clinical trials so that we are able to demonstrate, based on human trials, good safety data for the drug candidate and some data indicating its effectiveness. We thus leverage the value of our technology portfolio through corporate, governmental and non-governmental partnerships. This approach allows us to maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product. Our current collaborations include the commercialization of an oral human rotavirus vaccine. We are exploring potential development and commercialization collaborations for certain drug candidates such as CDX-011 and CDX-1127. Furthermore, while we plan to retain the rights to develop and commercialize rindopepimut in North America, we are exploring potential partnership opportunities to commercialize rindopepimut outside of North America.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body&#146;s own proteins or cells. A number of our immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. We expect that a large percentage of our research and development expenses will be incurred in support of our current and future clinical trial programs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Rindopepimut (CDX-110)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rindopepimut is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III, or EGFRvIII. EGFRvIII is a mutated form of the epidermal growth factor receptor, or EGFR, that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. EGFRvIII is expressed in approximately 30% of glioblastoma, or GB, tumors the most common and aggressive form of brain cancer.&#160; The rindopepimut vaccine is composed of the EGFRvIII peptide linked to a carrier protein called Keyhole Limpet Hemocyanin, or KLH, and administered together with the adjuvant GM-CSF.&#160; The Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA, have both granted orphan drug designation for rindopepimut for the treatment of EGFRvIII expressing GB and the FDA has also granted Fast Track designation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Glembatumumab Vedotin (CDX-011)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-011 is an antibody-drug conjugate for the treatment of patients with glycoprotein NMB, or GPNMB, expressing advanced, refractory breast cancer.&#160; CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers, including breast cancer and melanoma.&#160; The FDA has granted Fast Track designation to CDX-011 for the treatment of advanced, refractory/resistant GPNMB-expressing breast cancer.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CDX-1127</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-1127 is a human monoclonal antibody that targets CD27, a potentially important target for immunotherapy of various cancers.&#160; CD27 acts downstream from CD40 and may provide a novel way to regulate the immune responses. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. CDX-1127 is an agonist antibody designed to have two potential therapeutic mechanisms. CDX-1127 has been shown to activate immune cells that can target and eliminate cancerous cells in tumor-bearing mice and to directly kill or inhibit the growth of CD27-expressing lymphomas and leukemias in vitro and in vivo. Both mechanisms have been seen even at low doses in preclinical models.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Other Clinical and Pre-Clinical Programs</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have several other programs in clinical and pre-clinical development. The status of the other programs that we currently believe are material to our business is summarized in the table below:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_002633_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\106466\12-29921-1\task5718210\29921-1-ba-03.htm',USER='106466',CD='Dec 21 00:31 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="21%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.36%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Product Candidate</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.62%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Indication/Field</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="31%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:31.74%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Stage of Clinical Development</font></b></p>    </td>   </tr>
<tr>
<td width="21%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:21.36%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:41.62%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="31%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:31.74%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.36%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-1401</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Multiple solid tumors</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phase 1</font></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.36%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.36%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-301</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cancer, autoimmune disease and transplant</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phase 1</font></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.36%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.36%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-1135</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Renal disease</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preclinical</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Rotarix</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 1997, we licensed our oral rotavirus strain to GlaxoSmithKline plc, or Glaxo, and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. We licensed-in the rotavirus strain that was used to develop Glaxo&#146;s Rotarix rotavirus vaccine in 1995 and owe a license fee of 30% to Cincinnati Children&#146;s Hospital Medical Center, or CCH, on net royalties received from Glaxo. &#160;In May 2005, we entered into an agreement whereby an affiliate of Paul Royalty Fund II, L.P., or PRF, purchased a 70% interest in the net royalties we received on worldwide sales of Rotarix.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In December 2012, a U.S. patent for our rotavirus strain that we licensed to Glaxo expired. &#160;The Glaxo agreement expires upon the expiration, lapse or invalidation of the last relevant patent right (patent or patent application) covered by the Glaxo agreement, although Glaxo may terminate the agreement upon 90 days prior written notice. &#160;A patent application in Mexico with a projected final expiry date in May 2013 is under appeal. &#160;The PRF agreement provided for a normal expiry of the PRF agreement on December 12, 2012 except that the PRF agreement stays in effect until</font><font size="2" style="font-size:10.0pt;"> PRF receives their final royalty payment.&#160; In addition, the PRF agreement provides for an exclusive 120-day right of negotiation for extension in certain circumstances.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Corporate Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a Delaware corporation organized in 1983.&#160; On October 1, 2009, a wholly-owned subsidiary of Celldex merged with and into CuraGen Corporation. On December 31, 2009, CuraGen Corporate was merged with and into Celldex and the separate existence of CuraGen ceased.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our principal executive offices are located at 119 Fourth Avenue, Needham, Massachusetts 02494 and our telephone number is (781) 433-0771. Our corporate website is www.celldextherapeutics.com. The information on our website is not incorporated by reference into this prospectus.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_002654_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\106466\12-29921-1\task5718210\29921-1-ba-03.htm',USER='106466',CD='Dec 21 00:31 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></b><a name="SpecialNoteRegardingForwardlookin_002657"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as &#147;anticipate,&#148; &#147;estimate,&#148; &#147;plans,&#148; &#147;projects,&#148; &#147;continuing,&#148; &#147;ongoing,&#148; &#147;expects,&#148; &#147;management believes,&#148; &#147;we believe,&#148; &#147;we intend&#148; and similar words or phrases. Accordingly, these statements involve estimates, assumptions and uncertainties, which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in this prospectus or discussed in documents incorporated by reference in this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forward-looking statements are subject to known and unknown risks and uncertainties, which change over time, and are based on management&#146;s expectations and assumptions at the time the statements are made, and are not guarantees of future results. Our actual results may differ materially from those expressed or anticipated in the forward-looking statements for many reasons including the factors described in the section entitled &#147;Risk Factors&#148; in this prospectus and in any risk factors described in a supplement to this prospectus or in other filings.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made.&#160; We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe in the reports we file from time to time with the SEC after the date of this prospectus. We undertake no obligation to revise or update the forward-looking statements contained in this prospectus at any time. All forward-looking statements are qualified in their entirety by this cautionary statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RISK FACTORS</font></b><a name="RiskFactors_002704"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks and other information we include or incorporate by reference in this prospectus and any prospectus supplement. In particular, you should consider the risk factors under the heading &#147;Risk Factors&#148; included in our most recent Annual Report on Form 10-K, as may be revised or supplemented by our subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, each of which are on file with the SEC and are incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also affect our business operations. Additional risk factors may be included in a prospectus supplement relating to a particular offering of securities. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus is qualified in its entirety by these risk factors.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RATIOS OF COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS TO EARNINGS</font></b><a name="RatiosOfCombinedFixedChargesAndPr_002707"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth our consolidated ratios of earnings to combined fixed charges and preferred stock dividends for the years ended December 31, 2011, 2010, 2009, 2008 and 2007.&#160; We do not have any outstanding shares of preferred stock and therefore have not paid any preferred stock dividends.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_002709_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\106466\12-29921-1\task5718210\29921-1-ba-03.htm',USER='106466',CD='Dec 21 00:31 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Ratios of Combined Fixed Charges</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.68%;">
<tr>
<td width="25%" valign="bottom" style="padding:0in 0in 0in 0in;width:25.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="69%" colspan="9" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:69.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Years ended December 31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="25%" valign="bottom" style="padding:0in 0in 0in 0in;width:25.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2010</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2009</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2008</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="11%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2007</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="25%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.7%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1) &#160;Due to our losses from continuing operations for the years ended December 31, 2011, 2010, 2009, 2008 and 2007 earnings were insufficient to cover fixed charges by $43.4 million, $6.5 million, $36.9 million, $48.8 million, and $15.5 million, respectively.&#160; For this reason, no ratios are provided.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">USE OF PROCEEDS</font></b><a name="UseOfProceeds_002919"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise provided in the applicable prospectus supplement to this prospectus used to offer specific securities, we expect to use the net proceeds from any offering of securities by us for general corporate purposes, which may include acquisitions, capital expenditures, investments, and the repayment, redemption or refinancing of all or a portion of any indebtedness or other securities outstanding at a particular time, to fund our operations until we receive FDA approval of our products and are able to commercialize our products and to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities in anticipation of FDA approval of our products.&#160; Pending the application of the net proceeds, we expect to invest the net proceeds in short-term, interest-bearing instruments with a maturity of three months or less at the date of purchase and consist primarily of investments in money market mutual funds with commercial banks and financial institutions or other investment-grade securities.&#160; Such investments may include depositing such net proceeds into, and maintaining cash balances with, financial institutions in excess of insured limits.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTIONS OF SECURITIES WE MAY OFFER</font></b><a name="DescriptionsOfSecuritiesWeMayoffe_002921"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus contains summary descriptions of the common stock, preferred stock, warrants, depositary shares and units that we may offer and sell from time to time. The preferred stock may also be exchangeable for and/or convertible into shares of common stock or another series of preferred stock. When one or more of these securities are offered in the future, a prospectus supplement will explain the particular terms of the securities and the extent to which these general provisions may apply. These summary descriptions and any summary descriptions in the applicable prospectus supplement do not purport to be complete descriptions of the terms and conditions of each security and are qualified in their entirety by reference to our third restated certificate of incorporation, as amended, our by-laws and by applicable Delaware law and any other documents referenced in such summary descriptions and from which such summary descriptions are derived. If any particular terms of a security described in the applicable prospectus supplement differ from any of the terms described herein, then the terms described herein will be deemed superseded by the terms set forth in that prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may issue securities in book-entry form through one or more depositaries, such as The Depository Trust Company, Euroclear or Clearstream, named in the applicable prospectus supplement. Each sale of a security in book-entry form will settle in immediately available funds through the applicable depositary, unless otherwise stated. We will issue the securities only in registered form, without coupons, although we may issue the securities in bearer form if so specified in the applicable prospectus supplement. If any securities are to be listed or quoted on a securities exchange or quotation system, the applicable prospectus supplement will say so.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF COMMON STOCK</font></b><a name="DescriptionOfCommonStock_002923"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of December 18, 2012 we are authorized to issue up to 297,000,000 shares of common stock, $.001 par value per share. As of December 18, 2012, approximately 63,682,919 shares of common stock were outstanding.&#160; All outstanding shares of our common stock are fully paid and non-assessable. Our common stock is listed on the NASDAQ Global Market under the symbol &#147;CLDX&#148;.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_002925_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\106466\12-29921-1\task5718210\29921-1-ba-03.htm',USER='106466',CD='Dec 21 00:31 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Dividends</font></i></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Board of Directors may, out of funds legally available, at any regular or special meeting, declare dividends to the holders of shares of our common stock as and when they deem expedient, subject to the rights of holders of the preferred stock, if any.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Voting</font></i></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each share of common stock entitles the holders to one vote per share on all matters requiring a vote of the stockholders, including the election of directors. No holders of shares of common stock shall have the right to vote such shares cumulatively in any election for the board of directors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Rights Upon Liquidation</font></i></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event of our voluntary or involuntary liquidation, dissolution, or winding up, the holders of our common stock will be entitled to share equally in our assets available for distribution after payment in full of all debts and after the holders of preferred stock, if any, have received their liquidation preferences in full.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Miscellaneous</font></i></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No holders of shares of our common stock shall have any preemptive rights to subscribe for, purchase or receive any shares of any class, whether now or hereafter authorized, or any options or warrants to purchase any such shares, or any securities convertible into or exchanged for any such shares, which may at any time be issued, sold or offered for sale by Celldex.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Anti-Takeover Provisions</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certain provisions in our third restated certificate of incorporation, as amended, and applicable Delaware corporate, as well as our shareholder rights agreement, may have the effect of discouraging a change of control of Celldex, even if such a transaction is favored by some of our stockholders and could result in stockholders receiving a substantial premium over the current market price of our shares. The primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring control of our corporation. These provisions may also tend to perpetuate present management and make it difficult for stockholders owning less than a majority of the shares to be able to elect even a single director.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to our shareholder rights agreement (referred to in this prospectus as the rights agreement) a dividend of one Preferred Stock Purchase Right (referred to in this prospectus as a right) for each share of common stock of Celldex was declared for each outstanding share of common stock of Celldex on November 11, 2004.&#160; Each share of common stock of Celldex issued after such date is also issued with a right.&#160; Each right entitles the registered holder to purchase from Celldex a unit consisting of one one-ten thousandth of a share of Celldex Series C-1 Junior Participating Cumulative Preferred Stock, at a cash exercise price of $35 per unit, subject to adjustment as specified in the rights agreement.&#160; We describe the rights more completely in the rights agreement itself, which is contained in Exhibit 4.1 to our Registration Statement on Form 8-A filed on November 8, 2004.&#160; The summary of the provisions of the rights agreement is qualified in its entirety by reference to that agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Computershare Trust Company, N.A. is presently the transfer agent and registrar for our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF PREFERRED STOCK</font></b><a name="DescriptionOfPreferredStock_002933"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At September 30, 2012, the Company had authorized preferred stock comprised of 3,000,000 shares of Class C Preferred Stock of which 350,000 shares has been designated as Class C-1 Junior Participating Cumulative Preferred Stock, the terms of which are to be determined by our Board of Directors. As of December 18, 2012, there was no preferred stock outstanding.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_002935_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\106466\12-29921-1\task5718210\29921-1-ba-03.htm',USER='106466',CD='Dec 21 00:31 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Class C Preferred Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This section describes the general terms and provisions of our Class C Preferred Stock. The applicable prospectus supplement will describe the specific terms of the shares of preferred stock offered through that prospectus supplement, as well as any general terms described in this section that will not apply to those shares of preferred stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our board of directors has been authorized to provide for the issuance of the 2,650,000 unissued and undesignated shares of our Class C Preferred Stock In general, our third restated certificate of incorporation, as amended, authorizes our board of directors to issue new shares of our common stock or preferred stock without further stockholder action, provided that there are sufficient authorized shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to each series of our Class C Preferred Stock, our board of directors has the authority to fix the following terms:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the designation of the series;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the number of shares within the series;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether dividends are cumulative and, if cumulative, the dates from which dividends are cumulative;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the rate of any dividends, any conditions upon which dividends are payable, and the dates of payment of dividends;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below under &#147;Description of Depositary Shares&#148;;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether the shares are redeemable, the redemption price and the terms of redemption;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the amount payable to you for each share you own if we dissolve or liquidate;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether the shares are convertible or exchangeable, the price or rate of conversion or exchange, and the applicable terms and conditions;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any restrictions on issuance of shares in the same series or any other series;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">voting rights applicable to the series of preferred stock; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any other rights, priorities, preferences, restrictions or limitations of such series.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The rights with respect to any shares of our Class C Preferred Stock will be subordinate to the rights of our general creditors. Shares of our Class C Preferred Stock that we issue in accordance with their terms will be fully paid and nonassessable, and will not be entitled to preemptive rights unless specified in the applicable prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to issue preferred stock, or rights to purchase such shares, could discourage an unsolicited acquisition proposal. For example, we could impede a business combination by issuing a series of preferred stock containing class voting rights that would enable the holders of such preferred stock to block a business combination transaction. Alternatively, we could facilitate a business combination transaction by issuing a series of preferred stock having sufficient voting rights to provide a required percentage vote of the stockholders. Additionally, under certain circumstances, our issuance of preferred stock could adversely affect the voting power of the holders of our common stock. Although our board of directors is required to make any determination to issue any preferred stock based on its judgment as to the best interests of our stockholders, our board of directors could act in a manner that would discourage an acquisition attempt or other transaction that some, or a majority, of our stockholders might</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_002948_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\106466\12-29921-1\task5718210\29921-1-ba-03.htm',USER='106466',CD='Dec 21 00:31 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">believe to be in their best interests or in which stockholders might receive a premium for their stock over prevailing market prices of such stock. Our board of directors does not at present intend to seek stockholder approval prior to any issuance of currently authorized stock, unless otherwise required by law or applicable stock exchange requirements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Terms of the Preferred Stock That We May Offer and Sell to You</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We summarize below some of the provisions that will apply to the preferred stock that we may offer to you unless the applicable prospectus supplement provides otherwise. This summary may not contain all information that is important to you. You should read the prospectus supplement, which will contain additional information and which may update or change some of the information below. Prior to the issuance of a new series of preferred stock, we will further amend our third restated certificate of incorporation, as amended, designating the stock of that series and the terms of that series. We will file a copy of the certificate of designation that contains the terms of each new series of preferred stock with the SEC each time we issue a new series of preferred stock. Each certificate of designation will establish the number of shares included in a designated series and fix the designation, powers, privileges, preferences and rights of the shares of each series as well as any applicable qualifications, limitations or restrictions. You should refer to the applicable certificate of designation as well as our third restated certificate of incorporation, as amended, before deciding to buy shares of our preferred stock as described in the applicable prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our board of directors has the authority, without further action by the stockholders, to issue preferred stock in one or more series and to fix the number of shares, dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking funds, and any other rights, preferences, privileges and restrictions applicable to each such series of preferred stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The issuance of any preferred stock could adversely affect the rights of the holders of common stock and, therefore, reduce the value of the common stock. The ability of our board of directors to issue preferred stock could discourage, delay or prevent a takeover or other corporate action.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The terms of any particular series of preferred stock will be described in the prospectus supplement relating to that particular series of preferred stock, including, where applicable:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the designation, stated value and liquidation preference of such preferred stock;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the number of shares within the series;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the offering price;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the dividend rate or rates (or method of calculation), the date or dates from which dividends shall accrue, and whether such dividends shall be cumulative or noncumulative and, if cumulative, the dates from which dividends shall commence to cumulate;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below under &#147;Description of Depositary Shares&#148;);</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any redemption or sinking fund provisions;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the amount that shares of such series shall be entitled to receive in the event of our liquidation, dissolution or winding-up;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the terms and conditions, if any, on which shares of such series shall be convertible or exchangeable for shares of our stock of any other class or classes, or other series of the same class;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the voting rights, if any, of shares of such series; the status as to reissuance or sale of shares of such series redeemed, purchased or otherwise reacquired, or surrendered to us on conversion or exchange;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_003054_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\106466\12-29921-1\task5718210\29921-1-ba-03.htm',USER='106466',CD='Dec 21 00:31 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conditions and restrictions, if any, on the payment of dividends or on the making of other distributions on, or the purchase, redemption or other acquisition by us or any subsidiary, of the common stock or of any other class of our shares ranking junior to the shares of such series as to dividends or upon liquidation;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conditions and restrictions, if any, on the creation of indebtedness by us or by any subsidiary, or on the issuance of any additional stock ranking on a parity with or prior to the shares of such series as to dividends or upon liquidation; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any additional dividend, liquidation, redemption, sinking or retirement fund and other rights, preferences, privileges, limitations and restrictions of such preferred stock.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The description of the terms of a particular series of preferred stock in the applicable prospectus supplement will not be complete. You should refer to the applicable amendment to our third restated certificate of incorporation, as amended, for complete information regarding a series of preferred stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The preferred stock will, when issued against payment of the consideration payable therefor, be fully paid and nonassessable. Unless otherwise specified in the applicable prospectus supplement, each series of preferred stock will, upon issuance, rank senior to the common stock and on a parity in all respects with each other outstanding series of preferred stock. The rights of the holders of our preferred stock will be subordinate to that of our general creditors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF WARRANTS</font></b><a name="DescriptionOfWarrants_003101"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We summarize below some of the provisions that will apply to the warrants unless the applicable prospectus supplement provides otherwise. This summary may not contain all information that is important to you. The complete terms of the warrants will be contained in the applicable warrant certificate and warrant agreement. These documents have been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the warrant certificate and the warrant agreement. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">General</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may issue, together with other securities or separately, warrants to purchase common stock, preferred stock or other securities. We may issue the warrants under warrant agreements to be entered into between us and a bank or trust company, as warrant agent, all as set forth in the applicable prospectus supplement. The warrant agent would act solely as our agent in connection with the warrants of the series being offered and would not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The applicable prospectus supplement will describe the following terms, where applicable, of warrants in respect of which this prospectus is being delivered:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the title of the warrants;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the designation, amount and terms of the securities for which the warrants are exercisable and the procedures and conditions relating to the exercise of such warrants;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the designation and terms of the other securities, if any, with which the warrants are to be issued and the number of warrants issued with each such security;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the price or prices at which the warrants will be issued;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the aggregate number of warrants;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_003108_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\106466\12-29921-1\task5718210\29921-1-ba-03.htm',USER='106466',CD='Dec 21 00:31 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the warrants;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the price or prices at which the securities purchasable upon exercise of the warrants may be purchased;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if applicable, the date on and after which the warrants and the securities purchasable upon exercise of the warrants will be separately transferable;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if applicable, a discussion of the material U.S. federal income tax considerations applicable to the warrants;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the date on which the right to exercise the warrants shall commence and the date on which the right shall expire;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if applicable, the maximum or minimum number of warrants which may be exercised at any time;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the identity of the warrant agent;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any mandatory or optional redemption provision;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether the warrants are to be issued in registered or bearer form;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether the warrants are extendible and the period or periods of such extendibility;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">information with respect to book-entry procedures, if any; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any other terms of the warrants.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding-up or to exercise voting rights, if any.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exercise of Warrants</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each warrant will entitle the holder thereof to purchase such number of shares of common stock or preferred stock or other securities at the exercise price as will in each case be set forth in, or be determinable as set forth in, the applicable prospectus supplement. Warrants may be exercised at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. Warrants may be exercised as set forth in the applicable prospectus supplement relating to the warrants offered thereby. Upon receipt of payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will, as soon as practicable, forward the purchased securities. If less than all of the warrants represented by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Enforceability of Rights of Holders of Warrants</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_002758_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\105621\12-29921-1\task5718219\29921-1-ba-05.htm',USER='105621',CD='Dec 21 00:30 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, that holder&#146;s warrant(s).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Modification of the Warrant Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The warrant agreement will permit us and the warrant agent, without the consent of the warrant holders, to supplement or amend the agreement in the following circumstances:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">to cure any ambiguity;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">to correct or supplement any provision which may be defective or inconsistent with any other provisions; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">to add new provisions regarding matters or questions that we and the warrant agent may deem necessary or desirable and which do not adversely affect the interests of the warrant holders.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF DEPOSITARY SHARES</font></b><a name="DescriptionOfDepositaryShares_002819"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We summarize below some of the provisions that will apply to depositary shares unless the applicable prospectus supplement provides otherwise. This summary may not contain all information that is important to you. The complete terms of the depositary shares will be contained in the depositary agreement and depositary receipt applicable to any depositary shares. These documents have been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the depositary agreement and the depositary receipt. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">General</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may, at our option, elect to offer fractional or multiple shares of common stock or preferred stock, rather than single shares of common stock or preferred stock (to be set forth in the prospectus supplement relating to such depositary shares). In the event we elect to do so, depositary receipts evidencing depositary shares will be issued to the public.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The shares of common stock or any class or series of preferred stock represented by depositary shares will be deposited under a deposit agreement among us, a depositary selected by us, and the holders of the depositary receipts. The depositary will be a bank or trust company having its principal office in the United States and having a combined capital and surplus of at least $50,000,000. Subject to the terms of the deposit agreement, each owner of a depositary share will be entitled, in proportion to the applicable fraction of a share of common stock or preferred stock represented by such depositary share, to all the rights and preferences of the shares of common stock or preferred stock represented by the depositary share, including dividend, voting, redemption and liquidation rights.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Depositary receipts will be distributed to those persons purchasing the fractional shares of common stock or the related class or series of preferred shares in accordance with the terms of the offering described in the related prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF UNITS</font></b><a name="DescriptionOfUnits_002825"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement may describe:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_002834_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\105621\12-29921-1\task5718219\29921-1-ba-05.htm',USER='105621',CD='Dec 21 00:30 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the terms of the unit agreement governing the units;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">United States federal income tax considerations relevant to the units; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether the units will be issued in fully registered global form.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This summary of certain general terms of units and any summary description of units in the applicable prospectus supplement do not purport to be complete and are qualified in their entirety by reference to all provisions of the applicable unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units. The forms of the unit agreements and other documents relating to a particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions that may be important to you.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PLAN OF DISTRIBUTION</font></b><a name="PlanOfDistribution_002839"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions, block trades or a combination of these methods. A distribution of the securities offered by this prospectus may also be effected through the issuance of derivative securities, including without limitation, warrants and subscriptions. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">at a fixed price or prices, which may be changed;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">at market prices prevailing at the time of sale;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">at prices related to such prevailing market prices;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">at varying prices determined at the time of sale; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">at negotiated prices.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">A prospectus supplement or supplements will describe the terms of the offering of the securities, including:</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the name or names of the underwriters, dealers or agents participating in the offering, if any;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the purchase price of the securities sold by us to any underwriter or dealer and the net proceeds we expect to receive from the offering;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any over-allotment options under which underwriters may purchase additional securities from us;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any agency fees or underwriting discounts or commissions and other items constituting agents&#146; or underwriters&#146; compensation;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any public offering price;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any discounts or concessions allowed or reallowed or paid to dealers; and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_002850_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\105621\12-29921-1\task5718219\29921-1-ba-05.htm',USER='105621',CD='Dec 21 00:30 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">any securities exchange or market on which the securities may be listed.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or commissions or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may sell securities directly or through agents we designate from time to time.&#160; We will name any agent involved in the offering and sale of securities and we will describe any commissions and other compensation we will pay the agent in the prospectus supplement.&#160; Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities.&#160; Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any agents or underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. There is currently no market for any of the offered securities, other than our common stock which is listed on the NASDAQ Global Market. We have no current plans for listing of the preferred stock, warrants or subscription rights on any securities exchange or quotation system; any such listing with respect to any particular preferred stock, warrants or subscription rights will be described in the applicable prospectus supplement or other offering materials, as the case may be.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act.&#160; Overallotment involves sales in excess of the offering size, which create a short position.&#160; Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.&#160; Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions.&#160; Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions.&#160; Those activities may cause the price of the securities to be higher than it would otherwise be.&#160; If commenced, the underwriters may discontinue any of the activities at any time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any agents and underwriters who are qualified market makers on the NASDAQ Global Market may engage in passive market making transactions in the securities on the NASDAQ Global Market in accordance with Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities.&#160; Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers.&#160; In general, a passive market maker must display its bid at a price not in</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_002907_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\105621\12-29921-1\task5718219\29921-1-ba-05.htm',USER='105621',CD='Dec 21 00:30 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LEGAL MATTERS</font></b><a name="LegalMatters_002914"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon for us by Lowenstein Sandler PC, Roseland, New Jersey. If the validity of the securities offered hereby in connection with offerings made pursuant to this prospectus are passed upon by counsel for the underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXPERTS</font></b><a name="Experts_002916"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#146;s Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011 have been so incorporated in reliance on the report(s)&nbsp;of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</font></b><a name="WhereYouCanFindMoreInformation_002918"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have filed with the SEC a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act of which this prospectus forms a part. This prospectus does not contain all of the information set forth in the registration statement. This prospectus contains descriptions of certain agreements or documents that are exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions and are not necessarily complete, and each statement is qualified in all respects by reference to such agreement or document. For further information about us, please refer to the registration statement and the documents incorporated by reference in this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at <i>http://www.sec.gov</i>. The SEC&#146;s website contains reports, proxy statements and other information regarding issuers, such as Celldex Therapeutics,&nbsp;Inc., that file electronically with the SEC. You may also read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room, located at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. We make available free of charge through our web site our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, Proxy Statements on Schedule 14A and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. Our website address is <i>http://www.celldextherapeutics.com</i>. Please note that our website address is provided as an inactive textual reference only. Information contained on or accessible through our website is not part of this prospectus or the prospectus supplement, and is therefore not incorporated by reference unless such information is otherwise specifically referenced elsewhere in this prospectus or the prospectus supplement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</font></b><a name="IncorporationOfCertainDocumentsBy_002920"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus the information we have filed with the SEC, which means that we can disclose important information to you by referring you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus. We incorporate by reference into this prospectus the information contained in the documents listed below, which is considered to be a part of this prospectus:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_002923_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\105621\12-29921-1\task5718219\29921-1-ba-05.htm',USER='105621',CD='Dec 21 00:30 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2011, filed with the SEC on March&nbsp;8, 2012 (including the portions of our Proxy Statement on Schedule 14A, filed with the SEC on April&nbsp;24, 2012, incorporated by reference therein);</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2012, June&nbsp;30, 2012 and September&nbsp;30, 2012, filed on May&nbsp;4, 2012, August&nbsp;9, 2012 and November&nbsp;2, 2012, respectively;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our Current Reports on Form&nbsp;8-K filed with the SEC on February&nbsp;23, 2012, February&nbsp;24, 2012, March&nbsp;7, 2012,&#160; April&nbsp;3, 2012,&#160; June&nbsp;14, 2012, September&nbsp;24, 2012 and December&nbsp;21, 2012 (in each case, not including any information furnished under Items 2.02 or 7.01 of Form&nbsp;8-K, including the related exhibits, which information is not incorporated by reference herein);</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The description of our Common Stock contained in our registration statement on Form&nbsp;8-A, filed with the SEC on September&nbsp;22, 1986 under Section&nbsp;12 of the Securities Exchange Act, and any amendments or reports filed for the purpose of updating such description; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The description of the rights to purchase our Series&nbsp;C-1 Junior Participating Cumulative Preferred Stock contained in our registration statement on Form&nbsp;S-4, filed with the SEC on December&nbsp;21, 2007, our registration statement on Form&nbsp;8-A filed with the SEC on November&nbsp;8, 2004, our registration statement on Form&nbsp;8-A/A filed with the SEC on October&nbsp;22, 2007, our registration statement on Form&nbsp;8-A/A filed with the SEC on March&nbsp;7, 2008, and any amendment or report filed with the SEC for the purposes of updating such descriptions.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We also incorporate by reference all documents we file under Sections&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act (a)&nbsp;after the initial filing date of the registration statement of which this prospectus is a part and before the effectiveness of the registration statement and (b)&nbsp;after the effectiveness of the registration statement and before the filing of a post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities covered by this prospectus then remaining unsold. The most recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of this prospectus, commencing on the date on which the document is filed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item 2.02 or 7.01 of Form&nbsp;8-K.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by reference other than exhibits to those documents. &#160;Requests should be addressed to:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Celldex Therapeutics,&nbsp;Inc. <br>  </font></b><font size="2" style="font-size:10.0pt;">Attention: Investor Relations <br> 119 Fourth Avenue</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Needham, Massachusetts 02494<br> Telephone number: (781) 433-0771</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_002944_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\105621\12-29921-1\task5718219\29921-1-ba-05.htm',USER='105621',CD='Dec 21 00:30 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;font-weight:bold;">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" color="#ff4040" face="Times New Roman" style="color:#FF4040;font-size:10.0pt;font-weight:bold;">SUBJECT TO COMPLETION, DATED DECEMBER 21, 2012</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROSPECTUS</font></b><a name="Prospectus_004645"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-weight:bold;"><img border="0" width="261" height="64" src="g299211ba07i001.jpg" alt="GRAPHIC"></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Up to $26,600,000 of Shares</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Common Stock</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In accordance with the terms of our existing sales agreement with Cantor Fitzgerald&nbsp;&amp; Co., as amended, we may offer and sell shares of our common stock, $0.001 par value per share, having an aggregate offering price of up to $44,000,000 from time to time through Cantor Fitzgerald&nbsp;&amp; Co. acting as agent.&#160; As of December&nbsp;18, 2012, we had issued and sold shares of our common stock having an aggregate offering price of $17,400,000 pursuant to our prior registration statement on Form&nbsp;S-3 (File No.&nbsp;333-165899).&#160; Accordingly, we may issue and sell additional shares of our common stock having an aggregate offering price of up to $26,600,000 pursuant to this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our common stock is listed on the NASDAQ Global Market under the symbol &#147;CLDX.&#148; The last reported sale price of our common stock on the NASDAQ Global Market on December&nbsp;18, 2012 was $6.64&nbsp;per share.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales of our common stock, if any, under this prospectus may be made in sales deemed to be &#147;at-the-market&#148; equity offerings as defined in Rule&nbsp;415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through the NASDAQ Global Market, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law. Cantor Fitzgerald&nbsp;&amp; Co. will act as sales agent on a best efforts basis and use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between Cantor Fitzgerald&nbsp;&amp; Co. and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cantor Fitzgerald&nbsp;&amp; Co. will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold. In connection with the sale of the common stock on our behalf, Cantor Fitzgerald&nbsp;&amp; Co. may be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act of 1933, as amended, and the compensation of Cantor Fitzgerald&nbsp;&amp; Co. may be deemed to be underwriting commissions or discounts.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Before buying shares of our common stock, you should carefully consider the risk factors described in &#147;Risk Factors&#148; beginning on page&nbsp;ATM-8 of this prospectus and those contained in the documents incorporated by reference in this prospectus.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved of anyone&#146;s investment in these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img border="0" width="185" height="62" src="g299211ba07i002.gif" alt="GRAPHIC"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-07.htm',USER='105981',CD='Dec 21 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Table of Contents</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="89%" valign="bottom" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Page</font></b></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;"><a href="#Prospectus_004645" title="Click to goto ">Prospectus</a></font></u></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AboutThisProspectus_003151" title="Click to goto ">About This   Prospectus</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-1</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#SpecialNoteRegardingForwardlookin_003208" title="Click to goto ">Cautionary   Note Regarding Forward-Looking Statements</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-2</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#AboutCelldexTherapeuticsinc__003234" title="Click to goto ">About   Celldex Therapeutics,&nbsp;Inc.</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-3</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TheOffering_003808" title="Click to goto ">The   Offering</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-7</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#RiskFactors_003818" title="Click to goto ">Risk   Factors</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-8</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#UseOfProceeds_003834" title="Click to goto ">Use of   Proceeds</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-10</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Dilution_003844" title="Click to goto ">Dilution</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-10</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PlanOfDistribution_003853" title="Click to goto ">Plan   of Distribution</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-12</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#LegalMatters_003901" title="Click to goto ">Legal   Matters</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-13</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Experts_003910" title="Click to goto ">Experts</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-13</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#WhereYouCanFindMoreInformation_003911" title="Click to goto ">Where You Can Find More Information</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-13</font></p>    </td>   </tr>
<tr>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#IncorporationOfCertainDocumentsBy_003918" title="Click to goto ">Incorporation of Documents By Reference</a></font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM-14</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -i-<a name="PB_i_003143_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -i-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-07.htm',USER='105981',CD='Dec 21 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABOUT THIS PROSPECTUS</font></b><a name="AboutThisProspectus_003151"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#147;shelf&#148; registration process. Under the shelf registration process, we may offer and sell shares of our common stock having an aggregate offering price of up to $26,600,000 from time to time under this prospectus at prices and on terms to be determined by market conditions at the time of offering.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under this prospectus. You should read the registration statement and the accompanying exhibits for further information.&#160; The registration statement, including the exhibits and the documents incorporated or deemed incorporated herein by reference, can be read and are available to the public over the Internet at the SEC&#146;s website at <i>http://www.sec.gov</i> as described under the heading &#147;Where You Can Find More Information.&#148;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus describes the specific terms of the common stock we are offering and also adds to, and updates information contained in the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus that was filed with the SEC before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date - for example, a document incorporated by reference into this prospectus - the statement in the document having the later date modifies or supersedes the earlier statement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You should rely only on the information contained in, or incorporated by reference into this prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Cantor Fitzgerald&nbsp;&amp; Co., or Cantor, has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and Cantor is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, the documents incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The distribution of this prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for the person to make an offer or solicitation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Unless this prospectus indicates otherwise or the context otherwise requires, the terms &#147;we,&#148; &#147;our,&#148; &#147;us,&#148; &#147;Celldex&#148; or the &#147;Company&#148; as used in this prospectus refer to Celldex Therapeutics,&nbsp;Inc. and its subsidiaries</font></i><font size="2" style="font-size:10.0pt;">.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -1-<a name="PB_1_003227_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -1-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-07.htm',USER='105981',CD='Dec 21 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></b><a name="SpecialNoteRegardingForwardlookin_003208"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as &#147;anticipate,&#148; &#147;estimate,&#148; &#147;plans,&#148; &#147;projects,&#148; &#147;continuing,&#148; &#147;ongoing,&#148; &#147;expects,&#148; &#147;management believes,&#148; &#147;we believe,&#148; &#147;we intend&#148; and similar words or phrases. Accordingly, these statements involve estimates, assumptions and uncertainties, which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in this prospectus or discussed in documents incorporated by reference in this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forward-looking statements are subject to known and unknown risks and uncertainties, which change over time, and are based on management&#146;s expectations and assumptions at the time the statements are made, and are not guarantees of future results. Our actual results may differ materially from those expressed or anticipated in the forward-looking statements for many reasons including the factors described in the section entitled &#147;Risk Factors&#148; in this prospectus and in any risk factors described in a supplement to this prospectus or in other filings.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made.&#160; We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe in the reports we file from time to time with the SEC after the date of this prospectus. We undertake no obligation to revise or update the forward-looking statements contained in this prospectus at any time. All forward-looking statements are qualified in their entirety by this cautionary statement.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -2-<a name="PB_2_003231_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -2-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-07.htm',USER='105981',CD='Dec 21 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABOUT CELLDEX THERAPEUTICS,&nbsp;INC.</font></b><a name="AboutCelldexTherapeuticsinc__003234"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:39.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Our lead drug candidates include rindopepimut (CDX-110), an immunotherapeutic vaccine in a pivotal Phase 3 study for the treatment of front-line glioblastoma and a Phase 2 study for the treatment of recurrent glioblastoma, CDX-011, an antibody-drug conjugate which recently completed a randomized Phase 2b study for the treatment of advanced breast cancer and CDX-1127, a therapeutic human antibody in a Phase 1 study for cancer indications. We have additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology&#153; program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. Our drug candidates address market opportunities for which we believe current therapies are inadequate or non-existent.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Generally our strategy is to develop and demonstrate proof-of-concept for our drug candidates before leveraging their value through partnerships or, in appropriate situations, continuing late stage development through commercialization ourselves. Demonstrating proof-of-concept for a drug candidate generally involves bringing it through Phase 1 clinical trials and one or more Phase 2 clinical trials so that we are able to demonstrate, based on human trials, good safety data for the drug candidate and some data indicating its effectiveness. We thus leverage the value of our technology portfolio through corporate, governmental and non-governmental partnerships. This approach allows us to maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product. Our current collaborations include the commercialization of an oral human rotavirus vaccine. We are exploring potential development and commercialization collaborations for certain drug candidates such as CDX-011 and CDX-1127. Furthermore, while we plan to retain the rights to develop and commercialize rindopepimut in North America, we are exploring potential partnership opportunities to commercialize rindopepimut outside of North America.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. We are using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body&#146;s own proteins or cells. A number of our immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. We expect that a large percentage of our research and development expenses will be incurred in support of our current and future clinical trial programs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RINDOPEPIMUT (CDX-110)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rindopepimut is an experimental immunothepeutic vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III, or EGFRvIII. EGFRvIII is a mutated form of the epidermal growth factor receptor, or EGFR, that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. EGFRvIII is expressed in approximately 30% of glioblastoma, or GB, tumors the most common and aggressive form of brain cancer.&#160; The rindopepimut vaccine is composed of the EGFRvIII peptide linked to a carrier protein called Keyhole Limpet Hemocyanin, or KLH, and administered together with the adjuvant GM-CSF.&#160; The Food and Drug Administration, or FDA, and the European Medicines Agency, or&#160; EMA, have both granted orphan drug designation for rindopepimut for the treatment of EGFRvIII expressing GB, and the FDA has also granted Fast Track designation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based on the results of the three prior Phase 2 trials, we have entered into a pivotal (registration) program for rindopepimut in patients with surgically resected EGFRvIII-positive GB. In December&nbsp;2011, we initiated ACT IV, a pivotal, randomized, double-blind, controlled Phase 3 study of rindopepimut, expected to enroll up to 440 patients at over 150 centers worldwide to recruit approximately 374 patients with gross total resection to be included in the primary analysis. Our targeted patient accrual is 24 months and another 18 to 24 months of follow-up. In early 2013, we anticipate initiating a parallel, randomized, double-blind, controlled Phase 2 study in western Europe to optimize accrual of the pivotal (registration) study and to further support potential future commercial efforts in this region, assuming rindopepimut is approved by the EMA. We anticipate these two studies to cost over $60 million during their duration.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -3-<a name="PB_3_003250_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -3-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-07.htm',USER='105981',CD='Dec 21 22:52 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">GLEMBATUMUMAB VEDOTIN (CDX-011)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-011 is an antibody-drug conjugate for the treatment of patients with glycoprotein NMB, or GPNMB, expressing advanced, refractory breast cancer.&#160; CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers, including breast cancer and melanoma.&#160; The FDA has granted Fast Track designation to CDX-011 for the treatment of advanced, refractory/resistant GPNMB-expressing breast cancer.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In December&nbsp;2011, we completed enrollment of EMERGE, a randomized, multi-center Phase 2b study of CDX-011 in 122 patients with heavily pre-treated, advanced, GPNMB-positive breast cancer. Patients were randomized (2:1) to receive either CDX-011 or single-agent Investigator&#146;s Choice, or IC, chemotherapy. Patients randomized to receive IC are allowed to cross over to CDX-011 following disease progression. Activity endpoints include response rate and progression-free survival.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In December&nbsp;2012, we announced final results from the EMERGE study which suggested that CDX-011 induces significant response rates compared to currently available therapies in patient subsets with advanced, refractory breast cancers with high GPNMB expression (expression in&#160; greater than 25% of tumor cells) and in patients with triple negative breast cancer.&#160; The overall survival, or OS and progression free survival, or PFS, of patients treated with CDX-011 was also observed to be greatest in patients with triple negative breast cancer who also highly express GPNMB and all patients with high GPNMB expression as show below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Phase 2b EMERGE Final Survival Results: Survival Benefit of CDX-011 is Greatest in Patients with Triple Negative Disease that Highly Expresses (<u>&gt;</u>25%) GPNMB and All Patients with High GPNMB Expression*</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">All&nbsp;Patients</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Triple&nbsp;Negative</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">High&nbsp;GPNMB</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">Expression</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Triple&nbsp;Negative&nbsp;and</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">High&nbsp;GPNMB<br>   Expression</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CDX-011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">IC</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CDX-011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">IC</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CDX-011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">IC</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CDX-011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">IC</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="23%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Median PFS (months)</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.0</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.6</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.7</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.5</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.0</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.5</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Median OS (months)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.5</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.9</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.5</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.0</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.0</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.5</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">*Analyses include all treated patients. Patients who initially received IC and subsequently crossed over to receive CDX-011 (n=15) are included in the PFS analysis for each treatment. These patients, with a median OS of 12.5 months (range 4.4 to 21.0 months), are assigned to the IC arm only for OS analysis.</font></i></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Phase 2b EMERGE Final Overall Response Results: Activity of CDX-011 is Greatest in Patients with Triple Negative Disease that Highly Expresses (<u>&gt;</u>25%) GPNMB and All Patients with High GPNMB Expression*</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">All&nbsp;Patients</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Triple&nbsp;Negative</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">High&nbsp;GPNMB</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">Expression</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="17%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:17.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Triple&nbsp;Negative&nbsp;and</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">High&nbsp;GPNMB<br>   Expression</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="23%" valign="bottom" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CDX-011</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">(n=81)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">IC</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">(n=36)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CDX-011</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">(n=27)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">IC</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">(n=9)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CDX-011</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">(n=25)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">IC</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">(n=8)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">CDX-011</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">(n=12)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="7%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">IC</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">(n=4)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="23%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">% Response (% Confirmed)</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16 (10)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14 (8)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19 (7)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32 (16)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13 (13)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33 (8)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">% Disease Control Rate</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">67</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">64</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="bottom" style="padding:0in 0in 0in 0in;width:7.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">*Responses per RECIST 1.1; IC = Investigator&#146;s Choice; CDX-011 arm includes 15 patients who crossed over to receive CDX-011 treatment after progression on IC. Analysis of best response excludes patients who discontinued from study without evaluable post-baseline radiographic imaging (n=16 for CDX-011 arm; n=5 for IC arm).</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -4-<a name="PB_4_003256_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -4-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-07.htm',USER='105981',CD='Dec 21 22:52 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CDX-1127</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-1127 is a human monoclonal antibody that targets CD27, a potentially important target for immunotherapy of various cancers.&#160; CD27 acts downstream from CD40 and may provide a novel way to regulate the immune responses. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. CDX-1127 is an agonist antibody designed to have two potential therapeutic mechanisms. CDX-1127 has been shown to activate immune cells that can target and eliminate cancerous cells in tumor-bearing mice and to directly kill or inhibit the growth of CD27-expressing lymphomas and leukemias in vitro and in vivo. Both mechanisms have been seen even at low doses in preclinical models.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In November&nbsp;2011, we initiated an open label, dose-escalating Phase 1 study of CDX-1127 in patients with selected malignant solid tumors or hematologic cancers at multiple clinical sites in the United States. The Phase 1 study is designed to test five escalating doses of CDX-1127 to determine a Phase 2 dose for further development based on safety, tolerability, potential activity and immunogenicity. The study will accrue approximately 30 patients in each of the two arms, either selected refractory or relapsed solid tumors or lymphomas or leukemias known to express CD27. Patients will have received all appropriate prior therapies for their specific disease. The trial design incorporates both single dosing and multiple dosing regimens at each dose level. We expect to complete enrollment in the solid tumor arm by the end of 2012 and in the lymphoma and leukemia arm in the first half of 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OTHER CLINICAL AND PRE-CLINICAL PROGRAMS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have several other programs in clinical and pre-clinical development. The status of the other programs that we currently believe are material to our business is summarized in the table below:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="21%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Product&nbsp;Candidate</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.62%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Indication/Field</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="31%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:31.74%;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Stage&nbsp;of&nbsp;Clinical&nbsp;Development</font></b></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:21.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="41%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="31%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-1401</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Multiple solid tumors</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phase 1</font></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-301</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cancer, autoimmune disease and transplant</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phase 1</font></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="21%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:21.64%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CDX-1135</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.62%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Renal disease</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.74%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preclinical</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ROTARIX</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 1997, we licensed our oral rotavirus strain to GlaxoSmithKline plc, or Glaxo, and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. We licensed-in the rotavirus strain that was used to develop Glaxo&#146;s Rotarix rotavirus vaccine in 1995 and owe a license fee of 30% to Cincinnati Children&#146;s Hospital Medical Center, or CCH, on net royalties received from Glaxo.&nbsp; In May&nbsp;2005, we entered into an agreement whereby an affiliate of Paul Royalty Fund II, L.P., or PRF, purchased a 70% interest in the net royalties we received on worldwide sales of Rotarix.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In December&nbsp;2012, a U.S. patent for our rotavirus strain that we licensed to Glaxo expired.&nbsp; The Glaxo agreement expires upon the expiration, lapse or invalidation of the last relevant patent right (patent or patent application) covered by the Glaxo agreement, although Glaxo may terminate the agreement upon 90 days prior written notice.&nbsp; A patent application in Mexico with a projected final expiry date in May&nbsp;2013 is under appeal.&nbsp; The PRF agreement provided for a normal expiry of the PRF agreement on December&nbsp;12, 2012 except that the PRF agreement stays in effect until</font><font size="2" style="font-size:10.0pt;"> PRF receives their final royalty payment.&#160; In addition, the PRF agreement provides for an exclusive 120-day right of negotiation for extension in certain circumstances.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CORPORATE INFORMATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a Delaware corporation organized in 1983.&#160; On October&nbsp;1, 2009, a wholly-owned subsidiary of Celldex merged with and into CuraGen Corporation. On December&nbsp;31, 2009, CuraGen Corporate was merged with and into Celldex and the separate existence of CuraGen ceased.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -5-<a name="PB_5_190538_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -5-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our principal executive offices are located at 119 Fourth Avenue, Needham, Massachusetts 02494 and our telephone number is (781) 433-0771. Our corporate website is www.celldextherapeutics.com. The information on our website is not incorporated by reference into this prospectus.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -6-<a name="PB_6_190538_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -6-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THE OFFERING</font></b><a name="TheOffering_003808"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock we are offering pursuant to the   prospectus</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares   having an aggregate offering price of up to $26,600,000.</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock to be outstanding after this offering</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">64,813,374   shares</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manner of offering</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;At-the-market&#148;   offering that may be made from time to time through our agent, Cantor   Fitzgerald&nbsp;&amp; Co. See &#147;Plan of Distribution&#148; beginning on   page&nbsp;ATM-12.</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Use of proceeds</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We   expect to use the net proceeds from this offering to fund clinical trials of   our product candidates and for working capital and other general corporate   purposes. See &#147;Use of Proceeds&#148; on page&nbsp;ATM-10 of this prospectus.</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk factors</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investing   in our common stock involves a high degree of risk. Please read the   information contained in and incorporated by reference under the heading   &#147;Risk Factors&#148; on page&nbsp;ATM-8 of this prospectus, and under similar   headings in the other documents that are filed after the date hereof and   incorporated by reference into this prospectus.</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NASDAQ Global Market common stock symbol</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="66%" valign="top" style="padding:0in 0in 0in 0in;width:66.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CLDX</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The number of shares of common stock to be outstanding after this offering in the table above is based on 60,807,350 shares of common stock outstanding as of September&nbsp;30, 2012 and assumes the sale of shares having an aggregate offering price of $26,600,000 at an assumed sale price of $6.64, which was the last reported sale price of our common stock on the NASDAQ Global Market on December&nbsp;18, 2012. This number excludes, all as of September&nbsp;30, 2012:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">5,321,026 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $5.99 per share;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">3,380,865 shares available for future issuance under our equity compensation plans; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">2,875,569 shares of common stock issued since September&nbsp;30, 2012 through December&nbsp;18, 2012 which raised $16.6 million in net proceeds.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -7-<a name="PB_7_190538_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -7-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">RISK FACTORS</font></b><a name="RiskFactors_003818"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Investing in our securities involves significant risks. Before making an investment decision, you should carefully consider the risks and other information we include or incorporate by reference in this prospectus and the accompanying prospectus. In particular, you should consider the risk factors under the heading &#147;Risk Factors&#148; included in our most recent Annual Report on Form&nbsp;10-K, as may be revised or supplemented by our subsequent Quarterly Reports on Form&nbsp;10-Q or Current Reports on Form&nbsp;8-K, each of which are on file with the SEC and are incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. The risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also affect our business operations. Our business, financial condition or results of operations could be materially adversely affected by any of these risks.&nbsp;The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment.&nbsp;This prospectus is qualified in its entirety by these risk factors.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Additional Risks Related to this Offering</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">We currently have no product revenue and will need to raise capital to operate our business in addition to funds we receive in this offering.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, we have generated no product revenue. Until, and unless, we complete clinical trials and further development, and receive approval from the FDA and other regulatory authorities for our product candidates, we cannot sell our drugs and will not have product revenue. Therefore, for the foreseeable future, we will have to fund all of our operations and development expenditures from cash on hand, equity or debt financings, licensing fees and grants.&#160; While the funds we receive in this offering will help fund our operations, additional financing will also be required.&#160; If we do not succeed in raising additional funds on acceptable terms, we might not be able to complete planned preclinical and clinical trials or obtain approval of any product candidates from the FDA and other regulatory authorities. In addition, we could be forced to discontinue product development, reduce or forego sales and marketing efforts, forego attractive business opportunities or curtail operations. Any additional sources of financing could involve the issuance of our equity securities, which would have a dilutive effect on our stockholders.&#160; No assurance can be given that additional financing will be available to us when needed on acceptable terms, or at all.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because we have not designated the amount of net proceeds from this offering to be used for any particular purpose, our management will have broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering.&#160; Our management may use the net proceeds for corporate purposes that may not improve our financial condition or market value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">You will experience immediate and substantial dilution in the book value per share of the common stock you purchase.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because the price per share of our common stock being offered may be higher than the book value per share of our common stock, you may suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering.&#160; See the section entitled &#147;Dilution&#148; below for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering.&#160; In addition, we have a significant number of options and restricted stock outstanding.&#160; If the holders of these securities exercise or convert them or become vested in them, as applicable, you may incur further dilution.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -8-<a name="PB_8_190538_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -8-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales of a substantial number of shares of our common stock or other equity-related securities in the public markets could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities, including sales hereunder through Cantor.&#160; We cannot predict the effect that future sales of our common stock or other equity-related securities would have on the market price of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Our history of losses and uncertainty of future profitability make our common stock a highly speculative investment.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have had no commercial revenue to date from sales of our human therapeutic or vaccine products and cannot predict when we will have commercial revenue from such sales. We had an accumulated deficit of $247&nbsp;million as of September&nbsp;30, 2012. We expect to spend substantial funds to continue the research and development testing of our products that we have in the preclinical and clinical testing stages of development that have not been partnered.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In anticipation of FDA approval of these products, we will need to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities. These investments will increase if and when any of these products receive FDA approval. We cannot predict how quickly our lead products will progress through the regulatory approval process. As a result, we may continue to lose money for several years.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We cannot be certain that we will achieve or sustain profitability in the future. Failure to achieve profitability could diminish our ability to sustain operations, pay dividends on our common stock, obtain additional required funds and make required payments on our present or future indebtedness.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Our share price has been and could remain volatile.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The market price of our common stock has historically experienced and may continue to experience significant volatility. During 2012, our common stock traded as low as $2.65 and as high as $7.20.&#160; Our progress in developing and commercializing our products, the impact of government regulations on our products and industry, the potential sale of a large volume of our common stock by stockholders, our quarterly operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our competitors could cause the market price of our common stock to fluctuate substantially with significant market losses. If our stockholders sell a substantial number of shares of common stock, especially if those sales are made during a short period of time, those sales could adversely affect the market price of our common stock and could impair our ability to raise capital. In addition, in recent years, the stock market has experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their operating performance and may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our stock, which could result in substantial costs and diversion of management&#146;s attention and resources and could harm our stock price, business, prospects, results of operations and financial condition.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -9-<a name="PB_9_190538_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -9-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">USE OF PROCEEDS</font></b><a name="UseOfProceeds_003834"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We intend to use the net proceeds from the sale of the shares of our common stock offered pursuant to this prospectus to fund clinical trials of our product candidates and for working capital and other general corporate purposes.&#160; At this time, we have not determined the approximate amount of net proceeds that will be allocated to each of the uses of proceeds stated above.&#160; In addition, we may use the net proceeds from this offering for a variety of other corporate uses, including in-licenses or acquisitions of complementary products, technologies or companies, although we currently have no commitments or agreements for any such transactions. Our management will retain broad discretion as to the allocation of the net proceeds from this offering. Pending application of the net proceeds as described above, we intend to invest the net proceeds generally in short-term, investment grade, interest bearing securities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DILUTION</font></b><a name="Dilution_003844"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our net tangible book value on September&nbsp;30, 2012 was approximately $58.0 million, or $0.95 per share. &#147;Net tangible book value&#148; is total assets minus the sum of liabilities and intangible assets. &#147;Net tangible book value per share&#148; is net tangible book value divided by the total number of shares outstanding.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">After giving effect to the sale of shares of our common stock in the aggregate amount of $26,600,000 in this offering at an assumed offering price of $6.64 per share, which was the last reported sale of our common stock on the NASDAQ Global Market on December&nbsp;18, 2012, and after deducting estimated offering commissions and expenses payable by us, our net tangible book value as of September&nbsp;30, 2012 would have been approximately $83.7 million, or $1.29 per share of common stock. This represents an immediate increase in net tangible book value of $0.34 per share to our existing stockholders and an immediate dilution in net tangible book value of $5.35 per share to investors participating in this offering. The following table illustrates this dilution per share to investors participating in this offering:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assumed offering price per share</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.64</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net tangible book value per share as of   September&nbsp;30, 2012</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.95</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Increase in net tangible book value per share   attributable to new investors </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.34</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="bottom" style="padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pro forma net tangible book value per share after   giving effect to the offering</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.29</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dilution per share to new investors</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.35</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The table above assumes, for illustrative purposes, that an aggregate of 4,006,024 shares of our common stock are sold at a price of $6.64 per share, the last reported sale price of our common stock on the NASDAQ Global Market on December&nbsp;18, 2012, for aggregate gross proceeds of $26,600,000.&#160; The shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $0.50 per share in the price at which the shares are sold from the assumed offering price of $6.64 per share shown in the table above, assuming all of our common stock in the aggregate amount of $26,600,000 is sold at that price, would increase our as adjusted net tangible book value per share after the offering to $1.30 per share and would increase the dilution in net tangible book value per share to new investors to $5.84 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $0.50 per share in the price at which the shares are sold from the assumed offering price of $6.64 per share shown in the table above, assuming all of our common stock in the aggregate amount of $26,600,000 is sold at that price, would decrease our as adjusted net tangible book value per share after the offering to $1.28 per share and would decrease the dilution in net tangible book value per share to new investors to $4.86 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The above discussion and table are based on 60,807,350 shares of our common stock issued and outstanding as of September&nbsp;30, 2012, which does not include the following, all as of September&nbsp;30, 2012:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -10-<a name="PB_10_190538_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -10-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">5,321,026 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $5.99 per share;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">3,380,865 shares available for future issuance under our equity compensation plans; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">2,875,569 shares of common stock issued since September&nbsp;30, 2012 through December&nbsp;18, 2012 which raised $16.6 million in net proceeds.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the extent that any of these outstanding options or warrants are exercised, there will be further dilution to new investors.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -11-<a name="PB_11_190538_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -11-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PLAN OF DISTRIBUTION</font></b><a name="PlanOfDistribution_003853"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment No.&nbsp;1 to our existing Controlled Equity Offering</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font><font size="2" style="font-size:10.0pt;">&#160;sales agreement with Cantor provides for the issuance and sale by us of shares of our common stock having an aggregate offering price of up to $44,000,000 from time to time through Cantor acting as agent. Our existing sales agreement has been filed as an exhibit to our Current Report on Form&nbsp;8-K filed with the SEC on January&nbsp;6, 2011, and Amendment No.&nbsp;1 to the sales agreement has been filed as an exhibit to our Current Report on Form&nbsp;8-K filed with the SEC on September&nbsp;24, 2012; and each is incorporated by reference in this prospectus. As of December&nbsp;18, 2012, we had issued and sold shares of our common stock having an aggregate offering price of $17,400,000 pursuant to our prior registration statement on Form&nbsp;S-3 (File No.&nbsp;333-165899).&#160; Accordingly, we may issue and sell additional shares of our common stock having an aggregate offering price of up to $26,600,000 pursuant to this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Upon delivery of a placement notice and subject to the terms and conditions of the sales agreement, as amended, Cantor may sell our common stock by any method permitted by law deemed to be an &#147;at-the-market&#148; offering, as defined in Rule&nbsp;415 promulgated under the Securities Act, including sales made directly on the NASDAQ Global Market, on any other existing trading market for our common stock or to or through a market maker. Cantor may also sell our common stock by any other method permitted by law. We may instruct Cantor not to sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or Cantor may suspend the offering of common stock upon notice and subject to other conditions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will pay Cantor commissions, in cash, for its services in acting as agent in the sale of our common stock. Cantor will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time.&#160; We have also agreed to reimburse Cantor for certain specified expenses, including the fees and disbursements of its legal counsel in an amount not to exceed $50,000. We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to Cantor under the terms of the sales agreement, will be approximately $69,000.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Settlement for sales of our common stock will occur on the third business day following the date on which any sales are made, or on some other date that is agreed upon by us and Cantor in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Cantor may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cantor will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase the common stock shares under the terms and subject to the conditions set forth in the sales agreement. In connection with the sale of the common stock on our behalf, Cantor may, and will with respect to sales effected in an &#147;at-the-market offering,&#148; be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor may be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cantor against certain civil liabilities, including liabilities under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The offering of our common stock pursuant to the sales agreement will terminate upon the earlier of (i)&nbsp;the sale of all shares of our common stock subject to the sales agreement, or (ii)&nbsp;termination of the sales agreement as</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -12-<a name="PB_12_190538_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -12-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">permitted therein. We and Cantor may each terminate the sales agreement at any time upon ten days prior notice.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cantor and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, Cantor will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus in electronic format may be made available on a website maintained by Cantor and Cantor may distribute this prospectus electronically.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LEGAL MATTERS</font></b><a name="LegalMatters_003901"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The validity of the securities being offered hereby will be passed upon by Lowenstein Sandler PC, Roseland, New Jersey.&#160; Cantor is being represented in connection with this offering by Reed Smith LLP, New York, New York.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXPERTS</font></b><a name="Experts_003910"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#146;s Report on Internal Control over Financial Reporting) incorporated in this prospectus by reference to our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011 have been so incorporated in reliance on the report(s)&nbsp;of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</font></b><a name="WhereYouCanFindMoreInformation_003911"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have filed with the SEC a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act of which this prospectus and the accompanying prospectus form a part. This prospectus does not contain all of the information set forth in the registration statement. This prospectus contains descriptions of certain agreements or documents that are exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions and are not necessarily complete, and each statement is qualified in all respects by reference to such agreement or document. For further information about us, please refer to the registration statement and the documents incorporated by reference in this prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at <i>http://www.sec.gov</i>. The SEC&#146;s website contains reports, proxy statements and other information regarding issuers, such as Celldex Therapeutics,&nbsp;Inc., that file electronically with the SEC. You may also read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room, located at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. We make available free of charge through our web site our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, Proxy Statements on Schedule 14A and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. Our website address is <i>http://www.celldextherapeutics.com</i>. Please note that our website address is provided as an inactive textual reference only. Information contained on or accessible through our website is not part of this prospectus and is therefore not incorporated by reference unless such information is otherwise specifically referenced elsewhere in this prospectus.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -13-<a name="PB_13_190538_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -13-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</font></b><a name="IncorporationOfCertainDocumentsBy_003918"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus the information we have filed with the SEC, which means that we can disclose important information to you by referring you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus. We incorporate by reference into this prospectus the information contained in the documents listed below, which is considered to be a part of this prospectus:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2011, filed with the SEC on March&nbsp;8, 2012 (including the portions of our Proxy Statement on Schedule 14A, filed with the SEC on April&nbsp;24, 2012, incorporated by reference therein);</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2012, June&nbsp;30, 2012 and September&nbsp;30, 2012, filed on May&nbsp;4, 2012, August&nbsp;9, 2012 and November&nbsp;2, 2012, respectively;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our Current Reports on Form&nbsp;8-K filed with the SEC on February&nbsp;23, 2012, February&nbsp;24, 2012, March&nbsp;7, 2012,&#160; April&nbsp;3, 2012,&#160; June&nbsp;14, 2012, September&nbsp;24, 2012 and December&nbsp;21, 2012 (in each case, not including any information furnished under Items 2.02 or 7.01 of Form&nbsp;8-K, including the related exhibits, which information is not incorporated by reference herein);</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The description of our Common Stock contained in our registration statement on Form&nbsp;8-A, filed with the SEC on September&nbsp;22, 1986 under Section&nbsp;12 of the Securities Exchange Act, and any amendments or reports filed for the purpose of updating such description; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The description of the rights to purchase our Series&nbsp;C-1 Junior Participating Cumulative Preferred Stock contained in our registration statement on Form&nbsp;S-4, filed with the SEC on December&nbsp;21, 2007, our registration statement on Form&nbsp;8-A filed with the SEC on November&nbsp;8, 2004, our registration statement on Form&nbsp;8-A/A filed with the SEC on October&nbsp;22, 2007, our registration statement on Form&nbsp;8-A/A filed with the SEC on March&nbsp;7, 2008, and any amendment or report filed with the SEC for the purposes of updating such descriptions.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We also incorporate by reference all documents we file under Sections&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act (a)&nbsp;after the initial filing date of the registration statement of which this prospectus is a part and before the effectiveness of the registration statement and (b)&nbsp;after the effectiveness of the registration statement and before the filing of a post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities covered by this prospectus then remaining unsold. The most recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of this prospectus, commencing on the date on which the document is filed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item 2.02 or 7.01 of Form&nbsp;8-K.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by reference other than exhibits to those documents.&#160; Requests should be addressed to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Celldex Therapeutics,&nbsp;Inc. <br>  </font></b><font size="2" style="font-size:10.0pt;">Attention: Investor Relations <br> 119 Fourth Avenue</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Needham, Massachusetts 02494<br> Telephone number: (781) 433-0771</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ATM -14-<a name="PB_14_190538_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='ATM -14-',FILE='C:\JMS\105537\12-29921-1\task5719911\29921-1-ba-09.htm',USER='105537',CD='Dec 21 19:12 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-weight:bold;"><img border="0" width="261" height="63" src="g299211ba11i001.jpg" alt="GRAPHIC"></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Up to $26,600,000 of Shares</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common Stock</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Prospectus</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img border="0" width="185" height="62" src="g299211ba11i002.gif" alt="GRAPHIC"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2012</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-11.htm',USER='105981',CD='Dec 21 22:53 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;II</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INFORMATION NOT REQUIRED IN THE PROSPECTUS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .6in;text-indent:-.6in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;14.</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Other Expenses of Issuance and Distribution.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth the estimated costs and expenses payable by the Registrant in connection with the registration of the securities being registered under this Registration Statement. All amounts shown are estimates except the Securities and Exchange Commission registration statement filing fee:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;width:80.0%;">
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration Statement filing fee</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,652</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Printing fees</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,000</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Legal fees and expenses</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounting fees</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,000</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Miscellaneous</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>
<tr>
<td width="80%" valign="top" style="padding:0in 0in 0in 0in;width:80.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">68,652</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*&#160;&#160;&#160;&#160;&#160; Estimated </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .6in;text-indent:-.6in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 15.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Indemnification of Directors and Officers.</font></b></p>
<p style="margin:0in 0in .0001pt 51.7pt;text-indent:-51.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex is a Delaware corporation. In accordance with the Delaware General Corporation Law (the &#147;DGCL&#148;), Article&nbsp;Six of the Registrant&#146;s Third Restated Certificate of Incorporation, as amended, provides that no director of the Registrant shall be personally liable to the Registrant or its stockholders for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director&#146;s duty of loyalty to Celldex or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL, or (iv)&nbsp;for any transaction from which the director derived an improper personal benefit.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The DGCL permits, but does not require, a corporation to indemnify its directors, officers, employees or agents and expressly provides that the indemnification provided for under the DGCL shall not be deemed exclusive of any indemnification right under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The DGCL permits indemnification against expenses and certain other liabilities arising out of legal actions brought or threatened against such persons for their conduct on behalf of the corporation, provided that each such person acted in good faith and in a manner that he or she reasonably believed was in or not opposed to the corporation&#146;s best interests and in the case of a criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The DGCL does not allow indemnification of directors in the case of an action by or in the right of the corporation (including stockholder derivative suits) unless the directors successfully defend the action or indemnification is ordered by the court. The Amended and Restated Bylaws of Celldex (the &#147;Bylaws&#148;) provide for indemnification to the directors, officers, employees and agents of Celldex consistent with that authorized by the DGCL. Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors and officers of Celldex pursuant to the foregoing provision or otherwise, Celldex has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Exchange Act of 1934, as amended, and is therefore, unenforceable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex currently carries a directors&#146; and officers&#146; liability insurance policy which provides for payment of expenses of Celldex&#146;s directors and officers in connection with threatened, pending or completed actions, suits or proceedings against them in their capacities as directors and officers, in accordance with the Bylaws and the DGCL.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-1-<a name="PB_1_002949_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-1-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-11.htm',USER='105981',CD='Dec 21 22:53 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 16.&#160; Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="5%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:5.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="40%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Location</font></b></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales   Agreement, dated January&nbsp;6, 2011, between Celldex   Therapeutics,&nbsp;Inc. and Cantor Fitzgerald&nbsp;&amp; Co.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;10.1.3 of Celldex&#146;s Current Report on   Form&nbsp;8-K, filed January&nbsp;6, 2011.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment   No.&nbsp;1, dated September&nbsp;20, 2012, to Sales Agreement, dated   January&nbsp;6, 2011, between Celldex Therapeutics,&nbsp;Inc. and Cantor   Fitzgerald&nbsp;&amp; Co.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;10.1 of Celldex&#146;s Current Report on   Form&nbsp;8-K, filed September&nbsp;24, 2012.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement   and Plan of Merger, dated as of May&nbsp;28, 2009, by and among Celldex,   Cottrell Merger Sub,&nbsp;Inc. and CuraGen Corporation.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;2.1 Celldex&#146;s Registration Statement on   Form&nbsp;S-4 (Reg. N. 333-160257), filed June&nbsp;26, 2009.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third   Restated Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Registration Statement on   Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate   of Amendment of Third Restated Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Registration Statement on   Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second   Certificate of Amendment of Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.2 of Celldex&#146;s Registration Statement on   Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third   Certificate of Amendment of Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Quarterly Report on   Form&nbsp;10-Q, filed May&nbsp;10, 2002</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended   and Restated By-Laws of Celldex as of March&nbsp;14, 2007</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.5 of Celldex&#146;s Annual Report on   Form&nbsp;10-K, filed March&nbsp;18, 2008</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate   of Designations, Preferences and Rights of a Series&nbsp;of Preferred Stock   of Celldex classifying and designating the Series&nbsp;C-1 Junior Participating   Cumulative Preferred Stock</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Registration Statement on   Form&nbsp;8-A filed November&nbsp;8, 2004</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate   of Elimination of Series&nbsp;C-1 Junior Participating Cumulative Preferred   Stock</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.6 of Celldex&#146;s Annual Report on   Form&nbsp;10-K, filed March&nbsp;16, 2005</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.8</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fourth   Certificate of Amendment of Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Current Report on Form&nbsp;8-K   filed on March&nbsp;11, 2008</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.9</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fifth   Certificate of Amendment of Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.2 of Celldex&#146;s Current Report on Form&nbsp;8-K   filed on March&nbsp;11, 2008</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.10</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shareholder   Rights Agreement dated November&nbsp;5, 2004 between Celldex and </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;4.1 of Celldex&#146;s Registration Statement on   Form&nbsp;8-A filed November&nbsp;8, </font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-2-<a name="PB_2_003101_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-2-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-11.htm',USER='105981',CD='Dec 21 22:53 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EquiServe   Trust Company, N.A. as Rights Agent</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2004</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.11</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment   No.&nbsp;1 to Shareholder Rights Agreement dated October&nbsp;19, 2007   between Celldex and Computershare Trust Company, N.A. (formerly EquiServe   Trust Company, N.A.) as Rights Agent</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;10.1 of Celldex&#146;s Registration Statement on   Form&nbsp;8-A/A filed October&nbsp;22, 2007</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.12</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment   No.&nbsp;2 to Shareholder Rights Agreement dated March&nbsp;7, 2008, between   Celldex and Computershare Trust Company, N.A. (formerly EquiServe Trust   Company, N.A.), as Rights Agent.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;10.1 of Celldex&#146;s Registration Statement on   Form&nbsp;8-A12G/A filed on March&nbsp;7, 2008.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.13</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen   of Common Stock Certificate</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed   herewith</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.14</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Warrant Agreement</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To   be filed subsequently by an amendment to the Registration Statement or by a   Current Report of the Registrant on a Current Report on Form&nbsp;8-K and   incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.15</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Warrant Certificate</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(included   in Exhibit&nbsp;4.14)</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.16</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen   of Preferred Stock Certificate</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To   be filed subsequently by an amendment to the Registration Statement or by a   Current Report of the Registrant on a Current Report on Form&nbsp;8-K and   incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.17</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Depositary Agreement</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To   be filed subsequently by an amendment to the Registration Statement or by a   Current Report of the Registrant on a Current Report on Form&nbsp;8-K and   incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.18</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Depositary Receipt</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(included   in Exhibit&nbsp;4.17)</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.19</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Unit Agreement</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To   be filed subsequently by an amendment to the Registration Statement or by a   Current Report of the Registrant on a Current Report on Form&nbsp;8-K and   incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Opinion   of Lowenstein Sandler PC as to the legality of the securities being   registered</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed   herewith</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Computation   of Ratio of Combined Fixed Charges and Preferred Stock Dividends to Earnings</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed   herewith</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent   of PricewaterhouseCoopers LLP,&nbsp;Independent Registered Public Accounting   Firm</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed   herewith</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent   of Lowenstein Sandler PC</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Included   in Exhibit&nbsp;5.1</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Powers   of Attorney</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Included   on signature pages&nbsp;to this Registration Statement</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-3-<a name="PB_3_003115_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-3-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-11.htm',USER='105981',CD='Dec 21 22:53 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt 40.5pt;text-indent:-40.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt .6in;text-indent:-.6in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 17.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Undertakings.</font></b></p>
<p style="margin:0in 0in .0001pt 40.5pt;text-indent:-40.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The undersigned registrant hereby undertakes:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .6in;text-indent:-22.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font></p>
<p style="margin:0in 0in .0001pt .6in;text-indent:-22.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 44.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To include any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act;</font></p>
<p style="margin:0in 0in .0001pt 44.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 44.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration statement; and</font></p>
<p style="margin:0in 0in .0001pt 44.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 44.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</font></p>
<p style="margin:0in 0in .0001pt 44.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">provided, however</font></i><font size="2" style="font-size:10.0pt;">, Paragraphs (a)(1)(i), (a)(1)(ii)&nbsp;and (a)(1)(iii)&nbsp;of this section do not apply if the registration statement is on Form&nbsp;S-3 or Form&nbsp;F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d)&nbsp;of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;that is part of the registration statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial<i> bona fide</i> offering thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; That, for the purpose of determining liability under the Securities Act to any purchaser, (A)&nbsp;each prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3)&nbsp;shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and (B)&nbsp;each prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7)&nbsp;as part of a registration statement in reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a)&nbsp;of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-4-<a name="PB_4_003150_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-4-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-11.htm',USER='105981',CD='Dec 21 22:53 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160; The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)&#160;&#160;&#160;&#160;&#160; Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</font></p>
<p style="margin:0in 0in .0001pt 22.0pt;text-indent:22.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d)&nbsp;of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial<i> bona fide</i> offering thereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-5-<a name="PB_5_003212_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-5-',FILE='C:\JMS\105981\12-29921-1\task5720350\29921-1-ba-11.htm',USER='105981',CD='Dec 21 22:53 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&nbsp;S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Needham, Commonwealth of Massachusetts, on December&nbsp;21, 2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Anthony S. Marucci</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony   S. Marucci</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES AND POWER OF ATTORNEY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Anthony S. Marucci and Avery W. Catlin, or any one of them, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including pre-effective and post-effective amendments) to this registration statement on Form&nbsp;S-3 and any subsequent registration filed pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="27%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Signature</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Title</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Date</font></b></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Anthony S. Marucci</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony   S. Marucci</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director,   Chief Executive Officer and President (Principal Executive Officer)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Avery W. Catlin</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery   W. Catlin</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior   Vice President, Treasurer and Chief Financial Officer (Principal Financial   Officer and Principal Accounting Officer)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Larry Ellberger</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Larry   Ellberger</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Herbert J. Conrad</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Herbert   J. Conrad</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   George O. Elston</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">George   O. Elston</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Harry H. Penner,&nbsp;Jr.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Harry   H. Penner,&nbsp;Jr.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-6-<a name="PB_6_003637_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-6-',FILE='C:\JMS\105342\12-29921-1\task5718412\29921-1-ba-13.htm',USER='105342',CD='Dec 21 01:56 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Timothy M. Shannon, M.D.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Timothy   M. Shannon, M.D.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Karen L. Shoos</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>    </td>   </tr>
<tr>
<td width="27%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:27.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Karen   L. Shoos</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="top" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-7-<a name="PB_7_003656_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-7-',FILE='C:\JMS\105342\12-29921-1\task5718412\29921-1-ba-13.htm',USER='105342',CD='Dec 21 01:56 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="5%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:5.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="40%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="49%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Location</font></b></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sales   Agreement, dated January&nbsp;6, 2011, between Celldex   Therapeutics,&nbsp;Inc. and Cantor Fitzgerald&nbsp;&amp; Co.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;10.1.3 of Celldex&#146;s Current Report on   Form&nbsp;8-K, filed January&nbsp;6, 2011.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment   No.&nbsp;1, dated September&nbsp;20, 2012, to Sales Agreement, dated   January&nbsp;6, 2011, between Celldex Therapeutics,&nbsp;Inc. and Cantor   Fitzgerald&nbsp;&amp; Co.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;10.1 of Celldex&#146;s Current Report on   Form&nbsp;8-K, filed September&nbsp;24, 2012.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement   and Plan of Merger, dated as of May&nbsp;28, 2009, by and among Celldex,   Cottrell Merger Sub,&nbsp;Inc. and CuraGen Corporation.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;2.1 Celldex&#146;s Registration Statement on   Form&nbsp;S-4 (Reg. N. 333-160257), filed June&nbsp;26, 2009.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third   Restated Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Registration Statement on   Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate   of Amendment of Third Restated Certificate of Incorporation of Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Registration Statement on Form&nbsp;S-4   (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second   Certificate of Amendment of Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.2 of Celldex&#146;s Registration Statement on   Form&nbsp;S-4 (Reg. No.&nbsp;333-59215), filed July&nbsp;16, 1998</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third   Certificate of Amendment of Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Quarterly Report on   Form&nbsp;10-Q, filed May&nbsp;10, 2002</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended   and Restated By-Laws of Celldex as of March&nbsp;14, 2007</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.5 of Celldex&#146;s Annual Report on   Form&nbsp;10-K, filed March&nbsp;18, 2008</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate   of Designations, Preferences and Rights of a Series&nbsp;of Preferred Stock   of Celldex classifying and designating the Series&nbsp;C-1 Junior   Participating Cumulative Preferred Stock</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Registration Statement on   Form&nbsp;8-A filed November&nbsp;8, 2004</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate   of Elimination of Series&nbsp;C-1 Junior Participating Cumulative Preferred   Stock</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.6 of Celldex&#146;s Annual Report on   Form&nbsp;10-K, filed March&nbsp;16, 2005</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.8</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fourth   Certificate of Amendment of Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.1 of Celldex&#146;s Current Report on Form&nbsp;8-K   filed on March&nbsp;11, 2008</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.9</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fifth   Certificate of Amendment of Third Restated Certificate of Incorporation of   Celldex</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;3.2 of Celldex&#146;s Current Report on Form&nbsp;8-K   filed on March&nbsp;11, 2008</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.10</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shareholder   Rights Agreement dated November&nbsp;5, 2004 between Celldex and </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;4.1 of Celldex&#146;s Registration Statement on   Form&nbsp;8-A filed November&nbsp;8, </font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-8-<a name="PB_8_003828_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-8-',FILE='C:\JMS\105342\12-29921-1\task5718412\29921-1-ba-13.htm',USER='105342',CD='Dec 21 01:56 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EquiServe   Trust Company, N.A. as Rights Agent</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2004</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.11</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment   No.&nbsp;1 to Shareholder Rights Agreement dated October&nbsp;19, 2007   between Celldex and Computershare Trust Company, N.A. (formerly EquiServe   Trust Company, N.A.) as Rights Agent</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;10.1 of Celldex&#146;s Registration Statement on   Form&nbsp;8-A/A filed October&nbsp;22, 2007</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.12</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment   No.&nbsp;2 to Shareholder Rights Agreement dated March&nbsp;7, 2008, between   Celldex and Computershare Trust Company, N.A. (formerly EquiServe Trust   Company, N.A.), as Rights Agent.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated   by reference to Exhibit&nbsp;10.1 of Celldex&#146;s Registration Statement on   Form&nbsp;8-A12G/A filed on March&nbsp;7, 2008.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.13</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen   of Common Stock Certificate</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed   herewith</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.14</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Warrant Agreement</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To   be filed subsequently by an amendment to the Registration Statement or by a   Current Report of the Registrant on a Current Report on Form&nbsp;8-K and   incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.15</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Warrant Certificate</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(included   in Exhibit&nbsp;4.14)</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.16</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen   of Preferred Stock Certificate</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To   be filed subsequently by an amendment to the Registration Statement or by a   Current Report of the Registrant on a Current Report on Form&nbsp;8-K and   incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.17</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Depositary Agreement</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To   be filed subsequently by an amendment to the Registration Statement or by a   Current Report of the Registrant on a Current Report on Form&nbsp;8-K and   incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.18</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Depositary Receipt</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(included   in Exhibit&nbsp;4.17)</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.19</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Unit Agreement</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To   be filed subsequently by an amendment to the Registration Statement or by a   Current Report of the Registrant on a Current Report on Form&nbsp;8-K and   incorporated by reference therein.</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Opinion   of Lowenstein Sandler PC as to the legality of the securities being   registered</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed   herewith</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Computation   of Ratio of Combined Fixed Charges and Preferred Stock Dividends to Earnings</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed   herewith</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent   of PricewaterhouseCoopers LLP,&nbsp;Independent Registered Public Accounting   Firm</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed   herewith</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent   of Lowenstein Sandler PC</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Included   in Exhibit&nbsp;5.1</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Powers   of Attorney</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Included   on signature pages&nbsp;to this Registration Statement</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Part II-9-<a name="PB_9_003835_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='Part II-9-',FILE='C:\JMS\105342\12-29921-1\task5718412\29921-1-ba-13.htm',USER='105342',CD='Dec 21 01:56 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>2
<FILENAME>a12-29921_1ex4d13.htm
<DESCRIPTION>EX-4.13
<TEXT>

<html>

<head>






</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 4.13</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="93%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:93.04%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="681" height="880" src="g299211kai001.gif"></font></p>
  </td>
  <td width="6%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:6.96%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ZQ|00000187|AVAN|C02|CUS|C0000022632|CAPIN|00453000|1051
  </font><font size="1" color="white" style="color:white;font-size:1.0pt;">COMMON STOCK </font><font size="1" color="white" style="color:white;font-size:1.0pt;">PAR VALUE $0,001 </font><font size="1" color="white" style="color:white;font-size:1.0pt;">Certificate
  Number </font><font size="1" color="white" style="color:white;font-size:1.0pt;">ZQ00000187 </font><font size="1" color="white" style="color:white;font-size:1.0pt;">THIS
  CERTIFIES THAT is the owner of Celldex </font><font size="1" color="white" style="color:white;font-size:1.0pt;">INCORPORATED
  UNDER THE LAWS OF THE STATE OF DELAWARE </font><font size="1" color="white" style="color:white;font-size:1.0pt;">therapeutics
  COMPUTERSHARE SHAREHOLDER SERVICES INC SPECIMEN </font><font size="1" color="white" style="color:white;font-size:1.0pt;">CERTIFICATE</font><font size="1" color="white" style="color:white;font-size:1.0pt;"> **ONE** </font><font size="1" color="white" style="color:white;font-size:1.0pt;">COMMON STOCK </font><font size="1" color="white" style="color:white;font-size:1.0pt;">THIS CERTIFICATE
  IS TRANSFERABLE IN CANTON, MA AND JERSEY CITY, NJ </font><font size="1" color="white" style="color:white;font-size:1.0pt;">CUSIP
  15117B 10 3 </font><font size="1" color="white" style="color:white;font-size:1.0pt;">SEE REVERSE FOR CERTAIN
  DEFINITIONS </font><font size="1" color="white" style="color:white;font-size:1.0pt;">Shares FULLY PAID AND
  NON-ASSESSABLE SHARES OF THE COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF CELLDEX THERAPEUTICS, INC. transferable
  on the books of the Corporation by the holder hereof in person or by duly
  authorized attorney, upon surrender of this Certificate properly endorsed.
  This Certificate is not valid unless countersigned by the Transfer Agent and
  registered by the Registrar. WITNESS the
  facsimile seal of the Corporation and the facsimile signatures of its duly
  authorized officers. </font><font size="1" color="white" style="color:white;font-size:1.0pt;">President and
  Chief Executive Officer Senior </font><font size="1" color="white" style="color:white;font-size:1.0pt;">vice</font><font size="1" color="white" style="color:white;font-size:1.0pt;"> president</font><font size="1" color="white" style="color:white;font-size:1.0pt;">
  and Chief Financial Officer DATED 25-MAR-2010 COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER
  AGENT AND REGISTRAR. </font><font size="1" color="white" style="color:white;font-size:1.0pt;">229682 SPECIMEN
  1 1 1 1 1</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105981\12-29921-1\task5721027\29921-1-ka.htm',USER='105981',CD='Dec 22 02:46 2012' -->


<br clear="all" style="page-break-before:always;">


<div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="80%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:80.92%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="1" color="white" face="Times New Roman" style="color:white;"><img width="667" height="863" src="g299211kai002.gif"></font></p>
  </td>
  <td width="19%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:19.08%;">
  <p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">This
  certificate also evidences and entitles the holder hereof to certain Rights
  as set forth in a Shareholder Rights Agreement between Celldex Therapeutics,
  Inc. and Computershare Trust Company, N.A. (or any successor thereto), as
  Rights Agent, dated as of November 5, 2004 as amended, restated, renewed,
  supplemented or extended from time to time (the &#147;Rights Agreement&#148;), the
  terms of which are hereby incorporated herein by reference and a copy of
  which is on file at the principal offices of Celldex Therapeutics, Inc. and
  the stock transfer administration office of the Rights Agent. Under certain circumstances,
  as set forth in the Rights Agreement, such Rights will be evidenced by
  separate certificates and will no longer be evidenced by this certificate.
  Celldex Therapeutics, Inc. may redeem the Rights at a redemption price of
  $0.01 per Right, subject to adjustment, under the terms of the Rights
  Agreement. Celldex Therapeutics, Inc. will mail to the holder of this
  certificate a copy of the Rights Agreement, as in effect on the date of
  mailing, without charge promptly after receipt of a written request therefor.
  Under certain circumstances, Rights issued to or held by Acquiring Persons or
  any Affiliates or Associates thereof (as defined in the Rights Agreement),
  and any subsequent holder of such Rights, may become null and void. The
  Rights shall not be exercisable, and shall be void so long as held, by a
  holder in any jurisdiction, where the requisite qualification, if any, to the
  issuance to such holder, or the exercise by such holder, of the Rights in
  such jurisdiction shall not have been obtained or be obtainable. The
  following abbreviations, when used in the inscription on the face of this
  certificate, shall be construed as though they were written out in full
  according to applicable laws or regulations: TEN COM - as tenants in common
  UNIF GIFT MIN ACT- Custodian (Cust) (Minor) TEN ENT - as tenants by the
  entireties under Uniform Gifts to Minors Act (State) JT TEN- as joint tenants
  with right of survivorship UNIF TRF MIN ACT Custodian (until age) and not as
  tenants in common (Cust) (Minor) under Uniform Transfers to Minors Act
  (State) Additional abbreviations may also be used though not in the above
  list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE
  For value received, hereby sell, assign and transfer unto (PLEASE PRINT OR TYPEWRITE
  NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) represented by the
  within Certificate, and do hereby irrevocably constitute and appoint to
  transfer the said shares on the books of the within-named Corporation with
  full power of substitution in the premises. Shares Attorney Dated: 20
  Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE
  GUARANTEED BY AN ELIGIBLE. GUARANTOR INSTITUTION (Banks, Stockbroker, Savings
  and Loan Association and Credit Unions) WITH MEMBERSHIP IN AN APPROVED
  SIGNATURE GUARANTEE MEDALLION PROGRAM. PURSUANT TO S.E.C RULE 17Ad-15.
  SPECIMEN Signature: Signature: Notice: The signature to this assignment must
  correspond with the name as written upon the face of the certificate, in
  every particular, without alteration or enlargement, or any change whatever.
  SECURITY INSTRUCTIONS THIS IS WATERMARKED PAPER. DO NOT ACCEPT WITHOUT NOTING
  WATERMARK. HOLD TO LIGHT TO VERIFY WATERMARK</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105981\12-29921-1\task5721027\29921-1-ka.htm',USER='105981',CD='Dec 22 02:46 2012' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>a12-29921_1ex5d1.htm
<DESCRIPTION>EX-5.1
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 5.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Celldex Therapeutics, Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">119 Fourth Avenue</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Needham, Massachusetts 02494</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Re: Shelf Registration Statement of Celldex Therapeutics,&nbsp;Inc. on Form&nbsp;S-3</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have acted as counsel to Celldex Therapeutics,&nbsp;Inc., a Delaware corporation (the &#147;Company&#148;), in connection with its filing of a shelf registration statement on Form&nbsp;S-3 (the &#147;Registration Statement&#148;), including the base prospectus constituting a part thereof (the &#147;Base Prospectus&#148;) </font><font size="2" style="font-size:10.0pt;">and the ATM prospectus constituting a part thereof, </font><font size="2" style="font-size:10.0pt;">to which this opinion is attached, filed with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). We have been requested by the Company to render this opinion in connection with the filing of the Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Base Prospectus provides that it will be supplemented in the future by one or more supplements to the Prospectus (each a &#147;Prospectus Supplement&#148;). The Prospectus, as supplemented by various Prospectus Supplements, will provide for the registration by the Company of up to $200,000,000 aggregate offering price of (i)&nbsp; shares of preferred stock, par value $0.001 per share, in one or more series or classes (the &#147;Preferred Stock&#148;), (ii)&nbsp;shares of common stock, par value $0.001 per share, (and associated rights to purchase the registrant&#146;s Series&nbsp;C-1 Junior Participating Cumulative Preferred Stock) (the &#147;Common Stock&#148;), (iii)&nbsp;warrants to purchase Common Stock or Preferred Stock (the &#147;Warrants&#148;), (iv)&nbsp;depositary shares (evidenced by depositary receipts) representing fractional interests in shares of Common Stock or Preferred Stock (the &#147;Depositary Shares&#148;), or (v)&nbsp;units composed of the foregoing (the &#147;Units&#148;). The Preferred Stock, Common Stock, Warrants, Depositary Shares and the Units are collectively referred to herein as the &#147;Securities.&#148; The Preferred Stock may be exchangeable for and/or convertible into shares of Common Stock or another series of Preferred Stock. The Units may be exchangeable and/or settled into the Securities comprising the Units.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The ATM prospectus relates to the sale by the Company of shares of common stock having an aggregate offering price of up to $26,600,000 (the &#147;ATM Shares&#148;) under a sales agreement dated as of January&nbsp;6, 2011, as amended on September&nbsp;20, 2012, (the &#147;Sales Agreement&#148;) between the Company and Cantor Fitzgerald &amp; Co.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In rendering our opinion, we have reviewed the Registration Statement and the exhibits thereto and the Sales Agreement. We have also reviewed such corporate documents and records of the Company, such certificates of public officials and officers of the Company and such other matters as we have deemed necessary or appropriate for purposes of this opinion.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except to the extent we opine as to the binding effect of certain documents as set forth in paragraphs 3, 4 and 5 below, we have assumed that all documents referenced below are the valid and binding obligations of and enforceable against the parties thereto. We have also assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the conformity to authentic original documents of all documents submitted to us as certified, conformed or photostatic copies and the legal capacities of all natural persons.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based on the foregoing, and subject to the assumptions, limitations and qualifications set forth herein, we are of the opinion that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" style="padding:0in 0in 0in 0in;width:4.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font></p>    </td>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;When   a new class or series of Preferred Stock has been duly established in   accordance with the terms of the restated certificate of incorporation of the   Company, as amended (&#147;Charter&#148;), the by-laws of the Company (&#147;Bylaws&#148;) and   applicable law (in the event that the Preferred Stock is a new class or   series of Preferred Stock), and upon adoption by the Board of Directors of   the Company of a resolution in form and content as required by applicable   law, and (b)&nbsp;assuming that appropriate certificates of amendment to the   Company&#146;s Charter relating to such class or series of Preferred Stock have   been duly approved by the Company&#146;s Board of Directors and been filed with   and accepted for record by the State of Delaware, and (c)&nbsp;assuming that   the Registration Statement and any required post-effective amendment(s)&nbsp;thereto   and any and all Prospectus Supplement(s)&nbsp;required by applicable laws   have become effective under the Securities Act, and (d)&nbsp;assuming that   upon the issuance of such Preferred Stock, the total number of issued and   outstanding shares of the applicable class or series of Preferred Stock will   not exceed the total number of shares of Preferred Stock or the number of   shares of such class or series of Preferred Stock that the Company is then   authorized to issue under its Charter, then upon issuance and </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\12-29921-1\task5719987\29921-1-ke.htm',USER='105537',CD='Dec 21 20:02 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" style="padding:0in 0in 0in 0in;width:4.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">delivery   of and payment for such shares in the manner contemplated by the Registration   Statement, the Prospectus and the related Prospectus Supplement(s)&nbsp;and   by such resolution, such shares of such class or series of Preferred Stock   (including any Preferred Stock duly issued upon (i)&nbsp;the exchange or conversion   of any shares of Preferred Stock that are exchangeable or convertible into   another class or series of Preferred Stock, (ii)&nbsp;the exercise of any   duly issued Warrants exercisable for Preferred Stock, or (iii)&nbsp;the   exchange or settlement of Units that are exchangeable or able to be settled   for Preferred Stock), will be validly issued, fully paid and non-assessable. </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" style="padding:0in 0in 0in 0in;width:4.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font></p>    </td>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;Except   for the ATM Shares, upon adoption by the Board of Directors of the Company of   a resolution in form and content as required by applicable law authorizing   the issuance and sale of Common Stock, and (b)&nbsp;assuming that the   Registration Statement and any required post-effective amendment(s)&nbsp;thereto   and any and all Prospectus Supplement(s)&nbsp;required by applicable laws   have become effective under the Securities Act, and (c)&nbsp;assuming that   upon the issuance of such Common Stock, the total number of issued and   outstanding shares of Common Stock will not exceed the total number of shares   of Common Stock that the Company is then authorized to issue under its   Charter, then upon issuance and delivery of and payment for such shares in   the manner contemplated by the Registration Statement, the Prospectus and the   related Prospectus Supplement(s)&nbsp;and by such resolution, such shares of   Common Stock being issued by the Company (including any Common Stock duly   issued upon (i)&nbsp;the exchange or conversion of any shares of Preferred   Stock that are exchangeable or convertible into Common Stock, (ii)&nbsp;the   exercise of any duly issued Warrants exercisable for Common Stock, or   (iii)&nbsp;the exchange or settlement of Units that are exchangeable or able   to be settled for Common Stock), will be validly issued, fully paid and   non-assessable. </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" style="padding:0in 0in 0in 0in;width:4.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font></p>    </td>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With respect to the ATM   Shares, such ATM Shares have been duly authorized for issuance and (a) when   the Registration Statement has become effective under the Securities Act, and   (b) when the ATM Shares have been issued and sold in accordance with the   Sales Agreement, and as described in the Registration Statement and ATM Prospectus,   the ATM Shares will be validly issued, fully paid and non-assessable.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" style="padding:0in 0in 0in 0in;width:4.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font></p>    </td>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;When   a warrant agreement relating to the Warrants has been duly authorized (the &#147;Warrant   Agreement&#148;), executed and delivered and the Warrants and the securities of the   Company for which the Warrants will be exercisable have been duly authorized   by the Company&#146;s Board of Directors, and (b)&nbsp;assuming that the terms of   the Warrants and of their issuance and sale have been duly established in   conformity with the Company&#146;s Charter and Bylaws and the Warrant Agreement,   and (c)&nbsp;assuming that the Registration Statement and any required   post-effective amendment thereto and any and all Prospectus Supplement(s)&nbsp;required   by applicable laws have all become effective under the Securities Act, and   (d)&nbsp;assuming that the terms of the Warrants as executed and delivered   are as described in the Registration Statement, the Prospectus and the   related Prospectus Supplement(s), and (e)&nbsp;assuming that the Warrants, as   executed and delivered, do not violate any law applicable to the Company or   result in a default under or breach of any agreement or instrument binding   upon the Company, and (f)&nbsp;assuming that the Warrants as executed and   delivered comply with all requirements and restrictions, if any, applicable   to the Company, whether imposed by any court or governmental or regulatory   body having jurisdiction over the Company, and (g)&nbsp;assuming that the   Warrants are then issued and sold as contemplated in the Registration   Statement, the Prospectus and the Prospectus Supplement(s), then upon   issuance of and delivery of and payment for such Warrants in the manner   contemplated by the Registration Statement, the Prospectus and the related   Prospectus Supplement and the Warrant Agreement and by such resolution, the   Warrants (including any Warrants issued upon the exchange or settlement of   Units that are exchangeable or able to be settled for Warrants) will   constitute valid and binding obligations of the Company. </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" style="padding:0in 0in 0in 0in;width:4.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font></p>    </td>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;When   a depositary agreement relating to the Depositary Shares has been duly   authorized (the &#147;Depositary Agreement&#148;), executed and delivered and the   Depositary Shares have been duly authorized by the Company&#146;s Board of   Directors, and (b)&nbsp;assuming that the terms of the Depositary Shares and   of their issuance and sale have been duly established in conformity with the   Company&#146;s Charter and Bylaws and the Depositary Agreement, and   (c)&nbsp;assuming that the Registration Statement and any required   post-effective amendment thereto and any and all Prospectus Supplement(s)&nbsp;required   by applicable laws have all become effective under the Securities Act, and   (d)&nbsp;assuming that the terms of the Depositary Shares as executed and   delivered are as described in the Registration Statement, the Prospectus and   the related Prospectus Supplement(s), and (e)&nbsp;assuming that the   Depositary Shares, as executed and delivered, do not violate any law   applicable to the Company or result in a default under or breach of any   agreement or instrument binding upon the Company, and (f)&nbsp;assuming that   the Depositary Shares as executed </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\12-29921-1\task5719987\29921-1-ke.htm',USER='105537',CD='Dec 21 20:02 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" style="padding:0in 0in 0in 0in;width:4.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and   delivered comply with all requirements and restrictions, if any, applicable   to the Company, whether imposed by any court or governmental or regulatory   body having jurisdiction over the Company, and (g)&nbsp;assuming the   depositary receipts evidencing the Depositary Shares have been duly issued   against the deposit of the Common Stock or Preferred Stock in accordance with   the Depositary Agreement and issued and sold as contemplated in the Registration   Statement, the Prospectus and the Prospectus Supplement(s), then upon   issuance of and delivery of and payment for such Depositary Shares in the   manner contemplated by the Registration Statement, the Prospectus and the   related Prospectus Supplement and by such resolution, the depositary receipts   evidencing Depositary Shares (including any depositary receipts evidencing   Depositary Shares issued upon the exchange or settlement of Units   exchangeable or able to be settled for Depositary Shares) will entitle holders   thereof to the rights specified in the Depositary Agreement.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" style="padding:0in 0in 0in 0in;width:4.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font></p>    </td>
<td width="91%" valign="top" style="padding:0in 0in 0in 0in;width:91.72%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;When   a unit agreement relating to the Units has been duly authorized (the &#147;Unit   Agreement&#148;), executed and delivered and the Units have been duly authorized   by the Company&#146;s Board of Directors, and (b)&nbsp;assuming that the terms of   the Units and of their issuance and sale have been duly established in   conformity with the Unit Agreement, and (c)&nbsp;assuming that the   Registration Statement and any required post-effective amendment thereto and   any and all Prospectus Supplement(s)&nbsp;required by applicable laws have   all become effective under the Securities Act, and (d)&nbsp;assuming that the   terms of the Units as executed and delivered are as described in the   Registration Statement, the Prospectus and the related Prospectus   Supplement(s), and (e)&nbsp;assuming that the Units, as executed and   delivered, do not violate any law applicable to the Company or result in a   default under or breach of any agreement or instrument binding upon the   Company, and (f)&nbsp;assuming that the Units as executed and delivered   comply with all requirements and restrictions, if any, applicable to the   Company, whether imposed by any court or governmental or regulatory body   having jurisdiction over the Company, and (g)&nbsp;assuming that the Units   are then issued and sold as contemplated in the Registration Statement, the   Prospectus and the Prospectus Supplement(s), then upon issuance of and   delivery of and payment for such Units in the manner contemplated by the   Registration Statement, the Prospectus and the related Prospectus Supplement   and the Unit Agreement and by such resolution, the Units will constitute   valid and binding obligations of the Company. </font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The opinions set forth above are subject to the following exceptions, limitations and qualifications: (i)&nbsp;the effect of bankruptcy, insolvency, reorganization, arrangement, moratorium, fraudulent conveyance, fraudulent transfer and other similar laws relating to or affecting the rights of creditors; (ii)&nbsp;the effect of general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance, injunctive relief and other equitable remedies), regardless of whether considered in a proceeding at law or in equity, (iii)&nbsp;the effect of public policy considerations that may limit the rights of the parties to obtain further remedies, (iv)&nbsp;we express no opinion with respect to the enforceability of provisions relating to choice of law, choice of venue, jurisdiction or waivers of jury trial, and (v)&nbsp;we express no opinion with respect to the enforceability of any waiver of any usury defense.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the extent that the obligations of the Company with respect to the Securities may be dependent on such matters, we assume for purposes of this opinion that the other party under the Warrant Agreement for any Warrants, under the Unit Agreement for any Units and under the Deposit Agreement for any Depository Shares, namely the warrant agent, the unit agent or the depositary, respectively, is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization; that such other party is duly qualified to engage in the activities contemplated by such Warrant Agreement, Unit Agreement or Deposit Agreement, as applicable; that such Warrant Agreement, Unit Agreement or Deposit Agreement has been duly authorized, executed and delivered by such other party and constitutes the legally valid, binding and enforceable obligation of such other party, enforceable against such other party in accordance with its terms; that such other party is in compliance, generally and with respect to performance of its obligations under such Warrant Agreement, Unit Agreement, or Deposit Agreement, as applicable, with all applicable laws and regulations; and that such other party has the requisite organizational and legal power and authority to perform its obligations under such Warrant Agreement, Unit Agreement or Deposit Agreement, as applicable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\12-29921-1\task5719987\29921-1-ke.htm',USER='105537',CD='Dec 21 20:02 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our opinion is limited to the federal laws of the United States and to the Delaware General Corporation law.&#160; We express no opinion as to the effect of the law of any other jurisdiction. Our opinion is rendered as of the date hereof, and we assume no obligation to advise you of changes in law or fact (or the effect thereof on the opinions expressed herein) that hereafter may come to our attention.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item&nbsp;601(b)(5)&nbsp;of Regulation S-K under the Securities Act and to the use of our name therein and in the related Prospectus and any Prospectus Supplement under the caption &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the Rules&nbsp;and Regulations of the Commission promulgated thereunder.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very truly yours,</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LOWENSTEIN SANDLER PC</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.0pt;text-indent:-12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Lowenstein Sandler PC</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105537\12-29921-1\task5719987\29921-1-ke.htm',USER='105537',CD='Dec 21 20:02 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>a12-29921_1ex12d1.htm
<DESCRIPTION>EX-12.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;12.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CELLDEX PHARMACEUTICALS,&nbsp;INC.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">COMPUTATION OF RATIO OF EARNINGS TO COMBINED FIXED CHARGES</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="40%" valign="bottom" style="padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="14" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:55.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Year&nbsp;Ended&nbsp;December&nbsp;31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="40%" valign="bottom" style="padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2010</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2009</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2008</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2007</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="40%" valign="bottom" style="padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="55%" colspan="14" valign="bottom" style="padding:0in 0in 0in 0in;width:55.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(In&nbsp;thousands)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="40%" valign="bottom" style="padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss from continuing   operations before taxes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(43,399</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,455</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(36,850</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(48,756</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15,508</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="bottom" style="padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fixed Charges:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expensed and   amortization of debt discount</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,796</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,337</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">452</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">156</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimate of interest   within rental expense (2)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">841</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">821</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">825</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">726</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total fixed charges</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,637</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,158</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,277</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">882</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss as defined for ratio   to fixed charges</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(40,762</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,297</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(35,573</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(47,874</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="7%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:7.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15,409</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ratio of earnings to fixed   charges</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>
<td width="9%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:9.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Due to the Company&#146;s loss from continuing operations for the years ended December&nbsp;31, 2011, 2010, 2009, 2008, and 2007 earnings were insufficient to cover fixed charges by $43.4 million, $6.5 million, $36.9 million, $48.8 million, and $15.5 million, respectively.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Interest component on rentals estimated to be one-third of rentals</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105621\12-29921-1\task5718401\29921-1-kl.htm',USER='105621',CD='Dec 21 01:47 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a12-29921_1ex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;23.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We hereby consent to the incorporation by reference in this Registration Statement on Form&nbsp;S-3, of our report dated March&nbsp;8, 2012 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Celldex Therapeutics Inc.&#146;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011.&#160; We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ PricewaterhouseCoopers&nbsp;LLP</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston, Massachusetts</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;21, 2012</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105621\12-29921-1\task5718401\29921-1-ku.htm',USER='105621',CD='Dec 21 01:48 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g299211ba11i001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g299211ba11i001.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!%35),3%]'4D%02$E#4SI;0T5,3$1%
M6%]42$5205!%551)0U-=0T5,3$1%6%]42$5205!%551)0U-?0U],3T=/+D50
M4__;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_``!$(`#\!!0,!(@`"$0$#$0'_Q``?```"`@("`P$````````````)
M"@`(!@<%"P$"!`/_Q`!($``!!`(!`@0$`P`,#`<!```$`@,%!@$'"`D1`!(3
M%`H5%B$7,4$8&B(C)#A187%XM_`9)B<R6')U@9&4H=$I,S0U-CK60O_$`!T!
M``(#``,!`0````````````4&!`<(``(#"0'_Q``T$0`"`P`"`00!`@0$!04`
M```"`P$$!081$@`'$R$4%2((,3)!%B,S420F87&S-39"=<'_V@`,`P$``A$#
M$0`_`'^/'JI248SE6<8QC&<YSG^3'WSG^C&/OG/Z8^^?MX]LY[?W_P"O]&/S
MS_-XZ^7K8=7'F5MC=^S^*T?$;-XDZ9HLB95)K5YCOTQLW9XB\YR/9]E3T(0Z
MXNHVF/\`+(5FI5&?,I,K736#965N#I"5Q[SP#@6I[@[)9.;8J5`KI_*O6[;(
MZKUO,5R:JPE#[39(H$%JB`@I'YW(`H/TI<RYAG\+RXTKR;%DFL^"K6KA/;G^
M/EXFXHE2`B/LC.9*8[^-;"B1]-J\D>LSTXN+AYD!L'DG4[%<0'7!RZ1J5B0V
MY9P2F5+0^)+,T0>8B:^4PM&6W1K#,1+Z'<^FIO"L*PFC:?B>^FMF2P"H'DD@
M3)'H_.E:=`S'8;]53>#,C(O*YOVV48P_AO$3DWTEX3D/#^%-)Z]!.,)3AM&$
MH;3_`)K:$X0VG_50G&$)_P!V,>)XU=0_AIX0BN`7]'?OVO'_`#'A9J4TR77W
M*JXTW$L>_N!8]\_?V4Q]>LZ7/?GE3GD5.CDTZ\%^Q1)?89X_[-:;Q@BG^\K6
MJ.OJ![^Y[17C?UE^G%RB.`@=?<E:C7[E(J;9%H^V&9'4EG++><PVR#%LWL:'
MB)\UY><(:%KLS+O+6I*$HRI6,9*%A6%8[XSW_P"F?YOMG[_?\\?RX^_Y>.FH
M5C"DY0O"5HS^:%IPM"O]9"L92K_?C/ADWHA]6KF9K;>VKN)TC%;'Y9:=V#+`
MU2&UZDOY_L;5`BWFL%6ZB6>?(1Z-(JD?ZDA:*I<)X&FQD&.Z9#S%3)9].4K[
MGO\`#I&1G7-GBFNRRB@AUNUF[+*RG172$L:=;1`:U8B6$&7PV4HB0&>K),\0
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M@$<`(RT*$"*TT,(,TVPPVAM"4XO._./[34<NA&%E[W/M'/K:NI;WJWY^?QM-
MR/EJ9U+-.12S1!<0RQ9=W*CZD/E2X5JJ:G&G[BV]&W.M?R.'TKCL[/K93?Q+
MFVRM,#9NVKH^3!I$SL$H`8@QB?+P8!&:8\E\/7U4Y?YC9)7J+5.1NYLDJ2>R
M5=N0#S4B4OR/N2!EF6`DML]1:?LG$`0E7E0^HI&<Y:1@5XW'\09TB"!KSO"P
MN\H>.<+("HL%@L,@QNG6Z0?5'CVVY:]MPU?W5JC).2&!(J8L+8E<Q)O#I<'F
M'E*!)>'\<;,0\58(J3@IR,CYF&FHXV)EXB6#'D8N5BI(9T.0C),`MMT4Z./$
M>>%-"):<')'=<9>;4A><9$H]W]2TP$<GX]Q7DN24P#J+\*A1<"2Z$_P+M%*6
MT['A'2W^#I`H@O&9B)B>SVSSJP&[`V-_#T8CR7;3J6;*S8,R0_F5K)F%E4E_
M6OR7Y#,QWU,Q(^.F[U*](=2341=[UNV74+[4'@(K:^HK`:(79:'-'#>N*0P6
M,EAJR4V:4V7],V\0,-B3R$<"?'Q$Y'2,4*1GPFQQLX,\G^F_UR7">/6B=PS/
M"/9<XY4).XP-5FY?7L!J?;4`FP"P,W9,NOM,CZ7V:'&,HD)$ATT.$A6'2W'/
MF9*B7$9R>A:Q"2EDLTO%UZOP4:9,3LY-R`D3#0L3'#K+D926E#WAP8Z-CQ6G
M233C"&111VG'WW6VD*5A=Y]AX>3LU6\6N1=PMS-I[&8F7A9N9XW8+SRKW@;#
M&W4:,CX-F7?&:H83&P9D<X?K:VCEO7OU_P`;7R;MG,OMA1)K7"J^/CH5O*("
M46`*"\@Z7YBR0$%R`QRWB>%9.2_Q-6NHO83^H^#/'FV\JK,LYV*C+@81.UVL
M6*2%+6T_]!4NN5NR['O48XRWYAI90-5&*]5LH%LZ/4R21J"0ZWO65HT<U>=D
M])J5`UPA!1IAR-8\DZZ\/'#O)QEXR:)$LJ(AMEM6,++E:RRP1W]TTVV.E6,$
MJ_M#SER*[WY]+,*V,'4J;&SDY=ZR)1V/A2NW%60(NIB`<M1Q,3W$1$S$)WN1
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MV^K3R!W#L#<EC@.035>A)O84^_8)**@\ZNHDIF)!)(2E;`&9(\T[(Z>Z?<E/
M._YSBN]5.FGRZY1;,ZZ/,K1.PM_;3N>F:9)\O6JGK"Q6@F0I==:J&Z*S"U5N
M(AG$89$37H@HB-B?(K.1`WG&4YRE>>^P?A1OXH')'^LTS_8_KGQ33I-__8HY
MX?[7YP?V]U'Q=>IEY@<A]_%AG417GX(LH+&I7@*+);2B64PA?C6/HBCR3`%^
MZ?O[]55GZ.@6/[/&5VT1WM0AN%+V25H?!D^-@I+MP]__`!.2C^W741Z=K\3Q
MJ+>N^-2\:M76O<V[KO#:^UQ2X]<A.V*:>4EM'VRD6.C@V$/2$U.RI'D!A("(
M%-F)F0=9!C0B2'$H\*^7_P")>V7M>_2&ONGWP2OV\70EO*$F+:S<)FQR@N6'
MDCR.=5:D@Y^2@HY9#2GQW)VYL%F"-K9>$BRU*0/2?&^#\GY8%AV+F$ZG4GJW
MHV7UJ&;6+J)\&WKK45_DB"$I2##;`D)2N!F)]6MN<LP>.DE6I>%5JS'=>DE3
MK=UXQ,QY!5JK:V`[@HAAB"YD2&#[B8AN#PLY\2WR:Y#<9])<9YOCWNC8NF)B
MS[5OD389/7=B(KIDS&`ZX?D`@9%X=*E$BBGXP8PTKMALC&'<?NL)SBN[/Q`/
M4-T$>U.\W.EU<J1J];S#!MHKE<V]K9Z);>;'>60W)[*A[)295]ME]+B`#K%6
M$N+6D5R2&=;>4BN_Q"','0_.'@UPUWCQ[MZ;143=X;*AYF/,%7%VJDV@74N"
M9"H7>`=6Z_`V,%DH8G(JGB0Y&.*"F84^3A3PI`BS>!>W6YB\^XDW>RJ5[$NW
M[%?\RM8S]S':W]-ML&N]M1MJNMO[?-:K4+(Y"25!>$S"-RSFV1J\1Y&O)OV*
MNK6I*=%:PBUFZ`!%VL,N2NPM+&+CR\28B3@.^CD>XB6\>)EAG;;Q8XU6JT2Y
M\_9;+H#35@L,[*/Y)DYJ<FM;UJ2EI:1)5C"B#I*0*(,+?5C&72'W',XQE7;Q
M8+Q67A7]N'/$_O\`Z-.A_P"RJI^!?]1/KX\7."UPEM-U>!F>1F^X%]`5FI%,
MF0(&I4.1=;0IN'O.P2Q9=@6RYR^/ZE3K,'9IP%2LC3K<$4X.R]5E3CFSR3D%
MW*X_F/T+<V[A17K``@E(6"&6.:<KKU:X20!\KF*2)$`>4$0Q+X_<S,/$IZ.S
M?53K_BU8ESR(C:TT!/@I80;GN/\`<7QJ!C)B"+QZB9@[7B>%`X[K=]9F]Q>;
MKK/I-2DA076AB0Y!>K^2ED46*42XAD@&5&&K.)9AYKR-X?C(`AII25%N*R,\
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MPA9J)%O@Y#;0=7FG1XJ%3%-3Z5X^FK`ETV&F7GXQ#+R!IB/,=JBW?J46(5<;
M^.=ELI3\@,@";$Q'QDR`E:SF9^A883/4]=]3T:V>5\?X_8RJNSHAGLV[,5,Q
MCT6OQ+%HI"!05X$'2KM/S&5A:L)ED=R'E`E,&+\3Q,9QG[X_O_VSC]<?GC/@
M>O4;ZCFE^F]I=G9NRV2;7;[.>Y!ZLU-"2#$?9]C3HV!WI)L4T@4X>#K]?!?0
M?9+1("/`1;;@0+31LS*Q4:8:S,R_L7ZN7EU77;]UPHJU4#Y,:POY1'<P(B,1
M)L89"M2Q)C#$!(H+7[]/,IV+]^PNK3JK)MBPV>@6`_WGJ)(BF9@0`8(S.1`!
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MY091R3Y97?DGM)S=O(#<FVW%H6C86P9^QA^EDG++<6\ZV%##L8-;:+2P-#`@
M#LH)::>0VTE+C;:L>1.;<3N7.W.'FRF-@ZOE$N!'9##N]'E''55>^P(Q&'<Q
MDPPWA:@Y$=&7OD=F";S+0+[SF6?=1Y!\8=5?'?<[8XWR@M:G<?76J\;*5BM,
M?-3`)E2R`>I!]=R1B+=5@DMXFR9$O-BVXDJ>_1/Y9R:ARU`[O`-S4L)16\(8
M_'I*.*M*Y0\?&6**LE-BW7&1.;!'=IFNQ+5V@><JN)V\N&&X[%H_?U-*JEQ@
MEJ?!-:P055KI7UNJ:C[E0[`Z*(Q9:I*^7/MI!EIDL$I+\/.@1,Z$?%C5P\=F
M;?=?\)>NAQ1<B)T7`=I@6<K!DV$12-S\;MAR0R59<"(<;<:+AY=0"$DC*]>F
M;'@1L)?0S("-KA$EA.D#R))ZDKO3;?G:B'=V5/V1S9ZDF/4S\(6X7ZG9V:Q%
M)<1+D.$P2V1FZ=A])S=N<56WY9L-A^?1]/\`VQ][\#FV%8M:EBMF:>3FLTM.
M1DIHV<^L(P_3HS'F?QB1##Z<P5A#2A80X9@HG<H]O6TVY>CQ2Q'(>.<B>E6)
M=JF#3^:U,PFG8(?$?DF1,8;,`/:V"\4-`UQ3/B9Q%WKS7W)!:/X_T]ZU6V52
M@^7D'W%!5>CU=LM@22NEYG<MN,P59BE$(2Z]ELB1E#%,P]?CI:;+$CWNP2XH
M\0N&W0YXRS=WME@"FMDSD8,+LG<!\:,UL';%@:R[(1NN];UITXA^,K[17?,#
M2XPY3?E'5:+K*E$"ES(63U*H\)^AAQ0%KE:`?,GI]W+SRUJCBMQ<AMBB@H0[
M*3!N4MMAPT9A3:5+0VQ3==PCZ!8T-P\UL>:5VY4<LMO<OMDE;%VK,=VV/7%J
M%*BWR\4^@PSV6_-%5L$EQ6<OE899<FYXI.9>?*;0\:XT*R#'@Y(]^?XB+/(#
M;A8DLJXP'VFC)2#[Y#,2J]L2$]@B)Z;4S1+KOQ:\C8*S08U-;CWL=0CN*N_[
MF7JO::TS\E'CJGA$PVQ(S!"4Q,3`P06K@_M5-:H;'M8]Z>O53M/+'E+LK5E^
M@HBI5JVPA%BT5!A90](0C%.PK,[6I^6QGO89Z;@2DVA\X=`P0I$++!1PN`$,
MON%LY&R4C#\?MY2\.IU,M%:=VA)1>62&Q'L2(-%GR@LM%.X4T,Y@EIK*"'4J
M;97C#BTY2G./"+/"VZGZ\Y<<;+='97Z\?NF@`/-MN9:41&V:=&J4P+E?F3C"
M28B?.95A>?)G*L>?"D_N<O[3D.!8826@)1GW$9,QI\/(L95C'K1\D*]'FM^;
MMG&,N"OO)[]L]LJ_+/Y>*1X+LOOH)M\ILMIZ(F<E$1\B3('P$Q$0'43\JQ&.
MA%<`/41$>K$]AN:[/..([:]RZRYK9VM:5^<R!$SJZ2HMUXGP`5C\#SMI2M8P
M":RZZ0`06,>DS?A(X>.=E.;E@<9PN7%K_&^''*RK/F1&GN;:DBVL([]L^N8$
M*\M?;OG+2<9SG&,=G2?"$_1-V`YTX.K5NWAEN<A57`V3(6'CV*;,$H#"5?J3
M:'K!I&4=>4G+;XNPJX:;&UTA*D-'&W>OX;7Y2\8P^OC.,X[X_P"W_'&?OC./
MUQG[XS]L^-%^^J&3[@7-89EF?OYF)J95D>Y58I3E5*GFL^Y&8AU9LS`S]00E
M,=&,RY>TCE_X.KYT_LN8^AJT-!!=0Q%F-"Q8\##^J.EV%C$S]3XS$3U'4>?$
M\3QXSGMC.<_I^GZYS^F,=^WWSG[8Q^N<]O%.^K-]>N<MX5COE&%?;MWRG"OY
MNW?[_P!'A4[XHCEA<:7J/1_#C7AD@,;R)EYNU[&:C'W1B9VCTF0A8>M4-[T_
ML3%W.^3HILF/YD8?14!0"4$`R!3"]:7'GYRCY8]>>E<9.+?("\Q'&/7>PJO6
M]@0-*E(9JFVNOZ3#*MN^IHTY,:>Z^#,SC9NMVSAI%#<A@6-:`6VHYIU5>OBF
MZ<MCE=PSO-K>E`==6/54]3I"1CL>5^/Q5=J`S-R(C7B$OA(E6JU=@31L.BJQ
MZ@+"R$%L(PTU?WMSP></W%X(O?93>[3Q7\KJYHBUCZI#0NV<U=U+%JZMK97F
MX*5D715Q@B[[CU3O-N5_JO"N6'CC86JCJ*P'7I(%I>)7*R+IUG"1Q\!"[\8V
ME$1(OF1_EWZ8]Z8/3ITCT\=#5FL0\779'>ED@HN1WAM0K,<39['<BPA7YFOQ
MTPOL9&4*M2'JQ59K83@X.!Q,S$DT9/24E($$VS)1F>_\/#^_;OG!H^,Y[?EW
MSA[&?M^GW^WA7&-^%JX@S0`<O$<K>49\5*"CR,6<-):H('-C3F4%@%L$(H"4
M/M$B/,O-O(2A#J%X6E*4JQC'V_M5?BE_I1<JO^<U7_\`@?"SK4^#;>C;U-7W
M/V+>A=<;K+W<'N29,*?L8B=V?C6N/V+4/0*6`K6(@(QZ-9MKEV51JY^=P#+K
M4ZJ@4A2N65X&`&!CRF8R/WF?V9L+LF',F<R4E/K57Q&W3NUB#K%/4,T/'`:_
MVQKVYU7\:GJ.@6'^L86QST?$5[:!"8AQA0VPZ+<WJ]E5E$9;D)6(DW29@I\N
MOQ1+1&:=RDEN9'00VEOJSDL%WFQ<'>1->V,^PQD9).PZ#0[S1[A(Y&PA#(WS
MR7@7I](XW<9E$LEIGLVC"4T&OWPS?`W6,`JR[0YM;VU_5E&"1BYZ^W'1M4K^
M3SU*2#'N2ECI\?&9+-<;6D01;^7B5MJPRVM2,]B!@\5M,\/>BURUU+H';DGN
M_5CO'7EQ<J[L.1GJA96I1=IH]M(E1HJ9HHHE8+C(^5%+%;S'MKR@I)B"G5E)
M=[,VCK\;M\9X5BU>0:7)M/#YE2C,U+N!9RHKXEKX_P`C)_(=:NPV$VE(<D9?
M!`F!2"A4@9]`Z6;NU]OE6I9QL_!HZO&+4WLZIL)T"=IH$_BTI2JO5E7R()B6
M3\,^;))A,DSF(I'\*-_%`Y(_UFF?[']<^*:=)O[?$4<\/]K\X?[>ZEXN7\*-
M_%`Y(_UFF?[']<^*9])W'?XB;GEC^66YPX_X[ZJ6/#3K?^Y?XA_[?\O!_P":
MCZ7<W_T7V4_^V+_Q,]>W7;V!M'G5U.>.W2_UW/.0]6K,QKP*39QEXN+3M+;$
M;FQ35]GP`T8R>/K#4)(Y44POU7`4R-K\CS&95U33:/$WB-HOA;IRMZ5T)3`*
MK6(407,K*)9979[S8$CH:D;G>IQ#31=AM$RZE9)996<#`H6W%PPD;#!@QXZB
MNV9`+1/Q4-4M6Q'&UU^\[-UPJ`DIY>&Q&$;;XW,ZOJ10C[SRFVV(R\O?)07%
MK;0R2RXGTV_+VR\"G_-3^GVQC./Y,X^V<?[L_;Q7_N78?G<7]L^.T#)."WAN
M?R!JTS()O;>HQS-!]CQZA[JYB,+AOE-:'F(>/G/;IP1*KV_SK;N`+-=7);F.
MLV]&VKE404%)29F)^);A(I*0\8=*X/\`</77Q2<7&S,<=$2X`<G%28A,?)1D
M@,R;'2`!C*QRPC@2D.B&!E,..,DBDLNL/M.+;=;6A2L9Z^'XAGIU53A3MRI;
M-T/&HI_'GD>Y8)$C6,*X2-4Z%N:F1><3"8.'P^L("%LU:GW)>N@MMX17WT6Z
M%B$AP"@(X7L+?"D/Q8^Q:V-HOBOJ91C"[?.;5O&QV0$/(42-5ZCKZ0JAAQ`^
M$J<:8,FKQ'AANK4VEYT0U+>'<CO99\_8K7U*'N)BTJ+&E4UBL5=*I$D275UT
M[%@7FO[&&4V)&PMW4&$"804`U@E[>[6;GW.%Z=JT"QLYT(L4K/T+5N*RA1)$
M_HI79`Y4Q7<@<R!2,FL)$EG(SE?*\,.B+3-W54EH78(W$CCS2-8O.*[+%V%L
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M37QJ^]&1PZOHT,^YHAFH59L6%UW:0$ZM:![EB()`85$K(0=!B:OMWG$E&8[?
MP\/[=^V<FCYSCO\`GVSE[.?O^OW^_@8?5'Z=6E^H9Q_M-;D8VN1N^:Q!24KH
M[:8[<>W9J_;P!""HNM2,JVM!LE1;45C$+8J^:Z2"TV<B=CAAYZ*C3&1=?M5?
MBE_I1<JO^<U7_P#@?'SF?"Q\1X\0D\_E9RB"""'?+,,+DM3#"B"C-+?())(>
MHB&6&&&6UO//.K0VTTA3BU)0G.<).33X-B:5/5RO<_7J7Z3UOK/5P>W!"P"B
M?$HC=Z8MD=K:HHD&KDUF)`4Q+5I6>7ZU&SG:'`,NQ3MI)+U,Y77(9`XB)*)+
M'GP,)GR6R.B68B8R)#W'X_"\\L+3?]$[DXBWZ4?)D^-T_#3VNPI)3[DE%:ZO
MY4XQ,5-MYQU:5Q],O\)+)"'PVWB,$LXT:/GV(P3`Q+>J)TXXOEM3G-GZR`!C
M>1-(AULQZE9P,)M&L`H)*Q0YMWS(89F6777'*58"<=@#77(61=1#2/N8O4'2
M8Z;/#;AKL/;6R>*7+:3Y'OVRDU^E7:)3>=,WB*K[&)YZR5Z5(?UC%L2$9(%K
M#EAP42)B0Y`19SB!B'A&WABT<A^0>IN+6GKOO3=UJ$I^N*%%_,IR5)0L@A]Q
MYYL.,AH>.8PHN9L$])/C1$#"A-N%RDF6.*RG&%+<;7/=-&'R_F>T.%2M.I;M
MBH::94'5;A:=JO7BQ**9#\P/?H$UZH@2(S='7D)^/J/G\6KZ_ML'&^<C5L55
M4["GV!N*>-6O48TJ5Q%^)(%6,](A`/\`J`E,BP27+!,#W"#JWS5"T]L?4?)2
MI[(OFZ]&5"T2&OH6&B7I#:FX4T<4MR0U.9#G8%(SMFM,`/MI<.6X=88&.D"R
M&#+#!FHF@_<,.+'(3K\<QK)S1Y?.2$5Q8ILVW#IB(DB0C8*9BX=]V0KW'O49
M+C&?\6(A)#16V;J,XW*FOR)7<INVV1#M=Y.J;/W!U?+[RFY+:8XU&ZKLVC)6
M'NM>L.MWR1,7.JL%,*AZU:YS,DPH[E558R/'OT/-T<<8>T5IHV`/`C9BOT.:
MMK`_2&YYT;=.O(OCC9(JI4#<%`C)$N(B*O!1M3K>RZY@MV3FK;"PL4*#%`77
M$K(G2NQ(0,5A9\F:7<0V,LR$N-$1,#DO(/9>YR+@VUF5Z_.+E>G6Q^6?F+LM
MIXUJJ-BU2K_"3$IV)!E99.AHO7,'!01A7:^H>)Z;M?9X]PCG&Y8T,*M-JQP_
M2=796J<[51?"*5?1<_HRT,V`8ME9DE^;$)B2:;56M`S-=KL#48"%JM6AHJNU
MJN10$'7X"#CQ8J%A(6*%:"C(F)C`FF0X^-C@V61`@A6FV!AVFVFD)0G&/$\<
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M5[_$3_QJOJSU\_Q7?E_J^?\`_GZ*]'R]^_Y?IV[]^W\WC8_\/>1^5P[?L^/?
MS\0Y?3[^_N2MHF([_P!^O]NY]:S]M;8J]KO;-<^,2',H;,]QWU_B#=B>_P#I
M_P!_K_OUUZ(CUS[$FURG%*<PI+BWZMNH9;N.V<J]K;*,UA.58^_EQA*?W/?M
MWQC/;OCOX`=X+MU.[%]4:]XAR_J>IYQ^1HWF[]__`$UWH*>W?OG\O-]O`B?&
M5>?(_%YAO5NNH1:6J(^_KPJUQZ^_^L3ZSO[XG#/=+E+(ZZ,L8OK[_JX]DS_^
M]^K"<2JF9>>4G'.I@,-$D3.[M9(RT^WAT?(D?;8N:DW"&\_98X\5&'$OI_5I
ME>.V?RSV$:?R^WY9SG./Z%9SG'Y_T^%-.ACQBDKUN^>Y+3T:ZBF:<`D*[4BR
M!\^VE]F6F-4$7D);B<M/_2%1-,=.4WW4-(6:'PG*7F7,(;,\./`Z3*^4ZRR)
M'\VQ)JB8Z[2H(6)?[]$SY>I_N,1,?4QZU!_#+QZSE\*O[%I9*GD6I+Z@E$C)
MY]!454NZF(F(;:F[X=_1*%;!F1.)E=/K9]&$SG`D/DOQH5$UWE?38@8&7B"S
M_I^.W;78%O#M=C7K!ZS`U;V/5E-8'IEJ,6,"<$XS7K#)1XD?`3,$,[C5\0AR
M@X0KC^,W4VXX[+L=EHP\="L7QYM%+WBN#"0H=HRX5^[.!U?:Y2QT#I!O5>LL
M#\^&8][($V*1(?F277?&O-B:CU7MV&57=K:VH6S*^K"\9@]@4^O7*([+QC"\
M8C[%'2(J/-VQWRVVC/?&,]\9QC/C1&+[AU9PZW%N:\?5RS#H2<Y+?RVY^WBB
MR8\U4=%0LDZL=1(TW#X?0+EGP*4H+2U.%V(U;'(.+;#./:UR!C07^.NYE:9!
MU`LMTF2(B_KZFRN9/^HH&&&;"`KCXGSINYBU2'R;DQ@M+B48A,Z@B?F"T9&R
M_DA)>+]F#P.AW&`E97*I(R0K#J!UA>8I(W>1G7FY8=0ER2XM=+GC7L^#E;N*
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M8=NC!TBXCIRZ\EK_`+*-C;7RHVQ!@`7V7BGLFUO7=79)3*,:RIASK+1$HWF0
M2-(W6U.I:Q:)L&/;!'8AH2/<,W?U?NG6)U&N*I^O:^1&0^ZM=RR]@Z0L$N\L
M:)Q:V8]^-E*A8BFF"71ZS>H1]Z'/*;9<^52K4#8%LDMPRQ7RK>)X3G\UY'8Y
M4',VWS+?7=5=79\8A:R3$`JL"8_8-,$#%;\;^@J_DL_+R*99U<6Q$\>+C"Z8
MCCG5.JQ'<^;(9^XWFW^HK)-_SY=/[H=$''7B,0DOP@ZW.[.F8!'\'NIIH?;B
M&-4#CUNAV\4,/&SJY307'PXF#DX>R2D9";5HT8.VT+1[S2[/G**R$)&--69A
MD4X<K$W\3/TQXF(^9!S&]Y\K([CR82,TM*A2*G4/*:0+DNQS,'`MO/-XP6VX
MN8]K@92?4?01W&P<;9>FM1[GA<5S;VK]>[2KZ596B#V)3*Y=(E"\J0K*V@+'
M&R(S*\J0A7G9;;7YD)SW[IQXK1"=,_IZ5R<>L<-PFXN!3+[V2%&8TAK]_P!-
M_)&"L.C#EP9`8BT/XPMO(H[/II_>V\):[MY<+G*/;/=L,U=KAFWGZU@Y=>3Q
MO<KHR+EH_P!SGA7O4GNHP]DD9)KF8A,_1&1$<K-7`YWDI#/S.3Y=S.0,*J,V
MLQS=&M7'Z6DG57K7:E00("QPP11'4P,=1"J>YMK\Q_B0-N:_U'I?4MCT-P2U
MK=46&S[&M:<R<=F02AR))N-CFVFF*M:-AQ5=.DQ=?:EI14RW$2$R=)6BRJ!=
MS+Q+-W*[3]"X]]*3DKI36<4W`:^U7P<W+2*K'J4QA8\-7M-V,%A\\AIH=HF1
M-RTY(2YZFT*.DRC#7?WQ]>?!"8J(A*Q$!Q,+'1<!!0X:1@(V,##B8B+`&1G*
M6`PA&A@0!&&\9[-,-,LMHQG/EQC'?QPY4W1[)3)27+DJQ8:$;#R^9<]PJ*G*
MJ;!#CE-3:3GDK-B38UL9@QF2;=R^-Z39#)*,X2XC`7;YV&@[C]+-R48?&.,V
MQNYN'7LLL,:[\A3K5W0ON&&7+]CP@)L&H5UUE\:EB,G+"69Q:*"MEVCJEI[V
M]3:J[J6%+0(5UIE*TTZ8'(5J566B1`)S)G(FT_*1\5BOA0W6G.'_`"1RTZT[
MC')IG&<M.MNXQG.GM<YQC.6U*QC/;[]L]L]OOV[>*9])EYA7Q%7/%"7V%N)E
M^<.%-H?:4XG*=]U'S84VE>5X\OY*[IQY<_97;/V\.*Z55I.2HD;;-`CZZ5KN
MY>>;BYK6$;7P*Q8LM+5%+E&'JX((#(N(4`H!1>4N.8P)[?U/*SA*<AB-8ZWK
M]DD+E!4"DPMNEE'JE+1$U.OQMBDE2A""Y)1\X%',2IF9`IMLD[));N2R&T/$
M9<=0E6"]KW,KW-'W&T@RCA?/LP:2`BZ!QGQYUS%Q,BOXVQF$_4!"8F"[@OK[
M%T>$Q&;P-2=5+U<5L#?&PI7FK22P)E<I(&D("8&)BR":!1,2/<3$^@`]>OI0
MWWF=7*7R;XSBX)Y*:0A2(HVJ!&(AIK9VO03B++%`U.5QZ*6MD4:Q.%RM,8+-
MCF9827F(MF1'EVX)MZG_``V^)<A]=5UC2/4AU7M.J;EUZA%7G=BU2HI?D)XZ
M)3[-\C9NJI@BM6RDW/S,X3-J@@YJ)EI)Q\YJ*K:'<`);W_/\_&CML<9..F^<
MC*W;HC3^W'`D.M@O[)UO4+H4"AYE0[N`C+!$'F">=E>6\^W?;[8\N4]LH1E,
M7(YUE.X_4XIS7!9OY68QS,30HWOT[;Q8LEYV*Z'DEZ;=1I]%%:R$`N>I[.%5
MQ3,TN):"MFSR'BNN&/H7P6&K3MU?S,K4E,0*7M4)K97LK'L?G3,D<3,3XR;"
M,#>X?BA>"52K12].TO=^Z+Z4SZ5?K3U.:UG`D23J6\#CS-EM)[\F&PMYW+.5
M5^IV<];K2VQP7/48<6LUU4ZAS<VW2*1U%.=(^=:SW(6\2VL]*:+.`+@W:#IV
MIT@RXQQ@T),%KE:K#2$G(/?+(F?0FWV,U^=NUC8CFI:$#<[`K4_!+A?HN7'L
M6G^*V@-=6,0CW0=DJFJ*7&6,)_+>&LK!GT1"I@'/DQY>P9K&,>9><8[N+RJP
M%NU[0M@#!AWNE5*Z"1[[I(`MMK4)91PB7V<CO$",S8)S8S[S&<L.O,I0XXUG
M+:U*1GR^&#CON3Q'A&M4N\2XC=@?,AT]#;U$V]BS3E91^!1E-,:68HW_`!-L
M6%H;8L+#X))83WZ$;'!^1\JS[%7DO(JQ?M&:%++I-K9Z+0F$Q<MR;BLWF"OY
M!4EABE1G\D0<_P`J?Z;TY1>0_38TQI'9$?\`-Z'M;AIJ:D649E3*2<Q5ATU6
M`G#8PEUHAH65CG'&92&/PTYD*4##,;QE;*<^%(]3[4YR?#@[VO.M]JZUF-X<
M+=CVC,D!8H_W4-3[66@=@2-V!0;@Z)(P]%VJB"8#B[YK:UY8#GE1S"&"%!@P
M5PR^$""%&!"1L<(*!'QXHX0((0[(@808C*!Q1!!1T-L###,-MLL#LMH99:0A
MMM"4)2G'QS<#"66*.@[%$1<]"R@ZQ)*(F8\25BY$5S'9P8^./9(",87C[*9)
M8=;5COC*?OX4^-\ZC&G=SM/'1O\`%^1NE^EAVK#*Y`\&DRO=H7E`3*=^O!>,
M/!<PT8&"&"!1K8=OB,Z0Y%RAI-R-[#3":.JA(.$TRL`=5MU6%`6*CY")E1''
MA,E,=^1"0`:_\31TS)B":EI.2WQ5Y!3`[C]=E=-24E)#.NNJ;?8R?5YF>KK^
M1&TX*>>9FLL+&<;RPMTCU!FQR<R^MSM7J25^=X1]+CC_`+GG)G;H!%4O.R):
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MU*R,.YD!B?OT,'II\*M6=(+A'.YVU=:5"V)YLO;W)C;11`\/3HZ2#BF0V(>.
ME#&!"E4RA0K#4%`+,0DR9DR):7&`&+L;<6TLSOC=7(SXC/G#`Z%T%\WHG#S4
MLIF;8/E!W$QU2J:GVHN9W;M`00@@*4V9:V/>1>J-?OOX=B1"%Q#*A?/L*QH>
MSM3-`LWDUY=6J?/?4@ZC&Z3:$0<K\]%B"635%(K,Q@CYH/&E#L%J?2`0T$0P
MT1E;3K3:TX)7C>/VKK\+I^IIU=0-C72"*NPNOZW'5JKV.RU^"=<CBK)B#APP
M'Y0"+=RX&N0<:>2+G+C.'$8RI.8>%[D#CZ>_RR_1'7YOJ&T<O8N6$Q2QK%N(
M!EI6=*"AUR%'*:0?,M590K4"C69C/?:XG6O4,?CR]1.7Q6BVM6O9RI\;6H8D
M$ULYMLG#X#882S8N`)]EK9+^OXY]<'Q6XMZ>X<:.I6@-'UQ-?H]-"RC+Y&6'
M[!:)XK"')NY7"58'&S-VVQF(]Y+RBVFT]\#@@,!Q0$<"*$GJD]/JT:YM;O.O
MB8B2KMBJ\RQ>MGUNH(=9EH*;CR&2,;=I`(;#B5);6ETC8L&VRL<D=PNR9$(%
M(LXY#'_CU6A#J%MN)2M"TJ0M"L84E258RE25)SC.%)4G.<*3G&<9QG.,XSC.
M<>*HWJL\B&R>D]SKEAYVYOF9';&Z92R;?RE/F3284DR9*)9$E$S'<3$[EW!<
M3EW'O\/V512&K"FXMVF$+LXEVL,13MT"&0E<I\1$UB0"Y/DHB'L3$3G!'JG:
M8Y&:D03N#8&N]6[@I:(N*OD=8K/!5>!LA!C)?R^WTMR4DTH)B9Q,>4X;$MNN
M%5N3:(`?]0!V)..G@BBM(Z;7V\VJ-:*[=^WFH-15V[]N_;O#9[=^V._\O;'B
M>(]56HFNI3[-6RU80!V"2U9-Z^H,@%I1!R/7E,3T11)1`^74?N/2YO0S*5+1
MU\+7N54"E^FW.O5FW9#L1>Y*[[%B\E^,.("@6M$VB"X.%C\&^=&:]Y'ZJMNG
MMGQ.92J6X#VSZV%(8E8>1'7@F)L,`<MMWY=/01[;,A%FX;<0A]KTB&2`WR1G
MDP>2'3RVWQ7WA2Z3L($ZP:DO.R:?5*QN"O".,P4U#V6W1<(H.4=2V0S3;PU'
MG.9=@I-66'C$^ZKQ4R!C*FGGO''RD3&383D=,1X,I'O.#.O`R08YX;RPRF31
M5.BE-NL.*'+'9)84MO*F"&FGVLH=;0M,+<X[3VQ6;)^&TGJ%6!&"[""\I4X)
MF(8J9[F([$@*9D2ZDQ->]R?:?!]QE5;%HIS]O/\`$:FHI0M^2M#)85"^B27^
M53(B,EQ\BVUF,-B6>#'I>EM8=@<?-+@;BU+I77FPZS(RVQHF*L-HO&WPKVR8
M'IZRWB,!1&0@FOJHJ*>E29@DHEYR4/PRVVT-A+N4Y?R*CZ_S_A$OJGUNW^1;
MY?Y_-GMV^G?2[>;'W[?IV_Z_IX9PN'0)F+7;[;:L<O%`_5%LL]GP%G2F"LA8
ML<](S?LLE9V>SDG(GO\`V^2<LLY(RWE[+365^FG2/[6DD?Q6_%']FM_"?I_Y
M!\M_`)/?R>T]IZ_O?Q<[]^W[KTO;?S>I^OC7_#.1^TW$LRYFYNFO.JV,NZB*
MR\[=:,6KL(EL014FS$&:YF?WPN)[F)CN?)9N<0Y"E&10Q^.HI9^7LUKB:M1^
M75KH0MUE[26D+*Q\B;8-A1`^9F93U/?JL41LSCWO&'T5IW=6M]AV.1K-\G8"
MO6JC[A"HS+0FZ+O56SOF4$7KRTJD78@@,5P9;<J%@AO#K.<,Y=2XC7'&3IU;
M5Y5;SN-.I84I6M+479EOJMKW#-"*=C(R&J]ME8?,;7W'66A;A?"(X!I+<8#C
M(`!CR3[&_&@Y2T25.G]`J9JEOJ-J_9>J.^EK96+1['&E?:Y,^G)^.G/9I)QL
M][(V2_8>VP3Z+V1\N^MAIW*/(IB^,BHR%#;CHB/!BP&5D+9!CA!P0V5%$O%D
M9:%%;:8;R^2^\0\I#:<O/NN/.94ZXM6<]^Z?'N![VQFZG'7"TW,O6=\U(T$,
MO/.:D5!8=X5?&L1!\3%9?7C/CVN8$O7AH^S5'FNM1U.3T0S9I/\`EOC4"G%W
MD*QKU:]6M<OU6DQ=>JNI"S*8*P:6>"&H/MPZYTEI;7O'O6-3U'JZ$3!4ZGQ^
M`H]A;N2CSB'7%DR4U-'J2EV3G9H]U^2F)%U*5%&D.J0AEA++#6UO$\3P!6L%
M`"E@*UK$06`1`B`#$"(B,?4",1$1$?41'4>KZK5J].NBI40JM5JI77K5T`*D
MH0D(6I*EA$"M:P$0`!B!$8B(B(CU/$\3Q/'?U[^IXGB>)XYZYZGB>)XGCGKG
MJ>)XGB>.>N>M,\A8K84UIG8,;JVV0-(NS]?)5%V2RU==RA@A1\I(FV"J\W*P
MJC%R<&U(Q8CWS!K$>68Q(*:+2+D-\4O2_B+^!TP):0G[17I2@RVN]M.:OJ<5
M5LPLO2@@R]ECV@:PSZ9,AJV/S<]WE(\AJ+A\1(>?EZDF*_A/@V$K',3$7(Q)
M*W6QI,`R/(6PI"'T,&C.BNJ94XVZA+J6W5*;4MMQ.%X3E2%IQE.:)\5.&-RX
MV:&O?':4WN1LO7\E&V"%U>T;KR&K)^MXJSLV54VT:9&S!;]Q?/E+`F5<=->C
MVQG1718]D,0O#0X>U4:>I5M`MIK'/T*ID+X%:V..JQ/FDFAYBR%N&2!9S\@I
M)D1"UFNO]S"NV>:8VU7KW7U5<6Y1CO:G1A-6K;NNQ[%";-%MU`N59"K=41HJ
MVI_+#/;;``J5K%8-NA]Q\V.,W3?X\\EZQL;62M(U.<J]3'T69K9LV8L5`FMC
M2]?D+1-[')G$2HMAE+$:3@&*@@08^/AOEQJB""FCA"B2<_N;-PTSM;2.@-?W
MZIZ5*V97IK85YW==*'.;.:HE*B"\@1H%<H,"R4J>LMCDQS@TK/0J,CT,,Y?<
M&07DX7,YCITJE>GU3."OXN>@JI9JW^4WZ)PY[_Z;V(N^9_Q1^J$8&]YA?RO_
M`.0O^AV]Y^^]_;8VYR5X@26YKQJ#=&K]NR^B]]:6'F8:L;!!K$9=H>5J-E':
M'L%4M-,F30`I:.*RWD@-Q!XS@C[Y.7<%86QD42G/UZU#\=!OB8I8D2)V888N
M4;!U4UBFRKX>ZXI$(6^LGO\`T&K.29"-0XOSW'XQ.3G6-42'CGMR$I=L#:L+
MOT[%I7-<_(:6M2_3^\U5%*5U=+)I%_3FWZCB.TJO'!+F7L[=@?)"AWZ9K^Q9
MG2`@LW2M[5.A6.@U+:M6GXV=(CBR*C8Q`EP]B@9&'4#,@`^8-WS92G"/026?
MP/34VYSJY0UJG<A=S;`U9'Z5D@+A70:!6]=9B[3=):*D'8YB^$SRS3&80(":
M8.B!8:.=PQ*!@*-(;9?4E1-O-!<8[SJ^.V_)[4Y"7O?&R=S$*5.V6Q"_3]-K
M$>/%F1<7#Z^UD#+'P-0CV$FN$2>(TE#LP^T-ZZFD"M=\HX=\=/V*''37F@\V
M[ZZS0V[`W]4_),5WYI\]M4S9N_R?YG,X$]K\WP'_`.Y$9>]O[CNWEWTFYU2I
MHRW.FVZU"D)OFZ(?`239MUBH*LPM[I=X5H:,S+7P7C,.<PCF6,N'A\M.WQ`M
MN_M#3S,_DK]$(TPKF^\>WELXU2V%U-30/0_'R/S0.2O:2V2D@OWK3'F=D-/(
M_J!<C:',\A;/%\J^/E2FM56N2%U_Q>H>KCM_$V&M5TW#*T;8V]!-M@:YM$LP
MAY<W'/G!BU]U@@11,<XEA]R\7-OEYN74_#'1F_=0#5:,V!M*W:&$>B)Z+78(
M+V^T*\1+FP+>'R@"&FW)!08#4MAQ!8POJ/);]97=.IC>E/M,*A;EX_TCF`=4
M>,NV[';;D7KY&FJI)7/$O:3DR.8*:V.Y,#2LI4V2A(MN1:&'CY26C17HY!$:
MDLA]W#>H_J2S4?IZ\8=(W^^8N\]!;_XYZXE;U!P0]/68#[JP5V/,BHALF3:C
M2X:#>!$#)=(*=)+C6Y0O&7R7FL"C_6JU38=8_+3$T#-)S9!D+MBYLE\)1;>0
MQ*V+A9KKTTR*YB:RB&/-'L3[BY&)SV_J_K=`#XPY]"RS8KV1J[B=*X3)SW!N
MZ;$"RE:JC5?5R\&F:ZI0S(J.4'Y&X_QCYG<7.1O&6C\DMH:UWGK3E'8Y37"R
MZ?K%&NI;5NS4QJ92(`BGQI8U5FJQ1#S<<R=,M)D7PF3#"&@"QV<&:HY1\^MC
ML\I]DZ"H6_-<<7JAI2OP*9>\6_3MJW7-[)V'984>?;KH<3!@EA5>IP09@0\M
M*/X:EW'U$OQ_S%M38P5G:-P3VK*;SU;N+DYRDF.0H7'UR:=TG4_PYK^OV(^:
MD1&HQFYWH^#D2L6NV#`MXPZ4R%&M%R(H,DI333;\<_DNUN%.QC=^6[D5QIY)
MRG':[[0J4-5-L1Q.MJYM*K7+-7&P#5[&Q#STE$XA+-$@82'B0:=,;>:;2M+#
M*GY),A,.OKE68*8N*5.@LQ0ZT+KT4HJ0+`BP-],]%>_S8#]16R$P40?C,5I/
MV<KGS,BTO/'D%2D?*JMA.9?VTW^31QT,,$VTCJIY/0+XV\CB+RT1RNO8BA#0
MA\),<LZM2G4'W;,=+/9_*B.B*_3]YZRL+=%.))K$F12YN5CK[5()RVP5;L:@
M)/,#9ZS81Y`$8Y:%AG$$(94MH9E/BPNXN3NV*9L3IL5R"/@6HODU:B8K:R"H
M!DI\X-K6D':$)@7U%(S`N?-3R5Y<:25G(ZD,=O*CS9V$1P;AIKAI<^(UVVWL
MW8"]@1<OFU;;N4N]8;D=:I:9%L29X<67+-#`BHJ7`CTQ%4&(1'!1`B8Y!'K/
M/G.:&K?3JW4]M+B]LC;O,:1VH-Q8EVG:54OP<K]0B7X%FO-0/MR"8BTOF/6@
MQH<)$C:Y3,JZ0!'""-Q[3SAII78E;817'_B'2=3(6U@NKKA+Z]^67S=$O'LG
M5"@#E`NAO@03/CU,^SJ/N/7C,5'ZIHG:P^"U;EM&CEU5Y^EE\F.WR>Q=4S33
M).OX;EU7,S%71N2AJ2/X_B(]'<EZOO61ZN'%E=3V;1X(B4U7LZ0UT_*ZT7-K
MI])B@0,;+K,VK%F$59I:Z.,RJX"?97#MU5!X[;L7,Y"RLNVM]V/*`]431.K6
MJUKLB,GN+6RK2]:SZ+#&;+CRXZV$",Q,+L%U.9Z'K!2$I>DJ\(O`!Y7F)>3E
MQ7VSCD-P_M6V=^Z(Y&ZTW:9I^_:6C+)6',.42$OD59J?;C`7;#$^SEY".1$'
MG1[4A%XE<8D<C-R#98@PYH#+SF:V;B^JQ<R=;<M/K;(>-?:9MVH_H3$!A[,K
MFTS;LQB?Q8_F[60L@8=P/B.Q"D^X\OJY-9[^GCU&C;6V[*UMB';E&X)E8$P9
M4$:D6)`3<1!*Y6X3"061+A0*^0``0F)XYO5+W(BJU;T#H>Y'&]\++--+ZUG"
M!6*.F2$OOL;7.J52\JP@JU9C:T4D4XLI0E:*1QFY><?+:[\HI?C#L[66G=><
M>MBS^GZ#7++K,.^2NX[W2QF2)Y^SV:6F`QZ?`29KK8$8_"B/D!CF#J.:P\.2
M4O;W*??O,/4W!F!VK#ZHC8'D2\_3HO:,'6XY_;L7J\`\PL.Y7F#AH(EWZJ!B
M6QA)``%TDL:.'ET*F'2FHLMU?!7GIX;+:N^_ICCQRSLNA*+R<D2;!MJ@HUK7
MKSVM,P,\!:+#0[)(34/(TLRQ`D/I*6(R22P0\I;)GHL1C,9O"[<*P9+BWKWC
M;J[<>U=.%ZG553Z%M&L6*0=MJ)VL9*6LVWI;/CL6Z*L3\A(DV.ODF!QQ;Y+:
MA\#H"&:QT77U)3?$XNC9-%H1?^<DDM<3SFN5%$F7XTBCH8DIIB,R(F+#[L+\
M:V7S::/)E.'D:=>SE[2EZ,<DSFT+N@[3>>4[C>:RP[](E&;(+`VLP%KDEHL*
MLV(_5:@W=/\`/K>ALC<&JUR\X1<AJLPW678V6W5F8X@[&J\B4)(YFX.8UZ7%
MN,%L>X:8]H<-)2>6U#DX>?9P0T.W/&V;YT?6^0MVDMC\K>2=BV=='8F&@8F1
MUQJR@Z:#$C(MV4(>5,`1^+*BP2AI$EC.9,AP8A@<9H7'JCI';%GB`"N4`/B"
M9D((_&6Z0`R1DRF/(61I&/U,=05ZS,#U'G']`J]>E[T(7*JU%AUP:_X"O\L2
<BV2BL,)<N38_Q8]7[9CP4WD6J0+@1FQ'^BO_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g299211ba11i002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g299211ba11i002.gif
M1TE&.#EAN``^`/<```$!`0@'!P@'"`L*"Q`/#Q`/$!,2$Q@7%Q@7&!P;&P``
M/2`?'R`?("0C)"@G)R@G*"PK*S`O,#0S,S@W-S@W.#LZ.P``1``&2@`+30`/
M4``44P`85P$<60L650D95PD=6@8A70LD7Q$A70TF8`\H8A,F8!,K9!HM91<Q
M:!PS:BDO9R0V;",Y;BHZ;R8\<2H^<BU"=3)%=S%&>#-(>3Q-?3U1?T`_/T`_
M0$!`/T1#0TA'1TA'2$Q+2U!/4%545%556EA75UE76%Q;6T!1?UI<8V!?7V!?
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MT;O`S[S"TL"_O\"_P,3#P\C'Q\C'R,C(Q\S+R\''U<3)U\;+V<G.V\W1W=#/
MS]#/T-/3T]#4W]C7U]C7V-S;V\O2X]+6X=;9X]O=Y=O?Z-_@Y]_AZ.#?W^/C
MX^'CZ>;H[NCGY^SL[.;J\>OM\>_P]/#O[_#P[_/S]/;W^??X^?CW]_[^_@``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````"X`#X```C^`'L)'-AKET!5
MCM)@N7)ES!Y/!@E*%)A+U:I5L&"IBC7QH*J/'W-UW&41H\9:O3YB5)4QXT58
M)E=JG"4PHD!>N7)V)%BK9$:6+5NBW$FTJ-&C1R=E":$A@U.G&C:\&%2TUHL/
M)4)H#2%B$D&#9CIH_1`"Q`J.$L]T*#&";`<OD-:*V$IW!-L1<\N*^.#"UL!1
M>[R\2('"+AA/'77-\)`U*UVZ)FB@@82TLN7+L+QHP+"!PP<.H$-OIH)VHID+
M'#:H[GP!3<&!NUAD2*V:@P4[KP>RB%K[@I@S%D"L'KZ!]W#0&EP(5$1EPP6G
MJ*>(`>.H(RH,H&L3+ZXZ`X8,-%#^71Y/GB"G$MA#JU]_(48NFP=3A^[\`<,5
MB;E,=%:_P83(@;!\%AH(&*B!17K9K:<@:!>D$0L5WW$@'`=VP/+51+70P-EZ
MG>VW'@8GQ`)?>202Y8AJG^T'`H>AM9:;06(@J)X&+\#62RH?>!@:!G?D-HJ.
M'&"`QPP:S&=DAPIJ0$4*&`BHP0J(Y2:13;OH<8*,"](&P@4]CECBEP*AX@&2
MV6%@YFQ`?D`+03_RIQT)0PGT"'9DIE8"2@9-4J1\&X#`"`F@K;BBAT"JEX&'
M&H0HI2J<>,*)*AW-$L:A'S1EJ7R&9@'FIE_!L">?'WB1QQU4?!I:!HSD5D63
MM''X24W^O>"!I7P7]-&++KW<@<&*R*6@R`5G>E<G:$^9R1]H'ISRFBI>Q,"!
M!M!^\,(9(J%26A\>8#`#%30,`4-MAM['*9@&V=$DH2=$*=`8&0@(&@9GW-H+
M)Z8:69\B!%V1'I`;N!!1%G0BQT(LCC1B,".,I+#G?A_DT0@C#Y.@(X^YQ?("
M:OQ9\,@N'YB@1T2;6"%1'K.IAP$94HY;GB[Z8<J!!YR\9I`J=5X0KT%5E$SL
MARA'](*I$]O:BQ4R8E!%1RX`C0)!C.@,&ISX?;M>!EZH$I6V7DVY2RT3[JB'
MRF#V@24&7J2\R[<A?("5!G@(!(G3&UQ1@H<9'&U0+7,KN%_^<@9Y.B`&N.&Z
MBT$XKJ=!#`7MDHO")H,Q92]Z8'PJ#8OLN5D8!L$'2;T?K`+VES2TB^D&ZA)4
M$2VHQ[)*YC)\NL$(M20M7W(#T9L@H>]&LLL(9&+0R(N]/%+R?O:]-HGH^Z&:
M<B_'?UB%N9]]AD$,J;R&BAXMMRC&YR72DCURREVV2-%C]+*;D=7WDL>N;IJ<
MQ2@+9U>Z0+)^V&4O,?('0FFPZJE>?54HP[Z04P+*]((&%M!1>W#%O?(HHEX8
MT-1.O+2+ULWG`^*A@M,P@*]>F"%@+IM/"*J@HPV@@!<7.L/8JF,0%NA(`RSP
M$O-TUAD-P&`(10)7:C20JDUX0#W^'L`"_QIX&33(B$!MD^'C]G`!=V$`"P+)
M'_':UHN<A:8^:!@#J[)C*@*)2R*K.E;Z:L&[['P@`U28B$'$EB/]E9"+MF+C
MLVA`Q!*I,#N=P0`+D5(+%+PP:W?<41=ZD9\.L68/JW`.!BX`K0TL$EB.',/@
M>*(?=YF0@9Y`4@V/UI'\&2D%9&*89S;PNS"D1P,TB%,=+0.&>FE`$FJLP@MD
M``,8R$`%?8B<H:8P$#W("(8I":$&(M&++8"A#YM(12Q@X0E&W*%9&OB:C3*Y
MF>3QTB!OFYK=\/,]U9`@#</:C)DPX`%/\**2'&C0*L>#!C3M:`_`^Q6T,A"5
M"^CA9[?^,\$,9#"#O(E0%Z@P550*,0$'Q,(3@[B#'>S0ATF@915O^`,I4"B0
M26``!GL`99#,\)I(N(X#:'R<\#Z$!3LT<4996(0B\B`&#YP@%XRXP(I0N<[+
MX,%ISZJ1>:(G&BIH,46B@594YM.A6(QO1R<@1``@,`<8``M8C]S`"<K0"P<`
M0``+D$`0A`"'F-4B>D(R'DXW<">9%>1\)F,$P#X4LX$\P@+WJ8$&0&##=2H1
M-A'QQ)&>105(K,(3>F#*U,CPO2PI"`.3^."[L+`+4]1!(([0@-I<IH$+#"$'
M`,BL9@-QJ]`AQRL&@44(@(0!J@Y$%U?`*8UFT;+]]&EUDYS^10@NH(A4S!4#
M(JOC'PQ0`5=41H,AI&=J-J2>"WCA-`E2#Z_P")H/M,8+&`B!T7I!AAK`RHHC
MB`'#ZFH)(1P```$`P"L>T8+A^8<@^-3A!KSP*#N4UT@@Y40LM(,<&$@$%;2!
M18PRT#/N[>((`-@!`)2PO%X``@E(>`)-+.HNPS87`R]`10E^.)^G6!A(-`(E
MC7IA!P6H(3>;2\X>).L9P,&F#@MX0\X^55=8K<^2[\ICO=+)T<A^J&P$&6D$
M5Y$M>#90"`"`0BX"@(2.)$*S"/A/&"3GX""M(!==`.$&4N"(1T#B$59^!`KJ
M59L/U&)\&OB=362``1;L06<88(3^07C!A@,<X10G#11XN%FH*RK(N`()Y(/+
MESG(L4H#G@"#!191X!(9Q`<`.$(O@@``0T@))PNX:@`P01#H%JG!S7T6!JA`
MBTYTD6(3\4(&EBLAYPXB%A[XS"ALQ`@+4*%I@M*`5S0!@2#'BL0K.F-_7\,(
M!/'KBIOAJ$'`(+K/@"`#TGS-^D9`5RMP8M!@,PB`(9"+4BSU<5"X:J(G0H@7
M>,<IJA$G!R@G$`0ZY3L7*.LD$W<'"XCS.QFPP!=Z@0)@:<!S$GE!)&CQG$66
MH!=S"$``'-V+,KA[G/&NSD0F41\[&PX#*_C=0&!P\'%>0%T&&8,%O(,!"Z"!
M`S?CE$'^LAT`2_0B"0`0!$%0>.3P-N`]:GP$&F0Y@A&\(`MV*-TD!J&(1?B<
M$.+I2"UZK@BB+V(01%A"'U0*"2^-X@=+(/H@4/&$S)I<(*L@A,^+K@A&,'`@
MHA"$)4:A!4=^1ZAF>A(>1&(31J!!#7!/`QH^)A%.O#T-:D`#*B#1UDT9)!"9
M34(O-`&`'DA)<0G0=B*00@M51GO`1GD#`"I`$"5D-A&8B,!CC6(02X07`+?H
M!2KZD`4KQ.`%5*C"'3KQGYJ6)Q0&`$`#9L$+""2`)C:JN@``(/B[4O!QB2NT
MC28Y.#8`H!3!GX@I=N^$7O#BOYF%0B\23^!UK_LK#<CL')S^S_F1#*[/WA>^
MH6>1?0``HA>67[Q$CKS[E[O>*%DERJ&M+A`D9/8!O3#^`GQ;E)%G-@?`<R'O
M1R*(!@`^`'``L'WP07[:=G4#&"D!P`8%9A"&D%D2@$)S`%X`0`J)$``)0`H"
M>"&8D%D!`((/."X&(7D`8`"[4('5-Q`HE&V[UWLG>"&"``"A4&BF\%TIUPL5
M*'`#(`'@M7B^5Q"U!@!K('XU>!D_V&@WJ&@CTG*RUWI+.!!1``"FL!.\((0`
MP`.](`L(H($`@``!8`#/-Q"`P`-M,"+&!P``6(6;`H:9Y0-UL&UJ9%6[1X1P
M^!IM@(6/,PL5D%F4IPE"&%X!\`?^GF<`N+<+EI=9G+4+;,`#F!5>"8`#!+:'
MY+$+O!"(+@<`$O@X4J!M@H>)`T%X>O@:@&B!K_`$GQ=>!,8#8XA[N;![`$``
M.<@+/#``&G@`#=``;D"*EV$0EB=PF:5RF=-GEJ"!"T"%F+@+"4!Y!!$(Y7<$
M=9!X!O!Y`.`*IA!>!?`>!I$(%:`$)B@0``8`$O`*>`4KGW-]UQ>"ZO@X-TB,
M$:`)RZ.)5B5PIPB,%>@#I.`*AM`#F=4`<P!@/%`*V1=>.]`+5YAH,C1);J"!
M.7A7$R$+N)=\^"$+7X(+KD`E(R(*NQ=>/D"%_F@)*!2*,ZB$2QAPF@4`"<`&
MB:`#`$#^!^@'7N%E":X0>SN`"[U`"I)(`6\0?'6X>R^8"$KP!/1H8%=G$+/@
M!A4@<'2P"SO0BUXX2:60!`,0@;"R"P/I:+D`!9LG$8*P`XF'`(=@"1#@``OP
M@KA0:[L7!-&8`[H(`!,`",38`+@@D7`X"W^@!'^@"8UE``:0@\FH@1-@"=?(
M!@;Q"I&F?=S7A`UPAE6G66S`:`=(@>6G`ST0`)B564DH$'.@BQ5P``*`>ZY@
M59DU"Z$8`!@Y$*6PF>:8`,18C,ZW"X&X>PD`<ZX`DP%9CAKH@,#HCKT0"@(`
M`1BY"X4(7CE``$*0@\X7B+I8!*_1@;TI$)$IA@+`!JL9BIG^I6BA0((`H`-K
MQF@,F7T@*`L-(`&7D'W2"%X1V0MT$'N[)P2]4'7$*($&`60"5W("D0AAN'LY
M0)'YR7LHN8??EPL)<'L"00<T"0!!D`M9R'T`&5X'(`LHI`GP*:#N.6!SL)G$
M.1!`MGM%U@L/*0`"AWRI&``2T`M_P)*Y,`L)T`#S"5Y(L'L'\!_:>9(NJH$2
M,$DH1XQM(!""L'N[5P$H1)\`,*&_^8X7`@0!@'R[0`I7"5X#@'P%$8,+2G`6
MJH$)@)&$)WVS`),$0(\HA&BZF`.#DPNU%EZ_*`L3H&V8D`L/`'D5@`"R<&0`
M``%MV`,&09_A)9^]8)(!(`#,>87^Q`B>!I99N^<`-.$*NAA>B^<*_)>D$Y&,
M?_`:G!A>Y]=G&4B,?FH*L4>,CK8+#4!YLW"$TH="`-9^.MD+DC>D7RB$NR<%
MO8!H$=`+0M"DO!![GOB0!`""<;"@"?F%GPH`FY>:X46GO2"=X64`#YJJ`."G
M$@"%F#@+4)`$D?H:.0"C*/20@;IM?09XQ&@`&.D*"%`!TR@002``O@4$-"D+
M!K&I`G>4KG``^3E1L/J=N8!H/+`+:]!HO0!@`=``H0`!`T!I@+"@[C>KV@:-
M)*>!CI8(C1I>!">%R&J*`[I*4"F($C$+";B?P$I1WP@`C0H`G"4+"9`#*SJ&
M&/F0*G?^"=JF:(,7H'&0.&VZ>]MWJ0'6``(@D\:G<DTH`0B@BVZPD(9(:;U0
MA\OJ6RA'AD*YD]]5GP*1H[M'<#J0H@2ZDQJ(`/!Q"0.`D9APH3X`LH<:!;IY
M@*:0`!)@LIEU?AGXD[T0B`!``33!"XFW>PEI$/:W>UX8B`6@@0.0!#11=94J
MA\3H`[/0KUBE@=L7G"0:7BH'9&T`MRE:"D^;63KP&K"HBWZ:@;ZYA`;1G08`
M`4^)0L\'!0?0"Y80EY"7&Y(7!:20603`"Z2```G`"RKHA1D8!0)QL`%6$SN0
M59E%I9L*``OP"J&I"8DW8#0A"X&H<KV0M^!U?@)A"KA0CF_^:)ZBV`LP20>$
M)W"NX*()D('@98*61Z,868&R"HR\T`!;.A%SX`!U$)<+(+T4`60_.8R6@`DH
MBI&U]G(9.(K(&UX\P`9OD'VF@&@P6X<Z"@$-H(V9Y98J.@`(H'Z'H($&<`@3
M(6#Z:0F5FP.F$`$=6XZ!8)X(X`J`!P!%A@N,UKB+=["5^9N:$(8^,`>6$`JA
M8`C9%I!NH).*XPIO`)CJ!V!/<+`[@$*S$(9T8'D2B`D`Z9TDN'A"B)']:HB6
M^Q[;V&B6((0]0!.[X*)`2(]4LF@```0*:8"I>@0#(``$!\)K$`H#X`"^58'=
MR)\#\)F)E@N,!K.2*@M*<(0K60'^0@`(_X%"`#D`08"1):F!TC<07"@`@[N=
MAN#'%6""&<@#?FR(BVP0C*:+#2"]]ZE9QCBI@1I[NDMX@NBD?\J2!O@?I0H`
M5N7!VBNR`D``BRNI!"$+EF`)EW`)UVH3I&`)%7D3;*`$1SD0KO`$4H".!>$&
M!)<+<S`'ZA<13Y``$T#%#7`)4S('3D!P!%$'1W`$]-L13!P%#YJL:Z!^L.$&
M0L#-40L%0!#-J$F-;&?+1X&7AC9!O3`+B+9[$\#%\D?/`#T2)*)$\%'08=P+
M@5"YXBI\OS>@!5UH#6DV]AS0#Y@Y.6R(^4C1&FW+!F$*@7@$Q!C.&SW2DBH(
MWY4(0`9I>1--TBSM>L8G`*_`NP?8TC0-A_YG`)J@">$E`<Q8TS[]?J$X`*&0
M"[%7`:OYTTAM5[UP@XUFG.;HSTD=U414>XVVA:LLU5A-1*5@CJ*0?9>8U6`=
7;;J9`.P<UF:]*;-`!W^PJF=M&0$!`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g299211kai001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g299211kai001.gif
M1TE&.#EAJ`)P`_<```($!Q<9&@@0%A(;)1HD)Q4I-"<H*2@L-"LS-SL\/#0U
M-BTP,!HB'A`M=S@\1"DY22HV>0\D83Q$1S1(5C-*=A=$=D-$1$M+3$1(2TA,
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M_?GV]O/R[=[BW<'`OH*!?2'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``L`````*@"<`,`"/\`]0D<2+"@P8,($RI<R+"APX<0(TJ<2+&BQ8L8
M,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.GSY]`
M@PH=2K2HT:-(DRI=RK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@PXH=2[:LV;-H
MTZI=R[:MV[=PX\J=2[>NW;MX\^K=R[>OW[^``PL>3+BPX<.($RM>S+BQX\>0
M(TN>3+FRY<N8,VO>S+FSY\^@0XL>3;JTZ=.H4ZM>S;JUZ]>P8\N>3;NV[=NX
M<^O>S;NW[]_`@PL?3KRX\>/(DRM?SKRY\^?0HTN?3KVZ]>O8LVO?SKV[]^_@
MPXO_'T^^O/GSZ-.K7\^^O?OW\./+GT^_OOW[^//KW\^_O___``8HX(`$%FC@
M@0@FJ.""##;HX(,01BCA0<'L,^&%?V%"#X8<ZG4//QV&*.*())9HXHDHIJCB
MBBRVZ.*+,,8HXXPTUFCCC3CFJ...//;HXX]`!BGDD$06:>212":IY)),-NGD
MDU!&*>645%9IY9589JGEEEQVZ>678(8IYIADEFGFF6BFJ>::;+;IYIMPQBGG
MG'36:>>=>.:IYYY\]NGGGX`&*NB@A!9JZ*&()JKHHHPVZNBCD$8JZ:245FKI
MI9AFJNFFG';JZ:>@ABKJJ*26:NJIJ*:JZJJLMNKJ=/B\_RKKK+36:NNMN.:J
MZZZ\]NKKK\`&*^RPQ!9K[+'()JOLLLPVZ^RST$8K[;345FOMM=AFJ^VVW';K
M[;?@ABONN.26:^ZYZ*:K[KKLMNONN_#&*^^\]-9K[[WXYJOOOOSVZ^^_C<4*
M\,`$%VSPP0@GK/#"##?L\,,01RSQQ!17;/'%&&>L\<8<=^SQQ^L*#/+())=L
M\LDHIZSRCODP)+*%%H;4LD`Q"S3S0;'>7-`^L>Y3,\T+Q2HP/C'G0_30,>,C
M\LM&"Y0S04+KD[34!2D]4,M%$VUA/C/CH_-`^]PLLCY-ZW.TV3R#7?/+8],L
M]D!C?YVJ,L$TT\PX^M`3C#\;XO\SB3GZT#U0,,[0#,PY9)\3#-7C-$/0.!OJ
MX\R&YIQC#CW[].-XWAOZ?'7D<!-$#S[*@*A//X`[;6&LF$N=.ME.+[2/.7*'
M=$]#]""^<SU@C]WSZOG$#'I)2\O^ZC\CJ&``(OIL0$(*%_BCCP?T3$+""('H
M$P@*'$RB#PHJ<-!,/R24KT\P'JP`B$"87"`U"B-PX(P_&ZA@@2&49*]/!_^<
MSD'D*\B$/BCA`1!E8@,6RD0*],&!<YR#!!S@@"$"!T%@Z*,2&Y`?^O31#.YQ
M0!G:0QP]_D&/9D0P>\H@@3[,\0\.K,!QP<#>AC8Q@@GJ`Q`<D!X__J$"O/F#
M`X58(?+_)L@/0(R`$OHX!_PP<<$-V-`0)&!>)OHWCA3\`Q"Z"T8@6N:,%`!"
M!9O01R:8:(@-G8,2YE`!/OJ1@D`X+A,HL&'@O$</0P2"A/WXA_<D]X]*"`08
M@%C</B9A",`A8G'ZT,2&Z$$)3%@H&).HQ.:",;Q5`<,"]`#$`L6(21*,8P,.
M[$`S+*`/3&P`$QRXX1V#N`%@H(")H-S$!1(0./==42#!2,`Y#"'%#5C`<1L0
M8#-TJ8\1*`")F0#``@TQ`@;R8P3,XX<%7`D,]#G#`^;0Q`:4L0$&!H(>FU#`
M.2ZP.'XDH!D;V`0^1@`(9Z3R`H9P!B`\L(\-^",0A6C&!93!_P%@4$(%&_0B
M)48PRF!<H!*!($$,_3&"0N12&2E`1#-(<,")-G(#S<!>)E2@#PND(!B%^)\^
M2&``$!)PC!;`!"!0H`\!3#`8F$RE!`VQ@7%8((4VO(`"SG>!213"'#U50?8L
M0`D6&$(9*;W`.1!!`F8RT(*!6("%&AI%?5Q`!21@(B9*RJJ6Y=*"^Z2:!9RA
MT!&`B`23Z.8X2!"(!4Y"!2D(8Q3%-U(F*N,"((+?!OHA$!($,1#9&T$F`+&^
M37A`'_\(HB]2<,U2C@"M/QRI.T&$#WJ8@P.`DQ^(3)E1@PZ.'MO,VP7,,0(4
M'*X9P5!H-__H66=@;X&%^$<@+(B"3/^0H'#8XR@E_G$.O*$@G_.PZB0XL(E_
M!(,?R!T!)L91N+9J,1BK%>,^4CC0`:ZOF(6@!"`N^TOH\H,$H\3<!@JQ@E)V
M,Q`C:*8AN@?"P@$B$)[%1%,7F`(H%FZ?**#;/Q#8#_>Y<QSDQ)LR`K$!1*J*
M:#T5"#FEM@\%D!5]@",!!@/'@2_JPQ`H2`$2)4A0!MJ5ELKH0##^P3QG(%`?
M/M7'`JZW`,Q98!P=`.$(+A"(`"B#$ASHQ_T6R`'HUJP?'`"1!PHWB00P5[5Y
MBUF,]2'-<>SC'Q[H9VHWD<K+\32)&0[B)E``"`$"`HJ(*Q\*5QL(O/85!?Q@
M`#[==^$$,!'_Q0G8!R8"@8D%IDT?B$B!,A1`#TPL@`,62"4^QZ%'^8&RQPG8
M$`H"4=[4^N(?_6@F)31L@<4IPP"8\$<'!@A/)*:@C8!KY0@LN`\6[,,9[AO'
MJ"7HQ+X:6%4US-L-1X`/1*"`I7OM<3]`:8%]_)!^^FCC':WJ6B;^4G*DQ'$I
M25D(ENJC$).8Q`B"H0P/D+&T^@!P)D9,@LA.`@`<O8!K]WC*VYH3'SAVG#)&
M4$^^TN.#K5SA!9H11'W03Y\P!=$^4@`,]ZV[$-F;A!4%J%P4+(X#MAY@>;$J
MD.]F+QR8]/#B3/GL$0!NSOP<R`J@FX))=&`2_B"!.9JQH4(8XAS-_T2!\\;!
M`9MB3H(JA",*/$#235A.'RL(A(4`+%_'MC78VP-K"J6WCQ&4L)OG\(`#KSS2
M5Z,J&`9@P082L#X")^`"#62!X@+-Q$ULX`),5#D)>FN!$2R0K.,5")"36+X>
MZT,%2'RV(5(@0!0W<QP!L."D!4+:0'!TI"SM`#_NNH+XB?'6@*"'`4@@6W=>
M&)X;4.\%J%S>ZT&1L:GDGM>;R6%#C",!P-B`,'!,"5K^H[XDV,<%".@/0Q@`
MDOS<IR'V<6MFYC*&A<!$`/RNB2GBG`2N7$'[<'D_9PL$$8A8^SX6<`%Z]%JH
MZ^4'V"5XZM(_F035!@8'*)'6=P,#K<`@:/\!KWC)IN?M?_00-R6`OP%^;$\@
M_605/LRAN6:D;AQXRT32'7<WJHUO<*FC.&:31"`D$/10.'D##'B##^<0.8`0
M1)%#.GEC#A9"@623#^>`.C0C7H7##YD`0K$"#!;$#\4`#)A0-\TD.88@/0*1
M"88P"9$S"8"`1-`E-9E`9Y2#/W]4"-*##X90"(53/8'`5\!`=_9&"784#)A`
M2(5D#G94.(`T>\WP@P:G4F8S"8"%#\%@05Y#"9G`A0)!-^9@08&#";N6;7F&
M.,%07P+##V'DA*]T/G#%5YE081O"3'YD#BM08`RT./2`"!L"72)71,\3.4!8
M*SJ##V,7$;73$('_L$<500\=@#<.D4(#^!">51/:!3L7H4\_(Q(Y]!!M\RI<
M<S/[X`ZC"!+F8#J1V`RIB!#G4(`(T386<@Y^=#6S"#6Z>(FQ,S7%8S.X&"O.
M0(8M\XI!LT*(8(P&\8F[R(FZZ$8*H8PK,XW4&"726(U]0338:!CTX`[;.!C;
M0`[UP#O?&!CUP`Q;6(Z"<8Z9P%?D@@_DN`[M,`_U,`_KL`[GL`ZKLP[TN"'K
M,#KF,`\P8Q#:V#;7^#6-&!CW<`_V4`_,>!,):101.1X3.17.\`5^\`R*L`5?
M\`5_X`=A\`<?^06@H`B/X`>*L`J@\`A7\`6/\)*JD`BJ\)(R:9(OZ0B/_Z`*
M?D"2H.`+?N`(L1`+EN`(CK`(H("3C+"2<?`(_.`,_$`/[#".\&`VXPB55K,/
M]S`/HQ,Z5+,S9H,/\P"6];`TO,,[17,1,_.0$'$S,V.*&8$UC,@2C=B6N*@0
M.M,R"8F7=4D1%8D1:FDS7",5@=F770&76",WI8B7@1F-%[B8,\$-1C`$U^`(
M1[`%8!`&7.`%81`'70`*I6`$7$`$8J`$8=`)&\D%2L`%9E`&7F`$7F`&4Z`$
M8,`%8[`$1J`$6]`)99`$4\`%2\`%1Q`*OCD&9#`%90`%2H`$90`&[>`(UT`.
MV9`-[3"=ZI`-W^`-V2`.\\`.W-D.WM`.]7"/_/_(#NW`G?0`E=M)GM<0G=I@
MG=-)GM'I#>Q@#JQ3#_!0E?5P#_DYCO,07.,(C_UYGN>IGZ-3H/LPCOJP#OJ0
ME?3PG[=C,_3PH#:S#_0XEIPSH+>C-`O9-P/QH/<0H?7P#IASC1+ZE0NIH<=8
MHG\I$"7JF`8AH?<0,Q[J$25:$(3)$0EYC5-QHUF!-?O`#UP3-D":#T#*,_F`
M.<$3-F$C-4IC-/!XI%9#-F%C-/G@D%[3I"QA#4NP!.'@"5)@F5Q0!IP)!KY@
M#%^P!5-P!)T`!D/0!-+`"*7`"%\`G$B@")<9!U[0!%0P!680I[:P"Q3`!"VY
M!7BP!:Q`#'&PG*\)!F#_(`5X\`7;L`K6X`W><)V5J@[82:G?T`[P``_J@*G?
MP`[ID`[P\`WI4)[JT*GDF:KJT)[5J0W?$*OB\`W9H`VP^JGKP`Z?J@[WP`[P
M$`_J,*JG^@WK\*OJ(`Z?2JG>@`[)FJRD"@_>\*GHP`W<N0[IP)WW$`_WD`[Q
ML`[Q8)_Q``_KH`[,V@Z?F@[H\`WPD`ZIB@[K2JKE$`_/6@_I$*WHL)[>4`ZZ
MVJW>ZJV_JI_ED`X+J9^CZJD!^P[K\)_ZH)6=.H[LD*[L<#OU"`_P6`\->I_V
M>0_K2JWPL)#UT*WO$`_Q\`[KNJS1J@[=P*S>4*R>&J[P(*HLRYWU@*GJX*O?
M_]JQV2J5]]FI-=NQG1H/#;F?"RFN(NNQ/-NQ_/BOXSB60Z,T^)"A7ZDT]9`/
M"PFTG7H[6"LP3,NB7(FU!P&U>\F(#QDW)Y&(8#&8"]HU!*D/]G`U>HD07!,U
M7E,V.KH1QT`$1*`,>&`$1X";6Q`&JP`-H/`%0Z`$1[`(].`(9J`(1Q`#CA`)
MH``+78`';X`#MQD*81`&K@`'K-`$$!`&7A`'L-`-5Q`#2C`$K0`+K(`'7="Z
M9J`$24`%VW`)W$"KZJ"NL7J[MLL.(OL-\<`-W1`/O/NKHUJL\KJNW\`-Z5`-
MU5"[U8`-J$JKX)`-E,JLN=NPGKJMJ=JIWQ"LNWJ=N_\JK9_:O93ZJ\0;#]VK
M#N$:O.NZKOKYK>B[J][@J;MZ#]NKONK+K9[ZJ]?IJ>A@G=<)#J:JOA]+JN$J
MLC]+O-^KKN.J#[[:H.%Z#[[[J1WKJQ2K-%$ILO6`N_)*P9UZGR*+OMT*#NB`
M#LU+O=60#=QPN[OJJ>F0OICJJ=1;J?#0#>JKL<8:OM3[O^;[PBT;PLK+K=Q:
M#K1JJ=@IP.P:#^5PG@O+#F$YCO,HM?7`G?!0N\`;KPRL#OG9J>4YEO3`CPN[
M#K?##KFZ#WT#CV!LQE8C-+<3@4T;-KRSE08X.K_(Q%##.E!*CD[*.:(CH*PC
M,`+*E0A12051HY4E-W<V$_3_\`[@D`S,`+SIT`WK4`[C(*KGF0^`PX#TL,0B
MB@_V<,@;8K&>_*/W4%E@?!#",SHU&A+$4`,X4`Q=(`5>,`5=<`6*P`Z,8`,]
ML`2Y\+Q%"095``,R4`40D)JQ,`M/4`9,8`9?H`U7``8N4`-E\`(UL)2O4`SJ
M$`VC$`-'0`380`Q2P`52D`2S'`;L8`G`&ZNQF@VI"L.?.K/82;VUFL+/&PTI
M;*NV&@W$H`W$D`O1L`NPH`W24`W1H`W52;WCF[[L;)^Z&J_O4,"^R[W9\,'=
M"ZPON\Z?^KX4?+/Z2ZK?8)_WJ;T?K*H>S-#ST+#Z.;,(#*SJ4+N46KLMRYW/
MNI#Z_]"I25P.K-J]*$W3^\L.ZEH.(ZV?'INJ40G2M>NN[/`.Y:"Q13NT]*NI
MUED-KNK!W/FINDK![&"=-,RS+KNN-3NSUJD.X*"^P.JK+`R^/,NJV)F\M`K`
MG^J=VTO%.YO1&WS6[!R?\JFJ"\F[S^K!1&W!+US4STJJ]M"Q^0F_^KF@"[JT
M([VS+YNJX=G86$NO\XNSOQJNQONQ^WFQF?V^XDJR,]NI."VP!/P.`ZNM&ARB
M4<G4MQ/2_SJPHJJO^9D.^PD/2\VB)>JU'8HS=GD/?1DKW8`+IO`$>_`&4?`&
M71`'<T`':B`*I"`'HE`%IR`*J#`'5/`&GC`'DA`'?)`'GO\`!Z0P!Z(P!XR0
M!WCP"7'P!J=@"YMK"JOP"JW@"8PPW^4M"IY`"G%@"?J@"[UP"2"1#%6P!>OP
M!D_@!>$,!KEP!42@`U5P!*M``7>0!$8`!J%0"E]@!#DP!3;@FSG`J$N0X420
M`ST``3B`X*3P!3B0FR`P"C;0"42P!8G@"5U0!5ZP!4D`!N0`"^4@U5I]T.S,
MJE+]S=#@S\S[G2ELJ;O*G>B`G;":#00-#02]S_P,#=$@#=$0G=%9L\FJP?@;
MK=W[#6,-K=V+K#7K#=5@NQ],JCX=K?:YP>W[JS.;OM_)JC6;P=U*VUI\CZ6J
ML00KO-_`O!:]KO2JKBZ[H#\[Q>C_^M>B^K(I?;0^?;6\,[`\.XZD>@\G>[O[
MV["'3;^8BIVS6@V:NJ^EFJHG.[^QJJFW^ZT?&]>!S@W,.]$@[:D/F];=FPW,
M>M9G_N<&K>56K:O[&Z[L7*J_2JFW6ZG*^J\?O+V>&JTN>[RCJK'JF\#U.JHB
MFPXDB[$8:X\1F^RQ'JV\>SL?K;'A>=@&+.Z-#<+R.L78;NKKBMH:"Z\O3-L&
MK*T#RPW?V@[IH`\J3=&T;;Y%2[(^G:KRRJ[<(*Z\L]J^R@XCFK$+^K1F(Z%5
M6LKZWJ$T':.\75D/R@VXD`M5<`=[4-QZD`=N,`6,\`U6$`4_\`-CX`/J/0I6
M``5WP)IV_P`%>)`'>Z`&)Q\%46`%;Q`'GG`'5F`'3R`%92`%NS`'1+^G'>\&
M>!`'I)`/;M`#C.`1+9,,3T`$QI`'?"L%2A`*NB`%>C#T%+`+H_`&1I`$ITL!
MTU`*\MT%G2`%3M`*Y!`'3$`%<7`%K3`'R0`+0V`$4-`#1W`*D4`'+C`%3<#,
MW2`%1C`%$KX%U'`)UL#CZURKM0H-E/J\E'H-]SD-WE`/YNJI?\ZIWL`-2\X-
MMFJ=6/Z_E(KEV"D-NP`-NZ`-QA`-UR"?6ES%M>OD*ZP.TE#LU?D-UZ`-JU^=
M[.`-^LL.0'W9/$OM[3N_"1VJ-`O4-7O2]4BO(=JP\VO`H&[#E?_ZL>'ZK!A+
MKVFNKB?[K3G;L+PJKE4,V0E;M>%*QN]`VYZ?OOO[SL9OO[K[J0#<UMY`YK3M
MK@`!CYTZ;]Z^%?P&SAL\>.KBJ:N7[EN]=>K8P3L(#]RW;^H8UE,7$F3'ANHZ
MAGR8[9NV;-D(#@QI45VY;P+CM8M9DF,V;]FTA40',MXWB>E`8A2(KB9$@?"\
M&:T'+YU%>/>^O7O';=TZ>%NYLKO'[MV]>O>&LHN7+AY->/'6331;MJI3>'+3
M,?08-5Y4LVF_E6,8CR&\=^7NW2MY,1YBC]_BI1U\^-Z\=?5&KKL6[UU;D!XA
M%VS8%F]@AAV-FJVZV>34=O4>UZ,WMNS_8<OW])'55R\?/GWT]/T&CH\W/GJ\
MN]UJ5:7*GCU4WNSY%"N9*#M1HN2Y8X7"*5MT>HUZ8P6*GE-/[J2J0J7*FU.F
M;/&Z\>1-G#=Z[IC:9>J-ESME](!_8PYW]N@!%.`.1#!!!16DI@8<C/'BB2>D
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M1M[808TF%G%ZCE'LJ.$)3YJP!15/3/'A!AVJ$(4.7NCPY(X;JM`C#EBV82,)
M*:0X)992O)C"BBKPN`,/4>[)(PA&],EG0=EG!RZ9'8@@AQ$CP`##B"ETZ`26
M2(@Q9H@EEIA"B1R,F..)!JZX8I=50/$C%[WA<(25,,*`H`$PRM#!##"X(&+[
M;N280Q$OC.#BB$ZZ>**3=5I)IQMM%,I&FFBXN8N@D)S*!CRZ@8W!J.,:WD"&
M,;`Q#6A48QC(>(4PC!&-7<!"&])(1BYVL8O_!A)#&MO0F3KLEXY:#85_:=*&
M-J)1#750`V4M\08S[B*F`];/).I05#V"YD*CQ",W-[M'.OB'LGNH@RQW64<W
M=&:8=82%'5-)!V#JHBQ?03&*Z>#*/8)6E;+\9E26*8=6#C477AWF-NR("%>X
M(99ZZ,.']WB'44K5QG4(YAM8`HQ'XAB1F!Q$'9[Z%JY&AJK!I"4>[4I'N[B!
M*W)()1WC8(=6#O-$--+$&X(ABUO@@2JBL*-=H:')0V`VC1M^RR(D$T@]T$$.
M=K1C'I_T!DX<XDE"40MH:(RB1Y12J-`8<I/S0%E4[B)%(M*F+$TLX\_HT124
ML:,<@AG,$RU#K+K,_P.8:JG)1<A2#G0\4367M&%5//FQ2PG$((X9%C7TT9#'
M$`5E=RE79U8CDD.:I"8-V8A3=H*HL,EK:AR!S%TJ)IC:H#&(6*2($+$XMG)T
M`XOT:&-N]/$.R_QF'UNQA]=:884[W"$*5;@#+W3Q!#+4@!7WTX0;7#$*)M3`
M#D#H@15^T`LG5,<./TC%'7[`@Q[LX09.B$,I&'&)=$0#%3HHW3=V0;<]T,$^
MC+B'&EX0A]O0SJH*(H8-B#"-3APA%%TPPAAJ``I'M&&D/#C"$WC0@"_LXCVD
M2$(2N.`'6(#A"U\PPBE(L84>$,$)TC"%*#Q1`QE,P0A&2((CFG$%8U!!0O\Q
M*,,;G@`&:Y!"B!N$QMB\$:F:7:24U8A&0;#1P$_"+)BU4M0WQ.$3:O2D:KA(
MQ@>+H0MI\$1LY:@C.<JA#Q&"=AII(@9+T,$_>$0#(BCK1C)8F`YMN#`M$-7'
M.MYAT$=-$RV(:6)9KLB5=5J#'+:AZ%[*00[IWJ.)(4R'E=*!E764@R)AL8Q8
M)$,FADBRC16=S1$M0XZ,4=2]PWK46,+8D&X@IL!!J\=TZP<3!N_K*>5HAWN5
M8C24K<,;U-"7`0O"#6[PI2LD9`<YZ$$6<HRK+J.:QX>98:DH8N0::L15-^S9
M+HNDV!ZH:@=93ODH:@P&)(52AYC@H124/=,O(#'_F3?:>\QTT&,=^C!,5!),
MT=S`D2M;F>24(1J6=;2C'0]!,CN[`IMCQA&>BXF*1:#"CA!ZHRS>P,<\"@4.
ME1`$'BZI!C;L:9BNN24D\A+(,[EAD-)<+22KZL;8L(@.<(!#&GRZ(#B:"RBP
MO,.A\-A&19^,&+G,-[_WS<VH>#4/?#249.6U37',JP][W",9MP#'$Z"P'"^<
MH@YJC0(/7.&$-^3A!S_@@RU.H88&/($&.OB!#IY0"CC0``A`H,$3;!"%.?`"
M%59(0ASF@`57Z.`..J!"*5PA!3VHX0Y4.(4]\A`%4ES5W0B*AH.FT;M02.$)
M24`"-$@!"U%`P`A;(,(4_TCQ#5"$`0[)V`4.N-"$(TC!"$J80A*4H`0;'&$=
MI)#"%9XA#37L@`D.AX`NX."*./S`!CSP0AQT`(9UO"(9RN5&-N[!C=6VY&8A
MJ08QVL3A(-;$U8,8!#E<LPU"9"$9ZXA&*RZ!#7"\XA9P:T4RCG,):W`C%VS0
M@I1>\0IBE&,<N"!(-NHQ#4)8`E&NB,4M;C&,>AP#$I;H!J!?T8@><Z,8'7Z'
M,-KQSG6.HRO&VBU$*T.;*VU%Z&)A,T;0&`\GNQ$U(Q/B.KAQF*9$I3*62187
M>?8-)_.%-K:)J(C-R/@FHC$WRBK,OMBQ3$IIK#6;-:)`"D64J*##*(D?3%NB
MV/\-'WJR:F([_5C6X??3U..)B"',.@^3+,L\A2@>N4<WKO'.=-CI5NMRY6PB
MTHXX&S^ZDQ^,L[Y5KFU<,HBYK\NCVE)'$M-&++W2ASML<P][;$;*TO5F@L>Q
MWGI\=Y-"%"&&<*A2N3VY8+.H8`@AJHH1.YC%Z`USX(MVR@NU:*ATV(B(X`9W
MR)21(`JMB(=NB(B&^`92.J2:``=JX(8JH09DL)[:HA..T**U"!JMJ(=K2"@V
M,R2WH(@GJXVH``Z*6*?L`@ZR2+`RN3QX2)M[`(=DL`4JN(,I:((NX`4G<*HH
M>`))T(544(-?LP,:$(5OL(5E<`17R(,XB`,F=`,GF(7_1X"%5LBY"D`#,G@"
M)QB%_""",MB#,L@#<*`"**@/-YB#?N`#/HB$=WNWV.F&.^B$::`"*<"#))@"
M+I@@..B"(^""$-F":!"%+N`",P@#,,@%1NB"2`P#+I`"3X"X(9"#6(`%'`B#
M+?@#.,"%4]B!B?N#+NB$5:@&L$J"E4L"W'D%J`F)=GBRAC@7;\"&:&`30'&,
MO;`P>+B$`\@"#"``9K@%`IB`#QB`2X`'!P``9)`&`1B`8/!&3>"&`A@`:["$
M`M"`#'B`5R`'`OB`>Q`$#5`':?@&8GB`##"`#A`&!S@`!RB`+(`$!)@`!W``
M9N"&$T``@;R%36"`=2@&!="`_ZW`A[)8%JGH&2RJC+1HJ'>@!R62#.V2BK#@
MAFV`A_I+"ZJI"27*KFDBBU;"(OBJ%(O!2!^DC=MC(]-+L%@ABWF0E8Z8OHA0
MB[IXAQ+3F2:2B8L@"F\8!VH`R7<XB<.(HZ;AAH[@!F9(RN^[/(I:%LJKH[H`
M"RWJBKU@F<'0&3-S#$"!%W4H#&+$!N/[B!K<.TP"B9:(!K>8/(<H!ZDD)=>X
M&`LS";%X*%1IHMP8O%C!BM^P,CB"*./SKS:2"L@(-#HZP/FB"9I)"Z'C"WQX
M&5Q@!CA*"UVP!<](03C:AF:(!W#8!6O8I&V8O&M(!L<@AG=8"Q(:KYGAAKP$
MATCYKO]N8(9QP(;86A1XB!J+F<$P2K1NV(9E8(9MV`9RF(;V6J\P6H??L@8,
MFXJ+("$B3+#;@*[>0"ZH`;U[H(9;L(0GJ!LJ2`5?VX$?V`%7D`8XJ``Z,!T@
M"((?H``^<(=+:`5&0(5CP((YL`5&<(1+B`9=L((HN($HN(,G<`,=8(1N,(4<
M>((;J`$ZD`4IH((]P`-&L`>I>AU#?+=D^($A6`91:``\P`,HC(4KH`(><`$=
M2`(<>`5HF(*4^X).Z(1$T(=H\`0>>((OZ`(K4`(I,`9]L!T\`(,N>`,B.()J
M2(08V((8P('=8015D((I``,IT($MN(9(*!..J`8L(1E<`1C_<:B(@^BF]*L,
M?3B`$]"'8Q@!7-"`#:`'>C"!`#B&#!"`18"$`4``:9@``5B#5QB``^"&!YC'
M>\``"5@'!!"`6S@$#2B'*<F"`E@'82B!%1.$`Q@O!,B","$`%="%`"@&?>B`
M%-`$!*`&!_@`8LRB7LD\LR0S-WHF`&NCD5RG5!H5BJJ+08,'2HN5NA"(*DN'
M>2B+$4LE8_4--@,]P1A+Q)`,LP`]HRP+$"(($JH?4[D-L^F_PSL*J>`?=+`&
M;W@'*+N981F(!#O7BXB*K(C6_'I3HJ0HA(J(46$SH_@(ZAO!/FF)0UL(R;N'
M<?`[R[`(RV@Q55D(<+&(,+J+$$,B_]PRRW4`AZXPFW;H,/,B!WN(B.FJ!X\M
MBYB1#'U0UEBQ#(HR!U/)I&YXIKF0"ZS`(M_+BP1D!NM\IFV8``1@Q[^0`&Q$
M`*D+R'2XA`#H@'X@`"?0!T@0`#:`!T(@``)`@$BXAS60@*Z0`$S0I$$H``(`
M`6E0`0*0``E`@&&XQ@=X`%TH(A,H@`,H@65``1"(AU9``&[D'ZP@PL4HV6'!
MBF&1O7=B3L`@H;+(!WO(!SC"V+7@,-Z;N6$8*3S\`2`@@RAPA5-HA6G0`9B"
M`NO0`37(`QUP@2>8@U,HA3R8`VN`!3DXA5/@`VBC@3R($#NX`R_@`2EP`G=@
M!%-`A2?XJ/\IB(,\*(-2B`<U"`)1(-$2I8$:F`80(8)8&`4(``,E8`4N@`(C
MC8-O\`(O`(,MV()2"`582`=EJ(=>>(1YT`=8<`0.,X=HB`-/`(,CF`(F!05I
M0*H>X`(WT(,M"(4(4(504((8"(-U6`1RN`8Z.S1V4,9$F1BCD(BYC(ID((!-
ML(9DT(=SI(1YL`9?$`!A^(`)$($0"`$'Z-,)``$V.$AA*(!&T#E)&(!7T``1
MT``V*(%[8"%Q<``!>(!:D+%!0(`*/H!@_(80F(`TD(!WX#Y]T(0"F(`!2%5E
MH92RH(B]<`U]P(?!*XN&,H@G&B]@RI_ZN89I*%/-VBQ$<9B/T+'_JC@O?#`F
M4S$,DK&-VWBOVN@-P]`8<Z`\,THEOX4HB*J_W#BQM.@?.UJ6RAB8MBB,>&6]
M)I(5C-!;T.L560&OL?C64:E6DKF9B^RAK1$((;*238:'V&`6-!*G$TLP5(F(
M#!NBNZ`H+<(B$MH&BEJRQXA8@=@*X1N'L6@UB!(ZE"69<J&RDD$F1]+;H4"^
M67X(9X$(LV"*5+Z'#I"`>]B$`&`&%4"`;;`'#9B`82```9"&$P"`#E`&`2B`
M82A42-`%`3B$>6`#`7B%$@"`1L"'`9@$?4"'<&Z$;C@`1&`&2"``$[`$95B`
M0+`&+1@`:F!;9;`$=D8!#0"'`3"!*F/,_ZJ:/_DCPO1CM1&C!V`>,"%ZH_F[
MAWPHC.6CAKCKAF*PA1_0`S>X@1Z`*6C0@6&P`C3X`2N8@F-CA?98!SGX-2M@
M!%>(`CN@@CEP!2;H@1M0`VZ8Q5+8`1X8`_%0`T_0!0K@!2:`@L;YA%$P`SB(
M!SZX@78[WJL:!AJ0`G*0+"+X`EFP`C,P@RW@@A[(@2TX!5;8`CS@@BZ(`U#(
M`T9@AGDPAV6H!%50!4L0AF1)!U!@!%+`@\_A`C!0A%V8@R(@`B;P!"DP`RB]
MAB9X:S&P!D9H!V\`!XBH!T2).8]HAY)10&5I!P(>:0)8@PHF@6V0``[XC4`(
M@&W`@$;@64N0`/]F<`!(<(`':`0%Z`<$T(*Z8(,#8(8'&`800``5F(?/%@9A
M.(83"(!E4(<5<("U((!7:(L.&`%#0("LJ05EN`4`6`01<`#S*A?0V\$\8HAK
MP(9K6,'DXKUE&)MM*(=KV`;A1)/?(H=MF`9DD)=HL`9HP(:J^2-LP`9Q:#)8
M7I8N2K`ETE>((L;NO(C$^PU[V+3YFX=&PC\VPS+SHLDGBH=(P1F!`"&0,(BA
M&;P10XR+E`J=T8R^A&-*5CXTNC^SF5;O(Q6!$`ZLD*):(0BEV!>=.2/M:H?>
M^*)8<;*T>(HXDF)T,"_VT@<T,INX<*,O2M>@@2,ZQ@J>_#SO\R$_OKS_Q:#,
M]$O<B"CD_[$]1U&+#XR'`X"$M?"A!""$F;.$%GZ``H`$#6#'8#B``G"$"9B`
M0C`$!="'=K@&`6B$+#@`"1"&`["$>4`&<\B``@@!2+#F=R"`2]`'04B`>JB&
MAB8$$&@#??B&9=`'(7Z`#F`6='B()WHD%T('='!9^9H-K*B-K4BQ786C=-@[
M7Z=DE9&(:!`&4J`!/?`UMU8$74`%6R!J()@04NB&77"#+I@#?7`"6?L!)F`"
M*P""*-AI"OB&1<`;8AB'.8@0>RL"8F"$I=(!'EB"_X""4K@'*Z"!$?UJV;$-
M7:"!)+"&-^"!*9"")I`&.H"!H!H1P;H;+^`"_SSH`CQH!0%RA":0@1F8@09P
M`1A``C\PAGJ`!NSHTB[8WCA@!2_`@2,H!2F(@5#(!238`BD0@S`8!T<X!W)8
ME&PXDVAJC3.FAFJP!F1`!H(E!#D'@0`PAT@0@$&X!`'0@F\X@%8-@$Q@@&,P
M@$9X@`'8!`$X!T'@\TH0@$#@!SXM;PY8!VCX!A,P@&T8!`:XA:IE``[3@`,8
M!J:%A'%@;5L8@!1HA`&@AVT@`$)@ELF\ANQ$AFI`06^8OJJPDB*"XJZ@*(J@
M!\J@8I!L<LL\"=&X(W9`A_9ZAW'`+=N#3'S(B@V?R;#P3NVK#=M(3*HDA]3^
MY"[2F-KH'\!8Y+:!L/]]B:/+NX?)OQ)9=3)Y<0>\?>39X,%3XQ_I`E>#,9M3
MJC3)"XR&'302/S$W[K^MP'%2D2;B6B28X9E\-2]K@&*-8995MN(JBRCIBAV*
M$.6R\%A'-B_+`*8@\HB[X.0J289H&&EF4"YMP(8_`0AOS)(EX\8MVK)DU+@5
M6'2OV[![$];`N\=HP*L'(B90`!%"%X80$T1D$63(@KYV[`P<ZJ#BQ(0"ENJU
MXS=LD(8!:^S=&D!H'2$$]]*E*X#H`IMZT;RU,S%`A(16ZKQEJV8M'3ENTZYQ
M\]8MVKA[[,J-6U?O[#I][][5TW>OK;ZX]=YA-7M/[=U[;^^54W8*R!,K0.S_
MS.DFR0>/*&2F-+&5JTN5.'F>.#+VZDF5**.DX,$318>G7:28W,G3Y8LK:5N\
M5+'C(X^I>&[R6(ER9XJ3>*CXK(KK^S?PX,)]WQT&9`JY/%"@2%'"2H>-'*5D
MN5BU:\F4)U[R>/ETL(@.&2Y<&*$"P04,&S@>+9/D!0^8)TV4A$EFQ8BV,$(@
M*&*$0TES88SC2#O6?/,--M[4<X\Z\+3CC8/KB)7.0NO`<Q8[];BCB003"!//
M-Z]\,`$ATFBS!B:0!%*,(,RH<`DE@O23`C#EK/'``XB<,TX*S.@S""+M5%,-
M-B<X\``AZ=1C20?I=+.-D21:4P^'$H`PCB8="$-._R,3W$(.-<Q@TXTWZ5P3
M3SWPI"/A/?:L\\U4:<)SX3WPT&7..OC<@\\[ZZP3#YKO<`,/A';JE0X[[;0U
M%SSLS%-.,M&0D]4ZB-YCUEEQZ>5G6Q+ZN=8]?69Z3SQZU4G/HFC6R=:<2K*C
MIJIBT4,..V72@VH]I=;##CH7XD-/.N5D6$\^BRZ*CUOZV%F/G_.D\]8[R:XS
MSZQS,CM/FNI8J*8W"I[UC9)G;<I6J._D0^H]])2SSCMPI@//.MRL>19=[^BE
M:#D*IA//L_HL2`^H=S'[3CSZX+E.-TJ::DY>9@E;SE4'71/I-]-@0Q0\():3
M*\?P?D,H.FBF@TXWW<!C@O\#U!P2P#!9''!+-`]H<$L!D`@@`DRW7)`)`&R8
MX$<F`D!2CR,`O(*!">5,`$`K<2ES@"[W2"!!/,L,`,D]MPB@23V1#'","`^,
MT\H`K:C@@#XG%%".LNS<I<\\L;Y%CUMG(4O--5<![*]><?V:#SWVV)-./P77
M0^W;?`G#2P,_G$)'!7DXH<8-/=!@1PV%9:9&%9WDP40W^T33A1%@M,(($SZT
M4HX]3NR1QQUWV/'&-I'$4(8--_"`!QR3O:''$U!XLLX;49`R'/+)`Y?,'F",
M8\<31N2`PQVH4&'#%[F\@$0SI:CQQ!UN?`)-)#+D8,L=/#`!BS56)"&%+%5$
M\(7_-G%(`0;I8+P"RPLX)$/$&<(0BBD080E'H`\S2%&K740#'O.8!SRNH0YU
MI.-6#J+5G)3E+W+4R5_\(L92Z&(/=42#*&_Y1ITJ110E$24?[CA'.[!1D&Y4
MPT)A80>BQK&,@51#'752!S?N<8UN("@7;E,2-X05#5P08QC6P%5;\.0ONV!J
M'>4@2C72D42MH(,<Z2C0-M9A#:Y4`QK6H$8YN%$-=&0#&]4X$+_J@0][A(H<
M?JJ(G]8!#6]@(QK5,%E%YK*@@;F-7G-YASUN]0ZZB8LM\^"&A.A!I[4,4EQH
M*D<\UO$J<JCC&NT0HY+TL:ZS6(H=['A'HUZU-]_L@VYQ_V&+H.9QRG=@2U-N
M*0<ZY)(.MJ!#D^SP4[[J(<E`UNDM:(D'N1;$)GB(PY2*XE0AQS$XMU!#DQ<Z
M"ZHTB4QZF(,>>JG'QO)AL$2:PUBZX@97O#'$:$1#'>TX1X;F<:E*2>A"^3!7
ML<QBKWEH$E-LJ<8]MA&"#A$"'MQP``(.@`%F*$,!MU@`)%2P@6!LP!H,P$0*
M_I$/%`Q@`@\(A#Y&L`)]7"(`F^B&,L:Q@0$DE!+Z&`<!N)8.0@C@`0580SFV
M(8$#/``#];B1/K@A@#6\E)%*LHM;Z#(W?>Q#'_CXU3S&T0UFH)`X;7$'LN[Q
M#6YTXUS$NL<\]E&-6Y#B!U#8`?\X:O"#-]"A$V3H@Q5\H!L[T(8*I[!%'DC1
M#W[8(Q+)$*<IHO$.<@S#$Z'@`Q6H,(8Q,"(;/O#"$\C0G3@\P079J$(5:L"(
M>SSA!<=3'FB'DXP:%($;5OC!%)K#A5+$(`E&*(<H9,">9.3"?KS@10P@$`=7
MX*$7TNA&,;JQ"T8\`A0[@,`C>'&'+83"$MV`QA%R``M3Q(`(5Y"%$I*0!"70
MIQR1((<Q=N&-1)E#)::L(#O(T0YT@#64IN*+-;C!C#!Z@UWO8$:WID$-;ZC#
ME(1JAS:RT0TOQNL=['"G"M.Q#&I<A1S>6",NU^$-9#!#7MZPQANI(8TE&N,8
MQK"&LY3_!`]U6.,8T[#067K%EG6,8QOD*`<YML&,:M1W759<RSJ\"<$_Y6HH
M6HP'F;I5C6APXQO4H+$IL34MN.3#A*VZAIFZP0UL*NM";C'FX30U#TV)BY0+
M,F:\L#4P>#V+*-^0I3CJD8VY7!$>:JED1:!U(710"WE[8@<],F2G"F)K3_I`
MU2CK\2Q-3J@;Y:`EHK*BCTA^BED+8LNAIU@IMA!EP)5JBYTXB(]K%/(NQ6)6
M-O7DU'K8HT\5<5OBP&F.<E"C+(?+V!4O19-OS@62U$`'#A>I+J),BQS6F'2.
MM?B-@LU7'^!Z1S&&<>-UD(,>F=2O$\EQ#6P4`RS*N,4X6AD._VN0@QG=.,8P
MW(')9%S"'?%05T*0D0QZ!`,2R7C(.\IQB5OPBQK"J.`MA"'C:XS#3%@A1Z`$
M#1??X`,NI+)CO*/EEE_YJRVD&H<=E=4.?50#%Z:(0A2>P`A3.,$+72B%$6[P
MA%'4]@YQP,,=2J$*42P"GK`@Q1S@P`A2P((9]X@$*T`1BC=0079S@,9FDN"#
M3[C!$TGP!#&,4(;2T$,-/7!$:*,.'%U4@`C<N,,3CB"%K*NB$V4P`C1,D0,9
M0&`:D9`"*^)1A!QX@A5=2`4H%)&+::PB$:S8`AA2D00(X,(59=B"-4@!`QD<
M`1ISD`(7.J&(_W"7/MU@!+4/-*=U4/^P6^P81WW?G(Y:W@4>VS`(/>Y9CDO%
MHQPT[!8U2!B-:0Q)&]J(1C>0,8V2?04;T]@7J?SEXB%'0QO=4I.:R)0-8T2#
M&L,@QI"^(49D7&,=[=`+P8+O1V9$@QDGWL:ZN,$60>^+)FT19S[L<:YOVJO4
MI>*7A<KT*CUKLDSM*(>W^R1+.7T9+O1H,1H71;"\(+)O;[NR6\#+@@B@/V&(
MF]7#QS3(O.!:AER:_[W%-:F%O0B2/N0#/A1+<!2<./E+HYB%WZ!*HBA3AJS8
MG_V2GXR#H*3%+UU((;F%%86*PP',(L&-]IU%G*&*7%Q1P[E%)C'+I>"#!X(3
MZQ@+C*6#-<3_0S?%VQ0ADCWHRCBLEQ>1PS)\'C4@1#3(WC0H`X-]WE9,PS18
MPS04PS$L!(8=630<@Y-0P[[`P\>02J5<R`1U@S400R[0H3,T`S><`S_0!84P
M0U84#,$`"C4D@QB6@WZEPSB0FI297O5M0S1L`S*,PS1PPSR\`Y3-Q2E-VEN4
M18R1`[+XS2<"!U^00SWL@QSYB\)5H+3ETC[L`S6T0BL`P6(9`2/P@@OPP"A@
MP0_D02[`P1N`@11XP7N`0N&`@@[0`#*^0#+>@"BXPSHH0B=X`AYTP1V\P1>P
M`M;!02H\00WPPBKH0!7<011X@C[@#B-('3KJ@R[00!+$@QI`@1),_X$5$`$H
M?`(%Z``K=(,:U,`02($TP`%9P0`M@,(5<,$K4,,TM`,^+$,WR,(>$`$8S((4
MB($XP`$IE`(.Z``1^,(N<$$."`$KA`$13($2'%`8K`,I/!^<H`6A=$LT8$-%
M))(,M@403L,V.-R?T8T[L(60'5DW3"(WQ$-79&+(I(,Z?(,V0`,T2%LR&!H\
MT!$;94,V0`,VO$,8O4H?Y4(V$`,L^)ZUX$,[M,/L15\W2(,T_%$U$`0E2IK`
MB%A_30J,J0.N61$YH"$Z?<,UK-Y4=8,$98/A+(I:Q`4]_$EZO9A\J8J_T,U=
M.`LZ]1LX,9*?E-KW"0RTQ!L$,<NZB`6A0?^@*/%7@ZB##:*#-[Q%AH#5WH"F
M6M"17!0,/K3B)X9BCH6?,662O:2+LE"2OSS+(F'*P!P.NUC+;YJ%FYE*6T3:
M6]C#Z+D)L"R(OYP2!*9+;1H364@(!RT(/LB3J/Q2.R`#.<S)+[G2_S5*D5G%
M-50#-XS#6#C?G+`@O!B3O\C3>*$%)JWG%Y'#-'C1'PU#64K#-V21A1R864J#
M.G0#B$P5.'2#,-R"0CQ+190*F$@#-.1"-=P:&S9*-9@E.`Q)\@5E.:@#!\[%
ME:5:/-`1]%G1M$R+/,B#4X7BJ/4)VS@5<%@@.V!#6N@#0;@"#P!!%/3`&^0!
M#=P`$Y3#$^A`.WC_PA1XP1MP#AV80C9,P8_2P`N\`!Y`090&P0WX`#BXPAN\
M@3A6`<]U@Q44`3A0P0V\0![$P0V\P1A$!CUX00^<8SI&G2[P(S>\P1-,P?L@
M'B]000R`0B2<@A7PP!"L`BS8PA/$P'MT02C`03/D@Z.^`S\(PQPP01C,00U`
M@"\T`B_`@0X4@2(4%Q4H@1G@07,HP1*(@12$`3DL0CET:)K,&J%$P^B1VEO,
MRZ[$"RG&1;$@RNAQ`SGT'CK`WJYD#*F`T[`U2L8T2*O4@QTE##,@0U7T2EEV
M`R[@`C1HPS4(6EFL0U[VT(CY"1&992Y00SPT2*C@4%CVEZ"]B>D]6#9P_T6+
M80,V7(,G?=$VM(.O846+?<.&88,A0D,_V`D_?5F;Y$.-"I/IT9"A">9=W$I<
MF,.O;0,*75(]_5FTQ-DZ]-)>9-(ZG`LI@MF%K,FS>)->7%/!`:`+MH6YY$4%
M.E6-`L=3\4V5/=J?20@V,><(VJP781(XS8M:Y)AM^M^L_(E>D$.\'5K/$M&<
M*$C#/EJIA4H%`LJ5L8EO],GGC=>T-&>%V@E74<-"E(,X-(H/S@VB/)]**!.G
M_(N?5*".O:I;V$./;0I7;<,XP%@UY*4VG"7NQ0,\Q%X\1,.&J9&&@8,T9.C=
M=D4W@`-H3@6]FEXR5`.@U(,/I<DN#9N@=06A*?]FP]4HJ6P@$$Y*K@Y'/L"8
M=5ZGIA2<H#T?1)@":B'&#?1"'MQ`#<0"'31`'M!#*SC!EN9!*^A"$+S`*,B"
M&WB!)&"#*[C!&XS"*;P`$'A#*[R!E_Y`*P1>`V#!+MP`$(C"+OR`#51!\#""
M/83"*$!=G(96,;Q!)\S#*$!!:BD!$<`!++@6(TC"*I1"$N``#L1",MP`##0!
M+[0"-*C)()!#/C@"&E;#*+!")[P`<K&#%^"`$2#!+SQ"*VR!$)@!+1"!$4S!
MJ=+'.:S"@?C0L+P),\SJ@HC34*P#-BB*P/A&G@`+,WB;9Z+#H)4*J4A2.GA#
M-&0#X+YK5TQ#%XVF%H'_)3L1PROHPH0>B%3*(3O\V3<$*S$@PS)<15CLZC8L
MA,"@2CMDPS0@`S)L0S:4B<C:<)K,`_C]QJYH"L!(;CP<&!!]@SU,RA<2A3"9
M4K(HX:*QPWW>GEST#;+0PR`&I9Q9$ELDU9K$&2+9RZ+-2UZD29^D"QW=DZDD
MBV^,K;]LC`TC2Q2Q*%-ABJ8DCK_P8!..2[C<YI1PJSQ-LEYXDQS-`XDR9V*J
MRP9MK3>@R;D\2ZCLA0M&Y^&8"CDT0ZNRRUP$H2-SPWX9A+QD<88P;)Z1@WDN
MPY#EYQD9L^QMPS5(,3=\WA^!2"U#D@"F0\$U[#<00S*HPY"<I4'T0S)<Q;M0
M_RZIE&4NH',.7PI>^A$V@,N%D)F3<%4R8,7II</=^IHZD$.+]4E9:,HZV`,E
MHX4U9(@K^<8&WH-Z.=7_E2)3<=HW+(,H\,`49!P0W$$3_"@I@(,._(`;&$,R
MY$$2N`$X_``$E,$L?-PLJ(,E$`-7>L$HO`$-4$$W>`(4?`(L)(,D1,$/5`,I
MT`#V,,(-_`!F]<`<V$,7\,!GE:_R"$,5A,$T0*\20`$]X@(7+$$,1$(NN,$7
M3,$4[$`CV`)Z:$'=30,]2((,@($J#,$@6$,W;($BY$$#R(`?^`(.+,$3)$$B
M+`)T$0%>?X(2&`$7',%5EX,C[(NNG$4]J.''9-"G9?_L-'S9EH7R7;##-?"L
MFF4#!>7*%1D$,OA1I5@#]1U8MUS,O,;>,4BB#$T#-#!#.B`#HK@9.0C#,`S#
M:4<#.'C#-\0P.-/#)QJ40FR#-A/T)WUQ+>L#+L?%M.19GIF2@241NZR)&(V8
M.F3#QU054VV*67"#.&1#.[#*.&Q9WUQ>BP'<8,+HK3B+-7";,I&:69237LQ#
M?>F%FPR6=M>?(+F-`_G37;#)]S'*-]VP(KOL_\'HKU@3*I(:QSSL@IN*M4@V
M'EG*7KSJGCP5<WY3W93*E4FNE"5,QM!1(;]%6H0*W%X*<8ZA#B:+_UW>YWU*
MG@E3FBS:H5G#-ES%-2P#Q+7_@Q:APQ7MRV"NQ6XRBQ5]'JNE`^N9B!M%PY^(
MK!IM@SS-":!T0[Y9S$)DS(5X0ZO"B<AT0YA,`R[L%W^=!3*E0S0D`S+<+0N!
M9I'A;%N@R9S$6UU>TZ@@R\G6[&837"7W"8R"HF*N@S3<@BGH`/L^`0]0@2M`
M00]HP3#`P0T$@2=T@^O8`A\$02?\0A=TP2Y$@B5<82*4`AX8@2OD01#0P2Z8
MQC7,`0VLU3>XP0^4P?$"01)$015(]3W$00WT!E4KSYS&P#+0@124P124P2@$
M3PZ$POP2`Q/DP!28@CZXP@M003JL0BB(`]R@PJ4^`K*D0QPH`B^\00-<P3Y(
M0Q4D_P$1?($ZN,%H/($8X$$GC*0P@@$Y.$*:M*&;O8E;/%_?;-"OM:@M#<55
MU(D-=[?;I%$Y]&W"U$-0ZD.Y/I\ZF+$PT8-Y'L,YZ!<:B=)<'$,U'-H[5(,N
MX$(R2`,Q;(O%8IB948.)?</GJ9?*YMB(5<,VO(OI>5M\89Z0"_FLV!B/3]4U
M2.@U\!<W])>#:THB61&]-HK,>C(2IH,Y1,O)_A^W9G9<E*:FH!*G!."CX63=
MH&*T'-);?#*?GXN%2#QI?]GIPFRRZ(E8?+B$/*UDZHJH5`0JT4FVX.2TI,,&
MRBST_1DY7%FII!^XO,N(-C(K?[*]Z.9Y=D.T)+@XV<,Y%/_AR_YQ:PY%]IT1
MC&W?7-!:15Q3!75*$]<-JA23J?#++JD#-=R"+=C"XP+<76S5D$`^WX*+,9.Y
M&H;+R!P$F0?9-$A#5?Q1R31(KC1()A&%O.P?)4,?@/,+-Y0^32KFIYW#P!%'
M7,R#.?QYP]Y*/4C#,;!NKD/!#5B!)_A`$+Q!,MC"#Z#!#92"*\!!-5!`'O3"
M$_@`'A"#.YA#/O"#.VP#0$CBL>34GAW0/)EJU>/,CV3%Z-`P4LH'D"E/GD")
M<^^.#4;Z0(84.9)D29#X]!&KH<.;%RA5I'BQ]:1,E2^M5MDR`F6*HGRV)+;2
M!BM:,W-S:MAH$B[8+5*Q>*F9<67_GS0=2I:`&8>%51<H1/"<.J*$RQ0PUU:M
M2P>/[;UR[>I]4P=/7[UU(-]1:W?O)#V1[-:AJU=/7S!!BW#I>R5L&Z1#E^Y:
MT[1NW:UFD-H)>\6M&29EQ6[5<GRK'#=<;+:9R[1M&BYCE:3=2S9,+2YT\`:3
MZR9-VJYN\_CZU;<N&[9T:M]QL^:-6[5HWKS1VW=7']_JA`>/7`?O6W=KZLJE
M^WZ-W3V^YM?9NU[.V[5UA.D1KL[WW;MS[P;OTZ<?9#ERY>JAYYUXZ+GG'7O>
M>\<\D,[+IQ[SK.-K'';JL:>><>I1L!UV]$%)07KL*<>Z?*J;[T'J0,H')9#J
MV0L_\^*[_\>>^NXQ1\%[[**'POK\,N^==MZC\!YZB`P)'R+306D='-\+D,5[
MOHGGGK6:Y"O`(U.4\IYUN.'F/9%PK"N\<LQ9L2Y\\+D'GW(H"V^P]WPDS,:Z
MXI&K&FZR:<<Y=9CA9AIDTK&/&W7FF0<>MY9\,)YNJ.&F''7BV<::<GB#!IIN
MXLGGG7'2&;2;:OIT-)UJZKFS&VSH62<><L9)!I=HB`&'FW3N@4<=:J9)!IIJ
MIJ'F&F:J22:::!KM9LDA!;00)'/&F?50?>C!)Q_K\$(Q).OF.8>D-._IAAA7
M>*C"BA^@>$(25&BH8I4Y2+GA!C)Z<>J%&^YX@Y%(AMG''6B[)/\D#B_RN.$%
M5Z;9Y0X>:I`CDE;>"((51WZ(XHDJWN"!D77>H.$CDSCN6"1<;#"BFSRBJ$()
M)3SQ)(\DCF@%%C<8*6.*(2S)A087D&#%C5?.606'4GC1(9%;4&%"D3D:F"$1
M99P(]PA%VH`&C!RFD.*3.)2X2(DNP%EEP'H``VR>>G!CQ\PM%S02I'W(67([
MOE0HP9(/D''@!'TR&&00%?1Q9@1]A"%!DP>P@82%;K:Q(!AD`CEAC4(H*:>;
M+"9@`Y(.5EA&'T$^6.,2#22PQI`2LL%%&"\#K=4;:P*E)Q]^ZHG&F&6F66?`
M>`[-T)MTZ"D4'[LX7<97<MI9BTUN<+O_AQUVUCH41W+8(0>==NBRYSS\](%G
M'6^P69+$#D$2\)UU.`0_I.3\PQ$W>_*))YWJXGEOQNLBW+(>;BITQ\"ZMDSG
MP>K>$2ASX(@PYLG070I8$C2IPQP.D@^TV&>]^E3''@7B7X$@9+_Q_0\E:0J)
M788C#_!ML"YNX])@W%>.$A').K:+1SFJL9;]7$M&RID0M4B4)G6PHQO66(<%
M\9>H-X6'&;<PXC"8T8UA;(,9[7B%,=ZA#FO$PQK"<,<R-(,,;AA#%]TH(BYP
M,8UTB.<8[Q`1-;IH#5U\(QG'V$8RDJ$+7%`#'O&HSCJ&(0UH&,,:WRB'/;JA
MBUXA@VS?"-8K_VY1#76HB1M^[`8[N*.J>\0C'MSH!C>001=]D.@=(Y%<)\TG
MDGB8XUG4"HD\4)0/51(F&K@PQ0^J\(,;\(`)J/B!#:Q@C#KPP@<]N`$5[E&'
M%]"@%+)P13KB80I1Z(,9;.C&.VR!BE[0X`5OL(<;;O`#*T0C#K#PP@L4`0H=
M2.P);YB"*-R1!R"0HD0><Z=(2)2+'1B!&U5X@A>FP`4E=$(:^K1$(G(ABAPH
MX0C8B$<-&G"%4VS!%=6(AR6T!0MX6,,45.B$'EPP@U7HPPU&0$(1H.$%5GPA
M":%(Q1*(@!5]AJ$<D:C'6@ASCG5`KT/3D4]XM'<2,\GC03)Z!SDVA_\(380@
M"XLHP3D^<(E!"((OA*A$%B!1B"P(8A,L*,<X..`.9S1"!2M8@S#8P0TM:.`5
M'R"'(##QC@]L0Q`B>,4:!`&)$EB#&_&@!C4R925U#.N9X8$+M,HQ1;:,,1W=
M6,8RAF&-'(W1&N0@QS7&N(YQS-22PVK4-^JA2A+=8VSIV`:GW@>A+QEH'-NP
M%IKZPPQR8"=\:^$&,TQ+MAI%BI+Z:%N&)NFED`BH'N6`1XS&B)L,P6,>^+D1
M#7'421>:DB3U.!(DW\&AP6CO//*)!WX&,[XE<8A39!/)/$)9).&@R7[AB^Y+
MO\&\<G32>I2Q3F^'@;\226L^YJ"&B``82N+_O2<^G:16JK@4#7%<PQO&0($#
M#'$(3.B#!9,`!"92L`)(D(T0)E@!("CQ`4$THA(:R,()(&$!!W!U$R8(P1H0
M`8E(F$`$B]#'"2[QB@E43@0B*($F:@6(8@SB!(,@'^4V@(@0]%@3^C#!(>`!
MXW28`!>#^,`F;O$!$52"QR?0!1M,L(9AZ(/#^B!$""3Q#40P0Q^W.$$)`K')
M0PCC$/EH1B;X5Y>Z/.B!(G%2A^23CVL0@Q03BP*Y>&$%']B`"=*(A!-N8`<H
M.*$<:J`!#6PQ!T^L(QE?J($=DO`$4]1C#E8PQ:.!T`TG,$$-/MB")++!A'05
M,PIOJ,(=RN`)=_"!_PZ.>.>MKZ4/:=R!#N5X@\2XP(4S?,$67N`",1;!BB8D
M00K:F)0;7-")*;S!$XE083[X8XE'O$$*;TA"#+"!#&^X(0E%4(0H6J$(,;`"
M%$;0YQ&XL`4PM,,1O55'7=JVH.NBEA[6,%">':0/!`F\@)T$A`H@H0L15'@2
M'*C%!C`QI$UH8!"9"(&3(<$W>GB`'IA8`PE40(E7*.,6B]"`%M;`C$"\@AX?
M&(<*-,`,01RB'!_83G7&N(UN&+)XY"-'H$`RCU1-(QK'Z$<W1#3)22+=/(=*
M$X4>B*.U1*-XU-`BG+++H'I<HQCB$,>A>C>D\1&(,FA:$0$OB4S7U2IYZ_^@
MQCK400]DLH4[N)$A>N23)NS@R!OJ$(<Z>BN<$IT'0J#T2SQZRK%:.8@=.RS;
M.LK!(;[`P[_Z,&Z&$`\<TV)73=#"QSX\>&>U4>M$\.A4_"@?IG;NXQW)>)]?
MS+2/<FP#M]5Q1][)@8UV@,CRV8'?[%GWHGL`U1DET$<A2K")"TS"#X`8`288
MPPP-#&,<D!!$%BH!#$04XA88R`<E!*$/#DQB!(T81AK6X(1N"`,2Y`A!".QA
M"!+H(P1MT(0<J5$"0V3A%9#PXCU$P!#X(0&2(0LTH!LZ(`WB00,TX!8Z`!(H
M#A-4(`1J@1E8@!)J(1G6(!D.(03*H0,Z8!U4X!;_0N`02.`8].$0VN`6,D$_
M2.`2%N`2E"'-TH8O;(=CR$$_OH<OL&$83N$)[B`*["`/WF"6WH`7*``<U.D'
MNN`;[L$*@H`7JB$.;&&3.*H!:``<5.D4P(`;IND'X*$;WN`)C*`3N*$)9H*6
M\B`47(T.JL`3[H$*;B`2K!#7;LT6:L`(K$$-GD`*I*`+SHD4>N`(A*$;XH`'
ME$`2>,$1S,$J0@$/N*`+(D$<PF$=YN$:L*$4N,`(X(`5O,`/],$2(L$5HD`)
MQ,`72($1D.`(=D$*@NUDE``,SL$1B$1*K&$;($3@KF52$BA\T@2\,LN4!*'(
MAF$-XN$82``%SJ$?3J!+_]ZA!`H!$HH,$0!A!1KA$M)`!3[`XT[`$""A4[+@
M`1H!$E+@$!KA'$M@$#9A#4)@&^B!$.A*';XA&F*(Z*I!\+9D&:S!&O3A..C,
M&2LI/)J#6(1G'\7!&QQKIMZ!'IPG';XA4+2G'=2A>'AKLR@$'M#A&O:"?WRO
M'JSA'.H!O.HB/@8C2@@#-R#O4*P!&\3!/"*K';BA;<JC'__G)':$+BR1'<0A
M&@BC'W`A$A:!$"0!%[:AA.RG'A#OUFQG^++!4:(DLJ:%+NJC@/C"'MYG.\B&
M\LIA;'JJ\[Z'058D3:Q'3;9!>]!!+2AO@TCDA]"$3;#'+U`DL/SB>U0$3<1A
M'O^`1$T,Z$1*HQS<04'L[!WV01@\@,M*(!,R`!,&01E*K!'TH1@X`%J4005(
M(!`R@1!4``36X/A,@,$PX0(>$!%20`2ZX3@&8<;Z@1+20!]6X/UN01JX@01N
MP1),(`V"81OR(:[XP0+60`*V`1%.(`0L00NX:@7B`1)&0!,0(0-$X!9*(`1D
M\P380`*881-.X`2`X1]&(`0H`06VK!)`,,WT004P(00"`1(F`5J8Q$K((4)"
M21_<X4CX0Q^J(1=F8@SL:13VX`;&0`<D011L00[M@`E@01^L@`:L`!I.011<
M81D^#0AZ``R0H1E0H12&P=&LX!YR00K&X`G@@!CDH&C_@"`'0*$4JJ!DIF`.
M[D$-;,`5[-`.6X$&E(`<QK`*J.`*P&`6G*`,PF`?),$(9L8<?C`1TF$.("`,
M:,$+N@`4'"$2(H$1.B$,)H(5(``)U"$7;M0>L*`&I"`,H"$1IF`+0*$3N$`*
MD@`0O\`<(J%0V$(:,&A!$H4>R,%,S*>W<(A!+*\8`.1`[N$<S,$<]($7<*$;
MNJ%V*F1+UJ$?AB$9Z@&19J\9BN$8O.$=F*$0X($;+@$;7N$2B*$2HB$=;B$8
MTH$:F$,;H.$6^N&W^C$AX\>/*&D<S$$>0"]22H,>JT$PP`9'M@0=1!)'V"&`
MRJ$?N@,ZX&)!?F>F_D.!\%+P_T8"+Q\(*3O)03COWT#"&Z+A&I+#'=R''M9K
M'D3$O^KG@O@"AC34"1Y@``1``-!5`!Y`"W`!1[`D;3Q&@^!!!`C@$`@##@;@
M;L@&E+IR,``6``]@$RPO*BW/'72P]T1"!PD/'MAD22XI];(#/\KA&A:)1!QD
M;.H">5ADLTJH;59D+EED&[@!,&7D'KX'\M)A'#0A,@V!$O3A^09A#:C,!-SB
M!`2A$%2@$%`@$UZ!$%K!&3H@!><O`PC!`\9!'U+`$`9!$AHA!$0@&`QA!82,
M_@C!B,RC!-;@!&Y!`6YA+=*@$.AA`^YA#=9@!2X!`C6@'$Q``2`!$H*A!+I1
MX$(`$_^0:`7*80TT(0T.@1"R$1@J@0-4(!C>X1`@H1F4P2](@!)(H!DLP!"@
M!3Y*)!^L920"93!41-=TH15X``JB``K(H`KBX$#C@!K40!2H(`J"H`^8@1$>
M;12J0`VZ`1?D@`GNH16<P!74P0WH0!0>;0_Z@0IJ@`R@@!'@(!D<[0V\X!.B
MP`>J``J\P`WN80XTYD5QS15J0`FLX0W&`)^DP!.DH0ARH`C$(0\HP!*RX1G"
M8`_R8!72X0L@X`M``0P>)A=TP11<P1/`(`]@``*<`1E`H0R^8!6^P16>0`G:
M815L(`84(17\T!6E(`[6P1$HHTZHH7?^QT`L!.X^STC\0D#_KB-%"@CR4L4>
MKBM\IH$8,,4O7H221B7GDBLDV(%7<'$:.*4<%H4;B.$5=J4:J*$;7B$9ML,=
MW`$3[:(]NB$:<-B`V"$<L&$9D.DXU*%+AH$8],(:(.LLI^$6R$&36&2]9J0:
MC&$<_&TD6H3`1!+V3N*G0*DO\.Q-:^5&*`-.2B0=Y%&%N4$7=.$57H$9L,<N
M_*<7*2]R'T4=V*``!*``.D`+"&$-5$`$$$!=LZ`;UFZ]F*LDB`2$0````H%"
MV@``C,]VA"2#WD$PQL@='D``'),RY"-,2.1!%O(D.N2X[&*ZUJ$T$>\\+(\<
M%"OQM&XKZT(_,@LD[.&SPA(E7MF,_PSO'7;P'+;AO@:CF/6A',X!'PX+&<[A
M$`K!&EYA&;:A$`ZA&V[A$":!$J8!%F:7&8Y!$Y)!&)BA&2)E&(:A&M:`$-;/
M'MS!G2$!&1R#$%[A'C"5&BYA#5Z!&HQAAW$A&1R!&HZ!#2X!2BZA$H3A%@@A
M&1KAJS+A%F2D$I@6$BIA',H!$2#7'BAA$PPA!91A$E1`$"@:$`S!+PQ!&"`W
M$RH!6NY"\(AD/D>"<OGB>Y+A%5Q!!SKT1'7`%$J!!Q2A%19!&F3)!U!!'URA
M`6Z@%ZA`#5J!&MQ!&:#E&-SA%=1`#8#B!99)$FP`")(`&Q;!%*H@!TJ!<T'7
M"L;`"$S!'O\<;6.LMV-(!!=H@`BN(0ZF0`GDS188X25(`1L:H`FL`0X2@15&
M(0\6`1/@P0DHP`N(X`B$X!%\Q@B*0`IJ``>@H?JZH!-*@1&PH!?X``(`B@C*
M``Q@80OZD`N\(`RN81&<BSNH`;SJ8UHF:>OJ3)9YKZ?M3$12Q4#&J!JJ@1B\
M01_,`8%`J1R@81K(@4B.I(!&11U^CAMPDR]>:!O>"!9>(1(N(3S6X5-!8AN*
MP1@H(W=TN!JZP1O*`QZN(1H&Y1NPX9(H#1FN`:@6)$/2X1B.8?:.Y5HH@QJL
M@5E#8J;4>"0H=1U>.:=!PAV*,F"OXQU,RSR8AQS<)Q)$8`(&H,/_!Z``$&#*
M`,11,IE%DA9'(`4+V!4U1@(?T@$2$'D"F"$?0@0PS4=CM>.W`!``#@$E%@&4
M;4OR",@\$&1[MN,!``!FQX?V7'D?,I>#CM6_ZF$;P@,_F`/PM*0ZL+N-O[)%
M&FBWY,,>5FMA?P<]+*CI`$0MR&$9!D@]/H@=F`$9NL$]GL1`]L4<NBA"P$%*
MI`%4D@&[O\&2!N4:"*,9WL&+P($:V&=<X8@9L*-3RM(;<@%6I$&^ZZ)/0()6
M)@F'!:,<_/B#QN<X;MG-281]^N-]FLOR.LGLC`0?`-4D^#0DE,@5DF`*[`DF
M&($*R.`4<*(*@&`'YN`8JX$"V%<'U"`/_R)!/>Q('Y(A#JI`!T#!#FQ`&XKA
M&^B@!G@@#G#"1#U!$J#`<^^@"KP@#NS!$^R@%>[ZG6P!"I0`&?#`%6-1&IQ`
M!HP@&5IA"ER!%/2`%$ZA%.8`%6"!'+X!#GA@!F9`!E9"!FP`!F`@#K*A&VRA
M%!0A$?(]#B1!%YB@$YA!$7*`"%:!$:K&#+P`#,@A$8YD46@E<K,#D#D&@ZJ#
M62U1[I:D/<L!A[W!]UBD'IA!&[PA'B0/'P!S')BACQRR?0AC'9JA-+A[&UX(
M&7`AB',!%H8!%ZK![JZ!4RS)BV9E5,!!&XB!&'`!&_+[>-H!&8H!&[AA'$Q)
MLAQE&Z[A*QFD/O]6ZTCL@1],W2XZ+]?<(EJP+91*`X$XLE;&`2Z01QT6(9([
MG`$*(/'350`08`U^Q)+GXQT.!7?D0``<X!KV0^_8CB^.80(`(`3BQY?W(57:
M`96B^WQZ2@0``!'X8@U`F3+$I!8?1.Z8ATLF0``L89HE!8$J*%HRA##>`3C8
MP5L1+]39A!W<Y\%CY*K<@D'Z7A_"P4P*1#BTB[GPX1++A[FXY%BFQ1[4`Y#O
MZAOHHARR8`VH01^`H1'(@0UN@1O.402TX`2H@1!$H!4,#1Z2X1;608\CNAX`
M8EHA?<!J2<O5[98N>)"8E;O%;!"A8=RX=>MFR9(@-BJ2(4)T:YTN0J__]&F"
M!.E6,FNWE*5[9XW2.'?,@F6Z9$N7-&[C[N7;MDT?MW+=K)G3AQ1IOGOUQNFC
MAP]?4J10I^K#=T_?O759D5:+UHI'%2]EHE#9925('5NF;D!11"V2+GV*JI3:
M`Z6**$G:M%4;=NI-E#N]?KC1)VQ5L2Y`=.3:%(?&FUU5H$2)4J7*G'Q\JL2R
M"CJT:-"XS(2QUF6*$BF>I,7)$>I2`S#:7,7A0\H3*5>\P;D#1^='#QLW>$BA
MH\L>.-Z@2'62Y<D3HUFEEA2!ED2*KUQ2MGA1\@5;HG7UX'FK=X_<.GWUD-8C
MQPYTOJOOHEZ=>B^=/7I9KU'+6L\UZ&EU3W[L_V1CC#?TU&.//?G,=P\UR%!#
MCE1:/57/-NN04\XZZ91#SSK5=-,*))?@PDPRKPQS#3&M#$,,,>H`!18LQ.1"
M3#3I6$/.-,E\`V1[Z2'#33SJI(,44^E<]$TY[Z`'3WM(L3,->4G-AY0YYA18
MH#[OW!-/AO24@Y^7`G;)E#U>5O--/-),(,``<C+`@)QR%D!``0,(X(`U^O#3
M'GKI?`./.KH<(,`M^K#S3E5)W4.//MM((,`E7JY'SY?MX1-I>??,\RDY[8D`
MP"&1$@)`"?>TLTX\W6S)8'OQY!,/./!\```D7I8S3SGE9$7//H^RDPX]],!S
M#U;PS%-///K!$X]ZD?_JD\\X/2%EX7SXG*,4:.E8F&12`:X'VCWF/`EL@TB5
MPPU7]43ZCCXE'%*((-MXH$$Y*K!P3PC#K*%!(R<`TD@(D@R@2R1K5$/,/804
MH(X)!;PS00CZE)..!OE*P$8^@1BB`20?L-7*+0&3<`@DFVP`R0JO:$#(":^$
ML,8:DYRP3PFOE`.,!B:$0$D:FR00`ALB?+-&)4@!8K$*F^@CB#"@=?K./M-.
MM0ZY2>V#53WK+:4/-6!-,08894`QAQM!6,%*/'5`844D]L#QQBG?//%"*K)(
M,8H>KI"RBRB@7!$*'S3LT,TN=WA1#R,YE+''.:081PHJ4-Q1Q1Y<,$(/'C?_
MD#):Z*)+U0H,1UCCQ11''*%-$66`TDH<2B31!3;0=&)&)Z6`4@HKL`03S)/$
M?)A,4,$`T\HIH'32R?**E%+-*E(D@80KGW@R1"R3<Z$$&-]$,L\Z[%33'E20
M4JO/-?%.A:6CWH)J#C+>4,,.5^FX6R`YX_"*C8#UU/.DIQ!E&ET*%SV8`10G
MH<M#QYB&-;:Q#%AH@QC0@,8K;.0->!##$J]HQ8J:L0UL1*,;Z1@0/KK!C6I\
M14CK0"$\?/6D9KUC&^[82C?@@4/TH.<=ZU@?^I1BCFV@Z4M(F:&4K`(/;GR)
M2_RAQS>D80H]#4!/="H`G>RTIP+HZ0"'>)*QTA&/_R;!`P0`.,%6>F4U3EWE
M5VI:`P`Z\+]WP$,?(B&$"#(P`1"<8!#%>`HYBG4/4AT"*8,`P`B0<HYWV",=
MR9#$"4```BU<XH;T<```,,&>#:VG&Y(0`23;L`A<K(,>R"CA/;8QC&[$@U@8
MBP<W!I6.:0AC&MO`"K.,Q2Q]M.,HR7K2@^CQ$FPM:%/G4$>DNM*5>%AC?>.8
M!W_N80]V9>4>[S@*.\:A*F-A(@MI:(8A/D")$Y2C%B'H%YGLJ(6:L0$LW6C$
M!,!A@@\$XP0?2,8Z,E&"$"3C!`]8Q!H(L89`KL$AP>!`)DZ`B$M`(@O,4,$Q
M3A`"2`@C!(<XA#DRL0%-L/\'$)#XQC&$D0:H94(?D!!!%M9QC'L4H@":$`0F
M44")JX`K*4<1C3F$99]N9>T^T2"&*7B@ACM$P0JZX,,/7+"(7-Q`"M*0!BGR
M@(HYZ((9.IC!*>C`!SY(@AI%Y8,;4O&"&F1#&IX8A2<DP0UM2$$'TIB#"W10
M"E=PP0MXH$(91'&/._P`=*+KJVA*IP1LA`$'6W!$+G;0B40P8@M;,`,1_#`/
M4("!%IYPP]]\@8]PA",6B6C&.>#P"'$T8Q_8`(4JX@`&3X`B#KO0!0C`P(4P
M7"$W1O`#=J0P!$6@@Q6<6@<VH)F5?4@)'^WH"OOTP:W0X&,:XN"&.XK%E2>5
MT$O_Y+B&A]C3#7=@B8Z^VA]HMC6,;<3+N.DX1C'&L8YY(,4;EL!%*V!1#6X8
MXQ4XFB\QO-&NI;@2'>F`SS33X0T/C<-37D/O-;B14W.4`Q[O@(8WV,$4`E&3
M7-M%I%,`I+5WD.FX^H`',\3W/WW$0RO<B`2B"$``!@B`3BNF$XNUN*<U.,MK
MY`AC/)A1``$$(S_O>(=Z\W&4>LC#/OY(``:XP9Y[]",$`HA3`0[P@"8/8`W6
M:&:D0@``0Q#RC?JP!PWC(8(]"0#&<8J$/B0``*4Q:!W<6,,``-!D/35Y`I%(
MQ_DJ,>9;C(\8W+B'*I,Q@2F^`D#R&&6PUC%@F>9T*_8P_RX]^(&4=9RC0!7F
M[HBQA14Z;H,_^4`/L=YCC1",XQ8I4`$B3K`&%?CC!!*@AR%6H(\0`,,>;,C"
M"2ZA`$MP8QC@6(,G11`"08A``VM(QPE,D($UG$`2&@A!&_0Y`4N=HQ\CH(0A
MEB&,3:C@$((PQR:&@>HV9"0>]B!!`$]`B7Q<HA(GT(<*)H%<"2B*'/H(!"((
MH0&-KN$6!60/3:]F%6-)12K&7<<<LT*-89CB"7>X@Q6ZX`HK1&$*S*!#`USD
M!E*4(@]U*(4XK($#*P`A"$&@02FL\((@``$*."#&.$@1AU&<XA2*>`4I&N`&
M7E3!#G&`!1:F0(<W3$$.][!"#?],X=>D/TH?K9#!$:`ANR^((PY46`4K5@.!
M+4S!"+[@QASP$(I0>"(4J]#',O!`!,9V(0Q;4(0O]C$,.(!"$7/OQ"JZ004>
M=.((6[B"U:EP!5788@=@2`0WD$Z/:V0C2=-42CON<Z5(*_<<UYBC>Y[IJ7)8
MXU=)X2&6UH&Q+ZUC/EC:"CF*08ZLJ"D?T2S&A[M"CW%,(^$`%@8LHO$*7+R"
M&.7I1C6P,5UZ;*,=[[!NDGF4CG:,XVJ^K=_C2_^-BD0C:ZM/2H=$`_H"T8,=
M`Z*C#ZF%I6M<8U%S_-\]V"4,!(Q9Q2YN?_L%@`A7Q2-*]X!'-^[1"#Z1HU%T
M5*YZJ17_(DZR#G!R`(%`0YF2#&Q````0`@8G1Z0R$/=02.TV*.```F-6"<M0
M#D"Q"90""1,``)8@%`>$9@1P",)P#!&D"1T0)XW085J1!@+P`*)4#386#TPV
M`:T0#\("&N*@-3)%+>P0'Q4F+.9`;Y2V7?.07#XQ7.FP#99G7/6`#M95"1WP
M`9LP2.-P`H?0#,50`OG@#X&@#YC@`2N`",(@AB&`"2K`;X-P"%D`"2&0!K@@
M,N1P",-P"3]S"RUC"7F4!MWP#:T0`BH@#&MP""E@"(.@#VGPAHB0!;4@`FUP
M`I%0#RI`)O9@#343`HT@"/JP!IBD#RO`#)6@#)Z("/T@`8>P_P9I,`SN\$-7
M0P\UA2U)00__]T-4D7I(T0VYT`I)4`5T0`5R00,VP`JM\`:BD`QU(`JAH`=\
MP`BNL`O9P`YP8`,T0'(W4'+6^`;-!`VN4%:G(`NE$`?7P`BM(0<TH`/0(`D\
M-P=>T`;K4`6?HW3SJ`^P(`-($`U&(`6O8`E)T`3%0`QQ$`=><`5F,`5;``LD
M$@>G8'?IX`A7L`5@@`>,]0=@T`5-$`K`8`I@4`J*0`K0D`VD8`1>\`5AL#F.
M,#=<<`7"$`=2@`3<L`KWL`_?H`X^$1KQ@7U6@0_V8`[H%2Y@TAX]<@WT%GF1
M$H#3Q1X;IA4>4@X`I!0%`A/'<&D%4O]>PQ`/!=(--H(+N%`-[(!*&Y9$V:`.
MX@)@2N1OM3@/[?!\VE(/E#<@8`,/[9`-T#"$W:(/[O"#4R$JLS@5_"$:3J(/
M^]!HY?`*W9`,R3`-)4@G>>)^!A```5`+\?`CK\`,]:,.\>%&&K`.#Y8L20$N
M-KD/]0<.U0`/:R``",`,[`%`6$(-E"((YQ=(N9(5J&(QWV`/:0``&+`-[])#
M^F6:ZE<)]5`D('@!I4B+PG((*'8)\6!PL=DG3V(.8#9FQ[`-^X$4PA5I2FF7
MZE$N&"(:])!<6[->6O,@`!)?WH`,4,$M^1!?Y_=`718BU#`/H\8U'<8-V]`*
MR\`-]H`>12'_2\2`#<9P"Q11#KY0,K=P#!<1#_V@0L+P#M52#,[@#LV0(B!B
M";_"#,(@#,$P#)O79?HP#I4`%..`B<O0$T&Q"<<`HJG)#,I@"5*)9)DV%3GU
M73/5+?B@-=2`"Z8`!7M`!D]@#%ZU!;I``3HP"L1`"DE:"J+@":<`C<R0#](@
M"6I@!49@!6JP"`MQ#;!0"J?`"$E:.9X`#:6@`TRP#2"P![Q@"U5P!\#X"?IP
M"GQ0=O28=*YP!EO`#9[P!;$`!CHP!6*0#*3`"))0`TM@!JOS".20#(S@"-L0
M#470"42@!'^@!$=P!5_0!&5@!(N`#ZL`!ZZ@#M:@"$P`!EN`!$<`_PM?4`Z)
M``9+<`2[(P6DL`V1D"Q$89-/$2ZC00]$:7U(5@^V2%/%9PTX>27"V4)[J17"
MV1X,YEV_ZB!:,0[MDHOL,0[8,#Q9H:C<X`W1T`[4@`U(L0W&("[6H".,-P_3
M<`Q"$FGD8`WK$87T4"7HDQ7X@`[&\%M6,1_75R[6,%SX`2J@`4`E]"#Z\`H/
M@`47@0OE0"GN9T4L9@":X`[N$`^7<`"0<`_L4`Z/AV7M5I-]R9?"TBSIH`W>
MT`WJ)PP;4D+_<S\$,0`!H`SM,0(`T`A9$0@`@`):@0EC%@P78W#L$0]"]`%-
MYH+I``D"(`'G4"O%PBD?H@^&```9,"9SQ/\-N((!G(>;"$`)[J`I%M(@7F-<
M4^$U%88E_!<:^U`.-CH?Y!`-[K,4]<<-_E$/`U</WP`-Y3`AY9,/[_!'U]`,
MO_H_WB`-ZH`-5G(/XE=Y]=`-N&`)Q"`-K[`*T1`-`RH,OP)<7D-`M(@4U#`-
MY'!,VZ5$`-1H$+(>`/0>W,`?]M`,TY(5\_$.%C$:9#*P5K$EV-<5T;"C4;`'
M-F`+JV`#LB`+ID`%/\H(^K`+>B`*IR!SLM`*N&`-WQH,3K$/P+"BQN`*L\`+
M>5`*2YH+WT`*4V`'1`4+G_`"ND`*-J`':N`)ZT`'.S"\E4:GH=$*4_`%%:<(
MG:`$16`&,M`*K9#_",%P!S>0!$:0!$3P!=#@"^FP"E_0/3W'"(PP=[!`"EW`
M!&;`"=>P"LNP"HS5!%[`=Y;@"DH`<GG0!4L`!IV`!XJP#9+@'M[PH?OP?\PB
MBP$7#H'2*DE"N-;7KL6"++68%..0#'Y)(.RQ(!O8>/NWKIQK9^RA84L2+XQD
M#-Q`#M5`#M2`,<L`+U6R?>TA#,M00!&R#.4A+N?P89`'KO]!+5TAA-&`9+G*
M'GT6&FUY(0$'<)*G85WF,!/P`!00#P,:#VCF?@/```"`FF`"#G50``\P`7WF
M-?+"9=_0?63,'E+1#BKD#>J`*AT@+O[*R")X#[@2G%##@%KA1JHB7IE2_P_W
MTQ/!$"=*DPYDA`@BABSQ<)5,43^4HF8+,BD"\`'Q<`AQ<@C=4`Y@8UQ;<42,
MEQ^W^(KNRQ[A8*-GW)2?J17;8`W\VF_K,`WE<"T70@_>P"$'YQ4J]`VPUPWC
MD,3P@`MJ7`ZXQXNY0)4HN#Y0R0S<$&)@LYGW26E9\4):<0[;T)0+(L^6IV'G
M`IC=D@\[.<:A,2WNBP_*K$OW\7NN<`,[8`K)0`5>\`9QX`16\`2:J@O0@`>B
MP*0@S0AV%@\1+`K@8`IP,-+V<`Z.<`K145:>L!)/\`E24`540`J@``7(X05/
ML`-RL`YO0`-F]KZADQ6FX'3,T`5=``:F,04\\/\(CZ`(L:`+3I`$2<`%7/`$
M1]`)2=``3Y!SC+`(B:![DB`'<2`+7M`%$(`#B7"152`%4J`$6X`%[;`*L1`+
M3.`%4D`$G="2CM`-D9`/^Q`/U7`/[N!,@5F$VCD5YD`>%C%B7<&Y[B%^V0`/
M].`G_!DB!:(.W;`^K,=Z&4(.VS"M;;P.!\8.8?)'6U%-34E-U9`,T$`,U"G+
M]9`,PE`,RY!Z]3`-S!!`[.`+T4"L88,,XQ<L6<%(P0)^5$$-ZJ!(Y8$/Y<%<
M41'=Z!-B5O&K0\;&D09PF39#]N`J(D`!$X``$R`-:FP/6-9B=`(`+,`NJM0&
M$R#?`G`(!;(>*O"T'0;_85/!->_"#^'#?>R005H``&EP"YH@#*^`";=P"QH*
M#,6`WUF@%3'K@OIPR1UF22ZH0/7`#O3`#1#&#0@``#&U#7*B"<W0#=)`#=0`
M%&+3#>M`*H3@)>D@L25;X&Y$"9+9;YV7ETG10W&L4\#:E\7\*$*T7>^B#^1`
M#%8RH\L@#E("-O"*#>8G)-8P#)2;%>L0#0*"%#?&#.UAF-4@V]S`XDC!$OJ!
M)17Q#=5P'A<B7O6@8$O$%#[A$SNR'J:TW(MD#4B"K_K0).L0PY$F+`PM&I.M
M#]+@"XRP!TS05G3`"-(@"E50`W95!6H0#[N0!WDP"JA0"EU`#N1`!VHP&%1P
M_P=E8`5S``[FT`::'@>>\`G0D`ZI@79)\`:JP`QW\`:\,`PUL`>'(=1\5=2A
MXPH](`;$\`9B(`9<$`J=@`5#L-5A<`G<8`1O$,!C0`1#L`5X\`WXN:?0\`58
M``VKD`AW?0]XL'4Y4`5/D`1F4`2PP`VA,`1'D`,;_`E@``86S0CE0(D&%V#[
M<4STD`]C@GW\_"O(<B%<L4:[F15ZFZR?D@[L@`];4I[:-P[.P'GU@"7D@`S,
M`$CL42SET`Q;<B[;8!':``W&@"Q@4P\I`MLU.2;?8"SW@`[8`'Q:@234<`WF
M$"D!3T?]52;<T`[W\ZLXZ2'M:A^#3I[S$2(_/J_AHO^$5M$5XQ`4K3`!XST!
M!3`!N0`.V44(3<;>+"!_X"`"#P`"5U\``>4K%@X`!S`.\##<U&T.G+(/'J(%
M(I`,^L""`@``>\_W?:_W`'`!7Y(!`.`'2"$(J2(4448)C>*44<(?;(9F2G,,
M<A(`<"9E37;YE4\"5]%"W6`/QT```J`%S'`/4CF[5O$K380?H^=OV\F#=HD/
M9POU^N#S7[LJR("340&RSW`.QK+<]4`1JQMAW.#;;;LHR6!G3%$/+D%'R7`-
MU2`_5&R[I`DIR4`-0X'/\BST[B$J3$$.#N$E7)(4Z8`.G;VZ1UY*4G*K`60.
MX0!IXD)ZH/&OH7$-TQ(-QN#_"!2`"L2P`S=`!;8`$+A<C;)3A8Z5.=1TN1(U
M"D^U17&JE'ES<,P>-5.Z+`*7AQ6H7;R\,9*2A\J=.::(>:/R!$PR3SRH[+-2
M8Y6^>_IT[N39T^=/G:M@(%'W28F8,$04)6M""PF3&+$DN3)BA$F<3N(8L?GR
M)<P1"HQD%3ER)$R81UA&<GGRA`@H7+JP$&GRR8LC:4VD@*'"I1.U2/?PP:NV
M3E\]<_CTX:M7CUS.G8S?61N'SW#/=>7*K<M)3R>[=#KK79M7CQX]<_EPZDMG
M[MWFG?5RL@OV>-_E<=[([=.7KQRW9/&Z$8/EK7%CGLAR=?O6[5XY>.4>TTL7
MKYJW_W7FZJUK7>Z=9WSOZN$[9XZGZ7K<RM7#>:]>.7WFK%WVS`ZR3M[ZYI%C
MCS\G/GG(X0F?>U2C1YEU()E@`@H>>*"`!RZ)IY][(!'@PD#`T26>840H8,$'
M&@PA'6ZZT4>7`01`AAW.5CL-'\7TTP<2``AP!IX.`"@!$4(:$:012"`A))!%
M+&FDD4K*N2<#``K1:1``0M!GFP,`T$2?=[(TC9QTUO%&'0T`H$2?8P8H8`5`
MUE"!#4G66&.10;)P<P5(]%EG'76\B0<21PH08`WUZ'FM/YS4TX>>>W*"C$#\
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M*10AI0N?O2""E!V2^4(*6!)1)`P<;G@#ARER,.*+*Y)(0@H9N,AAB"T8$444
MHF]Q(HXXDNC$""I46:4),I+P(FC_;R2A9QUXK,GU/LA0/>^UT$Z+=QIF-H6L
MGM`RV[:>?.IY%B=SF$D'44L/78?+9CX5<,IEWH%LFU>XT>>;6Y))IYYVMGV\
MMWO&(:::>]))YYKWK'DG'6G6B8<<>_23=<I('1?]4')BO&>=9]]AYMF<UI$'
MGWW(.6<Q??:9YQ[>T%5-GW&&]RG&Q<#G_IY%0F1P@@<+D.2;=/)9`X`4]$DF
M%UU`6!#$!0M0)IYX9)-`@!/`HW^KN1Z\<O(!`9B@728``"`<]1-+'>\>(0!`
M(W1""`"8`"<?`,`A]%$.U]A#,-S@3SH08*4/%F``S*A9O,IQCGIT`QZ1$,`#
M(%$``+#A_Q[N<$=C[M,-P_R')^$`7SZ,=XUU&%$GD'G'ILZ5$W.0XVZR>0ZO
MO(6<<F!C'>BXACW640][U,,:UN@63L2SF?GH@QWDF,PUN`$/Q)'#&M'`1S6(
M00UBF"Y1!DI&-*+AC6M@HQLF(M%ZTK$W>*3C'>0PT6KT(9QCM.@PBKD'-IKH
M$SC:R3N*`F-O=/(=>N0C'I7KR6F`0H\8)>,5T'A#*4:A@R?8@0FZ>`,O^M&$
M*3PA"E&``AULH8M>``$((>/%+:C`"T<PPA9QL`(4DL`+:.+!"E7PPAV>$`=B
MX((-X-C!':(`A$[(XA.+L`<J[D"SFZ73)SE9Q1C^@(P=*.%G5/_H@B+8,0<E
M,&$+K\C%."X!AT<P`0(XJ`($NM`%6LS!"TDP`KY&X84Y4&`*2X#`$?`0AU!L
M@QNX@`,.XC`$:<#B"UV00A6Z@`-2I,,1]9@':%B:J]C<HW,[X<^YQB&:U31Q
M')[;5J*:1PUJP(=U[N$&XEK#N,-8"A_F@.$XUB&XWR`C'CMAQBW@2`Q1M>,P
MH*)'?G:2CFD<`Q[JP,8UH%6X:$PU'M:`SC1@F@YWN,<[.SF53C3S+--L0S'F
M:,<Z%"./U.FD>#K9GDZB2,I'F6<?7E4,.=H!"?LQR$$54.$BRD$Z`&3B'O'`
M1631]]D)("`9\/"6)@8P`$A,*WR$2I?_/BYQ(6"PYQ8`4(`]4*F8[-W-'H'0
M@#!T,H$F/0D`)S@,&W2D27-0*AW6N$<Q4F0(^U"0$)H\!X#,D9WX`"(-Q=B.
M[B[A)Q2X]D)IN(=M$:4:Q,UC0(JAAU9]D@]Z=-$>7E7-.MK5D^;1`XSZ1=ZA
MRN$.5\%C';"C!SH*1%3;O4,<AYM//9@!1\<P5QW;ZD<YV-&.V64#&[!`!I;L
MP8_MT8,:QC"&.KZQC60(U1WDP`8+5W,/<@@C'?=I##.FD<3>-,Y.GI&'/,HE
M&\?IPQU92NHDJ[>8<LBP4>!#Y4^.MY-JM,(5;[B#-ST1AR@\X0T4T,4K(KH'
M.MP!"$_XP0NL_\`(8>C""770Q2)X(0DJM,(7BK#!"Z;``R!@I`I2P`,DA@$'
M4M"A"FIPPQA20652\,,*#5B$.AW=$U9`80O&D`(7Q,`%K&S!$;#8A1NV0)9%
M2`,,?Y#"$VI0"D?D`AJ,4$0IC/`$6"1S%[O(@RRJP@4\8($8K\!"$1B!!%+8
M`A==P$,GXH!I(SQB'8N@!SLN;#O(",8P3[7K33^7CWN8!UWE:/9Z$L4.>,"C
M'=.8AF?X!F-N6#L>G4G4.&XJ&VYX+AWL(U%.QO$-9#2&&'><1XS2@V.?F`,7
MH<G&-!*U&6,<\D[E(/=]PH@\]^J$.DU\APA[LQWP@`\?CCW>B_"K2/^@)$9\
M$A\')"APO@=\=@`G`$<W:@$`2TB#&KTH0`$J@#X1H*\""'CP4W$U`0$<8!A8
M`J7']7$+'`[B4/%P!P($$`E]P+&\B2+M;`G0#)V$"1*J@9(*MG4+,_FV'`^_
M6_M`<*%*Y.02`+@`K]X1C[>78Q^*:01MSWB/841``"'`1SOBL0@!H%:-F<%)
M-T(3+W/08QR)@2`[QN.3;2!6-)R133P.?YB*'Z9:.KE<;_#!#6NP)S>](4=A
M]$%&G5##&J4I:CFH\0YLB.,ZVH`&-J::#]P7UDZJ["(WF!$IG*Q#]3W9QBV6
M4:[8/88?T]N)*0]E.\['PQZ3RM0VTB'4>WC_QE+IV,8VV(,/W?O$AX2*!BY:
M$04U6$$*GK"%&H!P$#643A)\\`$9QF`#-PR#&O%8R![X<`I).(51N(-32`9Z
MD`9;J((*<!@?$(4YF`9BR`,EJ((=<`-3<`4\J`*)8`1]H`,:$(5'"T%]B(2A
M"`=/6`(E`(-.^(0XP`-/8`56P(,ID((BZ(0N,`)%X`:.P0534`1%V`)7:(55
M,(8K\`,P6`58R`52Z`9)R`$P4`0IV((NZ`0\`(=6V`*T\80NT`LOZ()H<`3!
MV([*T"\#ZKMV&(?P2SS5L`P8H8>YZ@]XN(8;6P^+ZXSNP11MT8=VF(?-.(U0
MLB\24J\>T@<Y,@UO_\"&6W".WL@/=(D7GE"':I"5="`&^]B&87"K<+,3_5L-
MU?@-K0(?P&$5W%L,>4"BYP&??6B&B7N6&,&V>Z`=GM@>?`B'[).'GH">2-"`
M\Z&`FJN``5@#7;@$20"`2&B%5S"%!YF`F[N?#_F&3_FB=^`&#1"``E`!X",L
M?:`&-WB``1`!:.0,L!L`0G!$?>B&!\BL#X*'LV,#X5H#:+F'$Z"M8CB4'?*,
M=-""`7@``<`$HML``-B`=X.CKM('6"B``+B2[QB'`Q@`#>",>8@'9F@#,TFM
M=>`-X?B.R.`\9#`/GLB/X@D_T1@YG>"&T'B/+Y*X92`M=+"&RF$&^"@'VO_I
MMPO3I*=B#VYK(L>9E@&S#W+0(VYXA=\).$O9AW!8!N?`NVU(E$-)!AEBC^V@
M!@Q3AW:QATRT$W)H$6_A%.CXE,)"+VYHAG()'YSP#>^8E'/IB1##L7R0AM?1
M@3O``R_0`5Z0@Q[H@2FX`5-@!$D0A2CP`3IP!5[0A1NH`AVP@QL`@AXX!2K0
M@1_HRS?P`5Y@"#R0&T;(A4B@`QYH@CO8@E;X!AV(@C<8&4:PAS>X@580P4<S
M!1D(@W0@"R[H`BSL@CA0A"*`@SDP@AW@@3'0`2H@!4N0A#F(`U#``S"`@T1@
M!%*`@RX8*5)@!#B0!$DP!2IPPB;8@2;`@U+H`B__8`0WR#22,H(Y@(96X(9M
M\(9QP`7$B0?K6X=K*0=HN(8>2KS$.Y[_^CU,09?'2!1J($EX>`>LDXU/D@[L
M0PR=B`;2TH?>P;S+Z8]X0!YJ08=HD+%/@AZ<`(_OV8?1*(9BN`=DH(89NX=D
MV)#56(=E$!"EQ!)D\*J=Z(9AZ(]]0!36L`9\F`?&(E'X("5LRX;[\HESF+O'
M*ZQZP(6<NY\%H:PU:`4Y:`,`$(%%8`-D?(`*2,;\^0#$08?M>)9QP,<:^H`U
M8(-%6`,1T,=?K`?KN9N<:(04Z8!&:(5;:`5(.`$!(`!"<`Q$"9-&R`D,4H&H
M2P=[$`%J7`-<Z#Y=D$@!_[@$X*J%PX!(!Z#&1G"&<3@&9G@%-L`A2_B@>P`'
MX,H`17H'=G`]>*3&2]`'?MB'=.B&<<#1/04*RU"B[QDYU>@?>-BIU=D')+H6
M]?JJR9@QG"`0<B"'?DB>G)"=>`NR8K"&2)D'9HB&Y\`%9I"-U5F,@>2)<1`&
MM[H'8FBP*=D_;K`MQ#DX8WV6S5F,UQ"/=Q"?>A@'TR.L`CD4]6">)^(V>\,^
MZQDYFTQ*G2"&-M6R-W@#.\B#5I`$'M"#&F@%-L6%15@%4<@#'U"#P^P!'[`#
M']B#)-@#*:`")N`!.^"!*JB"3R`%4@`#8P`%2\B#'R@%'@"#7#"%,IB"*K,"
M4__0!S6@`5/`-M2T&<40BB:8!A_P`2O@@89J`BQ8!$(@!#9H`SDX6CE@!#E)
M!#AH!*%E6C@8!#;0@D20`^,D!*'M3JL=!#>0@T6`@T7X@CCXVCF``SF8`S?X
M`CC0RR.!A$APVTBP!+>5VTN`A$:(A$VP6TBP!+F-A+:-!&)@*<UCCVVPAL9Q
M5@!=AVN`UQV%'&XPJUE)%&8H%:4LAV;XHF%Y(V1@OA>5.'2!$4(Y%U>D!F%8
M#V;8O^>PANLZC.B8AFWH'=RKAV8X!^:K'FR;AF_8":\B!X[,2'JPAO8!/YY`
M!R?RI/A@C^+5AVM(!A,0@<AR$'T\`4L0@340`"=HTEK_*-)E_)`"&,=Q0`Y1
M6H=Y&`80X,;`$P``"#HGN(3LPP?'HR)]$`8)"(`+.:T+D0#?F@SHZ``!,(0+
MRB#N,;![D`,_`0#ZO1`'N(5[.,<Z<8]X^`812)$X/:WTG8!;X)X)`3H$Z(</
M>HQO2(9$,:X"H`3U4@=I>-:=@`?ON44`]8EY2%Z=X!;D6*+X"(=#VHG2.+UH
MN0\8$14\M)/"88_&H89FQ0EG8(;CR2-,X0>><#[=_2!8((9DZ51984\LT:A[
M:(=&JH=CF(:<9)3#@!2A(BS5L`9E<(=+B3K#*(=39:EM\Y;G&#LC6R<IVHED
MP`5)J`([B`,W>`,JF(-NH`)/_Z"!/&`$5T@&4Z"#/;B!!K`#-[""7O"$7NB%
M+I")4^"%42B%@M$#%T`(1K"$?D!D/>@!.*"";^!.-3`(D2$&?=@#,D"GFKT9
M4K`!)+"&55B%:(`#)<`#4&@#5W"%7[(%^LD%5\@%7!`(6[B$2]`%2Q#"2WB%
M2[`%:2;85A!&4U#F5ZB$2[B%6]`$6Z#F:%9F:1;G2V@%7*`?-N7F-HV+81@&
M8M`%=7Z%5[B%2\"%6\"%5;"$RH&4+]*6G!"/X[E*`\$6!6TB3'&/Z)B^J1LC
M,Q(0OVH4'*;AGQC%WUT'=^"&/*FX<HB']9"-H((KA;X':U@^SW"51^J6W=@)
MU>@W<_]04??($F[;'GN#83MA#\'HB7-@AT80@2&%D`DH@#60!/L!@`EH`Q-X
MT@]).:4NAGRX))_*DMYYAV"@!$%8`TCP!^;C!WYP#S@V-V:P!#5!A$L(AJ1*
ME&U)AF88:7KHAELX!LNIC@_:!#_P`!8`!$LP#WM@AK$V:SIDAD/(@A,(@4$X
M!-]JC#!2AC4P!&?(C`&R!FC@AGF@!T-(@4!P!WOX!FI`R\/@/J"PGB/K":;R
MB5!"AM#X#O`)!ZQ;HNPCQ&+XHM!E!B3*B7C`AW(HAFO\76-0E'(8AD/"A6@P
M;'N8OI'C#=48Q6XP!FVXL/?8!F[)79.\AOS$E.YQ8IT8!Y;_C,7XR+9R4(P8
MN1;1*%>)*U['H6V1/)1KU`<[BH0J>P-/J+(O(`5P2(9I^@$H$`54&(4XF(,\
M>(,/-@97<`-4L`4WD`1=B(-(,&9H<`,UH(,\*`58:(4NT#(KL(9DL(0WJ*8[
MH+(RD`1]((B;B.6;D84]Z(1<V`$=D((D&`(N:((OR(5=L(60T(9=R`5IB`8[
MR@4<5S7ZT85=T`5>2`9SEH9A@(6X"$Q>D`9=D&8<GW%>$&8>UX5D@`8DUP5P
MD(9JB`8KMW*F5(?]_(8O20>@FK=J$(YJZ`9UD.<IRN+,=@]"D1T9]K</W0_S
M>#*=L#A0<1R8%`U9B3RQ;+[R?B\[_Z&&*\\&>.B&]V"/:#QTQ_E>SC,L5/EG
M_2!>\#E5426E.\$)>%7*_NI(Q>`']1))V[$%"G`"$:@`4Z<L+5B$'2B"`:``
M'YB`&[HY*)UU$8BKTWB//4*/FH$>\]"Q5CRE[Z.'=3L70;DO-\R)[MN)#\-A
MBQ,/Q^F=T(T71#F>3<%/1.F&HJJN<_$<ZPNEQ;!IH@,*/@2*=8@XB;M)B1L/
M:K^&2%E7.)*CZ6F,ZZ&.97CH8/T-2TD/P\N5=,`&</"&/#H=*L)(E98\G>B&
M7&"':$@&UDB'8U`2]KC*T",M;]D&9A`=G[*3=[@N4!QCIFH1>%"-=]@&:K@&
M8U@Q:[B&:_\8!^OKAG*@<)(DS]\`\VK9##=2)6)HIFG2@S?8`SS8@SGH!8+0
M`2M@V%GJ!EX@!4_(`U'8@V-:&#?P!$^@`VBRA6[0A2>`@CU0OSUPA0MDA$_X
MA#L80"^@@U'@0#MX`0X'<:#("5"(`3%PABE0@C#@`K_8@B\@AAE'\EW8-V*`
M!FCH>VCXA5>8AE\P!EO@IX4Y9UT8?%PP!E]`AE>@A'/&<5N`AEQ(PAR'AK]7
MM7V#ABCW!BP7_6J8AFK`ACS!,&[@!F\H50OS!G'P!H)EXKM2$FP#=W*`AIR8
MAUMEC<SP*W.SE,R#A\=@SUYM%YSL'FA]Z+.LGC_'QM,3_<#EABO_GRK$Z2O[
M"-9G@:GJ(8>]X0;%B.S*6(QV8"^F@@SG.7>`UO@!H:M/GY>=J)9[!(&38Q`(
M&(`V:(.;$P`&D8!+N#F`H#!!((4'N/3MTZ?OWCMX^?2MPV<.GSY\\^@I5'@/
M(46%^#IF3)B/'LEZ&>NE4_AN7;UU].XQ7+<.7CV8]^R]XV:2WCI[Z=;%O%>/
M7KER]>J5@T?Q8[Y[[KAMK#A/7[U\W+K=6W>1WE%[Y<A5U3<RH\N,]/`EK&@2
MW\.,^LB)"XET'4234=>EJS>OG-MZU(RBTT<3:=YU[>J]TU?N'=*-\)@E[0:O
M'-YTW8AY$UJ3<;Y]:16.=?NR6[1XR.C6_^-&C=W"=_>P<8NWT.0Z<OU<+]2\
MD!Q0E5$ADG/\D!RA18L((6=$2-(B2(L.08)TJ-&AYM*-'Y=#B(TD.8O@.&G3
MIPUY-^;).U'#I(X;)W7DE)\S!XL;1HSDX._B1LY].'!,Q6'%''0XX<1^6-"!
MQQM5W'%'''14(8D^>P0ABEL78IBAA@HI`H,8X<2AA!A'>-')%EK`HHLTQ$@3
M#331:`--,KE$4PD"!K10B3&O$!,-C]$0`PX;G.1"`"?`!$""!EDD@TN/K^0B
M#2PT-A(),<)<DPTRN!A333?51)---=-4PTTUZ7CC#3?JJ)-..O%PXXTZWW#3
MRB7FE*.3/N/8H_]//%&]<PXV%+&3F$+<Y$457?=05DX^#[E9SSAYM4,58^U,
M8Q=&)FV8X:,E39,.-(QQ0PQ?&UUCS#BYZ6,.0YQ210Y8Y]`S#T4D*9366?2<
MHY`YG^G#C5'Z)'I21K1Z=&%1]"0C`@@B3"`!!`^DD<8#$PCPP+60:#O!!`>`
M,,$@&(F%3TU4W?,2N14!BQ!&]UB$SV^W@F1N/<-LP],FA615#DPFU6,/.O`P
M]%)7,AGU*CWON!;/.MNDLQ%)'^GC&D/E$-7(,VZ^8P\SW.A#$F/Q!)P.:WVU
M1E?(Z^HSSU2@N7581OA@K!!7(:\CCS4TU;:0/M1LHQ!20A\3M&(MK5/_#CLX
M39,5-^NP4\XUT43\S32Y8,50QS"M+!H_0J-U,SF2(?.-0M$D(_,]ZJP3#3?P
M+%1..NIT@PS(C,X3U;`M+:703TI3E`XDE^BB2S*&%RX-+LDPWLWAQ"1#3"NW
MX**B+I,7;HLNE1-NRR6FU**)+79*<HLNGMLR>BN1F)++):W`XLHMK=ABBBNM
M6&*[)*V0THKOMN2B"RQV,D+%'%3H\$0><TA!RCU2N$!*I]-/[XD+8B3C@Q12
M4-'%%D>P\8HTU,C(#=K(Q!A-*P*8\(T&"$P#31:#C#.,)8>P(<`'KX"@B08!
MW&(0D4!&);)@"6T8(PO[@P7[IC&,0C1"'-B8_T:8U"2F:L`&'ME(4SJ^$0]X
M=+`;ZU`'.JIAB5:,(V$0L<=(^H61>:1E*7G"",7$0@V@1.4>Y/@).]8Q#70@
M1C6_R5`--<26?%`L'L=(AS!(MHYAS,8;U[C&1FQRCWQ59"'TN(8U^-*6AYA#
M')QJ"SXBTIN3K$,GZ5@76LSB$9`LY!SXP,@E/N`M"3Q@`&DX00$J,(`"%&`"
MF4!`("<``@>88!SKV@<]V$%##,&*B!&9V:W<4D9]2*`0"L%`"?3AE9[<XR'W
M<)-9<G@/8:TK*YYLBU`>0A1TO2,!Q]"'/#:@B6`I!![5>`?+0ID.=`Q1;A4S
ME+SVT99:A<22+YN'.?_<4C-\C(,QC'E85MJQ#7N$4E)OX09OV`$/<M#L:<22
M%#G&<11X4,-M.J3&-W2ACGO$PQT^T^*%\,'"8X+F'MTXAC=,!4*YH8,NU>`+
M.9B1F&W@D!O,@)LU;M:1<AQ#95G<R#:,]HY&X.(;WTA'G+B!#G3`B6[QT.@W
MNM&-<I@4$IJ(QS:H<3A=@",:QR#&-9(AC<,=(W+#8`8S#B>-:D@#&<GP$E`U
MFHTOW50:TJ!@-$B#06MT@QG3H,8RMA&-XIWB#E%XP^%.H0M]5($&D9@G]<KJ
MLU)$P`C)*,(4I'"$+73A"W"@T8O&!"8P#342`[";,*9A#`=\P`&#T(0`)"#_
M@@%((!($&,0$!@")#&3A%00(00`.@8@,9,`!B`"``UZ!R`,(8AVWN$8UP*&.
M:WRI&M7P1EYH,@Z6S`,>U_`&.^JACE>\(BT;:<A&UC&.4-8E9"`L2237D1.?
M]98<(=/A+5BSC6,T,R,PK&=9][$1M!2CG\,@6#>V41.A6&,;552(,OBB$9-L
M8U5BD:XQKH$08,V#&FX9"3V\$HT+D5&B182(.^KA#GM`PEL:N$0;3"$"0/ZQ
M``^X120LT09`8L!H;ID'2WPFD8RT14-E*:LE#H"`3>CC!!DPP02&@1'/:@`3
M]YA'%@ZQ`6'HPQ`2P``E*/**09S``Y0XRST.D8`U_V!$&2-8518RH8]`$*`#
MRSBR,%I2B!"LH6/K:$0'",$;I'1CO1O!B<WF>Y*O25(?YXBNSXQ+CV4HEVOX
M&-@URF&/>^[#'?!8!D;RX0YST`-,]F!D/N+1#=F$<AW)(`<[XD$,<N!I(?%(
MQBY<D0R2=2P?]9!';-51#T;ZUQ[Q(!D]A*&-:"`#'-+813:B48UX]`.FW\@%
M+T3-"VFT.A[>F(8MI`&->+3Q'BY5!SSD4<,U$F4=B&A%.;;!#&R<]AJ6V6B;
MMG&.J\0&%Q)@@0,&$`Q?2``FS!C&-]H$-'"@U+3?Z!%);VKJ,$7CIQ>\!@5=
M&HUS)V.VV(C&%+F1#68<8_\138B#%*HPA2U8(0F,R(<>]M`*LR(\(Z#`@12X
M(04O)&$+25!$*[2P"Z6V2$RD65$U(B$`9EC#&M/P.&,U0-@_#V`3]1#`+4Z`
M`$RN(002T(<FAK$)+61``+5@P.``D`4)2"`=UK#@-\8D<F^L`XB29DRA!H./
M=J3C%;?(L$+,V9+?,),JJC$)PS)B#G,<Y3=IA!M,^I'E>D#F0O6H%QP13@]<
M9&,;BZD&4KC.DG&P,F?CZ(A0,,:/MF=#'+[&L#WP88V4N.4F[(B&1*F2D'I4
MZHT9$<HZXL'">MQB`AUXQ0,`V?D_1@"0`EB#'`J@`F9L:/!EQ8>O^S:]II!#
M`FO_6)4(`D"-%21`'\%P@"8@$8!BZ,,!"IC$.,9A@5I`@@'-T$<6!/"*2Q#`
M$OH@A`2.X8$/Z&,3`K"&/@A@"'U0@@`K(`<]`G!+#7B@$@3@0/87<(D0=*!E
M7L*O0AQ&W8JPS))H68HH0T;H=SQ$GT6#*7B")Y""!SF$6-R"+8A)E(`#4&G#
M9+`%-Y`"*?!"+MC"+C#"*>1"*YR"-#C#\NT#!;K!';P!([A"-J1#QW@%*.0!
M'>R"0GA#'GA"'N"!+.0#.1!#+JB#*SQ()X3"+%R#.J0"'7C")S3('>C!*'P"
M'MB"/7`#'BP/+\2#**5#-=@"+_Q*1TS%/M3#-A#"+7`4_S>4%*]]0SG0"3QP
MPQI>Q3;$PR4(0#!T0QIH@B88P`F$P"U0@XB)@#D`0QNLP"U(@@80`C(@PR"8
M0!N8VS=`0S60%IB8FIA,`S9\FE)!@YJ\&S5XB12AC23$P1UXP2CH01RH@1U(
MR!O\P%@E',*5PA1T`3>\`<.!`1',PB:<`#3,FYE4@S;LXEU%`P&L@3>8@`+<
M@@`T0A80@B4`P#'`@P$,PC0``":(``'H`P(0P@D00#<,PB%(``ADP0`<`P$<
M0BT,0".DP1JLH4:9E)>D`SEX`P@QS&:D`X6U##OLT"U80F=4D0[E2Q&]TC:D
M&5685SLHEV)<%\<8RCIP'SQ8`_]8T-\JTA\]O%L\O`.<_$EPO%(\(%ZZ0,2I
M'$5BS!&8=48[?,3+),0<N4;C/<H(C8,Y!*!9],H0>=U"/`I,O`('7,(!3(""
M`5)/%L``K$$:#$)K8(AU-=Y#6I(9F8,\=`I,T(4$5()"?,`(Z`,D+(`^V,@:
MK,`!0`(F78(^\`,]'$(;G(`!.(,^J`#VZ<,%D(`^9``&'$('&``^O((!<-^'
M5<P!!(-B&$`PT(,!P-@Q1"4P2(`*$,(EY$4W2`.L\)A0@)/0=(9&?`W5981#
M9I%&6`,U#$6ZU`,K>`$9>($)TH$M?`,\5"0=V($GJ$$5J,$+[L$H=,-1Z$,N
M*,$>W$'_%>#F&^B!'JC!&P15Q+Q#\>SF)Q"G)_#"1O##/<P!&=@!*<`-,3S!
M'NQ!&7A".N!#->2"-J`"*.9!'NQ"/9!#=XZ";7K!&R3A&[A"/MC#&T`!'9B"
M0[0$&H)"*7#?0\B#1&W#(N@"&J:1W)`,.<"#P[A)GFQ#5+G#&A"`!*3!.V@"
M`1""`93`,&B`%@"E[P'"&B"`(!``)*S!Z&G`+71#(W+#`Z:).HB#:D4#-D"B
M:JU6-JB#-_P%-Y"6^3!"'NQ!*'J"@NS!'.Q#%+R`]$!D6;$"!%#`+3A!]X"!
M)X#!$"P"-'P:+P+5:G6#2W7<`3C``2Q"-YR`!"``)+P"`C#C_P@00"0@P"1H
M@0380P9D:08@``+H@LQ-XS&L`,NQ``8XP"&DP\?(B3J<R1E:&DJ<4U8(JEZ`
MU"5<`CU(FDK<T$NX7COVR>0EADQTQ,UL0V+PTEOXQ!<N`^*AS(:T7:>,VS"@
M1#3TR3MXUZ/2@WCQQ,JX1+J8%S[(D4>XA!>R`\7D@[^T!IA1Q#RH@SYL`YDE
MQ,OD"CVD!11Z'2_EPSDT0D^&7H(A6!I@TX9-'B/-$ZZX1;M4Q$;8RO3`A&MD
M0%?J0PBT)23DWB0X`#<(PPH`7P:`F#XTP@/H0H>M"HEM4B#H@P:H*R2@@#YD
M`@'TB@+<$C<H`/#1@P+XPSL@P%D6`_\D7%'O:8`$U,27P$I5/$1+<$J[G`6&
MX)FT:L1*$%JZT$,O[($:D$&#?*(3HA,\O`$0?$(51('+-H@=P`$\K`,UY((4
M)"%N*J$)Y@$J\%H]K((4[$$>O$%WYL$=2$(\D$0\S,$8[$$JD$PT=('1Y@$X
MM`,[4(,TU.C(>D(N\$,YR,<I%)P:]&8>C$(>N,(]?(,72"<>),.CO`,Y9$,I
MR,(TA(-)K%%&<,,B9%0'!:@W?!!KJ6&EPI.I@H,NW(([0((`3,(MO%P:L``Y
ML($6%,`*;,+,$4(!<&,69-X$G,!/\>)/5<,&?8.:J)8ZM`,WB*XCJI::J`8W
M8$,Y),,BE$+_]QBM&HR!*,1#%00!D`;I])1"`Q1!,E`!&,2!%Q2!%!`!'"3#
M4?7BE\A)-4`#,:2#-%R"1B7#-YC.HGV)XYC.NR4#OCC.4.D"-9CO)425+AS#
M)>3))7!;,D0#/+!).K09FAS%VBT75?1)5-1#/+3"*\"$*V&,.<V169!#?8H2
M0SC#5%#,8M0=501,?UW#/'"#.7T&97H*PMU#345M2G@%,[#$3H`3R":$<KV#
M>:T,1IR#>E5$,[D*HJI$S=A0K8;,1"@$/6H(99C%KF2?!FB`(3VLMWA+`:3!
M3;S#?K6*=7F$#4_/'%'$/H#9?%6L;I@``5""/HP`"U3E`N##.Y3`_QJ4``=@
MA`1<L3Y@@C6>0&7I@R`$0""0``$`'R5X`"2$`"'H0S,0``H,0@!<\3@LP`<H
MT@'<`A9[P"88P+Y"`@#<`H8*13HPWA#91(5ER,W,UU3D'S[T5[#`PTN`0QZL
MYAU0P1X@X1UX@C3PQ1OP@!Y4`10\@12\@154@13D`J+80@TLB!1``154P8(H
MR"FP`SNT`A68@1X<[1WL00U202M,S/&J`1^HPQ8IB!?@`1V``T^D`R^XP2B@
M0A2,P2Z\0SI(X2<47!78`8/8P1O(@CY(@WGJP1N4PCM=DS>4`C0XTE$TGN*^
M`DL\3674`SNL(`C]A)O\5_)=0C((`"3X0_\`Z$,)J$`E!(`N$(`*'`(!Y`,B
M((`PG,#S'>8`L,&XK58TJ`,9FBYI>8,V9$.<>`,XP(9JL8,WY`EE1,,<@`.`
M2&<<5,$3Y,(]6$$0F,+O4@\HT,`62&TG@`(5)`$>#$$;)(,W2`,OFEHUT,TW
M7`,U3(.<F-1/B=J[\2E0O5NZ@2XV8`,Q0$,W>(.I,;6,:,/BE<-(F90WH,1,
MY`FB;,08%65%L(,E1()FE$,SC80WU01/0`4WP-$7%J2YS)&>]$D\\`E59,IK
MK1<&@\8E(]PX3`/(<%-6"`PR@$0Y<-]T55VO7*LYN6&&T2.E76OD?<6Y5`R8
M[<-1>@2O((19I`7_QFS:1'P$25C#.80E:+1=G9D%9%M2LE!K<"=+&YT#)C0#
M/9C#JC2#,,`0/DP",%Q7,)PE1FC"Z44'6GK`*Z!`,U%$,13"*_@,,ZC`+0C#
M\N'#,Q0"."&W/9`#)-`A-7!#/V@"E!6#$4_#47(--Y`+95IK1;C#9WP&-)&+
MF[R$+7A!&92!%1RI>9:!%,2@/GC"#XQ!%$`!%#CM'4"!$<0!W+@"#8"B#E0!
M%3S!$TS!%%B!*R`&%5C!)^P!%$R!%\3!)Y1"'G3X1C!"%1QSKT:#%^@L%4B#
M1-R#-%2!'GC";9Z"/K`#')2!>=YF%WC!&$S!$\B"GQWO\7["+J@#.5B%_RNP
M1BA9`UVTA3LT0C0P#`@A!L-D1<18["A]\SM0'R&Z@R90Y2$$0CEXP`FL`2#4
M]SLDPPIHGC-<K@1D@4@_-3;0UC=TT1J*29JDR4FA@P>Q0SM0>K%APR(P`09&
MP6V^010\X4[[KD]K""@T`!(<0Q.(P2[$XA04`1RLUAI6`S6X"5ZDD9DX;TF-
M3_>FM#>LZ)=$0SH1P[P-E3<D`VET@_E$BMRD@SN4IE`0C$;2!(;-RQ-KA*$*
M)/EY!#.`!4Z00ZFN"SP@%%U03!F=RFX`DV+0&37DD$;4TZ<BG*0Q`RZ0S#18
M0Z!9`VN0RPTE"T2$^7SI4#_`BR6U]J>>Q6'`$?^NY(R&T(-(8L0^[.\U61Y7
M4(0]G!FG?L12[$,!UQ.VJMV^7V:7.?R^4PRGH,6L-CQ0D`NQD@M,],D*=))"
MG$.%#05%P$K!9"Q5A`Q(+@2B1(S-<,TZN)>Q=*MZ428^1#$_1%+&*K>PZA,\
M>4)Y>D$D?(,TN,$4W($4L()"O($-W/2"Q`$53`&,-X'9N,(-X,$=@,$<@$(7
M%&`<P$$,IL,38/@28'TRN`(>G+T72$-6@,(8D/(W#/D3Z*P5V,);!/X;O($=
MJ,$I>%<Q>T$IY((KP`(KE((K8$TZ=((Q[R8OQ#H4WM=:5+"\5-T@0)%0(.J_
ML$;'-`17..4VF,N?<!/_3E3D-EQ%.HQ#.YBJ&R*4F[V#+HP4-*A&J)A4!^4)
M//"Z-VR0FZ!)-]3O-4RZ[5,#(^R`*T0#$XP!T59!)/"#)^Q!(HAZIX""$H2!
M*PS!'ZP"*>A`'+C"(D0#2<U$Y7W09+C)BW[#-A1#@:93-=`)BYJ:-H!#-P!$
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MJ>'@(>]9PQ<MSR<NK#ZF`R>E2A5/H;_02.+EWKJXGIZ,>6)+GRT;4_"`T]>.
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M=SA8Y!YO5+7RFXU\BH>;1C"()YXL.4U'&F[BV:L<>_!Q1Y_@Z`G21R7?\:U0
M?2*Q!)CA]'$VHW+>"<VW\/39IYVPWB'GN*$RTJF<<NCA"9]EYN&-L*7R03;9
MI4A:AQBDQ"LGGW0,XZFQQ58R3!_2F%KMG;!`DF<=M98J)U-V"#/'FM<@8RPP
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M#R>J_Y@E#R]`T4>-%TC1F'Z06&D`"6:8,`()1UJ!(`Z)0$=XU%$/>$Q$/.%Y
M1SR^`0YX+`(`'[C'!`JQ#DR,XQ6W8(8E-J$"8*QA#=U(@P$BH05E[.,6)[#$
M.8"1"4'<XB99D8E(**.Q35SB*NZ:!C8(0X]MK,PI\TA05O!"CGO`(S#V*`<Y
MQJ&/I84$:?5CRC&LT0V>!&\YP<('1HXC(*VP!%@LD8O(O.*4F(V$)^1(QU+(
MT8ZN0.8Q-.286-(A%RDFBQZ/61?*"B4>E,4LBE%!UCT<!A*P,&<B)+')2XPF
MFWB\2!_6J`:"]$*2B9`#6F_)"%JBB(]S1(4?XT#,(I-1#O]IO.$.7MB%)Z^!
MCE@8H0I=R(H7@!"%.]@N>\&0PA2D((MZ,((&/7@#-Z:1CF]X`Q?3@,<Y[.&)
MNCW!&_D@HCX<H0,HY&%G<P!"%4:A#WY(XP=`N$$/;G`'<+@#'IZ(W#9]@)YU
MN*$,91@%/*21#6U\0W7JX(8^%($^.N2A%-1`2SJJ(:,UAD1YD$"&NO)A.R=>
M*R/ZB(=#%Z,:P.C()SNJCWC,D95R/"0=[JA&.KR1J7=,:R+<8P?SI)4.-G$O
M'MVPGEXXU3AJ.$(:.]##':30"5+D00[ZX`,-WG='0^GC?F)@AA2X<`0D$.,(
M3F!$IM+!CM(H32;L0%T\K@&/0QS_@`"$"$$A;D&`=$A``ML00`@D,(`0"$`3
MA!"`"0B`@FT0(`0'R(0?!)`!3>BC5Q+AHU'UT0I+Z$.4B%G'/,BQ,X3>XF<?
M&<<T?K:/-LY(2>2@!S'W6:@X@B20A2*'$D/SK&ULC!QM`DDYY#$/?-G$+CL!
M"6\VAA>4!<^)8(+B4\CQF,.<XXE3(^QP@P71X]3O,AO#&*'XE3*QS(@I$5G*
M/C*#59)L(QJZ>Z@3[Y%)3LUHAI`Y4E04@YQQ"24:=X#:+I8YCW)$8Q6MN,4W
MXA$''E@A#Q_)%#W*<`<RH*(>KJ"!?G:Q#GAX`QW&,*(TXT`#'GSB)P^%11.L
M``>2S*%N_WJXG2YL<(-M_H`.\;`+*:IP!QT`X0=E:X<G\%,*6+$C(22)4C[P
M$`4'[>$.MGB7;;X5,F9(HA_'W=@GL7H3LJ"%&^[8XD5(0J]X;",?Y7"'`?42
MFL#<9%CW<-,CT>)0V85EHA-#S41GQ(Z]O,,<^>C'(I91B2[<H`K0$$422)$/
M-[R`$<0E%"A@``9B)($+8$""(KZ!!388!:LZT5W.4JJ/0X1`$P=``"0PH0!]
MD$`#Z0C`,2*M#PS<XA"6AL0"`!%6!)P@"QO(R+16\\3ZW>,2K]`*/XJ[CW&$
MQDABN8H1\7(-:XC%*#,9QUZ8<8WF1F6+>MY81!I[CW<H@R0KV?]&Q8`6CFO$
M<1^D:<?(WIC)>XPC*;B)5AB->RUR8":R(Q-E5.:Q7&1_)+33G6/]!+8/G?BV
M71XIV6<C^A$N"I)CNDMD1"=2CJ?<@QWZL.I$'/N7CVD2+TYQ^''&2P]B=$$/
M;XA#+DSKDX\D(QZAJ"4>-`+E>&0G"I[0ARYNL`<J=.,FP:@',W0'CR[0P`:G
MR`=BWA$-:=CF'HP(P@WRFP]IW`#.M&`"-'U%AQMXX@WA/,5MYO"$)\R!@0OD
MA3;4D0URQ,,38XC"$[R@!UGLC"%"<:Q(F+$(9BP%$QMHQAH.<8]-E$`?D"B!
M,B90B5MD0!B&.,$V0E")8&"@&91003G_5("(8'!`&(4@`3E,<(ECA(`9B%@!
M,U0`B6!L?A.(V$86-+&,-23#$)L(!B+&$0E(4.LW]HC&(EI!#SE4@0ZYN,,3
MG*`/-SQA%<J.2B@:<`1<*$$*7TA4+HH`!W38PXBV"XL0PR-8?0Q"`OH0`0`H
M(0P#K",#&NB'`)@!"4LKX!:0"$`YV&`!2A#`$BF`A`DZL&H9"K\DEUB)/$#2
MCT\RS8OP@1E>8C`V1B,H"2B<XR5V`S"0P24*I8:&ZR*8@4300C.RZ#,XB26P
M82Z>`=\\B=9"QAJ"9YI\Q%^V*([6@?\B,"3<(9-$XAS<C3&2K5#\PB-D\&*@
M8EQ`ZRGF89'X_VUD_,W>V(4>V.7K&,,W]*@;N($>UDC+.`,?SDTG/&)'AF*`
MA(L>PH$'$\..\,%9OF(R]*OLO*`*&"$7T"$?P*&@DL$M\J!"O(`=*"O*GL`*
MD@`5]`$6;F`,X@P;HH$7=,$4<F$7(H()>H`'2D'(:(@L[.L'1D$SN@'IJ``4
M>&!R$*X/@H`/J""83H$:ID&=H.`'[H`.[L`3\N`.5D1'"`0*]"!M2B$;]($<
MM.$>F.&@1.(8W&XI,F$$BF$%%D\%UD`?UJ`#R"$$#D$9.N`6"($%MB$%!.$8
M.J`6&H$%E&$%!$$8)$`8`H$$F$$##B$9).`2!$$#F*$#7L@!A"$-//\@&!1`
M$("!`"ZA`T1`$@;@$D2@`ZC%=F:(&1S!$OA`#=2`%VRA!U!$'SQ!%((/_T0B
M%*;@#9(A"8Y`";@`"5S!$;3`JEX"'_!-XEZB$3Q`'ZB!`"9A'Q9``CK@`[8!
M`9AA$SK@'C#@$BP!`32``#@!'TI@`10@&%1`U>@B+.*M?C3A$B!J.+Y"*U9"
M'(#+FYP%9>@AX4YJN\S!'%;BV^H%&KP!!Q/R8HYA'=IAV\CA*U9B'L1!26CH
M_T)B'%[P6IH(*MKA6)!F+^RHB%H#+D5B'.;-W]`2*_--D-8B(WO#*78.`O-H
MN?AA'Y`E8##&-]XA6R9"-J:A&W['B0ZCW2+_J2LB8R*,)8A\RUGHH2P!PQHF
M`AOX#][HX0O:YP[*P`OF(!?B(1F@@1I>`@]XP`Z>P%QV9A=J8`J28)5,@0;(
MX`>>0`=DP`9LH`9@(`[RX1R8@!+1X[B>XC7HPK[21AWH(1MT@`:`(!9PH`=.
M`1[200IN@`_>@`9N@!?>JQ-H(`IX8`:@8`EL+`JD`!<F*@ZVR17@8`KV`#VL
M01O8(1SPP5Y"8AY:KQCFPF@X,U@"X27"@I%X4C&*$,WHPB[>@1^4HUCZI1QH
MC2<#AB?!(@;Y81OXH1R:H3E4(P:=Z"]THAD800Y.P09$X1:>0`J>@!'R@0I>
M0.6NTJ@>X0BVX!F>_^`(CH`+MD`1*M(NB69CQJ4?7"4TSD$9ZN'6S`$I:.4=
MMN%KMJ$9KL4<@"'(QF'=G,+5ZF<?8@TO:"L'O9`&4R:\N`L?Y$%F,/)-]B$>
M="'=\E(D/`)4WH0=C.)9@D4+(Z,UC@/;@F4N.\,N,V6[X.TF.HN&*A/9YFTM
MBI1.(3!=,*8>"E.+B`M'G6(DM,K?MJ(;U$$F8N:-"F8EQLO`)J++,`8C*?4=
MR+0Q5N$)=BH.=LH-5F'KXH$GXL`&@(`+HB<>K&$.HL`+J&`7]`&8>,`+3O$.
M[*`,=JIL^*$*/(P7KB4KZ,+>@,(BNB`*\.`3E*0=;B`(@``6I"`*3N$>H/_!
M"FX`%?*@!ZJ`%=(A&E2!!\A@#XS@#NX`QTY1INJK!ZA`%G;A#9X&'JI!&[CA
MDRK"MNK!$I(A69I!!8"0,=;"-YYB.7SC!HO0-S!B+8SF*59"8BT6,)TA$?(@
M#[!`&MQ`<*9`$O)!#6@@S_)R)4`A`HH@&I+`"([`"Z9`">`@$>8T6>HA"24C
M38%F58LF4C_B%OX*)+`!8ZSBL_+AC8C#2(CRN++B**I!&GSV:#_"9D+#USYB
ML2)#,:YEC,3"(\9+C("&AIJ'B)0":C<"*M9!"^_H6K=6+!(1+XS&:((%4DU&
M^!!#N(Y#8,(B1VQG71H*5`X(8Z+R8SYK=Z+BV)C_@PG511J,``]2@13PH`SP
M``RZ0!9VY1ZB-0HZ(17F(`^ZX`UVJ@ND`:E<P`;>0!;X8!3RX)_R0!3HX@W&
M"1QD!U#7Y3B`I0N>``\\@2>NX09>X`>J80[V@`_J81=\``AX@1&`8`\"A!H(
M9%OW`)7P5;WB@1G@H1-^@`I<(1U.80^K`1P\87?OTM]NHA'>#@F]"1#FZ$LU
M9B9(ABG@36(S!BJ04Q)T@`FZX7%.L0SF(!_R(`A$X6A+`0*D(!F,@`B0@`N4
M0$@;H;2DR`:!HJ%@A$#'5E/M5A\N06E]T),@(QP&2Q_Z$T"M8=N<@B^Q01O`
M0<Q`^&1&,)+4\EH>`V8\_P8H?!"-.A:(H2@H6A@D8@*PS.L<)N*.?#(O)U20
M@")F<#!3C6JYMF@S(D;?)DJFR(M<-#4XUL%<0`EI/$(UB'B10(,4CN`34F$/
MHJ`,4B0/ND0?[`L(\$`/[E-[JP`/Z*`:\+`'=*`*\L`-]"`*KD8*/,$>^$$\
MR1-O0P(MXN`'Y@`5LD(=?`!YO0$.HB#$2N$%;@`<IM<.`J0<&`'.IJ`*IL`*
MJH`*K$`/U*$;F"$4?F`*YL<5Q@`*2"$>WD#'*F,?RH$LUJ$1IJ&1ZS1RZ73G
MI@99D`5BH^(<%.$':@`7&"$*!J<,&.$>:E02CI818B`,D@$'I&`+Q,`(E"`,
M&O]AAB.5B8TYA/\*'\K!)B3",=HM:F$D*D7"&G[&0+7B&M(A&5`8A.]!LU#C
M9]:!W&ZB,Q-CE+I8,CI68*CADV8B+/`A!`V)+,Z4AB\:HS$8BOAVF%-X..X"
M1[QRN<CX8%ZBMP!T)A8!#.P8"J)@#$A6%":*#FP`"NX`#]3@7E,$#RBGL#H,
M-:4`#*K`##Y!$>:G'L13!WAA:!'5(^;`#C0N*ZZ!!VB`"M3!$=I5'4BADZ4!
M#LB@"DHA';;!%,IC#+Q`$12A$^+`?32C'#`,"G1!'Z`A6;T@%ZC`$0&T&5:B
M'"#AM.X(<#<:L`,["/72)YMA$:I`%*0!DIE@#ZJ@SDC_00UB@4Y70A%@0`RH
M80>0[PB(@`BVP)PS&K1O0?]*]"/,82WDH84SDBG6*&HI#H>CC"3HP2VT%H2O
M@5OJ8R;0-H_DX1G,BXA#XAS04CGJC1[&@34RR6\/R=\X1KD?!K2?^[G7`6+Y
M`2W%A:.W<-9"HKE1QASPY8B\P12ZX&KV(`Y&H0OXHPIHX`GV0!3NH`NH@%L]
M`1WPH1_B00?:=1:NX1I<`1JJ`4I7XPXZC!=\5X,W6IV>(`\.HQSNNPJ^80["
M-1OT8,#J"PB>(!6FX1U:X0>@0!3@P1SF@1JX02]`(@_4F^/:X1/V@`GT0(_5
M860,3A^X81'ZNEV00]_2N4[A_XU=](U0>)Q0SH$.*"`0J\`.J&`/IL`3\L$3
M[&!^(E45S.`/<`$'QED)C@`/AB`1_F)J,A7'H5LD;J'V9.8R\&$RD_AD%&T;
M)F--S:A?7L*]G)(>T($=E*;+\2\LAV(<//RXZH%-2U4>ZADDW(C?PF%.Y1)C
M]@52R=(IG!ARO=S1:;B[&<.-E&(U]-<Q+",LG+@'FT@X0((=POH=M"&\P>`4
M\\`5NJ'$D[4,S(`]\``.7*$>K.$5NH$)"B0:@"(90-4=8#M0;``]DAFAJ,D&
MHN!`]*$;>,`&F.`;5J&3`38(U.`>YH`2>R$:R"$2[CNF"_,=DD&1;*+!K(`Y
M/R$*?O\@"G1`#U#8'8Y"$F@<`ID:48V*P$5B)CSBLU;"Q_OW'.)`EZD`?7`/
M"E3."EY`@2.5S\0`&@!8"HX@%#P!!Q@A'@!SF9'%,N!M"C45:0Z=?B9>!CWB
M$BYAFKPB'$[ZN"QK1_9B)<Z!)][H47,DY=?!&I:AW^SVC,PA'%I5:;:-<4<U
MY:$EV3HBGB>S:,(PB",=,B9Z9-:B+`.7?0?[T3TKT6E(BJ:8AB+C'`XZ)-8A
M*_RB!(N+ZT-"-.?(LE`^9-[A%4[K%;`#:UBA&UA,#^)`$<#`[5=A&!9('**A
M&^)@"J+F';I!&]#!N.BA"WJ@![II(Y(M&4S!%71!/@?,$W3_XAJ2@`>>0!UR
M@09H8!28@`;LP!UT50=.@1C`NPIXH,.K(QJ")"/WX<VL0!82+A=2N0Q6,1UL
MHM.#Q1VX@:^70ADV(1_\(1CP`1,^*1A@R!""H1PFX1V801CJX1:.H1LT(1V*
MX17BX20VB!Z*H1;HX236X1;HP1F*@1XP81O281@0ZTJ5P1W>01CR`4SB81CR
M81RN]&G=00ZHP!:Z@`RL@`H89`[T(;U5KGZ-"B`\-3BR*X82)4>VE&JRJ)Z^
MAQ#SW8-(,1_%B!<=7MRX;^/%CAY#ALQTZ9Q'<L+T381(SUHZ?1;QT:-7;Q[$
M??C,/317CUZ[:\A6BO1H<>A&?/CT_]'39XY</6KT\*U;IU-?O77ZY"5E:M1<
M1YE"N<K49X\B/G+A0HXSAY3CUI`SC<J=2Y<NOJ)TP];=BY.>NXGTL)J%N"ZM
M4I4>EQY5O#%<4HL]]<W#MJYLI!I5[KBJ%^>&EU'WNL&+A]5>NJC$\$SILNM:
M-F+<\LF>&(<'CT]C[[W+9\H&#S4O&;F0$@>>/GA/>AA1UXW&BRH^:.BQ%P?*
M#5'3MIF"`L73/7LMRXT+S._<FR=17*E4YB0/'B]YOCUL"Y$:)&X;*2501@)%
M,`68*)/`)/DHD(8_#F@B2`;,8*#"*Q)H8H($#9Z@"0&9`&)!,`ZL<<D"E*20
M0#`6K*&)`?^WE'#!,1:DD8D!F'RP`B0%'$/"!>-X9`XCMG@RQ1E5>'''#XSH
MDT<01>Y55R<-B.$*$4@HD800>"2RACZ7(#`!!AILP,%2F7B0@08L**-/4IMP
M,`(F#SF#`@<D'/-0,"-P8,A6FY3``9OZ\`,(!RDT\Y!-KU0"43`HD."+/LVL
M$8@@@PRB"4P>M7*)/%I19,XUR]A$$3W8M",;1.Q8\Y8^YZR3%#W48+5,-!H9
M10]>C/'5D3SST)/6/NLL`Q$^\H!$T3R"/40//Y)9`Q$_R#HTEE+"*B4./KP.
M^BE6I^Y$3DC9*NG17=Z&.U>ME(K++4LP[5-/4N84>U$^@;E+T3G_R)YY43E5
M471/JEZ=Z4H<I,!:SDON[!!%'-#HXP@-3\3!#3?WN)/./;K5DT\T4P"!AS;A
M9&/,-?7`,\]$C-#@0QS?\-/1.O?$D809GL2##RA1>!&'.O5P(\43.H!#3`TT
M\&###7GHTX8./\A"SCN@_%!%)]S8TTX[^_"S#3R;WN'#%*6\4T\V<;B'1QRN
MK!KM.8TH>U$SP-#CCS/-8-(,/8A,HD\PP9@33#/.`.../\SDDXDUP?CCCB_!
MC(/).?U@0D\FS@0S23/%9$(/)L"<8X@RFE`R#B*46%-(.954TLTA_6QB2$CG
MP$'**3<X7<4>4#B2SQLT*&*N2!,QN84N_SB(00011R!1A"/W;`-))98T`D`)
M^KR813'*;&``,]$KD,DFU^MS00C-A("!/N,H4(@S!A2B#_>9&,*`H"@DX,R-
M$&42`"(/-1-`(908,!X@:UB#"0``"9&\XA)2N4@XZ%&.<M0J,$Z92%+&L0QL
M/60=\KC'RAPR#FR\8RZGZI9<-&B1>=3#'&G)ASG4]I#(4*0>Y)#7>-CRJ:C@
MHQUOB<N9&&..>LVG*JFZR#W80BYC%7%W2$SB1;(E0B4>Y2'E^,I&WH$,>4%D
M/`^)UKK4I4"LG`.'T9A#&;J0C'RX@QKN>,<3H'`'4^B#%#V`0A6Z\9![3*6!
M^M@'-9[0,'``H_\:W/"&3/;!#GK`0@=JF(,VP#,5<*#'"Z38ACX8,08]Y$&0
MT_@!%)[PC7(8H0=1@((-3J$/.$0A"J)XF"=L8(5.?.,=Z%B'1<X1#VZ8@PI1
MN$,NRL$-=9#B#IX811YVD0Z51:L<D"A'2**5%$/8;3Z(*=>I]H&7E>#E5QC9
MRF.$-1&)'.9=J&)$%:B`"BILL@I5F$,^0C&&1CAQ(Y[(`1AXL8.#'$0,2$@$
M8_`Q)I4LX!#EVH`$]*&"$3SD`O]8A_^8LH!R8&(!#Z$$1/OSD`ZD0!\&"(9D
M#)`2%7C``81XR"0N\)`-J`\B63C!0ZX)D5;<XDSKF@]2\E&/EUQD'=O_FD\[
MB#4LDSR$&P[A!C;T<BXG-K`>X;!)(35%+G,\@SY9)$>WWC$/J.[P3.,0%C[<
MP9)\F<.G\]&(IRYR1&^Q%(E-5%):WQF2?`AK'O+82#ZLX9.5:H1:QKHF%_6A
MJE^90S%3BT8>RG"'73PD'<SHQ@TV6212`*$*<8B5/LHAR8E,`VEJD`8S^E&/
M#[;P'L:X@1WN,`?Y="0/.KA#&4Q1%D\\X0Z=@`<]N('.)X!#'UWP012FH`-=
MZ&,.58@"'NK!C"LL]@W@T,4NI*&-:N1"%+S0AQM^\(9=T",9]X#&&_2@AU'L
M@AE@A0@R;3H73JQNK18Y*U&4U!'9J/>*<=#!_Q-*D8HIW.$.5;`='7Y`"K92
M)!13$(,NZID$(HAA"5AXA$Z68CV;Z,\9QM)'__3A`4`\!!`;$%!2ZK$`912"
M`P]1!@/H88'5Z2,0(U"&`?@Q$05P0A\O'4$@'C(.#Q3B$!V`L$,H<8!\>>05
MEIC/::RR4JM,3!_NN,L]Z.$I$YYI*ZKZZYG*$51L2-:_(5E'.B+#9'LQ)5?[
M!/-'RM$MO7WKJG"Y)E2C4D>]T"-:X;(AEN=,9UGEE"+N6`H\!+.5-^_$LQZI
M*DR4^:MQJ.,4=E!#*<3Q$'>8H@=CF`(H]*&('CPA#[4B1XXFL@XFA!(4K6"%
M)QCA"E*0PA+O((<1]O^@!R]X(AKW@,4-:E:%9-@#'Z2H61YDRXU'5F,?C'A"
M%:8PA61,,I2BJ`<[%,&#*CSA!SRP`Q.F$%P>V$*Z-ZC"+MY!C7N48P[<384K
MX`%HB"B/JW3I1X[JO)?W/N0<<M!!%$IQA]>^(0EST`<57M#?.8=B(,3`P4&.
MH(0M7"$1ARE$``2E#V>\KXYW,P`]+G#20HS`&0D`R0(P40@6A)@!YTB`B0/!
M@68HP%,EMM<&9HRJ#5R``Q9@N/=6]]Y\:"+(+%G'E<OQCG4H<R509@F[(CR3
M)>.1W1OQ]DLF0NBJYF0G$''(/LBUE"(^:R/F\/$2NP7G9;H;Z6`/>UUX&G7_
M'SI%Z)]"E[X^R#*R8N.79<!#*:31#6A4`0CUAL5O@1"%75-,)0U,AVRH,>PR
ME($[4K!"%=Z0SJ5@X0FC-<,3O"!L(8$A&TEA!!3LX(:77.,)U);&&VVPVS)@
M0Q]?H+9Z\*$(-MK!V4%2[1W>D`M]4+X*JY`-._31"CWP(0^R<,@#W1$)28K]
M^..0@QIL$8H>/';81;K#"T0132=.1!%-:@4$C'"0&"@"#EKH2"8$L"AV!>`5
M5K$()0+@O9.B(,4*@,@"@H$(CT>\_1<F03,,`&%])(`2>:0/'&!A^C`"*'!A
M'3`G!A!><G4)Z+<5];`-0E$4$0AT.^%C^'`.4V<L__-0#C;A$-:P;L>7#LE0
M4]:@$5D'5C1$9EFD51;!#P]D+-TR#R911.<P5I]B0FE55L?7@S[X$?1P=C)8
M%TTT$>]0%A2Q,JV0!WOP"9V@!FKP!D(R3MJ@#V]P`U80!]+`9526#O:0#\PP
M;%.`!W>`!U)X!Y_`!Z)@$[#P!'JP!YU0;U[@!>C$""M!,V7@!<IT#4=`AZ+7
M"BZ`3EU@'(I0!D]`"E(Q!YOW!OA527?@!8R8#/MP!U/P!K9@$>M`#]5`!W<P
M3%A!0^GR#I9P9S]89]8`!ZY`!S<`!)LT!DLP"K<S`TF"98K@`F"`"SDP!48@
M<)Y0!&S`#^.P<1?!`2!V8O\I\@$%2`(/,0(IP`\+("CGL&*;D``B18TCH`(E
M]0_Y8`#`T"?S1RDC0(`7P"?`D``VD2AR80GH5Q3D)DO5QT!ZL0_*\$#A$"OO
ML&[O\%7&)W;XD`XOL4(WP4(75!,440[Y@%<_E!0Y42_G4"NYPA3KT!$X82Q4
M$1+6H'4WD62EN)$<*1DX$5=*T2WTL&0>L0\>Z!$12&C7$@^D@`>?,`I[L`>S
MAU_>@5LWH`-XT`WXL0_F`!C3H`^K\`1G>%]T.#9C$`<YT@Y=4`9YP`A$J5I=
M4`W0H@BY1`>>9P5>$`52V0HX8(9YL!N>@%_])0^DD!E"L@>,=P=4``9O0`WF
ML'C_5:!W,!$5GJ`&H^`*?$81HDB*%:$O-P%-LQ%",)$47S$JU*20=[$/[;5A
M]C)-@_EU[B`'=.`%0,`#9X`>/)!OJCB+[T0;+B`&N&`$4J`$,2`%K@`!<F`/
M%A``?D`"*8`"VAB,%H`)(@``#%`,$;<)$@5A)%!R=:(4"2`(_Z$^P3!_DY!1
M!8@C*1!_*G=1$I8`PM`,&R".,Y96^;`)KT!31D86Y'`/>-$3,C,LY`"*9W(.
M.208,/0.&G5\ZS`-$T,.Y'4.`HDJV4(/X^!#\[$4#?DKC+$//A6$]^(I9:85
M1*44,M>1".J#-V0.Y)6$U]!U.T2>A#$35/<.]R`-8S,*_RUY2H\(#;+1!5BH
M!]S@-3RI$O90#NP0E'GP!HSX'K-S!TVX&_HP#%10!G$P!5Y`!7BP!ZX`&),$
M!'N0!\HR#530"7M@;,SP!)Z0!YXP*^*D;>R`:U`P!F7PHG=@!6\P"EJ8#U20
M&;671>;`"GKP":X0#_.ADN9P"59$#^=@1E]H$O)0+UF%9#!1%K."#\@2%[L!
M+TI1=2T$$Q;QA?E0%M]19$MD%..`!7V@"SG0;%'`1[#H"7NP"G0&"DG0!;GP
M!**9!*H0"T4@!_I@""NP`B0P`OV!+.>0`ATP`I10"#&G#YJ``1[P4JB2`A>0
M`FW**!V``07T$/YP`1ZPGONP`O\),`*"LA63<%XG9@$70`CQ,!&(X`]R<0N7
MX%GOH!CTT),F"A)\>D%Y!))G,@]2ED7S8!',\`[,P(/^15P.I!4^M0XW2%97
M1@_*T'7BBH-9%)(W-1%+QAA^=D5+L8/JFJ`$ZT3"(@^^(D(5B75(,:XK=9!!
M"%9Q@12P$`=[4`IYH`=FT`G7H!3W,`=YP*3;DG5;81'DX`A>H`=AB0>CT`EQ
MH`>=$`JFT$WVD`N>8`9CD!EZ$`O[Y`B*\`F.T`[Z<`VA4`JN(!_<T`JNX`JY
M\!VXX`FDP`OR@0N@0`JPX`JSP`J@P`JSP`N[4`[W$`FY0`S4$)#K0`W6X(Y*
MP4+F$`G_*@D1AJ``QU`"PKDAA=`!]+`)%N`V"'`+:]`!_<`"AT`BP?`/@!L"
MA'`+&%`,B!`"Z=`!C7`,'3`,AQ`"W:`"DW`,']`/AK`&Y>`AY9`&Q]`(C9`,
M*\`,E&`(1[0-<N`#HM`%/#`%W`$%?(!;0>`)Y<)6JB`$86`,/*`$$.`*>9`#
M7<`&$/I-%!$,Z):$IR(1%#,16O48-_%U5O%!?S<7^=`*J.:C45<.\'!"%`&#
M6_=D>82?4C8-Y)`=88</]6`-][!E?/40F0(1-D&#G[(6&!D.)N%DR^)`&]%V
M]7!E>%&B(4&2`5BP"(QTY4`.YLD1X4IUQB*"VIES9Z)%I#`'_V-#"J)`#/,Q
M#;M@"[F0"]>0%`9)$?*`"[H@#=,@#,)0#LP0#<3@CX*7+OI0#;#`"E:[DQ2Q
M9_$@D19Q#_PPJ/;`K_=0#Q2S9554%MTP,0Y1#L:05W9T>C=U97E$38J!3"((
M$<``"/T`"9K`#"G@#)B`".:`"25@#N-0`L)`"8*0#FD`"=N@`LJ`"2HP#FN`
M",P`/H<@".50`I"0Q\+0""=`#2<`"<<0K()PNA>`""QR"R1P`I<@`<6@`BB@
M=191#G+P`GS@"C=`!MR!;]+U`J5`9XH0`V&0"S"P!&&`"S4P!DTP"(H9%84Y
M&&X5$9!!5N_R%DPD12)1%-2[$=BI#__;D,4/<8]&+)Z2P1B9(K$@<:)640_C
ML(](-PZ9R`T@\1:9B"J*81/:!$TLT0PG5&;XJ2G;X!#7Q&8#6\MHEL#LK$00
M^!7]XI=*X2[1(BP\0584BA'W<`V[L`O18%.R80V&\63X,`_4%'7?,4LSP2O;
M(A'NA1@6<=!$D5X/#:CNY5Z,Q"C49#6SHA+K0#42J1OL8!P;D0XE^Q:*.5F0
M8$4BH1@H0,SBHD$0P:_D:P_N8`\VW:WY*E?Z\`Z2,`:0Y`.SY@7=H0]W$`2C
M7*#F<GTP$`:V8`1#T`E'(`:@L`9M8%85/=&_S&X'U-/,0,7W,`YZD1,,""S%
M0BU^QD!800[_RH"$[)8/$--V62%H>:03+#8H.K%FPD(/<25UGV)5%&$-S>"=
M&\$/6?=$.UV2[;S8WE+07M81;-;2:44MZ@6O%6%#Z?!!%%W0/A<K?179$\$3
M^]`.]2`/$U,-0IN$9S4J>+':0Q$.XU`/_FL.[%`4JL*^ANIE-Z48&X@NYF`)
M;SL7\T`"RE2RO?S0;C4J?>E$LR0'0=``DF`%9(!?25`'1O(";T#*+K`%VN<%
M7``!0Q`&B;`(NZ<82LW8(E$/EO!2NJ%,UU0/SM"@23$/!_INX94/_FL5CC$/
MS(`?=%84S+`MZX8/S7`J<P.$M=(6S\(N;)83[.)3;<%`[[!E;Q8M_\K0#[H-
M$:F2W]_$K40(H0>)WAP9L&1E$D6\$?1P&M>*XO.(O#*%GQ9!#SB]G[)!$RHQ
MDEE1%26*#V$1&>7@#-!,%UL]%->@3`XD5;J11P&+%?RPO.:`KU`'V#]E"0U*
M%Y0PSKV\W&!G#9+P!%10#:>P!%5@!9>F#W'0`VXT9XH@`T?`J%QP!U*0BT*0
M"%P%L2*^%_>@CJ@RA"PQ$_(B%5B>S1"Q#(RQ##K!#2S]3A*Q#55E4_A@*H76
M&`RH%//`#].D$_[Y%N'`9VCL$.LPGPGI$=N`/4D88;EM%+V]T\HM*^QUO!E>
M%ZG^ZF=&OGU6*RG]*^HB$QLV$U)%UT5V#__(0%X#W.EOMA7[8!/9^A'&DB^U
MLF#%PI.U,A6#DB-B#7;W8`W;0F4]J1NG<@Y#1%82VJ<B1`[;T`@=>^?>,@Z+
M0`>RP`-YD`LUH`914"1Y``6S0&>J(`9_,`VB"09#@`-<``*V<TUJYNKHG>>:
MD$#>/"C.0A_`4L&,4=I89$2$L2V!T4VSOCN\=-@\%9$[847U0.C8I`_DH#8=
MT0SK(-;KX`O(H@S``%<K%`SG8`[4$`S",`[CT`S!T#96$0S*`"_]H`PMSBC;
ML`W*<`[-T)#]P#?\T`P3WZ=G(KXR=2SLZU;C84.Z?,VZW"="IY#@Y.(BL?5+
MU'5K=<"H/AA"A*W_I^+$7J9-4D$.=\H1#-@N"]_32Y%>&*$I4C4L]7@3FSZ0
M@0%V](`,2Y$.L?$0FC8O,!U#A8V19](NA`#J1E'V!#L.C$`%71`%-)`,YU$#
M_=4%-(!P<P8&30T+."`%8+`%7.`%3+`(/G7+<L&#(4[Y_PT3KY`2[H*M9XW;
M^[#WJ;XN"VTL$L17YHD/QP#3;!4-R:"0F>AM[((ML3+?S$L5?DUA)*(^_G$(
M*)`%'&`.@;`"?K`!X[`!KLD!P#`"*Y`&)*`,_P`()$`"_,`!X%]R_H<(J=H!
M'$`)JZH"@8`)M\H!`)%)G[Y,)/296V$(A;YQ@2AM^,?A'*8.(T8$0V&Q_]`^
M??XLDC`$*!\]0,!(J!AA2%^^0LWT<<0T:9]*98+T8<)4,,4Y??CT&5(!:)R[
M?RA(.-,7;`6B%(;^\>-GR%FAHBKUT:.D8M(YIBC^T2ODK!F*0"@*%40!B./!
M0BB04@*4@E)/37[^^=('[%\*0,PJ43M7SYRA?<TPW62F;]*X?L'R[:,T:9*Y
MJ(80*<.W;N!F?/6NYML\$!^]T**;^0QMCAQJ??+,B::'[W5IVK5MWR9W;2"Y
M>P/K<6-]4'-H>N1HTT-.>Y_/<HO&W88.'?3FZ;:KZ^L=7?OF<7#FM)(#9,JG
M&U5`T;L3Q--V]J7!P/BS"L<1)43`A**P:-V^[/_7VZ\<*!__:`ONO__N@>25
MM4JCQYSA-CM''GT>O(JC<PKT2;;-VJ%G'68\,Y`]>(CA1I]SQD$MG-A(NXJT
MZC(+;;C]-MO@F0X4:.:?0OP8"!A.6.!)QQ64T8>$0D9XSH)`4AB(!$10X$>?
M"X#)!`44>"+A%BDW468<2CBXR8*!-C%H'!(P,8`2,RE1R9!`"BGDG'Z:&>&@
M"YZCQYT-Q+J`'W-&F,0"<YHYAR,.@EGIG`LN,(<#9_X)X)RT)#*DD($"&6&B
M%/SA8!QG2.,'F`V``<:">?1!`1,.F@$FRIM2H.>?3,[A`)!FFC$`D*0X^&<9
M0/T!9B!:"_E2F0U4P*G_210FN0`CN7)BP<1UE`D`DW!*T,>"#O3QH)D5Q,2U
MD!0N2J`00(+9!T3B>#K.FGT6;/&>["J$L2?/UNEL'G/H*2?$__!AAC1ZGO.M
MW\W@'8B>>T:KK<">=FO$N/8&E,[?BBDN;1LM+I&F"2MN\.*.&YK0IXH71+%8
MNS@@$..;)Y00@PLQB(%#BWI&TF<>>O*QA^+>8GLIN'OL`9K!Z5C#Q^&4:;ND
M%6L(?&<<"E^:)AQU7YIG'8(37ABU#/6I)^MMEH9NFL3T6<9@?;999]X&\=EG
MNGQ.Q2XY??BAA^X5@$%A$[.*PGF2%"3$I"P4/%!A'@M04$&02B892)!Q2[C`
M_Z82UMA@KA'\D1*%#8@%DYX-HL2D3)"*@LLR?9K9(%`.1NBGUA$LW>Q.>BX@
M@0,+_%D`A0L$*I)(?0Y!Y!]_$"E$!40$WR>0#1"YL,A@]>&@+42LNAM,<Q)0
MP2AE+%"!!.#/(4%6TE`0:)+272(A6!("":22@=H:")"J,NGGJC,)0H$O2C8)
M!K9\0BQLG4`3@5!!,`HQCA20(!C]N,")VG<!?U`B&$E3CCMJH[!US"9AI$$:
MB\S!D0SA(VL3PL8]!$0VV[1C&F`C!]T2QAF.+(A%`&(/:)"Q"-V4YA:$V`8D
M,F$-%31#$X@H!R2*H0]A0`X3AG@')(+!C$"4(Q.0L/]')80Q#B#6(A/N@,0Q
MSJ$)>A1#&/;81#.LL0E[,$,9]PC&-O@1C'H4@QGQ4$;4QG$SVHQC$+=@`A!J
M\(-/Q.$&KM`'%5S`BI>PD#:=B,`0<D$$,<1,"6"`0R+8T1FP]:8>,#H5/KK6
MR(=AQS?UD!?"@I,A&89&:?\!S3M:`0L4U<8:6^-,,]2V&6OPA#7R:.4Y)$:.
M=7!C:BS$AS6.H9EIJ.T=PGB'*]NA-`<1QX,;",8&9F(`8,!N'ZUCP3.*I*IF
M!(-1%\"$3SA%&0YL0B*'&,$R.E`)E.B#!0)IUD"^E)0+<"08=1I'2E+0#P60
M@!*(T`<E4@*Y?014&85@Z$O_-G`.6@UJ!)G0YCF`1@*7Z&,#(^"5,CP0B'`H
MH!#!V(0^`@$F?:S@,/1("2"<@:B!_$D?$*3214:@C$QT-!C*`$9"BH3/0G`@
M$/H80;!&$!F:%F(%`S&$(4@`"*D,1`6:Z$A:'$()8##I(`KXQP6488@$1(8#
MDZ`$"=)RC@0<+AC.:%T@,B&/5\*M-`@3#<:P9LJ$]>L=R(BF(VFSCFIHAAX2
MXNL\5%D;O(8&7J!I1B/401M(9&`9+%"!,`Q0"T1X(!@(V`0^0K`0$EQ@&QA8
M@R8(<`L5.(`9#EB!,`+@#Q5T2P%K\`4#;K&&!'0#`8"X10".$0(#;`,!:0B&
M`"@1_X(06&*U:\!`.N8%H&6PP18W$"004I&'*+A!'XQ`Q2D$2YLX/*$+KC`"
M?98@!C`XH1'M0(<WX+$.=LBK'N6H!SSBT;9Z\$<TON%(/=9!CWJ`B,!MN\=^
M7>F3Z8[W'JVPQ#Q,2)MRK&.7-2W:9NB1#MI<@S7\$*<^WO&A8Y*-'LB0;CG(
M$<T#4\.5YFCE0/A!#@\>S$3[`(0R4-#0#IP#HR-004(_^@]]I``IB`A$CANY
MTMGA8Z?ZR$()K(*D%`AD!![H`/HN,()1-;*![:R2/H[D#PN08`/->,@*+B#5
MJV`S0!P8%)CRL3D%6(EVN5O!/W1%#P\H0P%X^7,P+!`27?_EA0.40`$E_+&0
MU'"@,!;P"0J`<5;U^<00(\@1Y#C@CV#\8Q_*6``_.""01/L#$SP91P<P(5+6
M`>\Y)/"#/WZ'`D,`PQ\>>:M"SH'`8@A@I@)0QD6SN8D+$,2!$;R5M.Y:F^E.
MF)2PN>%`]L&NEZP&;-:PQWA#,PYOU$-A&8J-UVCCJLW$N#0.2T<C7%R:8K[#
MPNLXASW>X8YU;".:75U;,]Y1CG+<@QGIV$8_TL$,>Q^C'(QY1S"L80YEE.,8
MQ8C'+9JQCU>4XQ::L/@Q^@&)9FSB$LP`XB4@P==M>P<*/U##'?1@A2<P<@Y,
M((6V0],),?SA%40X0LRXH`0G+(+_'-W@1CR\@0YV%/@;Z8`'/'J3-(6UHQWW
M$!@JU]$.>'B[14&?+XOJ(8]U()@V>OT/A%FTCV@;&%XU+#M>HP<A@Y%C&_FH
ML8FM8>%RS.,=GB':51;L,+N5YASN8!&+1L,13SV,'DCASL[`UB^?-,A$&O6)
M9V*3C\9?A1_GP-OEQQ'MG[[D-?O85SFCQ(^9!H.BI!G'UE!T^9<$8X[`P`1-
MSV%JT_ND&>9PAH2:@7I`'`8UG8;<.82GX4R,QA_TV$>K,L$FFB8ET0-1QHEF
MXP]^1#\I434$NW9MY(X0C!_Y>*@@#N,/R^S-38$`!IX.48Q,3'LQG%.,`I]C
MB&`$HBCR_\L,8@.T';+3@]S<^;]\&`<;F@?/4(:GD3E^JX=V`(T!BY$"V9<"
M@8K:P)O2`(US6(07*@UY"1#/4"$!X4`=(SG_"`X0]*1H4QK0J(=L4R$;T[O0
M&(EPB`,CT`%1*(4RD((F@`)/R`<O>($\D+D`"8,8"(-<R+DM^(,MD((B2(1T
M`(=J\(8HE*]Z4(=O@`=UJ#JE>X=[2(=NJX=XF*]T4(<Q3(=TR+8K!`<K3+![
M6(=Z2`<PC(<`D9<Y?"7VF(=+N`1\D!O!<Z4;0HUWV8P5;!$-ZPG!:P?CN(?G
ML`8.8Z%[F#MSX)`)\3;0T)"K$+>[BKN7T*C:"`>-`@T;^L/&.O^.:.._3`S"
MI<&K.CQ%?_D_]B@':G,L5S$'7"J-3_HO`FFLVU,.4BQ$T:B'<\B'<N"&JV&A
M?>`-<F"1P`B-M8,07MR\#>)%AFB$'K)`[0@&F_@Z`9&;T%`A#('!@>B-#XR'
M>W@'>S#'H2&P<`P-:Y`$*2`%7<B!);`"*:B".<@'/'@!4#C%?/B"&/B#7)B/
M(Y`"+I`")&"$:L@&;\@&*,1"=:B';U`';NB&+(R'=""'^/J&>+BO>,B&;P"Z
M,A3#;_"&;E"'=,"Z,BQ)$+$O#R2-!OL/2,`JXFA)"EF.I+D:%LD'>#"\KQG$
MV$"E<%R':W#)$$F'PT(\?7@ZSO`V%!S_"!DBNW,;Q`ZCMN`(-]K0&=%8$)PQ
M$'M0Q54T$%'TRHIQ)099"PA<"X0!H5O</QD3O,;"(.5@1L[(L(0AH=*@&P%K
MD7>((9E;L8$(!XF!#J6)1NA(AT58!HN1#;VB&(SAP(>9EWS@AVP[QY5H3!P:
M"&Y8!"PHA2ZH@BJP@B[0`5-(I!>(N5/$@P8(`UO`@4Z@!2H(`S!H@D28AFCH
M!F\`AW;(!G3X!G;PABKL377HS6O`AFS`AFOHPOS"!G$`AVM0!W90!VS@AC$4
M27AP3H6,0@]4.E0BN=Z@O/]X!TO0DG/;%T:DH1<\F')4FP&I0./`A[OSC)\C
MFX!9AV:8#JD)_XUY(`>$.<'0^+Z56)!I^T;KN(IE(,\^7`X""<L$5=`%-<^[
M"BS:J":U+"4"B49Z0$`+1`ZTE#;6.#M+C)&5>(=TF(=:8B%S,(<%;+R^4XZN
MM`V$`8UM6(1P6,4,$1!BM+J1\(RX6<N'*3#ZHH>[^]&?M*N'Z0=&^(92@(([
M>(,I6%)2R`<JL('2#,(X0$U;.`(P\`(IV((ON()&6(9J$$EL0$AOX(9KR(9K
MB$)Q<$YV$(=L<--J@`>%_(9H0$CF!,Z$A$B'Y$W<Q`9LT`9Q4+JB>X?Z^B#9
M:!#DH%%BY,]+",]S&P=8U##`W`QWD]09"HUZ"`=/V@;26`=C8(>4L?\&9O"W
M!R71UM`_#0L'AWD.G8FV&VJ0`X5&2-TV4U11!K756PU"_YO0<L,0CL"83:R-
MN/RZ%"1$V)"-X&A#T""'=(C0I0&8=KC*=S!4D@M0[5@LVB"'1KC0B=G1Y+#)
MT?`)`7$'#$(.>C#'3Q(8WX"ZE^@0-NS->:#.^:JOFQD-H$F&1&`$*9B"."`#
M)GB"*I`$?1@%.UB%552$,GB$7%""(R""+?`"+FB"12`&:=`&;\A3-[T&A!S.
MA%1(,W73;!A#A6P'A$3(A:R&:,@&;<`&=0!9C$6'A"S#KNM"Y[R'+[PO=D@'
M=5&A;@2-=;V*>(B$2ZA`N\0&<S,11:V':2#_Q1/!(7QXQKJ))FM`!M0`.^H8
M"(>+!W.()GNH6?+LD%.]"HJJC3;40VX$D<=XD>-XB<;:A_RQC<&$#KC%U;D]
M1:7!!V#L/Z1QRWVQ#6"U0!;E*X3IH+BK5YGDI=A(SQ#!!WN[.Q%CL9X`2^V8
M2[TK6P!ICK.A#1;,-A4$(?[HD!FRNGIPMZZ3C7<XARV,A[EQ!WD;5"ULPZQ9
MAWDX5WIHAW$HAW18!S'DAC*L!W:8I@*[AGP=`SSP@C*@@B[@`D;8!R^P`498
MQ3C(@3_`!2-0@BT``R7<`D>`AFJH!FW06#?5!I7MWI*-!FU`63'UAFH0!VUX
MTVR(AN'LT_'=V(VM_UCCO,+J?,[Y`D-V*`?=+(=Q]`Q4TL[IX@9+>(6#<!A\
MZ:_2:-;00$8(M4MK\!KITH<RE=MJ/#'-P,M[^9FU>)"DX0=8+0W>V"!P739?
MY`S`1::JI=L6]DI3M$S:Z(<+IHT6U(Z1>$OBL+87BS98G;'[(D\69I`/J1MP
MHTJ\(CN'6;JOJXUT8(-HH(UTN`4\,H=\.(9WL(9FJ`=H>H=EZ`V"JX=M*(=G
M2C!N@(=DV(9XV(9[$.-[2(9N@.-[,*;?>,.<Q=EYLX?<I8=I:,/;W=W[1;H"
M8X=K(`4JJ((I@()#GH(ML`1],(,@T,>A=-8M:(`_<`4B4`(DV()-+@)&0/\&
M8H@&::!3:-A8]U59](4&:*!3A%19-^U3/\4&.L4&4'Y?*/1><8A"DT6'^.K-
M+KS?W6R',NRVK%,'#OI)-\Q=2&B%M&3@H#DWI5'48DT8$QX8SY@&;/B/="B&
ML>&7QH2'>>"'P-H'NDGBGJ#*V#!:?2"FAF&P<X-;%7;A>);G\9I<QHKF&]Z'
M5OP@=F8L<M2'7O*7>6`;2=R,#BJ-I]TV<^,D7&QB24@,>&D$`[@%#@B!3``M
M07``32@`2#B$`P"&8T``3'@'"4B5`-"$-4``:IB`$-`%!M`$$9"`;9B`-;B%
M`O@A#:`&#?@C"1@&0@`!9@@!0C@&"6@%Y;D%#7C_A4$X@=O]9C%,!W98!E#H
MS"E@.3J8@RD@A7KP`AI8CU/<`@CX`UC`Y.KE`B_H`D=(!F*`!FU0:_.MAECV
M4SIUTUH.W_)UWX6,AO+MWFAHZ_;=ZS?MWFS`Y;>&3OE*AY+MR.9D!]X4!ZIK
MAZ/336*ZADB`!1@F1=:(QB%]R@KQ3QL:#G:@!J@;AFJ@8=K5-WVPAVU0EW/@
MA@'DC%X,1-3@N@.=FI'0%]LPAW,X)IR1#?^2-AK^C\B=Y^$V,:\4$`QZI7*@
M)F86#89A#67,F_T;#0<D!VPHL;CEEX'85-'(SQ<[#EG-#'/;!\"KQG*(!&0P
MY^6XAUN`!&NHA%<XAD-@_X8K8@9$.`9?"`1F.`85D!]"V(1M6`-D>`5!X(9&
M,`1A2`-A@`1"Z`=!B(1:2(-A.`05.(9!J(1B"`%J.`032`86:(-;R(!;.($U
M>`6>S@(30(>G;H>ILX9KB`922#DS,`,U&(51J$=]B`(:0)E3#`/4S(8<4`(E
M,(,N"`4P<(1HV%YB4&OBS&NWQ@;KQ(:UG@;YC6MHR`9B,-\L?VON-5]NT`95
M?O*\!E_B=%-N^(:$!$[@++J&I$ZDBX>@@]=VB`1<@%7DK@T)DU#'.IC9\!H9
M6N+,Z`QV>-]['HAT0(8>V@9KJ(YR6`92[$1J!9$18HUC6@ZZN8YYL`:PU;!#
M9?]B>B;N3Y>Y<76DNO*_P30'>'[+S3;H060-`2.-=D"&=+8-9GB-X@B.K,SS
MN(7G"8F$9`";`O.,:/)`R7,1ONH72!BYWNB&>RA)?;C=>=#(IZ[(>O"&KG7#
M=!A4,,Q(>$"Z<NB&;_@&-S1CVZ3.*!S#8+X&8P"%.Z@"'GB"*.A,+V@%?7`#
M()!2F8N#&MB";-`!*`AR)("&+Y`#:<!R8ICE\LURO0:'O*;3O*Z&;CC9O$YE
M[AU?:%#R+S=?+"=E)/_8CE_ECHROA*2Z=?"&_G7.=$CQ^.)V;O`&2Q`&P2#+
M9\MUZ"A`$7[M2]4,<EA?:^#.TG@'<2C.J[`[#PY*4E3_,8<Y]2&E4#UW++BQ
MQ=IH8U"7^JEOT1`9D.Z\#<=C+-M@T6^%T`?!/=*HAVM(3XRIAU!U=4U_;>&&
MRFR&!,`B5'FI.@'F=GI@AW>8MT%E!VZXAT&`A'LH^355!S"5!C"M3758AV[(
M!C,'!VZ'^&M(P]ZLANA\>'"@AFH`!XAG>92]AO@:;.',A3G``SJH@B@8`SUX
M`R\0A7SPA#T0S5,,A3((!5C(@8&\I$XX`D<8AFC(A;56922'AF18ZVB8AHQ/
MAER(AF0H?HOG:[5.923/>.!7<E4FY2_GWH6\\HKM7HBLAFF0PJ/[2&O@AMM<
M!VHP27B@AD88!H;8U;H<6Z,=_]I`=$!N/-4%1"4L;@=K^-30.,3\[[HZ!PAS
MYLJ-PZ</W[IU\N09U.?PH+5F#1\ZQ&=NWSZ*^N8UI'>.WL.)%>O=&Z>18L:3
M*E>R;.GR)<R8,F?2;)FO9DMZ($_6<R>2XLZ3\U8&=7BS7M&#Z\*=_!BR'4AS
MR*S5<]GN&CZD("?^S)<4Y\J;VQI%H\>N7E5ZZ^"AG;>.W=EU]NB]:P=O[:M;
M\.!Y2[=77;5KWK)E`^=-739NU:IE4]>MW#INU\"),US-F[?%W;QUBU:-6^+%
MB;%=4Z>86S0YG=[<J5)%"A4NHNQ1<>$)K$M\?F+XV85D"YXC1I0@D30,&K%<
MTJ(Q)_^6#-HN8M*A)4LFG1ARYL:N0\MUO3DT:=#&2]<V'EHV8MJ8:\.VOAHX
M;-&F8>.F#ATZR>FZ<2OGC9LWU"S&C27"Z$/.3Q7Q<Y-&\UQTDD<_U3/..AJM
M<\Y$Y%RC3S[O1"/.--O<<V`SZ\RC(4CKU&,02/.<D]$\\ERTCCD4S7/C.%_I
MX]$Y'%JHSS[IG#-412+1X\X[]Y3#$D@,XO8DE%%*.25*5'*8H$/TU.AD2%UZ
M^9".#WFEDD!%.4A/50Z10Y(^XF`3ID?LI%/5/?>@]>5#*5E)T3:+&`/5/.^L
M\\Z=;[&C#UKW5)A..W"1$X\Z\*A3#G_HJ-,..(MAD]@UWWS_1MIB^Z6CSC?Q
MH=-.8N)((TTVS&'#6&#7#)@98^(,PT@WG4@1QQ14>#%%*_J\T<-M>W+810->
MV()$&'@,@<,40T@B#'+840?-,=%4)]TTT#"3C"[,Z0(-,MK!D@LLVTD737?C
M86-,-,1$@PUVTQB#W'C2E%<---%\X^EEI7'3#3N*K1/@-=-TTTTRD`SC4(TJ
M\=,C3^;H:+%&%E5(D3DF/9200^4@,T\XZUQ#SCKD>,/.B/.4N,Z(^KQ#SS[T
MI!.S/"'1DZ,^$9_43%!<AI..-40^Y-9!]."C=,A8`LF2S\9*/375+:59M4,9
MX<./TUEVO>,^6'JD$CX9<7D0/@95_U7/.NTXB*!&Y!24SDY9;5513#$_>9,U
MC23S#COKQ`-/.G&Q=1?A[,1CYUKPE/.-7_$`Z$T[_V53#7_@='/9Y8MY-B!_
MBPW&&37?=--O-=)\UOE@@066S36Y+))('F!((444;R1!BCY>S"#*TWO^`0,8
MN\2`1QQ&Y&!$$8NT\OPJK[2RR2617'()]*_`(@PPM[R2ERZ6O"*,+]%+'XOT
MK9BOB3&OQ(+)]^C?8LPPX\,RS'/:2J=Z=9M7\TTYVH&.:\@*'=_@!C.6X[<L
M18TBY"#'5[2D$K7@0V_ZN,<VQL$EN4TD'<RH$#W"$0YVI2,:W'"(DDI$D7>0
M8RY<RHB6,/\&I"5-D&SA",9*(*@/=R3%*2K!T$H:B+4A$E%*_`A3\$[R-28!
MA1\K25O9]*01G:AD'^:`(E`,`B.#-"1M:=I'.^I!N64`\1[O&,?,LB0.H^F#
M:U/<F(6D^!`GRB0CVV`$+M(!P'1X8R^2B\<ZO@&/>,0C'>501SS^=4B_')`;
M\/A&-KJQ'`%58SVK>M5B4N>Y;+!J,>!(1C4^%TKF)"8:VM"&ZK2Q26[H@A$[
M0(4MF+"$)T0!"IYPQQ1L((FIX2$">!!%#L(@!FB!@1%P2`0<OJ`%+7SA$5_X
M`C(3@84KL&$16FB#'Q[AAT3X01%PP,(@M,"&1"C"#UI(1"+8P`;_/PRBF]R<
MG2+0F0A'+*(1CZAG)"P!"4A$(A+[M,0E+%&)2@@4H/P4*"0LL8I(+,)`>%O)
M/.ZF1"4N322*BH>%$M*0>BRC9.0P!BQ>08RA*(D;1<''.YAA#@M6Y"-+S%)2
MZ.&,=HQ#B`X)A]+.=B"G(1&)1?PI4%^"Q*[E0Z<OD2(^>&BU=>@H'VFK(H>H
M6"0P#25L'],'R`XTC750""$JHHI#LJH4/8WH'@_2"!`SQC0(R3%K^BC'(EYA
M2,F5(Y$'(UPW(D<X0WZ#'?``T#H^DP[[1(,_U$B&OOC%G&@D-I2HE,9A0]D-
M5:9N.=JJQC2J08Q5F7)>S*ED-6R1"!P\_Z$4HKC=$Z`P!WTP@A&KF)HBCJ`(
M7M1`":P``PX8\04W-&$)0N!"#*Z0C41LP0QF\`(>FJ"-;L"B"SIX`A6Z@(0K
MK$(:\4!F'+80AF>"(A044((8(+"%*UQ!MTC`0BF.<`6%KF(<P8C&,HAA#68H
M@QD9I`8SBB&,95AC&_H]QC&$\;UAE*L=,6F1&REB5*,YZ1TU6AK'>C2/=.!"
M$\F@ES&,03EFE,,:%,E*,;BAMX:<XZP?!HE4P:0G+?$#9CI*&TXARJ2V!K7&
M-HZ)46'2M11G3*='"E,];+HCHQ@)*#4#TD_H`=:06,/#,N.&-0;+#6YLC![D
M0*O'0G*UD#!58O\ZDB!4^X2+0`KN@)':2SG2X1>_O$60AA0LY`0D26FLIQO=
M6E4RF(.+:(!#6YU;%;="^1Q]+59>Q-`L<RS+G/'``@Y>@$(5O/`&/%CA":Y@
MK15X9ZQ]J"(9SV"%#;@@!EZ(MQ.=B$,9N*"$(6!C%5T(@Q>DT`E7*&(9X^#'
M-1R1BY+,01K<V$8Z2`$*6G!!NW\H7A>4(&HQA**81S@"*\*P:F/@PA@R82D*
M<_P2%D4-'PRZ(E!V5`XZW6,N]9B'GE)6[7X-@QC=N$<U<)$793"H'N=HQCE@
M=F)\5_&*^9!C%R<&M"S-X]]@THE8L2R2FWBE'UL^25'%9)1]Z)1+#/?_$<8?
MJI*+ZU2*^=`;2QFD;9:,G&HT6\DY<MPU?M`XXU/D60UATO*;O,.J:%V&OA_2
ML2N_53K(6`9DR-&.ANQ#*Q0Y(KHU8HYS/_$D8?/I6_T62FIP`QW38$8UK,&-
M:4#.D-THI.,&-F5U[,>$\$G&89$!Z%55(\^@E$:>4X?VPC('L=+0!9ZUI;I5
MK4H;Q,`&,J@AGUO,P144@`(,<A"*.$@A$?N0P@L8,;4PX.`1L##"$8I`C#PD
MH1-A*$49B%`$6D##T6;@`A@440I0D((<_`A'+%0A>U5,XTBW8(0G0M$),*!^
M"[%HQ12(((9.^`$,<8`!*6`A@RT@`1:X((93_YU4E025[2$6O$?7QD'C>]#L
MY!3!?MH8;`]S'+$<]G`(2;;1Y&G0U!*^\,4KIA$/;\`"%JKD[S%T,8QWN&A(
M*+Q@SVC?!#5#/Q`%FCC11(S(^0')/K##/(R(B7`(4Z7%UE",5YR?4O5(/MC#
MB'Q<4=F#P1F%CR2)43C)Q8G@R#F-R.%)GD"<2G1@E7P-Q87$1#!(2H3@3^B)
M4[D<`+[5.^0#'=V$0;`<WC0$$'J;@NW(^5G<3:Q5\`SABT"=S;D<%"G-PSD$
M/]A4Q[P#19P#?R$#9S@'-]`++A@8V#!5S.0##]$8CUU0R;V$-23"(224)?23
M);0")#A"/ZT"0+7"'?]>PBOXD_5<CS_Q4R-`PB%(@B)"PB(TXB)(@BE$@B3(
M@21(8B5"@B200B2X0BL$E"FXPO5P8BN8@BE4SRWXX?.80OJ8`AS`P@X`P0Y$
M`1_$@0V@@CYT@0V8@M3@0WCYP2S$P!*(`1*$PBP,P1&,`A7$P!O80A=,@1F$
M0;,8GS'L`S2$@1#$``Q$``3$`&^H@CB(`RGXP;%!HZ@YPB@H`02`@B(,01CP
MPA^(P1$P7RR\2Q*U49A`6--5$4>@W#TZB$!P2%K4PS58`S*DPSJDPS@8`S(@
M@S&0`]VDPS,HPS*42[R0D3480RRL@C$HP]78@SWH$/9-$3TT0XS]$(7T#";_
M9`(F!,,M%`(P7((FN%\C7`(E6$(QW,(A6$(CO((E%,(K<,(K%`,PC,,EB`,G
M6((F"`(G:((AU((S^(,R%,,UO$(CM`(A:$(Z"$,Q&,(M!$,^'((FW`(G%,,F
M",,M8`(AC$,A"$,L;$(QU,,K](TO4,(D!`,E*,,K/(,SG(,\3((_]`,PO((R
M:`(S5`(SO`(E%$,QC(,R``,F,,,X](,RC$,FA,,F*(,P!,,V8$)]9<)'9,(V
ME%@P9`)FCL,XA(-IUI0Y^,,Y!,,YE`,/.<,XO,@\*(,R.$,SE$,S[(,SS(Q7
MO`,^S*8[*(/%E`,-T<--0`8]`!WVY<,QL(-'-@,__[C#-KA#,YS?SO2,.9R#
M.^Q0=UK,SI3;C@2%5-$#TB#GCG#<>';-%-H#]<T#S&F$%25(/=`-/<1,.A3#
M,3@'26C6IT##,ES11-`#![)$@MS@A[W4QSA#,0S#,)CE,;!D@`D#A0K#,20#
M@`&861[F+71HAUX")##"&\R!',P!([@!(\A!&[A!&U#!&\B!*,R!C-:!''2!
M(C`4%DRB)U`B)6)!(J0H'+16:\E!BL;!%\A!(G3!*O`"="7!&^P!#+A!/E3!
M#)S"+AY!.A(#$2R!$@@?*$"`#G2!.!P!%VQ#%SR!%X3!L2F"*(@#*.2`#<Q`
M#,@`%^0`#&RC$""!./C"&_]4`1@H@11LP1&H@BS@@">`@A%LHRH@03#"8RS@
M`BZXU<&QQ!1JQ#WD&#T080NF1,V8&-KL`P2]0Y+<PSSPA3'LEUG,"58QPP.!
MS#X,Y$&F0S,L`S1,PS)0FS!P0SJ@3)K1$)@PE3F0C-B,@S,0"3T`@VUN@B&<
M`R0$0R-D@!9\P`F8@`HT`B($`B6@@"9D00BH@B5D@0F$0"5\0"5H@0F$$RY8
M0B)8@CDE@@DT0B!D@1:(P"4,0@FH0#-T0"8T0R6\0A;DDQ8T0B9L@B"P@0F\
MPKDVPB;X019P3P<8`B240"44`@J0P"0$@B\`@S\40B'XP0<(@A8@I28,P@I0
MP@K_G$`E"((?!,(D3((P%,((;$(6C,`EJ(`@`$*U0D(E",,($)0@K`$AT.6U
M`H(A_,,D4,(F-`(ED,`E`,(AF$`6!,,D^,$:H`#!KL$FK`$D&((@;$((',,:
M(,(@"((A#$(69$&_9L(::$++!D(@9$(M&,(E',(@#*4@-((@0((F$,(AG,`M
M",(EK,'+HBTSK`$F#,(E5,(A7`(BW`(@0((@=.@F)!0D#,(P",+(5D(Q6`(F
M%$/24,05BB1&K`17-15&/-5#(`52,$,P?!`R&.>%4@-;<$/]08,Q6(,XW$,Z
M`)*OCDB:Q!2+<$E6[(W$Q40%480N',,LR,`=G`(5%($H_^0!'O"`#O``&>2`
M)("#&[2&&G@"'G1!/%"#*5"!KS#"'#S7)5R#-C1!''P"%\3!'<2!-F"!]=H`
M%"0!%4A"'MS!%GS"<WT!;>3B+H:7*NP"$2"!$BP!$K""&72I,<#!#,1"-,1!
M$J0I&(`"-!R!+Y7"#QA!%WP#*#S!$G0"+<P`!*S"+(0!%R3;$V#!.2A"`\1"
M*!#!'[C!'^1`#QR!&/C>O8@@2JC<#CZ1RM$,EJ2-.<B#1B%9!:7,6=2#<6(5
M9)0#B^3(.I3#3F3A,J"=SEW$/)1#)+0",13#J'Y8L)Y#D"6(5V0J$AW"VFKM
MMU9"(ZR#-9B`/T"",/C!)%`/)?]`0C51PDZJP"`D;1;XPCS`\25@0@ED`B)D
MPB2PP2`@Y2#DY"$<`B8@@B$+5"/HPRN<0+PVPB'>@@IL0@I<0B.L02,(0PD@
MPSJ8`,6RK#_H`R;X`0E@PLO"<28(`B$`[1J0,@D<@CX(;"#@\2%D`3!L0B68
M@$[6[2"$P`EH`B7P;86,[CZ<0R$$`R0@@R6<P!IDP1J\PB$8`B4@K0G<`B+L
M,B28<A:4P`D0`B2<*R'HPC:<LQ8,PC9S,L,NY2"<`"),@Q900C!4`B2$@"8$
M[AKT0\.HP!K<0BZS\3+?`C>8LC"@[3&<P`>(0!;0EWXUPB*<P#G?PB*0PR%,
M`OII1,3_M81%]%11:9L\>)_,'$->X$(_I$,U/.>O8>@P1!F-;$,K+,,T1`,Y
M$`K;_/3#T4S8X$/.D/0;SL0)DEP)Z@,NW$H25($;\$(#Y$$<Z`'N/,$86`$X
M@`(8@,$4=`$IC#5TN@,N.$(RZ,,WN$$N4`@Z,$(IC$(5O$&?CH</W`'U5H$=
MT!(-S$(<^``-L`(];.(K[,F(L,,6$,$CO$(,*`%X#4$G)+80?($VQ,`1Q((R
M1((G,$$B9,,C1(!M*0(I[`(Y#,,TS$(H^($J/$$##`$LJ(*L><(J+,,C",$5
MC"DWLH(?#(%C,Q\LZ-=%S"`77=`,<L@]8,2_Z43$E$W9H-@1_U7?T\"03F1J
M1G!JV"S%.;C-.K38`XV#-5BQ6@A$2C4#2=0)4XW#,#P#N-7#&6F?1SB#,C`5
M5Q4#9FX#/93#,U@#.8A0RIP<1UA1S>B$MV$$@0,)/T1D,^3#.;P#RS6$.4AG
M&^UET>W#.%`9]Y7-C<A#,^`;/Q3@F&"$/#"#->2,3CB#/IS#.$BEK"X)AMQ;
M.-07@4Y,/>Q#,"A#,P2#,P3#/O##K968+X0#C1,GAP3#C4.E3&V#62[FBS0#
M)C@#:>H#:C;#."R#DEF#/].#,EA#:U;"BQ`X1B@#)90#+2>#?GGN,QB"9/9#
M)6C",<S7)-Q",RC#_FW".PQFLVIR)?\,Y29P0R5P9B84PB8T0S%D@@ID@B%4
M`N)>`B&\0C=80CDX0R'LDUO>`H@.@R8T`B9<@DL&PB;HPR`,%%H6@CX$`\O>
M0CD,`B9,;"/@T`PR2-J<;GH27=ADA&E:A!$>A!4!9SE`D-K43#C(PS745,H4
MPRL<`SE0RC8`G<S<-WO3B)6!=SFH'S,L`S4XPWUNM]:<PVUJ$=@$<8"+B;=!
M-W0K"'K>1-C$3!1-W.A6!,7]&\7APBVX@AI8`1-`PQPTP1RH01[XP`T\`2Q`
MPQ>L1A<4WBI,#T&8PRWH@B;D13[T0S-8`BB4PB?$FANX@2(P@QO\P!.HP1QX
MP2=4P!O``@S_V($:D$(SP'6DLERE/LDZ&)\JK$(.@%>7BH$J=&D8X$(1$`$$
M/,(T#`$5^$(L0,`5S(+GL<(C@$(TQ()HYX$2A`*4^L$S*,(4,,(Y(($0$($J
M0`,23$$3A((.BX$2'$'S&8,O.)&>4!^E]M01,9$3R4-*<)$Y4`.1>$4^E,,Y
M*.8VU,.8&,2#GTPY7)&,H$Q#\,.L.L.2'/<Y#,ER!H-9[M>N)D1UZX,\:,41
M*3>0B)Q'C&0Q,`40`J%TXJ8RE)@R+,0S]$@S;.$V$*<SR$/213Z0H[@[V$-"
MK-2(@/=%,,4^%G@]\!R'%-6":-Q3&55*VT2-25'+*77%J<T$G0V#_U@#>EH?
M3'$("&*A6Z'8Q!T$I@H@V3!5BID[@9IGBXB)DM##5-SDH.A$S+PWQ3B$/Y+?
MT]##-I3#.WBDQ=3,1TSWA_F0U9BT@AZ50<P'0*SBH2:*D5VF&HQ!M>/&J%:=
M]KS!,R</G47MX.FB4H/&"X\T@MP!MP[:'#Q5]LR),P74*BHNU+BR\:,7*AY/
MHC"1=,])C5;Z[ND3.I1H4:-']>T+`Z$3+"-$E(@A@H05D25AAL&R.J13J2_6
MAFR)U&6*(F3)D,5CM@Q<GAQ(0NT1$JL5E%)^EA"AXFK5$!B>0,6(JD3)$5C&
MENG#AU3H/GI"QRE3YBR8N7[T^#5KIH_>X_]FF3;3,T<OG[YF_LPE->=NW+C.
MY\R=.[<O7&QRSL[9>U>OW#IZZ\9MZ]R9G[MWUI`M5H[/G+-Q]<[QFW<.W[YY
M0L\YV\;;W+UUY,@]5KPOW;IE\^CMTX>^:+YZ]9H!>F7HT*9`F2@5HC3)TH=!
M)A*9A`1.$!D!$$NRF*0081`I01`3-O%CDT8.J0018%#`Y!!$"*D%D3542.,8
M2@1)8PT_+LFB$4$,`4:38!HIYI!&(,F"$DP`,2288(I!Q)I`LK`ODW"`R>0?
M?X)Y!I%@#*'D%4(@,>221C!90Y@);VD&$V$`R:205S"!!!-_?"E&&$P,N263
M2H2!I!)+"EEG$TW_A,G$G&`J*?,S93+9I!E#7O'EF5<V.<<78:P9IQ)GE!EG
M$TJ4V62R8"0;IYES_"GG%F&V:2V86Y;99AMA@`'FEFUN&2<88<XI9YMBRA%F
MF5BW*>>8<8ZY;)QSQG'&'%_&R:<<>H*Q)Y]]F)$M5&6V<<>=;5(;2KRCS-F,
ML7D6XRS;QN:YQYQURAF'F7+(?689<G:KAYQMWH'G'GNJ$PH?[\RQAIRA@J)G
MFW7>L<=?[^XIQQSA%%NOGN_::4<]QAANV.&C2M/'F%=(&8@,'ASIXH4<XJ`&
MASMTZ8*,*+BHHA-/3"$'#AI8#H*&*%QF^896X'E$$3"J:&(*,NA`AHDJ_W:A
M@H8&5JDBB"JJD,*3=:CH`9:'H29JGJ54F26'(X20"HE.0B&BB5;P`",&,:Z8
M9I55(%`BCB[``$48H8[E1QHWXK@BCBT@"*,51G(1@H@B2`'%DR.4B"4,J)18
M(JI?G)FF8/46-DH]0DY0X(,4@+G@,4PTOP#)#E!0P)"D[+DG#1924&`2<Q+8
M@(4--LDD@15&V.`93E#XH`05@AEAFS4X",$"30@A1)D-2*#]G&,TT""$8]8-
M!X424!BAD4(F$:J^V%381)]`5A!DC1.F68<;>J9K1ASGS)EN6GGI>:><>O1A
MQH0L"`$PA0T*80:1<0HA`DL,XA#X:00(&M&($/_<@AD?4$$FJA0(:S1#&<4H
MAC7"@8AF",(7E=#`&D`0`D14:`VUN(4),$$($1""0BK,`@BR,(A!:*$1R;C%
M]?R@@D.(H!`AR((@.,$)/[`@$,I`09$V`0D5#`,1)X"$)@:8A34TXGZ;V$0*
M"A&.5P@B&9`01",J,0A!E``1_8`$)-;`A@^P(02">(4F-#'&1F3A!)GH@"`*
M`0A,*$.'G.@`)_(S"1-8`HC!``8)F$0)%.AG$DW"'O:$(0A(-,(_)WA0"/S1
M"$(<X@.6,$0*%D&(-:R!$)H(P2M40$I!$*(0*J!$E*XXB14UP@^4J,0:#A$E
M2C0C$)98`R(N88)5HC'_&$79EE'L$2W2%*4SU:%'4"(V%'S0HQSI8$8RCC&,
M=-3C'KSA)E#6<8QF1$X?P($-=>B1CGBHDYOJ>D]ON%$.=G23F<=43&GR@8]H
M1HV9_"R*,&`!BB5,@0<V<((KO-`#(N`"!B_0Q2T8404\2.$-H,#&$RJ0BE0\
MP0=Q8`<CC/"#3XRA`7-(AB>\,(4J*`$,K5A%`]P0C1X`X0=X2((-H&`'*WC"
M'G%X@BOT03]_-@P?8H@!*ZHB!J7ZC15_B`$25J&(62B!"$+P@SF^,`,B@,(5
MNXC&/'SAO6<\XA[?T$7@E"`#(F0#%WY#`BA@P0A2"&$(OVA"#*9`F".(X3#3
M_R!G9Y"B3WTD0!GZ"(8%A(*)!.CC`H<LA#Z<D8*"*=8>^J!$(,:A@'X]!A`K
M$$H*.K">!&1"'^%(P#@D@`E]]$,?:R@$)D9@#WZDY@+>(T$)WC$,>9@C$!Z8
MC1\`(106H$`?A@@`">;1#&M88!*PJD<[)!..=<`ML*/I3&7)P0QA**,2C7C%
M*TA[BRQ,21/,P`0PE`&,5L1C&)=P4S`R40QS,`@8^AC'O83RBA3X8A*'N`64
M;B$:0KPB&<-HQ"`:L0PT3N(6_T7&("QAB4H0HAGV*$0I@S&)5V2A$J^@$":>
M@8G\;$(_*<`$BS9Q"TCHHQ:D+,03(W$(0V`"$R].`__Q1E"/+6I"!9"8A#O,
M(0@5$((;AYBB(>B3!1-P@D6'&$$S@A&(8&2A$(8H!"=\D8E&<,(9APB$/PRA
MH$WXHQ"%D(=1)I$)_QIY#8-80S(:$8A);`(3(<#1(!81B39H892-N.,:3'`"
M9KAC$(`X!"%64(@37$\%E=C$&DBP!F6`2!B5N,0)(@&)%1S"'K=`0?:BEI[7
M$`PH\O)-_*C9C-&8HQSXJ&8ZRM&->)1C&,S81E#J\0YS]*L>G6E-,]:Q+6I2
M8QO=>$_IO'.<8:6C&]VHIKZ<08[5',L<YF!.9_))/WTN9A_XF*:W]9G/8Q4,
MV^'V-CD9IIY7$,,1/7C"%*#_X(-34(`&,]`%*H#PAEU0(Q*?8,(<OD&%!@"!
M%W*X12[`L0QFN.(4<T#%#1H@"FE,80JCD(,WJ-$T8GRA`27M1`V>8`4K\(`1
M]Z""#2(QU(?-XP@QZ,0JEK`$,2@!";3X@]:@`8HM)&X)('#&%%P@!$:TC1NO
MT`)5CH"$5]1C%6U;`@QB`(U'C$T)G0C#*SH1`QR`019@,((2IK"%)JSB%LC8
MY^,8DX!B*L,`*""!!3R@CQ'X*0$7P*P^4K-(S@BE&0EP^P44)3I#;&!TC"TF
M/2PPC@V,(!"!T$<A$*$,"V`B$,$E00=T-%W`3H(#0E$!X0UQ@<=RP!\C0`UC
M27N-_VL@PQK27,<\S+&/<\Q#'M_!UCK6P8]\,HP?\PJ*4>Z!GM\7I1[XB,<W
M]!&Q:1:L8?$0#[J!HA[Q9.LQP]?'.<:I&'[@G1[NV`<_QB$4?CAF-.<82FGV
M(7M[N*,XCP'R8RPEE-X(Q1R-"D8S2),;9P"#'_PX!SV4(1CX(1CZ81_(85=B
M3S'<H1BN@QG&@1^<01C0+1_.(1CJX1:`H1PNJ++&@1(291R$01.<81Z>`8*"
MHY@J(1WZ`8(V8Q(T`?]NX1TRX1BV`8(N`5.L80U&I)&"P1\@@1)4A1Z`H1`*
MRY^R9??>XRB"0G[X93<4`Q^$JIR`PAW*P1JFB_B"(A[>(?_YA&(+B\([AH4Q
M[$GER/!AL@47V(T'!NH)DF`/\H`,=J`5=,$):,`%;,$9KF`/=,$4:.`->&$+
MWD`7),$5J@$6%L$5JD`-4*$'*$`:2L$-NF`>YL`&C(`*VJ$+H"`*WN`+;@`(
M="H)&,$>\L`.=J$,&68=P$`)6,$5H((+Q,`,P@`)B.`(7$$+J.$+8F`)_F"<
MF``"0`$:P*`4YB$?OL&HD"`;@`(6PD`58H$(("`6ZB$4E$`(D``65@$.P(`(
MAN`+I%$)MH`+M@`6<`$9SL^8H$\?+*"P)&]'`N$"]&$#5N<<C(0#7$,?2("X
MTB,3G,$"]L,0]F$2^#$!@NLQ"`O_[RS@'#:``U0`!<8A!8I(`4C@`DB`'^@A
M$U;``2A!'][A,29A`U+C'U9@/Q)@$I1![39`!3AC\N9A"^G'.^3AS(;B'*1-
M'LQO^8CB'2I!$Y3A1>C!&C)A&U2@`R8``P1A&X#A4K)``AP``R"!'M0D`2C!
M'""!&YCA!#2@&[;!`SC@`S[`!#3A'C"A!([!$KAA'(3L&#C`!%1`+8FH'T8`
M!5;`!$K`!.:A&+)@!5#@'P3A&>BA&.C!$G9'$'Q#'RJ$'IK!50KA,(7"$`HK
M/93AC"JA/L(O'U3L$BCA$C"!&80B8/2A'0Q!!2Y!'^2!'R9#*.@!'^SD-/5!
M&$*#,VXA_Q@T88]@$ADPP1?\X4Q4RQD2(RGT`1.*J33ZP8K"3RB6P5J&PE:$
MX1C"82CX@1F:P1F8(1A:S[[&@=6VH0NIJRBB17+68V'&\"@*8?$X@`0XP`-"
M(`0ZX`(N(`2V,@0^8`30<P,VH`,T@`/H\P-"@`7@DP-*H`0ZH`0NX`/L<P5*
M8`1.H`-.(`56X`3NT2H[0"T55`54(`5.8`568"TM%`760'Q(X`1&*052"1``
M(0M40'Q40$0!H?(:+P52-$4/0<;PR,JJ3$2M;!(FX8SV@Q)F[!R1`A>$@11L
M@`>D0`J6H`I*H09>@!%LP19V(`JB`!I(80ZB`0=&P1;@@`OR0/\7P*$;[D$=
MJD$:WD`'YJ`7=.`)JF$./&$5G@`(=``6<N$EK"`5=@`GHL`*H$`4[.$-Q@"H
M3!$IS"$,EC$6<L`5Q:`3P"`LCH`5L``:L``JCH`<F:`!PD`;5$$1B&$=AJ$)
M0``)8L$=E.%LFN$1AD`(7D$?'&$)BH`(H"$1XL`3C.!50P$,Q&`+MN`(?L$8
ML($?*DMRIB5R"C)SA((2%LMS2$"U^B$!G$$HUK&X%$`9+F#\'N,?1L"P%@`3
M.D/M["L!SJ&Q"B9'@D&RZ&\#S,\0%F#7S&\3XDX?.,#Q[%%'.>"R$H^QGD$C
MR65;Y&$>=F4=K`\IRN$$-&$0/-3("$'_!31@DC!!`#2`$@CA`1X`!")A$PR@
MT08!`!1@$=8`$MA```1`!'`!``KV`T````Z,``AA$%XA$C"``!9!!$#@`0@@
M!-*@$D[```(-!#Z@`S8A!!`@!$:`!#Y@``8AF&AV`@Z@``S!'`(@`R#A`X3!
M!!B`#01A&!9!``C`$J9D#1C@!#`@!"3``#3A%A(@`<YS`A`@:(=!$RJA$C)@
M!$:``Q#`#Y3A`#*`$PSA'S`!`"8$$FXA`!)@&)ZH$0`@`X0G`13`3S:``"0@
M<3'@`HRA!1P@PRX$`";!5%#@`!Q``Q"`192A`SH`&`S!%P+A%0YW`0A@=IZ!
M5`0``1Q@`:CV_XP(P``6(`$.H`0:K%&.`0.;X54JX1@JX19>8;M\P1IX11E6
M<)<88[;R(2A&P!"R0S(LR$R$X4IN81/FS!)B4TTP$`-C1Q,N81/>Z+PRX8T:
M#!,LK1$@R'ICLQ+$1!.L:!,L`1(.01`@+(DB\XSHPQ"@I,PJH<RL#!$*(1`$
M(1#*#!"J+(\:#Q$:+X']((%10`4&N$53-`U25`5((`&VKV$B9AA>011T(`K8
M<`IR0!3R(`C>0!(B80YNX`9(@1@LP15<``CH@`JJ0!%NX1ZNRQYP(0Z\@`KB
MX`9JH!HB@1?<(@?RP!0<00J``*6@0`J>X";L(A^>@`9RH4^1@N68HO\5H&(+
MD$`)PF`+I$`(N&`7OJ`+FD`,D``)E.$E8L`3\$`1A($8NJ`(P"$.CN`5MH$1
M_``4A``"HLX2A"#LNN`*5L$48"`'AC04S)@PMB`6HJ$<^.$*Q7!7[7$SE($$
MU,,?2,`>,\%9+4`!2&LH*L$#Y-,9\($#-L`#+@`1-N$?A*(0$&L?``_O/)(#
M#D\?$&$2^F$!V/8",B$0$B`]#Z$*'X,2W%%=/:L9#(26A0)Y]$$!_&$SU^$<
MK&$9K,V&EV\?ZD$>@B);SDT?NF&09J052F"2`*#!V*`8M%8?LJ``!H$-+N$6
M,"$`9-8!+C<2?.D!$$`+"&$`LD"]*@$`(('_$`Z`$#+M%C#W%F:$#33@&(Y!
M$S3@`R[A&!;A%DH#$B9`_M9A!!!`'PY``W`A"Q8!`3Q`&5[6&(CL`Q``H2MA
M`$)`;BED#23@.OWV`$(@$A!`!."7>"YAE`A!'QR@!.PA$X1!`$K@&0*`(?>7
M$@P`$TY@$4X``1X@!)AA&"JG&QJ!&>8A`"8O`]*`7&J3$RPA`S+@%1"!'_PA
M`%*@$43@`"XA$BH!&`P`$JQA`4B@$4A`$U+@&1;@!))A#8!!9T-@$Q8@$R"A
M&!2L&-:``%1,&)B!`21`$$X@$#9$!1!:0R@A!"HAAOKKLB8A$"@!$0B/^8QB
MFM1C!%0+@VVX._"E_S2B4"/-@1D@.?GHX9N(8K;?X3N#JK4W\Q[NX>RH./GR
MP;>/]P*VTV%P(1<6H0>@(`F>0`=\@!>8@(1;`11D(85K@!3>X0M>H`=X@15L
MH1OT`1=*5<7L01I.00].009>`!3J`0YN0`>L0!H6H16FX`9@P0N"@`M^X`>J
MX$[YH0EJX&E^F_C$``;@:FR$@*J((!9400BN`!2^`!J,X(P[01\8X06.B@OB
MX!78P1I*M1AB(1^.01&.H!2.H`&N0!]@(0>(@`A4817"H&N0X`^)0`SVBC!@
MP1=VTS3?9[3'P3&^\PB5(3ID8S0X8QR$#3/0+3WPKMOTP1WHP36&8U<`D/\2
M,F%(5G,26L_59N,<G@$?UD$SLF-'@.$Z]"&]]$$3PH$VR&$Q9.,QF%RX%Z,S
M>JU^A*'5PB'\"D$!<".^T(L>'(`0[D$9_.$6\.$`.(@#"B$!@*4%!D$!F*$8
M$*!4UN&?S\0`D('!WE%SBN$<#$$!MN$0DF$2%N!0K"Q9"\$`Z`$V-B$`!*$?
MTB``3(`2DA6".N`#@.$#(F$0#D`8J,0`@*$$,(``_<`!KO,8$$$`#&$<Q)8U
MF:%/+"A,2"``"&$2\(0$@&$#$$L9!D&IW_H22)80%`![(,$`S`$0BLD`3@`8
M-&`#F`$?_&%-S,$$,L`8*(%*%*`#?($`OB03B*O_$`X@&!R@`]"$1,C!``[!
M'*Q,$P;@>A*@'X!0(]/\`.IA&RIA&$+``':Z>VZ!'"8A!1)I#7;=:D^@E`@!
M$Q#!T3#A`1FF--Y56W9/*.HAN)_P.L+!7JZ!&N0!W%YRU95C'^J%'/"/^:3/
M,6RX',Y!?LC%VH@BGW[C`,N#'.)AYDMCFD[3,89C.,C-,:"<.>9EW+QS/`0K
MN+WM^HC;82(&%R"*N:&`!YH@%?+@"5X`"\"!$;I`!\K`!JA@')C@!7:@%-Z`
M%=;A%I3@!W)!"IA`%\BA(CJA`5Z@"IBA!GJ`"9[`#QY!%W;`!M[`%=X`"(#`
M2=6@#KZA"FS`%`:\*-A!_PE@X,45AS"@0A7^0`D<815*X1&.(`?"0!R:P15F
M0`IDM1/<8!6^#[AQ`0Q2$0RXH`$>X1RP(11>]0]8H0M<X0C`@!>:0`F28`J2
M@`N(P!B>`1N8B2(91C2`'&*$2OK2(_VN3Q_`#\KS83BXC2*]C2)+(SUT-5YX
M,R:+VSKDH1[JY?X`0I_`@?K6T=LW$%_!9\'($=2GD)XY?O0>6GQX3R$B!_KH
M45SW3E\&2/KN#3Q025D"3`KT!?O@BX"^;0$Z>,"@0)"^3`320=3GH8,^?OH,
M<50X*0"'#!L4!-)W*,`%!PLR"+(W%-('"Q8*"=S`X(.'#QD0E(.Z0E\Q!/WR
M&?\*,,)#"`UK\NE+(,&#!PT8E#T,M,!"!W\52PBPX$"!!0;G=EK(QPQ!,'W^
M&*!0L6;#@LD="&S`L"%!)GPE!BA(L$"#@$S;&!2CEZ]BL`#D4'SH6,Z</@1/
MWQ6SMD"9/P$K.)0HL>:>)@)K3F0Q(0#3O77;SLYLIF^<N6/&Z%E3-FP;O<;C
M*)[;=_"B0(4C,'64>"[?/H4"]YG#AU_>^GWGSY&3AU!"]:RW3H'ZR+..//0E
MI(\]Y?@W#X(*H9>>>@_A0T]$[O"#'D$!6OC0.Q59=,X&(WYHD4GZ$!--(D^4
M0<43H<1QPP]OX.)$-50`\40<Z="S0Q"Z(/.%*_OL<TS_$C3<8$L]YX#213)T
MO*#&/JV\8<4-;AR#!QU,`*'&*5U$$<483S`2SQ,VL%(2B&ZJQXX1+H#BBA)V
MBD&$$K`@,40<J[!BQ!9)Y&+)*_4@X44<7G#QARK+D#,1,[.8(<46?Y@Q!#7,
M,#*+%$D(06<L6\#@""-&)"&%$EPH$<LTT^ACUT/F-/:F/ONX,R)!L8*HHD7X
M[%KKKO)8T\PX\1FDT#WGK(-//0O6MTXXSI!#:WWFC#/BLR:9,Q%]^=AE#SV6
M:)*),(=P8@TD#KPB#"&0O)+%,A)`$DP@P?2S#P.54)*`,P+XDD4'C1#0R"L&
M9#$()):,0PDB!ARBB2#E>'"!_S#*C(-"`L?4<LDA#DR3\"N-C#.(`XX84]8\
MY03S3BW,5')"`(3`<P`*YVS"#"8&!(//`ANDL((`:?!3"`&80))`!^7DAL`:
MPF!222/EN./.,L608PTYEZ@`@%<;H+#-,L!@0H`P^G1@026$$*"3)@$8<HD!
M"]#S3CT:<)!)U)P\,\\''SRCB3!N-[*,`=;D4X])SP0@CPJWA32@!(AT-`\Y
M!_AS#`-KK"'("8;D<XD`'Y!`P`'+"&37.^L`"^M`6,6:ZT7/#L2!>P]5I`PF
MPH3#CS*9G'-.)I.=HWLS\LPCC##`^&+./,7X`HQN^R"XSCCS%"3?Z=$J\YI`
MXY2#8?\SA)W33#_GE`//-LTX=)%']8VCWGFUJC<.!]6^R2(I4R11116I>&$#
M('@!%FZ(QHZFP`1NT*,(03!%-4I1BF&L(QD[Z,$/;&$/<<CB$];(`Y7T@0PI
M'*$'KAA&$W8AA1[P0!*GF$(5RO`$4;B#$7LPV_QNJ(]V<"$)LV@%$<1@)R6`
M`11(($(<M"&H&BA"'TSX@S"B@0,AQ"(42B@5*T`!"U"$H@E=8(48(%"*>Y!B
M",&(!@QR8`1'(`-/G4A%%[8P!2EP@0BP$(8U6H=#7Q'$)`>971YOB)[KX6,>
MYK"/-=8ANWU$:#YMP@>W'#*ABZ!(/0I1"#-88`AA9`(0A4#_02``\(%;G*`1
MG1E$!A:@B7YL0!F-&,`:1"`!313@,X<81``"`8P!9&$1D%C#!X+Q"@%`8AB(
ML(8!3B""03@B"PF@Q"'6L(@!#&(-C;!$)A9Q@@.,@`VOR$`&`C$)!!`"$R9H
MAP0"$`T,?&`0']@$(A@0C$DHX!`F4($&`C`)$RS@%H>X!0(D4`M@6$`"PD`$
M)$ZP@J,1`A`60$0C3I",#K3@%3\3!#"HV;5@"*`#)*#`!,2Y"01<XA*O<$`)
M-%$,"VA@'.,X!"4XT0BR6"(0K]"$`4I0C`6<`!+.*(0P2!"<"UB`$)L(A"8T
M@8!";$(3@=B$`()AB`5`0AC'J,0M_R`A@@$PXQ::.,`**H&)3&RB$H*X!24,
M4=2J3B(8F$`$6YEA"$Q,@A+^F,SM8B>0]EPD&"@`QB02$(Y)8,`9X;@`)NB1
M@DH8X@+G>04@.D`)W:``$)E0@3/6\2'\G(,??M@`1#9`ELD(PP+*4`@F+J"/
M89P@!0Y8028D0`()/&5V))@<QE+@%8*8@P0H(`%V6.<FA9R#L;52""YNT8H>
M)&$*/6#"$]0`!1N@(AI8\((+@_"&8ASA!38X117>((UA)`$(Z@"##G"!C"[D
M`0\->($=MD&%'KPA"EX`13:D8`,J'($64]"!%:0P!4^LHPE)>,4?:\4.08$B
M%T8XPA'@&/\**1@!!G&XAA+$@`MT.((*BF"$-UH!`1"P0A&T4$4LH(&+4)3"
M#ZS@0@3B$(](O`$/B1A'--XP!$O4HP@YR`$LP,"%.'IA"[%(!C8.G(]>J:>/
M&<H'?6"3Y-GMRH\#B0U%JFRA^<AC0#]1Y#K,42`E$\21YLB0K\9##V=-<B#G
M"$0A[`,(0U!B&X00@`1.<,Y#8,(:'4@`(32@@0*(X!+9O,4M`*"!;:2!`81H
M`Z,I459$]+,IT]0``MI@"1$<-`'ZN(4@ZJR%-A0B#94(A`@(T`8M6$(7`/"L
M!#302TL0(`3EN(`&$K:--1@.+^>`A#\@88!^&,(#'=$'(`*PAEO_6&`";&A#
M&R!1B$D@@A+!\(`#(`&Q#&"@$1FX\QH0L88`>%H"E^"E)@0@@C448!!9@,0E
M`/`/>W1``MU@!EQ5<%`'$*(;'2-`&IBA`0)4(A*7(,0`!*$+#9"[%LT@Q!H0
M$()CN$,8@;Z%%IKF[GA<H@0B8/0);H$(`5`"$[4XA@IN80D5%,(?F##$"FYA
M"!2,PQDHF,0DW$EM[(!(?B/(A#ZX%1L,`0([^S#$.6YANT"0[RGZJ(3.,V&(
MG^.C$)/Q12&^99%"6"`%+N%`,+"SB1(D6A^:X(!G!4*/"S"#$EX9QP5T0Y#%
M/L40_]#'!GR.'Y>H0!^!8/H?^<$!=[PI_U;4((8H?G`''D"AN;R0A!3<0(I*
MV`(*3]C!'/2AB!<`H1=04$,R]'$)7.CC&:^`AS2J$`54V(`&J*"'%6SP@RI`
M8PZN\((.2@&*'%C0"E;@`2K8X0,A'?A-^+B""U31BBUL00Q;"$,II%`&'>C"
M"0TX!2P2H450Q($4WC@%#;@@!B3@``F_N((0D"`&/S0`#M]X12?P$(HO*((5
MNJ``!+"!A2=,@12>F,(4GL`%6Y`+N!`-J(-#_*`0]8!7.)1W$'$DL4%\#(@/
M\C`.D&(K%T@0\["`5F8.[N!'^($/&4$/%8$/C&0KY^`,]&`/S9`KP?!*B'`,
MX4`.!0()*\`":__0#^60#\J0'/:`"/YP#Y?P<L"0!N<0#^80#_H@#-4A"$%1
M`A+G#OW@#H50`N^P#<F@"1_0`39A`0G0#\!0`N.P#<=@#Y-@`>?@#BM```B`
M`85PA":P!M1Q#YO@`+?@`<#0#Q>C#".0!I3``?KP#H$H`@E0#`YP``MP``=@
M`&G`<,[@#,$0`@0@`0;``<?0#1TP`O=P"^Z0.9M``"/5")/Q`1QP"`OP,H&0
M:SO3`0P@`7AQ&L"0`2Q0"_9P#)"@`")0"?V`"`B``!^``"4`"<<0`@)P`1+0
M`0BP#0&7`190C(-@"800``@P;_=D"($@`+>`:RFP,X'0"(;`!K5P"U;_%0R;
M4`ON4`NE9@CC6`E09PAP5RN0]1Y-5@Z!,!_TD0F48"LRIP^4@`+I^!.9\&:-
M40B&``Q^D`D448(:J`_7(PPCT'0)@`@;$`S?LP''4`_EH`PL4&PHX!64P`*!
MP`)>L2`(80B`P'?N@0+X^!#!P`'],#^S4R(+:!&Q,@RY,`=68%U0``5,P`K]
MYPJ,T`I=H`,\(`K@P`S$0"5=\`2C\`:K`"OP(!"W``=[X`-WT`,T(`WCP`M,
MP`,Z8`I@0`I>4`6\\`530`918`5V``6B4`X_0`.V\!/#IQ[S@`00P`JX0`1(
ML`5'H`BO``,R\`71H`1CZ0EQ4`HS0B?0P`VW_Z`$->`",!`#2"`$,C`#$$`$
MI?`-S-`*G?`)H%`*>,`%QD`*3_`+QD`$0G`%KK`%7B`%BP(+KP`-<HD>"!B7
M<FF;%D$/]S""ZU$?NTE)P35FP#40(X@A_!`N]%"!Z7`,VW`Q`A$/[Q`.!E$/
M^4`1_$`UQFD/6#<KUF$/6*$/TTD0W8DZ"'$/WY(/]O`.[(,1`I&=9F8K)N$@
MP)5D=J&`K.,.]V`/\?`M]X"?)7$0".$.UD$0ZR`,%6$75X8ZS6`/;4$0]*`,
M_.`,6`8,4\.<7Y<,S*`/QU`,L&(7U@`_)G$,DP`)=U01YJ`,P2`XFJ`/W=`/
MF>`/+FD2YU`,PA`,M?_@#[[@#N8P&>]P/OH0C`VB#^X`+N<0+JVS#_"#=K;2
M#.>0(3+Y$'>'FX'P9/HP5Q#Q#WXQ%,J@`G:U"?^`(7Q7")CP#/H`/.;P([:B
M$/Y0`OJ`D<;&=>[``4CJ#'_H$1>`'9/0`<``"?8S9D5ADHB`DO@X($ZF#\T`
M")-S8.?@`40Q/ZT@#*3``SD9!5*0"S>0`Z<0";9@!%%0!;E@"\-`#SX@"K(`
M!EZ`!K90#>A3';M0!4R@!JD`)O:@"<G@"/TC!;H0"7G@`FYP"OQC!U&@?W-0
M#E00!*YPF^HA#D0@`ZK@"C^T?+,0"T2P!-$``DN@"K"0!Z"@"*``"JS`"JW_
M\`KT``ZCD"4U(`,VH`-,0`K9P`[0L`JD\`B,0`NE,`=Q``O3$`<0X`M_``.*
M0`UPP`65(@6O&0UV(9P']BLF>*S%!2L9HA#R82&_@@_,8B&[26480@_ST"$6
MT@R38`@BN@:80`D@5PC1]DQ^L*5%Y0>"L`:5L`*'(`@J\`J0\+'^@`B?!@AK
MD`8KL`*0D`G*8%"$X"X90`C*H`DP@P@,MU.6$`*7(`C."`DFH`GM5E.5P`S]
M-`F'4`N38"Z9H#N:4`MLM59ZZ@^&4`O)Q@P^A3.0X$S^T`Q/HPR7H`Q:ZU>:
MH%3"T`B;2`G.T`P8V0A/TPS-X`[!H`S*4"S1<PO]_U`LP1`,_E`,5(,)RG`,
MP&`-LS@,P&`/UP(_P1`.^Z`,(VB=M-D/QB*%S(!([V`/MQ`?^W`+RE`.M;`-
MU<$/$#IS44@UQ3(3S(""_+"D[O`.]S`1S;`-'6$^+&@^^(`M$.LANJ(/>-.;
ML((/<N41@-`/SE!WS;!WF&"2QI8)^Y`/<G6!_NA(#3B<.^$!^;`)A\!W3[$/
M&X"A^J`,)"`0_#B_)FD/%S`9L5,()KF_S8N/L5(O+N%9"CL_PX6DO"(0Q#`,
MG@`%H5`%4O`$LB`)0,`#N<`,3>`#-2`*^H`%<T`-NM``4-`+\S4*DN`*IM`*
MB>`)3_`&M-`#%9`,SP`&7_^0#TU0`TV0J6"0`VY@"U7@?V-0!5#`".KP!#D`
MEPO[$.U0!"Y`"J1`!%R``Z8`"C@0"HQ`"CF0KJ6@#879"3,R!Z3`"K"`#>&@
M#]B@#=F0#;@`O,[@"[$P!YT`!G$0"ITP![$0#N8'`XP`"GAP!'\`"P0F!4.0
M"\;P*DB,L(9\8+YYL0*!H+(S@O=1;-Z['DS*#U^6!<70"/92`B,0`AV0`H90
M""DP<B.@"8?0`2P[%SM[`:NU`HBP``3``A(@``@@"+(,``.P``)``)H@`@+@
M``]```'`:),``(=`<6EP;EF0`06`"X(0-`2``0(@<X2```Q@``50S5]3`M6<
M``S_@`@[FP8CH`Q-80B1&`)I0`@H8`!KL`F]1``&D``8L`:U(,HDD`)(10`*
M@$_'4`*M:`'"W!Z%L``*((D$D`&CM`(E$`#0#`F`<%HC``C_H``;4(V4Y0$M
MP(T3X``2@`#Q3`B5$`(B0`ELD`8B@`&6L#6%0`E^0`D-!PE9T`BU$`)K`#?0
M=`*64`AK<`C,L`:$<`FW\&V:,`A.RSFO,%>3T%2$T`@J@`@IZ5=V)4G_J0\L
MH*(5`1L7V%8J+1`V&PA^$0S_4)*W(!#U@@B5<"2!``@JB9L5X0][%PP030+P
M0P]Q+1#-P'5%$77Z@`D>4!R(X$>%,#G\4%LHP*@"80X6_Q`().`/?V02X^`!
M3LJ\*X(,BB`%<>##7D`-3;!ZN2`-/F`%TK`.FQD*H/`-I/`"/]`+52`+C'`*
MX$$*KO"J/=``I@`/I(`'>8`+TF`*3Y`']^`&-%`#<R`)J'<'=U`%PGH'>]`*
MB#P0[0!'L=`*,#`$8.`*5,`#9M`)5"!"8!`#Q-`*;H`'G=`)<LP*\C`KPO`(
MEC`/OH`%L.`-Y&`EGO!^XQT']N4$2*`$6R`%I7`I]P<'_54$N_`*KW*PS&W@
MB#PBPIDA^\`/X$EE:+>;_&$.$(L0?'4T@K`-F7"TX^`.:7T+FP`()!`(_F"W
M#GT,@G`TFP`,AB``ZJL)$P``P?\P"`M`")2@#.5L")!``+Y0`BP[`!+`$B%`
M"9HP"6E@`"5#`!Z+;&MPXG!Q":PH`H8P#C1-"`R``)-#`@`P`H_(`9K``@A0
MY`"0`&E`TP+P%"O``">P!I2P``Q0"TH%""R)`#NK`0Q`"9.P`"1`"<*0!@*0
MAW`1`B7@`"$P"(0@`0_`#.I,``F@$@R@`I0```+``FE@"(<@````")`@`*1H
M":]F`J_```0@`H1P"">``-@F`B>P29\\2BI`"):@YO<@#"*@`1T0"0]5<`Y7
M"9<@`H=P"1UP"<PPTVM``IBP">.P"280`FR`"220"9/@#Q%:*R&@HFN&IK9"
M(2.8+0W_.H+E8=4?V!'>0I\/BG838=43WD>H<SX&>B&S&Q'!L(#T\'5R.3&0
MC67ZD`S)(`E3D).=$`E/8`<^,`T[T`"ZT`J1P`JC\`EN8`GYP`@T8`=`\`,W
M8`6\4`5!P`-D``458`KN8`IQ\`FCX`FOH",-(`F1L`-6@`JY\`11H`9J,`9S
M0`XZT`.Y<.#ET`0YH`KZ@P/)\`A%P`BQX`E&L`-)X`6!H@ZK@`=Q4-^E\`4=
MZ`A;0`54$`=*V061X!>,(`F=H`B*,`>,H`VF4`,/G`-O0/6M4`2*D`U?8`1X
MD`NO0`UX=.!S3_>2K!Z[(A'N6;$5L;'KD6:X\O<B(A\<<A&]_V(7_;``FW`6
M]'`+]-`,!E`M)J$S[#X!(:`/KLP/YZD`AF`/1NX6+:$/26AS^2`!ZEN^%_`Y
M`M'50Q$,[A`(J+4&KY8&S<`/B*T/"U`)^@`,Y7,!QY`/&](/#"`,_4`4+)`)
MB(\)M&(`B*`,"_`@.W@XD!``?M$,QY`&?Y@&"'`.P(`713B%5JX,P,``AG`6
MA`L.M5#-(7`/V[`""B"\Q]`,AJ`,F^"Q[**US,`RM4`(^D\)R0`,P@`0Q9HI
M@U1HT@EA*K:5L]3LEC)`AO3=4K%I'+T5A?R14*8/GSZ0(46"9%%+)+Y[^O+E
MVT>/GSE\]#[N4_E1W[Z8_.C1HYDOI?]-?3)OA@2J<B3(F?CP]0S*$R<]ED<]
M*ATJ]69,JUGU]?-`3RO(?"!AW3KU1HT:*ZY,50ARB5D74=3F?#HE*H\H6]WT
MV?+Q@FT0(#0$T_"AZUXN4IX\C1K%B)2N&Z764;E1H14C*VKLJ*D#[P:-7!Z_
MCCY:SX<+5I*,>,IE)`FC<[@8,>E"1<T31^URB5+DR4VQ5U^*>.'B1<J6,5Z.
M*')TC9$B15]658/5Y`D5+S_<R`&7#`J/2)'VX%A5CAMI].G5KV??/F0^?/Q&
MSAS)S]FM<<$R;>KG3ABS8R#9AA)E_,E$OV#&R429<39QAI]QFLF$&7^$44:9
M0A@PX`)$E.'_)Q@".I!@`PE6N*>0`$X0))`.&#B$GF``F$2?30+HQQX6#'!'
M@17T"<8<FKS2(`-($"GD'V7R@20`"TBXQ9Y\S-%)GS0NT`>0#8)AH*,$#'$G
M@(Z\LN>>J%9*@X$1"CD&I'$,:`:D2@(X1ID`)MED$THPT6<$"_1Q!RPR#4E`
M'TPD@(2#?-S9H`X,\JE%@$R<$<899>S14A<$]*R2M+#"4@\H3T>CYZ*@I/*J
M@UI<`E*HD&@Z"KZ=IBRJ58]X<B\K^(+*1Z9Z6+)IIYO,:>8<<YP*J5>:9ATM
MGWXD\&JTE'(19I4I-J-"&EU^>"(:"*I(Y;)11'%%%E9<8668=-8Q_Z6/SP2[
MP8=3[J&G%5E<2:445D;)PQ-H6'D"#EMH>$*=2)ZH`H\R1*'GCB!:N56K=I`0
MXA=HE.B-BR2V<(2:)F0Q8@N0M_!CE6Y<B2.6>9#@8N4NCG#9#R3$^`.$=F)1
MA!%CM''DBC!`-@*41WPQQ@\EDG!C%Y"A><4:HQYV^FFH2?LH):WP,8?,^'P,
MA`1*+-C`D$`"0<'(20+Q8),-OEXA!0XX,,2@3%"@9!(2"KD@A4``F:22?T9@
M``!#-B%``Q8PN,`#$CA(X`,+#+!@&`Q(,&0!"Y2Y@`%@2+#@@!$,2).#2>8.
M9)(1"$```0P22"'T$#88(8`+:AF!DA,`(?^!@1168*`6%ABX)`$2)F$`;*XM
MH.2?22;!A!)*4DC``#11"&2!!"RP0`$#,,E$@`TL8(!Z?KPVY!]*4,CD'T,`
M,8"2R1%9/Q@#W#>$D@`,L)^!R@-A8!+%\_EG`4SX(QC.6)X_#!$,!!YP',YH
M1C#Z40M,(-`?RM#$))3ACG,<PQW!H$0_`C>.<[AC0<W(AS_\T0],*`,8%SK'
M3<*BK*&,X!9!V4<-C;*4J_#$)1%R"3]:0A4;NH0>Y_"*#:LBDIY\Q"8XQ.%-
M7`665R$1)*["2=1"PA5[I"<7PX@$%]2P@UU(H@BI8(4J;O`$)N3"&XD1!2E*
MT0I2[`(;X1B'/9C_`0YL9&,9^J!4-%@A"E1X`A2D$(4HI,&**_R`"K/P1!F^
M@(LN2.$-4)##.KJ0`UA8423M,`(15A&+(W2B$T>X`A>N``TLY*(42IC"$;:@
M!"2`XAK3P`88MG"$1,Q"%5=@12)648I.*.$+6GC&,I#QBBL400I*X,(6XJ",
M+ZCB$4/XPQ&^`,P_/$,8TT"*)KWY3?>\$(:OLIJ/$$&"Q"4`$(780"'V@0)_
M!,("AI`>)MZ6`$P4@@29",0&D(<(0Y"`&?J8!`J&4@C`&8(![.R`]+IF@6`$
MPA".6\$_,-&Y201``2A`P0@$$`@.7.`6*1C!&BR0@#0HKA(:V(0*5G"!_R.M
MH!]I\$`"`H&)"_SC'P:87`(JD8(%8(``:P`J)EA@T7^@(*`D<$"7FH'"$0!@
M!#OM&_-2X`&_42(8'$!!1%G`@7\4HJ.%&$$F#``FZ[FCIFE8@"%DY(\`3%""
MA0`&`R**)@58`!`6F`3Z)M&!LG5@!9(C`2`"P5,/I($$)8"$(500B!+4S0.'
M2*D@+H")$+!@`YA(P0;<(5$/>(`2%Y`>,-`S@F!X4S[@9*W3FF&!)U9-'\D0
MAB-RX`525(,)<<`"*:[0!2_HP0G?@(4GYB`*/?""%;#8QSG2<8M(M.(>R``%
M,N@8#UFTPA-Q^$1CJH$,'=R!"E+``RM(`8%5K/^""5;@@23B\04W9#)441.'
M&'!@"EA(P0N="$,7D!`&,+!""]/`PA1LD`0IA`$)5W`##'``ACR0`@Z)B$4L
M6!$',)AB#D>(P0S"\`AE3J$,.QA#$881BT^"@@AE"*\96@8-83!MOJVE<8V=
M]I((-<.$X[B0.3)1B&84(E+*"`:1_:$/93BC$I0X1S,:&-&.4$(`F*@A0INQ
M"0$(8Q,"#(<^_@$F!`)"1LZ@1"8ND(`+C`,3F=L?_;)@06$`(`W]6$`::H&(
M312HKHB@A$$"P()`""*"*.B2!!*`B$DTXV^%*,;S-@$(9:0``,I(7OH"8-!,
M&"(`@<C'INDV.GH&H!#_A<#$/_21"0X(@`.4"(0SSLJ/,],#!0@@1"$,<(`2
M8,(`@0A&`%*K$GM,`A&B+H3[!*`!<PBJ$LJ[P`B,!(C#38*>E-A`&@)1I5J\
M8PT?X(`F1H`E%ABB2H4P1`HZ@(@5M+,$_]C`!?(6B'&D9P-C`P0BPF8(1!SB
M;<F3=NB6-[>]46(3F/CWG3(!#&#X(^'`"$:%#(1P!$:<R!$/!L)-6'&*%YG(
M%]+X`"GE#&?TXZE.[@<(07@.E+]$ASMAN1!KN');T>2UL;6*IZ`Q#$7<P0C9
M8`05(O$*.%"A!C^H0A+B$(](`+,3I1@%*/3Q#5)0@0IO4$1MMD`*>XP##JGX
M_P08.A&*6%2C"SW8@PVL4`4Z6"(.<Y"&+62@AD]\8PZ>R.0WZWL$;#Q""6!8
M&2U&200QQ.`+W2C8%'`@A2:X``IT,$4Z2!&*3IBW"8ZY62N^L0LJ/`$'.%`"
M$<Q@!2I\@QB=SX$1C/")3NQ!"7'@PBZ,<8UNVECVLY_/2;XRXZ=1P@`+P-XD
M\N'JO"9``7'-1`">I0\2+,`<(*$$`"BQDCT9`"284$`)5."U+"8``23H@.9,
M/=$2K"%U?\I'/?1Q52H-:B5K`(">G)$`#H0-=T31A^Y4<`@.&`"$`CCR.3Q5
M"P#H`$%0@1'@@&#(!S&3FR_S!7Q`!`70AUI@`'?H!_\`P``?,8!^4`8`D)XU
M$#=_P`0`R(1UT(?F\P"54(9]X`=^:`9@L`=[Z(<$"0KY.(=R.(=^N(0#/(9@
M.(>LF\!QX`=F4(9:.`<0>HA^N`5?`(9SN),,C#?Z.[Z1"*@44`&.0@%THD(2
M6($1T,(1V("0&H$.N(`.:+?0XH#0V@`/\!H/2!LTM(!FZRBOX0#7X0`2Z$(Y
MO$,O9,/0N@`^O``T%$,^;+<+L``'&$0^M)[J.3-$#+X$$+[J:<1'A$0WM)X+
M4`!#7(`+P+VL(`9L*#!;V(4C8`)1B(=6$`4U&(,J0$57^`9>.(52"`50X(95
M<`,F>(,JX`,HT(,WN`,F\(3_:&@%12B%4C"%7/@&4W""/"B#*I"".3"%;_@$
M+Y@#6-@#)J"">C`"&PB-;U('(H``4H`&(E`"<20";0`#,S@"*8B!1%`%6W`#
M<9R",'"$9I`9)-@"(C@""I@%)%B"<$2"4/`#7X`%["`"(Y`"7KB$5Q`",SB]
M(=`&14"")I@"UG,%7""'(Z(]C,S(?0@+>BB6=P`$2)B$0QBI%,`$:U`>N4&!
MLM$;3<B$#]0$%-B$2@!)SJ(;84B?8/B'-$@#?:N%8Q`V2G`;KF$?3%`!3'"&
M4:,$0`B&9B`X@S"$22B$AK.&2R!`#GB'30B&2J`L#@@!R6%!0)``!1`$?VA*
M9B`'_W/P!TAP!T.HA(H;AVU(`V'HR'[H&PLXH6`H!WZPAUM`(11H-AX+AC0X
MP'UP!AH4!D!0@35PJ0W(!)TH!!8`'F7P"DU`!'ZHA318P17P/6?8@/Q(*3G4
M@`*H!'LH@7+0AW/@A\2T!W=P02@ADS&AFEU9B2R2BGS(.OF`$JO`AUVI"N@[
M"II[&"C,2/3PE"KZ"!TJEI<@0G,8AY)[3B=S3B>;SI%+LH%P!B>\/9`@AEL@
M!BJP!4D``BBP`DE@AC:PA1JX@RIX@R>8@VB`!V@`!5PHAQU0SR>X`Q_0/"MX
M@C<X@RHPAU5@!&B(AUSPA*GC`DG*!4>P!CB8`AVP@VS(`_\HV`5^D()L!"=Q
M(((8@`58`+QFD@+4VX(8Z(0<`(4O8(1+.`(\Z`10\`,Q$`('30(CR(%WS`$B
ML`$9X((8V((K``4P*(,S^(12P($A-0.(I`+,<QDNX#MK>#WB?%(H!8ER,($L
M,(%`*`0-H$-`*$!G0`3C*803L(1*>``/8($14#)(*`$3^``-F``'&`1XJL,T
M.`$6V,D$6(-#*`$/ZH!,V(#-7`%#V`#)28!,P`0/4$F.LJA",*Q"8!Y#N`5!
MT+<1:(0U@`1".(%XJIM_\`=`0($U"`%$6!&Z21^:,@1!@(1*;81`V(014(92
M^X!KJP422(,4,*A#*!(+J`04\(#_%`C42HB_0SB!-+B%0["$>BNLG/2'L(K)
M21"$/C,$#JB%-5@!$4@#?F*>0,!,GEP#2A@$1%@#09B$%3B$$#`!2-``04@#
M%3"(%?`'%'"&*5R!4[43@/J')4.!?G!61*B%F'++32B$O(&$0>":S3R&K)2(
MX)0*,E&)C50*F>`'(MJ)EJBBJ?`(FJ.*I@$*C'TBF\B5V/O8*'T8JLD%72"%
M-T"%.`@O*[`"7<""9"`%*;`"'Z"#]2*%;M@&::B-'Z"#77`%.C@%+"@%6X@#
M*2@#4D@'7-`&4F`"*5"#*G@",(@$4F@"7<"!47`#*7`C3W"%=YB#&G"%BX2:
M=B""&5@%_U)8`I`)@T[P`UB`AAB0@B$`!4N@AF9@O3#``1<`@R)@@E``@U0`
M`R3`@2;P`E:@@S@H`ASP@@;`@2T`@RZPA'Y8!5,8@E8J!5[`@R[@.R]0@BU@
MAU>`O9`-7=E[!T$X`4/(`D,@.$-8@4R+"!((&PV@ATKH`'TR+#TAA!(@!&Z`
MA,D*FQ1`!`Y8@S0H@318`4#8DX@8@7)+@4R;A*6$5FGK5&E#A']P!I'`A`U8
M@!4`U$#0``-```+```-0*K9A``\@``6`A$.0`/SQGN=!!`Q(`W<@!$,3RV;[
MGQ#@@%L(!`4`@!0X!`00A@YD`0_`A,BJ!'9*OA+H@`0P@0T(`?\#R`)?V*A@
MF"IS"*DRW81,@,$-2($3"(0,4*Q@F(3J:9$"@(006`#E`01WX(`."`06.(%;
M(`2F(@0/6(%F0`0&X+-)N(`U4(9F<(8B([-`Z`=>6X,".($)D``.*,D5R#<'
MJ(02\(`LL#X6T(`U\+7V:(EGP0K1M;&B2%@KP@5<<`4OF`)1P`XFT(,X<(7!
MPX([>-`IV`,=J`([>($;\()>N(4Z8(1?U(4Y<`-;8`0G<($?^(0WH(([F`+V
ME()%Z`9):`572`(6NP-9\(0W$`5W8`(;<!A-^HAV$((&6`456QDNX"\M"`57
M:`4A>%$E@(46A0,I@`(I@`53V`50"`/_5I@FQ_@"49@%17"%-\B!+3"#.(`#
M<D@$(0@#S@V%,/H"[C)E)5@&8[!(,?YB;'8:H>B'6=F'>&O.=X`*H-B'9O"*
M8@F);2#"_KA-UNP/?5@^>0@&<E8&*?E!*>$)?L"$>+-!^\"$?G"BWBD$M#$`
M0F`&X1,$=#J!0C@'!7";O#%?35#,RQD!%@`$9F"`-&#H!"@!,R6!<T`!`[B%
M2?```PB!--B`70N<0N```!"$8!"AO&*``,"`MEJ!`'``WL,?BY(<&MDRB$"!
M?%`&%J"$(R.$-)B$<*,$@(*$-!`$D3ZR%4`!2%`!2&@&2A`&2F@L=\"3U^4@
MK5H#CA@)>@B$_Q'@K$%8A!-8@S70!V@-!DC0A/`S!$B`!!)0@5M8@Q/0A$KH
M2'IP!Z&XYO?@(T,H9^89B#S!B>5)K0^,P0C)!$HP!_UHB12"D4C1AW%`.'K8
M!G_0"?U8K<MVA\+<P?P0N2#^P9:+#Z\8E18R!P9AEHL(DI5["9#H2-%XBA82
M#?:@FE=X!5,8@RAP@CU(!3G(`1U@`BA@!,)S`R^X`2B`@AMX`T;0!7HXAE;X
M65(XSU/(`U<(AW@@!2]8`AMXVB?PA"+8!7#(@QTP@AXP`E%(A3T`KC<@!7>@
M@S+8!7!JAS`0@UCP!7$4@S`P`R_H@BWXA%4(A3\(O,8E`AS0!F/PA/]9@`4P
MX+LO@`5%T(;\]@(S&"12(`9M,#T_\`,=2`)/\()38(4YB`,O4`0PD()E6H)7
M@`49RV89MZ)^Z(=WP$Z(O9&F:`ESR(=RB+>-=$*7H(E[IA4(\>+9EH]S/@I;
M"6PIJI'E`PEUT@<%.-Z1,(`9H0E,$(`H]P<#L`ES:#]]2`!*&`GUL>P`V(20
MN``-F&T+&,.1<(`1&(K$*17<5@^J&8D\'XF5@*'?K(H\#Y5R`I:P2(F^+I5Z
M,`?R6X>4R!4@H0_UH`=_DJB,``8.`"A]:(8+F(2OX0`A,RA`X(`16%420(%_
M"'7710$]`80$T`@4P!M6M1W41`$54(%,<+;_37"WX/%",VLXLN:'%%!SL=FG
M?UB=CNJS0D@!U41)"R"WK0(L0.@@]N$HKQ@GK?`47"!9*)B"*B@#+_@&)V!/
M*C`"4X@$:*`"*U`D1B"&8H"#3GB"*-`6(."%)-`!**""+OB$18B'.=`O*'@"
M27"%:.@"'G@""74%7<".*J@"*I"#>.B")Z@[;VH'^X)ESDNP,-`O+A`#)/@#
M))C1HHD#4+@910"P+\C<*_B#3MB")5U2$V713L"#VU`"&_@8_NJ"%5V9,N""
M;4^"8?@%:IAQH7^:;<B`$L@"#Z"G?V"!1K@$IH8$00B!-3@W]CF2L.F'M3D2
M<16;%-@G$K"WS@H&_Q48GU?GFG##,T3P!UV5MD,@`4R0'$"=!!70A%LXLTQP
M>^TI!&4P`,4$A$MH5T$(`'W3A'$@`5_+!&$X@0#@,TRHD4!0!@4@GV8X!$JP
MAA5`@'&H*1A)W4F`!$QXA1-8@&+8GR.TAF"H'H8[AY"JAW*PAW4X!TJX!6#`
M!&9XB?WX0:M6$%\HD&UX,F;0!"$6AF9P!P;!A($H,F&PP69XAW%0,R)B!F$H
MAW*`$7/8!F6H!WN@AW?H!W^`"1\2(1\YAF)X:7U^!V"(-V&(\F80!NN/\O;`
M!["QIZ]WAOA3\V9PFVB_=&4(JTGHK($[=8`PA.F?/TPC`#G3A^@"I4*3]/\!
M0O$/42%]E!#IXS?I`B!_'#*1V!<HF#(#)"@%VI`B!25]*<YA6O$OA<<.F0(%
MXH#2D+]@@?B1^`<,W[\-'C8A,H3"$#U]3I]"C2K5*3%JI*KDF5)%BBM33VQ\
M@L(K3BQ59N9X&G4G"HTJ-8`PJ3`FBA4:0&ST@%*#CJ=2>;S$<75%SIPH=)@\
M.<6'B1K`7FRM4V,#UM3*EJ>*(P(C%JDC7[H<V<*%"Y(M891P`>/IR)%?I8:`
M2>WE3Z<M1_Z8`7-$29@K6SKAZ:*$U3,_1-Z\.0)&"A?12HYTV9(CR9-ML+KE
MNZQ]._?NWK^##P_U&(8L)D@$,T>)Q`85&BZ$0,'_(00)3"1()'!V@8.R%(8Z
M&$+)!2L$4TD*\F$B'R`CH.`!)<!L@`@E*`C2#`D6;+"!,YED,LD_(]RWP20K
MC),&(`P8(-$D%IR$R0("!/`B`)0`(@`!`>"8P'H)-",!`8U84D@A#(Q`R0(`
MV"C`!6L@X$`E!SB@C`J!3**"020$4,(M#C!P2`*'K&!!`(4()($`"QA@0)8<
MI&%!"0>2,,DD'HQCR(@(!!)"`FL<@H(**%A0"0(9"'*(!@!.D@`D++"`U`@L
MG)"&G3D%D@(&(5S02""'!((")BEP@`(@*102"""($)*`(!DHD(D':ZS@@2%I
MJ'#1)H5LD$8"RHCGU#F`_T`(B"'!-#-")L'H$PP*F:Q0R#_$!A-`,"04$HQ#
M#E&2"0>`%)()K_\`HH^']*!`J@J&Z&-?G884HHP_'F0R@C[_;()"I2LA,@D`
M_KCDC"'_!$)),QP4TDREF:`@(B;^I,#/"AT110(P'ORS\`B\BH>/4[@DH\@3
M;^AQQQMS:(,+$V[08(LNW01SR1Q=//'"'CH<48HGX(@BQ0U1C+*+%U[P,`44
M-$3Q!BFO]%.--''H@(</TISB!<AY)"?-/4\$X8H^V?5:63M$Y`!++HQ``XIR
MM(!A!!YB'$'+%L;L,D0#,1`12AE*X%&*&4=P0007J"D7"A)4X.&)%#A4@(,K
MN?]LX0D82'02!A>A=!$'*='DLLHXJUC#==>?@QZZZ-QMDXDUF`3"+R:(;%).
M(YG<4DDSDY`93#"4J+`)N_],0HE_!?'C#`F5X%10)L!BXN&__I`0B#Z5T!X(
MP/K\EP(PYBP;D2";>!!`E2A,N(\R`HR@0J&]]\,`"Y=4$L`:./V3R0D&`(+L
M.0&TI$`&(JQ!0@B0)$`!F"@!_<ADD$,((A``4$`"<+0&0U@@42FB!S^Z=X(5
M[`D#@FA3"M(0"!*PBP/_0@0+)+`&$Z3A$/HPU`DT((@0(`(1)0B$!"@Q"0,D
M10+*.(8'5+"`$AS+'`P*02!4$((U""(F';@`J`R1`@O_I(`>%TM#!PX1@@XT
MPTX+$$0E&%"+6FR@`YMHB`60U35_M,L9A4`$,"CQCT+LXQR9T$<FDE<(U:4K
M$#PY!STF`8Q\*<-9<_26/O;A1MOQRQ#FT(>S*!$,0`2B0]0+1AW1I8S4,040
MQ1"7"@IA#B<V9!SB,H0R#':L9TR"'X48!R!6@(E"G,-.DPB$'T3Y.5P,@Q%C
M>,,>]H"'-S!B&-+(Q0WP(`,J=$,2C)@#'J20!U?@DA1Q8(4C*$`'5P2F&Z38
MA11X@)4XY&(82EC"&XS0"EW88@MQN$,>\C"'.YA"'U^!QNBB0@[-S`(.2!"#
M$L0@!=Y`1SE;V,(CAM`%;9S"_PA=\,)"P=`),#2!"UW@0F@J]S,IW$$*I="&
M%XR@"#QL01%*``-OIL"<(_CA"UOH!BR\X;EZPC2F,A7//CZ7#\^]5"KT:(K&
M>`H5>FA,'^=P2G:&:H[LW#`?]%B'/CC@`7TLP'GE<(K&#(`N??AC1OIHRBT,
M$`Q1C@-_^3``)OIA#V;P2A`*L(@!G$&/H09"`.98P08*H8(L!&`%=+1'`C90
M"U%ZX`);I4<];E&.?FB"$L(XQSC\08ES.)(2SMA$)8IQ#F'HXQ:44,8D-K$-
M9PA#&<PXQDCLA)1W,&,2VZB%,%30#.H9XK7-.`$E-!&(8R@#$]8P1.J:\=I@
M$&B-S/\8AC5(XH]S*$,3ACA$,X)QBV#4(G4SA4I-I1)4JEKFNE+)CG:?HK'J
M/F4?X-58/C1V77XLTC+@O<<^%HD/\N;#'.`-#]=:\0I66.$-8(#"7SKAB3P0
MHQ2N&(,.J-"%).A`&]O0Q2Y.,0<O3*$+W;"$-KH`A2XPPA70:$4U2(&#*.3!
M"HPQA2BB<8I2*"(.>*#"&_*`AT6<HPI`T!I,-78-(L0`%K,0`X^E$)M.>($+
M8:!%&)`0`R4@X0I7@`4K7/Q0AS8!%*6HS9/WT(5VQN$/?MC"%(B@A":$(C9F
MH!P7S/"W*TBA&[,@QW3;[.;IFL-;R@"&[<:!"4SXJQ_.<(?_OX*QC68`8Q+!
MV`0P@*&)8U1"&?UXJS.8@6=E9*(9C0T&8\]A#G,`PQG]P(0R=MH,?]!C'/0`
M!C_&H8QQI(<>VRB&.YK1UV.,8PT"^"H#.("),0Y+'PRHA#X2@@(#4#!=!L@'
M>L^AU04\A!_U<`H@UKH/#'!@J,I@P!K&!PQ]:.P?!GA*`DBP57V,P`+TL,:?
MQV$/G%ZFO#>]C#TL\]+YW@,\.5VW=N8KNO%BMY#ZQO;6J%K3Z@9UON;5;GG#
MRV_S]KN0U<TI=:T;%<_-EVOT[E4NN-&)&ZCA#A!V)AVJ<`5/-($'4*@"%4SA
M8%+D@0YYN,,H1N&%.<R"<J/0`QY&_]%B5TC3"F5(0@]^X`E/=*$*M.@$%8*L
M!S>8H17OT(,=5A%3&TLN%K%0@A&.X`4P2,X,LXC&%OZPA"'$(0Y/B('4\[`+
M8BBB$T+6QB.@\09U=L$3QG"$V(;@-SCL0`J18$0N6.%0/&"=G\TIAC'8S/`W
M(S[QWAF'0PS!K4KUSE,H6$$6'("??_`6!8V(H`<PL(80-()4B+"`(7H8`D!,
MPA!!64'`+$")#:`@]O[YQU(LX`^0Y*14&YC)"$*0A1)L@@`$4(`"2*")1I#`
M``E8`/,MD(D`C,!9M`M`('!U(9#(R0"]4\`A`E3]3>`G!9GXAP(6T`$$&&`-
M:R``(%X9#/],,.!`_C"`@^XX`@$HP``H,H`R#"$(0#B2<B&"(!B"ZF%""MW"
M,A0#,!Q#4F"""(U1"@0#,PA#+<S."&@""1P")AR#,*``(FB"/:1!(0C#"M0"
M`FV"/P#+<D'"!C:6)OB$M=R*,`@#=#7#.]B6[51+ZFF"(-B2X@%A$,84U\#"
M,42"&\S!'%3!$T@-1CU!%<2!&P"=%?0"*33!S]T!%8`"D&&4%]R!#WA!.[58
M$E*!-/""%S#!*3S!)RQ4%6B<%##!%#"4$L!"/E!!ULS4-0R!$*S"(J"&%'B!
M&6R!(]B"(L!!#$B!%'P!,C`"%XS!$`S!%8""(LP"*W2"WT$`&)S_@B*`PBXX
M@BJ$`0X@@1G@`1RD@Q?(P!0D@2+X0C'$P1;@`83)X190`RP,U>$)82[JXE-D
M0E*@7DYT``=`@C^@``EL0NH`R#\0X`G\2:6,@`,(@B!P@`HP%@DP"""0``J,
M0`J80`F4RD*XDO>4"GM@PH+\Q!J4@`H@0BVP@#<VBP<$@S]L0"/XPP4X`S"L
M0/*A0&Z=PPC\PY2,0!KD2S"D00EQP`H`@R!8``F.@"IMP"9T0"-0P@JL"B"4
M``>,`S`H@)5,`@E<@.TH@^WXUB3XRS'XD*XD0#!N0@KD2P(H10(`P@=<9`JL
M@`*80`=T``I<P"9DPAIHP*$@0@*HP`BD_Y\$(,(&L,`%``,**,`YK``B'(`$
M'`(!2,#VK4$"$,())(!_6.-(`(*.)("$"(($G`"LW$(!CL`:3,`$9$`'_.`N
MPF5<7D:\Z<,P%$,KD$(NF,(=W,$GQ`$5Z($74($LM($K)(,-V,`.D($HE()@
M[D(9:,430&84_$`8-L$;E,(=)`$%Z(`:@(,E2!D3Q,$G2,$GX`$>T`$NX$(K
M!`,_3($-T%A,38/=&8,J&$$B3H%#$8,CQ(`9Q$`K&$,VP$(BA`(7Z$`-?,$0
MB,$7?`$L1`X2A,$7S,(??,'8E8$+&,%O,`(NI$/=B<$0Q$(R+-0=F(%)>4$^
MP`)3R>5Z*EYV*/^5/@"#/XP#)9A#.90#'R5+>K1F)OB#,_"#,."9,_@6/?B#
M.32#9BW:)/A#,\@1/VA".+R?(?@"<F'"L`!@_=!()IS#M:%$,1!")3S#G&W"
MG('/<F'""83:@_0."?`*)($:,!0)P-@0`*:!,1X"OQR(MH@?)F0")%0"(I"#
M[KS)13C2)FB(5'0D)9@((JB`"JQ!NGS$)-A'"D""<J5!"%0"L[Q"(6S")JS!
M!LS1)3!C+0A"(220(?0/)$CD(<20"D1$"@!"!PA+P?"#O8S`"12*07`"3@B)
M\ZF`MTU""<`*J@3#/JQ$"AS#J+P6>S)JHZX"+GQ!@>W!&T"!%+R!%TC_`58\
M`1V\`1/,`3PD`Q70P3+E`2A(C1OBP1U4`12"`1Y\@B<P@A<PF!<X@2AX@5]Z
M017D*A7<P2]-E"[H0Q7<0&S"U#((00S\0C3<YA9(`1'LPA?$0`QL00R4`@4X
MPB.@AB(H0A=T`024P9$I`0XHP18\@0X8`1'H`!DT@!0T#BC$!B@T0A'D`A'<
M@9=U@2PT01*@QA0HP37XPCPD7*,*['39F\$%K,/Q&W=T%RXZ1<'V"L-N5U14
M5U,TK';1`]?@0W;00[L]!5!E1#Z,PSEDASWPP]:X@U.$FLC:@SN<PSN4%UUJ
M+##P2CF,PWLUA3W4E#T(PZ+J@S+P@SV(5LU:_\,X*!4?!4.H^>Q;\4.HH9H]
M!(,SE)(^O,//OD,S:`(][,,MR)=0^<,V#.S7"B%=OL(P>`5RO$&JXD$>5$$7
M?,(;W,`-E`$43$$>L,(J6&(HS$$>Z('*E4+>YD$GC((GO,$JJ`(UQ8$>\$`/
MW$"I.H$>I,+/A.$=6,$4F`(_Z,`+4(9,B<,00,`OM`+?*($2F`$LB"X8/"(I
ML$(H'($0]),8^`(V*((K+-1S=`$OX$`37*84B((B0(,C;,$5[,9P>$(KY,`G
M','>?(,B$($_'=@K&`-302S82F]ET$,AB%\E=*E=&4(*<NE)X$0Y`@/FW80C
M&0(B*(-DE6A!C%$="?\:ZBG+,W":)I")HKT2NP3:G0U+,SB#,Z#:9F5+2$["
M,YC#.)A#/]Q.2`*#I=F9,O#1G?%#6=69G366,BB#9>W#3I%$<YW#5U'0/KB#
M.7Q5/?"9/31#/33#-IR#,[Q7R;K#8J$L/;2F,O"O,VRH6WU5/DA:1B!7/^2P
MO;D#/Y3:!>_#.\2;QM+#.YR#/="#.]0#Q8)7=3UQ92S;4[AGQ';7]&)Q/7%-
M+@C#5;Q!%="!+,1!%Y0"+\3"%GS"&/@`7SS!#?`"@V7#+C!"Q]%!-T2"-LP!
M%<0!*+`",<!"A^&`'>"!$TQ!&8R"*2#4)^S!)_P%'<1!&<R!.4R!'<3"3&'_
MPQ$0@2I$@A2PS1;0PA44P1!(00RL`C=@00R$@1`LP1+D@"C&`C58(AC@7!&P
M`BM\02S``C_X@A@(@0PLP2@K@D<E4PXL@1`@`1>4`AB8YQ9$`RR\919#<V7X
M0R`T@PJL0`A@@`/<2K<Q##!H"TH\Y%+0U21PP"0H`_DI`[=L`&?9D`U5`B!P
M"`GXPP>(@`I87@(40CGFXPA`"`?\`PEP`+580.RU`%U5Z#^4`+A\$,&HQ`;X
MSH=,P@B,0#\TSPIT`#E'GQ]PP"8L`"*$VPKX@TQ(2$!#$+L`PK:$`)D80IB,
M'@=XWAJ0B0@A`@=H``D4BIV@P"0H`")<R(J\45@&_P),KX<_6,`_)$#J58HO
MNI&P1%_`?)Y1JB#!'#6CJ("M00(E&$(F%`*`<`!+%@('8*\_H!$PX#/DW5ZG
M^"\'``,''$)68DPTP_7HX$(TB-T=J$$[@8$H4,,<E($5X($2,$(Y2,(<=,(3
M[,`=B$(K2(,IS,$F,@'=@L(VS<$N/`$0G&T<;)@1+,$8,($KV,(IC&:J`D85
MD((Y@`$91$),Q1LR;$$9S,(J0$<GQ,!W<H$I>,(M;,,13,$1L`V2,4(>W(`,
MF,$?,((B?($J^,)P/@(H),(6R$`,,`(>&$&0E0$-*((8.`,=Z($H2#<7X``>
M<`%S7$,L#%5<F_=3F$,@)/_1)@A"(ZR!L$Q(NM1*LU#6*XW?)/1#(7!+`4H(
MLV""5/B$D``")!!"")0`)>2WIY#)!4Q*(#`()90`(`QE(>AD19`S"40$[34/
MI42?"'DD(JR`(8#(2:-`/@2#!Z3`!JC>4ER`]CX@/ZNX/EP`"006);1$(7C`
M02R*DP;#$VU``DB`>F_`"-"#"C@#)8Q`1)/`\:R'"F2"BBL#!R@`&AG"`F#"
M`(]#ED-69XU$"EQ``H2`"83`"21%(%1"H%P`"]@5!_BS40!*"A1)/`;%?8Q`
M1UL`@RC%"!#,)DA+J:3`!T!""6!`2T3O>1LZ5!!A,B0"%.R!71<.+Y""#^S!
M#23_0S)\PRLTMB+X@`OL`0]P@3OM`AB4P0WP5RKD[0X\`5MX02=$@B4P@S3@
M`M-`@1.HPRG0`1[HP:0J@3340\P0:STMPQ"0<BO\!A@,`2:#`3$,`32$QA:@
MQA`T`31``RYP@R+@KA2P0BQ<@2KX@2K([A)`X3<P@RN40A/H0'A+P10\PC$T
M@2Y@@0Z4@0QX02G@P13@@C&TPZ&;MU)1;,/B9[")&C^4]T[MPSR(UUOQD1#O
M0S.\M<+U[**!FCF\E5.`5GOM`[&80PHK0SB`,#X8Z,(#@R_0`Z1)6BGQ`S#0
MPZ=5PE<UPV8%0^]L0C\(F@'S0WX#P_8V0S]`VCDT0S[[_P,I(0*R+*CMB)]%
M!,(MO(,[K($FO#,E]827EM4<!8,*6`LIN8L_A"0]Z%DY^D)N!0,P1)).Z=%`
MO!]2),0DI$`S;((S/.6=><@D-`,F`(/9\U9%2(D?`0,\!P*D=5]6%X2P`,*'
MW,*`5X(A7)N^(WZZ.<78>L6J;@4OM,$/^``>Z,`I,`&L)@$8RT(GO$$%J,%;
M/`$.D$$BUL!7Y(4.5$$HE$+?4D$K.,$R5<',P($MY$$7R*$>5($TQ$,5V$`K
M6'(,R,`O.((-L`(CX,`,.($N0(,BT,(.H$88B`$I5$,T,`(6/,(]%$&0-<$6
M((&728$1E,$94,`ZO$(G,$(T:/\#(S"![4]!CKF!YSY!$N!`'.Q"U[6#+X1#
MXI]W$1OLUUYQQ`*$/H$#"18DF"^?084+%>)C^!#B0X<0$RJL^'"?0W,&]^G#
MQV\@/GKZ,@J\&!%E2I4K6;9T^;)@OGOZ6AEK!:7*FRZ=>#7)X^3.$U?$;#VQ
MH@,('5C1YHQR4^4)%1^VBB2)$J5**3C?/KVI`D4''U>XND0!(DK*KE9<NEBI
M`H:4-Q\T2L%\B"T'#%APJCAQ]42)I7=PCL3@<G@*-&B@XN#YQ,A2LDY&MG@I
MLV0*%S!'0.7J!JI4GC>ELKDZPJ7,%B)Q&-4S942)(U!@(`A[M?&D7=V[>??V
M_7MA;IC_'142)Q[28T.!QPL>9RYPXD/A!J<OC"ZP'L-\$Y]+!_X=?'CQ+&]-
MB^3UCN,G3()8H1`-G)H;>WH`Z5$CR9-DWWC!(M6+%"-<N464I>@Q!8PG=C!+
MAU.:2`8=4'9X(@DJ2$G%$ROTR(.5<G:PX17PQ(&@`?]B@""64(;X0Q$P:B!"
M"2YP8(4;.#KII+%0$M$G'5B:D.((,(PPHHM8]ID'CE"^<,P31Z"!8P@PI,A!
MC#A6(:6(+K0I@@LEC'FE'9/&&Y/,,LT\$\TTU5R3S3;-K"B7:6#IXI-2;*C"
M"CQP:>669W"(H@<[JM@#BCSRJ*&'.UJQI`TY=+E%%SC<T(44_S=<L($1*IY0
MHXHJF)`B$F4<(>44*LR@PM`]XK"EG#?$`B\<,:2818X:S$!BER=XB*,3+Z;8
MXH@XX)D-#QQ#`>61=I3I)I=$C-FG%3F^,>89>3PIQ1,P/L&#-76:X&(+)<+X
M)%P<IKE""AB4N,:7C?2ISLUXY9V7WGKMO1???&?"9<\W7/GB"3V2<`.7(G1Q
M2U,[H,!B&G"Z8881+XR(0QM6J#BEBU%L48.),A@IIQMOY"BB4Z/R:*45.&QQ
M08\GC/`DE3?F2$>-*%8!;YDE<H!E#BJ5\&*5)O"`@Y49I.B"%U<\Z2041129
M9998H#G'G'-\B2665VZI9QICH)G%$_]0%`$%QT^@T46*)(A0I11%</C"EB&F
M6&*):'P1YUUX\]V;[[[]_AOPP,>LJ!5L2-%!F[]ZF!096%S1`2<OJB"%G&-<
M(<62>"C(J8HH="#C!BN8>.,),%SS1)=XB&%$BCNZ^,$+8Q:QA@DH?*"#&%&J
MX&6;)VPPY3?BGHG!A544@=&,)F")!08D9I$\%5+`"&5ILEF!Y9=]8OD"A!,;
M@$&((501!Q]H3'$%E+!!"26.2V:A;9;"2)$&"2G*$,-+6.81G/_^_?\?@`'<
MVRN,`8<]O$$73BA#*][A""SLP`MXH$(7OO&-7,SA6O-[4A+V8`<[_"`*:LA#
M$>)`C%SD(17_C&#%+KZ1*2_<P0O^2@8WI%"H8WBB!HRX!Q6"T(K?5,08.9#!
M*R:S!2X$JPLY(((BXC&$)6@C#'\`12+``(=8/",<6A`"#%S0@!HPH0$S@``$
M:A")=BP&#V!@!-FDD(PO'($9?XB!#,"@"B28P0Q26,(T;B-`/_X1D($4Y"`+
M,I-%^*(5-V!"-5K!A%8D(FTZ\$$9CM"*<HA"#Y_PQ"A$L0A]G"-H5&A")ZCP
MJ5;$8QN,.,4H.A&V7$BC"5/`0PW0,`5%G+`+T6C%#O:`AW=\Z&:^J<@T:O`"
M6(!B"5)00A/"((NYP<`4;FC`(X2QBBV$(A1=@(4XD!"!3^AQ"8K@_\5ZC."K
M"/BA':4PPXT2X8A8K"("16#&$,X`AE5\00E'")<2LM%'A!`2H`$5Z$`).CB!
M%(X1B3K".MPP!12^T"UPN`<I\C"*/(C"%:RXA3["<0WSX$(?Q)A#*Z11CG*4
M`A6C`,7Z0,%()>21#%U0A"AT((I6=$$'/+#%.)X`!%B\JS<5@49>=G&*)"A3
M"4L(!1)R$`-7@(,(4O"#-F"Q!2RH(AM#:$`<9`&&68""&+C(Q5?_,`LB1"`,
MX&!$&EM!CE^$80G9($8,8%"$7^#O",KD0C1BL8Z"_A6P@17L8`4R$WW@8AJ,
MZ-04&&$**MB!$;'(P1.>P`M=;+(4H2#%*O],88MHA.,<]^A'-9@A#6GHXQ;.
M&`<K1&$*T(3-%=GH!!*F``57P.(-->`%5/90!5/8@P][T`5XGK&%,L2"$3G(
M01*F$(,XN"()0W@$*[Y`A!C,3PJQP(868.`%6HA!#*M(!"EB00JG(8$+M-!!
M`V+1CTXT@1Z/@``1PK`\NF$3"5M0IAG$<`S]$1;``1;P@`6'BV%XH@HOE,(T
M6O&"*43#"'/(A2U$\0D41L\5ML!&/:(1AQW0@`8OH$$/H'`*>.@C&K<-12I.
M(8I2@`(:HUC<+G!0!G!<X@EWB,,43N$.WX7H-PZ9!@Y@X`A/*%$)2LC!%O!P
M&E9$HA0XD$(18`'_BU=,`P*?B(.X.K&*<5R#'=9@!BS`D`,EX&$*$&A'*T"Q
M"B(L80BI2,0JAB"$JB)!"7-3PA;D)(]]=,0A$PET0A*"#WR<Y-#)R4AT$)*0
MC&QG(!5)M$<*K0_#.F0[D`X)/OX<DH08%CK(2;2DD1/J48<:.95.SD0<S6E+
M<]K0[\+'3`P-Z4,?>CL=(76L_QGH6#^:U?\$=*(3W9%'O^L>VW&(L=^U:$@/
MN]"[)@FK9Y*/>F0:V,U>M:S?=>WLS)HDR;%TIY,=;(_X^I_UH`>Q&[UN;%,Z
M.?7X,T+N,6AK9_K0W[XUK?>A;$++VM"81G>FEY.WPJ)ZU?\6]\('#=2%_R='
MU8$6$ZBO`W%Q-SPZOB8(IBUM:C$Q'-ZD1GC#11[JB$,\T!W!!3(4&X<QV/8+
M-,@!*>)QA"^D`PXH_$0G\,"*:,Q##B`&<1!Z$.(*5(`)O(C'*UCAB6NU317)
ML$(JR.$%%Q1A%W.80GK*`(IQ)$$&=?DVPF%2#!*M`@YF7D(^C3"+/!"!$5UP
MA1M@L(0M(&,>BFB`$D!!A$X\8AI^O@<YZ&$\+A`!%#J(@"K600PI$&&):`<%
MW]V\!,@G60G66,4YPJV2BE/')14QK-[`'6G`_1,A'+^.3#H/5()_?-+WT/6J
M9^UH@QB6UK).-D%RWYW<X/[5#K]'O1U>$(?L'O_9T48UHBU-:$U[Y-(=C\G'
M-VX0<S/GT]XI_L>S(Z9_*B3W9?H\15IRDHKHC6_*UH<QD$&'*L2AAF\@AA=N
ML`-C2*$!HM"%*1CA"4WF@ARHH`'T@`Q^0`>HP!N:X`9ZH``;(!?.@1'Z[Q1*
MP1&B`0XBH!5>`0KL8`Y8P0R>((*\0!+VX0F"X&8F`OET8QJ&``)@@1%L0(DL
MC^^*8`:ZH!3B@`YT8`EBP`^:`0=>0`CL2!&R`1T2(1;TX1!BH1QV`4AB(8RX
M@!X2`0:&X`A^P1$<@0MB(`Q^`?*2(`GRB0NN(1;(8?L>PA`P02&:@1^"P1E0
MXCI`K3LD#O2:806$@<#_+`(ET*_4&&WZ_"W<V*TZNJ_4%@+4>$_36"\D^HT[
M3$+22H_WA@\Z\@'0-$W01,WDX$T.+RX2#^(@;"W\[C#]!`(6AD$2H.`..H4*
MH,$);B`(M*$;@,`.7&$<6L$-O$`4TJ$)&L`.H"$.>*$5;&$8;.$44B$/],`%
M($`Q0B$"C:$<8$$'RJ`>NH"+3H$4IB`*O,`+I``4Z*$(:N"GO@,;(``&5*%G
M<L`(DB`4MF`(E,P3<,$+;("YA@`6<,$%7H`(;A`48$$4($`,6"$&FL`2("$.
MO"`.ZI$(RJ$3;``,\`<,B*$3(&`*\LL+<,`+P47S_$H/!0(3,D$?E*$9Q(T$
M_S)A!0#A'.BA(\;!&O1A)*"C&1S")$UB(LYA(N@!)"IB)4EB'`3B'T8@)_G&
M'<9A')IA',[A')K!&91A')0A&,:!'HA2'H;2'(*A'(JA&:KF',J!:LQ!*^F!
M*^GA'?AA#3>B'@[-'93!'<YA'-:!*5^2*SN"*[=-)%92X?0A.^A!$"FB^R3-
M'@1B'>[A+JWO]F0BU[YO]%CBGPHQ)1#3X9[/+O(2#T'1;Y*!%Y.@"J;`"*S@
M$U[A"6X`9:C@!FC`%<QA"T2!&5"!!M0@9J!`#^;@MD)#%)A@#SZ!!JP`'%X!
M#.B`'IJ@0ARA&[H`"*S@!JUQ#\I@"D2!&\K"%<`#&_^,(`=<00Z(8`J8"Q32
M)096"@3280I@P`@4`<4:X`FTX1:^X!5&`AI@H`&D@-.>P18<81E*`09PP!W*
MP0F4"`RJ`0E@(0YRP`:X0!:4P`A^90NP8?/*D"$*`1,*(05(X!\&(@%((`44
M8`4V@!_\@052`!`&8AQ0``4X`!A(@!\F`1'T`04"801(``7.(1P<M!#X004N
M8!($8AQ(8`,0P1PN8`0XCV^:P1`J`1$FP1``P1`"(1`,@02"M!`H80,XX0,0
M`052`!(X`!(,`1&`%$2']!^`(04*P1""%`5(`$2UE`0JP0$:(0,05`4V(1"T
M5$B#5`4P81(F`4@IP1!&8!+_*&$3,B$%,F$$IG0%`B$%,&%+>W1+WY02@H%0
MSQ`%)D$9,`$8#$$99G0-SG0$`'43*F%+`742,L$?*@$3`($2,N$$!.$5E,$?
M)J$9@'03`$$3TF`C-V$3@@$8,,$?-M(9,H%19742!$$8E.$8,*$9,$$0@"$0
MZI03@H$2@.%59U43"C48@B$3,@$8,L$0,J$9KE(9S.$5A*$6#"$8$*%9_8$-
MFU49G"$8SL$9^J$9E,$:@@$3F/(<^J$L7Z$9-H$9M+49@@$IG:$[(+--#`L7
MDL$3H"`)H,`HN&`5=N`'6&$57($)HF`J<$$3\`$']&`4FN`-\@`:RF$=WJ$=
MFL$5_[A`"JH@%<8@#O1A%73!$KH`"K0IFEP`#TKA"&JK"HA3%,IA#O9`$G`F
MSV(AB<[1","@%'0@"2*@"Z!A$6I`!JH`"2P!&EZ@`>#`%)J`%*S!&12!!AI@
M!WRA'<Z!#:Y`%;9`.\OA%M2@N8@`%\8&"8P`!T+!#+8@"4!V"[@A%O9')5"`
M2"?5'P:"`S+A'U)`'RP`$T9`!28A`)1!(`"!!/0A!;J4$CA@`?QA!$8`!?X6
M&$;@'_S!`#9!`?)6(#B@$/XV$Q*5?PKA<[F214F`!`(!!0"!`SC`#]9@!3:A
M`Q)7$@MB(T:@'U22'@R!`_X!!2)7<$W@`QR`$BC!`H"!'O_Z02NIIA\XCP2`
M`2SI(1A&(!!60'(38`0L0`5*U!`\H!+&@0W)M5F#H1G@-%V;54%)H`-&(`'^
M`0,\P`$"81-&X%C!%5J=U1_*]Q^481.``1A4@`,\H`1(8`%28`-2@`5*@!)*
M8%HQX5,=V%4QH1)&8%8!%1!60`5*`!`\8'4-@`0LH!&RX$\GP5(IP4>#-!@2
M54LI`1`N(`5&<A(6H!$\H`,R0!`:`0$$P1`.`1$J(1!Z=$@QP6XG004*@0-(
M`!'^P1!0H!!40`),0`(T@016($L1(1!4(!CXE5XJ`A>J066?8`I^``IR`!I2
MH0=.`0M(X063HAK,814:``A^@@__YB`9WL4>1N)*/N$)YL`&=(`?PH$9O"`_
M^*\5%&L7W``GI"!@IL`3[L$(:,`3E%,(&@`4>L;RE,L-<*@&<0%5;&`'O\`;
M:J`!8D`1S``6Z,$2F&`.M@0+K.$=\D`*].X%AJ`9AL`%D@P,]BH)8L`(5NH(
M($\*PF4:5H%N(\(ALG0<YI0$5I($4OA"Z?0"AC4%VE`?5&!!,:$#_($#4.`?
M$B!T#8%R+V!U50!)<50?-@`81'024B"=_X8XQB%WPZUX@V%"S8%1QR$3`@$3
M#D$3>DW1.D(30*(CT#08S"%:PX$2Z,&'#<$?4J`G"VX@-B&>]:$?4``1VM40
M*CI6'303_RX@;_<U5L.-'J@W'/@V$YZW$D*@!##!`]!P(=AU(.@A!4I`$#2A
M!#:!!`"!B#V@$#H@1/=5&0(AIE57IQ%!$*B8$RK!<QN7FA5B$K(81B47$`H!
M!4X@`PAA#4)@#61W#5RO()SA0FMW$SA@<%&W`[1:`S3`@2^`FF]-B^WE%J+A
M!;V`!Z+@!J!@%Q;P#DB!#J"+!VY`%-S!#5X`"&2A"?B@+U?!%NX!%FP!'I+A
M">(`%1H`-/DA07H`#Z+A"T3!#9[`%A2!!Z!`"K""Q^J!"5P`>'ZCWJ!!!AK@
M!F4`"F#`"W$`%KC@!>:@2/Y`!GH@":P!&BK`'D&!$51!%?#A%?^Z01^`@1GB
M(18Z@0M"`0)>``R:`13@D0AF0;R\``;B@!1B`$;DQLRP`1KF8?Q`CXE1@!(*
MP0*8F40O%'`+X1^"X0+<11@4`!@N8$$#H(<!0!\XP+V#X1_^H1^:.0$>^A\"
MH1^.MTT!Z28-;CA*CB7*6SE@$J(]PCBJ3R7+X2U-DM7DT-CR0:`'8A_HP1ZL
M<AQ&W-W^[-",[2;?E23<;23PH1F:`;1PK=]4G!YJMW:C\AS<P1R4(1^(TAZ4
M01-^]2,UK=-&/'=U+1C\P1SR`2G'`1C*@5V;-1/L@3''`Y_?&B(,"Q:,(0[R
M@P>2`!6HX`>L@`;RP!;@P`J`P`QTP!3_F*$&:.`&2N$-Z$`:;"$)?"`9F,`'
M=D$7F"`.YN`%7B`/G*$)H.`-FJ`+3$$;C$`'WD`*]*`*C.`)6H<4\J$*@B!G
MOR,:+H45ND`&>(`'/)D)%*$&9H`1+D$18B`'($`6A'L.&L`,C@`"N.`*?,'"
M$\(1P(`(<(`+GJ!$OF`6&$$&<.`*'$$50"$&OD`5AD3*E.`+J2$6PD0EG*$J
M?10D!$)'R3>YFV$?EABJ!2(85J`2!,(?X)DC,R&+?75W_Y0?*&';!:(02``-
M?=5OFJ$2_($2P/46GK7?&X$3?"$I@4%'#6%5,P$1[M<?&EY68[4?CM)_E:%1
ME>%=C9)4GV$3__SA&2A!*8W2&4)>&2Q^*&?<&LZ!$CZ2)OG!'(JA')A!$Y0A
M$Y;7',Z2*(DR'^A!*\?!'+!=*YMW'_P!*9G!'>A9'_B!*R=B?_ZL*4WR7?G!
M'J(^'\PA)_LAZK&\PO>U]4R".,YAQ'4C(Z4#7L+^-]*=RR.B%9:!$72@4ZK@
M$YC`!H+`%';I&^2#!]Y`'\:A`GI`%[9!%6!A&^B!&';`!9Y`&MS!&4A!%*"!
M#E[`#FBB"J3`"$@!%S8;*6C`%/)`![!Q"EAA'ZC`!1CAAP3"&+B(%/!`!I*`
M!_+B#A@!!F9`%))!"FS`!DC!%&3`$Z#!DS_A#I+@$XQ!%>8V%B*!%?^V(`>*
MQ0:.8!G:]A*4X-<501L2P05J(!0.3VV8ZPBPP1+(\&\44W#&8>,Q(1@*`<$S
M@1(PH00(P4&[F04Z@`4B=!)F5%8C>!,PX4"#P=[K%!-\=Q(LUWH#`2`P;+!`
M*<4&0X4P(3+$<!*B8"0H%6)X2((@1(`F<3#D8<6%#H$V3$)8:%*@0H$,!=J4
M<E*A0@<-J<#$(5B"$B-(0.+@[R0@0!,1_4,D,5`*0)18E!!D")**8!="I/%0
MR`)"%8$F_0.J`D4P0X#`(EKQCR$E0YLFD:@T(A"*?Y.`G@P4"-"_3)-,OOQW
M,%.F8X&LD1A4B(2A$&E18BH4UM`D99L*51K_.4F0,FK'-@&[=4@3I$V.-U&:
M)'J<OM.H4ZM>S5HU/GW!)M%K3;NV[=NX<^O>?3K?/7VYF"F:$F4*CS&EF$"Y
M@0>6KAT]@$3A-<Y&$#ZMO)RJ=PY7DB!DHM&;!XI*LC@OZ.0SI09*#E&ZNN3Y
M`>0'(T55RE3A0FK>&S*D\&9;/J<9,T42L'0APQ,YV-##'1#P\((KILA@`Q/9
M@)*$%+'@T0`.M'"QQ2J/S`++*HZ0LH,9=[SP0C2L*(%$-;`TL`01T+2R!!1(
MX&&$$4DLH8,1U\1"CH"[O;;:/K@I29N32$89)9234():/B5\4(@_'6"R`2"5
MK-`!)22@0!L])/"#_QHP%@1"R0@II*#")!]<@)`!P*`VCIJHI1",/J^=4T((
M88V`P@6"F-`!4PE,H@\]]/!CCCF0ZH/0H_;P0T(*_XS`P@B@BKG&)2/(-DX_
MYZ1J3C_F+&;..,Z<,T@((J2A`0$=L"!F&K>H`,@YRB@SCC+!--,,9"N88VPS
MDZAP`@<H>`"M!8B@X(\A)&#BC#/!<$LL,.:D0(DRF0!3$`D;K&#(`">(0.L:
MD)1`B%^8`(-))<+XXT\F(]B+"2:&H+"""B:<$(()[G:@22`A?(;6),U(B9LS
ME$`I\<489XP;@<`M$\<34?"@`P]Y>((##798@T4>-P`1!!7A,/%"$'ET@?]*
M.8T4$84V1S!Q"S=NO.%)`PV,,@P.45#1Q1RDR`(#$&K`\D8/9/@0115SE#/%
M&`%JK`_'OP!)RALY-)B#$K+HX`($M^#@PBG2)(*$&6*`,0H9$1@!C2*C=/*,
M,[C$`DHHG30002F@@(&$(DW`DHT;-2BR2@,RA`%-V4DH8<01U\`RC]>@ARZZ
M@/GL8SJD]^133S[-F/9H/O;0X\XXP/2C3#.PT[./[KLS.0ZDO@,SFS+GX#,.
M/N;X$LPSF/!S#SWY*&..Z:\UPV<^Y1BBS#OT!+,/)>8P0TD@UYZCSSZE?XV:
M.<Z<SV0@F/33#"7G4.+,,8804DL*RJ#&9&K]^!/_:@@1B&#T`Q/,,$0PF+&&
M-.S/2JUQ!B92,[['/,P0S3#$&EY"`M>Q9ER`TL<Y4I"&300#$0N[1"-.L`9A
M?.`0M`E&(5(SB144XA@JV,0:/+`)$7!@$X?H@#M&UYK9$/&(2-1-/F"!#4;H
M8`I&B$(0;)`+*J3'$:LHA8-T8`MS7*$!0)!%'G)1#7V\XAAF;$4\B.&)4>R!
M!B\P!3S@@`,>4"$:BW"%A$H!!QJ(#`A5^`$?Z'$#&IAB=->(00-*\88E\,`&
M,`!#$V1`@SGLH@%3J`82E+"$(TAA"YW8!1T:P`4QQ,`%83`&!"`@`S/D(`*>
M>`4>H/C)+?Q!%Q0@@CR<_Y"#)BBB"S9(`A>.H(1I.()/24RF,J6$#TB5#A_[
MP`<T2P>]TS`I'P3B!_=">)O7\`.;Y].'/<YA#WO\CS?8Y)AJU+F;_]E#=.QD
MIQ)]@S$CHD^=L'/'.5L33=2XXQWT?-VCRK&-<I3#FLM,J$*12*!\M"(:GDC"
M$ZI@!2#T`!1&`((G2*$(Z]0`&JZ0PR5>4(4O&.$.B2"&:FX!AR<\`0^%'`8I
MM%$%'O`@$I$@14UMT04@0.$)5J!"#UR1CR<$@13@!!TV:@`#:'@A!SI0FRNZ
M\((QQ,$(-OA$')8P!B4T(0QFV$(DZD$*&31@!C!HP"I?0+0G[.(<80"#&;B@
M!/\I3&$*V<E!+.(@@PC$P1,0>((9E'`$:UABB`M-K&)3XPR&9*1*(\F(KTH2
MEULP!A$<@(E)3L*0A:A$&0PQ1"4$D0(.U`L8ON`$,#9PB!4@`A&ERHHA*(&(
M0AP"?I0`#65&0(E,W"(8F]`$"BI!B#1`8@692,LF,D$)2OP+&,[P!S#,!0Q$
M8"(8!JP%,P"1%D/XHQ#<FBXP_!&,<MTN&.,%1C`P`0EF6(,9VW"')FHQC$TH
M8US!4H;\G-$Z89W*6+331'RWT0]^!.,6VP`&L8(!*V65@Q][.@<]4J4J<QAP
M'_RPASOHX8QQN*,?[FC&.=P1.T@!CW>5DET_[E%.@*;_8QO8VX<[S)>:?2[V
MQCBNS6]6L;<:0.''-+C#*8)``SA`HPI!`,(<?($'^"3A#JR(`Q3FD(M6#(,>
MPVB%+:J@@U&<8@=SD(8G2B&*J.J`%[#0P0NHP(H8+"&020""*/*!9$F,#A85
MZ,$LXD`$&_R@%!]+PAOTT``73$$5>.`"%ZC@!2]L(12Q",8W1&&%0KY`!DSX
MPB[8`0M8A,$+;RB#%^(@A3\P0@HQR($LDJ"#/+B""D0@[!:P$8M[V#C'N!8=
M/OBQCN*511_C.,<XW`*G#73``A;(50AJT8$TR,]8MI,?\4:`76-Q`@5^0`$*
M3+"!-6A@`A*H!"0P0(E@2%<9_]/UBS-6H!GT4J+;(Z`5`DS@@#5((`V(L-,E
MSH(7LV"B6=UEBU!&0(@%&$(!(]C`G.S$D$`,124K4<EK)Z*!+*Q!!!6Q50@R
M<`)-:*`0B#!*)>CRDK"H2RC5"L$:!'&(-&A0`8>*5PK`4H@4."0%#L<$"281
M)T/\0P,G$$0C",&"6I0@#2Q80Q`U,0*4&()3#/E')9!2%\:PH!*4N"TD"!&"
M1FC@N"=(R3\"08(\Y?KLN";0/EJ1BR[<@#Y`Z+(.ZF,-7;Q]!]?0A1FJP(M8
M-``-MHC#'40!AU8LHQ5?^,03WI`'&M2@&Z2@`AW>H04<W"`.WF`"$*R`"B]`
M@0Q6,/_"#TS!CTF*XLXUH`$KNO"#&KQ!%A&H0A7R\`0HV"`'GI`&$^[ZA"Z0
MHA-YN$4S]M&-6\3C&]&`AC["<8Y5A(+,L&[T&ZC1!2(\80ISD(\.*``.*2S!
M"V"H1BR,B/;RAXY`UTV-8OIAB'Y8%S`KP$0:`&$Q_V7B-*^AQ`=\08Y-O"(3
MAI`,&H0(D,`"S$`;F!`Q3.(,6Y$)EW`"EM`!E]!R\+(!FL!-JE%>J$$/*I`"
M`*-R0A<PFU`,O(6`CG(:]+`&)I`%B"`54D$((C`J)H`(5^(_L)$"YP--AK`"
M^+8")0`2\S<":;$!_;,[NF-B^A`(>6(.L-$N,3@!(<`"M1+_`H:@"1ZP!OPP
M.ZD"8N?0#\"`@UTX#H9@*VF0!NZ2!AT@`LC%<\%`#\N"6.87AXEE"M`0!S]P
MAS[E"M]1`5M&`Z=0#K:@!GKP!'>P"VH0!%;`"WDP"K90#=A0#:*PB*5P`Q70
M"])`!V^`"JT@#\8`!3\`#D[`5GRP!RWS`U`@9_8`"J,`"Z-C#%)`!K`P!PU@
M!8.(`XS0!+8'`PY2!+OP,3^U!8E0:KMF#&`@!I9P#8J`!*N`#?>`#5N`!UM@
M!%Q%!:<`"C'P5$\P!'CP!'L0`8R0!TD``5)`#:]0#W)XCDAT:ZGQ3KFACJ>Q
M80V5&NJ$#QQC.JLQ&Y*2CZ[A/_1`_X_0M`_"\BCC<`_EL`[FL`W,,`YMJ';<
M]!J3DH/YL!GE8`["<`^GT@W"@`G"(&"ZPS%.0@_*\#_X0`F:D`P4N0W.`"[!
M0`G^`!KUAQK=@AK](!G"P`RU8`^-L)$J@0F`($#R>!KF8':G$1>8D`Z5<`NU
M<`FW``EN8A),B(Y0J4P<LPK$T`D\8(H\H`9S-V6]`$;JD`A5D`118`55,`J\
M8`4NH`=V0`,T0`??H`85<`.I$`4OD`?00`=/8`=40`5@8`R.$`%W8`HW,`9W
M<`<W<)4^90KTT`53<$A>PS&O0`0RL`I=D`->``%*``:X``Q,D`,UP"`PX`6[
MT`1$(`6)1O\$?M`.D:`<I;1)1Q`&5\`-S]`$/X`'8#`%/H`%T=`$.2`%.&`#
M1M`XI#`%2P`&5"`%7"!^Y!>5S$D;YQ`KK6,.YV`LPJ(,_F`.S30.\_`*FU`.
ME#`_S#"=]/`JK0-A^Z`LXQ!LYQ`,Y[`/'<8/YP`,VU`,J'(,Y?`.R,,/_(!A
MU31-D+(GNA-"S:`[ZP!LRRD@^/`;Y>2.M9$/4")/Z(1/&)-4&L..S7FA"<4Q
MK;`W/&`%4:`#L=`%#9`#GT`'-H`*D2`%4,`$98`'G>`)IH`/CU`#+D!D-.`#
M<,16.T`,Y;`(G7`'5.`#5#`&;I`,.O`&KB`%--``I/`$FW>*<\;_!#:P"OKP
M&Z`3#3`P`ZP@I5V``S(@`U*`"ZMP"IZ@`SE@!#(P9K.P!5Y`!)&@#2#0!$F0
M!%1@!$40!DJP!40P!&$@#3L@!4>`!Z20"T=0`T20!&;`"*30"L@@ISR@!)U@
MI]RP"@R*H5'Y%89@7;7U$HX5"((@"(3P`95@`AEP"!N0`@J0%PC!$!/A<YN`
M`IQ5"/\0$2]A%)2@`-Y6"&FP`2#'&"ZA$@E!=9QZ`251$BGP"AS7`1\0"!<`
M"367`H6``G81"(@0%XR!`C!1")F`"5D7#!^P!BNP!IB``BJ!$"?!"4`Q"=SJ
M=)F``BIP"\0R+BL7,#IW%B/Q;Y#07).P_Y*SE5L,(7S6<%UX<0NCP1#,E0G2
M!5SKU0SE52[2M1(HV0S"X`Z(D%R(4`L/D0GYE0G"$`S$`BP+1BR;<`ZOT@^V
MXP_CX`_<DH"M,YU/::DPBTZG00K4P`@W``51\`:P<`=2H`:HT``HDPN*<`=Y
MT&A?L%'1T`[=P`@_<`-$PY9,0`K=,`ZW\%=XX`5Y$&J@X`I/X'IZ\';:X`D\
M4`4^%2!"U35>PR2_$`,R``M@L`0NE0-6P*1-@`1SX&-)D`-$``&.4`IX4`K,
M@`4NL`1&0)PYL`0XL`5*H`0P0`2W4`U3X`6SH`@Q$$R9@P.K@`2D4)E0M05F
M8`1@X`V.4*DQ"_^5[^,HKX$F'&`"S+H&'7`"69`%+/`F*B!.?!)-3-(/)'"$
M^D`3_R`P!J$"M"("D%`+&W!_KS(I$F8^A0`,PM8](]"!99(`&_"#)C`2*S`)
M_>`,P>(/Y]4/AY`"`21B"Y$"%Z`""+`&&+`"5*%SVD,LF/`WP>(,(Z$,FN!;
M#60")H"^:Q"%0$<))4`4N;6MSM5<F4`"R;4)BY$&)W`"*S`"*Y`"+(`"$0$(
M*E`(!7L6*1$(RD"NK1H()G`(!2,("P`)$L`"'C`"A\`"JXK!@)`%C>`2.H<)
M=!$(<`((:;#"KN4!@%`"F$`6&TP7/EFZ1%P;_],*TO`&4%`#<[`,#6#_!Z'`
M"'3@!3P`!*8`#E20LU+P>I_P";=@#LZC"[J`#+K`"_%@8'`P"J7@"5-0!7<P
M!J&0#66P`S]@!W?P!GM0`WG`"C#P8Z1`#U(``YYP?OH0"Q!0`[#`"$1@!D_0
M`%2`>Y9`"L=`"C.0MU/0($?P"'\0`S@@:*+@"F+@";"@!*P0"YZ0`TD0`X_P
M>TK@`C"@.3P@`[:0#%^0"TVP!$L02=`(!MW0"B]9Q%#Y&L[0#_BG#^I*/+Y`
M#\#`L,!@")F0$.HC3_1P?VNRK\UP7?1+#IAP"(V`"2I`8ZQQ.S))KL>P&.-`
M`L)P"!BA%H&0!MC$)$]W&N:B#]:0`AC@`1E`_PG,4`*WL`90*`@KP&R9X`L3
MM`_=A18I@`*;P">"<`*0``P!S5K^@`)ID`EI$`BTT0PSA!J3(##\TG)I<`F`
M$!&&T`$1TQH<C!K*0`(O1`@:(`@:0`B"`"T_O-&LP8"H80\:40*%P`)IX!$X
MET.&P`%,^,O`?-2G8:6YT`]S(`-Y<`I>X`)\P`1NT`,\<#4[H(A3\`9O,`6?
M,`J?P`WV4`Z>``?$P`_&0`>F0`[\D`M5P$B$:`9F,`N,L`-E4,5[4)@Z0`.S
M(`5`0`-_+`4\@+:@XPLX4`.Q(`5$`"15\`DZ@`,[@`-,0`VF4`.HK-@RD`0N
M$`&CL`B@X`E?``JKP/\(@.8$IO`&HV`#$8`$0Q`#=^4%+V`$H,`,2"`B2I`$
M>*`$=W4$9A`/XX?4P!TZI+LQJ)$Z#LHQ]'`/SM#.&Y`2PY8"U#)!^9`"`&``
M@K`&#!``]Y</YF```V"?&Z8/&(`!^M#=U<T`V6T``=`,X4`))E`"WLL,RK`"
M@J`OVZ`,Y6"/$#J>]E2>^3`;[F`.V)-?RO#?ZB--ZF.$@6(_]4`/Y9`/UD`/
MX]`,ZA4,0Z0D])B#D@)-]'@,P%`.'V8.Y>`/ZTF2MX`)YHB!P;WBP$$-H-!J
M.T`&=N`*K9`$-B`#5[,$><`+;D`%;W`'>P`&;N`.KB!E/5`%:F`<5B`*]Z#_
M"TQP!WAP!UU`!6]J!$_T`CV@`V%@"5[P!%*@16@@"N^0!WK0"H0,"UY0!0GR
M(S5@!*5`"CAP![WI!-2`!V9@`S@@!6CE"HSP#6[+"G_@"HD`!ZN@"G_0"8J@
M#ZLP"FK0`$E`!#'P4Z3P"E>0!#RPQ'GP"490FHL;#;!@U"R.8U[(K=A57J)Q
M0H^17LZP"960"81P"X;P"IK@#YB0">B%L-JB7NH%&2B@7PI)7B<0#/DJ0^A%
M+-R"7?I5G?EE0M,Y#MM@#IO`#,=P"YJ0``Q```KPZAY@[1A@"/I0"`"`"-L`
MDLK0`0`0#..^``"@`<P00/C@`!RP?`90".8@#O(P_P_A$`[[@`D)<``'8`"3
M4`L(0``$$`"O4)#QQ9^FTT^S,4T$LFO6!#WUP(3E)$Y(HD[]N#%6:ALI'NH>
MKQJY<`U=\.4\0&1JD`RZP`>?,`4_Q@-T``Y%3FIP``Y/P`11,`8X^P-[0`;U
M806F``M%$`="[PK2(*=<G0=NP`C$0`P350-Q4`4V,`?N4`0ZX)B/J0^_@`,-
M``MQH`,2I01B0`Q]M@,Z``.*0`158`1GJ@:EP`I$$&M$D`,X,`2>``U#\/9+
ML`-=(`2/X`E1\`./K@-@\`6,``-)4`2$J`U-P`124`9'T`7,D`N@_O&)!2SK
MY0P+H0SU$@R9A0)MH0"!P/\!5QC",5T)_U8ES241$.T/HT'#Y'H!@(`"''`(
M"&`K*$&L53);G.7,)"U:@6`!6N%R$F#"_1L"AR`"""`!PT\):2`!$Z`!&@D`
M.K$"A'`!EB`(`J#\MQ``""``W:X`PI``&&`)AA``;;$0#A&M`-/]:U`)E9`&
M!,]"*H<!KXJM&E06_U`(FQ`6T=HL(X`6`(')4"9`'@1Q@(2BT"1$A0)-*O1O
M$B!,A2H]/(2(1*%@FC`18K8&$0H4F$A`-%2($B5$$"=EHB1PTB1#*3#YRX1)
M&:5"F51H$F0($R9*E2;UTY=4Z5*F39T^A1I5ZE2J5:U>I;I/7ZMIHJBDBA+$
M!PW_5(N<D*H!)0H5'59V[?K$B-NI'E-T,)'B(PD-'T]^!%%C39(74.`D67DR
MY8D-*;D80?,!!`>447F2V'I7Q`8KK%/SZ7L%`X*N.$FD>/&RA9&K)SARY-BE
MR!63)WF\,($QQ061!DJFX)ABQ$B./2YJN)`18X@G/%5T=%FEA=0,,T2VL,*S
MA0L7*5+BM'O56?QX\N7-5\6421\^??1(H$"TB0,E%"E1;,"T`84^K4W-_;M'
M*?D*B6@%0%2`1`42.#$D@6>@*D09I8(9X1]`4"!A@PU4`*2$%28)8!)E1G!'
M'P(IU`<8`"AI;QP41B!!`P$P4`&`-"P`P)`1*&'!`GWX_S$@$'W,X2>32NA!
M"@4,)$A`D`T4`.0""?Y)(1,2`AFGGW/&::;+8,[!)`5^G.FR)@Y@Y("%$%@@
M@0-_)D'!GWZ*4<899;[\,H5@E`'&&4HX6..$$$1`@)`3-'"@$$PX"$293#(!
MQI^;,`D&DQ$J'0J0%%+@H*#W-DAA@TQ2\&,324T=YSQ55V6U5?$^>X481J#0
MHPH8>`B"CU-$`8<4&IZXP8X;>*"C%&WH&)8*2:29PXU6GD#%%B]^@((*7G(Y
MY8D*K(@"BA[>X$42+$ZY@0P*HB@ECRD8H<<+&TAQ%587;K#EC2>2(**[)T[Q
MI`@<CF"BB5?8T>(+*!IX`8H:NO_(XXY/DG!-!T].@<,3%X`((H(:WI""E&QB
M@0,,Y9"`!A0IN%,"M2_$B66?_ER%.6:9G6)/GWSPZ2^??(BD9Q]SAORQ&6?&
M<>;G]93J;Q]Z;K;9F2_I,><<G_79II@]@\&'GJ/YLUF?HKEV9I)@]FE&0F#<
M$6:F8`HIT6;V\NG/'P`VT><><U3B)Q`!K!$F@!&4\0``0,ZYX`*;%1#``,49
M`(`$_NHI!));FIG$G$V`X:DDBJ!J!I.E*'EH'$/>-"082@`IQ!`5SG%*JTF:
M4:J9%0BYI)(UA#%!$TM4^*<6%2KAW)"E"D$]DT!`)X&2?T:8A$=^9H8^>NFM
M^DP?5Y;_<0,**?8H8Q0=@`#?"6Y::4*'/?:(X@8K8(B`CBXD<>2-.7J1)A)%
MW+!%#C=<>$$-'Z*P@Q>B\)Q8O,(-='B#%_!`!3O$00I3X`4\I/"N>('&.*W`
M0PZD@`<I:/`(<>!%)XJ0`].<H@E$($(HMH"'4G2B"T,X&0YP(`4JX.`)9E!$
M*I(0A2CDP`N/B(41:F":7<`"#T=00A+!P)TN6",6TX-B%,=3L^HIA1_CT%I_
MSO&S<]A#:5;)VCYJII5W1*6*-6M*%:FGCTP`P'-,28$`]F$/`2!"'_U@0`CT
M(0$.)&4!&R"0(5*B'J9H;2IH7,K+D,84-:[G,V_#!]R24CU#_]8M*37+VCF6
MIC.E1=*12>F9ULS1,S'RYWGT&,<XSL&/?-"#E(B48BQE21Z=Z<,4QIB#]J(@
M!5O,(0=X6,(8U%`-1N!!!S5`3`/XT`IX%(,4MOB$+DSA!&',PA.OB$4^2'$'
M(+B`#$E(PAB:$`Y=L(4,1B@"+#XQA21080J2L,<<JF"*F,4"G,F(`P^2`(8N
M%*$)70"G*3RQ!"G(8`DRJ($72@$&*1#!"$HPP@.E`(4R+&$)2<C!0[E0"E8T
M``9$`($/JD`%6\SB"UP0PT/Q@`<C;.$+X*GD+&4:RV`8(A"(6$E*''*($0!B
M$IO`1"`HI)`+4,("E2`0(`29DH:L3?^0#UD>)391TTULH@.3*(%-%1*3YE'B
M$(:8A*1@4HE-4&($F#A')I3A#V6HP!""2('J,&&4F!1"$S2AA#(`4(A:O`2L
M_;!``(+1#P"L8!.0*(0;$\`!8`C#`"H(AS*:88Y^^",8>\*$B,[1C'&80RC.
M,$38@D$F8/1C''5RAI;J=-IQ!",3FNP'9^UT#C)=EA^KU*0YW+&/<J"2'U$C
M$C!@QX]Y/$\96PR&.YJA27XH36GFR%K6X,8>RKI,*:C\D3WR<8Y&SM2[WY7*
M9V)Q#48\00IK<8,T=E"%'?"@!Z7X01G\\H0W*$(7<[""%Q+S`R#0`1QT>$)M
MJ)"'.6@#%$7_H,(3J%`%.K3""DDP0A6@P`MBZ``*4_""%!AACCCHH145A`6^
M8"&%B#(AB4\X0D0W.`0CN&`*7`##;XP`SB1RP0Q&H`*)D^B;'!`AB4T`0Q7,
MD`-])L$377B@BKEPA)-](1U/!&^4H4>/<VR)'F"EAVS?0P(8*0!&&"+!H@#!
MI6;TPQRJ++,R2)#*.E&"!/_@0(9(``@+?,`#E$C!!3;1C,L&`QC`\+.+'O7G
M28Q@)"1000`,80$5Z"<0.Z+$3"AAB)6HY!8`L(`@*=$!1*P@`!=`0"T`P`()
MA(`9"`B``#0PDP!L("4T"81#E!J"%:3!!(A8`"4\H"8/3.("B`@$_R"4&HA_
M$!NG"C'$/PJQ`A2D0*D;68$'TN!J#RA$J2@(MD)4@`F)S#D%)+!`K-.P"0_4
M0@$HZ("A-:"Z-""B)BD(1+`G,HE-7<BM0DE=(4)@"!)D`A'`SC<B8"=E@GNW
M>JNH!AS&X(4I)'@4IV#"#8!P`U<LPA7_S,,G^+"#&]"@!PU(@A5>$`4U\*`"
M5*@`#8(0A!YXHA1X>$(3&(&%18!A"6C(@1MV08<JC&$*'+.%.XS``WJV2KPN
M<($JC-`%5Y`8#_+UPAV>((LXX"$4H9`"#'"0A"D<`8E*`(,2I%`%AL?`#$GX
MNA&>D(,=Z"`.>1@%$UPABDZ800DVAN@=6/\AAB94`W@%!WS,!GM=>%/J=8'(
MA.E\6A^H[`,82PF&"@*!"5,98@TU-0$G-K$!"3WE*$IQQGLF@0FWI@!TV)Z$
M!][HE*`:X`+*>(<A6!``!I0`$6E@``LZ,.X3&$``>M3'`L34C")-8A^G%$0'
M$-0!$EP)$1U802U6H(*N-048@&C/>@+Q(AVEX0(K6`,+1I")273`&:'D!Y7-
M\3-`^&/]]+#2&A2T`@F@(/P20(0F5F"(?'3VMKBE!TQ`@?Y+I0LA@5H;`0O0
M@!)H-'_8/F7H!S)1AN<)O`J,HL]8!6;(I2BH@CT8*5[0A;:S`CZ8`UT0AU:(
M@S>@`1I0@PJ0@C?_0`5><"<>B((WD(8XN(,&D((G>($I4(0Y@`5KN`97F`(;
MX($OJ`=/F(([6`MUR05^6((><(4*L@07L`%88((B$(X=3((=")@CX"`O\#$N
M2`T4$@XE$(/M0"(N2**&XHX7(P*NVZ`D,`,I"(4XV((M2$/4.(U.D((K*(?P
ML,!!E!D*5*/N8@I%XAJ;21JD421$3`JMR+*>N:X?X9(MXIJL<:5.2C]E4```
M8!P`V(#!RH=C$(`Q$P9F4`9($,4?^40````!2+45:0]_.!M[V`:O<8=RJ!1E
MF`0L<B5-Q!E].(=@X`]7PHEFH`=@&(=;"`9[`(:!6(E(I,:C`0;688]F_Q`$
M35`&:ZB$RGJ'6CB$2@B&0!"&K6$*9U"/FH$(2@`M9=B$TJF)3+`I123$>Y29
MSX`%9.B$`/."*FBG-Q"%:[`$)N`!&N@#;<"#,3""?A&%4Q@%3^`!*U"#&[@!
M\WD"/#B%3W`%"J"".(@#.I@&6,"!&N`!*9"&4["-*G@"LCN-2UB'"8(7H],'
M8V@`"M"&-S`"(C"#B\H7*C""4,"#&%B"!H@"&1""3O"$%'NH)#J"[=B"AGJH
M*1B"&N`./%`"(N""&)"!+2B"=3("-DP"[H@H)>@$:S`&?%1+J3@M.^$2+@$&
MR=J$3`B'S7*&(O$'/W$494BEU$HE+CDNSHHMR?_*!"S:A\XZ!U\XAV=PAG`0
M!LY2I3.+FMPZL\.DA]]:&GK(&GZ(I)X9I:,91J=0!LK+19O1&9W@C\_(AR[9
MAWR(P#OI,V`P&J6H)=,T#TB\S:7(!WL8C]JLOK4$SIEACU?`!D^H@BHH`W<J
M@SMX@R[@A5.0`F$!`AN``2G0!E+P`B.`@B<@`RBH`N;4@Q^P`B-@@CCX!#W@
M!3AP`2CH@A_8@S?(@UR0A"IX@SLH@PW:@RZH@E,HAQ:;25:!E1JH@59P@R%B
M)Q)2@B_(!59PC24P@O)R`2-(!3L,A27;R2T8`AS@`B+X*.\@A2THA5*(@!V(
MN2+P2D?@A3G@P@?B@H?_^@)N$,3@E%%]V`F:((CF68A)V(!XLY`+T-$X8YY,
M>ZI@B[5@\P<2,`1`$(1`^+::H#=L6X`U\`!$^+844(%"4`@+N:E,^(>:0`05
MX)29$`H4L!(48`&1X`";LA";:@B)J(A86XB-F,M*$(1:"('P0Q`2,`I!0IV*
M&#W*FX1`,(1-J+5:,-1)`"VP,JRS<HE(6XE(PY1X%`A`4*M*,9TZ_0=ZI(1@
M**NIN@5,`(9*!0:=B!3$$QIF:`9[F`1#-01?/(:KN:PZ"30^4P8('-5G0,QS
M$(9:8`:=Z,5^D*SSF]%AO8K/:(5JV((IJ`)]28(GZ((I@`)&N($>D@)/Z(14
M_U@"*/@!'I@",XB",4",*1B@XY2P)]`>/?!`+Z"!*'B".2`%WV#7,B@#+X`"
M+X@#:7B',B"#*0R05HD%,G0%*N"!&9L"=DH%4OB"X6@[6XB'+RB#*9B!&0"#
M*V`$5O""46@"&GB-%HH#%9($&'"!)QB#QI`&'W`!'J@!4""%4'"#!U*"9E6"
M,+`&1R#6FJ4$0FJ/*BV$$6BT8AN!2WF/1;R98:0'%.B9SZ@$9UN!%>"`#6`!
M/WB15]B$"PB&5@+&=7`E?1`X8L0'8*B0]U"!!4"!$D`!"3"$2M@`2CB'?C`M
MHBD;SRH$MO6S0.`R$N@``V`!W7L`2)"/5@6T/XN43/]P!D'-B5`]@3186A2(
M4A98@0XH"1+`J4FHA*$8BI@@/?*;RPN!,T/0@!,X@0[0$$Q8@8<04_*+-$,`
MAI,0I*0UM&\#A%QC`0Q(`'=C@4+X-T&--SS#*4"H!$"0B&9#`148A!)(@Q-(
M@#1@`0&4"(<0U,ZKV>=]"F-EABOP!%WH@C+(`SWPCCU(@E,PA3SHA3R@@AL0
M3X:[L"DH@RHP@CV`UFF%@O=]WP63@BT`!44H!9WK@C?P.2_0@S>@@D^8`R]H
M!7R0@A[XSU41+]<@ABY8@AS@@BE8@C+(A2/(@1Y8@ERPA5UP@Y62@AJP@230
MP2'HA$Z`,"E(4%88`B)X@1[_X($&V($]X`)&@(5O.(5.@`$CB`%>L(7N6(*8
MDX*5@3+HO<>;L2Y,=)E]J`3A.BVR025+I93VV(=ZZ!GIHH=@(*5]J*G`+$;U
M>)-,N(5"(`>FX0^<80]A^!FM<(9_V`1A<`9,Z(=)8(9-4-),X``)J1Y%P@FE
M&`?(U01_*(%@X("A.(%#N`11@8H[Z1I^4`$5H(1:(`%-0(%-.(3I\^/]@*6D
M"(9)6`HX.9Y`J`0%.8000%)#N(!4>8I"<`:N`08.2(%_VP!(0(C[2!T/*(3?
MG"1]<$#^T`I#>!%(8($2N`!:1EZ:X`"MP4TA1N97@`8D\P+]Y`*.X<-3H`,W
M>`,Z_V!"-6`"<3U.*UA.^DK?'K"#*NB6XVPX*N@"4`A1+]!@/)"Z.QB%##,%
M(B2%=^#!5:@@4*"!&Y"&+L@7?)$"6``!'(C#(0"%&("#)9BA3YC0&I"!UA@.
M&,""3BC)8\H!D/6!C#N['>@")\`"3\B!*:B!(E`$1C#ADTD"/`B'M$3FE>Z,
M8[[E\[!'VEPC6Z8E->)->["'<E@_W_S-1^*:+=*:GGD'5WJ'*JLRK;`NI&:/
M]'L;<QBL<2B'5.;+=V@&36"&Y+HDKI$DREJ*QK(&>U"&<F"&:]R)Q-L$I&;I
MM.X:7+@&.*B6,:"-*IB"+F@"4I"%'(""CQ;7/(@#H/R!)_^X@SL`R,28+RM@
M@K:;`BG0@UH9`QN8N(L]C8?M0)8D.UUX!RD(@BFD25B0@1R`!4;0@;6[@5)H
MNCW`:PK@A5)0`AO8`250#FAP!5L0!3KH!##`@U9XA3R`L55(!%W@E46``-/(
M@2/XA%)@!!PP`M0`!6W0PBFPN2VXAEBX9+4&KV:X64J0%**@M$Q8@]()!G_P
MAV7H;@'T"7]8"<JE/(%8JTPP;TS0!#^@E#_+!%\X!&!H!%N\66'P,]<"M-$B
MFOZNJ<'2$E4B1TRH!=,!S"ZIDS(SA\,T+<Z"0-_:HLFRAKM\!G?XK?0;I<ND
M(B_2!R[1!W=P!WNX!V78!GOHAW?_Z`><CNFFN$PUBIJDX,P6CPKM*H]#K`?=
MI.X=9XI(.`9/\,X[R*\RL`*ES(5..$[Z>@(=V`%>\`0`)K$EOP.?VX,?N`&U
MNX,]R`-F<8&Q?.$[R(-=:`[F5(SWC`,S:(5WT`%ZJ:!70+I<H((>2(*4&04;
MT-@88()N<(4*T`$IP!<=J&@AX(95<`0P@`-82(0KR(52T()54(1N^`((<`UP
M.H(IB`%0P`9&D('A(`)%`(4G*$LL((<8Y?$H&P=A&-5^$"28&`K)0P$.0($$
MR`(-,($0H%1#$XBA>!2B"*L1\`A(`!T3J!!`B+-!T``1*(%;"(0/:1Y*2QV(
MP`1`X(E(_RL$#ZB)*^&`\EN!"[B0$4`JI:J)0DB!^B`>AZB/#@BV?]`U3+B`
M-<B`-2"$#1"V?R@VWH&W0HA'1!"V0M@]0E@#2HB^!6Q<2.BU-&AE-44$"PDJ
M/DVVN)K<WM$1>IN$.2N$KU)WX@G4M5&>E/B'%9A<<@P$9B@!?R\!2M@VI=I3
M2@.K3,ZLLP7V2E"&7G4M2``&CK#=G'B4URKUY\6%:,@>;1X#*F`$72!0B]2!
M.8`'20`#/;"""M@#1N`#5H""-\`#&`@"&A#R.'"%.2@%\KT#,,@#:\"%DEP"
M-7A.1M".AEO"*FB%=$@"(+!GFFP%'L@!7*@"'M@#)<@-'/`$5_^P!&D`!0C0
M`1Z`@N%(@CVP@@@XR5``A56X`EA`UD58!54X@H/)@3RH`A)*;`?>@FJ8@SOP
M!"9``BZ@PRU0`D\@A[C?><"[V>LB@:PR"4HH@8\8A,F5/*B@!T!X&4A8`Q-@
MB7@[@4U0@1.(-,YSBL\P!%.FT150MCS[V4ZK74K`#WVHA]94:A.A&ZW8XQ=)
M`18X$]W+`DBPA/G`AU$"KBJCATB[(MI*`\2=-FEK?Q9(`TW@'7,H,RYQ!K<\
MG3$A$^(9=^0%B!4D2@1"X0\1B4S*@@5K%@R8/W_]``$#]I!2BD,C1J18L&9%
M"0>')GV@M#"3OV`I@2G#"#$3L$"`.J3_^;>!P\85&X"E`.0/(J9,Y_01+6KT
M*-*D2I<R;>KT*=2H4J.VVA:GBI<J3YZ8`>=)APX>NZY!8^3HCQ<:0<BX(`-E
MSRPF=W14J2)+C9H74'B\(/-I3BMBTB0]L7&#CK<W9:94F>+%2ZYU>_;`FNHT
MG[Y53ZI,ZV($CY<<4&+D0O)%3HXD2980@=")%:E=KJ34,-+%DQ0G;Z1X4G0$
M1H\[O!AYLF,#QA,F2Y1\,88$&@@E1'*8Z;3DR[58EK=S[^[].U-\2/'MRV=N
MG]%[^NK1.^>N&3U]^]"7UT=//#W,Z,M9PY<O/C_CV!>,,OTXDT\^_NF#CW_H
MG4//?/KT0XDS__RX,XX]RKBCS"TP3<+/>OKH)Y\^S3A3E#R&:*(,/\",4\@Y
M_D!2"##_G*B4,LH4Q4\:A@#33R']&!),+86@@`D@F"RE3"4[&@+(),$8PHPA
M:0!3"2*3`$)"?$I-TDQ1RJ``R";!K*&,"L`8LH(*MUQPR5)J&A7(!X+<D@(F
MAHR`22`7%!((!YB!-RBAA1KJW3V8524'%%1``447O%`!5A1`G$*!&C_\H$8J
MMFRA@PM+O'"##4$`D<<//0#Q0A!!]&"$**CHX842I<#1BA<]D&&$(J6X4<4>
M=^PQ12[I)-%#989B=@D,,/C2A!%_*&%##5@P`\8G7=B@&@YQE&),%_])(/$,
M+*$N8<06.1@A10Y').'"%^8TH005MI3RA1%0$+%O+%S$$IH,2X@!!A&,7&/)
MH0DKO#!3^]!CSCGGF0,A/Q6/,]\^_.0SCH#AM`?B4>@AA>`[XA6%SSF",KSR
M98>*[-T^[A"U3Z+YV$///?:X<]]2^(#L,#GNV#-THOF-8V#$+"N]----Y7+-
M&T]($84.HMCRA!Y,/`&#*Z3<D>\41C2AC222,.+&567,T4TB97011Q>D***-
M*$RH0<44>(#A"A4][%!&$K)MYM@3I+C#A`VNZ*,>H9BMXH(1KW21`Q@R,,$$
M-*JXF\,42E`.S1=$2,&%$ENPLHL51#BV1!+_6R0A11&EP.+'$&!PL<46LX22
M@Q52A%V%*.!TX;D17BQ11#*J-+T\\TX%$T@A_TRRB2'_!(*((1L$8@@EE!P)
M2`HHC$#)!I7(]$\AAB""2`HI/(]((8#(-,(D_F!2R":3='`("90@@H(A)F&(
M0%#B>H;P$2;N1PE#5*)_%L'$3P((OP(F<!.5R`0E,H&)##K#?IM(()[\X0QG
M8*(9_ZC$)`I10(;X(Q,/88A%8$@@9U!B$^-01C/.,8X,!H,2S#"),IS1C*.9
M2!GC.$<S^I&C<00C$\T8XCC,H0Q,,+$A.'3&T8Z81')4S!S].$?$&H(/>I`Q
M'\>(8C#<$8QUD)&,__-ISSC&2`]^Y,<>YN#'/7!FGW+D8V?TX".$2-2\01*2
M.XHBAO&44`8\C`(L.DA"$UH!#BFTC@ACX(&NU`".8)S"%**`ABF<D(M6D`(:
MKJA')*K0@QOL06R=>$(R'($''DSA"52`1AYL^08EM.(;.J"!XA)F"1?48!I4
M:$`9XH`#([S!73J``;N,,(LXK&L+2K`=PKKA"2+LH!2B2$(-&!$-?;P""6#H
MPA2V<(0M\((V4X!`#FSPACB$8IU[6$(.%%$-[12RG\O+V!SU@8A,[.,\_5C!
M/U"@@@UL8`0H\,,(5)"),>D0B^-HACF$V(P1"%&(E"`!3O[!@0V4`"0EV/]$
M(59@$H:<A"']($%0+*(G0(R`!"M8``I6P`$)%*(0/4(A)C9!B4H<,!.("$0F
M!#@)#A2"!"A`A`$,@=,10`\%0^WI)`18B$F8SQ"%P%XA-@`(1*S`$!?04P<L
MD(:E(@(0__A'`?^$O@$N<*LIL!X`26`($E@@$!MH1`AZ&@CK42)]*7P>2@\8
MUI["=0.U2,,)3B""0W"`$G/]4Y8`40A_J/!/F@#$"N"W">PA(@.(X,`F2I`&
ME&H6$3?R)VQC6Q1%/<,+4NC$+'_`RE4PPA6Z\($/?G"',D#!"&4X0@,>)0M&
M,"(1NO`*%CQA"SJHP04VH((1DF"&.SP!"&]XA27_CN"%-R1A#GC8`Q7JD@QR
M[,`&NW"9/E31`!C`H@@\D,$J\-"`QNSA!D_(00Q*D0LC<*$)1.!"*3X!BF(X
M@QZZ6`5FH`$+>1CC&)'P0AZH\+HG;*$4I:!`8]ZVFRE$(!=26((,OM`-4@A2
MMBY>6$.*0H\4!.*)ACC'))0!C$*D8**46`H_E%043*3`$,HX1":\>@Q$I`%Z
M(]"14OQACC"AX!]Y2@@',A$(JF;/'TN9WH[^00+L5=8"@#`$!_ZQB0W\6"DP
M*<HY.M`!['E@RS[=@"$VP9'%)043B#A9(6K:U!$()!`IT$`F3B`!`9GL9/JH
M<5&"X=04K(`%-$F#""1@_X);8.`0^J`C&<^#'CY]VD+_Z,`(2E""#F`@!"(0
MP5D1P8)R/"R*+WLQKI?'.%@P0PY48`45:$`&&XAB$5K@Q1LJ]0,HU,`)N\@%
M.5KQA!X\80^]R,,;4,&$49BB"3WHP1>R80M9>"$&9%`#$'KP!EVX0A2FV($7
M;!"%5-QA"K`8QQ?P<(M"8<9QG2.&&I99A4XT)@E=4`,,:N`%5\2!"F98S-L\
M,8=IR",6<?@"$YJPA4?`PAO78$0G/O&&VW6A"U]H12>,8(,IZ,$'RHR#*XJ@
M!"5<@1JKR#7.#75KAC5:92J+2I?L\VGQN.-!0]DY4?+!CY?Q0QGFF-A0+H;$
M'/\VV-$SLX_(QI@2>MBC&?M0A@Z#4:9-@$DI&2W*/BBAB6`T?1S.`(8YA*%V
MH2;%9,$8"E'.$0A_C`,8F:!'"8M!"1440Q#+6$H_@&&4`]["'$*Y!23,L:;\
M!2+GEB>D*[;1!2K0X@G!90(O1'$*4MB`"5$80Q4B00Y7N,$-TL!%`R;%`RA8
MP0I,H,)F:."&9C#""Y[0ABFNH`0R1,$&=[!%''(Q!"@$9Q1VL((MW!&',23K
M4+%8PA*,8048Y&!?O"A"`_(P!QX00195$!L2IA"&V[$B'JU`P@Q>T(`&1,`%
M\[T"*]H!"RY,H0Q<D$(3W$XI4$$-3,$>Y(`,#$<.S%S_$BB"-R#,Y44@5#"1
MCN7(0EC@)&2"%MV=,`##,Y10)3C$0CC##"W1$UV1,&#".5C,T6R"._@##@7#
M%YG#./!#/]3@@Y#1"O*#.>100=W'/C3#.N@0/5R,B$#(/-A''A%%HY%1R,Q,
MA/33SRD%XT!%HS'A45RAU2&%PTB@%Q(29KQ"-&S!$W0"O-V!--A"%%C!$XS!
M$T2!%.@"*\1!'.P!&;P!+I!"%QQ!%=B!&^Z!%;R!#O"!+GB"<+U!'IS"+GP!
M%%3!/,T!*V!#+/``$/#`)Q2?*72##B3.H6"&([A`#/@"%^3`$M1`#GC"#O0`
M#9`"*30`*]J`$O#?%GA!'!B#_R+$0"G*WQS$P7S)0&O,31Q(P1;\GQ0<01<0
M0Q%P@38400Y`@"<<@1$L0>?$@34HSQ=>(U($@P`A%90HE9ZT#P!Q@"&H``ED
M`91LP"20UI-LSY]00F7%3_6,0/0T0I5!P@4$`@M,@D(5F0H`4`JH`(_Y@_R@
MP&"A`)ZED)Y@`@NHP`>D%/H$PO546?2HP"0L$/PX&5%-`B:H@#]0U0@`0B70
MC_H@PD-"SV:AU#\8`B2@P&9A@I0$0QH<E0IL`@E40B%4@E!-3T520@]5P@+Q
MR=X]A`O%CZ0AI`;E23`D4%(VD4I@4"90!!,U@R:4`R4(@Y8]PY#`1$4\1`L9
M48$PA/\S$!5&@1$])%4_!((FH%`0!<,(31DVOF5WM,(U>((+Z$$I@,$3V(+6
MT$`#``$0P(`I[((C>@$=T$$9,$*)K$(3Z(`7=((72,W-M0)C[D%6),$LX((1
M\$`56%<2,$(N4$$43$$>X``4D$(Y3$$/Y`*_B8@^.`(,+`$T,($,(*`,2,$H
MY$`#-,$KS$`11,,LC(X7)`$<2`.)3<$NC!<<5(,NQ`$><,$L($$#2$$K8($4
M2$$7-`$C$$,<1$`<F,)K@@$HX$#W$8$2*$(ZO`)<IN?B*1Y1F,-@I<\(^`$)
M%$(6D("5'=46$L4XJ`#:?11$6D]H,5D:^(,A>$`P?!K%M)'_/@!",$`=,*C`
M/Z3`"&P`"5"5"IR5(:2`/^@0#4;11=%#^DP=,!`D0O&52.D4]XS/0\00,+BD
M,N19!ZG$"/R#"CB4`J0`"Z#`!90`)G``(JPH0[S0%`'"VU7$F(@/("1`3E'5
M!0R>BB95#_&DD5D9)K0HFND)!P#"`FA"`FQ`!GP`)B0$)DQ/_F15!DT"4@40
M)OQ#1*U`(7C`/_:5`DS""8#D`1W0:ZFGGC:%&'Z!%S!!*;R""^3!'>A!(T8!
M#[P!.(!!,EF!%YR")X#"-92#.=S"(J2#/B2#(K`(.^1"'GA",'K!'H"!-$2"
M#I`!#S@J$^A!Z<'"$ZR&+90#$8C%_VHZCG490V8NP7UQP1M`P!,8P3=T`0X<
M`2A\`RM$32XL0@380">`01R0@BL@@S&X0BB`@1?L3@2$&Q@`*C$D`QT86#;`
M00S`0!=T0@R,IQ"`03O<W)["Y<2<#`R^@Q3E@].-PS/`8(PI11"J3(L>43_T
M(##00S!``B6H"<@DA3.\C#*HD#,HPX86`CD4%B?<3]DEQ9L113^PI-\A0L9N
MD&9AP@9XF5*P1%&8`P=09$?>229L@@IPP"1X0"$LA93,"9YQ5O7@25AEU08$
M'5+<6*11%9^P0"6H@"&LP49@P@4(65+("6M2`D=,@O70V%<!@B8,@@?(3+MF
M[5(P3B1$@_]C&D&]=,$>V($4O($/W$"DE((7E,$==$$>C`(I,`(RT`,S\((G
MG<(I]$(ZV$,P+((LR,(G.`9HE$(WG-@3W`$>G%<#]$(LU,`>E`$I;,,.+(%J
M5J%W]%M\U4`,_`(5L$9J"$$J5$$.Y(`LL((.^*(VL,$2R(X0),$GX($2L`(C
MP($U:(,B.`(K;($9?((1R``KL$(8.$$W7`'W@0$V2`&'A8(28-\2',$2)$(T
ML*O6:NV(#`J#")U1:.'(%,KU+@A3+!U16*[W9F&$1*%\E(<[[,QZ:._Y8H9X
M@-&"N.5]T,,0?='X7AU1T)%X_$?`Z@/$Z,,V/$PS``,U!(/)B"__>MR'R33L
M_/J,U#$#@1BPR;#O]+;K*U"#(C2B%?B`-G1!`WQ"*>#`#7@"*90!5G#!'N0!
M'IB"/EC#)_!%$+S`"]``#5AB-'3#+I@!&."!&1#F)_06&>``'GS"$N`!+^3!
M%$1!8T2?)^B!,2B,*CR<+VS!OBB!$<0`&(@!#B0!*\""MLC`$4`#$OQ"$\A`
M*%#Q%I!"-_##.^S,.#@"%4N!(A`!$F##%M@"(\3`OD2#-G"!#"!!*)"G$AS!
M\BH".4AO!</E%+Z8%DYP(C\R)$^OHDQ#&&`%&0#!)X"`#=A`+[S""XP"+Y2<
M[]C!&\R!+N1"$=A`#L@PVL[P"[C`#]@"_S7TWMI*01FD,2PPJRWHP`P0`2P8
M@1(O6RMP@Q=`0?6!!^8Z0@T0P3149Q*D!@_D0"[/`!CX@2N\:A%T`BRT`@2\
M`!5\0AB`P2OD0X7D0SBLPRNX@12`A@OX[BJ8PKX002DLPBHD`1',PA4LX*\J
M@0R`0CCP4R0'M$`/-$$7]*"HQSV\PC5L`>WQ@`VHP2Y,P0L\02[4`!!\@S!\
M@11DF"=(`RK,L"S,P1-8@2EX@V=L02KL0`.<@NUBA1=L02)8@QLT`"N8P@U`
MBB?<0`]`P1/P0.8E@0P$TZ"HS".8HB]HRZOFP.'&@0OT0!PP0AZ4@0W(``3`
M`BG(,!,H0B=$P_\[P`(2C,,ZA($OG`,U_,$G5($,9^(.P$#KN`(<L,*[=((B
M*'5V)0$/,$(Z^()![S5?][5?%W0K@,L;HF84D`(%+($/M`,HW,`;[`(QK$(G
M,($K[,(-!($>S"$H@\,M?,,NE`(IC`(QR0(T4,$;L"(XG`(./$$U[,`,V\(;
M!`$M0<$-M$(]5`$/J&;CL"8CR$`2&`,3)($2`#<M@,$SZX`B\(TJ0\$1X,(<
M1,`+@($B(($N,`,C[$#W#8$C6$,R'$$GS('\P0$QU,`30*,4K((KP$!M*D(H
M&($13,$40($;<`-`_S5]U[=]WW>N*4HRQ$&J5@$:C#`<K)(K1((1T/#_`W8!
M*D1#%]R`*)#"%'R")\C!*R0#PY6"%=Q!*!B&-,P!;]"##]#`#>!!.QQ!%*@!
M*'`!$+SAH[A".H2%-"@,*,S`#CP#OG1.WL"`*B]B'/!"#<"`$=B"/KQ!!."!
M.%B"(AR>/K""_24+-8`!(ZA#'+S`%^B#+90!#@Q!*>!"$YR"NA3!'-Q!$K@W
M%S@".<PW?I\YFJ>YFB=,)%1#'/R`#HP!%.@`'G@"#/R`*1`#*"AU%.0"*,B"
M*>3`*`1N%8S"<XV#.TQ#,9Q"II2!+-P`'V`#S,%!$@3!$VC#*]@`#<R!)ZA*
M%23!$T"!+8Q#$TS!$QN*>CP"#=1`+(BN$@R!_Q+H@6CDP!6LPBFX@0\45QR0
MPQLT``5TPB[<2C&\WQ6(`1(,PS&T`A[L0BO$0`,H@CZ(PG(8@6=J];GDP"=\
MC1)TCB>4`WHN\IJ'N[B/N[@SCB540Q=`@1(_2A'HPAW0`!\X@BT$)P_PP2K@
M0A?0@!WD01/0@2.D0SWDPSWX1RML:Q64P0O\0"Z$PBY,&P^`PARL`NV1@A,`
MP0^P814`02YL0RFD`BXH3"SLPBT@`[OLR[J`02?`0!%X`ACL(@_$``0X@B38
M7WD.P2ZL0R0@P3E8`Q*\`CK\LB)@00.X`"EL0BHJ01BPP1=H`S][`?^U]Q00
M`;7+-[E7O=5?_7TSSO\PQX'4@'H.O($MT$`/S($I>-(25/:H&\$+`$$OE((N
MM,,Z*,(WZ`,IP$(]+$,GC`):TP`O:*(-!,<TT,&>ZP`O-(%2SUYWY8(U.,K'
M)TPB'$$31(,1$,'K9!<>9,,6&($G5$$N@,'H3GDN0$!==@*QOD(\',-\)$,Y
M&$,@@\(?S(`-Z((]!"<22,$V7$$H_"HQS$%J3$$2D`XKI,,Q8SWQ%[_Q/W(K
M+,,6U)(4&($9C,(3@(HH=`/7WT#QR4%XNX`4G`(8V`(YR`$,6($H-%LR+,/;
M2,$,]P(DN``/T`45Y((C@#@>I$(7G&H;1D$K>`-JZD(GZ@,8O`!`Y+CVI$;_
MDB5)<KA1E.2.K5-NB/1XTBW2-28[.A'A$B91.7W[Z.7KU@G/EB&*EG`I]PH<
M#R)%&)$"U4G)JCA*#";A0D31M5;Z@`85.I1H4:-'D295NI1I4Z=/H4:5.I5J
M5:M7L6;5NI5KUZJMIGV!<@?*F$Y/:-Q`Q6@1-R9`U*#2%\M%%7"6YFC3E\\6
M#1I0XNF[5F5.-"\OYN0KM>0&$U>L&'F!`N3-IR=1HMR)0NS<DQNYMN;+%\9%
M$FM2DN@P\H2(*RHYI+22=$0&D5V6OG"#A6.+(B]*XCCR1<X;-$M=O'119$9(
M*VZ*2KE*0N0)KDM@8"C:/>6@ER>,GKW2=\]K>?/G_]&G5[^>?7OW[^%/S:<O
M$C<P4*)`L2/K1Y`H:ABYQ14CHAACCWIRL>$'4[3Q!"QR/*GAABAX^889.FR!
M9HD73-&'E!Y^X"&71Q(YA0<>GCB%CBCV>.,-:*[1@0=HLIIO/C]F>$(9*9Y0
M`K4P1'&!AS`\M&&*0;;I1`HXDHDC@B9HX4*11QZ!!1907.E"BE20:"`1:;"8
M(A1WFB`BB3GHH6*)(F")PX@II`##"T^8^0F?^/#,4\\]^>S3SS\!E>^5:^)(
MXHD??ABCBCMJ^&$64[H`0PT@>"!%EQIH^$$6*TQ)9I4A/+'&""^,(<8)/IAX
M@89>;O&!!RBJ:.(56'8`8O^/+E)Y`L4JJHAF&RR\$"8T??QP00=EFC#B""64
M`&45(G)`PA898-!%'%"VP"..3K+II($MS`A#E3]R@>4+4,#H)(<&OJBF%)*Z
M6$4<4G1HHAPG9(`@%D^2F(*++:;P9)N?`BW8X(,13ECAA??<!Y9QI(#U"2"B
ML(*7*H"`%!91;H!"BFKT:>(%-63A`15D]EG%&WU\,<<;4GR018T&:`#'&BM^
MN"&/5JC@`PH==OFB!S(NL\(+7;BA!IE^0LM'D2DZF68++J10H@M/BIC"B%Q<
MB:"48K8(Q1,PI.@$%G"ZR($('""`(`PNVL:!"!@Z68<5.3UY%PMIO(A@%>FF
MN*+_%#"2&'4*4*PAF.'%&6_<\<<A!_2>5JB)(XK+>!B#"5/<L(,54EQY:P=H
MH%'&D1E"H4(-6N;H1A]ZZMF'GTCV&&,+,&A0XYQM7('B!BMRH<*U.(C9@@PK
MIO#B#AUR248**J(9KT9]PLA!#%B6Y8(+-ZH9(KM7XM#N$S/`8"243CR9A1AU
M6-D!@A=F>"&"&1JH`8E<TH'&%4\4"2641#P!"F+\01')^((,BD`,,&C/#%P`
M13C$$SD)3I""%;3@!8<RGT@DXSY24,,8DB`*4Z1%%+B``P_*`(IEY"$7R$B"
M'D81A2KLP1;4B(<ZVH$-43PA>:FX@2O.08IHQ,$..O"$_S1BT80<L$(/%5,4
M?F"!#1J@P75:F<\7(B"&:AS!"$HX`BE841)7;`$&6R`%*3I1BO.A#XS)*,<W
M6B&*-S"!"F^0!#'BL0UBK,(3Z`L%*.9PQEG@(09?&,80P#"+4OBH"DM@A35@
M@4%)3I*2E;0D>T03B=.,X0X\K((KF@"$'W3#%!0K0CMRX8,NC$,5+[`#+:Q@
M!5'`(1>K(,4<]F`%5-BA`7EH!RBL<`IR(&$)7B#%,Z1`!CV4@@I6X.0=IL`+
M9/``"-&SHCZ^X`(P:",'7#`"%HC1@#N``A196X(4F!$-,(!A)J`H!2NP<8YA
MW&,;PM)')LI!CU<4`Q:.Z&,<^O^H"%=$HPM(\%$K0@&&(03M33&(A3(B>$F)
M3I2B%;7H7N8C1"K<P0M6@$(G>&$$&>R`&IZP@2O6<0U0W"$/NS#'%AI@AU"X
MH1>HR(4P2*$'/."R`3Z`QR[H`(8X<&,:H7@"*:Z1@QLPCQ%3L(.+H!`-:D"!
M!]:<WA4@T(5J3`$&8&!%%XS`B#@@`2%>B`$8L,$(H:[S?#1*AR.V@`15..(*
M7_"%./1QBT3(P0N=Z,0C%`$--^#`"TMH0A<ZH8@AR.%N-B""*J8AGCMQ91^B
MN=,^@H+9HTQV+T+!1V6+,I\[X8.S1='L?(!R)]1FEK5!X>QJL:)9?93VHK6U
M[6TQ&PG_8GC!#G'@U2GFT%%23*,!3E"'(T@ABU+<H1.ZD$<8:A"%&P0A"&HX
MQ72#0(9,?4,97:`#*T*!BEM40P<UL`48IG`'5ZR""U.(PQZJ0(QHO(H:H=D'
M&;N`BZI%`A12^$(W6L$%*-2`"V(PPD#1U8D_,$*%V,!"%XX`!F91P;^+F,<J
MOO`(="FB$]J(!0ZD@`<02V$5M_""%$AA"B6DJQJQ\`IM9^M:I<B6*+*=+(U+
M"V,9,T7'F:5MCVE<XPKVN"A$QBR1=VR4(,M8LTL6BHT_\F2B(%G*27'R;2E(
MCU9LPPUDN$,9JI`+-[R`";J`11=XX8HYY.T4C&#$+KP!#T;<_\`O-`@"$*@;
MA!LH(H_[>T,I9.$)3T"#%$_H132.\`(@_*(++,7#&')1C5%\HKY6W(<B]J"(
M:!@!#]G80@YVL(INB*(394B"CYY0"FC$HA/_@^00M">%`A]!UO\:0C=@$;9$
MY"(;L"C"BKG@A4>P(AK&.$(2KJ`-,T``%->(9%?&@0(2D``%_3"$.5Z'B'$4
M8AQ`.8<A,*L,0\R6'H;@QT<V88A`%"(<^C#'N/7Q#G!C(A"!P`0]A&*.2>";
M'OZ8#SV"H8]@3&(3P!`*/3+![UOD8Q^9J`0F[J2,@.NC&=T6BC*P#91@8&+B
M`L>$,X#2#XEG@FG.H$3'@P&,<P2%'O\6IT<SG&%Q?F1<'_P8QSG&8?'4C@/?
MG8UR:X$"$L[2@Q[FZ'G137ME/<$6RWVB+=-GW)3+*KT\Y*%/-/8`!"HH9QIP
M<(PD8MH+5S!B#JB(0RA<(8M3\"(?YU@%%9"P@QW\X`F@2$8\P)'<4K`Y%(PX
MQ2X^D80KT4`4Y7"#%?*`!S400QAO<IW5KW)%&!RA&IXH@R?,H`0SX``:(&`%
M&Y@@A2TD@0=;@(4V0!$-<H#""!LQPQ:P(`8NT,0+1,`%.UJ1"&ZT`@M'(`(8
MS%"$+K0"#N(`06&]@"XPN((9S]8*9C.Q`']@PA#GL$`S]'&.!?0C`1,/1@+N
M9`X%4$(?*1C_`5#HL0`4!&($&]"'(02`"8H;@!\>X``@+O"/GQL"`)-P=P`*
M01^4X0+TX0(L(`4N(!!BK!D`(`#]P0/TX1\V`!-0@`!1(`#P#1!20"CX(0!0
M`"@*@0,*X0)((`))H!`6`!'X(0%(8`02(!.:H0,0P0/.SQ`XP!`Z`!"`@@,2
M0.,6@`0V@`/T0040(<9(0`%&X`(XH.?&801(X`;U80-`[AQ&@&F"00%`CAXX
M(`508`/&K0(O0`%*$!$ZX`(``=\PBQ[^P0,\8!/TH1\L(`Y'8#Z<P0(Z8`,N
MH!`,@?ST(1#ZX1DX8`,V8`1HSAQ48`-2P!PP"Q`V``6Z#1@4$-\"_P$8@"$%
M2*L/R6\<`$$%"@&S)@'D].'C@N(<`"$0_"\8`L$0#"$%_`\3"J$0Y@']#.$?
M,A'B0E'^AL(02&#B,`$3:&SC>BX3[.DC=,[=G"$8@D&SQD&SS`$87B$91_'H
MG$%V>NX<"G&RC(X>PL$<SN$<>@X?BN[HZ($?^&$>0.(<SBTH4(L>;JSG?FZV
MVC'H9`RV<FQ/Z&$1DH&WK.`*NB'TWJG+H@#-H,$3XB`/1B$5;,$5=($9;L$<
M[L&-SJ'B\"$;M`$6/D$67"$42N$30"<;YD`*E@#M1J$+YJ`7=(`*\,`*HH$8
M:N`)N&%8PJ`!PH`;D`,,B$`&GB`'=N$2?/_A'-Z@-HQ@":;`"1X!&D`!`I#@
M"%0A%C!,&7QA"US!$=Q`!XC@"JP$%)B`"%!C)Q0A&RYA#FPA!LQ`*!.+"V+A
M&(S!*_SA`LRA&8AN`U:.'RQ@'#9@XNJ0'?4!&"Q@+5?N(SR`:0:0'T9@$LZO
M'Q3@'#A`&8#B!8/"`PS!_<PA`1)`&090'RQ`,>DA`4#1&11@`9J1!)3!`H)B
M!"BA$`S@`S40'M]/`K%O`_Q/W/2A^P1N$I3A_*(L$%:@Y@CQ`MS0&9:P'Y10
M_C#!-A6``A40LT9@XD9+'Q#A`YMA`YHA`5;.'.92'U`@!=\P`;`M&`+@'"X@
MX.AA'X+!`##+`\C_#]\XH`2YC^,40.*4`;/.(1-4P`(PX3GA[0(RP1`L@!(H
MX=K0SP(*H1E0``([8!<-(0'H(04``.24`0#H;4'?$`#TSP(``1B<4!\6(`$P
MBP/D[TY08`4R@0-6P!G^@0=)@!(J80,*H42[;0-(P!`2\`'U81("@/QD"P<O
M`$%G,#UC+!-<U/T8L0/\+Q\$`0)CS!`"@`-(4``#`!>[<`15(,I*$2@FH0='
M0`BM<]SN9`1P<00R81,8(`$48#*!`A@,(`XWP!Q0(`$L8`%68!PN``7FTQ^"
M@A^F;00"$!#DCQX`8>7.`3I?A]K83_X"8=HNP/]DS!]&X!]&`.00P0F3__,]
M]B$2NJ$+;N`-,-(&\L`-[L`**,.]P&$48"@/\N837.$>R($;-K5"YD`.B$$<
M[B$7/"$/2'44YN`17L8*RL`*HB`4Z.`.=H`7%N'$H*`:J.$)BG58MD`&XD`7
MJD8*O.`3I$`&<H`**``,JN$+&D!KDB`)<"`)8*`(<L$1AH@1<"$,0`$7K@8:
M(L$3(L`%GN!;B6`)B(`(/"$92,$+X&`+B*`3MJ`*UHD+F"\MNV(\24!(]<$#
M5FX<%F`<$H!.!<X"*@NS`B$`0&ZR-L`#2&`_@>$"Y++B#``Q)VX"-6X#]N$[
M_Q03+,`W"]#@]L$"O&\P&Q4%-J$$S^T?5G022/]@$@Q!!\<1'SQ`$W50&081
M$!13&3B``P(!'\;A`%$@4C=6!;`O$Q)@45?.$!"!:/7!'Q+`!D5S_6)L!%9`
MW>AT/IK!`C:@$E:.!!$A!1*`'WP33HWN`@S!'VRP``T!$R:A&>IO,,=ALN"T
M+S&A+BW@'&).*"B!`/6!!%*`$B9A`0:.!,1SY>9#9]$O&#)!<1<W;Q-`_PR!
M`3*A2J,T$`0@$]@O*"Q@$P)1!T<`8NEA/_5A'!!U$W+S=2V.!/YA$Q27%#<!
M$/RA.H>"!$RQ'[PSX"Y`,:.P$EK68Z.S_)Y6'@.A""T3%5EP!Q63'Q2`:01.
M<=.V&2Y@`Q1S9SMK`]S_,`J#014_@A]ZCA(D=Q\XP!\V(!/VP1J#`4MA]$@)
ML`[U83!KKCH#@0'&K1\VP!WN20'XH0.2T1N'0AB.EQX*X?SV\QR"07O70[0L
M`1<*BQ&RH0K>X!74U0IFX`VLX`EL8=0$+0\^80]V01]>80ZL8`_F@`I4APY^
MXA8*DA'R`!1"`1IVH0DV*@>\(`[B0#H801T.[PZDB0=TX"6O"0D@X`JF07N\
MJ`M.`0^2P`R(8`O8(!DDH0MB8`ET(`>N(!HN01L<(1$Z08@=`;`401$@"QI6
M013J-0FDX`@Z80[2@0V^@`BF``>P`!3PP`MF;PM6(3S4TOV`@A\<@&DB<QPZ
M_P#[!%!S0Q$".>L"*$$9L&\%E-8#`&$%Z6$$(-D",@$H*A#_2$`NK1,%/O!X
M@8*5MU<?MM#>A!"S4&`5]^T."T%E`X$S&?5M%9-Z(Q(?^B%I';D?G,$9;(X?
MS@$1#."8\R$8`&$!^$$)`<$`).X"CI%+<38H.$`%-@YY:Z[A4,`"['0/*4%B
M`V$!'M<-%0`0/*`'\\$".!$01ID?#J$"<;$V:RYBS100:!$H*E=Q1\``G-``
MFF$2#(`$XC0H5O1U\,T0/O"A4Z`4-Z`?&+4T_P$%^$$%7A00SM,Z&5$9'A8%
M1CGD1L`"OA,H*N'\@H$`,8M]MUE]*6X!S/`=YX,N#?]@$MR7:>*WE>4O!0K!
M`V1'8>FA'VP3LQYX%=.4`\QA`^AT!#J`43<P*.HR-/M0;Z.4`\CO3CB@?.O2
M$`:S$"9!-$*Q48%!"N_/<9OA.2<A$\`VW.YO$U9NVK#6`LS!3I]S'YHZ$X*!
M$CQ`32G!'S*A+X-"$'2PE?V!!#"!,J$N/>I!MXR@#'*!$7H`"DX!'%J!$?:@
M0#A8%[Z!%\"H%&!!&N*`"A9E#V"%HZH@"E"!&_BH%$"A%:2!M+G@#O9@"N8@
M$JAA%SJA"DAA%>9@"&QA&*R@"BJM1O;!#XC@#^9A"WSD"$["%8H@!SS&".*@
M"RP!(7"E$UA!".B5"&(`O.'_*@=LP`AR8`J$8`MPX1',0`J:8`MBX5P,2@>T
M)N]PH`NXP$=@81@(EBLP@0`G"P4X($2%T`+6#Q$RP0#4+0#U,\9>!PLUSH`%
M<`&`P8`MP-Y4P#8==N6(MF/!<4PMLQ"`805L<VM[T!P8P/WH]APJ00$^>=PP
M`0`4<.5ND!^\5V7]K\*C<Q/RH<6=X0+ZH1F>@1]4^74,(!-@MVDYP0.4P1G,
M+T2!@G&CU]U@N:27,P44$'N=804"SAPN8!PX`,$#@:D]=G_U[\N#(A,.NT2C
M[`(,SCJY')%EC!(0F7\3-C^Q5"@RH0.\C:0WH.=.\!]XEG%W5A`0X5$+(14+
MX;`+_Y#.QX%HZ]+;RC<3))PP8_?/@8*C`T'_LBUS]2&JA^*SFN$0*8$#NDV4
M@6(##&X$[A9.\8UE8VP$Q9H>JO1`2_!%,2%[4VLU)^$##?P?%&!_MWI_R]<#
M@,$0'#,5-<M,E724.0`%_D$%5.XT+R!*.1`1T'9Q20`84G1&H1-F+9,$$@#3
M[Z]G%?/*R0_;7E1LZXWFVL,2KB$4\L`5IJ`'[*`&3D$23"$28(!7J$!?I>$;
M3J$5T@$6>F`/EN`-W"`)R@!:I6`,=$`7J,&=*B02C,8+WB`'8,$58"$9NH`*
M>.`3M.'!YB$9\D`/DL&^WB8,EF$(^B78PN!S8*`,C``,8/^!%7+A"W;*B^LU
M!Q"B$YH`))6`":I`"G"@"F)@)ZZ@"TH!"[0`&;0`>[@@#IH`%%X!#/#@#:9`
MPJ"!&J;!*TR.`P-A_;IM$KAP%PM53@40WH+.$"`Y&)37W7PW$!Q8V@(AXU`Q
M*`"A$@)AY?QA`P'A2E&`L)OAL!>=XD:`!4;`X/X!%P$A`#/=XB9!!>@R:0-N
M+0=1&?B!`RQ`3!&!'D@@!#:`_(+!`_!P$Q`!\L^6:MD4!>@A$`R@`XJSFC<@
M`106*)J!`Z[T'SXYX."4?5.+/@EQI@=P$,W0.U<@\`/N3OX[$!B1'CK6P8,B
M<5.=TQ,`$S;!`!#!GRDX:3-7"$O_=!,"X0+VX02!`0!RW^P#(1C0'P5TT`+<
M?@0^4#/?#P`F+C-70!D"'R@,@06`@E$!0AFE!,'P72ATCL0%8!WTC3.`:9PR
M?117`"HT(MB(2<HNT`M&#P4@>@N:;0B&Z0)%9QPHXM.7`A!%?1<H!0NVP-F(
MB85(S-1WCH/'31NV]=LPZ=^D?>;TB:1H01F@23\I8D+QTT.PF<Y4TO2G[R6)
M3103*$-!B>*(?B0"^0*4@I]/?2K2CCA7=>:F$13I11WAS&7>P80+&]:7+Y^^
M2]?@Y,DSI4:9&G-(6>H'YT:5'UZ8=+'%"YPH*)Y%:<LSI]1G5UV81#%5#1HT
M*D:J0*E2_Z83,#B@2.G(\R2/*T]>IN'2\:3;X>6$Q;S8\LR($B5FP(#IE$U.
M$PA<FLRIUDJ*ER0OEH`!,0L6+%)=A`QQ-:L4JT1#\,"8,07,EU:7%L51,@06
M7V2S12=X>`&&%TIH4PPNS#T(H3[[1$AAA1;N@P\]$$XXV$L4<:@//2#N<XZ&
M(.+#SS[TG,-/7^.<TXR&S3C33#.*S:1,,WUY6**(%(W#SS@\FF..,\X$H^,^
MP62"UT_G8`+,2_Q,E)<Y6^GCSY7`-.,.)89,8DB3(7J)"8>9%!*F/L'X0X\A
M^F"R)C#[%*)/)F`Y0\(_AFA8R#@4&4*E/L[$](^?=5(E82$HH/\`#$7!H+""
M"OR<0Z<^DP0R"5\3:F0`53IM@(D^)&`2T@B!Z+,)!QQ0.<X_/WVYT@@>CD!)
M(5=:$&I8^@2R@5-N8ME!"@E<D,`D_"C0@06N!K*`!1=<$-B;#>4S(0<*;'`!
M(,TDT&(F"6BH9@(C7,`7"6D9%,@(^^3#CP69H#"A,PJ,,T(''WS0YZDSC8`"
M)R/0><%6'EI(\$S[K-(,&%.\\8D7;SRA!A5@.-(8%&?L$84=4-B10P-SK`*-
M)W20`LLGI\`1QRY?2-'`#WI`P04>5>C@A133O%**)Z`\L4<2H(1RQQO?X&+#
M$]P4G->-^VPQPQ;12+>%$F"8T447LJC_\P474N3P!2EX*!%&*5]P`PLKH6S1
M!"]?J))+$UN4XHHVJWQAB11@X`&+$SGD<,2`K'1BAAF=3-U$$@@[B'2$+WE(
MK<&"#78C80,/3"'EB5].6.28;\[Y3Y93J'E5E(>N>&&?A^Y,6C/Q`Y;C^63X
MDHDA@HL8<Z_[*"$]]$3.CX;F<(C/.<*?TT^+12KSDCG-!*.,,TV%J.-,X]P4
MC#/[1+N/,K3WXP\P38WS/))^3IA)]3,)<\XSE5!R2##A?``BJH?X$A:;G5>X
MCR74Q%%&%V7@,8H\Y&`,2X@"'?K!B$\\@0=C8((1.N&*;XQ#%Z3(@RU($0=;
MY($.N0!'.T!1_P4>\*`,GNG$%Y;ABBI8X0DZN$,J/G&@/'B!&;H0834XIQAJ
MB0$&<;C&$90@A2YX80L'Z@0</M$)(T!`"5R```Y<H9Y%=($+7@@#%T@Q"U;`
MX0A=P$,<5I&>:7S!B5[(01*\$`I2P$$1<:`B'LQ`!2E,P1?&0-S][HC'/.IQ
MCWR$T.<^]R'+`<\E]U",AP;I$@_AXT:XDQ`^+#<Y?*R+(J_3E27C-Y/%45)7
MI'N<Y`KVDD[F!9!]A)`\##7*4AKF'F&Q13HZ404OY`$*G]!%$J!@`S+HP!9N
M``46JB"%4IQ"&HRPS0]V``4:Y"$7.P`"#WY`AS>80AR>F`,48+8+5_^\HH56
M&`4/>`&**2Q,#UXXQG%TH)S[S0,)$.@",7!@!":(,PE/F,(3C"!'"E#!!E.(
M1#;,L(4N;"$.7QB<%\J@"$5<07!F.!`8N-"%1]AB#D^H063PT(0C;,$+1[!;
MS;JP!&@8(Q;Z8*4J3XK2E*ITI2QMJ4OY2,I4%FP?F$S:2V="CU=L0PICN,,=
M[.`%4*R""568V2Z\8(Q(S.$4>>##'9X`A#/0H*A3T"44DC"%&T3A!C^(0QX\
M00HL*,(5(-@%49/@F5UTX0E5B,,;O-`-7%3A#D?K'+6\,(5'6$.HK&""%+@`
M!B,<*`=[N`XKE-"$+APA#G$`0Q,Z$8<F*"'_/UR8`A-+T0FIE2*Q<9`"%43A
M!B_H`;!;6*QCKP!9+OC"&L:XJ6M?"]O8RG:VM*VM:_-1#V),XPIOR,,>Z.`%
M,WSC$E=X0A1(H0MF0$,1HJB"#7APAR*``A2N&(X.<E"&5;`"#WBX`2UL0`,O
M>$(5FF"'-EPQA#(8`13W8,0=RN"%.-S!#/&`Q1[>0(T[OD,*1M@",A+QB$?(
MD0I=H,[6\``&4CPBL5TXXX&.`$,I_-4,4Y#"%L``"D5PX0^J$(,1FE"$1.#"
M0'$@PA^XL(6_B<%IL%@%-XI!/]O*>,8TKK&-;XQC/=K#$LN0+QWHP%@\Y,$4
MV8A#$I0`,5MT@A94_U"H*W+!BUPHP@UJ/4(N4&$&6:CG%$?PPAWRH`=L)%$'
M18@#+';QB3O@X0T-U<,<W-$*&1@-AQ2I!Q,:\(5AQ&`)2U#"$KS`YSA*X0D5
MJ((,IN`*8SBA"W^H3ARJ$T3N'@'!8=!/)_YP!5!\PQ-%>"`%\&!A)BY!G$H@
MPA&0D`QAM#;'K&ZUJU\-ZUBGU!ZK:$<IWN"&QN*A$Z-0@QYD$0H\0"$(:F`"
M#]Q`CFA<,&>C)<4N<J$+)^"!#J/8!2QRP0XL#*$*%!V#'ACABHG&P0MXN$/-
MRCV,7/"@"NF@<S[H<808Q.$;$M["%BI-A?B"PA.=>((+GF`%&,1@%\1@A?\C
MV(@'B+*"%;+X0A<ZT0E%/((4K%`9#BBP!QG$``RA\$0<`JH$/0Q.#)6&A3!B
M+.N4JWSE+&_YJ^V!"V0T@0M?J-E&]U#4MMY@#&P%12Y&(0I//"8/NQ[W)UA!
MA2KL(<UW&`4H&.$)1GAA9A5.11X\V["W>L%A=R@',7[PA'9O[D;W0$(,$D&,
MORIA"]4)0R>@D0TD;"$',6A%+!Y1H%!\H1W0*,7'P1"-+JS"%1KM!"NR`8HP
MP&(+8E`$*XS0T2V$HAH8O-O'K<@%2_A"&"[OO.<_#_K0P_05Q8C#)V`1AUBF
M.0QV<%DG2,$(->P!%6\H$''PH(<WR)'<5:5#'E+__Y@H\($7>FAR*5"[A"HL
MH0P$CF4<JG:.6R1_'736ASF*$`,XX`(':Y<"A4EAC>+*H`R>@,4S%&$$+ABA
M`4D`PQ%FL8I5F`(,0B`"*TH!"EFXH0EWD`$,[/8%VF`+8,`&8:`$CQ`)L#`U
M@)4@4V`,RT`,HB>!$TB!%5B!.<4,I'`*NB`'7/`&I8`%=+`'3S`*U00.C*`#
M/B!.I.`)2:`'H[!U5#`%<70'GQ4*4H`'HK!/-:`#NP`.<)`*3Z4'95`%J0!J
M<_`-NM`*XU`,W$4.^@4&2T`*X(`#%38=;@`+80`#>,`UCB!4"?()8$`$4V!&
MI_8)2``&21!'>#`%1*`$_Q`P!3C0!%JP77"P#JKP3E-P!%>01=:Q!5JS!?/P
M"G9D@85HB(>(B#1&#ZWP-&WE!4^P=0<E3G"P`Z/@!%3@"O'@"4WF"4$3!VS8
M19_069_@">0D9%`0"?%0-W%@"E)`"P_U!%1P!US`!%3P!F^`!]SP"DK@!4\X
M=A11#DD``U^@#G\E!4J0`ZW`"*-V!#F`!8\0<4F0`UR@"J``"Q30!#B`!#E`
M!#$`"D:``S@P!#'01%_@"J%@1$F`!*]``:V@!&*`!/`(#8IE17@U#H-8(3'E
M1X<14S7U.(KD.)`D.C?R2)[D.)XDD`;9(:+C.8GHD`_I<K3&#<3Q5MSE":5`
M-?\L.`5)P`-=X`-CT`G&``LY`PI(%`=C)0O\`PJ0172O)PEW$`5WD`1&8`1_
M4S4'\@9!,P5%-30U\`3HT#FLM`Y*(`.,$`T_]%>=<(,[,`5",`66@`LK4P,\
M$&]B``VO$#)YT`75L0J,\%!QP`BXH`O($`E[9EE($`NP\`V3=@6T0`2J0'CU
MJ`2O@`P16"'T\#RNY8]XI(\0*5,IUY>@Y)>B]VZOL#]C0&YZ<`>?Z`KJP`@R
M4U2FP`AE<`>Z@`J\8`RK0`L8]6RB,`M;D`>.EPO516_MYPE',`5(U`NSL&]W
M4`5L5@5C@`?4<!Q/\`UW-`]-X`*>@`U(@`1?4`93L`3_17`%7K`#KY`+7M`T
M2(8#?-8`:%EQ74`*O9F`7R`)VA`+G=``$+`$.;`$1P`&2H`$OE`-6&!J(`8X
M9A`&9B`%N'`+G!<A]?`/!L``%E`0(W``":``!A`,@+`!+\%*%Y`%,]$/'(`!
MSV()^M`,'I``%J``*#`.-?$F'O`,%)$)'3`"*Q`"*M`,)F`-=5("Y8`)(4`"
M*.`!FA`,*W`")9`%5T(/_U`)B)$/AY`&_Y`"H5()B/`/@?`/S&,($_(*E:`,
MAU`)D+`HS'`"C;(.*I``@,`AFV`!'!`8DZ,/A\`)^M`(],,/@3`1^$`)*V`(
M+9(7YV`.E20AFX1)+S$AYU`H_V?J$DKS(?T`(OW0)'O9D)GT(;VCCRHB2GEA
MIYO$2%6Q+HEA&!PR(K]8(7U:4K5#J+93.U610W@4.J03J9#J:O;P"M'`!7>P
M!VRT!UY@"ZBPB?'%"*UP#0^W!S?@`QMT"MFD@44P!:4@"J"P"[@@"I\`=GCP
M"6_@#8E0!(/&"*?@"HS@<)P:-+GX"CT0=NY&#TC@`G!@#$0$!V8T!2#0#HR0
M#-R0C;`*>4T`"],0"T0@!4Y@E`>7#6$5"Y[P!4H0`U8&"UW@AEXP!%SP1./`
M"J[`"CG0!3CP-E[0!+A@#-%`(9,@`(8`#/LY#PG``?[P)?/``0RP#B]1#P(0
M`KH"#/\`4!<7``#!4`P`@"F%0!47P`#B8``-,2'`D`4=(``K0`B8L+'Z4`@`
MH`PK,`"04`B!P`R"``"(T`@&H``4,0D`$``Z0@\,@`%K8``"T`P2(`"!D`(E
M\!8!0!$9$`!O\0$`4`*(L`D`4`GY@``*$`@!L`"68@"(P`$`@"B"L0`J(0`+
M0`_\$`!IH;(;8``&,!&:`Q@4,B$EBDJ%,0X)("8<H#H6$@R(H`\C(*:%00)7
M<A@:<1@WHAB98`&_L@][$@A;H:CF8+8<\"N<`Q*;D`G,80Z5H"$Q90WT``S]
MX*:#,0Z!`;F&&@R*L2[*D+C^2#RK2SFCDQB5I!A"^B,M,B'_FK.[?VI)L953
MW2`%[Q5?<<`*VN`$=D!"TI`+_0`*LMH%^/0&-S""I^!45I`$0C8*/J4#7#@%
M7B`*IG`+W4`-N8`#=R`%I@`.H/`8BVF+][!-4^"+F',CZ]`$2[!W<(`'I)`$
M5;@%U4`!O.`$;H@'3U`$C+`.MK`(Z4L%4,!X?W`$7("&G4`%94`$H<`.D!`)
M]>`($%`%]W8&:*D%;)`+,7`'4]`%HH!@L)"I%((`#2$HG-<"*)`^F8`/(V``
M\Q`[!*`I^O`,`)`6ZR``)]`,`2`,1Z(CS7``!X``?F)2^L`)`?`.^@`,3&P.
M,;L-).``^#`.?A((/TL7`J`A&7`!_P=`)_!``&D1#`#P"AJ``8(1"`F@%@R@
M(90``,6@)@``#(`@`.50)SXQ`@JP#?PP"9Q'.19``O-@``#@!_L0`/[`Q_2C
M#!X0NC\1#)T2#(9P$E^*`L%P#I5@""30*&>!`LV@#`I`%I2``F01#)-0",_P
M#("`".<P#@O@)8&!`6F!"9,0/3/QR3HR*9BPR11QQ\[@`<`P"882#)M@(B\Q
M`L'\/$^2N/[@)P<+/0J*N3\1#E1"`BL@ILJP`!&Z"4`B(?OP#.)0%1R@PYU\
M*M<#O$#A#A+B)[)+._HP#XJQ#O,@(18P#I1`%B'R(>L<%HK1RH@$I\)@`?K0
MS!U"J*<\$_^:<PXE\2$6,,R.Y#@[NKH&":<SP4HI@`%74@BY$B&'^I>%@2%Z
M1`^W4`YE\`958`9<8`J[8`0`!P54$`E,X`K`<9%9A`2WU`-`T`,\<%!)H`-2
MD$LZ0`5P(`O\U@49Y`3&0`0CN`1OD`M_:`?N6P7K0`QOL`?;4'WI(%FJ8`P0
MH`BY4`0[T`7;,`R,D&_2(09.0`S:``N[!@?;H`B,5UE20`1$P'9'T`1-,`^K
M4""Q<`V\D'I@0P2&%W.)<`1&D#(_A->M%9@4`<E800\>@@$!H``,8`#R\`$+
M@"'X4`X!P!?R("@"(`B*0<?,,``^RP!8H0^#(`")T)"%$`"$+`S_`J``"H``
M`D`-*B``]!D`LRP`#F``#G`JO]T,:T``88$`&G`"!'``[)`!!.``"S"V=QP6
M)A````T)```6P@``OO`!#F#0%-$,%@``!&`"?4L1"E`"\U``)D``G>P+'.``
MC8.G/Z(`P4`""U`)F-`!YF`("1`.#$`)E+``YW`!F*`H_4`0AC`"S<`!E^*Q
MDW`!F2`LS;``*.`'!K`.++`)&)$2H3LAB'`09H$("U`(DZLK@+``WD("*M`K
M&`$(%X!*XX("%D`/F)``)&"?1S$NFZ#AYX`KPK`!3YXB%($('=`!*O"W%M`D
MA=`I'^`!'>``S<`/*?#D%>HH#^W>P$`/_RN0``11#B2@`(:``D:>`H*R`8ZL
M#Y#P+).P`1Q@G_X0`"A@"#&J$!M@#@G!`KBB*]LR`AX0)B/`)P4M"`8`#"5`
M`A^0`AK"*X&0Q111"<HR`GZ""2RP`D`2X6<!"/,"LZ.B#\JP"23P/'Y0`H5P
M"$V1"2M`%<!`"8$@$200I@X1"(BP#MR``(+0)#<Q#L"`"=*,4]8`NA^R"90@
M2?V0"8U""6BN#_Q0[1)R#D>RSTH2#!.R#S-R1_9`#-0`!G*4(*<0"D;P5%;@
M!,EP"J/@`U90!E)0!>!@=XXP!Q#%!,[V5UWP!:`0";<@#:%%!5$`!:[@"*V0
M`U[@`WM@!6K#4_];%P78\`HVD`1UU3GI0`0RH`BMP`4Y@`OK'@?1\`5+(`,V
M<(Q<(`ZHYU80QPCO0`U-4%7JQ04WOP6.H`^K$`?I"4$G:`1?``8S`)Z[4`T/
M%0N18`9$X`C:L&H0\@$V?`A\X0!TPB$=T`(N00\#@`*2],>40"T&X`?F$`##
M\!/`4``.0``ZHABL=`@$0'W!$`"-4@E]+`@84`_\H+J!P`"^X.5XX0<`P.<"
M$"4$P*(J,!$.X`#,L#SZD`5F[L,`W0@`P'D7^PH=<``4<0Z4(`_A0`Z9D`4"
MT`&Y:]_X,`#+,`((8`"^4`)F3`_-(":4!+@HX"KG,`DJX`$*T`]"OLO_6ZH`
M*>`,_.`!A]L!AN`!;<$7\\"P;JX,"5"F&UX">AX(_B`N,X'H<!X(6`'*9YHI
M^V`!36$!S]`"E>`,37JFJIXG(^`FB)`G?J#%!&$!!D`G),`!X\`)S^,,YZP/
M"N`/A2`34@(0%_9Y0*&/A"!*&?0=6J#/(:4-^NA)U!?H@KY)))PM4-8O`"9]
M"3!M,*1O1*%`%NA-.J0O!8:0RE`@^D="7Z$-P0PXP[3@G,-Q!C`YNQ`L0;!Q
M%G[JV[1@'`<2SPQDHF2A&8F"^_114I"I@Y]@"BB1N#!N03,%@0X9X/?O'S`%
MP0(E",3/82`%EA1@VG1!TP5*A@3\ZUN)1"%\_PI2E/BPS,&)<0X/3PH@R$(A
M??CT^0N`(H$@?1M2<$@QKX4"0"D`K4B!CP,@"Y3X&5#AP:9F>B-4<"BXP<(*
MA\&%#R=>/+@]2\GPF,&#!PP>)E*:+,DCK1>/,6.F='H"!0J57=FDS5&T2Q(;
M;:!"33L'K0H3'E*\Z%!#!8NT4UZ@]-!!9=:;*+SX)(IN7LD!"F^,4W#!>QQ*
M1XH9XI`&AQPZ8:6+)]S`8XDM<C`#`EB(^0.,.+J(`Q1%VM'G&T6.Z&(6,*3`
M(IIU]`'%$R^\Z*03,&")!@DEILCA""[<*(6(/VSI9(@IB!'&F`6+\R4`$@8!
M("(%'$AAM&<X$`"%$O]&:,:``THH(1!@`&#!CPT$Z$B`P_XYY!P#'("'``LT
M"RX0`<S1)Q,WF0)@&14.T*022II)@8%]Q@G@@WT,Z*"00A;(DP!*]-3'`0>:
M"0:3>1`!P!=Y'.C`(4X`"$8?7P!X!1,`&L&GA#X=4$@>`SZ81[;@%AAAG@!\
M,8<!`7QY!8!*,`*`DG$R$<X#<P*QJ9`+^#%$`642V*>9!)S9))A_NKV(@T*4
MF023%`HR)(-).-F@&:7TX<`0$CC)X!]#4I@D.`M6]><"0`"Y:83,]#%D!',L
MD"B#9Q)0X1\4G'6(`V4J(H&$R/SA@"1]9MO$@19`.V<$!SZ(#*-3]2G!$)3_
M"CXG`7TN\`>C+`11`(403)AHLXNT<@88%/8]QP),""9JHD`V;L;@PS`39@,3
M.E`@YK8*X0"D,3>)B!X%G'%(&84-0L20?RCA0!^M;IF:@YDYV(2$$29!06'-
MY,8HA4`"D4@!?SR8Y*)Y$O`G+4HN2`&1@H)3(05]_$!D!!1N"3,0X#@HX1G8
M`"%8'FP_\*7@I@L*YFS-@HE(F0TVP=87!9[9(!Q].B`!F+9L4J:HB,918*E,
M%#Y'`5]:6%K3*(L_SI)HXM`CE"YRV$.'4U9AY9M(=*BBBBFJ\"(.5A2I@8DH
M>,F#$4F@(<841D1QI0L=7)A#%2K*&,.+)_9PXAA'_U:)A90I[O`AE4_@X0W=
M6(4-R%`CXQDO'PYIQQ%>H`ABY.`),I"$*!J`!U-T0@E)(((<MM&],'@B#J5@
M!2B2<8QBZ$,8%;/'+>HAC%ML`Q:@8,6..J$(1<"C%4'"`Q=(H8@MQ"`:75!"
M%X@`"V$L(X'"P40&+I"%>;AD`QVXP`(T,0D/8"`!"7B&"A)@`07DQ`(66(#G
M]'&.*BY``1@HA`&$\:<`8*9@D_#)9G;"%`$4HQ($(`"Q]&6`GW`B`"P(P#,T
MXX<`;(03^*"'9C1P@`,P``"&*!4#%+"`9SC$$*K21YJ<E8(`+.`C^KA%*`V0
M`'SX`P!><T@`.,`/`8"D$/\```DB1>F'?/PC``[1B@4@9Y._6<T`.N''F."5
M-P]DJR(L\,<&*)$"FP!B`S)10#@"$(A)*&P#G`A$(<+!@7UIYF+GV$!J"A((
M@FFE*L&PP#[HL8!PF(`2,9N99C:@-PML8@7`(0$@"L&"?1BB7Q>8!P/\40A_
MY&,!(-$'MX*Q#[[]0V":&=HX+@`21*1@)/OPA0H<LL!Y3>PP-LG$!8!QD:!X
M[0)87-66`O$/D^@-$`[01SO]B0*89@L8'I!(`I:FCVQI902:2(K,T/:GAFP@
M61[`1$WH08E].20C^2C$/UKV,G^(I&<)`$9LFF&(8`@"IOM8H./T(8A"D(`0
MP9C_Q"W^H;<.`,(7E,@$--&6`$V@8%6:&<$AR-9)GCHD$T;S0"-6&@A$$.4G
MRK!:"O[!.'H0K2#\L``K)Y&R!.!D9TM,(#V0]P8]D((+/=C##G3Q!?*=@0IZ
MF`(5C,"(;]R"&<@`!0_4\`9>1.(-7W`#+SSA'2P@@QFZ@,86BM"%,MRA#'O0
MQ1M8P88IZ($'=W#%)P9X"1A4(1Z<3>`ZC-``+!`#!UR`0@U<80LC&&%".,##
M+APQAU"$(A%Q\(0K6'&,<Y`C%G'@0A.V$(=5<$,?Q5@%#4L8BE1T@A2S*,46
M(C`'4TAA"P5&`A>XL(1<Q"(:!>.N@HAW5.-IJA[XP,<"_^GAI^`P4BO[,,>*
M^2&/>\P#'_:@1XWM@K9P-.,<^-A'CW6L8^&48QWEZ(<R?K*/?H3#'"3.!S^<
M\1-Z.`/%X7B&.?*AE7$$H\KZ:%@_T+8/?R@#S'[B!R;&D8]\-$L3^LB',C*Q
M0(<$@Q+!\-H^,&$(9?AC').H\9J;@=AS/'4B8TE6)IR%#T208!*(4(8AZ.5E
ML.XC!19(5G#HD;22(`(SFIBG0^CA`4KQ@QXD.`<_1@`P.+N$+`(;&0=&<(Y<
M?E$9X8C(2$9W`3]LEA(CX(#>`K&)@NVC`Q#[G"'TAH(1?,`2#BF=JR_P:LJ2
M8`.9N)T^^F&`%6R`8!#9#3\0._\P0%Q@`_A(`$X+P:T4;&`2P;C([[RLCW$P
M``5D$>K4@N,,!AB"8Q<X]P4V80&]:271^0`$"?B1@$F,`&$&H'4W!>`,=`+C
M*/\`#IOSL0*!J0`06%3&O%9@DZX^PP\:,8`F4J(/!0!;*RPP1$8W`[,X+\`9
M?BC!/"P@#&"0.@'C$#9;+U!2B(_`&5M+P+N=815@.`!LF^WP@NA!"FX@X0W@
M^((.F$"*;K3"%G-@0A7NL`52$$,=NW"%)])A"2*\00ITP)`4J/"&*NP!`KDH
M!B-0H8UL[-<+9<!#$7@!"FA8H@M1>((G<H&%/7SC%7NX0SE2W?3BD&/O)C3"
M%F+$"%S_S$`&C&B%&;S`"C#DH1.E2$0H8&$,:,`#%$-PP0L:T(`(O!X'BL"&
M.&;ABE)XPD*A``,CB+&%+[3B"C/H!#FV\%\N*($8N)@&Y+5RU!YKAJSTZ/$"
MF<QLM/'X^5]F<V86^/CN$^?#QMD^+\N_(+(&1RMP1K-PMK_`\P=#8B!^_O/A
MKWZFB[\XXX_2/OC/YIT!/UY2/^E+->+QO^W;&4VYAXG0C";+#,T0-;2AOC/J
MF)]ROXDX/U[2#.E#&YXC#B2+#*V(,KLX,:"R@"P[JG-P!KO@!WM`&V<0LW/8
MAQ4\A\@XAV#P,GKH!QYKAN>CAV9P,RO3!Q70&^%0!DQ0ALAH_P:OV;-5N;=5
M"4)]"`9#F"=ZP`1^,(<JI`0_"0QG`88G%"Q@F,)5V80UP`Q@F!FF4`%!R!BL
M\)I`",-)\`=#TP>("XZL2H$1B`Q,(($.>*A`\)--T(U5J8016(%QT$*T^8>E
M8`H.X(!,&)DH@KP%>0=8&`8NJ()(L`4NR`-R>(8X@`(=V`,S.`)/^`99&(4\
M.(7Z4@98V`(J4`,]R)%9?((N@`5<(`59H(52<`5PB(8O"#VXRX-68`=6B`(I
MP`53^((=N(9AT!X!H\3A:+]K,((<>`1?4`(E.`(C.()28`(R,`)PX(((V(5(
M`(-0`(4P`(-':(9A:((<R`$(<`$(P/^#'&@`%X`!'!""6+@&4B@1&N(O8F@"
M&+"&2%B")?@"6#@",/B",%`"8S`&;)!&BEPB`:S(_L-(C?R_`12.5&,_AV@0
M[/,T$&0SCAP_#520B^1(C>0LEHR2?N@`#13)EA0.%."`DZE)G=1)3%"8]MM)
MH.R^=["$:^@"&YB#7'`$*A`%4O`"(=&#))@Z6_"$4!@?46`$6-"'<)"$)Q@#
M18@#+^@"4%"B15"$3_B$/-"#4;`&6'B"-YB/*GB#5G"%*!@%=*"".Y@":F@%
M&WB"=*C)!;H&')`!19@&;3P"*<@!5_B"&&@`4M"%'&@":CB&1-B1.'`%6(@!
M".B$+O@"4%#_!6V`!45X!"G`@P:``5C0!;,,A>"3!E*`@"T8AAI(@BT@ACBH
M/.DX@FAX!63@+NK3$YI\O'S`!W/8K.%T)^$XP.*@R8[L/I`\JN_[J!#3R)0,
M2NN\3O6KR9?$SA3+O^2D2.+1DWZ@/@IT/^(PP,PXOP\C,3W1OHP<R9$LL>_4
M/PX3CG,`B><K,1X#L>8<SN(AL:!<H'*X!&IH@C*H`C!(!@K``[24@COP`C<`
M!VG0O5$`A5(XA53`!G-(AG.XA470!^2(A'%0AG6`AE+(/4_(`SPH!758A"?H
M'R9@A$6X`QSH!K`T@BKXAE;H`2I`((ULD&NH`1DH!6-(@A>=`B,(_Z`=@`!1
M@(<N,((BB`1X$(,K:(5LJ($&,(-0N(("\P5+Z%(DZ`0]:(`'T`9HZ`(I,(9N
MP((NF`)CR(8E(((B(`4ID`(N\`(I@,A8@)TEHH<.>+?S>SRN"4/-*(2"\,[]
M<XAF8,17XR7T=`A,,,+BV#Y\,8YQF"=,6)6+#(Y-;;KM;$[SY,^1M+[[ZX=#
M,TGCN#)/J\*C\A-EJ!C-D,+ZM#1,R`04$U7G'(>E,0=E*(<;&X[MD\__2\GJ
ME$YFXT#(TY-.79"?G,XH^51'Y<Z67%9I+9YW:`5JZ(([&(,JT`52P(,HL`4G
MH(`WL`5>,(4\0$M0.`56D`5L.`=P``=>./^O4[`%:?B&;;@&8F`%W$M'4.B$
M7-@%,+!&4C"%5'@"4,"%).@"*LC15I"!*BB':74(<LB!%P@%:(A'*)""&)`"
M:"@"%[@#1F`$&2""+4"&.(@$?OB"'HB#3JC34H@$6$B&7.P$)$""YR`")5`'
M9&`#:%@%',"!,+"$2,@!'(`%4M!9+DB";32&5U"B/KTH0)B93*@'H*H83RN$
MGNP'V@$J<_B'$F@&/^%53KVSI0&R?C`'2E@`=D+"DT%"B5W!8`C"<P"&?BBU
MAGHH14T8QK&T8+"+;#*(DL`'O$6;<R"S1J2'G.34XBE/BA`.[RQ6#S..GIS&
M**$$D>`E@BG"HZ+_!#DB#HNZ``XX"@6)P\&JJ1$@@9)0$*K@KO=+H!5@*,YZ
MOI:!/'H`A/P[&(E"`4R@!*_1C%K%U3AS"Y``4%$=AQ$M"65(@7()MNP+MI-1
MU>!HAC%<O^],OX(Y23C;/F?(![$MF.*LU@0J!U@XABVH@BZH@CBXABEH@#RP
MA2[0@UWPA$\XT5#PA%,(D7D@!T\(`AJ@@1>@@2`(`B"PA7L`AURPA5+X!%(H
MA5%@!%?0!CJ0`6AP`QJP!2>=@BY0@RB@'HCUT9:\!B(@@D<H4B.0`B-(`B,H
M$2@H!4<0!13&`4;H!DW`A0:8@B]@@CU0A$88P7O(!TO`@RT@`BG8`Q?X_P5?
M<`5=@``E(()5@(1<D((A<`0I.`)M5`(D,()7B(5,XBP+$`T+0!V06"E/VP`4
M2`%`(ET+&)N:\#6"$:<-((&=2X"2Z(`1H`0`*(0$N(`+2("52`#?H(=_8(#7
M0(%->,0`,#0^M@G5(0$#0(2"$2@/L`!@^`<!0(0O<H81V`"\^IT$D*;1C8A_
M\8`1&+55\:?Z'`%G40%@J(0->.6*&0V3.@?>N"=.E99I,P<4V`=^P)APF1=7
M.P<_A"E_0`$5&(&*,=01F)I,F+<QS(1"@&2?V9*9>>63R80`.*C)L,-5F804
M4$.',&.'2`&8:8:-DXAQ@(1+2(MS4`9@,`!W7O\59T@LM)D$0("=#:BX*NPQ
M3\/!2JBQ+!M#90"V,Z('NPV.3%B5'E/""RB)B:"'=W!48,!:>N"'8("U,QH'
MA9.()U/!B0@&/]&*[]6*<W@95@J.1;.`!-`H#QA#X%7#S6J0K)H$8%@`CPJ_
M%3.)0N"'I4*$=5L0;Q;>8/C<)>('%,C`\!0.B[J),-P`<!;?5)6(I^V"-WB#
M.ZB"4KB")7@"<'B&%Q@%7H@#4W"%4\`#4EBV5M@!__W?'ZB"`/Y?-0`';G@%
M/-`#5AB%44@$</`$'X@&5K"!S;,%**AJ/*B":K`$5918C<R'!LE66F`%8<"!
M*B`")!T"6V`$'C@"5H#_X!RPQE70!T5X`1@@!2(AA6-H!V*`MV6`AU`88E;(
M@0BX`GW0AB<@@AQP!&-(!%)8@AFY8B5(OB/P!EBXAMGE*B(LFQ1@IYV1N#,Z
MBPNHF(8.A*F-"-+5I&!X9W8K"8(P"G[@B)`0J%49`<0I"*MQB$.,+&#`!PL0
MA*O1AP6`*<V@!"QLZ),R"$R8A+/I"WQKAFM3!GZ("PLHB0NP*H*Q@/ESB`0`
M-J*18WU8#<PUF*-()&4(@)]R!@48!T?3'1I4@'Y0`%8V`!)0!MT("90P`'IP
M-;CH!]@PAP7(!']PBB^NM)@)A$S`%CT\F9Y0E**@M*K"B:["VM#X*7JPAVU8
M_RD2^(?N[H`U0`!`,`2N$@H.H(1_^0<%,,0C3X"A\0!:?BR;$&D05[C(&O!`
MV("-H8="\(`5L`!.,(@1"'!Y48!_<*81`(D1J+1\2(,IP@R%XV->M6,#^(=]
MV&0/"(;1N8PQ%QR#&"-@,P31W;GB,.9PY@`+X`!ZR`1,:`862(`5>+[94,.A
M-AC?\&\4\("4X``YHP0&*(2)OHE\#D(2X(U1,P#J35T@;X9YVC5#V"RVPIN?
MV`2KFD(&F*=\H`=-T(I)<`9S!H1F2(I[\`>O,81L&D.H5DE]>`?>/%^XLP)7
M@`8CJ`$G>(4:N`%><`9T_03=ZP93>($H8`2W9()9B/^%)J@"*W@#&A!W;<@#
M6B@[6V@%4X"`&SB%>/>"RYX"*;#J*N"&5N@ZQ]-):AB"&<#*'-`!#I*"*8B#
M(ZB!,LB%*P"#)%@"&4"":4B"UP,#);B":1"&*]@"?7"$)CB&;M@""O`$&VB`
M(J`&.)`!*(A1W2Z%'D`"5N`"*2`"),A3,2`&7Q"'V?4`+PN$%-B'9\,,K=":
M,TH`L(F,E3+4F/D;3I6V?X#GN#&)$,=R"_"3>?&I!E<-S#@8?;A).UP`L>)=
MBM$'MRB83-B`<)E#GAJ!8,";CE$`++)#/XZ9GC1F17N934B9[?,`9W$F$H#D
MH^.WJ:^*O3E5)]<K95``?JC_J`M8&IES[Q'X!PO`&YO`A`$O"&"8M@4H.`.8
MA&DJ&+C0"F,V-A6\"-5=^T*8A$+(A)7VA_)\%U0=\V=`A``(ACIR`'_H"V7R
M`'K9%W\`ADV@!%1?5%5/Y$Q@`((F?KM8`'^HK'.HH]<H!.#`[TE(@#)C@*1P
M%@OP!T`H"`Z/N6:X!08P"@'WBGTI)Q0H"-(/A@!H%O*_=('B&8#PMX">LP7G
M]-W3IW"?/A0K%%X(M"]!)A+__K$XIZ*<PH('%>K3M.$<)0_*#$QJMJ%0I@OC
M#``C00G3A7XD4J1`-"X!)D,F-P3;=.%C)0[`$@1#X4\?/GTC>"I@2?$"H&`P
M%9ZS_\#/G()@%PP5LN#L@CX+F0!]#;"T*<BV;M_"C2L7[CM+R,!X@5)FRB=0
M-:"HT<=H"A])UT!YF:.-5P,CL][DT75*&*Q<Q/)XVM/@2;95C#RMNK:K"Y1J
MSW#TD#*Z2A4\=ZAT:Y7CR;I\<V_'G0:AAJM<LY\8Z60&QA0CKKZ0<H)C2@QB
M['`T<`)+%:A-PN+`:$+D"[-;9O(8X_$"QS5L1;9(R:$H%R,=7(A(8:5$"1$O
M8J:]NH:[+3X#))0E`(P^)`C0CSX,F6.6(0'P8T$AR@@P22`CZ`,(`)0<J$\_
M!CCCC`#-L/#//@N,H,P"P20PCCX*5#("(/I<@,D*A>A3B/\*ABPP3C/]>+`4
M"9EP,(D^"?S#U)"5P!C(44Y-,LD&^F"2@#\6Z*/,!?24Y<\&`OXCI`H,3+*/
M,VTE(*0"F*#`08TC(/(DBE'J8\Y5^C@C9"$P4>F,`N-<H,R*RHRX"3^%]$0A
M)AL8HF8F9BF@C#(J-'-!,"`=U=0*B!3R8E/*4(D"C8`84DD@X_24@"$9<K")
M0I5LD(*IF:*H8@*^E+23/AM,,@*2YCB#P@:`&*#,/X8L"D@*)$RJ3S!4PIC)
M!OP\PZPA)`2"B#Y:!J(`"2L@VX&`%U#"YS\I&$D)B1QX`(P%DUY0B4OZI``(
M"4B>)*\^_"!B@%@C6$`"!R7\0Q;_/2FZ9=L(*BAD@8^%%/*/2A<@PI`^XRQ@
M8)S.(&)!("B,L"R6(VP"#%DIIH#)/X*`%,P_A2R0R22`"`464@K1Y,P&_VR"
M94(DG%H("3PKJX#-##4U`B;!J`E,)8!T]:0'E5C@IP>8[%>UU7/5-<T64TS!
MFA+0Y&$#$*NLTL4/3_3CB!NZN"-"%:7$\00=D8@""RRO//+&%*&X@8,7T5@B
M!3>^P.##&[F`D@04JY32=1=X=!%%.J_D4$4\5]]FFS[50.""*;#D,,431.`1
M"FI<S$*!+E3(D$,7W=13@0N\0!.&(OS8QD0#.*R#D"E<$,,+#0UHHX\B,2RQ
MA3I.,")+_PPQ;$$+%TIX\1XQL)!S=3Z8%))")DU1HJ;$RI(`R#_T!#-"(/_X
M@PF2P"S`3UN&;!`(LN&,8-$D]'!@""+F-`08YR#!"%)`CR[I0T(KV``'+#`)
M97B@`R3@!]*>(J2F!&(#/TN!.1;P#TPLP!D+G-HX*.0,"QRD1/ZX``DP,"E_
M,$`?FU`36P+1+P/X(P7:BIH^.#`"<"WK7NO"2@)&P`$4E`5="3A'`ORT`#]-
M@D@;4,:$$KA$"ZR``P;@'PH`88&!)4LA*+@)60"AJ3@I@!*7&A`B)I&I$3C#
M`T)B""5,M8D%H"!!P?!)00RT`11,HB8+2)(A7,+")P8C`,W@6/^DSK'"?32E
M&0P`1C"$IH!^3`08^[C`)A)5H15D(@'ZR,0(]J$``9G**0!82]#<D95F)$!5
M"AL!C2Q@/G)A8FH=&.6+_C&"0^Q29;Z@4C,48(YQ?"1#/U.(!R8U`D,8`A"9
M<`977H2E->K#AIYTAI*NY!1,^$--"6@&(/QAOE%.@@.%X(<!-&&(0.32&<$(
M1#-HYH%S`,,?"BA2T804"!60P%K.0(H'VA*,#6S`'U:B1$NL!*-`^HD$`L(<
M1:^VCE8<8PM5\$(5II"$.:@"!VIHQ2G>\(0G-*$;IE#'(GX@"RI,80NB&`<_
MYL&/>C`C%%-@`AY800->.,,4T&B"Z&S_80I/3*$(L.C"%*@@!=:HX1NKD`$5
M-%?1M^3#-MVH001($8L<&"$)1E`"+;KP!!@<01MR*$+H<N"$9-3@!1`@!1<4
MD0YC="$'/X#!%8I1CD<L@14@>`$,J&&)))S!!D5X'1P@(`4EE`(/.%`"%Z2`
M!&SDYZHT6\!$X8(/JX)D$P[*T%OH,3ZW2.RS^Y$?/;"D$'X<!+3G`""66JL/
MT^KC'*Z5'S[XL8]][+893=F'O9("$MN<`YGZ8($*Z`'`VS;C(/20;C]<&Z=@
M!`-!P.A',^BA#'/D(QCRTP<P#*&B9DSJ'.F=1#Y_BPE$&$B`;=E'3_P$C,Y"
M:1+^$%`F*"D@_T"L`$-MP<3/J*8L#G"@&>:8X"@OX,9Q()%0V?1`(?8Q"0O\
M`P69X)0R<AFD#'%J@9C@!P<.DHD0N*A"%QAC=]LTVO\T)!/Z*"1IU\1">B#K
M5L!020HTM@^.)5092.Q'`6720U\A,04<($$"Z)%BA30%!>321S.9]+(+%X(#
M?F*(,A1P1`4LY0*^+-$7!^0!^@VI&8%XH`4,H8!T`F(2#)C)$U?"-!7I@Q+K
M4EC_C#0"(<E+72TA5P("T98%*"#/%E`SGLK"/:6HQ4B:G?1;RG&):1S!"T^H
M`A>20(=L5$$*KJ`"-,3P!"B4`A[7P$$0\O"%-WA"$O:X%S^X\8Y&>/_""GG@
M0@7H,(]RQ($'.G"#*^;`BB6,PA4ZB`(4JO"$,?P@'8Z8@AMZ1^FW4",)26#$
M+G*@[23(``:G:`)Q3.&&4\!`!C(`0S=V,`,8A,(3KD#'.A)!"L'XH1_IB,07
M.M&`!NQ@&W"0`0]L`(HVM((1.2!"*;I`A+%*X;'$B$7VKO;9?#0E$Z=R2U,P
M#F4C,83`UOWX/FS#EI+7^$#Y^"U30"OIC[\<(7`YK<O9XMF%U&@HN;48Q[-)
MHWOD(R$@L7E;7$Y1MAC]N"FW:M*'?FVY$!TN(^>/LBSP7)8K9.4*6>/XS#%>
M?615(<I8R5OP4<^DF]:UYI`8;C7T7'WL*.O_SBB'_&CJ%N=B!4OG`&[=@Y%,
MA="C&<H8KSG\,2F"O'::]02&=U6D#$H(:!R3P(3@\QP.?AAB$CSO!]6`$8BE
M@&2:RNI\YK&$"2&!?914H\<D_E&)3'`^@=D-!*CJ^?1KV^8=N"#&%I(@!1X<
MH0EY"%L9>.$&4U"!!TF8@F5L\((]Q*(+O)@'.&3M#D:0PQRE8((M?/"")^1#
M$C?@@1%R08HX*"();N"%%7C`[#=(80_L@(4>Z,"1VX,$&5*8`BQ8X8(G)`$1
M+($-S$$<_%\>S,$<0(`1>($K1,(C-(`2=$(<=`$IE(,RE$,^N(,U7(,B=$$<
M@$$--,`5(,,P])X._\0!*\`!*>0`%;@"!2A!`$[!?%2#,8B#9D4=_NG@#MY&
M4^`#/IP65J7>5;E<T_U@V<T72`3A?&G.$GK<S,4%S0F=$M[&^!@A2-!#(:A(
M#F9(J)#6$AJ)(4P9#Y)A&98A&&).QYGAI-G&.JP",32!ICT!&*0.$/!`%]B"
M*UC!#=@!%5!!.9@"#53`',S"'9C")3A"#.2!&MP`(PC#(WS!*QC!"_2`-%A"
MY7#!!T+#(]A`%5#!'8B"$4"!'T9!.;2"#5C!K.U@,L``#)#"5.E`$MB`[^4!
M!%0`&+@""T(!#I2")\0!-<#`&RS"$4C!'-C"/?`#/F"),%S!$N!`%[Q!`__8
M@B,\@C'@0!(4`2F\`@OB0!Q(P</-QQ$<`3880SM0&B0UQ3D8R!$Z'7],W7YT
M'"3AG%RPW=&UW<<UG=)93=!I3C[.'!JNH0X"9$!"':75'$'B!A=>&Q>>EL0`
MI$+.%T2FE@]2(5.\(T+>QCJ\PC'L'Q60P2=X@@\$P0WP@A.\PB[$(A7P@C[,
MP0O4`3A<`BI`0SH(QO#P`3(:0QP,`S3T0!"`@S[D@1?P0!6D`QRT0B=``2HV
M7!2,`6ND`RC<`!6X@T#JPS3D0`ZX`NB<E`X\`?H]`0'B@AK4``7D02X,@2)<
M@\)U0BH<02*X0B*T0C;\0B*P`A@8P6?D0!-(@R+_-,$J0"41:$$KD,(0)$$G
MX`%P&,$6<,$68(,O5-S3`1)&*@.-0*1"`$.14!0E(!%#N-%M=!@]H,#?O<4Z
MK$$:G$`);("`70TF6("!Q85MS`0\MH5R@<04WASE#1W1:<YP5<FD0!+&T4,R
MQIP5.ETSX-G$C`D86A4]C$,0$AW?F8-N)2','0B61-U`8F1V:N=VZJ!ME`,L
M#(,5-&456$$HY`$4T(`5B`)[\``0J`$=4(,GT,`/H`(IC,(WL$,RJ($-[``=
M,`,__`(5G$(KW``-@$,RO(&F,0$UD,(<1,X/T,$G3,$=V$$5Y$$^D,(-W,'E
M["`VV$`#2((HR(`1$$$-__#B#M2`"[3"+HRH)!!#*^"!$GB"+L#`"\0!*&Q!
M*9!",N!"-)!"*4B!&8#!"S2`-+@"$6R!,"1#%S@C*Q`##AP!#GR"%.``$7"!
M&!@!-<"".5Z-?&&",JA7(&!(%U6)(6"";9A3LI27GQ@4)?B).6R"H%0)ECC#
M.!Q3($R*"GB3)F`"T6#7M5"->M%,,(R#//##.%#"1S0#;L(=,/38;>G#N*"7
M/H1#;%F#Q/A+,2F#,TC,."A#/8"$/2@#+$V",/A),V2@,A@()/&#[<6)="F`
M(>C=QXU<,P@`653D;7S8U:22U5""H<T/$ED50X*$O3!$3@PA7"`",#C4;3P%
M"?]L0`)@"$!.PL8923#02*Y6)G=R:[=Z:]'I0SF\@C%LFEGI0!>DPANX``^8
M@B.P@AOT0`_H`"R8P@L$@1WT(CN,PR+L`"_$P@Z0PC7``AR(@@Z\@`\D@QO8
M0!1(02<D@C50`0TD`2GP@10HS@^PQCHLP@M0P47BH#Y00PZX`"FXPL+A0)5^
M`A74``00PQ`TP"HL0QS@P!<805^Z`@Q$`"O0`AATPBJ80RO$`1S@`2TTP`N,
M@BF$P11X`1(H@C:L`EJ]`@3$P!&4@A$@CQB(P1'4()=:38"41?<L`"48`"94
M2S_$R,VH"TU40B%%46<E2KX`PQ%QP)/,C`54`B)$!)C_H8`!/`-&'(LY7``>
MC=$&K``P4(@1C4"C:-`&6$`^``/A7E*D,!FSS!@><=8_6`N-W=8%*,`F>%D"
MD,NB7``'3)W"C%("F(H%1*LAG(,'<$`1S9@%)`"A!,`&](H%2,J/)<`9(8(1
M"0@_H,"*&5HA;<D^%$+P%@(]&,`%C!<]9-"6\,/ZQ$B5C``*+(!KOE<@#`H)
M&)@A_`,E!(,R3`J!48T6U2D@J$!S!D.3&.\_^`D]4$(A_!&D`IB9PAV6F`.;
ME@6>7H#+,`0_:-S;Z0,&`"LE,,!!:((6*@2V-L,^B"]Y&8+\V!!S;BIY9<)X
M-0-^?>L&<W!VAMTYM((U)($7_TB!%TP!#WB!+4#!$K1"(NS"$_2`#\P!.-@"
M#KQ`'M@"']C"-C2#)2A$))Q#-^P"'XQ"#KP`$Z0#+.@`#_S`@$:")\#`%_""
M#MQ`%2A!%42!%Y3#*MB!&WS=TS4%,BC!&3@"Z&B;E2:!"]0`(VB#"R@!-8C!
M$BQ!$4A!''0",;@"#ESEO^$`*PP!!,"`#N``#-@">^S?%"RF$U"#%S0`-B@<
M$30!'@R!$"RF%$1#+`CP?EC`MU#"/QC:GP5"(112#B7`"7W0/$S"`E2"/[S=
M$'$3"2C$]4Y16<0O$E$+)F1$`&"",S!`E"P%A@4#,&S"","/AES2*0T)3508
M`8V1/O\@0J(UA2=50C,YC:I@"8"=@P&80S\$P$`)R04@3%M8P"TDT$`HPZD<
M@@+P0U=T$(\4`N=UD+!XP#Y0PI[PA.WMPTC06""HR0\M"^>%T`),0B(IPY/1
M28(50@)P<[4:P":I`";TLI%<`**D0"!L@K=DD)RI@,\80ILIS`9(R@8@@J_T
MPP(8@"%PC#^0C`5L@@&\"$,$`@/@""7$"[P\!$,L`+(80`;!\I*MP`6H(0<`
M`DT!@BCY4@;Q@U#L;2!$$R:H#U*L0-@J@`*LCP\-10E8@`=X;`=S=5??GG>N
M`KD^@1)TC0[D`1;H`!GDH13<0`]0036X`2X@@0Z,`A6XIRC_*$0]?!8_/$(5
M]$""-D`I;((IN$(/W,`/D`(L@`(1O,$H<&6H18$5>,$VM(*%;G5%-04U"*`B
MM((,`&`,N((H-(`7_`(.R``>D(+O*8$4X`47>((Z=$,7S,`+S(`+O,`+N,"[
M?4$\W(,C@`$8;`'$20$HK`(1A$$K*$$#Q`$T0(`29.T6<,,K6)O5#)$%4`(@
M&%K_Q%D&_6HAF`,FJ,#-\(/)Q!*4+1K<_0,LEX63U%./!`*Y\`PE=(P!9-@*
M>$4]C<,*@.XF\`R%\,,%-$.)W0IK^O0D!!B44,FQOD@P#)*#70``P30*L!-L
MX5`"^)`ZU1B8U0@LVP0+,-DXE)E)__@"OQB"*37#"-Q,>'M,AFA"`)"`!S`(
M+>79,VG,/RA`0^G#$P$-0]"#&)(`@#<9/6SR!3!$:H+$+$<%3?@2U9C1)*!`
M/;-7C:3`24R"V$Z"!W#J`BQK`@2OC*D`$C7%/[Q((`61US)$__`)E/1)*>_$
MJ32%!Q0:`W"`.82#`6Q")16"T0S(RF!WGPA)^,B)UQ5"^`9+F]W6MGIUHBNZ
MU8AK-"B.%$1!%!"!+7C!#B2!*9B"$=@`&4A#',1!+I0"79<"%U0!+[B"*8##
M-[2",:0"(LM"'N@`-)`"'7A&$O#`#"L"#00!*G2!^]EZ%:B!.D2"#70L#Y(#
M##0`(\@&#_\@`2L<9AD801Q<)0Z8`BEX`1A,`7SH@2(L0B3,0S.L`G`''QZL
M0C7<`R8X0B=P`5Y,`1A<02=X0A?$``3\01<H0>DP@CA>`1=00RQ,=]5L"R88
M@&8BS$H@0@H$N)IQ+_..D;SD\ZDPQ$T44R#MEP$$^(-,4H8Y!2*$DDH,W@4<
M13/\-Z]$18FU3"$H0#$92.>F`(V0@"@_25%#:B`4%"`\B2$(@*&Q10J@P$LT
MYZ)]Q:VH)M@A,S]GTY-,@@'LA&E=@#E14+`L$2!02"8$`A,=YS.-ZA%)/;QP
M`$THRS_T@U@,B3)\&)84$N8I=),Q43!HM=`;295)*[;ZP]3`RYK_2?AD<M;&
MF`@FF,Q!G0,_+`"Q$$K39Q.Y-`6R"L6M$!#.R<18C%*"+0!VJX",-06NQ.X^
MP!(BI+<F](F4_Y,SNZXSR#<384E"ZU#<#OVBJ_[J7XVX^@)73@$4Z(`9N`$/
M3,$;Q$,7^``3>,(]D`(3N`$X;,$+Z,$H.($>?,(I0`,TK()O=\$H`$$#$#:P
MXX(R0(`._``OS$)[@D$>M+47*$X4=(9;7_95K9H,E,+3YL!R1X`7N/\.3($S
M'H$W?($4+,$14($9?((VML-!O`(``80\7_OZC7-$ZE,G+DJ4;/G2[0H1(V>X
M*.KR)H(K1A"DB+EF+)T^D2-)EA0Y;L2__TG!,F'21PF8,D/Z,'%`T4P?B@TK
MS/$CL0&1OGTB^:7@,$E?,`XC,B7=`"A%L$DS$2&U@`C8A@LS1_339\C"!4J^
M2.C+!"B0!67_S.4,9HX#"17G?,I%(92F!Q(=<)XSX$QD/GW`%DSB<$[?B'%*
M.6Q`/'+?!F7Z)@$:?`$%!P_.//#CMZ'?/PXI4M!+`'BT!13\+(P3J4Q!VZ0)
MFG&P8&!$8J,;Y"4(ID\!L$D*<+[<L.D"\03C_)X;0<(0@*8B+?C3EV*%OP2;
M*"T(M`!0(12&-@0SX`\2`V4;#!GR33LQ"L+``G'P9^`?7A4*G#W]"@"I??#1
MAP04_%%`'^W,2?\@$V4\^(VZF?3AX`)S+L@DLDS^02&8!`+YL#U]-D@A$PZ4
M66`P`\X9AX%@Q$K0-9-DG)'&&FV\$<<<==R1QQY]I'&=88Q)0@<EGJCA%%1H
MH*$-)8$`IQ\J\.#B#5>@B8$&/6C!HQ1HJ*DFEU/BF"6*!JBHIA0@]&#$E7E(
M"6(45RB@@0E>F-!ABB>,^$&=56B(0[`?3<KG'GVHP4$&1G!I8`H\KI`A#R^,
MP`$&"'20815JDI@B#BG`\.(*>LQQY0H<XHCD"R+^0(:>=9KPP@PIMN!BBU5@
MP6$*''(@H@PC2(&@"U:XB&$+:U9I1]`9AYJQ4),&E/%9D985#)]]EM7_AQZ3
M/,-+F1$PJ<]9D[(5=ZAS1`L4,GJ&LG8H>F(L2=U\!!2)GG#H45<V=?7IISBZ
MA`HFQG*6Y<<<>=N=I))S`.$`6W\@#`8Q9\S9)Q/`A,ID$F4@#H8?BO.AAQ),
M*AXI$YSV,20%EX"A1*E`E'%I0TKT6<L9<U4(YF3$S$4AP'](`$3F`;]-2;!Q
M%'A7'^0R44$?9\H"AH0+`B$)A4I$,L>#3)226A^%?PIDJF82V&`$>H)1X)\1
M^,D'$`M6L"`8%%PR`*ED[;X;[[SUWIO&=%Z)YHDIN-"!"5%V`$(':;IHP!9;
MK+#BB3+,4"077&K@88\?;KCAE%%H"&(,/BJ0_T(:4JIX@XLGWG"D&QUHV,6+
M)'X819$;@(@BBBK4880&+\;-6S!JBDCT"QO`:,*(*4"1)HXWBMB#!QZ.L"44
M):KH@HLC'AG&D2.X0$+2*J288@A3=(F#""_"V.((4+2AH@<ICI#!B"Y@>66+
M,HB00M9H8EFG1_B05[2:%:AUB00?T=*'`A=($@9>JT?HRL0(.$02"#X+@C)2
MQ@6\DD&^[6T<).``!RSV01O59Q(7@)`)1Q*,#4R-A20(1#]>-"!YT8@>^<"'
MOO3A#@^R$(A!%.(0@32,7"@!"E.P`168(0,:>((//H`"-/(0!3",#P^?R$,W
MQ,&%)?7`!D`(PN=>4/\#1NC#%7C`@T).9P9>>((&J?B$#EQ0A5#H('=5\$(Z
M'#&*.Y3C@]/@0A56T0H*=&(+E()`)'*Q"E=<3@<QD`(CH*$(*32!$>V`P`V6
ML`0E&($)[$->#HH`CQ,@@0MXV`4K$GD$(BB!%:YPA2600`0<&.$31QA"-6"!
M+"+^$D<,%)0P@<FC=HWCA\E*IK3P8A9$`.9:Q*11M(CYK&`$XC$D05<$2=*,
M?P1B$\44YSC)2<Y[<,,8XYLD*N80*U!8P093&,4IWH"'/%#!"Y]0!"FJ\8U7
M.*$)0X``#&QP@S9THQS$8(0G\H"'.,0!#'-P11QX@*0W[.`3KJ#"%*I@A2K_
MP,,23Z@"`($GDFD8@0B1:`43[@"&'%0A"5U@!!*8X88J^(`)30!6*U0IC2\D
MP0>85$02OM"$3CA""40@JC0<P0A8S`$"2J`5%X@`BRPL8JBI\P(BN4"-562S
MG,#<QS;#6M8&FA6M:57K6MDJQ'((XQ5=V,,.J#&'&Y0"#GBXPQNJ``5>D*(+
M>GU#*601"DDPHRW;0,8QE*&+=."#'YH`Q2E.X88WY"$/GDA&*ZH0!2I\X@V>
M:$(3>-&%*.BA"NEH10WN\`ZR"BI0W,!!`QC!BAPTX0XZ>((.W%"*3C2"&T-(
M`@Z>P(,DV.!Q#:A!$U@1B55L@17E2$0<2$$*+.1`_P8YV$,7C+#;)"AA"A38
M12XZ\0LX*$$*0_#"'+X0!VYH@J1ME>]\Z5O?#R[3OOG5[]W6<0ML-`$*I2"%
M#^[@ACT\`0@WL,,-YE"-.)CA#EWH1"GN``U]P$,7=,C#-[[1ACD@@Q_K8.@H
MKN>%-X1"&U)X0A2>((4[4"$/-!@%(]Z@@X_>8@=3B,=K[78-&,!@%:1(@E*E
M\`DHU,`&.3!"+KJ!A2,\`<I@W`$,3F$+4C!"$K"P1!-B00HJ6$(1T`!#!%XP
M@QS$+KU;P`4TFB`14'YB"]B3PA?@\;_]WAG/>=;SGOG<9Y&L(QFPD$(5\*`#
M/8PB&J`X$A"`\`0F@,,43/\HPQXZ\88H&.,;=*C"$^SP!B]$@5.1N`<<JJ"'
M3NAA"E[X!BEX`(4>R""FI&B%$ZR@!BHDX0WI6,4-GA`2OE%CH)&(10[D9P0W
MXI;8,5@%*/:@U!S$``*Z(,4I7A$&5GRA$VYH!2D4`097A,$8J[#%*2*`A*02
MH1.K\`42IJ`$+SS!%:&0'Q6,<(1MK`)I?M;WOOG=;W__NT;I$,:M]#`'*20A
M":2(ABM:X8;DZ<`+J8!%+N"0AR?`@A%=^,&*41L'.WAA"FIP0C3<H+H\.`(7
MK&A"9ZM`!U/`HAMSH,**/0$%)L0#%#=H0GSO%BAL$,F1->!"ZJ9WA26\$@>F
M@`#_^G+`A3M\X@I#@'4#<I`#&$C!%2!80G9AD`0($,$3K#"#*Z_`B!C,P9-+
MB$$3M!&&,'1!"D8(PS*^"G"[WQWO>=>[6<NQC&H4^0W%/0,1<D&!7$BA#%,8
M0W'=P`M;N.$5X3`"GG1P!ST.DKMDL($MI.&)3O""%Y?$YQ1R<`N)T@$(&X]#
M*:#@A7N\@@^E^!W>AL(,,Y@!%J18@A1HY3UHK`(&,8@!*(BA#4;`H1-@L($,
MH.`"4K[!<%Q(PN!*D0,<S$`&9V@`NA&YB'*L8A5$F$(2.D&,/TC!"USP`AB*
MM8IY[!W^\9?__.E/(\'0(QK&>,(=2B$%/-7I%%S!&Z[`_PBH8`RH`(\^(15,
M8;>D`!1,81?@H!4\80ZT@12*ZP?V@!=*P:5XX`W&)PE.@1O@8!>ZP`>JH`8\
MH10\RQU6@0>Z`)#X)AIRP`4<H15RX).\9PJZ(!<`*P>\K@ON80YF)0<:P`J<
MH`N@(0Y$H0M@H.J\0!%"P15P@`N,(`)`P`RX@!3J@1&*0`ERH`NZP!5`00S"
M8.B&;@MT33;JCPW;T`W?<,_>(1E<(=7>X`Y&P0N80(IT0!9,P1,HP`N\0!0@
M!PI>X`<^011L`0X6H15<`1<\01$4)0Z>H`%LS`C`P"*,8,Z^00Z^P`VZH`GB
M()_>``KBX!XBP06DH!X^"!N*D/\4(D&2S&`+^(<+OJ`5*.X)H,`(KD`)<``"
M9,$3/B$4P*`7B2`/I``'M@`/8@`'N:`4O@`45`$'ED"FE,K=7&$5OD`)Q(`+
M;@^\NH`;5H$<X)`<R]$<SY&<WBH:T*\+1&H6W``*[``*GH`1HJ$3IL`(H*`*
M**`+DH$8X,$4;$$4/F$6&($4>`$/6,$4NH$:&&$.<&!\GH`*OD#A&$$*EN`)
M<``.3F$+%.]ZXN$5>H`+9N]N"H48:D`&7$'(IB#QC&`)N$!6&*'ZO"X)J@X,
MXH"[FG'\DH!_\-$(BI$*3\P(<N`)B(`(P&`(6"$6I*`ASI#]M@`,N`$62!(=
MJ](JKQ+_*W%$#N.!"Z8`#.Y@"G1A#G+@!Z#@!_+@$]./"?"`$7;!<*J`"4J.
MT7;A%%BLL^S`"4QAHN!N'DMA#DA!!Z#`"LA`"L"A4^Y@#*+@#L[A%6R`":CR
M;I)!!F8@$A0!W5Q)JHX`_;"`%*ZH"[Q@#*``&36QW00'']'KX!:"*='+"(P`
M#\H@#I*'(CQA?7AO"YK@".(LSKC!$2"31ZA),'@L4`9$@$:B.!TH*Y-3.9>3
MG-9A&5XAE:C`#$Q,%*`!!\J@\G8!X\+`(._`"J"`!WH`C&(3"OAJ!Z#,=H(@
MP42A%$H!"[#@%*X@%W3`#G1`"DZAYL;G#:S@$_)A%9[`#7@N_V^@80F@(!>P
M(`F>L0G>(`Z:P*&Z(!8BP1DML@9R8`F29PIPLPOHS0S*P*6\@/>(@`>0*`=J
M``;R`"&HH!4B`2JY(`X\(0Z8H!-V80N,@#??X<ZDZ>YX;)QT=-]\%#G+"DB9
MD[[(01=PH0O*(!`'+0XJ21&0@$$7LAOPX,!>0!]W`$:E816\@`>F@`I.00_V
M@`IPP`X:($L8X16J01M,P1%V8,BJ81<V:@JFX`ZBH`OTH1769`WU9AB@0`E6
M01&J3A.5H`AX[PB.@!1"%/W*H`Q^T`AX4L6\H`BF@']4C"$0#@I(Z1,\-'FH
M8+H:`NX^DR=!=`OJ`1;V]$;&81,`B?\2#B%;#"$86"83*J$1*.$?_,$9($$D
MB@$2Z*$8V@,2#N$WE$$%5,!BML$0,J8DUJ883"9(1P(3D*):H&4DSJ$9K,4X
M1:(?SH$>P"I<LA4Y[\4DKJ49D*F!=N@X;60<?--NAE1'GD6!W'5O`H5'B72(
MZM7?R`$:A@'D(.PF3>P4KL$/I$`T14$4\J`']J`4MN`4VA,![^`)=B!YJF`*
MYL`3>"%&/^%T4"$=NL`&=*"JI*T*P')D><\*ZB$2>L`+5E%O"H4::B`"+,&V
ME,`,VDT*D*`+P@`4/&$BB(`+:#`)9.%XS.V[]F=*RB#N&,+ZC"`.8L$(/M8(
M9*`,AH`40.'_"-B/]U)-"6XR'52!74MB*"8!`(+A'0)``*BA&03`'P*``Q"!
M`P;``!1@$@H!`,()$0"`'CH@`#3@`A*`$HJ!`"[@``1`&8QF`2Q``"1$'\9A
M`T2D;F@$&!@@/W`$$12W)%+`'Q"A$.QF$G)C1B9A`8)"'\P!$<[A`H2A1H8B
M*T;``T0W;\[!)0+A-^1U1@2#'PR!'UIH9J`)@9II)#9A!5SC'K;)AO"B&8`!
M+S`H*93A'`!#AP9E632F=R'C6\%61M"EFD9B'#!A7"9&FV2$77[S1FAW.06C
M'7+A&<H`)M^`"EH*+O.`%[RT"GA`"G)`!U(!%[Z`"Z@`GV9N#^Y`_P\@5@JH
MX'3>P!2P80AJ0`VZ@*6BH!32:`O>H`RH0`U>['3JX1%LP`OLX8.B83)7@1&4
MC'_`:PH\(1I605=DP`N(X0Z.#@^:`!1F`0S`P):X``=N6`IJX!+-@$;!H!2Z
M;I^>8,BD0#L[)7"XH`RX,0RLP1)0U4;.00`@01@((`"BU0#,(0`\5P%*0!_R
MP0\```/T`1$"0!\PX`1((A`80%0VH!8H00!<@S2ZF"8"P!\H"!`D!!-0(!/&
M91]0H#7ZP0\JB#+^P36`06Z6]QR481(FX1P*H2DP81R^*4$$F63^`4+\(2I$
MPIMFPA!RXUGH81)<0A\LH&Q$`A,,(!BJ`_]73P(3<.)9FL$`9J(9O&-Q_0$Q
M1(5YS09Y-1DP1(4?`".1AP(L7@(GMF59('/V].63B4,DS@%!4F!S:\09%*`1
M8G"!>!08+)<D*B&;[P*_:&)JJ*DD%"@8RJ*9HHDDFD59NL8"-J`MZ$$Q@F&7
M:42&LI42[L)&,N@<9B(0FB*#J*5I1N"'E-<?9&9&,&$#-$&$`H1&+BC/R@$6
M8&$)9%&/\(`*I&`_1R$4F.`-DN`30$$4JF`,..I_H\`+Q*<*RH`)<B=/1(H)
MJ$`6S*`3FH`)U.`)3L$+EH`*F"#5*/8-WH`.]&$5>J`+6#9O"@468$`&,.X'
ME2#QND`;5@$$AJ#_!\J`$73!'"9Q<5P@5Z2@$SJ!S>+N"+Q@85.A".@M`FQ@
M#[A,'R(!"<S@*!\!%A2A(60E>]+0$:PY1S!`!4A``S2@!%0``?`A`,JB'A"@
M`T0"!1`@```!$P2@'CS``#I@`S"`&<;!``3``F2F&10``!8`=QOHE)TF`4[9
M'\C#A3:7'OCA'WS#`@QA$PR@&72B$!0`$TI[*U!@/!C`/2Z@$,Z#`S`A//QA
M`PIA!()B0`J!/=R9/,!B95[[M3'!`[37`I:"`\;!`BS`8@HA`%)H`TC``IIA
M@T9`A1J($BR@@0H"$ZI;A3)!`2X`$!*`!!(@!;XB`2Z@+#9@`4;`$!0@_P&F
M&P48@!)4`!C\(;N9QA`:([Q'PAQ&H+K%6\&1MQ#"(@%DPQ`$(!!:NP-(H&,"
MX;M=8T!2(``NH1M*H`-2P(<*`;X3)"Z:=Q+Z@1("802"`1!6(QBDXBZ"0052
M`&DF*!#HP1DF(QC2(&1^6;@Q!)0=^RL"0!DVP36"H1_,029FIA#\816%P1#F
M620*>C)`=S)V"!C@XBZ4H1**8R2483WJ^Y;W81(:=UQF[QR$H2WXX98'(P$F
MQ!#.03;R85T9_!SVF&!&@AXFPS@3O"2RZ3A6@`6`0927Z9/UC!Q\P12L8!>,
M80N>[@Y>%+.\P1E/(0^L0`?*,@I&FJ,@U@[Q`/]WQ%2DRL`L04T1+"$5O,`5
M9B&PQH`,(N4'/.$4^-<>',$&GN!K>Z107B$&&B`6'"$'VNV3]DD'?CT&=@'E
MF(`)XD`1HD`&EF#[.,(,8*`,<,`+<N`3="4&;HD&K,`3&($+ZI$45"$&R@`"
M2&$7!HD*Q(`;P8`<5B'8D3,+!H``*J$2"``!"$$?`"`_\$$!S)D$2@`3&(`%
M#.`>,$`#**$1#*$?[B$8)AP`+,,9.AD`IELDS`//';<Q.O?.!6,36"`?*,$0
M`N$\+@`QE,$?P,-J4.".&W<I)J002"`3"J%S;V8%+J"!"L$#)F&/7QL8/$`Q
M-N$91B`%-`'H!V03IGO_'PP`&$:`H3E#'UZDN`&!PZ,&+Y1;*)9EQ2>A`]8[
M0:X8'_QV`SIF`2C!M[\"9Q)@$MQ^E!$ZG"Y@$G2"0.Y":%*`'U"`!-9V'#S\
M/A39`&)$&=3C'RS`'"R@$`RA`YS#<VGB+Z!C&19`$]+"P--B$@*A$"K!-P"@
M$%;``#!!;@L!$"9!!9I!`C(!!7)#=4N;!.96;:1F!`!@'"[``[C;&1"A`PP!
ME3$A`&+[-Q2@$EA>;GP[NA/`$`Y@)L+V*FR;Y0WA_BYD`S@@Z@.AM,T[`?XA
M`#1W!;Y"!3:!OQFFD_$B+<"['SK_*\`I`(X_`71"&>""0C1F`QP_*DA@\3?`
M_VE&@/_W`2!&D-B@0A\^?>=(C-@0+).!-1X\8)JDSU"'%<'X!1)XSAD@#A,O
M_%NFKZ3)DRA3JES)LN5*:L1@67E318J7-U/,Q)'R)H^5/5'XO.ED)<D8.U"J
M3"'S!`^>-TVZ5+%296J5)V6HS.GT"4PI5UWNE*GRZ<V34:>J4+$7BXR7=R[C
MHKRGS]>4,M!(Y5"RA,@6;46DX'A2P].1/SF(*/'R"-21'5%L\+"!`\LN)CEH
M0-GQA,:;5:KP&,FQ!4P-.D:N[-#1Q165*4K$'`G3#18]N2>%!1`P;IF``<7V
M!0"D;]^"@OH&ZO,``$$^!RF*E]Q@H:2!"X42E`04P/]=27\.]&V@N*$2AQ29
M$!$O66G$N02`,%WP9V&</DR9*`6R@.C?/T,<)&=(<I.,X$\@DW#000HD#%A2
M,(:08$$F&_Q3R#_^3&*!'Q\$@DEU)4T2G3X7)!B(/OGH$XP%^5Q03'*(I.`!
M"A6:9,@%**H8R`;*Z*.,!Q;I0V%)%Z0P`I$J=)")/H@4N0`@E&Q`HB$;\,/D
M"/]05*!TX:P@H0K^'!G,!D;JPX\%S934SP+ZJ("(/AS\HP('A@2B@'WZ-*.=
M,X4@H@`E%RQI#CTK<%#(.`4J@^.']Y%02"&&I(!)`I2D80">*S9(3W^%H(#0
M`LY<``R)F5BC228*%`),`N;_@*J/`I,`0AP'+"BC`JP+#)()GO0H$$Q%%P2C
M74G\)#!.EI,H`$PFYYAD`2;B!4))@!%NXH$R"L`YX&V49$)/`I,4<B(@))R#
M(PK_P%F("B0PR0&J_"AC@#EY+J`,"M'1.(F4[$I'0KN(;'".`LJD`0@P/%YP
M#B8D3.(I"APHLX`_E-1G2"72X:;QQAJ/@PLN7HQ1!1YWW`&&&65\(8T33T#1
MPQU,J)$'*5TD58474-A$\A136!$%&4D`\08>GE2AQA,[3+%#*6Y(44427E#Q
MQ!-&>Z*/(V/$<1O'+*58%Q$Y1))(#D?T50H>0Y210Q)44$,*&#GL)4,$KK3"
MC#>._ZS"B">,-&()(XJP@@4WMTRC2`-++"'#$IT88XH-4W!AAA*P@&&$%%PH
M`48WL6RML3D,,$"/<0'0PP\`(RYPY'(X*K,;/1X(8``#`A3B#P`*)"``)<T$
ML,`&`D27XC@+&,(?B9-$"4R<!E5$@KS`4!*`,_ANDD`@%XSS+[X;P9DN!SL"
MDT*X*"34;DDC%$*/!90`4H@^)128PCX;`%()B/HX8X`R_ER*PK9YLH`YGJ6/
M$2#"$$<J1+L.LH\$%((?P0C`)DC@*4",`%#Z\$<`FJ$,!@0C6/J8F*A:Y8]7
M_<-:^IB0!S2ACQ7\PP^4<)YT9J2/%*#`'P$"1@?DHX]Q6/^@6?DS@#Y00)P1
MN(\$_$C/052T`'Y<`!'C4``F1C`@"`6C&2,(%$.RE:!&5<(0XIJ6,C)1"._T
M4!F;L,#_9$4<?BR@'QM8$D,*40)+7(\^YC!`LV"5@A-UH`.Q2L,Z,A$(#`B"
M6`E(4R8L``P0X6-]YX"2/O9U`6@5)P&_`H2'`D0)$O"0!"L8@952A(D-D&`!
MF_C'B0RA@GY4!P4Q=%2#?,0^#_@H`?S8AP4&U`$/*.0?_ZO(D0ZR@1(N)Q@8
MH$<*"M$,%03B1,3$T@@X``P<Z>,?"5A!FI;(M6YZLR3M2`8LJ."%,NQA"G&(
M0Q=(H0M1F&$J>6`$%6J`BEW,(17_>X@:U?90A3+<80H\^`%/\B`+;>P`,FZ8
MPA[(T`M;>*$*7/BG/ZMPASB\PQ$O>`-=OKD26,2@`:YP!-FX,`71+($)4&A"
M-1B!`R-P00I)D,$4YN8(4)!"$5\`Q2JT``N<QB(1L&A"!"23A)I0(09^*(8K
M:L"#(1Q!#+20@A*D(`4PK,,2GM-8,&YQ&V74HCB8^)6*>J2B40F)$OC(A"$H
M80A$E#`8C_I5/I2!"!5@["1MI<2O)E%"$07B-OOP40PS0<5"*",?&_D5E0J"
MB<8.:!(82YXAFD$):&T$$+<Y"#]4L('WG<,/(T`!/93!`1($HA"8*,@^FM$/
M#6V`$OM8_\$DZ#$.<^P#2RI@H?OH@0*!I,DDSAC!"#Q`D690<`3-V,0*[G.<
M\52$`Z%-SJ_^,8(46``0_8`5-1<YD'Z@@"(1LA'X+)`"2H@)1Z5=@1Y+<@X#
MI,"%<$+!.,9S`>(<!!@+@!V4&#`);"'"``GJ#P<V,1\&3)):*`A$6U%@#@<H
MUY:!K28P_@$(1)2//RL(@+GD2%A#!(,`@8@@PM*`B=VI@#B%8,$XTI`"\Y0C
M!,L-K!&=`3YAF>0]YDC!,HF#@H*DR(#T,("'I$1!5-T'=2<!5P@G$5X.H*`?
M"<#'=UMH"$!$9T>+["&K2#`B!>MC$X8(;R!"()WT,=<='C"'*O^5X<DC40^8
MD_0PCIQ!"7Y(2!]9Y:B>XQ*.5X"E*@_M@AMVX8@]V"`)-VC#/+@1!Y)QA@YO
MD$45OO`)'?Q@!U+X1!5&L8=24($"7L##*$0QCR_4@`E,<`4O0-&$EU+T#6J(
M`SQ608,X;'3/):&+,6(@`UBL`@9>4$(#=)"#1,3"$=(`!0R(((4MR,`&70@%
M*7"0@R%XH12[<,,JL'$%4.C"$T_(@0ON\(DOZ(`'3#"#8B!0C;Q`XPI&4`(.
MS`"&JE9#%7GNIM=P39=]YPC7`&\)/O*1#WDT8QSG,,<ZPF$.?HPNX1D++$KV
M`5A\[(/B/?3<.9KA;Y-X[C8$QK/'@7C_$M:*G!\)#VP_@D&/?/##2OR@ETGZ
MX0R4TZ-9M'V0,IHA\?SYHA_V.7@/*>&/GIMC5.<P!":4,2IEV*Z'CQJM/_@Q
M*F>4D.G!R#JT,B&(25A).IM8)CV``8QY;`)*=YI$/_1AV&"40`63F,1M"^&,
M%10B#=V*H3!),`[>AD"^'J=1=)QQ/C.1H!^W2$`F(/;D&_MR!),PET!LMUP2
M.<,@`T_0ORJ!CPUX_GWDE>3_Z+&0"SB#L'F*HP&RR(%S"(2`'AC!=7.D#`N,
M`%8-=,=IFQ$@X6[`$-K;SR8:F?I"4)&T`4]^2M*!C%Q$M`L/K0(O>*&#,?2`
M%+R0ABT\P7TI_^2`##^`'!1X05$H_',4>?C!#6QP!QCH8`^>($4NL&$,4.``
M"D;(ABNF0(6JY/,.^K`*/?`&\)!\=/$*+E`#ID`*/?`)3^!^-&`*5]`%I@`!
M?9$#.%`$KL`*K=$-C%`#1%`$1]`%1[`%1/`%\)8#1B`*T=`%G\`+5``#3R`%
M\08"LX`$L7`%/.-2G3""R<`*^287'<<Q@=5SS7,2^7!K<<%-*5&$)M%S3*@Q
M1K@/^7!S#J<,XZ`,SF`.@U(24>A-_F8ZZX!PYQ"$#^(IRK=G0YB&'$5*SX(O
M3WB$)>$U]?!U)O%(_+"&*\&$7XAG14@/HX-R@U(.^V!;IK,/Y[`CQ?\!B'VG
MA?D`%S<G<L7A#H'E</I0#^9P$/1`+S=G.N8P#FFR#UA8$N:@#/R`)^P%#/:Q
M6OC0#.<0+]\A5ORP=`@ABY7P*^<@5FR8?.U`#-0P!5'S!E1P"J60`TT`!E#`
M!TY`!6\0!4R0!ZEP"ES`5#GP!%&P`T50"J;Q!#K@`I.1`V#`"Z@@4:+0!*R@
M!'N0!,_H:7<0!64P!7>P#Y'0`UW0A]^D:S9@`[!P!2Z@!SB``S#@!N+D"9TP
M!8FA`WD`#;!0!5T@!8M0#D7`%TL`47Z1!%RP!#C`!O10!%8@!;%`#*R@`SB@
M!$1`!*Q0"KP@"DS04EP0"D,`!N7@"&:XBS3_69,I83J;6(8X^6^X40]>>''?
M5(7[\$@MAQ+V:),<980G$87^QD`J$5A.B2)?F`]+-)1"@EI.6!SX<`\$AP]>
MZ37Y4`\I,G!S2`\^:1!6N91RB(1#25L.5PZ><VMDR9/-@`)D]83T8'%XYG!X
MF)<&X35S>909LY9'"(4K881+))A(J8;D0`RY0`5Z0`5)X`:\T`5D@`=38`2>
MP`M\0`4Z``5CL`-T``ZM@`N,P(%NP`C1X`CD5`J*``J@\`K)4`0UD00_,`JE
M(`I$P']C\`;?T`5<4`9E\`1Y<`ZMH`>@8(<!YPM/P`/:P`@ND)E/PPJK,`1$
M``%/0`0P``JSL`5*_[`%.V$$<!`/<>`$/T`U3$!52M`$T?`*35`$7N`%4]`$
MDC`+,+4$4D`$7<`(T/`()"4%8<`%6]`-K3"3BWF@`$</[@"(94B82XD/\[")
M[H`/7`B(YI`/AF@.Y]`/70B(+D=Q:2D77GEQ2HF@)GJ@>KB88PF(HW.@+?=(
M^!!S%)>B;*B8)\J8VA`)3O,&=S`*5J`#-[`$-M`*VI`'%#"<.*$#4G`#<J`-
MDM`*<8`*VI`(EK`+C"`*EB`-,,@$-G`S36`6HL`,H"`%4,`#.D`'I>`T=T`U
MY;`(41`')<I1![$*$.`"/=4`F28%#8`'.%`%-]`#8&,$T("94+`%7*`(9O]@
M->D@#6ZP`ZX@#5C`!(IP6-30%%L@!51PD;/0"`TP!C$P!$+0"4W0"3;@!:JP
M!3&P.9USHZSJ3?A0#YM(HBCA;_.P#^M@#L[`<.=`#H-B<9E%HW$X*(,2<QH#
MB*UZK,B:AK?!E5S3EGUG<?NPH(N(<7&J$H^D#PMZH7J9K-RZ,2ER#;CP"E.@
M!Z'0G%`0!;:P"J!0J5'P!&\`!650!'?0"4PP`U7P!JP@"J)`F=JP"#9U"D]P
M`PU`!5WP!'JP!W>P!%.`!=T@!WO0C$!@!U60!W@0!71P#Z!``UY@H!SC-;``
M`S8P"W"P!#6@"-K0`,*Y$U!0;:'`"U0S!4D@!:7_P'W`X'#T\`H4:@W&@*W)
MX`B>T!5*,`7U-@71@`1&D`0G`P9Q8`4-\&XTV`7IL`H<VZTGNC4SNH>5:(J=
M.#KU4*UZYI>:B!M^2;5D6[8H`5C>RJ+S0`YC6'-$V7"/E'`ZZ95TL9-4R!)D
MF7)C:[9\FP_D@`O",*X[\01DT`.Y4`3),`=2$`4/I0-%T`JG<`K9X`A,\`14
M@`>R\`5T4`6,X`KR68V\0`RN\`D\4`/R605CX`G@T`6_L`4\``2B&0H/>PZK
M``1>,`\!YS6X``-V"@<RD`-5U0I>D`-.4`H-@`-=T`G0]T]2!0:P0`K3$+57
M4`0Q@`,0T`2-,`WT$`NK_Z`(Y10YF/D(M&`$RU8*1U!OHE`*2V`$Y]L-I#"U
M?%NC@.@.,K<2]&`/M+5V]%`.<@&542AQ<UFLA<BQ5,F3\7O`)WJM0HAG$RJ4
M-MH25:B)M]&B+F&L!HS`R-H.MQ`+.#`*<Y`$.?`#<R`-D<L$2?`$/F`%HP`-
MTA`'-],-6.`$59`SY&2-UD@&18`-I!`%=\`+U0`'78!2X28+=P`-3J`#.N"N
MHP`%=)`/#-@$\(L;!*</L-``(`4'.:`#21`#J%`%$:`#LA`'.0`*C)`$9JP$
M7""@L'`/H0`!$=``+O`"<FS%$'`%;`L'7W`51Q"T8D`*7H`#7U`*20`!I]`*
M.?^P!+(!!MP0"\#*-5YS#F5X<"Q:A=8ZEG[8/!AW$`4<P$E)<0CGE96\#[6U
MK5WSB>2`<!IZ#NYP#MS$HIO8=X#XP"41HBXARQA\RTCIE:#LH',(<)H8H[=!
MHX$U#K:,R\GGMZMI!5/0!49P!WD@#:W0G%%`%3[0"[MP![T)"E>0![E0"D90
M%7H`CWM@!4S0!:U@#$U@!Q0;![8`"TP0!5*`!UU`!Z20#)L[@YX`!$\0@#SP
M!<6,&Y8P!5+0"H[``SA@`S(5!4+*"-(0`7#0#5)%!$M0!F"@",FP!1$P!DOP
M`@W0!;8``2]0`W>`@:NP"PU9!H;:`WZP#34@`_"@"$K_8(P%^P1HO#E2NV<'
M\4@*Y\GCX'`71\II^X2GV--:V4V;Z(K*:90V:X]$B7`>-RCS<!!*R!)0690E
M$<4FT<C&O-4)?*$N,<5C6<#_EI?_7)4'4:M!:-5<C:#7``O$4`-GD0<VH`=8
M8`9)T`,V8`<],`?4$`=@<!/.[`3,$`_0X`=,8`6>H`A&H`.,T'=4$`>*``9X
MH!;2,`<Z4`4Y4`,]T`FBX`E34`6>'05O\`ZP``2E\,\N80\!F`1+``MLT`-Q
M4XW0D`,O0,A,X`*D$`]P8*A)\`?((`414`2S@`>?0`K7,`RF&0>L\`<-``.E
ML`I@H`1EH`2>L`V)\`)<8`DR_T`$BC`+1PN\2A`&W'#37!.C0(35-1I8$ZP,
M#:>'I[@.ZU"B%J=P46V_S0+?@[*W:4BA\$O!:_W?)LK)(CHHB&C!<Y@/0#G+
M7WESYU`/72MPL%J%]!*G+8K>-#G5)YH/UH`+T5P&SED$/``*\/<:3\`$WO`*
M0S/9>>`*BM`*/2T/KZ`+>`8)N$`/Y+!2GC`*71`'=]`%GE`-1'`'5N`6GS`%
M=E`!MI`'7H"0^\`(06`%9PEPJAT+#5`#J_`%:Y,#,H`#<V`$4Z`#=4,!,>`$
MWV`*3M`%LP`&$9`#J=`%6Y`'K+`,MP`+H)"F9D`&$3`$YV`YI-`-N.`$1%`#
MX/`(-_]0`T?@&$<K50,:"U[+EF0-HXU^DX\$E4]H#Z"\RUF],<!<J^F0B?K`
MA8$5H2EQ#T1)ORI!UA0G#UWCRCJ9DPVZE9BN?*@-X+3.-18^RQ<LQ9K8E@IJ
MX$:9EU5HAGEYZU1M$/ZM$ESHE0[7H'=XH($%KK"@!%40%*2P!TB1ICU@!:Z0
MN6^@!WA@!KDY"G5&#NV4!W0`"J:P"]_P#K<0":&0"G=0!7'@!9X@#:$@!0+U
M"7NP!SO@!;SPS@BK#Z;0`U2`X6VH#[$``32P"U\`-CQ0NIT`G6/\"E(``S%0
M"J):"J<``U/P"7=@!*70"HNP#/7P"I$`"S3X"64``8D`#67_T`2Z$`:_&P>O
MT`5$T`2VD)V+?3EQ4`ZPT.@37%MJO8>O6HBEJ`Q8V.K^5L!6>;=;R0_EL.P:
MFM^#V1+T$`X<!,GF4*LY_4A<WX3K4`^WZJ"`2'&>Z`S-8*%4Z*M027`@*G)W
M&Q<8)W!QH=6U?O>9+A?'3I/[8"7TD/9[:"5>"YAROXAX=NRSOH0TJ>&P8`I(
M4`9JX`-T``LT$`2H4#-JD`M8,#+Q"7]R$`WZ$`E)0`.5_P)!$`0T\`.H(`W?
ML#<>_P9OX`6*8`IO<`-,4`I60`.IX`I,4`5V8`5W<`^D<`-QD.O?I-JO4*?9
MQ@-)``5)4`1-0`H[4`-Z$`EBC-"S_S`'K4`%+H`'7,`#9:`(V["(=.$(PXL$
MH<`##1`-B6"E,("!L)`+8+`#FID$09L$1\`%M!$+>V@ZQ-R_`&&.'C]W`^GM
M,R=PGSZ&#1T^A*@/7SZ)!@O2TT=/(#V,#>F=FT=OGD-YY]99$U;,7$1YZ_#)
M6_D0WSY\"<OQ.[@PXDZ9&77R=-@1Z%!]-(D>19I4Z5*F38\*Y8F/Z#ZH1*5F
M+.<,(T>/*[E>E4D/W[IU4?6=J]IPXLY\&@5FI*@OKM.F8!W:94KM52LI5:K\
ML/*EQHT?X*3<J`8&2ADJG_#0<56MRPX=-&B\N&/E!8T;/*!(:Q4'#QXO7=Y,
MD>9&!R\OEO_W*$I")HH/*O84T8@SEZY#BJM@R-CUQ8:2'$J(#(&F0\8<+*P8
MU8AQ!%<N%PV.L-I3RA<^8?ST*;/FC%&54J!F-.CT#)21)$5V/7*TQ84K4D.D
M&"'B18HB;I%TZW,'K;0>HHJBB>KY#Z@$U5H*'P?7&8>><I@1IAEKZFF(HGSN
M66>9><PI9QQKTC%GG7/,,6FDNZ2JQR2I\&)H+'Q"PFBA!=G*YZ?==N2Q1Q]_
MI$LJ>72$*!\8@Z0G0J&X*A(C?.[)2**"&%KP*B(]<FFG?<9YAIP,CV2**GS&
MZ4>@MO:Y,BDPI])GFE=<D>*)'WSH`99/>@B"#S<:\*0;6-S`XP[_.QSAY8D&
M^,C%C2[D`*<5)[H8998&>N!E%3.ZJ.*(.(B!I@8?DM$!""I<H4('**#XX8U[
M5MDCC[*`U,<2*<K0Y8LDB%`"!R-``<,%&-S()8Q.<EAB!C=8:>"%'#KYXI5Y
M0!EBE6^02,2:9.+X`XL&&C#C&AQDR$&*5A*!Y8@8P"BE"2)P54*).*B)!:.V
M9A*+)X/P8=*L?B+\$*%SHE2+(WPYVH>B$VT<:L9RMAGG'&7&2:B>>LKA!DJ[
M.!JG&&66"<>A?>H))TN9S!GK'')<@HD?%,4ZR)QW\L%I38]DSA!6FV_&><>/
M!HP1PYP9HDH??J1*4ZF"ZW'PK8CP?1FB_WTX-(>?<\8Q*B-SY)''0;,8PDD?
MI)=FZ*"IRZ$77XEX.^AG?<8QQA4=EIBB"A[R<,*&&_@P#(@Y=-&%E"KHH(:*
M!M1`A0I/=LD&FFB@D26.4L!H@`EP2*&B%%*J<<4+&WII93,J6-D!BBE0I2*?
M2**(0T4@6ZE!!E?86"*))&(HXXT<B#"B"U(BB:&&,JY`QI$(7IB#%"QNV:>8
M+QK`@0A7R)&F"RQ:<2$")M+!0G0BL(@%%B1PX((+6:0@8HHII/BB&T?XZ2??
MB*8D^2'="LP1K6":H<F>I@2.42-ZUHG)/N;1#')`R2%(.X<XR&$,<J0C*-8P
MA\^*8HYP-`,3RO_`FET`B#%R:&0D-.O?P(:V(ZW1Y49J0V$*G<8/`SZDA6K[
M&%)F4A'>4*1J'LM(/^9!I(5<Y6()@=A.\(6O'.4#+?IH1C_.QC,>)8B)3,D'
M-XB1BR?T16Y52$45;J`&6RCB!C?(`S6ZD`==F,(&>[!%'/9P"E*0`AO3\`,H
MXN"%5.2A!I?#`Q6Z$0D7]*`*O&`$#\C@B4YX9@Q0N,$=]`$'&E#AB5#4!RD@
MD`-8Q"$'3S""%#Z1@QK8H!1Q<$(W>.""):A"'Y%H`!FT\0HPY.)?NWA!`[:@
MCW(D8PZ.(,<G(M`$?9"#"C8@`BO"(81=;($(.>A")]K%!2ETHAR1<$?_3")B
MI(04K2@O,@?^G')"^44)'^$(1Y<X<@\#6F,<^*B'D_ZG#V<(8QO6>,>*SA$.
M>2CC'"TZASSFX:"#.2U&,WR*^W92KZB`D"TJ1&A"D;*/5X%M*/3@)D`3Y@YG
M",U,1/3(01[&$7,8"8<U.1%4Z'&-<)"#'#"*&D&+DLXQ-8Q)!H4(AKA)%`,I
MA8G<@`6<XC:Z*.2A"$E0`S%.884?Z,`3U9A#-)PPAO%)00^P@,<VXD$/:VS#
M$T_@01UWL(M/F((51OA!#VS!BRW8[11<2$(41@>$/$2RD2_TD2E<4(-=P&$)
M.C""$?;P`Q[8``:?(`43F)"$V.4"E2]H`BS`_T"*8#`B!TWP!`4&<8M;4`$4
MH-C6%NCAB1I(80E<>$4IX)`#+BRK$TM0@A&4T(EUO&)`'GWB5I0QTXK@"R%I
M(^A;!-(/9YPCFEI3Z3Y@0K3_U6,=R`B&+Z39$`H6PR3KN,?)Q@'`=>B(@LIX
MQCAVZ)%RF(.A\_1.1I+D%6MF-*(Y@ZE"U9LS@08E83R:"$?L\2_:!LQL^&JH
M1%`4DA.%HX<;K`J^FO&,<%QM+0Q!4,&B0A&N#*0A8M()53BJ-)7^Z$4/60<U
M7&&$N%$!"D9EQ0V\T(HYQ,((/(A"+W;1"AC<X!.=N(,C=+&.<N0C'\QP1WS>
M\`D@O.`4MH"&&7C@`_\ZF*(45.C!*+X0-RA480I/H,,B7["'FZUB6]"`0P]D
M=ZLJN(("/8A#(O+`V1K`@!'=V-81:&&$5=`C&6ZHAC[(U8YD["`.<1@>*9J!
M`Q<8P0NG:$,LQ"`#,("!"[AKUQ04T0Y'+"U"43&'5HQTI'K<@Q_V/(>`_B47
M*N&P(BG]$#[.T0QZF#0<\X"KC;?1#(B9Z&HPV:!#.%0,8#1#'@TARXE>)>IE
M*,.Y^P2*3CBBLH25=[W'1C;.TC908Y.0*LV.$972A*\CZF,=(C$)!3<=E(%]
MA+KK*'!UKU239J#EV31\L)IR=!66T07:#+%&,$A5ABK(R0VCB`,-R-`*2:S_
MP@I`($PW0$$#&^1!%J>H,2GLH(]MM$$:Y8#&*#XQ`QJHX1Z+D`$4F*`+1<1B
M"C3(`RF*L)@G5,&I\5A$#[H@P1XMI!4ZR`$TW+"$)SR!"$E@`C3"8`11-($5
M7:#!$KH`CF_LH`%44*8B!C$.JJGL'IN0PQ3,`+D&Y.*4;QM"+K[`BBL081:E
MB)T4E.`%)20"'99X8<&6#9%NX\B[&UDN3^8R4V446"QHB5`VFR$3B:WC&<\X
MQY,:4H]WZ$^_S:B[?QL"ZWWB@Q_D`.<Z5`="B2Z-9H]T2GJ3O?FZL%"(3/2H
MSI#B79K,9&".+Q$]AK3$<#BC&>&`RCQ&@C2I^"_3_TM;!S?>\8Y[T,,=&6'Z
MME$(%H@"Q?%/6=LP2,$%+U"ABK)P`Q5V\`17M((*/QC#%+K`C3C,H`:G``4J
ML.$,+=3`Y#J(!#=(\092U(`&0`"'$XA0!BG$P1':,`(-GI"'5##!+R57`WMH
M!3[@@]^#E5;P@CN(!C#(`1QH%R.@`T6`@2D`A5*8`QS@@:R+A&I@)$\X@B?8
M`E!`AG3""'90!3B8@B'``Q[8`750A6SH@AS8@BY@A55@!"-H`E)`@BE0`BF0
M@BT`@VVX!+4(FH&"J#3AB"2\(1=*PJ[QFHM*0M=+B!DQ!VOH((C0"&50AG*@
ML7*H!S1I!F"SMGUP&&<PA_]X>+!Q$(<"L[9P$(9G^"!]0)$"(D-G<#WM2B=R
M*(>$63NFB)J;P3S.$\2E"**=B!\MV8TEC(A[F,*S,;Z2\05A:(='TR^3:*%Y
M.`=@\`=^&#<?BJ!UV`9F()L!Z8@<V0=[*+VPD8ISB#`G(9"I$)-HVQ]RX(9E
M:(4GT`/&*(4WT`$>``->,`)P$`4=T($W^`9]:(U>8(=&<(5XH(@_>($@X`6&
M^)-=8`4:^(%T&(<XZ$$\:`<L.+)>S`-0>`,R*(,[J()[<`25,SP?60A)<@%8
M^`*:DX(I,()44`0>0#]2T($:@(!N>(4AL`5JT($=Z`0]\`%A8018@(5;`(4_
M&`+_+@@%XFB%=/B#+R@'<SD"4W"$*9!!;;@"'U0"'OR":6B$HN"?B!"+-:&'
M`@.3='H'M]@GEAN*>AB'$#&G%BF'>YB'<-BV)RDU3*@$>@(+_"*'=RB'I(00
M`(J1<R`1&@N&8<`??:JTNY"(>3`I<!L'FGR(/ER*XAO$L!3+&(F[%((KE5P(
MS).*'6(H<R`'DJ&'=/+"AIB'8@@&"'K"3%LN!R&'NEL'>9`@&O&8E9@GM!B:
M0S0:E#00S#N1W;"&86`%*;B#*6B,4:B!.T`"1C@%5^"")[@#)A`%?8B#(&`"
M6\B%4VB%8W";R:`"9JB%4T`%UJ`!'X@':M@",W`7F8,3_RC(`4^0A2J(@CN0
M@C<H!T8(`BD(Q*18"$=P@1R8!M@X`ER1`E:``!M(@GKHG#>PA610A"9(`EC8
MA0:`@%!P@RV8!5:`!DN`!58``T58LPB`@W10IO0AA?/A@GOH!".(@5#``R7@
M@B-@IB_(!O_0B)T@)YXI&=7!0G+8AG<P0)Z@"HO9!B\L!VNX-GTPH+8XB7$@
MAQ.A/3GL4`#:(12QN\'+F&7@AI>0O'5@A]Z;A]TCAV?PA6`HAI;PB;NX!G'X
M2]E#)[FKL)[8B2^\&<T;RR+M)9XQKB$5OHA0FH,:"WFP!FLHAF9H$384-0R1
MF')HAFU(B&W0PX=`D;_4)XE8/?]9PU!Z<`9@<(9YJ"ZUN-"C"#T?=1#!FZ9W
MFR9OP`978((F`\Z_Z8(:\(19`(.?>P(=J()CB`6"XX,YR`-H"`=&T`)Z@(4F
ML(7GO(-1F($74`-DZ`(=L`,O@`,W4)_!&2,JD`(OJ`(N>`-[6`4:>`,B'0K]
M484&@(%D``/4$KM.V(4FL$Y6H(!X[)LKP(/VM$5:Q8,C"`/=\84K\`,DZ(0G
MB(`X4#\\,`,O``-BT`4NB(%5^`(92().@),?5`(PZ(1(:`5[>,EC$`8A*H=;
M.X=GN+6@6(9,8`:(>`=K*(>8)`<.-3"&&`=N\+UR2))AV`;_489W(+QK<"!]
MN(9@Z*W__**E<+`&>K@'>Z"';9C0L!D'9\`&;#"9=2!!:R.+$BE,V<LG`M$(
MD,@:60P*:ZJ)K1FH^C+2F:V+<>")$H%0"#VA4K,FK^S*CB!#E_`2(M2O=XB'
M=[A)%"D\**G8AMDGC8"\CN$[`!*ULL#$:GL(3#P9'W)%M4"+A(!3?7B')<7"
M\H**?%"':H"%69D"+[`"(S@%7B"#-Q`%.,@&(XB"*#@%?8@%(K"!5)@#/'`%
M:A@'91`:9:`'8XB#+DB%''B!MEH%&X`"(^B&.,B#.?B!A12L*AB#-ZB"4;B'
M1'B!*/L1&],'4'`!%X@&4$"M\`$%*9B![YP%%_"$<,"".?@$_S.(@U"(A7V0
M!2+(U//H`268@1F`@!K``3Y8%3@(@]TM!22P!&EH@#CPABV0@B)8!6[T`N8C
M!4=HA1N)IV'0!,-ENQ<)!DW8.Z_A"F6`A%N`"&6X!4WPDF<`AF!PB'5HAG+0
M0Z=\A4LPAGHXAOY=AW=8!F`0!J8S"A,I"6NXI_MM!@OAO70HM>HBAVMX!F%`
M!FN8!G*HM+3ST'E@J;"@FG48VH$"D_8ZBA*BV17VD=LS1#`Q&T0T4,3TIZ@X
MF"2DX0>1BG(XAX4!$7*2&*2]!XFI!W+`A(D=O#FE/5WK4+S`!RFE()>8TX,P
MJ'HY,$=TFH)!$RWA2BW)AW&`AE60`O\R,#G*+(4NF()4:`57^((XF8-OT(5P
M0((RR`,FN`-/^-Z%\`YFD",F&-8*X`5F$`=%,`(H@(-8^(10L`++,0(J`,X[
M>`,Z*(>.]`1.<\?370(HB`;8V((ED`)OB`,7F(-5$((]@(5'V(,X2.104`56
M@(5U4(<YH(`7B*5D"8(>H`)N6(=5<(7+`H5.8`3^[*(N4`06RX%=*`7S`0,O
M2(166(4$P8=W6(A[A8HKB;1*\SUA4X:AQ1=W`,-M8`APZQ@3.0F0I3&0909-
MP`:36H9B8`=:N@5@R(0:C>88*5S\F5,>AI)Z$`9?>`:*%:YI$(9IB)!U*(9E
M:`>J2E^UF)'_@Z"'IC%34;-90RQ+CW"*Y&3AC`:*=8J(>E#0%)(9F@@)G/@)
M/9Z1EW@))1&)I!2)=*@'=E@'9A#%L#F9AW!#FP6+$GE*=BN1'L70C+@'`3H'
MJ2$ON3BA>WB1&X'5KN0T=(@&4MB",O`"RJR"7.@"%W`#4[@$(`"".&"T46"'
M1Z""4<"#*K`"5(@,;FB'G#(Y.I`%/'@#?;"%51`&1:@"(R"&50`%&[`";>B"
MOAB#*J""`,R%/0`%.TV*59@",1B'+\`5*'@%1W@",(@$.&C.A20%3P`#/""D
M3B"%5[@%>^B&71`%4<`#4D@&=J"'9H@%5@@%4)@%3^C>3F"%6?@#_PHH@EQH
M@O;\A2/HP2-0A'(80C"%/4MFB+/DNS0QKJ)!)TRTT!:BEW-PAI`QAWF0A[B4
M:6'H!@Q%D\)]!6:(L'00AF#80PQMF'M"!DLPAF$0!^TJRA-A4QX-"W=(!VM8
MB"L9+QAA*`B]XJ3PV4[3Z/624IIQAF`HX46TAE<H;X=H!U]`!H@XAV5HX)JX
M/*&@AFL@&G$H2J`06($X$H+YB+A#:@>9AXRY!68`V7<XB04GAV*0/(>0/8;P
M+GP($2HM"NX^KBW$9J2VMK?$$`'"ER_\497$F7G(A\=TA2KP`K@FCS9HEP*D
M@BB0`DF@!SDH@U'X1A=`A5$P`CX0!3X@!?]C<(-/L()/"+$;6"4U<(-U`(4C
M*`UUB`0>.(.0*P,R?@//7`<YL`$J6.J<?80&D`%8"`/4:H)M@(`JZ(10.!4>
MR`%6*`<P4`(SP(,X8(56@`5PT(5R>(9&6`A@B(5ZN,MBR&Q%4`0Y`@-8R`:Q
MXX(P\(1/H(482`16Z"PC>(1C\(6NG.BXD*`UJ>Z=8%-T@E@:HSV@?&=^^CME
MP!#3:XERP(1B&`9,J`8MY8=WL`E\96`5$>^-*09LB(170(:;)(MM((MQB%<$
M:Q$346YJ$`:>X8=R0(B8ZF*@V9\UZ?,`WXUZ4(FA4`9,D%I?;X5&P`:($`9+
M>`6("`<#AI)Q.&#_(&V(9K@%<!X'3+CU?5`&7[`&!ED:+1QR;XJF+?8(DZ`G
M<E@&`V>&<0!MD+V':SB&K920N/0A$WE8U3$N:Q@BEQ:)=SA*#.'Q.:WHA<)H
MI7`':E"^6<$#3-$&5X`"&P"%5["!*OB&;F`%//B$48"&;$@"&DB%3AB%/.`#
M7C`&43@%13@%Y7`%;P"%T7`%;OB&OZZ&2("`'J"#M86"!*R"-W@'4N@!-Y!9
MI5`%&$@":-B"&8B#Z&&S+F"/!IB")<@Z5]CL/``#3^`>?1"&6!B"'/`"15""
M)7`$7)#\+U"$3O`$T?`$:T@$&S"#^7N".`"%)FB"7?`$"'@"4*B$5@#3_Q=Z
M5W(HPHAP!E\X<*#9+GTHX/P"B3G5AWE@AF*PV?\1&8G(MORMAV8`AE=(B4D(
M!$@H!DH0AOZU!&$XAF)0URA]A5>PA%4PAN*6B+$E"ZSY:;(\!RO<"6M8ABLT
M0O?I^8RH=WO'?[5()Y6$AH*'B'(`B&7Z!A(<>.[<0'/DZ!5D6%#?N&#I])43
M%FZ@,VH,\SE\J.\<LG$>"9H;1V]?1X('Y:TS5V]?PV+%E@G3Q(Q<N70.]^U;
M%N[<NGOWUNDSAT_A/7KDT*VKI^]=4'SERA'5AX\@OG/CRHTLF*_KP)1@QXY$
M%XT5GDYXO,1Q187,%'98:$B#A><3J5)Q/(T;9_^$!P\:-&ZD>D*C!Q0U-J)9
M8[4W52E(R5PUH)*LR1X[KKY`N;,6SSU&/#J1+>WQZRH8.)(-@4)J51(OVXB!
MV>'#BQ<D>-"!ZA0G#IY5OH1UD3*E3)(D>*YPN6(,%QA&H11]*M7/E9$N>(PD
M>4-*&IPPCVY)H:4HTBN"^[@^G&;,VCFQ!-<A\T7.X[RK5JT%([KO*C[KS&.5
M/O0<(\P[0YF#U7_FM$-0/,7@HDDUY=!S#C"7"+(&)*]X8PTRKP@SS3$BPO**
M->V0,TTY^NFS#D_DR#.2/-:$X^)`7UUC33GQ@86/?O=\5)5'^,AG&DRF*;DD
MDTTZ^:23/.%(4#DBZ?/_E5=78MG0E$P*.9(]#QDY9H[YF#D0/LZ,\]]([<PS
M3TLX<K3...0L@XPEFI!#SCK6C&,-0U42J8\\S83SI53>)$-,-P)2M`X]?9KT
MT#WS,$3/D:9E"F4[U)#RA6]@N`)-#C2T<HL=IR3#2"FEM`)*'K+PTLTYBM0P
M@V`TV"`8#UQ0LPXLIRCBR"FGE&)*-6]\THVM-+CB2!1VX`%&'OO$(<,;6T+Y
MT%>@--#`+G,D,0L8,>00QSJLY%7#$5T0$4<NV<#B21WIQ`+#&$\H(44.21AA
MA!1X0!"+-9A]HLTNKR`A!1A*>%'*)\F4(@4,1.CBR1".3+,*0?3@*&0]YP`Z
M_])1^LR#T$/K3*E?4VRF3(Y3!:F\CSE)ZF.//>L$(TR8^+SC#3O*-`*)):^\
M,LPU^B1SRRN74#.?BL?$C%4XX=A<4#O6D+-@05GI@Q*F6`;X$,TP<CT2RMMZ
MJ3;;;;O]=6GFB#,UVM*4\V5!(P]T#SOZG=15EP0EA3>:A%N53SWT?'4D2FIV
M51*,=`\D)57T?&G.)HU0HDDQM]RRS3WOE,,,Z?FY0P\US(PSS3#87/.G-<O@
M(]1\7,^C+9IOLTW.65[L0447N8B"AV446%$*+Z:$,DJQKKABBRWCY$,-*'`\
M(44577P!35*SI.)**)Z$DE<INLB2Q`[:-#$%+\,T<?]')UWD80\H9<R!.]M?
MJ=+)',0HDI82B("'!N3"#6^0A!2,HP0D(*$+XHC%,I8!"@I000J>B,,1I$`%
M5KB!"T-0Q#6DP0AIN*()8E!"%8P0!2?X`@35R`$>N%`%1G@"#*VP!L<*%#B3
M#6@D].@AR;J2)!SA8T9"(2)1UD&D>EBC)?'HV#*8DA!(0$(8WGA%*Z*QC&V0
M`QFRZY@UBG$VDEQD2OLXQSSX`107K6-&`^%',U"&*3$!Q6I=V=0.MY5'W?&Q
MCS>STEC&L0ICC,4<NL`%>PJRD(&L8QBW2&17^I2I.19D',I(Y.)<M`]W>(0?
M<.)'),<Q1H*D$5,X,@=0SH'_"4@LHQS;>(<P+J$):J2C'*_(!"XNP3IK6,,8
MW"#'.\+2E"+J`V_TX(<I^;C'L6S)3.3HAEON((5=F(("ME#7$Z*0A#S``Q:C
M$$6K7'$*7FQ#&=-0VC<&<HQXE",8U)@%*F3Q"4]X`A2J^,;$RO"$7KBB%#NP
MA2EXL(<[S`\45?#$IIYDID.L@A',Z(01OC`%'$P!!*9P12NZT8H&)"<)4UA"
M$U:A"!@,`0F[(`4CX)"+7&#!$:SH!!*($`-&O"(11U""$I90!2(XH1S+8`4T
MBB`%(\0@#GJ0@B-@08P"`?(A[T`&,P`W$'F<@XWR,8>AS+&.:S`D2>N(3SI4
MIAZ6_XB)1^^PQS800@]F@$Y([R@&H&R9Q5@D(RS*"`?=YB$,9WA,3"'#D1*M
M<HZ%"&D>AR((1\YACL5VQ49.DEQ#%.K'R5(V=V0QAT7&\HY^,".8#S&'0^IQ
MH)@%#A\[8M(XA&&-8B;.(S7#RMDF(J9[F&.U(RD&7ST2CMBA[!S;J$0F7I&,
M;G01&<GHY2NF,;>PH".L]6`C48R$%7[HYVI?NTI"E?D0=+S3"$^0136Z4(4X
M+`)[0-B##TYAC$[LP1.=^`0M\I`.>^#S#G&01BNH0`=P"(@1>2A%)SQ1"D_,
MHAM)^$07O-`%3S@">\QXPP^L0`=S)((&7;!N_O21B`C@8/\:6U""$=("AB7P
M8`DQZ`(T7+&#*DS!NS;0@0N*((U=;,82VK`I-$`!AFBT`CL00$(-EL`%,92A
M!J#`1BR*``8B&*$):@$#%\RP"DO`0A^+]`@]FG&,;7AD'Z`<B#4RT8PW-G5R
MPGC%F,,AC*@:Y!GW<,<TEN'9?33#C5A1AC5FMXQ7`(,?Q=@(16ZQ('HX8QO'
M",8QWL$,E-VC+V+]VC+:8347`0D?^YC'<QFIGZ.0XRHP<VTYG`'$@JS'TEW:
M81XQC*3*LKK53ZHN[D!;S"OA`TO[,!R:[&P:<Y2C'ML89<?0=#64-&0?\L@*
MANO1#&44Z:[[F)H]R.$Y9B2#&=3_,`8Q<!&->@0V'PG2![?K`15-XH/;(^&(
MF"XUR<KFXQK&8$0GI!`-4MQA%-^(!1AZ\`0ZO.$.X,AQ'CPQBE(PXAW?<(/O
M]G`%+]QA"FJ0ACT2(>!0A#,=<)B"&89:!>%XP@ZK2,8./K$'?:S"!G'`G]J^
M$HH9$,$;C``Q%XA0BEWTP`P4F`(%H)&+/.#`"#K(@12R08I7@*(+5SC"$#RQ
MBB.`(0SG<04KNG&$&CQA"3GH!"G$X0<Q&$$12_"$*[BPA;&#@12MB$5?P$(G
M#%]H/LIPR%74'`P"Z>P9,*F',\8\D''TL!S-@,D\]*:>9=Q'2-MX!2:^:";,
M$N4>PKB%_S*:88_'C^,8R'!*H\=1U<E%%TYHXEH1P_$@5!)H;Q_1=4'"T0SY
MX`T?_,#U2)#)1Y2[NO;*7`?M3_,0^>0>*V`9=9#>`>R.36KW6/D;N)VBGWH<
MV_.:;$839RVD<12#*XH>AC"2L0VM4<.S1JJ3X.A1CUX7FTFN1WX0T[\M;$1C
M%4KX1#2DH!Q>+",7>J%"'NRPWV_PHA2RB`,W2((;4,$;5($T1<$;X$$4W`$C
M?(.Q7-0N5(,E@`$8[`'_E((QS`,<0`$7Z((C3($4Z`,HV$`I7,G;?,4^_`$,
M2`$\?$%.@2`8K$(1$$$.0`$/E`$.D((7&`'6,<(?$($-*($,Y/^`"\!`%\"!
M3.5`Q<@4*ZP"+;@!$QA!*S@!'+S!$DA!`&'4$$@!%W#!%,#"-+R"[)&%JIF@
M[RD#(%S`"%P`)SQ;4TQ.Q^R#HWB%/(3#H%S%0>3(0$S#GPW$^"4#5Q`:-T#"
MW`U$.0S#-'!#-=!#,/655EF%&[71@VR>'YK#3Z@:9MW.2*#$.`P*W(3%U6P$
M[FP**?Z([9UBDUQ([^D#-KQ"-9@AEM5)E]C,.Q##,ES*UK2)'17)132$<4$6
MFIR#,GQ9EU5:05"B8;7#?^!(?M"#-=@,MY'#E[@#,U0#-R0#9X6%,'`9FI3#
M?12$-QJ.I8W$<XF%D7"2$'5%/I2ADKC_6RO@02F00ADP'!5P@PB4T!T\017L
M8RE(0S0P0NOH(UO$`1-T@7+,0160P1-\@S2<PBYX@RLD`AA\`FXX037(`3?$
M@1H\P1U<@BU,02JXPQ?@`",L$Y-\13YLP0L403<@P14F4,`D`Q,L01'D`"_<
M`C7$@1F$0A=`@`R4`0Q40<B]07$0P1ET`1T801G(`!3HP!"$02G,P1=4@RGL
MPL7E00RLPBN801=BG!2T`C2TPFO=D6>9'F*AB4,`@@48@D-L@"`42-J$!2B-
MVCTLA!R>DE:Y2#W<`S*PAZ60PT34`SE0P^>8X%?4`S5,`S:@PT*\`W;-@U;=
M2##B`WR4GE6L_\,S>*)57(-T?=:"&$FF6449HI^8T!X[XA$JIJ:F],,>X<,R
M7$)=@84Y&$,X`)O-C$,LK,)]6`,P,-M#U,-N6:8B805@"H,PB%'7?,1@!0YD
M*LY#S,-]R&&G>40]D%XB`:="8-XV!$-GC0,W<`4U<,4]Y,2L0<0W$L0[@(YK
M`5N:'(FLN1H_[$,^6$,TQ((7C`(HZ(`5.($50$,GP$(V<`:+>4$45$$N1`,Q
M/($52,$G[$(K?,$LK`(HP$(<4,$4=`$O@`,O,,+Z3,$80,$;X((T=$$U%$$<
M0,$3,((LZ$$>N$,EN((IF*23>-T?6`,2),<4<($7B,I+$0$4[$LL"/_#%60<
M!-``*71!*=@"*LB!)`S!3"V/+)00&"CA$61<+N""(WR!(@A!)WS!-TA4&."&
MV"E"*ZR"9OHA/$Q#8=;#-4R#RF#)5RA#,#3#!I"`0^0#/SB#+^A#.&B",,P(
MD*`)$#DC,D0707B2?"K%,XC1/3##+8@$C&`*5-2#,6##@N"/.13#*Z`#10S6
MWH0#.?0B08S#,FAF.&0FW>0#RJ`$/V`))5D%.5"7<&+%I,@GJP6J:N:J*9(%
M/7!#F("%4ISI&.I#-"1-@606I006R?C',NK#->B",UR-0@R:#RU#F85%&I79
M5?P'C)C,H-&#YB6(/91#,?@6,'`C/6P1,[#_QW?"83,XPV\R@WPH%I99R&F,
MY9*L8OIA@S3$PAV\01Z4`1Z$@1TPP1PX@2[<`ATHAQ?@`7]R@0LD`2G<@BTL
MP@A)`BNP`AW$PBZ`@1C@0!50017H`8LIAQPL`QR<`AU``1@0X(K:`2-T@R24
MPBGTT5<H0AF$03OXP5`U`1[\;!ZP0C5`&;],`2F8`1%LP2ZH02X,`T]N01)H
M@R>00C4TP1?,P2I4PS)P02IXP1&0:1@LP1(`SS?D0B),`1BL!1<H070D%5B4
M0SPLPS"(Q#V<JCGH6D\$`PD4`DR4VS@.Q#(4C3/@2%_YX3(\0U8`"+$5R#U@
M2#&$B:.^`M_I@UGI_P,6#4CN7<,K($.!-`/=#D0PP.N6F(,R>.)+?`2^7D/,
MT,-[,E9#>$RF\`,DY8^,ZJKMFH:VX(Z^AH7@Z.&V5-6CF>![=N9`C)I5L.ZE
M[MXEE6=8G$,]3$V`N%XZ8-=X_MKH"`.<'FLYB$Y"C"7-&`G>N(-)7$WBNE9<
MLDWM9@E]VD(9W`$5E$$GV"<95$$4[($MM,(<Y$$.M&\1=($KZ`*PE((H?!,C
MG,(HZ,$IV$(ZY`(HO$$.W$$5_``>=`$LE$,G*`$9\`!;A`(>Q,$=[`$C<(-A
MY`'MG*`^^$$#Y$`YN.#:FD$-_>R%Q@$.R$`-)`$,[``CN`(L*$(>Q$$GX/\&
MUH&"(ES!%Q1Q^)`"-)#"#N"`&1C!$#2!#RN"&4!9)X!"&"C!%GS!(+6".G+-
MU,@>,7X%)7"`-23.A:2$8&8-:;[6WZQ#(_(NFHC#.I"#.#C$.B3#,3#$.1S#
MZ8P#-@"C1\B#,1@#3"@#,KCJ*W##7OHA0FC%\J$,/L310(0#,6H:\S:$,J!<
M'F4*\::;.MXN*(?%\)5)43!#XUG;2*1#/9S)Z^:(*+FJ1PC)JWZ6,,!$)=<#
M,[B#/?A(9(7%I*BJ4]%#CXQ$,)QO;;F)(6[-4!S#ZF$8S9A#6,'#1UQ%IG5R
M@<SRU^`/S<!A<KI:,#%#,52#%+"%-!'#'*`H%?#_0`^W@B14@16\@?_M0A.\
M`0]$@15$@0^X0A?\@#[N&Q6XPBZ$@AE,`1-\@BL<J0\\P8=F$1>4P1L4:![$
M@Q?,P!Q<LMN`P0PD03+@@`U<81(0@1041P9UP0Z<P@X8P2E\PQL4P1:HA8X:
M)!<,%!50`1A\01:_`1AL01QD0RP<@0U\`A/'W!%L07%0@1=P@10,02M,@R-\
M8D.<;\>D1#!8`+S>A#NXR%?0R3WH!RL[15]]25)@,TY<C35X5CT40R.>0"$L
M"3R\`B[``V5BFE>SU1M2KJ>)U7HT1#-L#>H![O`=4^%VLP\!#B>'LF%WA>K!
M7D$XPRL<@SZX@R58@GP<_X,Q_&I!\(.5K(-;QPP_5+(A'EI?)0D<U19$O`*S
MY4,X#+(;;V+QQJ>0G!'Q;</X,41UX8,E<;,SIDTX`$."'$@P*(ZJT5D3;2^?
M?(13M,A#?!GATG9R2Q7)C&;ZY@APBH,I-$$9Y`$=Y(%!1T(1?((.B((CW$(N
MQ`$ID$(>6$$*Z<$3W$`<&,$8U"\37,\3[$$/5`$>@$(J>(+_.@(<@`(/?,(3
M_+,KW,&_TL$8D((]Y$$/B(+-Z@,<S$`3,(,I(,\<=,%$2D$>[*!O\($TQ($-
MY$#_4J0.=$*\8<\4/,$45($4=$(H'$$<A,(7S*`2M(4I_.P1<`$>M/0=;,$<
MP/_!=$P#,G",,_9A0B"$.>36?$#%,&09!RA#@C1#(M%#)C#$-@A#Z@`?)<*$
M-X;#M1:W>B##-4!#,`&#2`A#(ZR`!T#U:7S)*Q`2/12J/FC"!;``!XP#/Q#%
M.0Q1452GM(8#D3]$+F)95Q4?'#,).QXVHG^6FNLA/H0#G-M#,D3#2'`#-4`6
MG0T$.>#"-+BJ?+R5WI&22NQ#.&#"W-$#,!B#,&2*8EEV\U[)&>^=0YS,WKE(
M?GR1:$8J,P2#;9'%-2"#4#RBR13(U&17QYCD#J%FD\`#-8Q#T>T!'N2!*.P!
M*9"#$QAD'C!"+J1#*\1!*5!!#?RK$?#3+)1"&?R`#XS_0BH82P+=00T4]!R0
M0C)0`S'D9R@X`3BX0AY@M[,_@2GL0QO<0%/OKI)\11>\@`Y0PQ4XS+],@1=P
M(1:&P1&P0A<PP2(@$!7X\!/\QH<]`1>`00*%`8F/LWY3P1PT@1M(J`\/P1:$
MP8I[P14X0B2(%#)80WI8PR58PCD9Q((T0S$T53PTJFEO0##T0R;PR#$N@#/4
M0R8XTB5825;?!S^00'P\GC``7^#9C#D\PS)DVRLP0S]`!"YTP"8$PI((13YL
MPAH4`B%1@@=0@CZ0`-DK1)XW!#ED@O'J0S,T0Y<81<D4Q'L6!22/\K"*2:(7
MON[<0SY\R2@*"?Z,F3-8``9@_\`*N,-7%(('Z$,P;,`%6(`#!$(A)(`':'XS
MD,`&>``)K!8_A,.@L\,\V`/^8+;-T,,_D``FC,,_C(#;ZP,PA`"75<):4X(@
MT$,P!((@J,`D\$.H^@,*3,(\%((@A,,R0((F8#XB8`)94(,P#,1>"VK7+,@H
M;^*1_&V7O1I86,,TT)L9Y+LBT&\H1,,N2`$=,$$5V((KT`+\5`\X7%0IW($H
MP((7D`)`Y(J3BE<L;7"HO`$3!Y8N*DGV/,FUZ],1+W@^X<GC!8X^4E5`Z1,Y
MDF1)DR=%[DNT!T^X(T2X&)$BA4LH,$FFA(G1!8<41ZXZT8FSL5.G.%NZ>,+#
MQ4PG//]>MG@"(X44,T=FCL3!`0:,$BI@MC2APH@1&"*KML'2=\^:-9+FS.GC
M1PX?27KUUCGCD$G?,V'\2BI+,.X=N7?-@M652X_>.7TI&*Q[=XM:/9+U]NF+
M*](<O77KQFEBMBT=O6'!+.Q%.7(?HD+T1"+BL&$!I$L8^KFC1X*3OKK!@(E4
MK`^8,M@DS^UC3'+?N)&=1X[#YXX2['WFZ@XGF<_9<9/>369>/9Y\>?/GT:=?
MC0_\\W(E\^G+MUE^O7SQ2\;=I$"9,`X?1+I``'_X468$#IBA1@)`S@E&DW,6
MH`28%!*@KQS'?&M/)'XVRPP80,:Q(!`+_-EL$@`HT8>!$?3_(2$`9YJQ`$89
M&^L`F!$006$2&0U@<8-,.%"&O'&:P><>PH0[Q[*1\.FN)'JT$VD>]M2KLCQJ
MILG%BRF\B`,//.ZX(X]33BFE"AZ^>D*'7=3!Y91>2@$##RILL867.2[R1)9=
M;.FFE1RFF(,*)O;0HQ1;2'$J#D_R>"H/1LY1Q`Y2K"0OGR^2,*(<1Y;(E"LY
M.P%%$3RF2$('*G)P891N;F$%%#`4^6.+5$HIQ9,FRI#BC5%(8>4;4&(8X@LB
M=/`BCT\^\8*KC+X(`PPS5%GF%936T7!#V#9`1!_I1%K2LDE2T*>>>NX9B1Y_
M8*L+DQ9(F(><=?0I321Z-ALN,W/N__F,GG+*8<::>A;@0+S5QC%DA$+T&>&#
M=_198P,,FI$/PHCG#<XW?/+91QE^SH%.GWV"F>?C?42>E[EQR-'G''SXV<2[
M(^E[\N.3K/TXRDIQSEGGU<RYYAJ3\"$2/Y*FL:0;D[B!A1G?NHEFGJ%'XC"3
M#=)Y)Y@+]*&$A$TX$*F00/0AAY!`_,'$F7T4Z$<D`R;1;+EUN+&O7)/>*RF0
M%`S98(1)^CF'$@52R,2"0LQ1P1`4S%&`A']2:$:99N8)A@02VO;@'$-6X,>#
MQS`I+Q@ACYP;GW4&#CMFW\HY75P,2\*'KI/.<6YG^?39YAA/I!C#"SV>>DJ*
M+CYQ@HHXGO^XPY17&)E#J3PZ">43,5'QY`T]\HBCE$<]<024-_8`H]0J*IIB
MHSSN>...,:KPI)XM:/"$]MGQVZ*!)ZAI@H<EIN@$#"](<04:)'2``QV(`A>@
MZ$08NH"$:+PB%J"(0Q=D@84OV,(-;BA%+J#ABBL\X@]EV(,NX+"$)82A">W8
M11S`X)1.=&$+7'#$,"R!NI6-Y!SPNDY)G*&/0FP@;)F1ATDNT#E]\&LDAK``
M/O;1G`T``F''*4=F1E>7><0E._E:!SL84XYM'.(=XUA`#LUCH!600!_OH$<*
M!+"-8"Q#'YNX`#_HD9EPD&`$>Z,A8.C1C,V88Q_Q84]G\$'%F:G_S!G%0,DX
MSF$MQ<21)#=CTNP@N1Z;?2P?V?%-?*"6,WI8HVXE(=))K-$*;)1D'P6<ECD8
MZ`V:*2,3'GA%(_RQN1*,(!,!\(<^&(>/5A1C!!NX`-@4X`PD8@!A&-K',H11
MCG?80SC(&4E\`$%&=$GN'QL(Q.0N4`A#&,(#*%#`U`R$B&`HH!##8,$\4H"(
M<;`($R/@!]8"(<3QT$,8VQ`7Z9XS-]^PCDDS+,GK3!(.P)C$'&`$FGKB,XYH
MM$(2KF!$$[Z$ARKT;A36FX,:^.`)+W0A%'E0@R="808UO*%Z4GA"'O+`!8S$
MP0FFT$45NE`**IAB#UZHPA0>F(2$>,$*_Y+0!QAL,(I(OF\+,Z!"-X8P!2YX
M@0M2>(0ZFD`$0+D"%^,@Q1?BH(0&+`$/$#A%(F;!"C`8`0=Q8`4KBA(#/1"A
M`4K`PQ>,`0U6Y,$)0P"#'+(1!R^X@1&.^,(18+%`?<P#$YM@W3D<<PUCC-)<
MS;A`/S;S#&"$8V;F:(8",$0/>\8%!2001G`"@0)G^.(MZ_B7</R2LGD@HQC%
M(,<QA'&+<2Q#&>7(P`(ZQ\CQG$,`9,P'PSP@B&9L`QDMJ@X^SM%+1$PB&"-`
M`6P0$8#<GJ,?F>`CE68VB:Z-)!,J"-HSR.:;D=RC+E`BR3W`8]X,27*H[;52
MZ:R$CY)]9[XDF?\'-_0YDG[!*VS1N$8F?=.,3%R`&N28Q`::D0`5_,,"*]"'
M"@"1#V:L04@;4@!E$]>YX5`#&??(ASWH]23+0"D3#$A!(``Q@B!^[!`K0,0%
M)D0"9^0#!2O@`&,L8(A\0&B)E-@`"0"A#TR0<06%&('LR*/%<;W+DN)MYDGP
MHAUZY'<DZS!2>&I6I?@L8Q@-W(5,OZ0'*8`)>`.Q!17"P@1/C*(*51C%)][P
MABB800IE*$,>4C'F5-P!"CIX@A>DP0I&N*(+A7K"*?+09EX0HQ7)V`<8>L"(
MH6*2"C.0PC::X`4H2$$)76`$%XA0!C),@117($8<J-")C#PA!S9(PA#_NF`$
M+\R$"TB0`@3*((,EV*`*<2@*'(C1B%T<@2D[`$4HPJ`(1GP!#D?0!C5BX1M-
M3`+)'0N;+RB;$GQ`&#OZH$<P*K&,QL`&$!8823VL00[`D"`8OIB$.2Z@B4P\
M@R3D,,>4NB6,5[!Q'<$PFSZ$40EAA@,?"MB$,,SMR)(`PP+ITD<P,$"/6PBC
M'IO80&,8;@B2Z7`$@)!'(TC`@7]X6Q\HN$`P]`&(X&2&$P"HQ#[J@@@`!((?
MX\B$`;+-)(7#UR[N]?F31=*/36!N-A:XP`9FXX$+C(`$A@@&Q83#<_@]<SL`
M_@Z5-Y2)@'G``<U(@8/=H8P%F..:(K%``CC0_X$5\!@%"0C$/@9:DFW8$V@L
M,T<^QA$,?Z!K[_PHTCB4<8YF[,,9P$AD,:RA#)'Y6RZ;*`0G@I&)0@#&LML"
M1(7-4X]VI(,NI,-'7?;!7\5@5[SS@.,C:882<SA'X>F)CS6Z(0J5EN$--OT$
M3;C@"2I$00U6\$0VK`&'/.B!$8WZ1">L<`=:F*$,=LA(')R'ATYH`QIQD,(H
MJ,`2+SQAS#-Y`A6Z(`5&X&,++J!4>_/A!1=L81U_D`(4E!`#4^S""'FP-0Y(
MD:@I&.$)G8A$-9P@#HR`!W*`"&(@%+3""$SE":``"W:!$10A#(B`"6+A"T!!
M#(@`"4!M%E9!"<"BJ?]6X19B:,=.IV3@*Q@20+<X8UN6(3,,@(Q$XAV$@1X*
M00$2H)H,P1\X`!'\0"3B@QZ6X8=(0ABHX?-4QAI@8QR,81TJ81P^(,CTP0+:
M9CPR`P4,89`&9QS*X16H00$P81_"00%2Y!G"81\,X`K[80/((06$"!,4P-_\
MX0+FAA,2H',$"A$,0(BTKFT(;B3JBSE6(^[0`V-^SCSH`1,`H0,2(`%(``7^
M@1(JP1^$0>\FH1",;`,20`%^"5W>1SU&AUKXJ<JP@9FL3B36@1S$P5JX(Q,,
MH0D?#AC0*VOTCB_T01FVR1`F81Y\P1"R8!,^AC$48US681N6)#^<H=MZCA[_
MSD8X4D9EXH(>9,<<ZF$<UF''C*%)4,[)*J4>CB$=VJ$NK`Q#D.@3YR4NZB&S
MLHPU4"+$(LD;LB$9]&I71.%84.@1>@%WF(`*JJ`'?F`7?&$51,&`\"`4ND`4
M9L$5W"`/6*(4YD`26H$5YD`*]"H'>.`.4J$)@`=,RB</S$</X*$4]N`4)DT^
MPJ`,P``9D$`)CL`,S"`4C@`&O*`&RD`5ID$+S*#5J@`&D,`37($=="$/RL`3
M0.$1'&@.0,$3<B$95H$5##`FBB`40*$<$D$1EJ`3B.`16H$+N``,M)(4K$$M
M5`\E4`!L3D(9Z.T?`"`3D(@>CL&0@*$#+L`7<LCD_S@`ZLHA',I0O.3ANKHE
MB?)E&MIA'7S!FF9&&=*&/,[!`IPC/ISA`HYC'PH!`T1B<N1K'IZA`U@D83+!
M&1+`,8#!`&Y)&?*P+\[.'"AK'BZ``2@&-0P`0^!BL%2GO%`"9`31/*2N$$DB
M&/XA$_=&;="C8$9@$0L!C)((/>I!&82PD:RA!4N"'X!A%:!AGEZA%<(A'3+/
M&C+A&+9E&H`!R4YB'YY!&>"E&7S!+33F&)8&GQJI'=S"))I!21I)'@1OH$+L
M-<<!&LN!':ZA/:,$YM`C/MYA&^2!8O"!C5)BL(8C7<"CCTYBD=8Q':MD&1AM
M?_"`4<"@"R)!&J!AIZC`$_]4X0Z>H!1.@1&T81<$[0WBH!LD01I:80[R0!22
M4A1XH168(`_XX`NXH`Q"01)X012D1R.^I`OT8`[&X0N@P'U:KTH\#`Q@8`O2
M(0RD``S"0`FDP`CP@!'B`!I@P0R&8-;H;"4A``8>P1&,00L<(194X1%F`59^
MX1&T(`)@@`M&:`N@8@@Z`1DLX0K`X`B0X`_"H!,4H85B81JFY9#:0QE'0)A*
M8AWB8AZ480,\0!E8YACN@1TLPQ!&+BY(@``LYA?E*QRPP_20"P5"#SOD81^L
MH1W:81/LR)(H8;L:M.1@51\ZH&TR8Q](1&1&X`HUPYO(2#::Y`.<87)(H!FT
M:P/_#($$9DE;S`$34"!;MB4%.B!912(8!.$<GB&1:,8[[0(N(-0NDO3G_&$#
M+("6[")B6,D<7B,8P&82@B,8P",34&`!?L03UZ$86:,=R&%H\&,<-L$M2A$?
M1/`<&.8D,N9]F$$3[*D;,B&92`DVJL4<,@$3XL(:-H&T^DT3G.,^STLVF>/;
M3N<>L*$9JVP>EN0<R,$=Z@$;H.%;S>,^]&$\F]$<^(ECF:1:OD-#K,,DRF4>
M_E!GKB$:(J$H-"(/4J@;XL`,=*!Z3($>-,$/0*$);"`*C`(<RF06XF`'J$`6
M0.$4P,$1&&$*_DS0B.$9OJ`)_,`(3D$6""TJ&$41O"`D_\+@!80JD@[V#R!@
M"\KA"SX!%(2`"+P``F!A$&+A%21P"I1`"88`L*JA&I!@"_IT%7S!#\[*#V;A
M$8Y`A+:`%PKB"I:`"Y1`#(3@$:X!%E;A%X8@#(R@"01-"5QA&`KU).8A,^8&
M,("!`W:,)#A$),ZA`RAA!,SA&2:!\$;`+2@'N?0!`WJ0'^CM=IW!'SY@!.9A
MM(1L`YK#-\1!'N3S%3I`B$9/AQ`&)2[+H,CN8O3!$`!A'Z8%$4A@'"8AFW`)
MZ>3!9Q'!`[1E$QHL<CC`$)2!X?Q@`U"@&<;A63>@$,`36975'^ZA07Y6'W1#
M!<.C)+#.7'"SD42"$A+``%)`._^`(1B2:Q^`H3HRH3GX@A)*A`/,01,TC#,J
M00%R#.C:JS9;1R3<03EJ1LK*(1_(05_Y*S^X165<\QFNHS/&P8_T*;^@IC,8
ME"00Z9^@SATXD1F,(3DA:5_HX1E$QG7LY0_G(12]C5OGQ8N]3774L4JP88&V
MP`Q\#0]H819"80GV(`=<@1B@(1E^0BJ(0`]^H`K>8&N]9`GT0/GHX`U,ZB:[
MA(&6(1VDH1-T(!2^H!I>(0[B@`L6!0Q$\@MRP'V&JH_"``+BX!W^``Q880N&
M@`J:8!T481:P0`.QX@A"`1P$(A+6P2I#00S\8$J/(`P>(0S^@`A:H1U6@71A
M(8V98@O_;#D2KB`:CD!6NL!5P@`:HB$6\/4M.HD>`,,2]:$]-6,X"B&`4^`9
MC.X?2,``@H,#?`$P?,Q#6&17&U&[]F$$4@!M*(%1?6,9XH(2+,`7^L$#LO$Y
M+H",4\Y64:)QTN$5PN$<6&`#_"`8.&0?_DT^22X<3"N+02_O*J&?548?FL&0
M?`$0-D$\6,9:CJ,]C'!>!L9E<3,S&I-MXLX<1N`<,N&6=,N1J`03//BEE\,<
MWC<!;JF"#5$ZL*X]X$YD[J)U&H-D2T(<EF&"O0T\[.$=XD,WY@63>)<?>M@W
M0'4D@L&0TH$9D#J2/(,=VH&\H$A*/JQTM-6^.JF1:L9)O@.@_Y7C._5A&::!
M')XE::E`&N1@"I#`#):`T$A!$I9J%&S!%/P6#Y)@#!YB">8@#I+@"9K@".Y@
M"$"!%78!`0<B$>"@%/)'#*;`%7*!"U3("TZA'A2!""2MO>[A"1J@"W(!`L(`
M%R3PE'T!%&:B"LK`"/):KKZ@%+Z`&(PALJ=@"LI`":;`#)X`?Y``&G*A"SJ!
M$3`(%CAMH\"@5R#Y"'``#HPA%(8@%I*A%;(LVZPM85#NJFG(`OKA&18Q&`IA
M`?QA!!P:`$AK'`[``I))"O6!!?3A1U"`$LQA`RY'`4@K,\@A8MR0M/"AG0)A
M',0C1L1XD,I8.*S#&:;A'.9A',B%&?\V@Q[:P1SX*XG681F,,*[W@1PH2S$:
M?!G4$_2,21##U:>M)#X*P0!4`,DH`6PX<9#&`3`4PX-IAB_^09Y2+@%0`#!N
M$\;-]R20T1WH@QS]4&3X"&B<X:NK3!OE@V'6X8F>0SBL;))41C=*AAR*P3)N
MH1L(T;V.P1ON83/6_%I(SUR\8QVR6&8:5+WHG&9*41^081BNHA,P<A1XH0OP
M(`[&P`INH4[&:@S>X`E$`99C(1$<P0VF``_`P0VDH`JPE!0L@1U(H?:JP`KV
MP!9R(1'R,0^@H!2TH0JZI`O,8!2X`5,4P;WVP0MX``^(00IB8!5F00J`+1&,
M(`<HH`J,8`?_JF$7X$"20Z$3OF`9YB$1NH`'S*`+W@`/O,(4L@;Z0L$3XF`5
MO,$5DNH3<"`)KJ`4T$$1G@`45B$,MD`1HL$8D)&@RN$:%.,<!D,S.KPD+J!M
M#D$`?+%6,?4<2&`#**$?:A4`3L`$%.!\B]P#G.$#Z.$$"J$1"H$$C.D59NL"
MA&$MYF424,"YQDC(*R4\Y2$Z\V$;;L$[Y$&(&\D7J+P=$*MT5D\S?KBIS<4=
MA*,V]R&1:J:&D-Q@AV@V^KD0K*N?7W-8)YY7SX%M>!<0$`'SMH4>@"$-1J(9
MR-7I>[Z1WMTN,F,Y[&M@_$D^A\/T?`.@G*P9**:^^H4;#A0,UZ$=_XHQRFF6
MYL.A'&##&H;!.GT.[XR!'!:X;M;A'O"MYPY4).1AD>QE))@)$)7<8Q7_)/AA
M&HRA%9ZB(Z%@_Q!;U-U`!_8`"NZ`"G1@"7A@#KHA'&(A#UA!&[``%G8A#T@A
M&L"!%)(@"7)@#ZK@">B`"5RA&U3!"*;`!I)OSU#T#CP!'DA!#T32;N\CE+M`
M&I#`"+:@%1IA"$RR*Y2@#'"`%7X!#\`@V>.`%CH!&_AA&;`!"YK`%V"A"<*@
MPO7!$A3A$Q:B*$@!&KH@!W);W<T`%([@"V8!%(9`"59A&@#"5[ER^@H:+$@O
MV#Z#]$@TT\<,F$%\^E"@T-<L!0E]XRR$X__@+$4*918N8"+W2L4)$X1&F`NT
MXIR##9`T3"(QJ6"^<^'JG1-6[][$@N."`3-W,*G2I0;E!=/WC)Y08><.+AM'
ML>`\<NNL+2QXKYX^>N>^ZCO'KR`^>@;G9=7*5M];AN;B*ETW;A[3O7S[+@5F
M8,1"?(:4*>MGT-D_$LKT!=MP[A^@@H)(I"A(:00F"P_I?2VZS5"^A84,&/*+
M.C73<TC?ULLW=ES:I&OU\6MF5A_2I?3LCG6&#[=!V/6F65-:;QU%?!3/G>L]
M=J%L?.7&+6,FM&#NI+!5&WQW[9J^=<4,KKOV-N[;KV*UNYNK%3[3M[6'KIXV
M#9:94J66D'D21S3_JV@CC1A53%%&%6](04HN7^!@Q1RE1,((*=6TXH8HIG3R
M!`5,C!+'%GB\08444[AQCB2NP$+%&$^H,4HHG:"R#A8\E.*=7_F,=@4,6QS3
MA!=$?,'*$'B``DL38A#A1C>LX!%')XJ`\DDIL(0C$3G/X#./,?*<\XHPK+"2
M2B=?D/)()[/L\H048/S!RBA@Q`#+(T7@040KW,""SW%*W;,--P?M0\(M9Y6C
MESSZ4/(!1<($((P^FY"`#PH<^)'./,H\9!LY^F#B!V*(8*)/)IOHDYQ'X9QE
MSCSG=*57CK+J$XXYU$1ZUC)BP5:..>-\MXT^[E154%T&\2,4/>V9A\\^_[XA
MY!53KC)%SSR[S2IK=Q1QPD`A^NSS:R&-';1!88W1<P$)"3S%SP8D>/`K(",`
M<T%CDURP";'C4**/,FPUH\!%^\B'[5[,';0<L0=E$@AC^FBB`B#C[%,(691D
M,LD^\E`"#""&!%)))?^@,,DXAP1B2%V8!)*)/KXTPP\FA@2#SRW3K*-).;=,
M0@DFYTPR26,#8^2+/N0\9$XFYMRRR27P<$6/,,$T=@XPP01353/`K`,N6\XX
MPY$S18TSCC)8T_,U4N-HLHPUFXZSCC[%!#O1L_B8,YM:QJK&CWH'V47/M=R]
MPPPSK2AB"BEFQ.$&&.$@D4L78'!AAAE3="&--/^ZL!-+%5*8@8HM7^QAQRFV
M=#%%'+;`0TT]L101AR>3YS''+5A0LX,>99"1ARM'[M-%#J<4S-1H8<#0Q3)7
M4(Z$)]K\@8,Q?N!@!CB.F/%)*J!T$HHKEEPCSR^.'"'$$$-<X4<L\V#C"RFL
M?`(*(Z%\\L4JT(`!01R^(-$)*TER@0<CQ*(;K]"'-8+EFW<HZU=RT4<@"K&.
M>M"C'!3!1`=690@6!"(G)#@-)2Y"#F:H!2W,V4W@"E(/@N@#&!S`1SC.X:EZ
M.,,:JR(>:A9BCF>L8QI!H0<^R('#N,VC'+!A1ES,T1I/,80<=X,//L[A)Z4X
MARFM6LIZ;)@CB@2"`:?_&HO$#'(.;RV*`R0@E3XNX`R`]:,0ETE!(/3!`4I,
M@ET6"$8AWI@5<Z#`'<5*``>P.*L\+FN%<00$RSB0B4*,0!D+<$X",A$`I=41
M$0KP`R4N8`A#^*,0'`#&!]90"0Y40@'-X$!&.GB!6V#@!/I0`3!&4`A#8*(0
M'BA$!\2HCQ(8P#$+>(<P+M`,"P1"`X+@([T,$4=$<&`3@#B'(480B`L$8P3!
M"$0@H!D,%%P`91PH!`J`\8]R=7(%&CC!&@RQS1)@XATJ'*%2FJ$P\\038<]R
MEC[F\2S[+,4=].#&.!PAA5VT0@D`RH4S8,$*+W!A#UUXQ"_2H0M3A"(/W<#"
M_Q\.U(4M2`$*=Z`"'LKPA7Q(HA2[Z,8S(M&%3MP!0+PP13<2T84E4$$7KIB"
M*_01AQR(`I`'@<T68*`(<5SA"&;@PA%*,00:4&$7IT@"-"3AA4]\0DJE:`4V
MR)$(&#3@!3-XP0M<T(`8'($8Y,`%+T+A"4^$@A9Q4`0TMN`)6?@A`EQH!QRV
M``8P(`$6PVC%>$2XQ%VUTS$8\!-;"O$!I%0B`>'`!`?090UDL$4HY:@'E^)6
M+$\)ARC,@(<A$*&/982#(N$(QSIJR-.^/.,9Z1#'.]+QK6OLPQR*TD=UZM$,
MH>1#@LY1#L+2N)1I6?%@M,E*.7S3'?L0++4%66QG"O_Q$(HT`VPCX-<Y+G".
M3/!K9OT:!W2:X2\Q5A`%923*4_+!'$-4A1X>V`!S994=+?[#(!LP(RIAAI,1
MD``8'<B'.1+0CW7<<F:&*$0Y5B`(2CQR$_4@P:0<=0L42$`8@*`$3C:AC$),
M9IH%>48@UJ`):V!`!?[@0##^^`X/1.H5&T'$"@SA2J5Q`"E6VT`F+$`)9^3D
MQBL<03-:UL&*7+,1M]@&)CX@MQ!H`A+)Q4=RDL(/P8$QGP8<Y$10BS`G[Z6R
MUCB&(VB!N3GDX13P6$4<=N"%/92A$^:8QBG2R@HYF$(<KV`"&/9P!R:\80]>
M<,(CL'$+1I0B#ZR8Q3=>D5+_+]RA"Y[`13P4,08W(",/57##/;H``U"\5RY%
M>,$1DG&$(RSA#%,@!1W,D`-2D"("<2"&1[\0BCCXP1?&$`(,N%`#&C0@#T_8
MZ@V6T``\?(,1<8B#H#UQA5T\(@*PP(42ID`%4AC!"W\(@Q)BD8P"CD4J^KC'
M,MYAD+`4Q!WOJ`0&*#$.7Y#`!#3>`-C"`4QW%(,@V=E&93%K$&LX(S=+<R"I
M=%@L>JP#*<G=]$&P80QTD*,;L9H'#=]2CF)@%A^P<8<P!O.W;<#'A^.QFT&V
M\[=![D@?L,D''Z%C<(,,P@&K\LPD%!:,%&0B!1M(2\,"(1&2^P8?V='Y0E"`
M"6=T_]&:W\),60I2`A+T/.5[$3C)'?A&?CB#!)4H2`<YHX\-_`,1P?!C/OJA
M`&><PP,R:X8A5K"&#C#C&!FV@#(Z^,9":"`0*JA%"=(PJ7_X(1B?[1<'W&*(
MI*\`&(@XQ`I*$`P/!&L$AO*'!5(P`GXH\H'.N(@A2+8!98SC'QPX#2;<^QCR
M\B,%'-`O/S[P@1"D8!*)I<<',N'=K"Q'/O!9",CSL8Y8)84>WEW*.N;Y<;&0
M8QFL2,),"^2).>QA"E'P*!-L,0Q/2+43ITA%'M9ACVATH0I48(0BF,`$:!C-
M$ZF80RA*X8E3//H)G^`!%:IPBE+$00V\@`4/]H"'>BAB"O\X8FX^^!$'4P`*
MX:`$4B`%7H`$I4`*,C`#;@`/8&`#K;`/JT`%G8`'T/`,$!!LBM`%?&`*U>`*
MIG`*=#`*1M``8.`.I/`''.@*ZQ`+.!`&Q7`%1*`$L"`+2L`%6[`%2D`*RZ!M
M^`!;/T0;X!8XL.$/(\`"'\`)S/%YRU!TP4`)V[`=^(`,X)84P0`V(Z</V%`>
M@Q=:XH$/1F0-RV5P^R`,Q[%V1=</19-<U"!E\R!:@[0/>B%E>^,6#.$;GB$7
M\O$K$A1<P)=:%*%@3J@/*>`/!7$.E,`6ET<QH$4/>;,/(*<3D:@=D0$(;$$)
M?Y2(67$.@?`5L-1`6(1>WF$-\%#_#]2@#!S@#QK!0OX0")!A$I107W^D`@K0
M+P8P#N9@`9DP-2G`+Q@`"6DP&1Z0&<!P`HB0#"$@+_Q`"0$0#!?`B\H0""C0
M#%D@"/@@#QMP")MP`6R4=0J@#!C`#).P`0N1"2N02YNP!H)P%OV@BO3P#Z](
M"6_4#`F`#Y^W0O.5%B.0+RAP#AL`#)6U"2P@-R8P#<TB%?=@A7\3*^9`7%8&
M%K8'?!3!<4J!3[Q!$<S0#:O`!6<&#J!@!*8P"IU0!5$@!:(0#[?@":60"I[@
M"JYP"NM`#N3@#9:`#`;4".G`#=O0#JP0@OSA"7C`"^+0!7@`!GB`!Z2@"#V@
M![H`!9YS_PKT8`9[X`H%!TCT<`4Y\`764(!2P`5&P`6D(`4RT`7CT`D\`(/Z
M\`5&X`C7``(-<`>IH`1@D`>BD`NMP`BF``9QT'X-\`C9D`A-0`KC<`57P(/Z
M``9)0`3$I@1;X`4["`NWH&WZL)/7H'L'<0W$(GO"0@V-\`$,U&WZ(`QT<Q#U
M8`VP=1#F<`Z720[8T`[-<`'L1`[1,![K\`Z$R'2[1PX$L0ZWD!W[4`P*LP\T
MA&]&8UO4,!'GP(G7HGOXP#5R`7($<8>[QPQ*A!SA((D\]0P&(!%D$PRK<@XE
MT$7F$!-A^'1F00_IP`RW<`S)D`S;H$`(4Q#^`D=@@P*XM`_/L?]>"I`3@;@7
M0Q-NW!`-@J(,*5`(5>$/:7`(QW`.&18(_;`O]S`.DT`/9A<WAI`"@%`(FP`,
MW$!XRJ`"*W`(Y8`(U:$"+!$:55$(P.`'):!ZP;!NC5`,]&`-8O0QI`(,*\`,
M*Q`")0`,L`$,WA(,66`)'7`"'G`UZ8("(6%'''"?CJ$"&#$"(]!Y@7`JGT5S
MI4<)'4`"''`+R]!%Y9`.\#`1;F$.\945>1@7LZ4=<Z%E5L06*#<<_$`1Q\`,
MJI!2=T`'R0`*<7`'N@`!5"`*TD`**UD*HY`*KF`+ML`,[H`.Y?`*IK.HW]`-
MXY`,KC`FLA`*H*"`T,`*72`%3:`+C(#_!U+`"W!@!'R&"O5P!#:@:59I0_N`
M!"X`!M2@!#J@!+EJ!*[@!A!P)+!0!#T@!;>0./5P!4G`5KG:":0`"]>@#;%`
M"F`@!E)`"WL0`]#@#G2P"J^P!#G`!7BI!#%0"JQ@!`:(@T3`"L)00&+Q#J^`
MFL,Q%L)PF2AD#8<P`FH!%N-`#<W@&_%0#O<0+6H1-^L0%_Q`#A-$"2R00O5P
M#>]`L-P01;E)<K#A#*]`#_!P#+MA#?*P#+$B6K0R<4<T&X^8G)Z23P/7+$H1
M'+6E%/"Y=&JA*//*7!;0GYN`2Q\C"%]!">61%/5P"6LP`05```0P`$4[M`JP
M!IM`-WY8$!M:_P@;L2@MXQCS12L+\`RA*+%)00[#$)IMBBK<X`SV,"CZ$"RW
MF5S[8)W,4`[@=@^815EE&P]>:PV]=Q#K@)OW!#9C`2B>0@UN*)]:>!!Y4Q#\
M`(E908GX&HEDL0W68`W<8`_E<`UQ40_;('(5B3#RL'0<-Q>CB*_RB1#H21L%
M00[6X`EW8)148`N^$`,\H`N>0'VZL%:C4'VIL`O0T`WQH`O!$P1>%01`H`-X
MT`WY(`RP,`O\P1^L``K0<`I<H`C2L`-0``ZPH`1TP&>BL`Y;8`.C\'2I10](
M,`-Q4`U)``5+H`1)H`130@6*$`IT``<R8`1(\`VQ\`P-<`2>4`1>T/\_X/85
MS,`(0L($G2`#6,`-C@`-.&`$2]`)@M8)4D"J2G#`4O`$2L`*V:9SY=`-5/8J
MP+<-Z>`V2=$,FD6:)B<6O>).L=%M!WL/]\`!F&`/8M$5]9`.!YFU26$-PM`5
MXW`<^[`J[3`-D0AP]1`.0A$WE.@LQ&400$P.+'L0UB`>2S$.2FP0Y&`/]!"W
MM"$6<LI<'(".\Q`.D%@5@J`";`$;>G@/PB`"!!``#I!@P5`VQ7`UF$`('$``
M!R`!3K-MNI%)<:$,2#H6OI(6A6`!H#G#HJL.W?"NW284Z8`+[;00/D0/X?&R
M[("<QN`I;+L.*E0.=',/QV"XWO4.UJ`M<,/_#:M)$=90#$YV#^2@"?9@#[A`
M#%88B<ORI@Q1'YT[%$+!3_E@%^5`#=;@5_J0#M70'O2`#%)&-K21>THAB2F+
MQ;J1IG^SIF9Q0*0P!K)3!0IH(F]P#TWP`]]`"FYP"K(@"HI`"MZP#EV@`SE`
M`^O\!CVPSC8`!>KG#:PP!Z"0"JP0"K;@#$9P"NA`!4;P`[*@"%6@!]4[#Q"X
M4_ZG#V'0`%W`#$,P!4LP!48P!*&@"D0@/$Y0#4^0`SG@!/J@"B\0`;8`!TG`
M"M3@#IJP#_SP#/F`"YV0`ZX@!3.``^U@#DA@`V!I#%=`KE(`#HD9P0>(`[$P
M#(9B0.90#X(R*,JI_QN".T$480XF:UL*8PU6&#?$L0W_HGMPD\QRXP'Q4`]!
M,0XWR0S%(+,2.P[<`+#SD'OSP$#A8`U1W1[M,`Y<,1?TT`ZOD11V2WLOE$_$
MLAWS0)H063?^20D+P!;\0`*M,12`\!3WP'''@``"H(V#12V>-``&T$7V\!72
M\6(.T;12JU]%-\A(/18\]`[`,"[.H`G"X"G`=0W>50R-P!8#81OS4`Q%70SW
M0`W,H`QK>PO=0`Z_0KGY4!WZ8`\.J2SG\`X.FYGX,`[=<&_6\"K=U@S#$`_K
M@`N"8GNPT7.PD15-UE.P$0_$D1X4.1;0H`P1!,SVD!WL%`]*/1I#I!U?T?\,
M9PV('+$-L)K82@$=RF(0US#`7N`%8%`&=P`.G3`%-H`*CE`#C-`-U"`*>9`*
MH]`*V?`$,$`+;V`%44`'N_!]5*`&=^`">@`.N9`*GY`'I'`)U>`'+J`(J\`#
M>N`)NQ"`8_!1GB`/74`#C+"]@#0:6Y`#7I`,2)`#W:H$7G"`,&`$O!`)7.`Y
M,U`#L1`&+]``J4,%X+#3.2`.PD`$L4`.C)`$G8`##4`#T0`),("#,0X*N3`$
M,>`)7O`$1&`$4V"`L7`)!70-F)7)?Z,PH)F?J9G"Y1"QY=`8W)"'`X$4THP.
M0M$,(7`+L"6VPPT1QG#63/$5L.H=Y3`-MXF([4#_#]U1#,]@#AA7PZ1=$._0
M.E:I#,^1%/N`68+[+5_A=/HT'GB(,+*.1?S)$1.S%SLB%.-0`@(0`H?84_2$
MQ>'P#P,0`DX(&S@T`CEA+,["#U5A#@M@[/Y'7&S1'-1P#Z-1H1@@`0AP"/2P
M`!B0`"%@#0&P`?5@`!OP"@8P`0>P"1A0"/A@&AUP``-P`B=```FP`<&``..^
M`N40`AX@`?W0`2*@#Z`H"`=0UQ?P``Z0`N%P``^0`>JN#X5P`1B``)2``1GP
M`&MP"QF0#YDP`N1@`AE@`LPP`A>P3<4RI2E@#LK0`9>2#Y/0`=\@#!YP#H#0
M`1\0*8-PC?I@`JY@#G[0_PAK\`W)L`+!L@[!P`;?<`NBD1?4L`;EL`^PP0Z>
M,:].-Q="G`S40F6SM1L+@0S1X`A=H`=F(`7P%U,\T`O[``9O``?)T`UQ0`6F
M``];`)>RX`6\X`JM8`JXL`JND`>V``4O,`?Q$.=Q``W>0`I,<`?WP`@V0`.B
ML`I54`9F<`=WT`GX``ID4)7^QP]A@`>E$`U'D`1+D`1YX`D0X/JSH`6P$`<P
MP`/QK`](T`!0``VSX`FV$`VM@`,V0`%2``VO(`F?``USH&M(?P40;`2*D`N,
M\`4UD`0Y(`MQ8+Y<$%"O$`LX/!S[C1!WS1;S,`_W@)[I0`XA'!;3P`P,]!;-
M@/\KR44,[4!RH_O)]3#%UD`0Y0`0QM;I(UA0'SZ#"0WF4]C0($)SUMYIJJ?/
MW#.#YHSIJX<07[MIZ?3M*RAQVSN#Y,)97%EP'4)]\_@5Q$>RH+B!]V`:?(GO
M7,.9#H4V)#F)`\%-AO39,V?3X#Z2R18X$$:0'KVA!G42?.;`@*6#")M1TH>5
M7B:$P5`0I&0AZ]NW-NN%LSE/'Z(+^OQ1(O%!WS8#DP@<$";@0R4,^AR@V.!'
M7P"R'03I&U'"'+-F#')!,I`I0"5$UC2(2->AD.(!E?0-&*0M`*8#@["]*H?/
MW"$!EH0%8';H`"0"^@Q=P(1`$X=:UA8@HH>0PPAE"8+_*4!QK@6B00!TI0!`
MS0*E0,$E"&CV.$,F!I<"0/JP@AVY=90`6&*S0=_/-0!4YZ-7CF!M@\ZIJ"*M
MZEF'P(2P<H@<!0EB!AE0I*AB"B^F>(.7(VP0Q9A0?-"!%'CF..4;2:380P\J
MF/!$E%9>*<811IKP(I4G:K!%F$X4H2>,''Z8PY@X>*!BECBLJ'`/*.8X!PP@
M1('K28+RV0>)!KH8Y@@IDI"BBSAP2,((6)J8A1$8>L`#&GV*:.`3;!IAQ!N"
M%&F@`33UR64+6+R)HH%6](EE"!RFR&61+EBQ08<<.C&#""Z\.`*6:(0Y9Z=[
MWBFG4KN<&HD><QJR!AAV@@$F_YA]$!JGJJL(*J:9=U:E9Q^LTDG'FGSL*:N<
M=-;)QYQKEF+&F'D:U">8<<HJ:!^FFB-GF7O*,F<<?FIZTIR3?,'JG(UNDO2@
M<\(1IAYF.C5UG'S6*49!7IO-YQR[[ONI('K:[?0A<O#!I]F&&&RH'F&A5(B?
M!8#19YP&#2DV(80T&:`$6PF"RM]ZY"$(D`"R:,B9%0`Q:UY]+CC-7Y`+.D=B
M@A#*8JV*/"#$(@,HF6`"#3XHP9(`-DA`&`P`T4<!32@+1)\.$/A@`W\6>."`
M%.HY9($2J`&A`!`.H,27"QJQ[P`''B#A'`(R\``18_TAH)YF`@CA`1$T64"X
M"\H)(?^#$[91;!*'%5"&H&`(Z+00#A`18(TU$CAF`T%*"($2$TXX1)\-$'#"
M[E8(D`"?>HJY!Y,"1#B!A++2T2"1#]*YAYN!]-G**IHTO50?*1,DJ=^#^#4(
MEV$\@6*,*:8H8PI2MHA"%E)8V:**'TP!!Y=R=ACEDR>\X&.7=>ZYZIU=XO!B
MBUG&4$.?5XR1Y(DQO."EE3F,H*(4*<B`@HHJR/!D'C!H\"3DK*0<`H8XDD$B
MARF,@,`34"0A!C!PA2.DP(,D/`$'QO!"`VKPB$?`X1G.^$,,J#"%(:RB&9?H
MPB,8@8,&D,(?B>!"#IZPB%:$`@(ZF,(G5(&$(RA!#%(`127_8)&0BFB$'/=@
MQC+L<@]R!&,8^$C',]Y%D&M8XQ4'``0'5%,,:BBQ%INXVR0F4X\0],P<],"&
M,%YQCS5LHAC,^$LP7K$.<FQC&]%X1@H(THP1J.`"F5B!,^8!C$T8)`LFL`@'
M4#`"0!"H',JPQE-@`@Q_:$(IKY!8.,AQ,&>08`0;^%0&LI"%1H1#0?L0"4/H
M\1-\C`-!^B#'/,PQJ83PPQSIV$E![A&.TBG$'!Q3R*OHEY`_'@00=SO'.`#Q
MCTQ@0D'-*H0`!C$23>'K2?A(E28"<(*",,0?',B$*_4!B&)EP@"P&PI#'.)-
M61[Q(/K0IC5(D`)(*&`;F#``,!PG_X!"?``3">C'./"1`1*8XS/ZX(!2+)`%
M;@!#&0JX!0(JH0DW4J<#T.3`)%1P``T$H!@*J$0'4&".`;P"&.5AB#(64(]@
MK.<`:_"H/B:Q@4O<8AROT4<"Z#82"P1#'X78A`'*\T=`E$`"'"C!,32PADJ4
M0Z<2Z$`Y)'")`A#`&==P@&KT049*J&`1`H"F/C!!@!,<8!@<:0@S#?(.`KT#
M)58)BL.$,J^=6*,:C*C"'B94AB>XPA4^4$0>6!$+'9`A"K;0ARH:<`-0N&$4
MDCA&6>H!JV0X(A12Z$0/:,`+>UQC"C\`TQQ,X84H2&,.2YA0%=[PA/EY(0BH
MN*50I"2&!O^`X1I(,$(2<I`#(>`A#C)(@BFTX`HIY*`'4`"')!HP@S@P@A3A
M6@48],&-+4BC'+A@!2@4L84&R,(17R!"#^;PB$:`P@8UV$,<=*`$)7#A"&9@
M!"%6H<R"U",:Z:C'*UZQC./>XA73@`<VC($1TZW#+H?PBR%*4((/-,($JK!$
M(]8@"$IPHA(H2,`F#J$%05C#$I6P!`(:(5](F``6KRC$"%)0CBR,H`,$(<'/
M@(&)#7!`$Y;PA3!4@`AF2&`RV\``,ZA1#C$BHA+$$$8QS!&(%$RB$/C`!`HX
MX`\36.(:AVC&(!JQC(&$`!-6)4$6,C"!+&#B'(4(A#@TX8=)]$/_Q^,H1SE&
M>9!I%+(AS2"'0]A%E%0Y!%:E+5D"!+8I?2AC!"BX``I2<$1(P'.<(RE9/@S=
M$'@XA%/ZN,7?3$<03,BM&9$FB#)LPH'3@#-D##FTIJ4GDH880@(;N)L*/.`!
M3)AC!9NP0)$S00)#WV,3"K!`4?61@BFO`0$:R$`E+G"6EBG@`QBXA47U@0)`
MC$"F'$C!',LV"0PD``$CQMLVE6'35]BT`QXP0"'\80`22$<?%E!*13!A@0M8
MH!__6``'%!",%:1@`_\8@3\L<`M]E$,!ERB&`SAQ`62H``#**`<"-G$,%3A#
M'YP8@3X6T`%,5&($'+@%!@)QB&HF9!UT_\$A2M!+:-9QDR!BC1(]&-)#5SPA
M"D^PPA/4@+X<O,$6K&"$#YY@@S?P(Q$O"`(OYI"';XS#%:1-AB3B@0TPQ($4
M-!@M/;Y@@QM4(1=N@$87>G"*4C#!"%-XP@5+00\G!.$4=&Z(E*[0@#C`@@A0
ML`$/%-B%4L"@"*N`@RJ*H(,GZ$(2D7@!#=[`A"TPXA;OX(:AM\&/1UPA#E@X
M`@Q\D(M$,**Z/W`#&V(!@R3,H@@W2((2B*"$#$8"%PJ!QS3F00TT(L,_^4!&
M(>\QC66`.LZ94(`*5"`,"UCC`S_5@B.T<`A![!D?*A!$"[1@R5?$P@0:.#@S
M-A$(+5B"!/PX9_\)A.$7?DZ9(!X(1C`:\8HX>F`-*G@%*=OM`4-L0_RW8$,6
M,"`(02B#I_H8A!\0@0@-I*`2)_B`%C2@!7C8!@>8"7,@`4%8A!,(A'_X!T`P
MA!,`@4'8`$1@@6+(,_]0"&>()8.@AW$X&$VS"W/00']II9`Q!/NXIO)@G8G1
M/H1X!0``FT%["WH0AEN(!X6HAWRX%WW`A0Q8F7+8AHH0A@-;@8PS!)G"A+QX
M'9&CB6VHE\XAD'1H,]9A"'C@!K-:"'K0!79XF'EXG>,JK)J@!UMA"'*P'(58
M!F?8!FN`E5UYAW$HAGH@G9K8!V50.'IH!E5J#G<HAW%@AFU@AGB0$F;_"(;R
M4(9A8`=-6(=UR`1AP(IER(1W:8:?\*9@H`0%`89)*`]G()8^I`=EZ!1[.(:*
M"`9G<(9P<`9+:(9XT(1S\`<'V(=[<`9\"X9:H,%;*(]@N(1#P+>$8+.$N(=[
M.)"&P(I[T!1C^8^$`$)J<`90F(*5>X)1\(0=*`,;0(5B((4NB((]N`%7X(<F
M>($;2(52R`/W8H(;X(4F,()6F(5..`7?H@$[.`<M@`*WP@))J(8NT($R2()2
MZ((EZ+HJ&`5SD`(H&#NR2XA\X(<M2`(O2(8D0!0>T`$=``4D<`$I,(5H.`(=
MN(%2<`4LD(8=F`)9X#HO:(5T<(=/HH=P^`(K_[@!-=B#%Z`#:>B";W`"&]B!
M.2`&4S`"'`B#/_`2(R""*8@!5F`&8M"7@J`&N:D'E*`<CL@)?1#&@Q@(AFB+
MBF"&Q"@!%3`<2X"$#4@VQT`!1,B`1CB$$=`$C%&!/*J'$:B$#!"$%=`'%>B`
M+)B&ACLVG<D$%&"!?DB!?T@!%!B$0\"$$_`'?6@&#`"K<I$`0W#+32B$%!"&
M??"#%;@'/R@$2BB$#.,9#&@$06B$>!B'#A"83+@`*4,$0T`$$B`+$\B`25C`
MGZ&6L3*(F>"'?O&F8/E%FGB*AS#&#:2S"W"J8,`*9[`E3``;A%"&`.`<D%$&
M2K@$-4,8AAB&6Q"&!/_(!!PC(T$HAFT`!FK+A/*@!PNH)GP(!V.@)=Y<AU9P
MA$*:!E5H!7M8AU4`A61@G68I!RD$)YA`!DFP!"#T"%M9AV2(!V;PHOHD!_E"
M!F1H!V,8SI*A!TTHCWW(P9%3Q&1`!BF,RGEP!HZ9ANC!!GAHE?+8AFX8G740
MAFG`AFBX!P*9AU;"BGV(EF.T%]Y4B'S`P;)H$&:`0P:AAWHHAPK$AQ\:*Y-[
M-*PPAU'"!WD@08(8AWYPB'Y`S_^0RJ\J!V>PA@BY@S)X@U'X`B/@@>?I@7B`
M@Q_X`3V0'ASH.5V(!%L`1',H@A<``G#@AV;@A5/(!E-X@>V!!BJ0@BDH!5C_
MT`)>>((DZ`%12(4JH`(ZJ()3H`=/V(-4.,A:6DA/0`8B2`($2J!.J((>J`)M
MV`(;>($[\`80,`-3(`4(V`)9\((J2`5':(U=<`10P`,>^`10R(''FL]6(`88
M@`$E6(53J`$>\`)2@($IN`,O\#Q92`9B(#-S6`EQ:#-O&JMZD%9ONH9.B9>"
MP(04X)1M8`%A"(8L.`%F(`0-2`-#,(1)F*1G.`0-.(1`N(5R6,T-<(=;"X02
M:(0TT(<2N`43Z``5(`ASX`""#881&(="\`-<,X$2J`5`J`ISL("A$81!"(82
MJ(0L4(%`\`<_4`%+$(0.&`%N10%,>(4,8(="^`<2_P"&;C@&@QV!#Q"&$S"$
M-2@$0"@RR:C9?Y@$G>E18?DD9-H):;&*=CG&DB$0GW`=A_`J^G$&!=@;F3J'
M#6B&N\&'F4"(#R"`V<P*'RT981@&!-&TD6L%A%.`99&;%:@$:]"$?46(XKRF
MHZB'9;"6H<"'6(B$8JD&4FB%?&@'&+DA@@A&?"D5@HB6<K@%4VB%>MBBG<`5
M8"0&2"B_=7B%5D"&@;&$33@8CF@&>T`O3WJ%2[@$^.((?+`&CR`(=J`&<:@(
M:\"$2U@';KB'="@'<Q$'8\B6AX"7W$T(WU2(=SB';;`7K!@'!MD(<Y@&<C$=
M@K$4TWD'N?D+_W@'<@"GG/_HEW=8AT!LB'$0)X,("8>8!F8@H0F1@CN0!3=0
M`YPC!E)(`A^P@RHPA7?0@1>P`UGH!%F(!WY@A1MP@1Y`!7=P!U/H`LUZ@2BP
M$RK@`A[(`VV(`^]2N5&PGBIPWU#@!RK0$)"3U(0T@A>(`V/`/".P`1N(D!=P
M`2R`AAA(@E/0!5(`!4EH`UAHH"50A3A0!%-8A$?(AEWP!"JX@S]H@`@@!6CX
M`E+P@U<@!2!P@2LX!R-8`@I0`RN@`E)@A"]P`5<0AALZ!EBPA&.XP"FDAX$@
MAS$DB'2@!F%HAVA2P7LP!B"-W!MUD'60,&&H%Q\M)!PM,^(E"&2`!6.PHUZ*
MAFK_V,`"'0;_X`=5TH=GL(18.`88#0=E4(9,N`0^/`=^D*D==(1QV(9C:(9]
M:(9G\(5E&(=E(`=A(",^S#=-8(9R:`9FJ*>[R81,R(=F`,][4",8;08">9B2
M>9=90IC"[1<AU0=^*%K=530FA8M`6`M]V`2%PP1*H(1_``:EP(I7$`"!*68<
M.C,;M0=O,HNR8(#)8(A@:+5!RP<5N!O$G)0M.K2S,@=\&0=QL09LJ(E[04^$
M(`E^&(28T0!""`$C(PMK4(`*#`1,2(9&V(1;P*1"<(<.&`02$+(-Z`!"V(0.
M(($2J,!FR802L(9@8#C"F:D-8(%_<`9$D)XU,`$5N*24_QJC(;.&?U@'$'N%
M0[B_PAJ604`$0=B&6UB#00@$?N@'(,.$?#B$;3B'!C2'8&C,0;@$3H"$0Y`(
M.NP492"$[SN8/BP(<R"'=K`)6(X'=F@.JR`0],(*3PH*>1`YV/E1+DZ(8B`&
M59`0*&BM/4`?'K@#5U"$4&`"('@!*V`&*>B[5/`$6U"'99@"*9B&+F@"7/`&
M4\B#/&B`(-B#9)`")B@#*8@#48`&7'V#YB+4)WB"*O`$<P"#('`228VF=1@"
M&L@#9U`"*-@!&\@!3P`#QXJ%+8@`/L`&/R@"+IB#+Y"$;&"""+B#60@\.(B%
M7[B"(XB#5("!F-2%+O`"3TB$*_^(!FFH`1>(A2YP`2-@!2]@`BG.D%W(A%SX
MBTN(!'SS)GQQ7FO]CV%X!6)H%O1Z!VO8AO(N/XYXAQM]!4M(Q'S#BI/@"&NH
MB&WP#R6JA&(HAW-PAVCH%9)@B')`!F!`3W.P!*%6""_2W()8AE=@!F^""F,X
MHW!`AFDXB&VXAQ"LM!%]AV:Q!JQ@)FIMD'DHI#@KB'+H%`PO&9_@)D64,VN^
M8'_Q@#SJAW<!!'EK!D#((X3``.9\DG@XAK(:M!J_AX91P7VH"$,P`"Y^!TWQ
M"))@`;+@987H71OE*OUDT7M8!OK.@'K8/W)"`'J`!`D(6`]`@'@8!$(@`4(@
M!T``!@?_Z`9BZ0!_``9F^(=C2H$0X*HU6``KW0!?X`<5N`5,NX5@T`0`F`3Q
MG`1"<`!(@+)B4($%<"36T(<5*`0"@(1`\`![/8$U`)H4((%5*P1SV(!"<(80
M&"A-"`%A\*]F0`&>R8(/V`9$*(%A`0"!^:E;D`#MVU&#:`8%80@"O?&!*(>M
M!4:"Z(B2`9#`]0A;.A:3BX>M#=QHP`9%2((J2(+<R8%3&`4:H(-%6&$>``(?
M&!$O`,=3.`53(`9]$(;"&H=7J`=L*`59F(,:&"USP`.\I@)HB(,(H0%;4`0D
M2`(HJ((HB`*!#(,;(*W2CI)Y.((-%H<D<"T;^`$O@(`:L()L_SB"'9`&*E@"
M*5B"+G@#+P"%;+`"%Y"!&9"!(?`$(Y@3&7"!"N`#:>B$.$#6W4&":7"%!AB%
M9*"!&B""4-`!)K@"+GB"4Q"&\=:'=("%4?(F]4IKTT$'<JB'>OBX;;`+HR20
M-"((:S`&K'#ID;/"62F(=S"'<F@';B@';/!18OB&>P"G>B!></(F9@!$WAR'
MED@(<V!V>^`'FQ`&'UK0:9">8DD'9N&&Y[4'N=GQ@AB'=0"KA,")<_#-<-"D
MAK@&[G48<CC]82YM<U``A6M,JZ"$$1@!SD&(2P``2GZ288`$@=&T9G@%BC"M
M6R@&*R0)9VB&2;``.T0!9:`'/UB+G?^@AW:04J'`AV$XAM(1P9&#AER@AF06
M]DQ``$+(`D*HAPV@A'I-@10P@4#8<P]8M6!8`$)`!&5@@1#X@%<8CD,H`>TK
M!A1(38#0Q$&?KTW'-J3P4RD3AQ',0NAK-D(?16<=,AF:U\(!,#^<,N#3AP*2
M/D`L-*VHE.4$I$S^4.CKYV^<AV`J4E`*I@_8!GV%/@S;M"(?(D.`]+%@$TR#
M)7WEN+&CJ,]<N)`4\[TK1D^JOGOZJ)7C2K&=OG1>N=:CN"\?5WIL]>6KQ_;>
M.K'TSOE"!DH*E"E/IDSQU`2('5>DC/SHP4N:)%@R[-PQ4J43-'W[]H6\]85)
MDSQ/;NQ:!2[_3H\G<4"!X@*%CZ(M3Z!4N0/%T[DK-%S!%:M[-V^XZXPT\&(L
M1@X>/?;(NJ$C51$(3T(9L5+%BY,N7L!T2W?*APL;-1J\"&]##2IUJ[A(H?*$
MR/0PIG(0X:.F`1!9/(PP2:+#U:M;]=Y58XPU[+`S#SWWW%-/-/5@P\U97:7#
MSCWT-%,//IB5DTY7[R"3#CWF6'-@/?5<4PX]UL33E3[O7&--7>_0!8PY]7@E
MS%;%X')//O@<R%4^E^ECU8.][98//U8)0\XU9%ECS3)>K3,-.]1PM8TU[XAU
MSS9IB;6.,KEUV<QNZUBSCV[[D%//5D2RV>95^E#24Y"Z*>.,9?I\__"!/FNR
MN<\]PUCRY9P57=(*E[R-4TPP:XX@#`G`P$2/,OT`XX\'8H4CS#-N4L2.)8OD
MH@\Y\^QV3"2>5$;)0)F(H$LDMUS"@2`;4+*",(TLD`(F,7D`20G)6"*,"+=L
MHT\@A&@BP3CT;*-))6MH(,REP33RRB29!-.,(8($P\$MP@##`I"&.!#,,\]\
M($P''QR2`44A;**/("I`XJX)66@23"8394*")AT0"TP@).B320<^77!(`MO8
M<T$A"?13P@D?K+%5/_-8&.16A^8SSCH:<G5/,UB*54^(NN%SH552T;,FC%RM
MPR4^Y.@#S3**2%8&%$GD80L3-^R!S1<W`/]!!RQQY$'-%WO,$D<4HX`#BR_Z
MC),,-'@\\8DM3ZAA32BD"-/%$D;H$HL4-C"Q2Q-)5#&%%5"4THP;8ZP")J=$
MLF5.&&#D84P..<``"Q['58$'$4'8P,@S8'#AA2AT@!$'*8R4$P\TC,Q!A1IT
MR"+-/;:0$@<887A"RB%T[`%+%S!`X,D<1W!112ASN"%%$JL@<XL^W[S2"B[6
MP/-..2%90W,]Z%!SS5;OC'-6U?/DD\XT&R\#RROM7%-7/:2NP\PQY,1\CSWU
MD'-]/-T,T\TKU<2SSCVP6*./-98P<\\[6*83#3/\3,B/.?_SR!V6P<<Z4C:-
M["$('NS87CN048[_"8UH'<GX!C&RD0YLP((:]5@'/,91C75\`Q[J@$<R7@&/
M>.!C0OK8QBW>D0\$(>@=UDC'H=1R#GS(PTQFH@@`4TB1L[RC+G?I#3UV>*:[
M;84$*M"',@CFE$(80DQW&D<`*F$WL?"O*S!<1['@D@][J*4<YZ`(&'=##@U,
M@B+X&$$P4&`(F."#'_YH1C\LP(PWD:-X;<H'6^BQB450`QY4VLTT(A$);A1L
M(IM8PS8N(0()Q$L9&QA!,?3A@#5\@`1OU(0*@J&)>(0@"X'`A`H,H0]#?(`;
MEUBE2`Q1"!(TPA&8L`0E"H&1$NBC$J_(Q"TL8(X57D`8WX($!O0!"08,_\(!
M_CC!!M*B29$4(@LH\$4FQD&"0OBB`Y2X@"4P0`E,'"P3%O#)1`*A@DG\8QPJ
M(,0&AI$.#_@"&&*BAX;6828U480>`CP'G_+Q2Y)Q)8\KXXH\Y+&;>80D+6_1
M1SW"4I:M&.,:C#`"%,K0MD\8(0D^Z$4LB/"#'23#&F"0@BMT00$?R,(-=V`%
M*%KQ+45\0@IS*(4-:""-6.SA#?<`A0MHH(9Y?.$)3\C#%7A`ABY,X09\J,<<
M[E"*N]W-'$B`@2=\`0,H'`$6]''#&Q#3@R@401R/:`(C2+$(1GRB$Z:@1AX?
M`0DJQ>(9]%@',42!AU2`H0N.8(04<K$*'?!@"O]*N,,4\-``)T2"$4[0P2Z,
M@0M]',,2ET#&.AQ*$9I19!W(>$58'LB5>=!P'6M:AR\L88EI8&.@%!$&R,Y"
MCVE\XQ[5P$4KH.$-#9$H&W011OQ>Z!1<"&.,*'N35^8Q#&,X"!YS(M,KA*'&
M>F2G',=X8#62$8]XJ$D8]3MA/:I+#.Y.J!S,,$?]&'J/<1QC'O-8QD#;4<#*
M[BDDZR!'2.A!CH6V3Z'E6*A8S"%<W5"(-T;DAU0N8,I]+.H>*SA$(SB0B3WI
MHQ$(.!!_6[:/`X'PA-S@AOM.^(UOI$,=ZF`'D/@1EW+0:$Y;P0#!MH()#R!"
M&5(,QC\HXH$TMDE':@S_V?WNL>$L420>UQA''\>A#WZ8:!SC4$8ZXI&/9C!C
M*^<PQCTTL0ERO$,8Y:A+)B"QB3D:61^8T"PW4M2,8-A#$XVX1#*$<0A#3&(<
MF^@'/9C!84U<:1N&R`<S;A$)3=RC'9QP\YO#G(DOG6,3F0!$(%(P#GX$`@6;
MH(<A6*B"-7Q)&84HF"DI'0@QE>,0@[#1)031@4K:@QIF4=$V$G2H-;4LGT9D
M:`%_*18"JE8JXXB*;MCQ,5+I`Q?&Z$02>``%8_.""SF@@2G"\`)1?*,5</#$
M%/3`BU#,``B]8$0I4`$.8BRC%:*(0REN0`-;\,(+4AC%')*1#";8@!=^:``-
M_SY!"AL`@0I3@`(=UK$%&H#BBE#ES3F$T(`W4`,&/<"#%&20ATX\`0<N:$`.
M7$"%:%"A"U_P@QN\<(3*&`,.3?"#(_R`!"7`HA_Z.((2XC"%+G1A"YT0!@Y*
M`P$B")413ZB!%QX!`QM`HS_OF,8RBM$\$WGE'*1B2SZH40P4=[$MTXB?6I1A
M"6Q80Q@%Y,H[P!*6LSAH'/!(QS"0H=P0W<,:]8`'.:AAC#*^L!C+N-L\E+&,
M65_V&-O(QYJJ48]^J)P>[0BSC^?1/(HPB!UBE(KPO+(-DM5C&VLZ1UW4\EFK
M&(@KY0A+/MS'%<P0,?2<PD<"**$/?^BD&4N$$TQ(1?\"=_%)*OC8T3VZP8UJ
M<".(PXB$+JX;0G"<[Q*O^)`^V%X/%+[#+>^X!0?LM!5Z$+AE&T,D"1!A&3`&
MNO*??\L^S+$.=MR/ULP0[9[H88]XC%T:VF"'A]Q"X(:VVBO<8(8]$%2/<:B)
M?.ZC1UI,M**8\=]67(/BO0./@`DR4!T^]%\F5%Y:+%^QU$4W$`."%,,UG`,P
MY!,]J)9!R1Z1Q,.0Z)B?V$-(L`,Q(!(S:$+]?04BY88Y;!G7P<7PB`5;O"!%
M<&!FA=ENX,,[I,604`0S&%E((,,TP,$4D,'.F,$</$$/T`$XS(`:Q,,B=`$4
MW`$=5$$>3$,<N,`>#(Y/@4/_%^1`#XQ"%3R;,GQ"&;S!&T"!&MQ"+-`'-"`&
M%Y0"$?2`=$!!'I0#&/3`4PT<F^3#.>3`"Z0")L!`%30!#"0!%ES.&SP!%R2!
M=Y1"TW1!',3!#GA"+*Q"$5C!$X!!$GB!%RA!#<"!,3"")W9!7BF"T-2`#TP!
M?E!!*\1"&)0!$3!<$K0"+,#"-:P,6W"#>]F:/I21/LP7;U1##DJ%/(3#/:0)
MS/0?K]$#D3546(0?/2R#.1C9T*U#,!0+'^U([/6A5)R%/;`%/MP"-X1#`9'#
M,V86S>@1/C@#9N##.;#%.S@#EXP=1=0@#^DC7(2$]SG%#?Y09Y&,#_*&.>#=
M-[I#_P*("27XPU24``HT0@D(PIRT0!:HB`ZFR"T@@,H5@A98@B:\`R!(0!K<
MPS$00B1`PCM@UPRF$#4P@R'L2AR-0TB\A2#=`CP`P@J045EH%YN,`RY$`YC,
M`V:]"5S,0RZX`BQHB`*FC)IXA8[<WS$H5]<)H]MI7?W=`S/P8#DD0S?`0SWP
MPSH<@SKH@C#\"-^5PS*D0S>4@X%P4#H@PS&D0YH4D3'0'SW$0S+HP@:1`S"\
MPS)LV8\$20J-2#CP`S^82<O$3/%UQ6(>B`8>R9Z<9<MDV2L$TC"X`X*LPS"D
M2&YLPS'HQOET`UH@TC=$G3XH74C(P]9-A9E8Q3J,4?OL6/]F<=A9($,T*,(3
MM(T1L((<O,`/H`(=*)4IO$$94`$4O`'JD,(ZD,(.S$!/T0`0O``-!`$-W(`K
MU,,HY)092`$9C,$71$,31$$I=`$-T``J3`$0E,&^\4$X'$$/X$:N?:-:F$,,
M-$`>)`,,E($7U-0.:`$TS`$N#$$/[(`.Y`!E@`(;J`$8Z(,3Q(`1+,$=X$%?
M4$$1Y,`9-``X.((4<$$9?,+1R$`.,$$.Z,$IP,(T?`$.$$$7,`(5P``Q"$,N
M()1[K0E=3`-HT9#F;0.O<1U9;,,OZ=@V%,LY/(.MK4.%:$Q8I,,U+!V6D1\^
MS`,P4)TQD$,Y_)(1+93,$$E=C(/_G<B>5WP1/K2#,5`#-HC#D.F#+A*?/KB7
M_!`811C9.2R+5.3?LJ286M1#.(B%F<S7?Z$%D^Z&!@H80-X:IS1#`HR1H.J#
M.RA#):B`%)T#`UB1-XH%)2@``9Q#,`3`*PQ")6`"`Q2#`60""I0`,6C`W-40
M5S!#,70`29P>"<Q:/)3#,-0#0W#%.10#44K%K`$#)Q@#UWDC@NP)-)`")"1#
MEC3/D/C?,M)#,0B#,,SI/(1%2*2#-0";TAW#+5S/6:Q#Y26?5)#*.P1#,8#1
M@8R#.>##,3QK79P7/?!@'Q+DRLBG4PA#-\2#.;B#]OS/M.[)3.H&95TDXKW#
M/`R)?>U)_SNL3*R%Q#O\5P$.2CA<@S"RPX]$0S0X0A?\0!2<PACN9R?80!#8
MP2EXPAYX@1E(:!Z(`C1(0S4D`A,``7720`_\`!^``S?D`AWH02=\XAN<!BM,
M@0X\`2TD@;:-0H=ZP12@PCD<@0VPPGP2B53!P!L@@Q&4`1C80`],00V8%"_`
M`10\P1$D@0M\P2HDPHF"@G$H@2*L`B.XP1'D@2?L@`W$0!A`PRZ``BNP0B*L
MQQ1X@14P`B2(@"I``-^20B.XQBX(`S&PZ2M<PMQ11#B0`SD@@X!(13ZP`SS`
M`T)QQ:KA@XND18"Y@[/Z@O=-@S!<*6KR`S=`0S1XUCJP8$@H@_].""-[C0/>
ML06N>JF`+0,P)-I$2L4U%$/\C$\U#)\U3$.8D4,VE(,106[EL<7'_**N%4-:
M#)0Y/`.A4D0SZ*D959(.1F_)$!%_]88R)`"!E8#L[H8R",#4L,DDK`$!F,,D
M&(`^2``&H`,"G(`"Z(0U9``&H&MO((@"'$(^6<6.4$2VB-E`R%[*W-JL7>!_
MS15<4.J(#,,P^&"LZ88]O`,YG(6<CL\XI(/V*:"HJ$E8C(-EPH,U(`@R!./_
M!$G_"1.6A`@!O8,RW`*6>04S-(.0.NW=L$4R$$,W&"0_C.8[V,.%@6M\R=X^
MD)]8R.ENG)=E[2JI'*01G8.M$1`84</_,G0"&`!!%5P#!`#!*%!BV\QL,KR!
M&>!!%;S!*:""'HC"M[H;,40#+TQ(/SB"(HS"*%@4'KP!'T`#%D1!%%0!';R!
M'M3`)^0"#N!!&>3!.8""'LA"#_-&.'#!'O1-$DP!L27!$3B!VG[!-H#`$MC`
M&$@!&/C!%VP!!-!`%+R!*X!"(B3"+K2"$YR"N-G`"\!`',B!%'2"'ZRR%$"`
M)#"&*ZA"$7@!$C!"(GR!$>P",.3"G5F"0\U#_+0#,.`9XW$)/6POU=C:B&P#
MS0C/BN!"+GAE-0P#,_"7-;R"+[`6X@D#J=07,M`,/6B=,E!=Y8K*EP6)^.93
M,(P9,#@112"#_S!,;^<90S'<PS7@`J]A@S%$Q5S$@C&NT*_>FC7XJ50,XYYZ
M7T;#!690:@?R1A&--$7S1C`L0/3M:DB@@)<&`P.(R4'2J3[<0@!(G@9D0/T6
MPP&4P`)H`A-U``A($6^DA0>DP*#HLSX@PD]ODYL,E+RN$`>K$#@ZQ5G@G:[J
M,S/<4<A0!#:`C!J%!#;<73[1X`PMI1H9F3FL24-MQ=;=PP>V&OG<`XI5*T%2
M,A3?PEHB$CUPV&C9155D5DA0M-*EPT&:0S'(YUU0JJ"Z,)T:63NS0@SLP2AX
M00WL`18,3@_PP!L``2^T@A>0+!7D`1W0P3>LB"E4`2SHPS"T@2F80_\^0(,9
MC`(=<(&$TH$IQ`+0+($KYX$75$$-\$+FS"PY?,$8G,)=ZP8Y#`$,?,(K_,W?
M[$$<U(`-X$`%=$(VP$$-3$$/#,$1Y``05,`<=`,<@((JP((D[$`ID,(C/,(<
MH$(ON(`+Z,`-/$$1H,<.V((WM`$%(($0[``?U(X4*,$3!%TQ@L\VBDKE'2F?
M9.8Q;IT]_="&E$.Q>$4ZP(-7+(,P`-3ST0-E\5'QX=^:E,,[A/`ZV)[J4NK,
M[)!<!.HOG0,*K,P\/%Z0C*F&+,,@N4.2N`5%6,,S('$*I0,U3,.0S$-5:*Y4
M^./V<`4^V)H\U-"%!/9(AW1C"IA'%VHF&`#_@?&N6)"`H`!#`.CIO$J%)A"`
M-73#&AB2)63!_"K`&B!")7"#"#A7;^CP!QPU?V6,!G=#/6#".`W*,J1XZ1(8
M`U,$A["X6M2?/TV#;A#8/1@(02KC.$BQ5#1)[.E0,*2J,")#IJ]#-]L/;`(;
M7,"(CF"7B42#,:B#P"$W5]@#-]@#+BA7/M"S5)P#/B%YD#0#L/ECD*CU8/:7
M_0`45XQ#-]^:?'+#/`C;'P#!'E!!%-R!+/@"&.@`OI&!%?!!.KC!$_RQ'EB!
M%5B.&MK!'G0!'O#`$]!!-T0#%\2!'WM!$T#;%N@`%.1`$!R'*7B"&EB!'CP!
M&?#!.$C!"Z#"J@<4_PXX7#00070D@13P0A5401(D`0SX@2IT0@_0]Q,T0"DL
M0R/`0AB$PA:0#B\HPA^$P2<T03N_`C1`0`U4@0[40!GL@30@P13P0!GH`"J8
MS1.\S>U89D1PGOVH\`_-P_]^R%QXQ0[.B$C+CS!X10TQ\5?7@\!4`C.0V/-J
M2)7.C(:D@TIJ22[D<P<"`@H@@LH5ZE7P`PF\J8K,@SUT^*^ZPR7$C#GPEH=<
MQCFDPSRTPUG,Y3V(`Y^<")=&+`\AK#X4.;C^H@NR#!8S<4D+F$E+162R23`H
M`($%@IT$PPBH``E<0)@!`P,0>Y'0M`%L0SDH0!LT@C`,PP(@0`)8PRM50O\C
M3+I8+`,SI(!%RF=6;$(Y5(*?F\F2#75NA$,L6((S$'K>S>:;;$.H4T2F+L,Z
M&)XR>#0S#$,QX)W]"&.@[N*B,L,K/$F7/$-]:74]-`/AR0\S<,D[U$\]^,(U
MW,/P"[Q4,`,\=`-HKDAY\1!%7\@YW&`<6<;_7M;*O.":`H0^@?K6Z:-W;V!"
M9^42#JQ7CQBV,%`^2>'!XXVN:*M`37E"Y8<H7J<^Z?'2I1H<+T"FD-GSI,L;
M*#S"@-+%1`\83Z:T*7HR1<J;.WQ<V6(RI8:=.SKHW`L3!%5#J5.I#LQW+L<,
M4LMB<)'BD=2<'#J\]+ASPXN2&TPZ,?)S!(82&3G_C,3YLJI+#1E&&CQI,$11
M+#5S0#W)\T52$2E'C.#0I:A+'$9=ED3#)<T@L&#C])%C*+`;KFGEZK&[AW"=
M,'+Z\A4K*!#?P'7SQJ5#.#"<-638ZNDSD693(TO%IB$<]TZ@LF'8T+$>9VP<
MOU?0V,%CULR@/A7_QDT:H2SA/H'FKM'+-Z)?]G3,J.GC%JL=.7:<]2$C=Z_@
M/7+F.D?K38Z^<:P1:!UG8KN'GOS&$2<V@<Y!B)YQ\)E0GWU6,XB_A#)DK2%^
M&DPH'WWFJ2J=$:L2J)D$Z$GH'&><`0:[V(`1`+Q[/I0*'WZ:25`839*Q1Q]F
M$`FFPF9NX0:_J58LYQT,_TK(SIE*,!&FF7SR(:<8?"C90*`0^5GF0@V+B27,
M@<QAIBIZ;M2GG5>8@2>?<I91IR%ZAA'&F7HR#/$=Y/0YYS6!QJDG'W-6[#*9
M6X11!YZ$YCGGG'S6*688>I:A1KS8EKFE/8&V*4B99?"IY\803SQU('PD92:=
M;9"S;C6$]AGGG(;"$;5./1NJQ\394C5UO!7GV7`@>O@YM*%\Y,&%&$6.^*2,
MKS"*Q(E5BHB"#"FD>`(57CKI9!I8:B!C"2_>,*(*(_*0PH@>K(C'F#@4^4:2
M)GZ20@<F<FG"&"E^X(&,.#IYPI5SC+C!%7W61/54<7!H((Y8<N!B"R6DH`(6
M:?\@T(&&3ESI1@YS/6FC@25NJ.`'(WIQ)!$*NE!W"AIHF"&*%Y;(@Q%"L)#F
M$D+B2.()-W#I9(HX0$GDY=!TT6>;2")I11UK3`SRE6(Z&U"@<FXY1I]ZREEG
MG=@.I8><>M[9YC,1*;V%G'=0V$0?!&_9I!QZZ&&GMWJ*N:45<>+6!Y<!US&&
MFVZ$N67%2E`8R!`5*E18S7V$N02["\#[,Y-+)E'A`Q$$":$$$P;9I*!TN"FG
MF0O-P68>:ZSI3>%U]%MGQ17Q>9T:J</[\S5\1MPGG#]K;>@V)8GM,NZ%"42V
MJF8LX&\-\,03R!GL.@L`$X65%\AN\=9IYV][8(==H'K_BJ=J@4H>#Z<00SSX
M1R`5--''.X49GGYZ@:Q)ARJRI;H'.06Q&[#B]JG7`*I!XP"2PL)Q'T'!+D(#
M*8<UWE$/:_1N0(\R&VFL@8]PK`@_RN@'[)HA#'VX`Q?M6-,^\L<\AC5$0/<P
M!X+*,0_PL68?[DA/JL)Q/'V4PX<BVH>:&A(;?-@M(6$+SXCPD;\NN4,>N</#
M$_;P!ALDP0AW@$8KP@$+&4#A"6/0@0_N8`M>S$$'5O`"'JIABB[(`@RDT,87
MD@`$@HW$BE#0(P^JL`M=P"$9.ZA"#7HPBD\8)AQ'Z`$K./3"4XGG'$?0`2-@
M01<I*$$)56@"*SRAAQTP`0)8_X"'*9BPK0;\0`U4D,9DO)`$'."`"Z&(0R^L
M\`0HN,`%77#$(LJQBB90`6A5.`4KED`&*F#A"^R"QBN&$;=A$,,;Q$!3W/(Q
M#C#IXQWI((U!E,&0=]2.',@"FVS*$1MSD,,:V]"'(=+@M7*<0QG"6$&<D`&[
M;5AF&ETS"#;H%`UH<`,7:%+&!NBQCR;J8P1$$DBFBB$,_J#`$)-8P08,40QJ
M8.(5\;1&,"IQB!*4X!#DF$<Q_$8@88P3-OIP'?A.,Q`!'81\^C#'!7='D&DX
ML5B'(J!!^"&5$"%Q*J1"U3DND)Z>&J2@^O@'(@:2`*9NKTL?6D<RAE&.>YA-
M;/00AO\)BT=$4Y6#&0:8'Z3^=PSLU&\@^UA'3&5CCA`!"Q_>``?L##J0><AN
M*NY`%@'ST2A'D>8>W(`ADKZ7Q)8RSQJ'"D=L^.&G".)CF_4H2#D:58YIO`,?
MT[@&5%/JR`]I%1GS`&+9Z'&-\7!/-F$+E$#F00]SX+0SP9.*FAYR(WFL-E4N
M[),^AE&,/%!A"E.H0BF:8(4<\(`*NHA$%W10!3W<P0=V6$(#JN`)6)`B#G$X
MA2YLX8E%K((18'#!"\8@!2CH@0Q0T$$72+&+)L3A#4L(2AG,%853N",4?&B%
M(QD6FW-TX0Z*^,41MN`%+RR!"UQX@RA@(8HJ3$&^4JA!!/3_D(HYG"(,7GA"
M#L!0A1Q`(0Y%4((7MA"+4+P!%34@0A=`(88G6.$-KJA&1Y[P$SH`-PG0@$4R
M&NF>;^#V-`6IAV<&<H]/P>8<JM*';<Q7OK`YL&L?.(<]5),=%$Q"'\M@Q@+O
M`8]J].D=^;@&-NI&C)/&9@/J6Y%X*!&(A`!5&9.P``<F`0QSK(,=RW"-,#A#
MCV.8YA:"^,`K"#*V5\RC'@=1V#PN@0U]X*U!J2G(A!J$CV=<+JT&16?_II>/
M?1!P82%2*U4*V^,BZB,!V0M&)HIUCA2D(#L;^$!VTD1$?*P#%Y8`!C9[DP]Z
MW&(2E;!'\9@(&V$48Q#+H,<K-!&(_T`$@T(S?44]`K$X(Y(#&]9+8D-+*L%8
MM"*?^3C?.W!;+""MXQHQO>H[MED^=)"C&]9@QH:J$8UJW$/<(6I',]J1Z(:L
MPQQW;1`]F.$.>RA1INMX!S-Z\[4^C:,<WH`%[6[$6?N=ZG:O0(XV5_0.<NR#
M?$RD1Z^0=><_36T@Y"B377$E%7G@0QX^_=L)%<TL14B!"S5.Q2IT,`8KV"$*
MT!!%'H#0W"G`P&/=,,<J=G$*6;BB"Z=PQ=,BH8]6S,'#;W!"#L8`AEWXXN93
M^#`M1`&4-_P@#^7HP@_VRU^&S<,(+WA#+I*@&"DD(0E;`(,.KC`+(A@A!E?\
MP1OP``8E&/]!#5X(@Q*(,`4#/X$(2WB"$7*0A"ZX@@D\,((4;#`%'7AB%F"8
M0AG*.P4S./X)O,"$,CPMD&HDHQ[M2*Q`($0[=OSI,_3X9D/,0>ZSI:,W]"@-
M8?6Q!D,(A!G((.(X)%".;7!C&_Q!"'+(8=K7*;P<N.":+T:@C\5ZVE`DN-`1
M]?$,$HR`$BCPP]]B,PW9#^@>Q<A@W"B!`343Y!C+.,VAVG&-9?2.0,8A'&+.
M=WH#>,BJ(;S!&M@!Y1("'^C#U&AM*J"JW!I"/"A*'_R!$@SB'T;@'_[!&>P'
M$3!@YJBB]09"&3`!:ZY*'^RA&2!!$YILH>HJ;I#!$=;@FUX!&/K_H1`4P`)V
M+1TT8;\Z`,N,:!R>0;8T1!->X898PQ[(`18<(1I:*CLLZ'S>S'RZ81CX)R'J
M81J$09T2(AJ.[17"!!_881C*1B"X01C\HQMNCPH-XADV)!Z&`1?H9.:P!!@8
M@A[09ASHP1JP@1N2P>+XZS;2`0Q%A!D:9!^:H4$0XA[>"5EV*]$.94T:Y!UN
MXS;4:K&F8A],3BJ`KT)B(T1PH1I800JZ@`NFH`O"80N@X,-^(!*8X+>@(`K>
M@!%L@1&P(`Z\X`Z6X!:S`0]J:0_<`!3<H!=@X22.H`N\@!%6P0]TH`FJX`92
M`1;XJ`NHP`I.@1NZH`<2QNU.I5"(H`'R_\`29,`+N,`(GH!=J$`*D.`+\H`)
MSNX.PL`,=@`'E*`3$@$,O$`,C"`)OB()IB`)+B()&(,(C"81,L\*FJ`4OL!B
M'HP=O8!=I,`3&B$6N"P9N@$>>.4/#6)6Z*&A>F,=QF$>=@LVO(<9Q`$97@%Q
M<`T7D.$:DF%O..!0N`%LQJ$@#J$0BD$3V,$:!.L>^.<=K*$VD$,+F8&9/H#/
M7H%KSN$5QF$$U*>N$&$#**&G^F$3V`8ARJ$=LD$8KFH:CD'(R.&DF$$#YJ<<
M5(.PS&<;D&$=K&$U6`CFR.'6:@5VUH$<"N+E$L(KNZP"%09K+LY,3-"%4B4P
M4P6AW&R([&8<,O^D=O0A$P3`'S!.*DP$$LTFT3+1*FS-1E!M!>*F'I;!$-;`
M#Z"M@L:A43P@>]**'V#+(.P2>88-%J*!"U&K'I!D*O0#(5KG?&1G')#!KU(E
M'3+!&&[O<<@!'5PE:W"A/5RG@I!''Y1A,-_A%I8A&;2M:QIJ0\+!>J8AG98A
M'$]E':*!&$YC',+P3[23(#JHD2*1'LHI(6).1([JT6)*J(9E*NY*YM8A'J0B
M%Z#!$<SE#:K@#O0`ZFY@"GB@NV2A"[K@$S[!$YZ`!VP`"FB@"J@1"*)@#&Y@
M#"HT"6S@!N;`%#ZA%TMA#N#@$YB@"X)`#48A#H0+#*:H8*@@!TYA/$__Q1R&
MX`7P8!6(X!,Z80NX@"(+3PJ\`!JN@!5"P0P:H`:P2`F\BT7!(`?HBPLBSPR2
M0`>T!>^:\0V,AA'FP!7"(`[P8(W2T0MDP0M@@!$:`186J!ZJP3;F03Q,+AWN
M5!C(<B!PX4*Z:LF*X14N81@D2QB821^.`1@(X?A.0PW703R+P00*E36V@1GH
MH=\$@AR,89JX(1)>`1(^X!Z$P1*B@2!:01,H`7[$(PM4@#\*RD@L81SN01V*
MX1J>(=V8H1RZH2#&81KP@1KP81D^@#H!J!@0@AVN(9SVH1V&IQZ487@L1"#D
M81EJ94*:@3[O$A)7+E6TM5BH`A^"*'889A(X_\`@4B`$!84>`"%[8L,!"D&?
M^F=A;(?=3J.E6%!A[($>Y`%!]*$8#"`8\B$V#D$!5``3#*4>(DH?QH&@<I0U
MWN$8BD?<N,<:K&0JI(_V6(0JO.8>QH$;F.<:KB$>F--&8H-VVJ9"3`50DJQ"
M,,L>E&&UUK)XUJ&>#&(8UN$8*DT"QW,?IF$8X"&;ZL8@:(=8TL$97*@>&.Y\
M($NFB"5!4BYM8!-:IV(=!*O(]"$7B&$.O*`*HB",@*`4ID$'B@`(]$`2DN$=
M7N$-/@$':(`,DH`61T$6DFGPU(`7\``/:L"67N`)4L$3;($9DL$5.F'S[.`;
MX.`)RL#QS&`+9N$<BO^@!W:!8:MB'7#@!;Q@%7+@"([@*YY`![A`#'3`#CB7
M,6Y.#S@7B[:`"C1W';<`[Z9`"0IR"L0`:,#@#\(@#(C`#:1`$:[@2+<`=;>%
M77)`&C(A">%!'>H!'HQ%--]!-1\-I9;,.?U$$X$O'?KA-=Z!&ZPA'KRF`UK3
M"B6H'$S@%8B(W9C!&$R$>8OA'3#!$KKA%@Z!#>HA'=K#'O)A&Y3!'5!@15)@
MUBA-'X!A!>SF'HP!/.MF&A1N0+:A4TY*'X3A`U8D+A,$%QS-(!I(IC[(5$JR
M:X#H8L/)(&J+]M*FB!J01:!V>&9K,$\D17I*31X0$RC!$()!$.PG$`(``CW_
MT8@:Q-_&(1,@P57,YZKLU2!&)39L4+!,Q1R`84C&@S,,H0/T(1B4H1"GIQV(
M81OR@1^DV'[PC7O"D&PV2V%TLF'-H\C<81\@D7O*P1[",!U>(T2N`4G*08W]
MC1["0;+4.(D(XN-RZAS"9,C4$$'&K#?88QS"A(5R](B"81FF@1LJ:!LF9(9&
M#5/7X1S\9""*DJT25F438F-ICGE:Z]1T!43NF).MEAA480M&;W.MP!.D814N
M21JA80Z`SA.8@`Z(011&@0JBH`R&0`>,H(J\X!08K`F`X`[4(`]T`1>*8/.H
MX!M<@1&$RPR\(`JBH`I$H1^ZX`E,(0(C]X>:(`D\_\$7<F`*WN#%H$`*P,`*
MJB`5C``*;N`'.(8'7&$4GN`&Y&M!><`+IH`+DF`)[(4'>@`*O(`5J*`&<*`,
M8&`*?J`48N%(PT`*JJ#`A.L)P.$5KEA09(>('*(8QN]#S.%33J=\NJ93`@O*
MH@$YF@$#MH$>ADW_ZN&,@200U@^-@74:@L\]D&$9-$`8N,$!D"$9"H)B[8<#
ME"$8+(!.IT892*!KAF$5LN$;JH',5`H=JL$:4.,8V@%QJFW)D"%W1HX@Z@%9
MZ:$97DLV='*U[N&N1,L:X*$C4ZXJ\.$*98,JALA;29@J+(#5@L'-SH$#@@$0
M,N$"Z',=`N#X/@3EY+J(U/]$&1JA$MKZI_Y3$WOMAW(M&?9O1Q*B&390'U#@
M'^@A$S(!-I-%($3U%NZA#LE'U.*&&GIC&F[A%OAG'&X!3>XA^5;+/@7B'1J*
M'-0)(:[B4([W4-Y!&8JAG)AA&&ZA'.*!&G2:'=+!OS9YY*[A%KH!0C#KM@I"
MY;;!'M+A2*+A,T;;`D'$I8H#&6H['8!JK61*'DAR;)(*:*N65J;B:\ZA`;&7
M>\A'LCC9K0CB0T(D&J2!%(:T$\S4P+1Q%U;A"3YA"<8`""K`!\"!%;H@"G".
M"Z#`#O1@##ZA"I*@"E)Q#CR!%R0!`HR@O,I4#Z2A%9JQ"LST#>C`0%$A'3QA
M#T3_P9NG@AFVH`SR(!:((`F\X`@\(@KN8!9FX0@@3PE0P0K(P`8>H0N^`!HZ
M`0Z,`$-U``9T``^&H`>J@*`[H28(*0KHP`K`J`M@`1J\8//HJY4\SQ9>H1O,
MXQZL`4A@^F+UX8`MF4,JV5/N(\A\.VNLP1WN`1N0PQ^86MS2D_;NH7[]80/Z
M(4,:KAJ0%2'J`:4/H1*$80.\(1E:03V%2@4FH0.`P7<28APNP!YN853C@1B@
MZ:J*@=6SYMBX88@LP$`T`1FJPWS@P5%?IWP:I!P(!SDOEF.Y87OC`5GP6B":
M<(0?IXBVAY)?:`.8NAG\03P,X0(NX`,TX1R0"!`(`#M,_^5#C@A9"FK@^J$<
M\@&(NP82KRI$8F,$/N`:,I$>4*`#..#X5D09W!4?%(#5G.&&3P1@G<'-XZ8X
MUD3<F#,=[@0YUA([Z@&H;S-G#8(:,B'Z'/`Q]2$:H$P?F@$8;F$T8;L;]"$9
M7D'C;F@?:$-L,C43;J$?W*'0"&(9U.JRF&$HH\$\03(<OXHTCN$SY"38`\Z^
M<<.QCLH<R`>R1BZ(R.&$&Z)M:%`V_&KWN*<)`3P:/,$+FL#`O*(+J@",\`!=
MC,`*[F`//D'#H@`*[N`.MN`.U.CT?N(GJL`*W!$//`'`4,D'Z``68N(.'`\*
MQJ"4A#D?KJ`'HF*G(C<?TF$(&O\`[XF`!Y0`**:`$7X!":0`!M2@#_A@'D!!
M"LJ@`1H`BW9@%$(!CG2@!_*N%+I@%(Q`";@``F!@#[Q@#N*A%7[)"(Y`$4I!
M<+T@#K9`]7D`&6"A/21E&@"V-^R5W>(&)04B'2QYR";+S\DM$LG!/_3!V;+#
M+%]#T?,!&#8@'YBA'60'0<!G'#YR&O+L`[*@$=R#Y&\#8/4!$`+!%PRE(<YA
M`]YA&4PH'7#!K]8A$_@'/^H!((Q-TZ>/7CY*?L(58S>/7;U[]ZCAHG:/X#U\
M]>@98T:P(\%UP^9!A*AOG[Y[[3QZQ!=.94=\*5WJR\=/IKYPUFRZ])>`8#!_
M^L9MZN?_D9Z^>@Q(E'19#Q^^E_E4XJM8T1ZW?/&HWK.G3Q,`2C/U_<.D3]F&
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M\4(>L!!1Q113/'%'*%W40(8+HSSRRQ%$<'$@#4&\`(0,0W0"PQA)3('#&TE`
M8,,,5;C@`QV*?.$'-JK0\H012"@R2QG]>:&$%$]$\XHU^-"33F\GU?/6..58
M5`XUG3'SU%SV,,.--7&>=,]W^I!C3$XH@#73.MNLN0Y#^O!D4C?=<*.7-?#D
M4\XXZW2##3L93(!,-_>4`TDNZMCCSCOZ8!)(0<KA<TX&KR!3SSG*;$</.:]<
MH\]3TT03C3?WU'0/,A<4\PYFQ]Y##C?7;$?04]9@(XY=@=VZS3@DJ;293?6T
M)-,ZUV$WF$R8FEA2`L&DFJY'FFS@2_]8E`B0R:XN/;=K8("]\U`^#U54C[YY
MP7//.`28H,\Z1A4"R%,D**-/,R40-`(*!9D[4V`TZ5..7AV9=%(\)\F$JDW!
M`=97G',!ELXTXJA4D35LWGNP,DT55T\SX;Y5CC'J=+1..->`_$XWLAK3"CL>
M(6=B/NO<$BE'!UNS753YO!.38..$VU$YYNQ#G4?K/(61.3&-J](YS(`LTS;T
MI.QS9Q5)@\T<7NS!1!=[W%%%%7&`84H<<>21X=Y,O!@C%7<<",4=9LAX8'LQ
M>O%&%Z$P8LH7NRBBQX6=?&%&%QU*P<<^BHQHL8D5B4,$#9Y``T,22R1A!"]=
M\*##$3&,X</_%#WTD,06H,#"1`55T&`%#C7H,(L4,.3`@PL_T."#EWZ$8801
M9E!@BA%D'%'$#[Q0H408"_J0S"O15,1-.F_1X_ZD?_G<SCGU6*,752>M(XPP
M>^6CU373H$<'@+&K-,6)'N581R;6$`P##`8>\?#5.J(A&7K4@QO3@`4^/C`"
M?;R"?^DPQBND@RI?4.Q]'+O5!RRQCFF\8AM;J4PTUE&/>D2#9<APR,&`$XA#
MV.,>["!'-(RQ&63$;SG8($<[FK&=N9S#6/.PGW*,H[6SC<,FY)"'3<Q1,H^$
M(S4EBDHA.$"0<_##),[(!#V$D8+!F$0%!N"(8_#QCT84IC`6#,M1__Q'F5"-
M(Q/"J*$%]:*!`Z3&,?3(Q#E0@`BQF2--"9A7%T_WE&V=[F`>P9?;/-*:31*$
M',?H4T'^0@\^<6P?'EN&K.CU%'X@XY&!:4<Q.).78E"D,,,HQSU>P0E+P`(8
MF;@'OG12CELD0QW<^,PVV+$.5.7#'9C2(KT"U8PC=J24UL2(QYCCL8.5S'U'
M,<HPY\&V>KW#+F')134D,84J4,$+5.C"AJ"0AU0D`0PN>D/=2.&%*4A!GR\J
MT!T`]"(`\6`*9<C#)^KVA"DHP0NL`,,4XO`&+IC!G50H0R_PH0@:B$*/E]0)
M.8;0@#?`(@=$,((-O.`)'$`A!TKX`2I<T?^%'-"`!S:(@")(`8MMN&$4>8A#
M*$@!BCS<811;@`8L2D$+",#@!S@H`AYH(8T=2$$)7.C!+$)A!"I<E0G"V(4T
M(%(-,'JD,!1QV3J6L0R;C,,8Y%B'5I:C*WQTH!B=H8<SBD.)#33C`M>A2CF^
M08WTU;`PT(#&!PIQ%&2\(B7%B(4U4@,,$M`#'O7`;$6N48P/X,(;MB#&/;B1
MC&UL@QM`K$8UU*&.EG1K&7:Y!0;XU8YH0",=H3J&^Q!H1(*$(W[*`HX^UK2K
M39K#K"H91TUD<ER;Z#(Y+AD'=$TTC@4X0Q^5((L^$.$'@I3`8;O%``+BE)I)
M5*(1F!"&-?*"VWC_7$:N&\O3+4QPB%?,(QVHRL(`"'@=94R"('HEB#-0H)="
M6(`@W;S-,!'\#F>YI)DV00VWYJ))0$DE'?!@1S?TD@]\1&5:XSBE4=BACFN4
M#!_-2LU(]+$,:URQ*?-XQ3>^8PU+M"(1B$A$)"ZA`C9TXS:N`D8RRC$/<KQC
M8_=HXK(.=L3-R$-LG<&'/;;1FWQ0[6`)3+#&`*4<?F&L(%KVB#U$J0^8K4(*
M50`3%.#9A5)`0Q%=*,,/U$`%'?B`%['(0QXJ*@4?[$$/5=B#.[M`!3?DH1.\
M",40C-`%*;CG$^?[PQT&*KGV[.$4YE`$&3ZZX)!Z1!PQ*L4J<K"$&.W!_P@W
MN`$0*J"+56P!!E9(`A1TX`(81.`+LU"$(N``BE*T@:ASB,,?5.&'"-C@!C)X
M`A3*8(0C[$(73K#!#G9@@T[T9TQ/F$8KJE'#:7#L63^D!S=D4@]T\,F3UJ#A
M-)@AF8K,XQKW,,<&LF:-Y-0F9(9P`"4N$`R]3,8HW'`:A>\A#`40HB#U(,8N
MH($.8;0"%]<8A%+F<3]]<.,2V/A`KJ)1#6H8XQWQ2,8ZO$$,;L"#Y.R0!S*P
M(9)Z'.,"E[K%--9W#VO`NQS,:,RSQ&$4<C#CB@21S$N*@TZ7F"-F'<-'%8OB
MK7J-(\PV><H__E$2>HPC'\%`@250`(AK1B4!#O\PRCA*T(Q#J$#KLZS'9[3R
MFFVH0!"#((0*#G$,?<!C#0!XQ3334D"G%"08)NG`?RW6Z;Y\PR;K,)M*[/4M
MY(+M.QC#1SKL0AER1,4DN-789SA&F>C$SRG3@*]CE+4.J9&DL-4P!BPL(6-\
M&,,6J&H$)#J-RGJT`Q8#V8V1/U(.=Y2#*Z':50V?K(]K=!-1-/3D;L8Q17TT
MF![G0"XX7^*QZ;J,S`!,Q!3&@-`R5,$-ICA%(HR0A!W,X1V@,`\7=$"'4^`A
M%'M[PPYXP(0\="$.I?#$+*X0H#N0@AC2@#O>MPNP$`?M82``!0KZH`A[0"*>
M!A?A(`4]\`C3T`-[`P/_/*`$5/`+H)`+O^`D.2`%.)`#1O!GT:,#5``*N]`)
M7:`-53(+K/`%,/`"-$`'>$`$0D`$4U`#21`#N%`-GY!K-:`$,9`A3V`%W[`*
MTD`/\3`-^.`Q%?$^XV!A(:-V[5!ZY8`OY(`R1\8-J#)!08$!US$.T4`-HD4O
ME"`"D7`!TW`-^O(O%;$-Q9!,[.`O!@`(V\`,\``/T9`+T%`-Q.`*N9`!)P`1
M1Q8/LY$,V5`"EN`-B35#[X`,T]`-%%0/\5`-W.`-U#!NII$I6:`"W,`:W"`I
MT7`-T&`-BG<.P%(-KS!N>F$/[-,1]R`2^F`.3:<2:B<3^%`.BB<8UB08J=%\
M_S)A$L&P`#5!"2D@8(BP"5&6)@6A`0&@%LPP`J]P""@P#2I@"?IP";Y0#,40
M",*P"1TP#2.0!24`#!W0",D!C9>`22[A=\)0"01A"!<P34^H$U&F$]\@C`<#
M=?CPB]<$D)^D*X&1%^MP#1P3>ATQ/T'G#<0W#RACB]*$#G9Q3O/P%.:`6NM`
M#481#Y#`!K`0#_`@#;M`':SP"FKW"G-!#Z@4%HB8#-'0-GK",?G08D@3,I]!
M#LS7$=?P%/M@#M'G32NQ&<W@-O=@$L448HD!$;&Q$NY@$Z;!,<1`#7`@!=Q7
M!6;@!=IP"C1P!$`P"M+P#:\`"@,5`S90!C6P.WJP"_]>8`=`<`=OP`MXX`4U
M@%`P,`6E@`?24`W,T`J,P`-)\`7?D`=2T`55\`9@$`6HD`]=0`.G\(!P,5(-
M$`>_D`-F(`4Y<`-+D((X(`LPL`1*H`0Z4`%Q&0>,``ZG4`,_H`-&(`5'4`5/
M@`=;0`0Y0`%Y(`VQ``JV\`8-(#LPT@2OH`5J,`<VP`4A&`I<H`3$``O:,`\1
MM)+[\!3^(QW3U&$:TQOGH)0$X0Z#I`_MH(D)Q&W6,`+)D2G6@`OCMA9K\`H>
M0`[8L`T;DWSWH"_%8'KV$`!9H`\E5P[<$`W?``[5T`K=X`@F\"^Q,0S&1`K9
M$`B70`RYH"N#<`B)E0[L@%G_^H"@F_$0\#`/S,`,AM!UDA$/Z:`.T`!`&#$3
M1F$-X)")($,2E6$R'S$P10>C)D8RD[0KYR",ZW`U4/>.^H`"@E"+TE4Q*^%A
MEU$"`=`(!&$.65`(Q8`(%O0!@&`(AO`!);`)"E`"C2`(KW`)%2$,!'```R$I
M[_A(98$)[F,!8,&/,I$/-\I[NAA7V!$.GN1;)^)\Z=D1&?$.U+`.[=,,@]$.
MV#`5'18.=E$//X9@:$)7*]D,R1$GDS&)A-`&S#!EW1`/X(`-TU`-N(`+N>`-
M_E.+;?,1VG`+W.`7PM!6#Y$.M]!6>K0.Q4!D29,:[W`.([-E%;,..I=\*O$.
MUH`8_R&C1PT6*6ZC-"+C3/HY#:1`!-S7!4W`"U^P`SKP!U!P"DY0"F4`!&IP
M"KK0!4L0!$!``T`@!48P!?L!`U5`?E!%!"S""F[0!7A@FHH@(T80!ZY@@)*#
M!U'`"_00!C;PF)!I$^(P!"_@"8X0`YU@!#)P`U-`#)8P!YX@!3*@`SA0!<E@
M"W%`!$>@!=S@`T\P!$_P!%WP!#X"!44`!3A0#U_0FJ"@#9]0!36P!#E0`_1Q
M"K)@!$2``TJ@!TI@!-FP"M.@#M^P7L]R?+=8%$UA$>G0#=MQ#M?!-A"6&["P
M&QWP'>_P%.E0#=Z0$\"@<9E0#LAP<M2`7Q"Q#?90#]^0#/_)4`P!L`((MPW3
M@`S#D&35<`G&8`F)@`VL2ANO0`QBD079$`\@(P@2D&[VL`[JP`[E<`GIB5D7
M]`K'``P<X`[<\`W=H`[$\`MSQ`]/\5;V`Q'V$!7V4&\@91+R8`W+M7C+4*=6
MQRUAPUP"::-&T0P&0!3.X+:[8A3.Z!A):PD!@`"WL"N0@`D=``F5D`4=4`D)
M4`DCT`B',`F-H)+Z0`TE(``B0$/?\`Y09Q*3X#!BL0&9!%)PP8^ZBF!G<S4O
MH0_GX&`J(:L=$Q:LH1)UN`Y0`V#D$`[[@)!)DZ-R:A(500[JT`W?88C,D$#R
MJ05M$!MY@8G=T`[B``W)``NK<!W_/UD0>.%"PI`.F1)Z[%4-MO5M*($,UC!,
MB')D7J=#%N1@;?-MMT(/)OP2%9$/RD`-7.$24#<2<T$,T:`*2O`B/_`&V!`&
M>>`#4;`#KN!^/P`$9/`&3A`-MA`*H/`&$7L'G_`-C"`%7O`)4S`*BB`-EG`%
M_30%+$4*<?`$2C`@IV`+3^`%4F`'4X`*]%`ZGA"P`BL$+L`B-F#&1Q`%IK`*
M8D"$MB,#^_H%1\`@Z;H%NY`+32!K>%`$7F`$8^()O``'.N`%9>!0>.`*3`!3
M7#`$8>`'OI`+56`'.@`F.@`-V\8.*T,R['M6('P2P\`-S`!#_\(O-00/IJH,
M*\`7!,$._[7!#7*X`;<@&=2@#A!!#L_@#9@5#>ZE%Z]``(.`7\VDRK>`"WI!
M#L.0!8M07]$`"[^B#N0`"/GI7NI@`@Z0#YA%#^TP#)=0#0Y!7M[0"G[+#!>@
M=M&`"ZO@MR=A%'E!#V>2%]'!%[P(HTO!14Q19LQ0IPCC)L_2$>8@D"Q1'&R:
M#RVI-(%`1OR0-0;A8=-T5O`@#!\0`!Y0"7^Q##)7#X60"8)P/LSP><60!0)@
M`)80#_S9RIRD#Y,`%,!@`$"7OK=A?>]X#CW*C_B0J#8,D%Q1#JTL,&5&89]T
M#NNC#VJ#9>0P$`X=8C!C$65K#,%P+.OP`=M&#-5`TWEH#".J5/_8,`R@D7GO
MD`S"0`S?<!JR<136P`SF($KU8`[D0%Q'X3/+<*M1T;FZ^AD6X7R`HB;@],)N
M^A3J4`[3D!4+1ITN`P]^.A[$\`55P`,_<`>SL`4]P`,X8`6HP`V8;04_`)M)
M@`=ND`S7L`JL(`F[0%.Y,`N9#`OTL`H1FP-[8`5,X`5=H`N[F02//`6G$`=4
MT$Y5D`?TL`4V\%%TO!+%AP,N(`F@T)MXD`@-P`?U5P,V0`-3(`.CL`HD2R9X
ML`=4L`[V``YUY@F[@`H40`>LX0Y-L"'M-`5&T`JL\#HYD`-,(`5(T`E$8`5S
MV0!+D`R,@`U["$.(9Q/[,*CO2`VZ<'C_+BQ7$.%[M\`!OR>+#4P0S*`!PE!W
MZ8`-O-P.R\`,T.`-4MT5"F`"PG`+-61W\<`,L%!W)]`(U)`(J[`*E]`.\$`,
MQ"`()Z`/X``+T*`"#*`6[\`-Q4`;HZJXUR`0F?4,'5!FMI4,'#,7^#`-P]!$
M;^AO1.L2\T`<A'%DW];0ZR!-8([F9].+^%@O"3!XB``4;+H4^A`,&C``!7,+
MVZ!S_$S7MR`(&!#3A[`=W0!R66$3S6`(`*8`_S7G4>?3'J&341>[E$$RA.%\
MND(OAO$1Z$L0]E#5[S-ZXX`+[7`1+EQ)R[`=AU5#Q<`1:1@/ZI`,Q%"'\<"G
M/`,+KS`,@+@=_^_`#+<0#92H2VA;#M?`#FV#-FYZ*7\Q&2'3-N9P#3DA3+*X
M,^W6T*'BII#Q;>]PJX&"7\XWU4,I$X<K2M&@#5><9L*]!'9P"G.P"MI`)L*M
M-SYP!T_0`%#P!J=`"GF0"+8@#:X0;*80;#5``WL`(P/%;&`@";`@!730"0\E
M./'J!;Q@#YUP!ZX@OL_M#&(`!:Z@"DM`!%00#3)P[WG@!4G0.U20#5_`(#C@
M!:%0"NW>#-NP#[%@?.,0"_?0#^.P"G,0"J&P!?FQ!6&@#6ZP!&(`!E70"4B?
MW8Q`!$O``[FP"B8'#]3P'9.TDS)QM!T1#[K>#;KD)_?P&\R``/!IMO]!EQ)5
MTP&:\$+U4`WH\`WN=13E4`VPT`U<`0D:\`'TL`POY!T/00T/!P+M#`LXCNN1
M``GJX`L=4`ZO``OL0`@+8`CM,"BU(!G`LE;3D%BM40_%H`'7@`O20"I'21#6
M00[0@`U^<A2240^6T1&!P1*Q2V;[&W5F^HXSZFG%>%WT8`[-T*-%<1+4,`@/
M0``"0``<T`$EP$$?8``",``+T`&W\!WQX`[N`!%4J!+.8`@FP0$=-+YOZOHE
M,4SF4.8=P^8%4>LZX7AG&RB0.A/VP,_MX!";U`['(!U/`5WI\`KH(%<G81+K
M@`L`\2U?/7WW].E[E6[0FGCP]''#]>V>P63_C;+IVX;+V[1;P[IM@X6-G3YR
MN+B-HS<Q7K=XW*C1.UBOFL%ZY<09I%?NX$YSXYB-VQF4'C-RZ\H9W/E.ISYZ
M],SE.[@M7="@Z_91+<@NW3VHT*"!FO(IC`XH.NP`H[(+3I,H5N[D,/+)%3%3
M4IA$N:.K%!567$+IZC)E"I5<NTAY*2(%S!0H7K#9FC.+B)<<3$KAD4**'YPQ
MI_)=Q1I:=%!\^J8AL>%)%1$B2KJP"G5D"RT(-J+0ZB1FBA?%7.:8,F;.EQ\Q
M0X0,$?/'5[U6<^)\`>-ERQ<JBD)Q$9+D$V\\54J%$:*$2C17U?3)C,?T7;UZ
M2,L1#'UN'=9[^*:A_P,'35<W=?K2V?NFG`OF<^D:=F1BQYY\3J@%&6ZBR269
M>-;3!Y]\\CGG%6+4J02#$&#B!A9MTN$FG7?T@20+7%:)Y1M7&+GDE55P\0>%
MC*C1IY`21D`F%V@^.$8?:J;9Y1MHDF$'GWWP">:#:[31!ISV)K(&F6N6(:>T
M"_-)29UNCL*J'G+$H8^D$^E;I[2@H,*''/BPD@>TT>:L4)]`+(!IG!/.I%.?
M>-R[!9(1-,`@@PDT6*.2?MZY)QYUUEDGG73^A`DK>@(QYZ!"+&!*SCX_W8D>
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MGW"(:("46%A;`H8X0HG`"%7,R.&-5HY0(@DNO#"B#%#JB46(&69H@((<8(#`
MA1F4@(8>1\"((P\NN)`B"5I4$:,*6,)HH)-?CD#_P@@EC*@F%FGJ@2<9=?)9
M!YY[X&E/2*`^H\J<?@]24V!'JZGFRS^[>8<$879:QQIKKMGVGA)J*0>>>%I9
M(YJM&CZ('!\K.8"#3-_I)AKGHX'&&!/:<&458UK!GAA<8EG$$A$6V64J%0KQ
MXQ58=!<D1&1VY>8>=MBY9AI+1A`'FF^D\;P=9JI)YQIRD+I7HY)AGM"0PQL`
M#,HY3A<4;D`L-.]HQZG.,34Z<6`$3-&',F9'I])`ZCP+W,D],/<-;7SC&_'X
M$SRX%)1]-(4?D\B4+PPP*A!2D$[;6`JL#*8FK*0I-/G8!D$N%)1Z=(-A.RG'
MJ(*"E&M8(QW?>-,]TB&._W3P!RGW*`<ZOI$,B12$'HUH@S2Z,1%UP",7EK`$
MQ*KQBEO@`ANKL`0L\%>/<0AC&@[9R3B,@0Q4#7$=R]`'I.J1#X-$JB#;2!=.
MND&5=9"C'>@82:H@",)RU-`_"*S*1/1A#&-\00IY:,(7JB`*:23""US``Q=B
MM@M>*"(.G;C#&Z#AB##,;`]Z>`(>IE"&ZKPB%UO``QY`<0IM*$(*9N@"&!21
M"%_`8@MF>,(=.I$#4>PC##R0F@W[A(TAR``5L="!$GH@@S%0H0<WZ$(V&H"#
M;KB!!T9X`A7`@(=9.*(!NWG!"V[`"Q\T@`9H6`($5#&+/\"A"X7;`1.RT047
M\/_B$4C0@0_>@`,H$$$*1HC&*J0Q,&UXHRGK&$D]&/4.6:$I*`CC$CZX^(Z1
MK$-;ZZC'.E:P08/<@QO6>$4R]($!0:3#&_DXA`FN88QH2&60#MF'_##P`66\
MISW:@,4K'.$(#9`B&[DPQ26P!XM66((4L``!%DQ!"&-\@!,LN$1_/C"!-4*C
M&C"M1S:,`0UQ3"(+]*B&.L#QD7%4@QO$F$I-[Y$K7"R2/N4`&$&41#MYB*8<
MS!"-PNJ1+QZNHQV8'(T.1<."%!SD%H?XU#TH9`]S8+$<U>(&-[J1CC)ZJ8S)
M`AVLD`((8!RD&0[P!P:U.35Z7&,T*1&-.7A(&FL<\2#_2C'(<.^QC6VLJ2#P
M\$8[L@&->43L(25:;4$(XA)O9.-_!K%$%NY'C<N^0@N1X"XQ6A&)2+0"&K@P
M1BY<88E7F*L@]T`',H!Q(D+>:QRW"&((#Y*.FN`P*.8PE3[@08YK,*H<PXW)
M.[:!0%B-`\([F7!HZA%8?;@5%#78@R+<4(8]N`$,-H!!/'50"FU$1P]X\$(9
MWJ"/872B"56HPARZL(,NF`(>R_A"'O+@B3UPP135N,)N>L"#),0!%IVPV2B.
M4`94S`,,U-PMG9@1`QB(PA$PP($-7&`#6TAA!B^`11P:D(AVD.('=S#"'7;1
MA0C88!:JP,,I>"$-7J""#J*0_T4#7N`)5H"A"5Q0PAO2L0H9`.$60\B!$F31
M!!@D07*46P4XYJ$.;^Q"M.DZ44WAQ4)\P'0G^R#(59J1IM.>IQO)2$8Z5E`)
M[?X+'NUH131"L(8,%Z(#]X@&,;K!#>:92![M.(8"6-".752#&BY=A2,BL8P.
M$,(6D4C&+<J!C&L%6Q\J&$0T8`$-#80W"[F`Q0<<D*UO&`P;PE@&,N`!B$#H
M`QW<T`8SS$$._L4#/DTYR#2PT4=8\6,:[=8D/:JK#W-,,#3T<(;G=L*J>W0#
M)C`99,/"X:D*50TK%Q8-!];@*T-@HDX?/T_H:IH3>(1`&)V#!SS684)OP.,;
MODO/Q/_U$8QF-&."P4@`)?0Q#XX?A'05LB2HQ(19IO0**^T(QZG`I?,+I:,=
M,('50+C1#Q#BEQQ69\>9;,J-6Y-C&U"Q1SJTD8TD#HP>(;"%-J;!#&)HP17>
M>(54(V&+5L`B%\2HQAM-88MDU"-@_8/&M%X%E76@XQJWJ"$YF$&-47/%'?:0
M8FKIP:IT##%>YW#'.IXR<<\G.$S6#8H]():>8,$A"5`HA2EJ4`4KC&(*!^6"
M&GB1"#"8P0MWP`,J1O$->W@C%G"`ACV0D0A8(%8;GDA%'+R`!T]X`A:QN$(G
MI``%X!_T!KH(Q?9[L8XNW$`468ZLD(Q@@U.L(@=)(((-=*#_AQST(`BS@`8,
M<M`$:,`B9JU0A3K;CBT@A55`MUT0!5%(ICF@`1>8!5(P`B_X!6CP)!UP!6A0
M@ARH@5#(@1Q8`M;(`7!8A6EH/!)BAW*@A@V+"7U8&(,`C=`QO),[D:N`!XMC
M%/88"&9XARS(`B^B!WNP!\P!EC4``5P`AWF;H0U+ARS0@FIX%G90AWI8@`R8
M!VQXA?;J'FKX"`VXA7A(!UP@@$6XAG9HAWJX!F8`A!!H!VH@!Q-80A"X%BT0
M`2U0!V@@AF%X!5P(AW-HK'\(!G$@AEF8+F.PAJ,0K9JJAVV8AFIX'WS`N@HA
MAV=;!X"9")BX!VN0!WPPKGW#A_HP_X@58H=P0!4UJ92B""$U<410H0?0`!A]
M*(<.4(%,P81FL(9QR(?A6JQ[&!81DB(M9(8!:(1[H`:R*T-X2(><`"G/X<6#
M"`1:TX=,,`!#Z#C1\#C401VFHXH+,P=XZ2]<F8].+!W3JXKF*HA\83QL@`\=
M.H=K*`V5*QYJ8`=X8(8Q>A4QF89RX`8#4S#;L09.*H<3:(5W,(9=8`1L02,T
M8J]L<X588"\0""-8^*II4`=LN`:N.`^CN)UPJ!2H,(AT8`9K>(?A@@H2:1-P
M@95Y0!6&8Y?2*(=1$XJ4I`J`HXJ17*0+@1)%J((D<`-;"`,OB(,[4(0GX($W
MX(5=F(-.B/^#,L`#5S@%47@%?A@'<6@%6\`%7."%>-B&<0`%/)`%4`"#-\B#
M/2@%;U"$,IB"-P@%+S`#&2@%6,"![N`#?0"%/9`:S4*_@\`&,5@"4G`$#\P!
M'L@!+_@$&Z@!1C!*%WB!+O"_.:@&W4B%4,`!3YB%5G`%%XD$7C"#(0@%/;"!
M+8"&46`"1WB$&+@!)E@%5<@!*1B%+_#`(U@")5"":K`$<"DC:J@YW\&CXZ)'
M?;B*>"R>W*2*<FB'=4B6220(89``7(`&:G`(8OD30LB`:-"&:C"!!QB&`<L`
M"1@$;6BC7.B&%4"!:VB%6,"%:J"[5C`%9M@`9YC'2R``+4"'8TC_!F1`!F+X
MQVE`!C_(`'0@A#50.Q.@A`\P!EBPA%SP!F_`AV58AE@``6*PA!C!AFJH.8L\
MCS,L!FMP!Z9@AUH9)*N#*:XP-9PHAZFHQH89APG"!^&JJ?-X"?K8!VQPH!:2
M2:,#.4::AWN8AZ90K`_@@.JZ!T+8A`I9N$`BB$;!'"_\ABP@@`<8@`-```T0
M!JV(%/:8"/8('7V8!%HCB$I8@-I2K)@T.HY;DB6A1JRX"D)JR2I5D)TX!^-"
M'1]*15)DE_L*BG?`AG;;"0M1$DA)"7R)F'4HD71X*1%BBF(8!XY@AGB`E'O(
M!FR`!6'(`C:8!DQP!6M!([^J!VIXA4L0_X9JR`4M<`(32`1<:(6I6H5H\)R8
ML@9R0`=R*,10P2(<8AW'NH5J:`\A8A7AH@>C,#6FX`8W)=+1J%%)\14HP1@H
MJ`(I>#X<\()2*`(>&`5/J`([*`,OZ(3J,X5O2`=8N((<D`$;D($:J`$?((5N
M>`Q/R`/@FP,\N(.ODH(=\()4T($J,`PI&(,NJ`)4X(<KZ`%3\)6[S%-]"`<A
M@`%'^(,AB+\D4`(A"+\7R`-;(`4=$%=7(`6/B8`Q^(,BL((N>`5\P1Q]N`0O
M(((:2*4&>)%08`4(&((\&`58>`0<4`15N`(D*)PD$`Q3,`5<B`=T4"^=XH:<
M`B!@8YAU0(;W>/^'==A('@*6[]*N$PD'#J"&8;A#:IB42]($#9`&:>"&$,B`
M1F`'_-*0$DB&;L!#7%"!!.B_;#"?81B2=%@'#L@"2_`&3/B`0K@'7'@%8R`&
M6$B'#X@$?2B!-6`'9(#2:,B":V#":^"&:>`&BH110?B`;!`'T`$=T7/;:Z`&
M9KB&]UB\P6(/0)V*E"`D0GV'6DPNI-N)<'"@:3PNESRU<("7$OVA]/,X=_'$
M;\L`9S@/?1"$28@7!+NB85&*F,J"`2```CB!:YB4=(#"7H$'IT(19=B&93@1
M0="`4:F'@J$*$4K%V?V4[C4(:R"3?_67="BZICM3T#`(?F@&2VP5;&C_!SP:
MKG,H1(5CF)P07T(,H?DH![;%!69@AF28!FU9A2*`!4SPA1.MAQ`9AM0RCW<@
MPD48(&K`!>$Y!ER@+[K;AFX8!U=%%8,X!D0"W?30H778AE<-#?.=Q!L-"F]P
M.IV[1&!-NJJ%BES0!D:``C*(@AW(`R:@`!W`@UW`@5%`A2>P`AQ[`T]0!%/`
MAB[0@22H`?DSIR#H@1TP@EW@!E'(`SVX@RT`@RI0!&U@@CPXA2VH@1M(!2]X
M@BIX@RB0&GZ5!?(%V(,0!R)X`2^#`1ZP@24P@A@`A2YH`"]@!%)0A1@P@AP@
MA6L0@P:X`=@0A5;X0AQIAEC`!U*@@T\(!0AX_P$WL(90*((82`)&D(18"`,I
M*`5'.`*%)8(D6((I((5%:`5XD`;Z>H5Z(`:MVCQ-4D0,6N!L.Q%N0-&3NX=I
M$`9^.8B:N@H4$`9NP)9;Z(9^TX=;R();6(57^(!+$`'HV=M'98$2R05P4`$'
M:`2-R(5(,`9]Z(=@.`0)&`9CR`81R`(0>);Y\`9QX`9"<(!$T`)OT(9ZX(!;
M@`>_'803^(9AP`9JB(;IB@1YAH=JD`:WD@;GL9(&VE!\X#!ZP(9IF`9K&`EZ
M<(<W*0>I&!:AR!-K,!6/4Q-JL:249!-@M49J]"%=+`A\()A*,`!G)(I-0(2"
M8.'U.)!Y\`;^4`8!&/\``5"&=.B=>,@&$_)"D*H'3=@&2`@2?2@&#U@!G;"'
MD+04KK#+W>*'R4(*>/`?IL,'>?A2%D()WM0A7?Q5H=B*=@B6(0T5!E/<(Z('
M=G")\J2&$]DP?X.(84@&;,@&:3`&$""$+%@$86`#+8@&;JB&9#B&=?`&+<B"
M86`=^#!A98"(7,A#:8@U^%!";HB']PD[$BX(0%VMW<2*<%@&#\K&_[$N6)F0
MR!*N'U*'3]0''U&$UTN"'+`#5P"#'OB!78"`'P`'4M@"O.`",#B%63`"&N@%
M4'B"'\@#;>B"USN%-ZB!4Y"%3\"#/)@^1<@H%Y@#6"`"'<Z#]Z.",H@"/JC_
M!S_H`5:88ZQ8AAC8;E)XO][.@4^(@QJ8`2EPA38@A23H@1=P@G"(@1>H`5>(
M`U'XAE=`@CB8AS"X`N&Y##^`@!E@@G+H`@A(@B=P!2SP!44P@B8`!3>(M,E1
M@BF`!5$@!FM0!Z)RMFA@VWJ\%R>J#U=,5!'*U-$+"E=-AZ\3K-*8!`YX"!IW
M;,B>!TV0`&-(!TI0`7M@@5N`!DN`A%<8!D+8DURHAA$HAD'(@$A5`4$X@0EH
MA&[H`&:0QP\8A`_`!F08QF;)A6M(!`>(A'3@<A08A&G(`&M8!PS0;"?<5&C(
M`#]@!VH0AFA@GR^!P:%;CTNTAFC`!5,LB'P`0GUP_X=B,`:8S%/ZG88A+36"
MD`?31;V#:"2"H2`+X3AZJ,9*/)-Z:"QE<(`1.!-E4(9F*(0(:TG,\2E]^``,
MF(82Z``I90<3BCFC.(9W"(1BB)="2`!"8(K(9H^`V4C@F@=[:;H0<FE_.9-*
M(9:!.V9&LC!P?&GC_%=660<#00I[P#@Q(42Y/@AC/%#E;0J/^Q,2208G&I*\
M^H:@'F!O4`=+`(%DT`4G<();:`-(B(=D&`9DT`036`2'H`=N8`8<2JU@2`9N
MF#D(@85D,`;X!6QN^(8&NKI*=P=^P,?4VD4=VH=UF`8W8;IS6-UX,;KA>2`0
M0KOAN8I;V(4P>`+>GH)2B/^!'*"!72B%),`#PLN%4O`"8K("&E"#4V@$6["%
M;P@&9H"%4A"%B.V!5.`%,"#C4_`&9YH"ZX8!&QB%4AB",S@#*H#6>O@"&Y#O
MKMXM@_`%&'`!4WB$'(B9"`P%(X`"&;@#5S`%';`-(#B%<("`""",S'"';9@#
M"J"`&LB#6)L#*?"$(G`!'.`&1GB"*<@!*BB%3JH!P0B%/WA-)1"#)-"&3.LO
M>I!E<*B*]3@M9-B*>?"\]VF':6@/F`*=B.FM7UU&<["`9CB(<BB&?H@&=I!F
M#\@M%,CU$3"Y0X"$;8@$9,"`0J@'87``9W`*3"B$2,4%7>"%=,@`3(`'0_"#
M9=C_@'7,-D*0`V)X"9BK!G'(@A)8AB8GAT/8@'1X+V(`"'V%5NR#5T^=OGO<
MZNF+5X\<N73ER%F[9BW:-'3P]-&K1T^?OG?KMBTK=X\COH0)Z5EKMJ_>/)`G
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MU>"E4\<PYSOI;&,..>5P8]E0'D643C6@*970.N$\F%-*]`AFU#T(8K@62`S!
MDLP?4CP!A1))Z)$'&4F8THH2/=0@S2UQZ`&-(SGLD4H<G9C"""S4@9(*'IZ4
M(D02TJP"ARCW))+#%'!PT\423]PQQ1%3>)&$%:?@`P84K!SU)9A&85/B+H\8
M0<846Z0BA0TY=()*$>QLX<(3I>BS3`,V?#,-*-J$LP\V,+Q@1#S\;.-)',B8
M8H,,U)0S!PXY>,&.$:E\P44<5__0,H447B@Q13>N@',/8]S`XXTVW7SSSFCK
MU(//.]UXPPXY&^7#D#C7J(-..FDU5`Y8]:03333LX//9)"S<0TY,Z5TB@BZ-
M$"+,!*U4$PD(Z60@3#?=(.<!)(V<4`\SW23W#DS<Y%)-!H4D<\(M]E@P##?5
M5+/&+=$8@PMUJ\"BS38E''+(/;VN\8$TWN!2US#'((,,>],88TPUS%Q#++$+
M>J76-^V(4Q,YU8@CSF+ZK+,..XS1XTTTU^`$DH4`4K/;4?0T8QD],3VXSX,3
M4EA44QPMQ9!228&D#`<9'&)9/M;@PLXE@L1SR#KNO%-./.F\<TX^V]!#33'?
M9,&-)I7_O!-3/9IP8($F,K%TRRWYK+.,,-R`Y!E(Z;PR#5#3W$*-/N4L,TQ5
M7ZZ#C#%R@?393,Y-K'A.VYRF#SG#*+/15]N(,TTNQGA%:C[Q.+W*+?&`)!)(
M[6#C#3:O"+-83/E\5L_)!E+SS</=4C-,9>EXHPXWZA#3B"TB@&."%M_H@LT&
MCK!SC0:1W-.-,'`C@U,\W,CW#5C4W'),--YPPWLT%ALH$3?'5*-9-=;0G%,]
MY6Q#SCODV,W:K?OH5+A1YY`#YCO:<91\E(,:\/@,/?9A#&TH(@E/F,(4='`'
M3\"`!Z;8!1YZL`0U]`(4I8`&#D:1BBG<812\T$4SZJ$,7>RB_Q-E*(4KGI"'
M:YB!%990PA*J`(U0&,$%<2A%#:0@!2B("!7\",4>O/29,#%13$20@2M4H0,>
M+($(>#!##J"`@T^<0A%*Z!0.2+$,&[R@"+CH1"A@T8HCZ(`/-J#"*RH!AE"0
M@@(S>((N(,$(,!!!":MPA2>>(`E3K((44M#!%+C@!6ZL`ASM8,PZ\,$.7+Q"
M%^5X1V2L,0V1U6,CC$G',HQQC7J,`S)@V89O;K6L<$R#&MSP"B%<-TIK#"($
MS-#'-Z31"$ATHQ7?6,,$%I&,5>0B&=X*@0-P@0M'O"(:ZKC'.J8AC5:\P@25
M.(8(D@$.$:QA&O"X11824@YI)`,7QO^`!C2NH8(#3$,=NGA%.;*0!2UHX!#U
M:,<XNE$-<O@/%]A@ATC:P0[>W&,>O;H'?ZS!,EQ0XW?P,`BI$@*/:DQC&M>8
M!U,$^)5U$(<;D5%)P:;A47W,PVB!*<J%'%04C\2,)Q;Z2%*4$I:8,&,$"3A$
M,%;#GW(P8Q#W$,0A[%&";FP"$/D(P39N08AN)(,:';G'-BJA`0=4HD/S28A'
M2$4/4P[E,^WXSSR^<1+>T..C0%DB2,KAJLLPY"23\<8]\K$/>^0$'E<S!RDQ
MF9##T&,<Q,#&1R*:$/8D@QGJB$<^[!$64BT+&<)PG^0"](Z'[I54\$`HJ>KA
MG.5XPQK((`3_,BYA@E9,X"[?P,<AV#`-$%BB&L2(1CK8,0YF+",>!E%'-X;A
M.F]<-A[,6,X[DH&,;D0C&</HQG#7T8YY+%<G\>C&-M+#DM]\Z1X.,6M.F'64
MN&X#NV--!VGTT0I>/&*(4)A"$G10BCOT(`^@@(44C``$/O#B%:"X@1KV((4Y
M2*)!,M&')<#`A2MTH@<_X`4KM/&%^.;!%*#@`A1(T84G/*$*59!"%(S()E@T
ML<,_,P8$7%`*5>"`"$18@@R,<`HVS<$5;F`%$HA@@RIP8P<O:$`,YP".;2RB
M%0`6A3Z;,(50"(H*X$B$%IH@A59\P;Y$0%(<B)#>)"1!"L<@A30N_PL6>*`C
M&Z\H'5890@YC(",;V!CKR20&WG2LPQF7!%\UZF&/F-&#',7M2G46\0$ML.%_
MZ0!'+F`AK-PF0PNZ:(4NJJ$.X2A5%Y'(!3>(P:]CZ"(9EXC$,-*@A5N,IQ$=
M@`<S1'`+>A0C&;IXSSVQ(8YC`.,5B'X%,JJ!GW3,(SV;40<\YL$.=?#:&UNM
M]3K&\0YKH'(8TT`&.5P64=XP!"8%;&@\/E)6I-!CV--PU7_^PQ%RN,JD)C7*
M9SQS(9_I9"@I]=D[!%.,%"B`!8<XANEV\@YWN",8[F"&,O+AYKR=Y!R:6($#
M.O"*SZS#'O:`S%!.!IK"O00H^+"L/=`Z#_^P%,UGC"E*7&67DW6,QB/:AJ9:
M9Y+8G81$K7)AQT`3\MQD)*,?VS"X3EP5%F'Q=!G,F)]FFM.<:M2+Y<S0;2Z\
M88E7W$,%EU@$",#AC&I\`^EM:(7>I/$-F=SC&LD@!C.HP>9X?*,<STE(.JB!
MC&T@P^:JZH9U%9N3YS+C&][`6C6VD8ZV'DOC@?E/NHUB#J&PIB@F`9.V<Q(+
M;RCB"%5(@A)XD`164($'[G4%*RA\`U28HPDT`$(J3''J>[RB&_K`CSZF48I4
M=$(&-^A%/;Z@!"BH`1R,<,03;C"+(R2A"@_T0A5DL8\K],`5??<P$T\"#1G8
M@+PXD$(5B8`#5H#_00=SF$,H'@$!'G@!%_%P0P.,P`H")\*I'[&,,CR!!R[\
M(08S&,7GAT"$&-AB#HLPTR=<@00E?%'`7=B&(WC^C6>^`]?>D(9)@,5,G$P]
M>,,U/)*T8=0]&`L]*`,U,)WI?`4^O`I-I$-$,(,PP`(L0`,\4$,T((/WM$<T
M4(/4*40RY`)UZ,=&U$,W0(,VC.`V[$XWO$+0A4LY@$,\D,,@:,$:+,(T60(N
M$$<U9`.O(0,Q:$,U!$B]$$,N"9<Q:*!UY`(Q6(>^&(,W)$,T5$,WB)0[I`,Z
MO))`(01O/-0ZT,/%7(Q&,$5@;97DQ-9`$91;0<3_=(BYQ112U$,^!`U;_W45
M3YQ$RLB9P6'7!%Y<X&#""5C`!:Q`)6C",<S=7JD<`3E#,&S""6B`!)1`(YP&
M9J$+-.C"U!T&1]S#-R2#6*7$2<R<1X#$.915P:3#[,!&_;#9?\%,-W@%6J55
M>FS#`:&+/>"#VMT#-D37*8(&;XR#6OU.6/3?2=B#_%`#-5C#1(#%4&3/$M4#
MNG326FA&)\&&/?3?*RS"-Z3#!QS#!V1!-!"#)>2")3Q`*V25:2R#<-0+-EQ#
M,R2#W)VB9F!A/V3=,A@3L*P#-V2/N7"#*Q&#?GP#.;1#.V@(N4$'UW3($IU$
M7WU4QD&%AA@%[9C5NH"!%TC!%#Q!&:2"&8C!#?^\@39T@1M4F`Y8030@P0O<
M0"KD@2UT0RQ(017`%Q/H@C60@B>``0Q,WBL8`1=,P1NT6"L,`0_@P2?@@4U:
M21EX`CTH@@V<`O`!'S8(@8@Y@HDEP1+D`!6X`@XDP2E$PBGDP!+HP'W`PC%`
MP"B`01%(01C`0@)]Q#SX@B)0@1'D`1[H0'T9`R@021/8PBK$@A)TP2J$@1$(
MI1)<&#*P@C?LGT-T$O=TX-SQQ'\@%$T@FS4R!JG46E",$\]Q0T=T!&M4&SU\
MQFVL0SPL1SRL@SJLPV4QUCHP`S-40S2H2S1\PS(<&S9H@S6`UTE,E!'BPBT@
MY#5<4CT,W3<P'3R<1S7_V(<EK,(J$,-F\`=;P(/_B4,T$*';:<,W:,,U8,-[
MN)TW\!9FI8-8Q8,WU`,[T(,XE*<UF`:SL"?,/9P^2(0U,,-NQ%7$X<-EZ0,\
M#$?)(`6!.MR#?,82W>+=%(53?`6ZJ,R7>`2VE8/:<8,P5,()F(`'6(`'=$`(
M?$`(A$`&=``&2$`&?``;7%.'`(L`<L,MX`*"O$H9&L/>)$1*V&?*W:%F+<,R
MN,-7X.%]@H\U]%W.W,//#:G0I)5CO<,V`$,EG(8U\F(Y3,,R$,A:Z<,X')ME
MJ`4Y7-LQ7$(RD(I#W"<L:,(TI$,XB)U%$$8TZ!HT&<M`01-_/-1$K`,YE`LD
M_S@",63!)0C#!Z#'/LS#,HB`=L2#/6Q#<]S",-R"0IWB:B+#;W%=-_1C,IPI
M6ZQ#.GC+*[%%<\Q,NMU&7'75?UDCL9G51S'+1QV+1,YAS7076IW$NH2"E5A!
M%>A!%!@!$^2!(\@!-$A!$DP!'<!#..#`@;U"(O#"/>S#+.2`#42!-(2&*3@"
M-(2!#>C!/D1"B!P!*!`#(\1!&$C!'9Q"1[Y!)TR!*XP#[_E>57;8+Q`!!)""
M*AB!%"@!%^2E*TA!#9#")5!!#H@8,C2!*YR#&]3`&WB"$)%")#C,-%0"(^R`
M%'Q"&.0`*<##*CB"*73!$.0`*-B7$B`L&'S1$83L%O]00RM$@ZK$0WL6H$&V
MPS74"CO``VR2PQNR0S)HX3<,`W*&Q3C4PS=``S$,P\WA6F7*&4?HAG7=@SVH
MQ?C<)C4<P_<DAS!,@V020RL,`RS@PGZ`5ZPXXRLDPSR\PS%8E*2UPGI^P_[M
M6@%&0X_@`C=XP\_:(W(9`S$80[%<@]GNW]EF`US!0SO``\KRFF:08"X1PS)<
M`S6$ISBT0[61RCOXHE9Q&T6P(F-AQE=80]C.G;;A@SR80\\0Q=W0@U*`+OSH
M3U=-VTDL!T5BR$F8SH%\A5",0S#$KB$4PB#$$MP$#S2]!YNQ@VI&E(&4PXTF
MA864@S44#CY@FTIX+F^@PS7_,.Y_4HXU*.!*4$Y3W<:%S$TQZ,,)>(!4*,,V
MO`,F]08T.(,X(0.%4@.9R5R'7,,K`.&JH$M"6%KV=D0ZL*PV;.`UB`,U+`,R
M7(/A.D>GKL<S,,-MUD(;W(,EB``Q"$.8MD,SA`.V.($N$&<T8,,WK.:!-$=L
MMH/;XL(P"$.#(-07=L,QF`I"Y58QW`)TL9GB8$:P,!:;<8,Q"B!34&[\H`4H
M+@6`.N)1Q`]=!9X^Y$(W*$)'5H$7I`(5,($7X`$LU,$N@$$45$$7W,.P/H$M
M:`,KS&0^Q$(.Z$`4@`,_*(HK5$,<V,`GZ(,Q@,$6/($:N0$TT!X3?((G4,$;
M>,$4_YS"/OB!'<C"NC*1_F!#&$Q!+CB"$7B!(DG!*1A!#N"`,R'!&XC"+8#"
M`ZU"C36`>SD!*]""*VQR*9""&I1"&#2`%73#*L2!)$@"*5#!%"A!-N""#Y""
M(W2"@"7!%DC!%E@#+#`#,3RF-:H#C>(">X9,*8&7-;8F@*I#-)#3D#*$A6B/
M-$3#)S7'"%[#,K1M)[9",JC/.1;7[6(#+F#S/23#+>1'S78+=GH#8>`'K*GG
M*US"--R#.4P#-)RC.9&33F;#!^J'0^Q?-<R*=$Q#%4Z,+YR3SZ*3?9C3<QK#
M,$2#"QKDB^:"-$B=-:`#6`Q4K?T/[=CI_A+#R8)%8A'02?^0@S`@ZCA8%F\D
M!6_LPX6\"NE^KDKAS[E]!/B*!*X%GF<<R]H]%6.@[,NFG&)9%]A]@]^:;2UF
MC4B4`VGN%4.HM,,-1<_0CMJ9FV!E%F,=AC3&#-5Y[L8]Q1I``C"L`"240#&$
MP&G>PS-A%?CJ4S_+%%W=)Q**IS(<0S=H73%X3229`\'Q7#I(TJ[`P\O"0T`B
M5,H]!(")P"NP04G@0@:Z`C2L@A:T@1R`0U-%@S5XA%Y=C'#I<C]G#4%VBT=]
M$C(`@S`0`Z):%V`/%SAHX7Z@@V]XRW#-Q]\E1%L3!4)IHU8GB$;<ME7]Q[<%
M<34P@@-Q2AQT`1Y$$!_L`G&K<A+_>((S(($+G%X<S$$_P$(3T$$V5!@O0,,/
M*0(,T``J0,.G[($74$$K0`,5/($7=$$JV%ZG<`%5*@(9V$(?A\EG_$(,N``I
M@((25$D8E,$N+$(2\(`K<$$#2$(QK,(6!`D>0#0.-$`HB,$7@$$G\((B@(&%
MFT$#/`$XP`(CA$(B2`(T5`,6R(`J7((.@($J8,,6;($2L+@44(,K(',R_`YX
M:<\VI,PZ;&'+?HPVQM9)S&.]!`])F0,W;`."3%Q,U%HV<#`W]`@W8$,M@D7E
M5`-C)$,S)0,Y2</Z=)(Z9,,SSW,T\"\6)H,&CB`S((,WM,/^<7`U7`,TM$(K
MX`(X1/1M_Y8#8-M61#S3/:W#/""S-V0#-&3#"V8#,;1#-2!A.?2YWF*-V<8#
M.*0YS!J$6EV,,+1,R[(9[<P=Z"P@5V`#-K"JP^G:C1Z&\2*</LP91MW&.;3T
M@LJ$ML%$1*GAU8!4*C*66FEC:W;#G+%9+JF#-X"#G1\6?ZC%U3Q2AA!'A]`:
MZ+8#.=BG3#P<\'KN(,8634ACS#UBLQG$[`RCT*C`!Z1`"&1""4#""$#'55N(
M`/+&@%@#VFFZ9='#.:C#./Q%!4_,;4J.:CI$._`YRFE&>UX#?S![FF,#;(F#
M%FA!+MSO%!I#H%T!+"R")5PP;I$Y,F0J86B#-K@M,5R#-]A61O]7@P=2PRMH
MG6:\64DL1D%UTD/5`WJL`]8`!^UH66S?,#>\C^Q$1EC8#^"5@X^6V\6]`CET
M@DU2`1=\T3=\012,@B*<0BGL`!1`02OLG@T``2]4P2DL!K?H0RPD@SU@`QU\
MPB?80`_L0C@<08G@`2[0P2Q,F"R(`A%`D!7@7B_00Q/T`%7.=W6AL0SD0"FP
M`A%(01F(01XH`@[H`"JT0P[X0#=\@2*D0BC$01PHPL4T@0S`@`N\0`W$`0S`
M``14P`T8V6]WPA>``BE\`1QT0PT,03MXPA%00$\>P19P`1B$032L`H.``S%(
M@SK8.5C8EFU9@@I,C#@`-LK91#$PQ#K_G",Q)$,XG$,Z_(3D`$N"T(,[=`UT
M$7MKYG@U!&%A502Z8`;;,73GY"98C$,\`#0TN`(U=4,]F,-3U.(VK-`VK(]S
ML%PTO$(Q+'0Y'`.7,4,V9`-`3!/'KINW;-BR95.G3=V]>-7`<7-73YTZ=OK8
MP6/G;9XX<>FX&4.&3.0T9-GJD:-WKUZ]>_K6:;1&;9RX<AA=XL.G;U\]?3I_
MRM.);QZ]G_J0ZJ1W#E^]>4B1TML']=X[>T;U%?7I,E^^=_?`OF09-AZ\=/#N
MG877TF5+?=_`5:P([QNZ=/7@K5MW%VDU8Z_((<7[[ITP8=.HSG.Z,RG4<MRP
MO=/[DB<^>D_%_X+EQHR;OGPN/5_SUGF%)GT=;AVZP$P?-UW,ND%U7&V;/GK,
M<%F[1^_8L':"9>M[66ZOM6VW<%';MLW::';MUI%#1\[:-&74NDTK5XU=NGCQ
MO'.SAU<2FWXBF-W[MOX;L5?4B'E39P]L/(?=J*6[MX[>-6O=T.'L+*I^LJ:<
M=)Q9IZW@&'PIGW7>*4?"<NBAQR>PA*-*LG)`D^TE>KQ)1S9\*$L''V*J4>0)
M*Z:08HHG3HD#"E?8<(6+)'@X)1YN8*F!BB^\0,43UG[:Z191[HB"$2.``,>=
M6*YXPHA<\F`E#B]XF4.*)ZJXPXLH4)$GC!]D8=#,,\U\R9@8<MCE$?\CO/""
MBV58F>&)7*[`XQ18X/A$ED[B^&068\;!YY0?:'A!T1>"H.$'5.*!!AI6/'&E
M%%`Z`8-2/!@IY@LJ2F%%##/,X*(+;DCAQAMXN"&FH&JJX;"<>]@8Y)`0HGEE
M&/G8L::=00R,IYZR8*%'!3;JN26#-<JAIIQQ[IGGGG'*88>-#SX8A)IDK"$G
M&F*BX2992U[*))-SRF'F&&Z^@><27.KY!BQRDOG&FVBHN6>81:+!99H3)`CA
MF!..T6>:++H149]%0H!G&Q,TF""++*+)!AI?H#$&FERJ28@88JCA!A+?ODGG
MED:\@>::04S(PI=76C9AA5ON:F><>=;IKA[_O9!JQS]CJO'FFFPN`FN=HO9)
M&A_)>OII'7R8HH>_>Q@#*B>LIBI*N);>J5`XQ13+",*O,@3+I?'884<=>.+Y
M)IZ<V=EOMV\J0L>;;X)6)YMV+7H[)I:FN26PC.#1IYYEBMFFJZRV\@DHR^@I
M1Z2\6,HG*JP$>VF;8=+39ZV7J+FXGD!(8$$0?3+)0+A++DGF$D$"`2000RK!
M99A;,#D$.4L.B>062P)!I)%#(#&D$$,F,<201FBO9))78+D$DD.8KP222AJ!
MA!)+*N'>DDM>>4433&K9A/5:6-?DE0T.T00$$PB))))6P!<&$TU:@:0678*Y
MO1CT#S&)05@"&*\(_\8K;G&+3&CB$NH[1C&0T3]A:$(3F;@%`R^X"7_<`AC"
M,)=AEA&,8]PB&,6PQ@DY9#:QU.,=V[B)<.YA.:2\I![6,`IC@E,.<]@B14_8
M@A2H8`4\V&('-R`%*41AA#&\`1JFD(8YFE"*4C3!"WS(1=I8N`U<:*D*HKK#
M/5I!#3:\H0IQ@`8LW)`#/)#""E"`PAN\,`54[.,*/6"%9]"41S/M!!LQ<$$K
M'I$$+BPA#K$(PQ@\$0L8/"$.MH@$'D+1B4YX(E2Y2%PYM!&'+L0!#Z(`AS2^
M,0Q8S`(4H8#%$1D!"E:$P@@0T,4K0/$(9(!!"6%0PA:XT0KYK.H;QB`&+O]P
M88RSK.,#60B&)83Q@1.PX1`.Z,`E#@&+9:0!$I!P`"/TP0Q2=&,-(EA$,FYQ
M`DA<0@6#X`8UAH&+:"@+$A^`A"-`$0UA#&(0K(N$"2X1/3:0,`4G,(8&/J"/
M:D1B#2G0Q1H(T8I;0$(+6JB&-430@6[04P0?.,0R!#&.Z9%#`8>`AS40@)Q;
M".(5EAB$.(+A!T(D0QB->(0Z++&&5ZC@%J_0PC`$\0%[:2$$X0A$"2AQ@!:4
MH!''$`8DJ'&-2DQC')J@Q#;680UG3.,:UQ`'?PP7E7<XQ2=9%<Y.FJ(8<T!N
M-PQB3`QY\I)VM$,QXXG03\C1#GBLC1WKN,=S5@+_%GQPR$+>V(A\U.*Y>J1C
M'.OX1C?HMA[1R,=N?\T+A`:+F><HK!ZSPMP\GA(<G"GH&G&#$(:2`E9]$,9"
MUUB';;SSDA9NHZLO,8<*+C%:%_:C&\H`1C`V(8Q;1&,9[K#M-)(QPF0,(WR8
M($0C&F$)2FQO$YBX!":^EXEAO!(3XJ/$)BBA/4Q0HA*'V$0EK%?-Z35B#6Q8
M`R36D`8M3(`-E.@F)!:QB#0<MQ')J^8B&D&(-+!`!80XQ'$/,8CNQ@X1A%!>
M(0+A7T0(`KF%.,2##U$(00B"$&L0A`H$L085;%C#:UC#(/HIB(F%X!:R84<]
MJ.&L=\#0+4"!R36>0@_+_^4#A_2HQCZ(08XK_<$,:K##*+HP!2!H`Q=22((.
MI,$,)GCB&KC(P1AD$0<JC$(4MG`%+!31B2=XXA,Z>$(W6N&%2.AC"TN@@B1R
M$8<D@*$4<9Q"&6'$CRWTX!1ZM'-P=@(-)?``%8HP@A1XL`PA/`$5CP"#&:"0
M!%+$PQ-O."(=6.$*4K@#&..H1R.,PHQ*V(-SVIP%*>!@"D8DPA'U\,,6-AD'
M4B1B"&Q`1@RX8*IML((<ZG#;SMJ1C%:X`BWD4(8@5E"(1DS@!,H<Q"L<\(%7
M*.,8*BAF-UJH"UV<X!8A>.4P("$!+4A@$_HX1BT.H8%&G"`+S90$-"31A@J+
M0/\#";R$)=(P`1&$`!(DZ.=AD=L!04C@%N^^!<NND0[44"Y;Q30!P"2P!G$&
MZ`%:R`+,LO`!$YB`=RAH!`BR$`)"9*$1'6BW(%B&B"S@@QT?>(932E""#W`@
M$"J`Q,0DC`(.8"(#6DA&-ZZ!CFM@R!XJB8<^^'(7&1((0T9Y6EAK@V>7L"1S
M9O/).PI'X[OL9ZNMI>%N?)*1G65$+0X)"S?*`8^YMLL;WJA&.KY!N(HL_2O2
M$HR"9@BA$QMNJV*Q'-7PX0[+^41!'"+15QWC#J.(Q7"G=0C@!UN59L2P'N,!
M+5+R88]O'.A"*A066FBX$7:0(QOHX$XYKD&.:DQC&LW_&`<W(#2.<VQ#]=9(
M1S/@09QNF"4=S(B'[;?ACG<D8\SZT$0;D&*?=*0C8?3A1CK<D:YN).,=:$\*
M5EAHCWZX@Q^4P5!*AN4.NQ)>CZ`=/-OHLIRIE<T>PK&<9:QQ#9_8@Q\,F@<W
M"I>+:.3A#GBX0Q4\@0TG].`&O'`%#_``',"!%$I!%&!!'>+@!?9@%N:`%TB!
M%Y(!%DHA%4)A%I+`!GIA&4AAC:9A&TB!"?A`'[K@!FC@%$#!"NS@#N8@"DYA
M'$!A#^YHZ.[,SF`A#+A@%F*!"(J`%R(!"3XA#L#`"'C@#J;`"*"!&.[@$SH!
MDD!A$?2!'ZX!"[8@#ECA"YH`_PRR`1_"`0Y801$8@0_XP!.0(18H``^88`N>
M@!1`(0YTP!10X0ETP`VZX130#AP^9QWN91>B`1O.(0V"H1OD30302Q",@1HR
M(`0$`1#&P00FX!5:PQXTP00@81PXH,#2@1`F(!+2P#2VX0260Q].X'4<0!(N
M81$(X0-$(`U"X!X6C'VZJ0V8@0368!/F*@T:0>/6(!U"(`26;0U>@@,,01]>
M1P7.H1#28`T^0`L\;`1NX1A\80+@8!%:0>(<X18Z`!(*801$0`2JX1`R@!!\
M3P.$(7C8)POTH1U,H!CT81PV@+S\@!+^P0&ZK9G\8`,XX0-:XOB^X1UP1H72
M81VXX?\ETH$<%&0KQ*,>+"1:&N\EX,$J9J@>FH(=PD%!O`,O8H(P6`*RV,%"
M]&(O=H8_+`2LVB$=Z`$C%2->UL8A[*.RS@(OX.%NV*$:7C(;UN([&O(=O((9
M;L&N[&&K,,(:BN$NV.+$P,(>?LXVNF8=1F_%[F$\P&I!"N_G4,]L5HP>XL$=
M%$8]CA*/\&)``"\KUB,=9J*P!K(:E@_UUF(N;'(]JF4[HL$DE.$U6$`7CJ<6
M0B`-'$#AAN$2Y.`6,&R:TJ`-GFO8#@X01``$VB`-=($;:B$P)2$+&.H$&M,=
M"&$;**$0+B$$5H!X^&$2*,$$UD`81L`/`B$_MN(>Q&XO\&7_&$[(&LZ!'$)O
M^/Y1..B!)(=O'=JA.M`N5AKO*)NR)V$((/$B.(8.'MJ!'>;AYUHA&D`!#/#`
M#)Z@%%[!"J)@#K1A")A`&EI!%$K!%1@A#G;A&^"@!CYA17C`#K2!"7P`"/+`
M"G;`%M+!%)`H#DIAMZZ``EQ!$:8`#V;!%:@`"KQ@#Z+`%>3L!UQA!F=032``
M`F+!#ZA`#8RA"`94&["@"6Y`#=Q@"7#I%3C)$R`I%XQA29+`"ZK`"*8`"JR@
M"(R!&1X!DCR!#O+@%)"A"("@"I@`!]Z`/T%!"KI`&YH@#(K@&$R!'=9C;<@!
M[>Z&&W`!G%B@`^8`'%+`FP[!@$Y@_Q"2H0-8`!+8@!"X(8&L(0,T@1DV0!A*
M0`*.404TH!+6P1K)`?6RH!(R0>*V]`-0`!`$H1*PY16`;0VT@`W$M!(TX"PZ
M8!$F8!`Z(!DRX!)*(`14P"<T00*R0`,@(028(056(`TLX01,H!$X8!CTX1H<
M0!K4@1F421`<P00ZX`,FX`-`X!54L9P^8%E"8!`<H`1.X!JPX1!:H!%$8%-+
MX`(,(0M$X!`HK`0>00LJX0)B(F=*4K#@KB7$@AQHSR?*@3`BY.?NP1SX0^S`
M`BOP81_@@1[RHTV]0R,&BQSBYL18:!Y`CSA:@OA0#R)WHK+0XBONX4"&SRSD
MHFWH@EWV1O\^#H)5U*$LP*XG[U487B$@Z^X>T.$OHJ&N\(*%MDI!/+(>V.$:
MHB$79L4A:5,QUF*T9J4<AH$:=&(X@8ZE[,$>MH$8I`$J=B(>L`$:JL'J]&$;
MDF%F6V(DZ6486F$8J@$[[)!NQ&6PS`(UNT&=&L\>+D$"*@$0$.$8.B`?5,`>
M.B`0!.$$3N`>%L$$T@`5E*D1C*$`V$`$(H'=DD'AZB&]:@$2JG08LJ`.)``2
M9D;EXD$0T<L<1B`+-.$8!6$3-&$<EH$<3F]6[(,AKR$OA@]7L2$:F$$8CF$;
MS@D9N&$:L&&MZHKI#`<AQ<*NZJ$=U.$8J`$T$/(G**-SK0$=,E+_'UI!&AC!
M"^[O"6R!$5S@!W*!&)P`%72!%$;!%$0A4%SA&^K!$8Z@!FB@>)_@!H)@!F3`
M"GBA'%Y!#4^!%4`!#V#!R5PA&9C`!HQ`%MR`";P`#Z)`%.AA"VA@%(X"0>V,
M&)C`"J0A$G[@%#[0"O*`%W!A%4S!"JC@#J0`#K3A&V"!$>8@$LJA"/#`=>?`
M#:S`#;K`#?:@"QPA'AB!%$S!%5JA%>#`"_(@#N@S5(@A$IC@":Z,#MS@&UR!
M\]9C'8B#&Z0A:+W!'3[IL/JA',!C'W;D'<#.&H#NYUJB&WA!%^*!^<KA&,"A
M&X8A&2"$&Y)!/_!A'/2#&QQW38^A&X(!_YRJH8A?81JZH1OB01C`3!?6`1=&
MIA^2X3BZH=_Z01W2P1Z4H1%NX1XTH;9ZXQTD00[`X1:Z`2)?`1RHH1HX:%UN
M@1HDP122X8I;(;@&0;>N@7Z(01B&0>?8X14.P1+@89UN81O>XQ4:`2@C^1HX
M@5W/8O@,AR5\`O,RLBKBIBIFJ"KHXQWL0VHN`H^HXB78`1WH:OMV9K2^(B]"
M>1[TPW#<;H92N2V@53:[#BW4@F_H)B,JPC[405SJCO(*9R60@C@@Y"94BSZ>
M[BNV@AH00V)C>>FJPB>6KQWH@42Z:OF@K35TX1OR82H$(QU"IJN@8EN8;VM<
MHAQT(4S/J1ND0?\;^!GLB&/XAB49<B$95+(-^D#=-N&@XB$-&CH-!N$#UD`8
M4S$5=0$2ZF`1J"$$VJ`-#B$>@@$2O&T3SFL-#*$>Y*`.ZB`-TN`2$E,7"*$6
M0EH?UB`QTR`9V@`2VA@A"2*+M3BU.B1#OOECRX8R/$0V/K):"6/&8'F&V*9:
M[5D?..84Z(`.U(`/I.%04($7=F`4>,$6)E@63$$6>*$7M$$;[L$:&$$-^L`'
M;J`/@(`.3"$>U$$:H*$4>N&K4:$4)$$;VBS2?.`.P*$5--@,JL`6]D$1@*#.
M9!!]&T0?C($(AH`75L$+0J$)B.`+C"`.6@$+;H$*IH`*O$`)C(`1L@'_%G2A
M&7QA/]F`%$)A!^B`"D!M"K8@#(0A'DQ!%W`AOII`D^!`1;%`$B"A$;I`"D)A
M%>(@#Z+!%+HA%Z1!)O4!'7#A%6R!7>)!BT/I=I)ANZMU6`S#&L#C*-_A&*+!
MH$<KC:^;I4RK5:(!+9X#-@=9$\(%-K2X&QB('%!3'6BK%72AD,$"\YAA&#3!
MFE]R5CS';=!8'2A"7LS"KX[SL)(!'932K[K!UB("&]#A&_ZU(NJC)3HO'58,
ML;@A&M2A&HKT'HYS^-3!<P_K'UNB7N]"+%UB+78&(:%NZ6"";+SB'8YT/(ZF
M<Z.E*FBY[.3CKL9F+^ZU6LR"&O3U^'R"($M2_S_V0^Q>/%_C@7#8IF10DUVZ
M057$[A_S0E@N1#`&:\7L@R?<P1Q<$C3B86,EPQU(5S`DXZC]INJ8#A_R0870
M&"RZ0EY^0H92-A[R'&?.89JW05C&(BR^`1GD!34A'#Q")KBJX1B0(1F6M!NL
M`1C6`!P(0;\T(!*8869"0'H0:N(LH0[`(0T.(0T0`,-"(+W:0`6L[1[8=KXJ
M`1$N=;[`@05:6A,0K!;<(0U6@!`JH1LP(0U*H!`(03]<0LK?9CNXX9RX(1ZH
MI3<S!%HE=L8^(Y6'+U;:@1S(81MPLBGS?#P69VN.+RR$0T1:H1O8X`ZZX`FT
M`0[<(!5:84>E(`YX0?\:3($/4.$41L$63J$7=&$<]*X;P($9D@$<].$<Q@$:
M4N'*1H&24H&'5J$)?H`.<H$1Z(`/NJ$+R,!U>X$?G.`&=J&I'?M,HL&/9F$5
MI(`6[J`&I$`'%.$78F$:H`$'$BT,>$`*MB`65`$)8B`)+F45NB`4OF'45H$4
M9AX&%&%2O@`,I.`(ML0(I"$95F$:_J`)MJ`(P.`3Q``,J"$6JD$;]AT:L$$=
MB$'^&A(>W$%8O@$:P`$@+9TS<&,8TJ$<UD8C[N$:B.$L:-FT[H$<B&$:Y*,:
M<"':F0'ML^$:,H886L*T\$+M82$=/@8:A@$_EI1SK94>E$$8T,)B!S9BKSO_
M(]3&&[`A[9797O*F&D!ICX-&&@Q"&ZIA<;%!&^YF1\I.'48#'CS/Q+\A&H`W
M9PKB8O=&&^("C;_C'4ZYZE9\+>"A&LRA**'U*RXC+/`!A5E9E,5.;(9%[)KY
M;GQB)83E*\"#+C9"(6YMQ=)!'2P#8B^/;1Z"KH&W:-'NQKVAPKU!KL"N7*.Y
M0@"BFK5T[^K5NW</7[ER]-X19(?PG;MXY,JY6W=/WSUVY.:E8Z?OX+UNV!`F
MU&<.G\9T]])I?!=29$9[]O2%3&BP7DAR]!#B0PCO8#UX+N_!@\>-&SIX[\81
MC,>.'3R(]C#62T>M&[=US*@E[9:NF[MC"[<U#,8-_]XZ;NFXL8'4S)FX+*_8
M(;NFSMN[6]'JC8,73%F]<O>VE5NW[M@Q9MR8W8IGCR`S9I<T48O6C5V[>`?U
MI4L'+]XW:EB[;4N&#!DY<EW+I=NVKARY=>2L;=MFC5NUW8>%YANJD9X^E?7H
MK;;W[EX\D\KUN:JV*,>4.;:*V'$#2@J5*5&Z?",U1T^I4J=.\8)'KAVL1=OT
MX7*D#MFY=Z[JCSH5ZI,W8UO*4+$RBAYEV*!+)&18$84MYXC!@RDV/0AAA!).
M^"`L7%2Q2R);>.'%)Y\8<<0.1S`A3C=/)*'($5(0P<,,-O22C"]^X`'-*B!,
M$\L7KHC"2Q,-&)$$%&6(8?]&#7D4@PT2<&PQXAM[="+%%IV0DPLWVGSS33;0
MP))+-M^$ELY$]8CVS7)7P:-.4M00$PTST2!#C3?(>---+L3D%4V>T533&#/I
ME/--/>I(-50UZA"%3SO7>%.--LET<TTYW'SYYS>?P7-/0P@=E!QHH<&C%9I$
M>9--.KM=(PV6I*JC3C974@,-G]UH`PTTV$2C#:[9\&FK.M=DXV6CI&H#[*]8
M:H--.^WLELV@U:2#W%#SW%-/._.,B>8ZG`:USD?KM+,I/FBB$P];1D5%3E1'
MM55--MZ4><\\[)0#U5#8?,/JN]]XHTY&&[$S&#OJQ/,I4=](PV\Z^$KE#3<C
MO:O_SK[97!//:T,%!1$UK\323CU6Z;-.,J]8DU%!Z^A#%+V88JJ/.,\80X^F
M!WDCC3'C:'20.?58@TPX]R0'CTV*7J/339Y%LTW0Z_0#VSOSM*,1S\_&M-PZ
MQ.!2#53?M`1J,IZJ1<]@?,)3SJ&,'L9--V"5*9H[Z73KS3K52"H"-?>40\T@
MX+#*-TM'M;-.5&$W]`X[^*P#3C?5>',-.N5@&Q$[\5P639;?L*531@^236\W
M[["UC=J,=4,-,]=T0PXZ`+\-TU#K,&6/.S71,\]:LV4>4M#T!%[//M$D0\H8
M58!CAA>FZ'*%%T8(_X,I]K0BBB>CR)*')/H<,P<45>"1_T<54KC!BS[4,-))
M?I\P@@LVVX&!`Q1=>!)*%WEX(\<.=Z"R3RCB4<A__\/A$PLQ+*%&2!"#%Y30
MB5UL00](>,,0=I$,4RR!"%PPPA-X80Q?Q"(18(@#&!AAC"]\00J=\`,L-A$-
M.+1O17@HA2NV08HM?$$-;EA%*+@`!BF$01'=8`4WO-0J=GB#&*_`AC>B,8TO
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M>1LZ\DB.5QB#-@`#V#IP`0MN8'-=Y\(2FM3AQ]0(!2%M@08NR*&1D``L&9BP
M6SW,@9%U4`,9RX@'R!"BCV[<`A=EJ@8QDG$RM>B$&;@81CF.XK%Z>*,5JW#7
M-P3F1)'=XBC>H(<]N$&,C=[Q*&!A"UNZ8:EKQ@,<B60+/+9!C%8LXAM:L80D
M\)4-J:C_`QV'6A<[UF&->EP54XCIUZ%<941O*.PC*[LEJ*ZQ&ZV\[75'68Y1
ME#.FGW7F6MP*"4K"9A!]2/$S%2M'-;`(F@=12XH'.4HU^)$+:"#!"]H0A0Z>
M8`MND,(3<7C#&Z+@AEQ\PQ9R(`4M/)&,573!"G<HPQV><`<]<&$)K$@&+$@Q
M"D:4(A?I>(04JN`%*'B!$<DX!R.B,(=0Y`$*=-C'%6YP"O\I5T+X\$4,;%`C
M)2BA#%SHPBZD,`4=%,D3(%A%'G3P!D^40A5-P($9<K`$"."@"H[(@0U@D(0E
M*`$"L&A%*/#P`R:,PA*)B(0GO$`%5UCB%6%0PA:X@$-NY--+_UG*8RY:\0IM
M5"-/U4`KEDZGMFAHRU+Q\`9*V?&-:.`B&KYB53:HNAQ,,6,8QZA4-6REFV14
M`QG&$,:=0G/'5I:CF%)L23*&80PY=NMU\T!3Q=1"-GYI$1Z_F@8U<#'B81#C
MP:W`Q32L(0Q<($/$KL@%+HBABVM,XV5^A88TB'$-<N`B-XRAQJ-^]2Z23.,:
M=$8K-JC(C('LS!KM**40=U8-]*1C,(-^73T\$I)W&*>CG^D63:4"CZBRJAO+
MH8<7![:UH7##P\TRI%K>(8XO"8JF?R*C.D@I*'EYY4^D*F2K\-4-0P<E7?BX
M:CD*]SB#8.E+^-CE5;QQU71X8TR$V?_(S[AQZX\($6#<L$<]F`J/TA6$'E'4
M*SM(HY%[(":2'P4'43P)%4G-0Q_CN`4US+$I07D#%I8@L3?$L3AOY.(2T0#-
MG^Q1CF&\`J2CA(>AL/+M:TH#'.E(55*P9`UT:"$2WTA&/4[`47$<ZG)Y4<<Z
MS!$V2-=#BAJ1'+7$>)!X6`,:>_+&&*FEG(R\;932V`6Q<C-*=;B&("UYG5YS
M<A3-$>=M?P*'--I%Z:/H-1\VN8>S;3(O9G1#'U5RA1=:P0C2>@$6FHC#*7R@
MAS>8H0QSX$4\8.$);30#!WNP@QK>T(0J<,$,[V,"*>8AB5/D0AW08,04\!"&
M'X@"%K:X!AS_GL`#->Q"$4_H!3_`@-SE*OY!L<`!#[0Q0C"4@4.=D,;?.X$#
M6^BB&IW8PRC>H`0B[*$&;TC"'>;@A3?HX`Y4&$4/R,"#)$@!"550Q"CN`(U7
MS.$1B7"%$B2QB"]T80I3V$,9//&.5G#C7JJ2MR5@D:VV?(-6NX!&-JZ6BRXB
MTL/J\`@Z=I&+:)2+5-#8-)8BM@M<I&IQ[;(4M>#AC1\C@XQ#:97)_V@4SDSC
MRX/*BZ<$]5+/E@[HL"M7X@T2Y@A:P`9:(`=MT`8-J`5MX`1M$(%:$($4>`(.
MR`98T`9L(`>+\(`?R`9LX(`5N`B)``<IZ`B+<((LF`B-$`G`!WR6_P"#D1`)
MC6`)-`@)-+@(E@`).YB#K1`).7@)10AA.6B#D'`)F+`)E=`*EO"$$%8)EK`*
M0P@)KX`+M_`*6-@*PK"%7G@+85@+MU`+S"`RPV!04'8,-28,RN`,PG`,NJ`,
M<4$-P<`,Q,`,VQ`-MT`,RS`-Q%`Z;-(/C](/S!`7S#`.Y;`-TK<.Z/`GW7!K
MAC$4LE$-VF(1;O,V=W0-[4`V"3$XY8`/^_`.0<$R^9`ICZ,/[J`YJ6@/_-`2
M4602II@/\T`/GZ$Y&9$/ID@38A0/>5%D4Q$1H*$3NY-R4!,2W/<1X")&1`6)
MNV0-*N,.#9<%HW0/E=`&\``.[9`9Z]"+:?_!*3@C$CG!#F$S:`:!*2JE&>GP
M.]B`;``3$L*H+1>39KK1%MH0AVXF#5^Q$..P#>0P#M-0#M9`&].@.-U"#9CB
M+YUA;#:!#^.0*A$3--&P#*"@!ZG0"?8C!:*0"6Q`#*2@!EXP!6]@!52P"[S@
M<VY`!5[@"=+`"'#@"GE@"Y(`!UT@"KJ@CMS`"%10!6,`!IW@!:>P"&Y@##LP
M"E[0!;3P>;DP#E+0`[:P>,N5$=#@7KO@!TE@!IW007C@"M`@!UB0!&\0![$P
M#5H0!UY0`SLP!V[0=?4A"T?``V]P"K;0946`!U0``4:`!U@0"=P@#'-0"D4P
M!U@`#9ZP=AS"!5+_P`CQ0`K"YB5>Y"5>LD12\0XIAB_HP$S70`SO(@W)H`W:
M8`W9(`V<E$ZY`@T21CHQUPW*$13"QC6<T1*3`BYEPS?]\B?Q$$FV60UCTG^0
M]D\3]TF-V6K>$`E8``=RD(+'29Q80)QN``?*V08<V`9NX(#$V9P4")W.68)8
M,((+V(%MD`C/B046Z)Q?T`;%*0>*``=LT)QNX`9QT(%P\)SDB05RT(#1F8)L
MP)Q8D`@@2`B$0)SJ.8)8,($5Z`03N`81.`@D"((1>*`1F`9KH('&69X.>*`)
MNJ`/N)W;V0:+8)SI.0CAZ8`A2H(DV`80R@:+0`B6,`R7L`B1H`LLRI\L_[@(
MC+"",0A\/V@)1&2#IB`)D>`(D4`*EA`)EV`+*V8)1O@*K=`*EW`+FG`)R=`/
MPR"&8W@+2KJDNC`,W9`,8?@*PA"&6WH+NG`+6;JEN@!F9HH+NI`,<&B&T-`-
MQW`:D\%&U!"0U;"9R<`-U.!FR>!SNX`9:H,,:I,,TD`*(L`+WZ`+(8`9WX`W
M1(%L:Z$1ZS`MU%(<YIA7G`(PAT8H"N5'U-`.2"16O0B,$0(9"^$.DQDQ])(V
M?((8;4$8&(%-@U80V88S&3$4PA8IH#%&^D`,V#`'5(`'G^`&>"`%=L`'HT`*
MT\`&N55V5?`$>>`&Z\4(N^!?72<-NL`(H``+C/]0!35`!Z>@"'.0!U1@!GM@
M!:V0#'*)"E5P!U(P!Z=`6;M0#D=P`T[YE,OE7#1@"Z"0!$@@!6`0"ITP!ZOP
M#;X@!5T`(I9`"ET@!;T`![O`#:P`"G'0!*^@"W"@#7BP!8K09=P`!WDP!T;@
M"::@"F+P!'&0!-J`#'$@)7B`!TT@!?^Z#:O08?A2<9!I2/EG#]IV%`-#,/^"
M)OB2'HADLYQ86!]W,BAC$`C!5H)R*`0C*A4C5>P@1TC11VE!1AXV%:`1%:P"
M#W(T,/`G88T2"1%(G<C9G.IYG&Z@G!RHG"3HME?@G%@@G118G!28"-HY@M.9
MG/:9GEH`!VY@G/3YGHG_D`AL,`>!FX(22I]JF;B*"P<H>*(=&KF#$+E*:@J+
M\`HXZ`B7T`JPD**DT`9":(.10`@Q:`F'<*1L`*1PT*.-``FL*PF-(`F7T*,V
M**0Q.`@<*@>1$+F+H)[`VY]L0`@LJ*!M0`BMX*2$(`FZ8`MLL`806*)ZJX`+
MN("0L"66X($=2(*[FYZ6H`N60`C02X$**`?02PAA*KX06J+<VX&#8`FXH+U[
MV[U[*P='*@?C6X+[RX$-6`?(^X3DZX`)"KU94*(0N@8)O*$:6IXD"@(3(`EM
M,`%8L`A=A`X.L6E5A1'H0`XH!XS4HA%!(47D<&C:DAP9T1,)^2<OUC#;,`[6
M_T`/^Z`/\;`-^4`O.YMR1J<<YA(4(=$M%V-(Q8$SR9$SZ<!GI90Y;:43$@D'
M;Z"3>>`*8/`#0/`$54`*]/"Q5O`#=O`$.T`%C``.W(`+K8`*ND`*3G`*NR`*
MKM`/X>`)6Z`$Q3<%*LD$/M<)17`$/W"RH4`'<9`';V`+Y=`%:I!<]ZI<OA`&
M;R`-HM4%<1`'I9"M?V`&H,`*;N`#.N`%1;`$G1`-L,`*I#!9A,D(K>`*H*`(
MBA`'\*,(N[`-PW`$1+`%75#%+E0*G0"RGO!?'=0)C$`-K1!)7LLJQ((O/[LR
MAQ(Q8(0F8>2:_W3"\J*KX\BI&Q=R;T-&ID8V/?M/Z_]"4\6\1!5W%`(C5=V$
M+V44,=6`#=K@"![X@1Q*@G"`H@U8O"?:@>?K@.F9@B':@";J@1P*O/N)@H>;
M",7+H75`G\#[!80P"/L)@O3Y@06]"`F="`G*T.R<H,4[OLR+T(;KSVPP#/R`
M"?ZP"?S@"_[@"_J`"<&0"<%P"X.P#<S`#[6P#?XP#L%P#.Z`"<S@#^]0"830
MALJ@#Y;@#+>P#9L0#,$@#/00#/V@#)G`#\+0#X>@"=:`"<H`#.?P#,RP#L+`
M#950#,N@#,K0"/?@@]1P"V]Z#)0`"8:@#,>PI9=0#HMP"<*0T"5U"\>@A991
M#*:[#!FT,=%0#,JPA6.*"Y7_H`F84`N-(*-#"@G`]X$$S;PM*@F:IU0L"`F,
M4+R0L`@]6@M%"'P<NJ'T20AM,`?T*8-"V`@%?;Z$0+CT"9]U$+TB&((/.-!M
M``(B``)U,`>+L#A+1`T`=<PD?":4FCE"`1J/\Q?G*!+#(1P@O+.DB!YY=F[S
M($?"YHA'EP_+@</7L@X%<55'&QH5L7';M@T788LWH3F%A0_$P`ZE\`9JH`96
MD`?:@`5YT`5T4`1)N@MQT,AS(`HJ.P>=H`B)\`95D`?2H`9TH`9YD`>K\`K7
MH`AXT`5@L`6V<`O(,,A3P`=<,`K&<`5[D`=Q,`JY8`^BP`>Z8,B'#"30<`5&
M0*Y'_S#'8'"81V`&1:`',:L*[/`*5]`)I-!!CHQ@G=`)PJ<(>=!!>@`'I%#!
MNU`&3#`'4H!#8L`%>&"4,,YV20`*Z6`)'18/0"5&68(I?/41^(`/5&5DRL$V
MN=.S5,09WE0/M:82,8,/):P18I1_G-&+N@I0%4-%8T(P$-DO1C',`'44@8Y(
M7K5$7H0.PLF`[+P(6;`&NRL'A^NAQLF=%OC9;9`%ZNF=VOD%!)RA)PH'W@N"
M(RB"(GBBXWN^Y[N=^4OJBQ"YE`Z@7<FA@Y"@$>T'$.W.<!`)OJ`)S5`)UG`)
MEO`,M_`!@F`)Q5`+)S`,RW`._M`/AN`,:P`)SI`&D)`/EO\P"%`M#,50#,^(
M"9IP"\J`"8C0#(6`"><`#./@#\X0")=0#,Y@"2=@@X=@#6L0#,!@#2J0`N-`
M">;`#)AP#)JP#<(0#()`%\5@`H10#LK@#O>>"0FZ#<&`"<T0#.:0"9C0I9?0
M#&Z8"9O@#L#0#];`#,H@#/YP"_>@TL++ZN<KHXMP")+@V/G+@@7]V6O`@L4K
M"8<@HXS0@02M\KQ+GY#0!H?`T/"<ZJS^@,A[Z74`@B%XOEH@`@PM"087**+"
M+T%Q#P"54OIP+6^#<CE1."%A43^Q$9BR585#J481%%JU:009#3^G&Y:B-M7`
M5*>4I]9`#NF`8=6@I\P@*2=C:*;_",*T2@\`HP[[X`KB\`4$?@=OD`>[L`I-
M``>@\`.ZH`7#P`A>4`J>95E28`9*X`558`1>$`=FL`-JH`.3QP1Y4`JLP`A?
MH`BWH`6@``9R\`9/\`6\P`B595EO``[AL`5`<`JK>.(3$@LQD`.YD`NP$`VM
MH.NO!<E7H*VDD`ND,`6!"P:PX`B)X`BK(`IP,`?B.@=@>0IGK`BD@)Y!KI>L
M\*YOX`5X\`>AH-^3__JKH`Z6P#4%<12)[F'*,8H,"1#Z[JFK=R_>O7L%[ZVK
MIPYA/'@((^+#IZ^B/HP6*QJ$&"]>/7CP#H:,:#`=O'403X:L!S$BR9/K.*8#
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M!1NV49NPPM+O.?W:Z`]`NO3#+ZRG%I0++*CJ`%".J`"LB\()Q?^""K\*Y7!#
M0J,"Q(\7;=1AQT1XU/E&'7W8:>>>=T(B)QV9$A((H8)TBJ@@D&1*9QX>2UJ'
M'79PO`>?>O+9D9UZZEGGI'+6X2:=D]2IIIUKKK$F'76HI`DCA!:J*<R/!&J2
M27CVR669+Z1X`PP][H!#&T:4"&,,7G`!)YE%YH@C"1SNX"$/1FSA)8XGH,C#
M%%>HT,.(3ZHP@@M63"&E&V:RP2*.-]Q(YY0X1O'BDSV>D&:?+FYP19]\,G+U
M55AC934?<HB)!IZ,\KFHU7WBH2>?5NWA9IMM/BI'GHJ`I,<<<][)YZ!ZN"G'
M'BJOF:8<@=ZAAQMNZG&''GW<80C,=[;_B14A6=,%,TQ8[U'WHG-9?=5=?9JD
MIYYW,"KHU2;OH8=>?>LQ,TR4R&FG'4>.^@(HJN#``@NHW."JC2XJ)`L++;9J
MBJFHFEI**;;F:`N+H0`+,8Y%AL)OD*_*2HLHH%)F,&5'\F,$,$486821N=A@
MF2A'$GF$D,_86"222-H8)))7(#FZ#48B:6000B+)C#5"'+&DDDN<;@622S1I
MQ>A;&KDDDD$ND:258VYQ&A=I8&&C$5SDL"0S9I:QI)%;U@#F%DN&N4680;):
M1A==(KGD$C:&:06_:"`A))I7IAEF&#EL86:05YA1)AEFV&B%<F:2V088=X)I
M1A(V#FEDD<\@_Y3CD+"<%C"2_/13$+_/\$M0OZ5$7'#""R&<D"SDR:)P/^$W
M#"M#21C)9D43B1QRQW::_!&>=V2JAYUXZDWH'GOL87<>G-Y1"-QZS*D7I285
MPK?&(@5"<IV-T(<'2(38$<A5F=S('DUZ!T+,5\"$?*\=ZMA'-*:AB"J\H0QX
MR$,7XF"+:#B""E5@`AUTP8A/X.$+7BB%*VR1#5>(XE!/.$4K%,$+7DC"%4UH
M@AX^D0AKM,()7<`#%41ABU-XP0V?R`,>O#`%7>RC"#S@A;J<&"M@N6H?^MA'
MJW*E+BMF!%X8B6*N>.6J+LZJBU;,(A:?R,4RGE&-:V3C&2LB#$ML+?]LK[A$
M'"$1"4M$`A*0<`0D&M$(1[P.D*\;A"`3\<=%.(UHB?B,ZQ;QND2`AA!PB-TB
M'#$(R142-')@65U8M@;8)8(-HDQ$)^NB!9:ETG6I]%E=3JF%IV@!EH30@A.<
M@(6L:"&266##&K1P`E>^SF>/)-I]%D&6IX`%=@*"'2$&(4EGLD&78Z$0(>JR
MAEXB\RMKX&6`"*&"+(0%#HN`V.XD"8=!W$=ISUQ0[C*#NZ,E\I&26(0DY"`)
M>HJE#@4BA#WQ><]Z0J(.3JLG/O7S3[KX3BCXT=D][TF(0QC4GK[+CUBL.1=Z
MVK,-Q]SH0<."3W"L*"=,BL>7^@4/@;FK2"C_=1>ZV(4N,Y4/(:TZB#[,9R-\
M'`E<`+-(2_4Q#WP`M2+D*,B_<@JF`;**?"UUDD)N&B,BX0,:ZP#%'=[@!4^$
MX@Y[\$0N<A&)/90!"J.X@Q7BP`YM$$,:M@A%'+IP"EZ<HAMYT(,>5`@-6*@C
M#E/(@R3>0(5/E,(4VG#%'\S@"4^\(0YQND4X8G`#6[2QC6E\UQ-A>D5U\12,
M7)1L9SV+V<^&5K27E=5%\"$/*N)C'ZNU!S_V40]ZO(,?_YK';/%%CW24(TKE
M,,<XS'$.:^BV',$]QSG&P8UQ#'<;UB#6.,81#G*0PQKAF`:QEA$.R#1#&<<8
MAC"L,8UB+$,9Q2A&_S".<0QA!$,9Z;U%>Y,QC&,L`S?(N$4QA"$XZPA.<,GH
MQC!08]Y;`,,8N!#&+391"TW0T1*:J./B-A''L'$-PGO$XR8J`38]WE$2D+#$
M(9S&8:GML1&5P!TB1;Q'IS7"=7L\Q(-1#`D/_]$0LY,<(?[8B`U;`L6@D032
M7E?/35(T=T:K747'N;RQ/.5"S:RH?HRF/`K1\Y&0\(8Z4,2D?]TCB^Y*$D^/
MM,8F<;9=E"TM1DSK+G#-:XNO8A\]*L*^>N##&.'8ZQWP<(<\C"H/9=C#*:3@
MA2J,(@^DL`4I6A$*5I0"%*0H!2E,`411I"(/LBB%)URQ"U<H`@QYF((7O/^P
MBU#@P1.D`$4G//$)3^AA#[LP!R-$D0MYB5;6LZ9UK6U]:USG6M>[YO6KTDCF
M6%-15UK\54Y72P]DTX,?5.3';/E1CF;SXQS\,,<ZFD4/>Y3#'>-`=CG(40[?
M3MNX[G#'-M;!#W?\MAG]*$<WMM$/>+OC'-OX!C.8L0UFG*,?[BA',HS!7&YT
MXQC]N/=Z;J&+8R#C%;@13>EJH0OXXJ*]NKA%,-K;BO:VM\"XT?@MZ(CQ6A@X
MY+?`^"V&<9`UZ[J,*<<'L'N=I%@)PQR@B(,CL/(%17RA"YZ(0R?<``I&=($1
MQ"!%%TKQB3C$(11M]4(G0MB%/.2AYY[H!!A*4;K_.,P!%$:/`QBXT(E.-,&"
M;G5"+OCAA2\0(]B]9GO;W?YVN,=]7I]-N68W:Y%XQ<JTKFJYK,C(93!EL55V
M7_L374[K+)IO[K[N;+!:=7@UVJ.,DX>\W"V?+M56Y!SAP-\SM"2,8F!)'^GP
M."R(X0W*18,;K_!J)%S1"E?D`AJMB$0KH!$+W%FB%>(P!C)\L0I8P,(5VL#%
M*EJAC63D@AOG\`(15E7YRT=?^M.G?O6M?WW#/YY54_1L%(%-QLEO]HM7U#X9
MT>A$8(6Q_-AG?T:X+^LP0I'O\W]5%5W%#W1H(QU:;G___?]_``Q``10_>8$^
M7+,BPFN7_\D(G_J?PVO`__])P`%T.S)KN?+)AY<:/`S4(LS:HM7"B-5:+<'3
M"(J@(HNHHO0[OPE<019L01=\01B,01FTM?`KK<&K/RS2OAG<01[L01_\02`,
M0KC#!][H!UB)!W*P!UEQ%WBIO/@30BB,0BF<0BJLP@"D!T`(@1/(`$W@HGO0
M!`T(@1"XA2S:AD,P@4-PA_\1F%<0A$DX!P[$!$#0A'RQD7RHA<Q8!BO<0S[L
M0S_\0T"$%118@&30!TE8`&7`B$D@`$A0!T(P`$/`B&8X@`^`A"Q`@%J0EQ-`
M`$A8@PMH!GU9@0V@A!,(@6U`%T#@`$NX!`U@@W0(1%B,15F<15ID/WI8`!7`
M"/]ZF(!,P`@+(($;T0`1P`A!>(!\H8<'6`.,*`8"T`6,\``4P(A-,`!0U`</
M`$9]H`1JQ(A;>(!%6,!:#$=Q'$=R+,<SHH="$(9E1`!_P`@4*(3_$4:,6(-A
M!)<0,`&,,`0"2#-FP0A$Z(!ZT0<4V`",*(1HG")ST`!E-$>&;$B'?$A`K(A^
MD(`1>+^^"P0$Z$5]2`.`Q(@/P$=],`0).`=?<`97*08)J`1]V`8$@$=XF:)@
M2(!+@$B:K$F;O,D75$)-0(`TP);W,X<5,`!*T`=P"08#4(%@6`$'6,A;F``$
M0(`$B$:BU(=I[(`%`(0%C*))6``4>#^<_$JP#$NQ?+O_>[@$`5!&>FD5;C``
M!6"&*WJ%"U``<#H!C!"&`B`$?3@&`HA$?2@'"3B!3$`$">A"F.N'#;@`3!A+
MQ5Q,QFS,SNJ'`5!&>]@5>PB!"1@'O',5)]$'+<0(3"@`=Y"\,)S'#,@(%@@!
MO`,&"6"!97-,UWQ-V%3,BE@!#0BVBM@$`L"65Z&$2'27SM2'3)"`;E#"-1@!
MC%@!0>C+D)2`5L$'!(A$9-N'E(M-ZJQ.ZY1%>I&`-+BP3:`$.-2'$SB!>G,&
M93`'=ZD$`W#+6D``TUA)!"`$>L#-H<Q&!3@&C.B`-&B52BB!Z^Q/__Q/6'R'
M$NB`"?"`$5B!:AP!#;@`"T@`_PN(Q%9)@P3(@/>,M4I8@`MP`*ET%ZM4@0[P
M`'>(4`]8`Q4H!$-(@?FTOND$4!9M41<-K7%H!O+L!W-H38P(ADTP%U>YAW*@
M!)-D0'O0A#38A#3+2T-8@S0`A#18@Q2M/F4HTA>-4BF5TC<SP=#:0"<"&`.<
M4B[M4B\-P!75NR>2SB\M4S,]4S1-4S5=4S9M4S=]4SB-4SF=4SJM4SN]4SS-
M4SW=4S[M4S_]4T`-5$$=5$(M5$,]5$1-5$5=5$9M5$=]5$B-5$F=5$JM5$N]
M5$S-5$W=5$[M5$_]5%`-55$=55(M55,]551-555=559M55=]55B-55F=55JM
M55N]5?]<S55=W55>[55?_55@#59A'59B+59C/59D359E759F;59G?59HC59I
MG59JK59KO59LS59MW59N[59O_59P#5=Q'5=R+5=S/5=T35=U75=V;5=W?5=X
MC5=YG5=ZK5=[O5=\S==L]4I][5<@Y`=U]%>!_<$2'%B#/5B$35B%75B&;5B'
M?5B(C5B)G5B*K5B+O5B,S5B-W5B.[5B/_5B0#5F1'5F2+5F3/5F435F575F6
M;5F7?5F8C5F9G5F:K5F;O5F<S5F=W5F>[5F?_5F@#5JA'5JB+5JC/5JD35JE
M75JF;5JG?5JHC5JIG5JJK5JKO5JLS5JMW5JN[5JO_5JP#5N>L1U;LBU;LSU;
MM$U;M5U;MFU;MWU;N(U;N9U;NJU;N[U;O,U;O=U;ONU;O_U;P`U<P1U<PBU<
MPSU<Q$U<Q5U<QFU<QWU<R(U<R9U<RJU<R[U<S,U<S=U<SNU<S_U<T`U=T1U=
MTBU=TSU=U$U=U5U=UFU=UWU=V(U=V9U=VJU=V[U=W,U=W=U=WNU=W_U=X`U>
0X1U>XBU>XSU>Y&77@```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g299211kai002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g299211kai002.gif
M1TE&.#EAJ`)P`_<``!L;'!04%@@*"QP=(AXB)2,D)"PL+"4G*BPM,BXQ-#0T
M-#P\/#4W.C`O,AX@(CP]0C\]2SL\?SE!/CU#0SM'13Y02D`^0D1$1$5&2D1+
M2TQ,3$='24U-4DA*5$I13DU34DQ65E!/5%-45%15659:6UQ<7%=765!13%U=
M8E=99DQ-9UU@7UUA8UID95U@=6!>7V%?8V)A761D9&5E:F9J:VMK;&=H:6UM
M<FIJ>&YR<VYV>'!O='!N>G%R;G-T='5U>G9Z>WAW>WQ\?'AX=FYP;T!`/S<[
MD3A*E#9-HTM5EU%;J%IFJ5QJM7U]@GEYA6%HGF9JJ6=LLVIVN'5ZJW9ZN&QQ
MK%]@FW=[Q6]YQ44[AGR`?GZ"@WV'B7R#O'J$MW>#K'R$PWJ(QWJ+TX%]?8!_
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MS::KY+6YYJZTYZ*=UKS`OK[!P[S"S+O"U[W#Y+/`\L&]O<"_P\&_R<&]V,&]
MX\+"O</#Q,7%RL;)RLC'RLO+S,C(Q\/$U<+%V\S-TLO,V\7*U\W1T\S3W-#/
MTM#.VM/4U-75VM79V]C7V]O;W-?8U\_0SL?*Y,S3Y=/4XM7:X]S<X]O=ZM;8
MZ=/3[MSAW][AXMSBZ]_IZ=WC\^#>W^#?Y>#@WN3DY.3EZN7JZ^CGZ^SL[.;H
MY^/E\N3K\^WM\NKI]^KQ[NWR\^SS^NWW]O#O\O'O^/7V[O3T]/7U^?7Y]O;Z
M^OCW^OS\]?W]_?CV]O#O[R'_"TU33T9&24-%.2XP%P````MM<T]035-/1D9)
M0T4Y+C!"/*3U`"'_"TU33T9&24-%.2XP&`````QC;5!02D-M<#`W,3(````#
M2`!SO``L`````*@"<`,`"/\`^PD<2+"@P8,($RI<R+"APX<0(TJ<2+&BQ8L8
M,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.GSY]`
M@PH=2K2HT:-(DRI=RK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ]@PXH=2[:LV;-H
MTZI=R[:MV[=PX\J=2[>NW;MX\^K=R[>OW[^``PL>3+BPX<.($RM>S+BQX\>0
M(TN>3+FRY<N8,VO>S+FSY\^@0XL>3;JTZ=.H4ZM>S;JUZ]>P8\N>3;NV[=NX
M<^O>S;NW[]_`@PL?3KRX\>/(DRM?SKRY\^?0HTN?3KVZ]>O8LVO?SKV[]^_@
MPXO_'T^^O/GSZ-.K7\^^O?OW\./+GT^_OOW[^//KW\^_O___``8HX(`$%FC@
M@0@FJ.""##;HX(,01BCAA!16:.&%&&:HX88<=NCAAR"&*.*())9HXHDHIJCB
MBBRVZ.*+,,8HXXPTUFCCC3CFJ...//;HXX]`!BGDD$06:>212":IY)),-NGD
MDU!&*>645%9IY9589JGEEEQVZ>678(8IYIADEFGFF6BFJ>::;+;IYIMPQBGG
MG'36:>>=>.:IYYY\]NGGGX`&*NB@A!9JZ*&()JKHHHPVZNBCD$8JZ:245FKI
MI9AFJNFFG';JZ:>@ABKJJ*26:NJIJ*:JZJJLMNKJJ[#&_RKKK+36:NNMN.:J
MZZZ\]NKKK\`&*^RPQ!9K[+'()JOLLLPVZ^RST$8K[;345FOMM=AFJ^VVW';K
M[;?@ABONN.26:^ZYZ*:K[KKLMNONN_#&*^^\]-9K[[WXYJOOOOSVZ^^_``<L
M\,`#WT/P:/L,E+!%"T_DS\%P[?/,--"8<T["]ZC33\,;*ZQ/QQOGL_'#!'%\
M$#\"\8/R7B9OU/*SU)3```=K#*'Q,W<XY$\QP^!QR09Y'*3.,PE10XA!"W.<
M,"9$]P.,P2!'G73""7\LT#Y);ZSQU1MSK([&^]RSS\-4(RV0/R8O3/+("D?-
M]4$OE]S0RW%G+5+<`UF-$MYEO_^-]]LZU?W0W_4E',0N_8A`!"/$7#)-&XR0
MC(@0U#PSQS/FX($&`\`0<X(/Q>1S"2+W/)/'.H5HT,\DDUQM#B;F-+)!/Y1`
MT\\TP'R<,##FA)TP(L_X\\P)U.QCCD#J&+P/.@)E+-`Z`N'3SSW23[_PXPE-
MP_HBDP`C1-'#D%Y0PHL`$_4S0B2<AR4'X?S0/7D0TX\ZT#N43\/$-#W0-(PL
MDLD^P-"?.:C1/*A))&NE0]O;,I8TL;D-9%03&>"N1C6[]4T?#<.;U3*8$,'-
M32&$0U'"A'")Q`$##7/``Q%LP(A_](,6-?B%'3JP!0S\0`.+$,$DA$`$.`@A
M$#5`PR3_MK`%%"!B!FR0@0;0L+$?J$$$0!`"#5"0ATN@H`8^$`@>9*"#._A@
M'34@H0]\P(!BU*`&P(A#"43PC#;(@(0U4,,TAE`"1`CD$3,@@C#84`(TJ(,-
M+QB"0.9XAWO@H0:(0,0&JH&)"TRB#=,00NL>X8-E"$0(0O!!&Q9!NSE`30XV
M0,0ZUA&_2Q3A'HM8`";V@8CD`<-\Q1#!):#W#/FIXQ(`)-H^B.$/3!A@&OU@
MPQSZ,;&!W(,8"9O&\>ZQ#A^80WC]J`0F^O%,@60"`&PP`1L(P4E@ML$'"1L"
M^\Y!D'LH+QYRBUX_[F"^?IRQ(-28Q"(2T0_=Y<&`"`&&#4HP_X=+M&YA>AN(
M.7)6$#948V.+P&?'%J&!$MQS$1)<I_*.5Y!UX,$A(9S?P^Y!"Z0I#7`<%,CH
MP"80<TSC&1BC:,=(MH_MP>Y^4@,92_NQ-H+0KVLX->8ZL#;!Y_C`?#8()AXN
METGH\8$-JX-`(MX`!$+\@PC`B.(BZO"#8O0C&VH``@D4L88:L``(:>A'/!"1
M!@P`00V5:$$C@&#'$T!/!$-`P1;4H(8\#,$'WY.!#V0P`Q[D(!IL:$,-)#8!
M($Q@"R98G$#ZP(4/".$%S[`!$:I8`X'H501HT``P@BA$//``&&P@@A`Z$(@'
M`(&3_<C#'&K`!Q\4`@-D@('![C`$-O^@`0W?1`01B,"&"U`"!4&P`1X4T+IJ
M,*`-0UB$7A%Q@AK,H0<OV*P-AH`'$PAD"$/X9@F(=@\AP(`-F*C!"XHA@QHP
MX!%"D`$;)H&'&<@`#0^[A`;4D0DB+`(3>3#!"^:@`1$P0@1"N`$&Z-D/3)"`
M!M30@0CLV`]$:&`(ZU"##:@A@LJZHP&+:(0(RB<#&)S`#RKP`7<100TAY*"=
MD40#,/M1QW\D4@1L,$<UFJ`(?"QB#M.`PR6<<0$\R.\.<]B'"(!1"S2P8!^+
MX&0Q"G$\'0Q!'RU@`RWB<0E:A.,#B/B&+2R`CF`@3B"$"`#1UD&+=?R#&N$8
MFL&F04!_4$/_'6_NQSH(N(]U:*P$YEN'!E#:CW\`4P8E'%O7ZN>\^1D0#6<4
M@<$,Y@,VB$!C)[1>V^[A`P,L(`\W(-I&Q\<W8LX!&-.TVT`P<8*.9?0X:)#?
M$/)AAT3F`0TE`.8SL%B#+<1!#2C<APWF@%Q!X,$.0YB##EJ@B!8L`@@ZX`(<
M!-&/<"`@$#3X`1#JH`@,S$#',DB8#.A0!V!40@#F:+0-S'$"(:`A$(\@PC?:
M<-M\`*,#=:A#("91`Q$(9`8Z\(`0;`"/QTYB&I7MQPG(D(<M]@,-0KC#(@@Q
MA&((@9]JN$0C9J`&@2"B$&W81W5W+0-WI'82ZL!N/Q9A`Q^H3@AN_\``']#`
M!X("0P;N%($F`7F/%Z#!KM_[IAPLSHC*3JX?Q!"D.6K`!D1^;PC?B`,<:(`'
M'Y2`Q58%Q@%*$`!U*)((_;`Y(S:[AD:80`CRZT<Q\""".UR@GP+Q`0EH`0<9
M:&$(0F"$0&K@AA^0`PUXO800'$&'3&3Q'EI01`EH08.$T:+I6"?F&J>1B>SZ
M(!-QP,`D+"#L'%0`$3+`PZ[QF@<MM&$%B'Z$"$Z0!PV\P&!Y6($@9*"(/`!B
MC4)H`0M84`<1S`$#.Y#&QJB+5!C(@`1Q.(`B]CH$8/C`!O1^@0AL8(-GR*".
MB!C])#1@1W5<P`1#F'4))G$!-"#B$C(01O\=V&"#-4!#!C;P7@F<V0]J:,!@
M`6R#$(#1!D1,>`@7N$,Q?)`'HRU"[B/4.N55`].`"#5P!\.C.6.P"+0@`S)0
M#?MG!^8P3-0`:\_P#)4@!(]09)[4,90@2UI``_`P:T@%'<JS:/Z0@IBP8NVW
M2O<0",\`#\P#@?0##[VS"':@#Y!P!]30#H\0#X+`!>CP,9>@!HH`#,)0"S\0
M"/@`!S\`3/I@#FH@!-,P#\.$")EC<^8P!#5`#(J`#HE`#'P@`_TD;9<P1M_3
M#V-D`W>0!_]013Y`!,/4#W/@`T,P"5GD?0DW"420"7:`<%IP"6F`!A\@$(R`
M!GB0#W/`!C[`!V[_(!#K]0RV-0="P(@^0`@BD`DRP`ATX'T"X3W],`2XA0F8
MYP_"90>9,&X_X`-,U`^,4(?F<'/$Y$R(X`.,X#."A`:8L`)U0`-P\$[1M3JJ
MXP.+H%L^H`XVL$F70'>+0`P[\'191P0F4`F7H`4PYS2!(`-#$'%Z-TUJ>`=(
MA7`GA0>JH`K54%GW4'](-0,BHSFP-CV9X`_#P$^30`P^,$0>$`=KL`\G$`<_
M%#3[]F9$H`8:<`?[L`4S$&QV8`/U$PA`0`0Y<`]<6`S`H`,1&0@$%PTT$`?'
M0PP*8`,<8'S]X'F/L`PF0%LU`'=XMP\^,`U$\'QM0`1H,`R90%M6E0Y/_X<&
M&,!\1#`$F$`&;:`!;``('!!;0H`",/!8U8`'=D1>T]-@1<!'/F"`+X`)F-`&
M)2`$"[`(:*``*G6/_=!\;9`Z/D!Z-6`.;G!7F/0,:T0$ZU<"_G`'X,@(>4`$
MQ$`,+%!'6[,Z-B`#=Q`'/J`#U9!0T=$RHM8/^1!1!:$/'V,U>I,V`440`54U
M]012!5295F,P^A`/'L=,"C,-+)4PZ%`_`D$-P+1H]V`.&J.::(,)R`!TC[`U
M]S`-[N`/&B.&Y%!2R:,.Y\`&Q7`/;X8'C+`/SI`&D0`-!#0_1#-+:7F7^S`-
M6C`'_D`+1#`)Y-`ZMX,'F*!)8J,/A"`#F5`-1/]0`]70.HQ@!V]'"+3`"#G3
M!D1CC]0D1,20!T)0!/4(#9FP"&Y`!C80-/W``SW0ASH01P*!!D.@`\5``W?8
M!G8@$$U`#&>$B,0`<'$`"?LW/6UP!W#P#X47EF<4<'NE>80P"<LH`UO``'$@
M2$(P!L0H!&#4=#[`:W-@`^1G@*@H`O4#!(K0#Q\P!W!P!U/X</>P!MYU"8KP
M`'9$=)0F?Y.0C)-0#2]`"UPY!]WC`Z9(#39P1OV#!OZ4!S5@57JVA2(@`^6#
M1G@@E`8`#!I`"7?@!O,77O<P!SEC?41CB<&`AW=@`B9`#/1G`S6)/E[9,37`
M22^@#H1`=I&0!WDP"<7_8`*>-0>8H`XB0'V,P`@RX`]M,`GKA09:X#2/<`<:
M8%7D8P(^0`V-*DB7H%+,P5.F!D$3A#9JDTX1Y#<*@S%5TS=M8Q#*@U%JD3:G
M-@TV0`:"9!#I0!#3@#$LV'X&,V<;`S7+:C[F=#OFX$+KP`_[H`[H(#:$A@G`
ML#5(=@>C]#7C"`S,B@YX`'(H10SWD$C^\$R8,`?%@P=#@#L2]`S10$R.,W8;
M(`2_^0S4P#T\@`;%B@D&,YB3(`-%P#3!]`*,L`XK!&K^`')W8`Y"@$.+8*J7
MX(F4=@*(,`TF(`+%D`GSEVI"X`]#8'M#)P*8@`?JP`C8B0DB4';KT)?%B`@S
M_UE>F="D][BHWY,P4G9PZL"H7IJIBS`\O(4&)B`#P+`(*3EKDD4-1,!.>:!7
MBV@#[VIXM44-F+`(18=&[50=U-!."4-O/Q41YJ!0!/$T#A&T%!EV'!.95U,,
M+M0WL/HV"D1!"Q$V`@&WG`8W(?5`XQ.X@-M3A)M.($1,C("V$>%`9E.X@4LW
MM%H0-640DVN8!K$(>*5+'80\K-@&$V0R9#.XQO0P^0`UHN:L8&,WZT!1<"9I
MU+13[7<\"?,/24,V"U,Z8B,RTR`_0L"R"5-,]U`-:),\6#-+!69F%X6W_I`Q
MW?J4JTH(_&IU+GH/C)!<`^%^6IM%.2L\CH,)U.`/C/]D3O'PG!H`FL%#35^#
M4B=P"2[4K@;C#M"3K!1;`/Y%4VZC#FA@0,2@`2AP`OHCN(.S3G*'"$<S=R5D
M$"N8JYO+J@=14Z%IMW-SK)WFO+/9N(<Y#<-0/.H@N].3NCV5@A5407CK422#
M01DTJZVZ06ZS#S#EJH]9F?^`3SS%JARS#LD*NLUS-1+$P-;Z00I\N`!LN'`C
MQ/U0#M[*'I'4!AM@J0@W!YG%23X[3`DC6"^`!R]0L4/`L!O`6<^`"8[&M#*9
M!P:`!C$;"2<@`B:P?V\4"09@!VR@`7,X$$50#=10!$1`.G.P".5&"P"@/S+0
M.D6+"=0W:_S7?/;7H/):#>C_@P;E*7:J6@,`T`]X4(+K``!8QS'F8`.[-`G,
M1`LD]3J]8P[/<`__D()[*3&TNZMF)F=@4TW),SWU<\H#,0FUJ*J2VV!?&Y8'
MY1#_L``F<`'@E;Q.TXJ5<Q#3(`+PP!#'>A"=LS^Y+!"+X`P1T4Q6U6><%`^)
M^Q#K8$D+\3K)21#/<`D&4PS<E0D4M0[,<T"U.L):L\/-LY<#4;E!/%.,J\!4
M0S(*A*NL>@^3JQP4BP<;,`>,@*5!Y;(=8[,;<PD+8`[D\%[[0`3W0'07A0,I
MX`ZC,P>)L`!\4`(F8`?J<`)MT*@690>%0`8A``-]@`D+0`BG%,\*0`V6.@DF
M,+-#_X!#Q7`"4.,.10"[YB`"NH!7SF4"=E5VPL4(3F>@HE@#%):</LNQB%""
M]4>`4<,(;.!^[Y4'!6!5#Y,')7`"Q,``(O!-EX`)3/0P0M!]:+`(2\E0VR<#
MZ^L$)N`&B]!'O"`"-X`,>?`"D'0!/1N*,H#&/'`/A3`#E\`("Y`)H45A[&0"
M->`/5!TU%`LZFU6"U&1=ZF`"NW`)P[`&<K`(&-`&F"`$-=!&N-0Q829WP)`'
MT]0(A"`\B``["I"L_>`.CP0,,!VT,.=/\Q,,,E#-TZ/9_>`-XDP0YE!":J``
M6[,.`E`)Z'`!QH-2[J`/TF-2TW,QQ7H).1`/RTI1_'PUR?_XM0DC#!<P`H'0
M2.5;`Q?P=Q)`V2'3/+[:N$@3:_:;,.!HOPLQ#00F4J]Y-OT`#R<`ST`,W_.3
MALTQ"0LP!PO`E$'7!GP$Q7*F`9;@!C*P!F[`!D(`83*P#F3H`Y?P`SQ`"3.`
M"$&0""$0#(UP`Y-@#HN07I4E!R9@`W20`FA`"=,'#(C`,08`TU18J'@6?8OP
M`B!S`N:3"8@FR39P"=20!\_`A?MP!S6`7#8W#+60!SU'V>'D<`R0,_>@`#)P
M``7<,9F:2&'YQSAU"?QU!TST`J\V!+8C$&T0737`"+-6`^J@:YS$"`S`!R:0
M69:P"PJ`")L5BN.)#@IT!XSP`L[_@&@+4--]!-`G*T0V0`PQ>0]P"<YHT'U=
M?0@+\P\7@-Z(4)<H8`DFL`8;0`M]1`@:$$I)4P)8Z7Z+P`&"D`(W,`8V@`8R
MP%SZ,T)HX-5HP$>$T(?[-`=#$`0*T.9T.`094`<@0`,[FC#4T`(_T`02MC\F
MD`/+``2-6L5"<`YR_7!760*UC@*7X`$U@`?[]Z6P5C_/`#3_VW[+8`XS\`%=
M7`-/)P//L`@&$`<K)03:!`POKC^6D)0`=^LEP+*W-0TX=P]W4`*QC0:13K$-
M$,<"06^88`<R<)?\1`@'(`UD4`/!``-I$(&K\P(&`.!'!0W>AP^U6$*3,PW%
M@`Z9\`\3_X,&YL,(#P<=P#`)U*":J9F.G&SI]^0.;L`']_";EZ`.P,`(&B`$
MTD`--0`'[H`(C"`'.\`(CC.S5DL(]P`,>E>)S1C14TD0^?`"ZW`)>'`/&O!@
MV02RY3L0:OK7$%H")3"BQ)!JL%9R`.T#F.5/;+`/63T''(Q&Z@``A#!V6/=R
MQ4S?@$ZF>"5WR'/@&Q!8_6`"ZE`$]M8\B)!#EW@'F30-.70)Q3`$([`+=G`)
MF<`!.8M%WR/:3,13=L`(6"<'')#UAEP#M"Q&_9`)0%X"B@GE/S4$,N!`ZR`"
MYM#;T(MU34`&9'!P:3#68W2]"T`#"Y9%3N`$.-`'AY0.]=>*"_]#;B-7#`98
M1ST71NAW<%KMBD/``&G@!#F@N77P/3,P!T&3,,3@!HU``D#0!K@$!$VP!4``
M!P!A8X@0(<]D2",3)T^_(26TU&CC@UH_BN;L(#JQCV(_??W,D:!$Y!^Q!3;Z
M"1F"Y@Z;?AKOX1$B@I!,<RW[S5'#`<V,2R*(H40S<,$E'S6&`"O11L.0"S`F
M^6ACTU^_&C[PB*A:0L2B136FS1GQ8PTC#&PND/&!:,&]C1X-3*K19`0?$8BL
MEJ@A@\BD!IA*R("QM`8;$6T-'T:<6/%BQHT=/X8<6?)DRI49:W2,N=]43(OT
M?3ZL6:,[P_[8[O.W+Y\ZQNJFM7R&KM__M']MIRU:UT_=)76F5^]3=^+.1$R7
MS)F[YYI8B7\V7FNDQOK9NF+$<O>K1NR936(U^N61,8W:ZXULB""B1JP?HWY6
M;?;#D]2<#1O/)FD00@U&>#DA^"PJX0=+9K"!F#E.<(.8J#:BQ0<T_.'C$CM*
MR(,-8,R1H81%&!F"CQ-,F`88-NXHQJ8V9/"!#33RND>C^?KY!R)$^!A"!#>B
M$@*1E-`H@:U^T%BD'T!TJ`,/$@;A`H^NUA$"DZ.>T:P&1*24R01$T&A#"#OF
M@,&2$9#9:`$T,,@AD1P*TVB1%J!IH0XA;'KFAWY`P`"//)Z9@1@!!`GDO$MX
MJ,8$<]`0@@UT_ZJ*`X],:O"QGV>*,4<#C?*A")T'U.BGA&JF+*&]$DI8`(3-
M^@'F`B$VH.6.!1"QJ88T4!""AV?>%$*&.2Q!1(9]\EC@S1<$PF0.$=:YLB7,
M:J!FCA(8P806-FQ8:1(4@EC#CD8PN(01&/*X9ZVVGAFB'Q0:X>..A=CP(<=%
MVKC@A1(0D0"1/-[-U#)[[\4W7WWWY;>Q?30#K<70,/OW/8+SV:>C?Q?6J&&*
M"-:L'WX*%OBPU!RF:"I]^#%VHX)#N^3AP_*I`9A^*E8LXK;PJ$GDE/M9Q`>5
M*1V5(H$_9NUDETC3366*>M/LF=0JJJ:E=?:9CBIJ%C%YHTNFN>>>2?\:!:XB
M<]1!PXX%JG'QGF*^NLY12M4A!B8/YA'D#'Z@?.8?8##QH=%G2MX')F+,P6.?
M-H90!YFT3H/9AT6><2.'9=JBPP9HJ`GY9Y.I0>0>'DO$8YUU=)"AF$7(*80>
M3(`1PH:G?2B0D$:GD4&#28!A-4T&9,CC$A-L\$?8!2>9A#L14++#AA<:Y\<$
M-&S`Z1DT\F$#D1($'T)O1GP0X05,:I`2#QB$0Z/$J7P8!I@3:IA$"!]4?X&'
M%VIP0\5T:[BD*@TNN6-4:KS;P8<@,$%#G;2,6ET!3!;81PV"@@D4^6`:)>I7
M`A6X0`8V,('%F,B]D..RB/E,9!AKR<6F0L'_#%JP@BY[V`9#8QC1($:$B:F@
M!1T8F7O0XF*3T<@D$)$[R-RC#6S`!$<20YX5(J8C'BO-"=L"#YLUJBW^8`TQ
M&F<3=6A$'93:!P\/LXZ632-G&7-&U(9F&D<5C2TM4@<P<O.,2["E&-N9PW8H
ML@ZV/`,82`3&1&@S#&HDQQSKF,1VJ#&)W;PI8Z]91R&*<8^CO682IO/'-/Q1
MDW/@P62:ZP<FXM=#2E;2DI=<##4&J0Y]P,,=\!!&/O(QC>T,(1/ZH,;8D'.=
MH[6$B(L@1#\09I,AJ`<R>%L,'B)HDTGDL!]W*($*VW*</)P#,0OS"-4\LHY%
MM`R(;;E'&4=",&@>_R<3C`C9-'CHFH=1DR+_H-H^.*:1$Z)&G`Z;RK\VB)I[
MB%`S-ZM9"'W$L(*EL(0@3"$(\8&/MJAS5*@Q5CW?<\&.D9`C/J.FPB[XL<T0
M;"I"M(DPGPFQT*SS9>]ABQ`U`U&/J5!EWBPH2%'(F*AATJ0G16F_8MBK1<C@
M'G#(`P.&L`5A#2$0>%!$'`3("!FP@`@V*$;O"O("&=Q!6<`8`A&@@0<;7.`U
M@Q(<(=YW,KO-$!-N8,`][%"02Z`!#>X(7PGVF`=UF",/-J"A!BRTB*^$#!B,
MH,8=;#D8MA)C$M/@HS\PH<9^B"`Z9:0(NNY*MGN80S;F>,YZ\B"X%Q`CH__.
MK$$)YE``-%P@#YC('6L089)^X/!D;<%//+OY&,T4`QA>)01[;$*-8*F'H3"B
MX441<P<T'"8336NFS28A42`28R+"/.!`*4*-IO&+8-28RCJN^$'=)/9AYN!H
M/V&4V(]]S*(@[-C'?'3=@144A.G,V#$[ZLY^4E.D*45O>M7KF&F4@`S`T-4<
MAJ"%3,D@$_<H09](L(42"*$2BT`$(M;`@1KEH0W?`,(='L&!&I!``S;`;TV8
M:HX3,$!F,&-`&TY`C`?`@("9P,KYYE"5(4QB*R*0P0N&\*P@464.!LB#!O#@
M@SMH``T:.!%%?$"(-B!"!#4:PAS:4`,1F.P>,I;_054T,@<9X.$^,I#!0'YA
M`Q,T3@;FV``B?O4":NP$#RWY'##[X>.]$B9Y"JC!,TJ@$ANT&!@B".8T:G"#
M8K0!!G-;2*Z`,8V(C/@<Q(#!(NY!&%H0X0:TP,0T3``X0BC`!D00PCWDC%L#
M_.-*N\G#'1"AZ2\7`PUJ7$<>!-V`+Q_GCNWQP2[V@0ASV,<<&N(AX^*!#\>N
M`QB860,1:K(/8K#F.([:1R4RT,33:`03K$+':7)6TG[$HR4_5!E;V+`+P_RC
M!$04PA(30XR%M*48,GB,411H/.&6>S$1$T)M#;.+%MN!VA1A]4;6H>[UUMO>
M]UX,)@IA`\`$HP5<:$$T_V@@A#;H0@=PT`(16+<%8`2B$+1%:X`)@0X=Q$$1
M+%"P&L#MG._4E@07L.6$+B$'?US@!^2`2EUT9!^(_`@-,N"Q=R:AVC8L@@CJ
M`+>)AX`AJN0F#\48`B+<4(RXV6`#0JBR+%7$D@ULAQ%WP,.,Y[,/'Y3`!C7X
MLIK[(3HB2`X-$A#""42("06\H`#NR`,1\F<#-CB2#3G20%HH`FD-5(,(B\C#
MC9]A`W8=*`TV]JH0[H#T&Z=!!CPU\$8X4"*-\)3@1,A##8C`@*(M0@.6'\Q2
M1+"BT.%!`C-H<;H<I($<$D(.`[D/#/B.!^71&$4:D,TT<G"#)K"A`8F#@0\H
MDO^'(KP`[R:8`2\:\(,XD,`&PF#`".Z0`VKD@54-GX$&1&`.LZ#A$1I``3%`
M,(,<E(`$Z!!"!NYPB07D80@H*-4:D&+`EU]`(VSH_1E_P(9U``$(CP!"(.QS
M"1OXH";36(`A8`3MF`96N0DBF`8T0`1B*(!BF`0T,`>BVX5(D`-R`(8\P`-_
MJ#,Q8@-&P`QB<`-,D)HY*(9]B!G.PAM!<Y&?4P?6BR8[``9U@!)@(`V\$2,%
M8!7$DH::6(,@R`1UH(5GP!MUL))BF`IUN`-U0`0/U(AI8!EUN"8CPK<II,(5
MHH8;$()SD)8Y4(0$R`%BL`,#J`$\B@9%((%&J`1J$`;_9+B$7?`Q-`"&24B'
M.GB$'P"&&FB!90`"JVNC%+N2IED''P@R/)@#-*`$&-`RK/LT0L`#(F@#%+B$
M(6@#1L@2&:`A!00WF",>!`RF%R`B31,"0F"#]KD'&UB6-G`M&S`_:CB!W$"$
M-IB#._`*DZ@!&["#1<@F<!.!2:`=M;,!3,A`F\@$^BJ!2]@LEA""-<`$8E"1
M2X`;<%N'$WBYT+$/--`]&<.#-A`!1KB299@$.Y@;#9"#K&D#J@NPSRH9FX";
M3ZL&(L,#-IB(\&$#]GF>DRA`;AL_&_@R?>B1.QR"IZ*/$.`!,L@$:4"?4/0(
M[PB/V5"#+;B!'^`%1+``.7"I_WZH.6)HJC8P`3KX@7A(`#3@`#@``GU`@1R8
ML==0A!Q@@730R.:9!A)XAET0`1*(!@18!JS:`G<(C#PP!T+X`0*1A*2(NW\4
M`;;P*D3XJ1MX@#4(`4K8`!I0@"%8`WVL@?B9AO<1GK9CB7NH"QFP@0*X@[10
M`!&`,VC1@!F`@:1H@Y\"QJO3@/CQAS58@[+`0?SP17@;`AP[&1MP`T*H@;.:
M%SFX`3NX`6B8@7[`A[>LRA)0#SZ0@Q(@@D((@1$X/39X%EA,"A-@CVD8`J9`
M@]>8AA<0`B(X$!_0O2I$S=3LH46`@]T+$H"A"-#8B)S!F7[(AIIP!RB1-R-K
M%',H(_^V<`<9O`=@")(F0HX"9`U/4X>7`(99>@92Z@<FF9IJN`=BV(=;FXV?
M,S5B\(?T@(B<&;^KH`6*>(8!)`9&^(<<`H9BJ!4U"H\[8`078H1G(`P#I`A:
M8`_0681B0)>ZP(1B8(1%L(&@T+U)V,H:6`0T$($VB(HUL,9G2!%")(8`X\]"
M68-$2`-UJ`%&H#<98!V*N`04L8\V0(,U\`J/D`%$$()W?!.OR`-@<`,#$X()
MZ(A"08.SBB`;DP$''9S!F`,?0"I&.8&:F`,,J`,2R(%A:`2>8`.-$`)&*`93
MI(0Y2`0(>X!&J`-%D(%O&(%I8``_HH0<0`%\"(0`O(<[Z(#_97B$#J`!?,"`
M;U"$#MB"?I`!!4"&^Y@#X)L$&&"6/%@($ZB--J@%:N"!&Z"#0LB$&4@'$%"$
M+8F(9XBZV:!%73"!"ZB)>^";!<`[_)D)8_0K/H!$.8`!:MB%!=@!C[`L-,B=
M?;`#,CC+&O`'$0"YO:.(13@5DZ`&W:,&#?`'8AC(?I`#0G"#(@B29[B`]1@"
M__.(#IB!JD@$._B1O=$]17N)VD*=N1&"UV"$%GU+:7@3WE+-<!57R-B'?6J)
MY?28SY#-9SH,A4D8$T(H@_JL$0(ACHFHC8`B?Y%7E9F8Q/`'$5J$.1"M1*+7
MJ:`&2=0]<\J'?S`'76B)%AF:0[)$_V.AA=Q0ATD`IWL`)W50!W=(!',`#N"X
MAPB*4JRQF6F`+G50+D1HFGTH!EN[`\3J!VK8AZMY3F#``]GH![1C%<?2".M`
MAC^[FDOHM1\%AC)B!+8PS"UX!+;:ASF`%HH`AFJ@!EK0A1E(@V!@E3L`@3B@
M!AH8@43HAPUX!/)\!#K`ATBXA*NH@UH@@1:HA3C`APD("W,`6SIP)&#8`%=Y
M0!_SBLCBK#8HAFI@@T+`@!K8A1G0!SB8@;N[@R%P!M:+S@O`B_8X@6\:`G]8
MK*,HB-V1Q5UX!AA8T?#@T"&X.A\@@B$(&7IH`![0"1F`AP7-B]-\L,I5AQ<X
M$1^`6@&=2O\H+``?T5VTXKA^N``WV`%+I(-]$`(R<(,2\$L34(<Y8`DYRX,Y
M*(*%4#.X88,[\:-Q]=[O;0Q,L`1J>`:>.2;-P(=L^"$.$IED<QAUNH=\O=>.
MPJ"&JIE]F*?YY:A\`B@2BE<@`B_$D+3P(F#Q^I=%8)G,<!0@85<8PH[?"M?U
M/3=YU2$VZ)'$T`>VR&":20<2`-EF<Z9DH@C2F`;2^`=%PJ=A(`?$;`G?>MC-
MV"#?7(=_\%!\;8E)4`_6*,#C2")"**M]((>KX4GXB*UBD(,R@I*:X$8?24!@
MJ`V/R(-R\`<[F`1_X,M@Z`<:L0D;RB&:)<]S0%EU6&%JJ*-AR-;_&4;9DWG.
MFL,,$1'"XP3?.)9C;[N`#7F!J#$B@5'6?:@#?P/7?G"#9CB,9P@"Q+C`PTB1
MT'%8R)B$-OBBP8LM1Z$%[HQ.6QJ919"AI[DB<C4,J&G@C;@'?2`8*7Q7&)ZH
M@!HM[&*H_YU?5*9@?"(O86)EZ;HG?>TG8."K@8*VPW"F/R8MR*"&+QLIBY$N
MJ6"N5E;@DS%`<_A'>OUD!\:N.9;F<=4(\5RLGW@!!((;]BF`XF2`.O@`%EB#
M>Q""&K"E*4&#=4"73UN#(5@$==@;8T2&-/BJ2"0&`5TC/&`$<W"T#9B#HG4Z
M:MNCL`$&]=```ZS%Y5`/DYF#\TD.0JBM_V=HD2\ZF9D0`:+`3AA1IZEHE(<Z
MHC$K!A(I9IMXNV<>:8WXT$3JLM8H+A&:@Y`AI^)B#`1E7Y>Y$)'Q!]/9B$S@
M(7=`&=,H+%OJWQ)"C4O0G(P6J8X83A&:((MYAF!XC7,`'#P>+6BKF'L:&EI^
MJ'0*X(TJKX`:ZG_M)HLB:M$0#7L5J',Z+U0^:_8MF!?RIPPJ8'.;YKJN0DCM
M"C@@@J(X36"X`QD8'O(`@EKHTAH0`KSHE'XH`E@<@B*@@Q%@!!2HA`W8FT5(
M'!.X`4FTU55Q`XJH`1/-@P6-`1E`%R&8@SQX`1'``PTH@4R@"&5Y`48@O9/1
M@-Q(#BCKL17CQ?\-<#Z\``8BP(/:8HLVR)T:8&US4!:6_=*&0`2_$($0.0%$
MH(7(P80-$)P"W``94FV1V>L0%=@[$)VV>$"V>D=M:NA28P",>-%(0H2<^8KS
MO-P-^8=0@]!,J*.=50!G]"U66X=,P(U\F(1U:#1U*(82T20GPF7=J(8V$$)B
M<`<K$C3J@!ES^(>)\('M,`=4\@=RJ(%JR!UGVF3=6(\%J`'+0DR:X2BS0(U/
MNV`)[H=)4``?V``[@`,PF8J)?5J=;8LB@.G%L&]0%H$208-=H@AG")?(>`:^
M<D+%8`1+T*Z.]A@1ZK4>\H>P:;MJVPU?LNLM1\U+2(-'H($A:P-,4*W_&?@!
M&&B"&F@9(0`&%E#>_CO'OB('3!`!F9F!1$"#>V"!^^N'1+B!&WB&9:@!.%`#
M#U!`W3")89"\.@MMD]B'#;B#-A!%'\@=_"(;@IL(G,LHV;8#$6"#%<O681BR
M1=@P-"B`VM`(!AX":N`Q$\"#&/AT=;"#AB"([MB=_ONJ3U=1/&"?25B`B1T5
M+'D!C)!%1!!FCJ@0X="`.4BW>2RU$JCN>8D/R:.($SCH7+&+)@L*@L`+MHA&
M4W]<K9B#!5`Q=A'%UC8!#=D`&]`('5&=X2F!4B$"#8`T1\(*-/#OW<$$#6"$
M3]D"U%T$">@E/(@R1>NO-8JLWTL*7!0!%B@&_S6@E]F(K%*IK74X`$KX,35(
M!_EJG'K4%EUX!C[P@40@LC:HA@)HA$"X<(HHAJ-SE'0A+AL(!GC(DGY@`(&=
MBGPX`),I@6+0D4OPATDP@<*8Q/40`M;`FOB9!&XIACF(.VI@@T6(JP+TP(I@
M`V+(A%J(0-^4AF%(CG1`AF:@!G.`!F<@SFZYA&>8`ZBYA$;(C>+H!V(`AGC8
MA]6Y94'S!Z/>B&F@!=;0^G68/H\H`&!H(3LRC[]N:BY7?'M[FV40!.DVW<;9
M`1Y``;QKL5=T9"'HBL&@"!1KLQJ(AY%G@W-@@:Z0@1'8B2W0@2WH@#@``3R8
MI*(:`EZ_!(+(`Q,@A/^S@KI)L%5PVP?I$3*)Z/P\-VS20X1Y)#AC1(.]6'LM
M8(#MT`AW;@^S6I%+L%5F,8$[<,1,0`=W64*O&C3BKI#:(@9,0(FV$(+(NP?3
M%%C=[(=TV`(X^``\>(1[J,5[P`0ZT(TA:,?VH.SC!XA^_2;YN'.)30UJ]VKX
MN-</C8!)`N^AF9.G7YXA&P@M>E:#F`A&A^R@$5$#T9!^^_H1<X-!B(U^=V92
MLW%/1HU%>-0)03.IQ)!I:*J9N*?(#05$;8KY2,FF#9&;Z&3ZZ"=#2"$\B-#4
M4/0M$(,A"M3UXP((&`LAB/KE@U$,!;@</R[@6+`2T8(7&VK>J!%,PXT[=FK_
MR*@S`0@E@3787'AF(I*-%"7(A#!Q$HT)B1,5%.NGU@`B$T3:N)&!9L@%/$7P
MP.NWF$T>$T-@VI#!AE$;#7#FO"!B(I-*&SXR8E)'C,@:9,7.[?I!SM("-\QK
MU``F`I$0&1H(B4!!ADZ-(7ALU(":H88Y@?VF^3`AI(T"'^FG*1`Q:<V"$'BI
M]:.FX5(--@S!PP8EV,"=#7BHMR"##3KX((012C@AA15:>"&&&6JXX8+P.*1>
M>OW<XX]`^SBDCT/F/%.B"(N0T\\Z_;B#SSSZK*,/,)?H\PT+B`#33RV/3*,.
M6?V8DP<F]SASSS3/W`/,$-28`]LZ<J"QXGIHH*'._R4?FB/$21C)P$@QDTS"
M7@G%9#*$%I<0`LQ%*Q%22S]LJ%,(+5S-A`DM*[3!!AL;$$$,(C8(H8L()3!R
MQQ!S%".#;#Z\4,,E/SZ$DCHU3$*$@(@0TX\P"K"A`1Z+F$/$5B+8(=`0:%3U
M`AM"S+'60W-H<,=K[Z&!!TQXR#!-/^H(A\@S!]C:QIN4SK$`&DH-@0@F*0FD
M@1PSL'$#,#(@@@<P#6F04Q[J^(`&(]VV>HD,]WPPR0=]`,%42CVE),(__?#:
MSPL^(#(K&C0@8PX/&3!2`UE#7#)-":CVXX\)NZ#0SP\<P+!(&B3:,<0_%Q`C
MQ`UNJ#-#=;18!DTC+=1A9/]\J<G0#R(<F"!'$"8@8HX()ORX4C\,=(9J3#8L
M,`PU-8A`R!R,2-N/".FA8<,DA4Y#R"2$"%%"&VTTQ,@<+-4@D!"1G!D3/C](
M<\D/EJ0S@G)\Y.$#4X2B0>TBR#0A!#0/R7"(%H'H$*YZT]R!A@R+O'!'>IFB
M@<D&3<#`QQH"D2,$&UF7<,(TD[1AAX]HJ,0AYYU[_CGHH8M>X3XX:\A(O0OJ
MP^#J_2@2#X;\@&ZZ0/[@O)+IN=-^3WJEKP>LOO^L1`Q9U*S(^TKF7++/-+3T
MPPBMZMRCCC\Q/H/(/L4`VP\PBDCISCT*(5)(C"PMPM\S_FR%9;>3J,/(.F@(
M$;[_#\`\HPXPVT]RL#]L^#`),J9A#F)<X@6+F`8UQ"4$:EQ"/9:`@1W(<0D3
M\*$:Q:#&(O:!B$D\`QCJF`0FCB,"8,@!#Y-8R`^:<`D?+`(8>!!!&Y[!AGV@
M(44U*$$F+H$)3+BP%B/X0"6FAH>5%",#)"#&'3[E&DK`81YNB$0-<)`UEEUD
M$3YH`S":$`01H&$:B\@#&[:0AAFD@659JP89\#"$$[@A"&D0@EH\(H0\7*)\
M/JC!&6P`C!)815Z+L=HB:O`A'Y!ACC7(0Z&*$<CHB`".-?@'(12T#ALP@@@E
M0$0-]D$$1I"!`VA`P1I@T(P%.`,-/T`$4(3@@P6PH0AN_WA3$-@@!T9DAQ&+
M$`0>&H")8CBD#1?(@PTP<8<#`.<9A/#!!E!`"#=<8@?`HL8++D:,&T[#:'C(
M`RW:L+G1<;.;WOPF."EDCO3X@T3JN8?P2J=.@:##',#:!XEL)R*VJ$<?]NQ'
MZ^QY3WW@0R7XH-T\MUDBW\%3)?G0G4!5L@]^^*Y$ZC'10,L9(9S)TZ$*61!`
M(911A[+.F^:T4$&_Z8\/M0X?4]%'0],1T@4QJ:/3.(>(^`,BF6[.=_<T1V=*
M)$^'``,-9+"!.OWQCWL((S'!<L@^U,$&.YB`&NF865)'JHYJ7%0EEV#$/?:1
MGO04`Q/FN(>/_&$.G/V#6_VXQ/\<W,F[2Q!C#EY5$9.VMT(.&J\?TB##)-SA
MACND8Q?TZ!(T9"B$=%@"$TK)WSB#$3\VW$.-Q"@&)<U1@N350`@$U-9*[@$F
M8%!#!FO8!Q\:"`^)H*$$'5S'.KCU#'-8*IRN?2UL8WNAE02B@0[M(",(D5"!
M>``!"Q`",BXB$'4$02#A6$:#+J$#?((NJQ7BY4,OL8A)Y.,9VTMJ[SBJ71']
M8Z@/S=UW:[JPAJX4H!3]J(-N]U`&-72@"S)G>S$J7X=N%+RR9>]\NZF./Y6/
M0IADQ'TK=(]ZF(,>&F)MD2QT#RP%N,$.?C"$-=1"/LC@#BM1@P8FH8$%KN-/
M9-&'!U;_I`%&[&)*B/@+'9#!"`S$`Q&4*)T^<A"`;_3C&9A0"&*[U)]/K>,9
MZYA&C-2!)2+MXP7;$\@Z$HP[AVB`P=,PP!`L@X<&RDF;S\MI>A'!!D3X@"R'
MVZV#BB&M<C4HO@M:Q*=<&#JM:I1!J+V$\GS`8-,A-;VX>RB)DNQ>&`'9'/#M
M!T-S1Y:0WAEW#37G/3X$SXK6="7ZB`=YS6D[W:FW=0K=[D3"NUZ(:M>^FX/O
MA];+4=/Y0QJ3,+!X-]IH6K"!RO(E;^W,2U#=3;K,"OTHK".LZUWS.D()*L$E
MFLRR_UU2E2+8@.;V48$4B&`,NF"#:4(0A!+0@0-QN`$:,%`#_V!Y1`UUB`<+
M9+`!/"@`DQI`@RXTL(%%E.`%&O"!"*HA@Q+\300:R`0#;L8RDV1+'43($[U-
M\@+^3.,%Z[%/,=I@J#ML8`W%6$`>"`)@L+H#$^M`1";:@`<4D,4')9C#.LS1
MA@PZ9!)S^*"0RV4./)2`&-28`Y`GL0@1$0(3_<#$S#]8@A^ADAAJ_4>(GO&+
MZ>TB1M2PN3_R9Z3T`0,>CNF/,QY:C/E4HQ__F,95,(%O&0R#)0XAQCKN40*8
M.JD_(1+1BY(Z%8;>X4<'W1PPYC"'H8AWO>9(5Z<EM`C=$OI!]V@#6:IQASWO
MUG>+&+PY--<@=13C$K3R485\G(<C"?^;O65W4"9D,(0$0T.Z=3M')"!T!SBV
M@1$T%5$Q&$PAWM$*0L#(AZ@GVNO9TY[V*Q&"&A_RJ3N,?"U$D$$>-([/##BB
M!G=@#PR>MX,?],,'<VA#,&`@A!C-`0`7(*/F?,`&8"#"`$3P@0U,D"`?^$,&
M7S+!M]H-#$SX@`C]1<0%&#$-!JCC*@UY1M(T5>,%U,``S\B#"/C`-'!`&PA!
M,91`#2".$.B65>2!`61"PK#!'=B$9Z!!K,B`#VB`+IQ5`,K`H,"$U0#@(I!'
M"90$JKA*'MQ!HOP-&FS`ITR"`K1!#0R%!'+/`O``^PD!$3"<#^`!K\A`,?Q2
MK!`!(6@`9(7_29WD2R;4QD^4P&_EE@9@$1YL@!!,@@THB@$00QN<`!M@P@+8
M`%F(RPELT`9H`##\A`;PQQP``QOH`B-@3AX(P8H\PQ72`C640)<920VLPQ#(
MP#/\Q!#XPR10ASD$TC-,T,Q-P@7(&4_D@3EA1S4P@CJ8`R:<4![0VSVP@?O@
M`1I0@S_@P1VL`R:P`6HA@@@HR#-(`)D(4#]4W20P`,M-PCH<$!+)U/M\RB4L
MSS00PP+803%8@@$0@I/HPC3L`S#P$F?<@_LX5&@``PJLQ2[X`R9P!3!DCQ`$
M"XF$R/`0P08XPZT@U30X!/(0`U+Y&8SPQ]M-@P@4PUI(R>^PE$V$_X]`#`F#
M,(D_`(L_5%7M[2,_!A@;9((0[$,,]4,QU$#-_<,<R4\#W8,&J,,_;,"^D($=
M!&!#V,`B$`$>U`$#;&`-Z((_U,`6J,%/M(&9A`2OY,$B7*0ZB,`Z5)8/Z%`-
M'&)35$-!*9()`*`YN$=5(((&Y$,PL80)N`8B,`+5N(9:[(.A%(,N^,`URL0"
M^,`%%(/\(`(1U$L>[$*F&-\0_$AI;46VE$H)K(S1C-ML$`,Q-,5*P!L:%&`_
M8!'+L$$_E,`BH`$1;%5X8`*I\(`08(([H$`DY`$'<!D5#0X;#(%P5$4_4$X_
MU,8,ED#_,$*SS('_5`4ESD$1],3#<04AW/^D0ZP#[XG`'&0"+536/YQ!U1&"
M"C(E'FC<E0P$$4P#0TP"9!H)Y*SA#<T!'_``"B!#";Z`$+C'M@V$#TPC^)7;
M0"RB".S`)&C)N+0!#]Q!^VD`&RB`'?2@#:0@8-3`&YF`S5$#Q+U`14Q"2F""
M?6C`$(Q!&XR!`FB+2O@`3K!!"&"`'5B`"5#G&!#"">!!(;CG&#3"&%@`PUT"
M#,C`"=0+B<B`S=T>#/!`(Q`"&1`"#$P*,="!--`##+@/-*R$.ZQ(#72`))R#
MU0P!)AS`-2V-AKW',-C`#K(!-13#'"@`SO&DIN`ATHE(&R#*"TR9")S`IY#(
M(L@`>7#GT@C!'1#_PI3T(Y(F:3>-2(RL`\ZLEHA(3TKB##G6V$LMPJB8RCW0
MPCU,%PN92$X10RTPRCJNR!R8P"(LA`U0PPE5XR1,B08L@E=5@^/-@?D-A`:,
M4!N\@)$-@0BP00WE`7]0PS6N0T&T%53B@<7EQ!`,`1$0@4!4PPL`0U"^QR3,
MC[T(R"3`1G!60P\.T0'\PL#`A@P,8B2AP6/Y#R>.RQPT0A6Z!<L`FPCL`[,(
M!#!`Y[CL71ZD@278P`B8(AZ0WT:8@!H!ZK8(Q#IFWI8Q@DT,01X@TGL@A#F8
M8@NNY26(`";@03%4@AGV`RUH0!Z<0![H`C`0`1KL0QY4W3TPRP*0Y!S)_^%`
M9(TJ]9CF?(D0_,CD!!8'S$!;WM&B",',/<_@W=!3=`8B8,#>%0/(3-,>%@,`
MREP<+J8)K`@AR(`EV($-N`,BZ!;6><:/;D!GG.4B7&,/W*<,-M`TG,"TU,`8
MR($(U$,/9$(/!!(BY$$F[<,P3.08C,$D6$`AG(`T+(Q5).@T;,`<U(`<%`(;
MR,P]Y`$9$`,],,<U-H-*J0,Y:,,,S!PT:,#1:DD_8"FI7&,-G`!3$H$03`-:
MH0$PJ-**`,.&,5@FXL$99`H1.$/(;0X:$,(E&"`:?)$&4&4>,*"2#B[A/I@;
M\$`>J!J@`1J)+`,-.!^8S5:2(%EK6%WMG!V>9?\:-?P`5-C./83=.K#IA_".
M4#$/Z`Y72HI(Q*G'IJ:'DS8)1310,1`!,)A#DH6<#P"8_TSBLZ0(EW6&#=C6
M?M40,&@**JW!Q:4!'PQ#`P4KX>0!,O#&!A+D#<`<&Q!!F9R56PT#+9P))IA`
M192E"6'2'012<!*#])$+;C%"OH0([;+H)6`.'@"+80GDP"#H>K0!+9"''<CA
M,"Q5$S!`=98>P`J$AM4`'L@!>42=-L#`&I31G_*$U`3.$#C?L=J&H_*`#:!!
M(LR!$)QB?S``NVF6"`B$?\C!'/S#SB[5O"V,0=:`"9!!TEK`/^Q`'O"L#=Q!
M'EQH$%B`&[@'$<+`LXW_`S7<10G<@_81P>$1@ASLK,$(01JX02)<@AS00"($
MK5TE0C_`P"Y(@QN(0)VVP3U<`")`9%TRY1HL0J%,(Y>-[+T"`R,PPK>,U,*0
MP5:T)-O00G'`GMJ.+#"$GRE2`QI<0((5KB$?LH2HET#=#GCMSGAMTT:MCCL<
MV8,46NQY#JFI,26WF2+GUYVI!'IU\B676:C=W,JH&B*XFGRA5T!],AU[<D`I
M&HF,+J[5RR<7\C95U$K0\=?)5%*U8F=(SSZD@UJ(P#2@;?6DSCT0PX]T:6LA
M0R/$R%>)E30"@S^H0]NI`[`48R3U`RNP`3GLPRNY@U71$48`F$"T$/68Y3CP
M_TJ(=-8B^$,AC8,EU$,SG,\X``,T3$,SP$`AZ`(/T`$Q,$(F6"$C%*)ZL)SF
M9`L;-`,O6((T``XPT$,0P``T6,(Y%$*(-$-B9((VL\*CR&%GJ%(J7\`+)(D0
MO$"9@*92$0MD^<`TP70>=)T@#D,F7!S#$H,=W$4U#,,D8%!S@E4)(S)1%[5&
M]=,E*(*H9=1*9`,\Q+.#K$,:W$`=S,,ST)0Y()>(.!?.H-0]T8[BE@Y7JP>)
MJ%=FE3)8YQJI03(\X<Y'X=I[492HR=.AE9E$U12CP9JA[?(BTU?=C=HH1VYZ
M53+HX$IK=8[B8L@SO$"=Y9>#)?:&.,0T;I.B+759K_]$-<1(1HU(A%0/0::A
M48<V4;_<--RJ.NP#)<B`%K#,BE#B:>\BVC+7"#0"]A;.D@A$)#``*@5O`R$7
M(MP`.3>!%E-R/-1+&U1=A7PD+CM(-=RJ9D!V/[B!ZCW(/ZBMD<S`"?S8$$C$
M2EPJP=G<ZM7L3J2>>CP#@\&>1LF4.SE(1;$R?JG#C\'UJ\GUI<G>4A/>IC&U
M)9?(ZL27JGG:8&_7/N2#>]M7(]?.?.FW8U<R=#=X@TS/?9G.,V"9:%?XX(H`
M"2@""O"`$_S`%G0`'(R+??B`QS&""!"!20Q>/VQ`(QB("#P#&LS`#0C$(Y"`
M/LR!#31"3V$`#30"`\RV"=S_@!R<FT`0@PF4P(@JB$R81(SX`[PIK(+,P>3\
M79=!E@02`37D@0S0P@<3RZ;\6!ZDL$!@PJS$:UIEZSJ0@R1NSC,`&!HP@$.D
M]+T>B`:DAQRW`1]M0$R43H^118^M!)"M!P-`9N[^"+"@@2/V0VA"<GKD0XJ4
M0&OH@D2TQBP_!'\@I"WC%XE@$B$XQ)_1`H5#R/XD,C`[R#T4`S$H.4!1`TU!
M-X,0J8@4(G?_F;T$B)$.D4"8@QM,1']M#C4H^26;66`+%7KY@TZ4PX(,`P(!
M^NEMT],8%F>)HU^72*#)]Y,6"6<+U.>&E.VP,EV;@_0(3WBI%Y$LMX6?^^S-
MP#.X_T$%Q($.5$"+`<$'3"9H7M$=/,,0/$-3ZL`RQ,3HA4`:8`!9-$("Y,`!
MQ(,':TX+P$$=:(/\/%!."$0QP,$*V(`-*!'O*8!$%"TF%$$&9IT(?+&!:`FX
MZN7?FD8;#`%#8!(;&(JTG+AI()NVX"'+$8$&U,L!,N40\!%!+@`'Q81U%T0_
M:,#%2<LZK&<)L`>QLL$!=,8=LI;S`0,9B(`,M$$1$"L,',T^1!EVK(.D:\`+
MM`&T8`)XJD-I,8+1KH<"$`,`6IDZ](`!$8,,7,`:(,(BT((7L1LA](`/[$)X
M"`'&8!(MW-V:DL<Y2015K<W460TQ/`,>$$^S?/8BB,`=\/]'2GY((\F$S54#
M(A0#(^!<`V%"I\\CS`$#`/`',7P+VY`%"&T.Y4N6S/G#)5##,%Q`ETP^0?+'
M2@R!`!`<,)Q#/IX#_ICPB@@9D\S',ZR$E*##!FBV"]\1'S')/HC`VE@=K!?Q
MI)$%,9#!>DZ"",B49R]:]<SRZ*X.0]W<K'S*AU#/G5T"'ZU4A-C!IK+!D7VR
M0Z3#K,0)NN__[)6`.00"0-"X4T<((A]H;"`2@J?$I#EM$%T2`HQ(OWXU)M7H
M-T>(C6)X[O4+I-&''3MK?*2K@0:/.2$^$`%C<T%=/X,B2A`AUF^?C)F3^E$K
MH4Y!GC8EV%RL46,.(C;%/`(3D=3_QI!);BXPZB>C!C!J-BS*F`;L0HE^/H;<
MZ:?KPB(>T_JUR;-U(<]^EQ:@&=)OXD5,_3;<*X;&(C41_89L$(&FAH]+%J<9
M$%%@W1HT,A#[R+/.1I['%O>5&`+,Q#U$>&K\(T($=1X3;(2L>^:C6#]U0S"5
MN'?A63]SC,Z8L'$ISY`A;"8!NRRB6)M)/O`0070'T0(9)A#)N-.FS1R[YC0B
MRLY(R!@\:#")4-.AC0)@_9[5N'1A$@HU-FC,L.BCD)H2+!"Y8`L/VM"`#0WL
MV(`(H-01(8T:"BDB)&)$:&,%'8281(8B\+#(!B$N84$1(>;PP80;BABB!#1@
MJ"&$'<ZQ_\V')MS89X,A,"!#`3N"*.&.2VR`89$/2A"AAA*^8<$$/H0X805&
M#-AIGWZ(N<"B=:`9H@9,;)B##:D46`0/`PM!@XQ$["+#G'Z*T&`,SDRXQ`X%
MYJCA!43FV*`$<Q:I@1`\\MB'D0+;F,:.J?(X08@II\S$ATE$,,$<3"ZH(22+
MYI@FMO,N:0,-N-89P@;&\`!F"!#%],ZB55EMU=5788U5UEEIK=766W'-5===
M;RTF)(6F4<?3::CQ@9%]+K&*F&?,(68LBS"9`ZA+B"&D2XN*40L:.Q9!A@\T
M-)@$DW4F000-(4Z=LDX:\,"SGWL^+&$8WS3*PP<?@&E,OAJ&6/]D#N6*(<8&
M#=KP`1,AY%J1"#8N@<JB"H?(0S<?2D2D!ALP.:,F1N03P4N+[AA"@Q*+*>&9
M:1`9XI+#)A&BL`O6D8$Q3"RF!EL3XF(##3=JH$8(^=2180ZM0OJGY1K$0H.0
MBK3DPV":"2.&-MO0`XNY?H!!R@01UEEDAS;L``:8-IYAK(UA?)AFCFH&*P$3
M.0B99)H[FOK.AW[R6&0S(7JXYQ)$.EA$C2W4\JV-2^ZN000@XMC"HCSRI8&+
M.FCHQP9JT(`'(C5J$`9K#?HA8X8;"MLB#T2F.6$#'XB8JQ\3A,@`C6=$F&$=
M1F;0CX@A"LED!#G<Z6<7!5`(H1#2:S#_X8Y$&`@"!@ULL.$'#J#A>HL:4D##
M!Q&>6<2&U%;-;545\^`*#S(L=<J$,<EA8`2>I%&'!W+N@<&<,=S`@(X;:L!#
M'3N(((07+&(2%]@`(TJ0EWM8)0\(\X$Z*&0#6DS)(L^A6$:Z\HR03&DA!2#$
M]AAA&;@8IAHO`,8+GD&($J#%#HBP"Z]@&$,9SI"&-;3AK2C8JAS6:H?O:A4_
M5J6.'PSA!Z!9U3Z>D<-IA"0?Z[#(/R[A#PKZ@R?`6%.SID2,2?A#BOF@(B8X
M`(Q["&9-U=K'/^[ACS7U0S11[,TS_#$)-JBC&GE;U1W2-@VX]&,=*]I'OH"Q
M#K7DH09KHL9G_R)3$+R5`!&36*,YU**.A5#C.1L@!#'4,0=BY`$-U7B7$&2`
M"$:<0`;#((()3'*'292@!M,@@@A.TR&^).(HB[K+"5B'"1F48`Y$`(8,1,`(
MAMA@$D3P@3GFD,)D]0\3DZ#&'.:`!D38S')<600;IM&&.RRE&#EP0QK4($MU
MU*`X6YF#?11A$43D(0U`4`,K3)`/$CQ#".;@#AY.`(1^G&,$BX`!BPI3@AP(
M0B@'R<-?^K&":>1#!GC0`A`0X88?Z*<&=^`!(A:Q`&=83@[.L`$9@M`,$:"@
MD1I81'9Z((="H``9*\@'$'AP@TAD!V47FX8YJ+B."U##'#`XU246T?]0,@A!
MDD<1$^TXD(Y]J,,<,S"'.G0CA#6@(!B[D`$F%A&#<W7E$B<H`3"NR89G8,P-
M;1`"81:1B3EH8$U3*J80:#$-$=C`'\^PV92JL0`A,&`1O#.KS8CA,B*`!V%$
M&&H>9'E#Q2Z6L8UUK`Q[Z*H=1E:RL1H&(IQ(V<=.XS.SFM)F8)A#RD9V-A:A
MX@:/F-J8V6L?%)P2(];81(NH@XIJM)Q:@M6/?\!E'Y>ZASKV04W(3&-*U%!'
M,7!&#9O=`Q/`-6YO?]N/:337'_?H[3JFD0=J3L.1ZE#'/=:Q#T34)AM<D,8Z
MG&B12UCQ+O.H@QH>R0ATN$$1\8B&/HCACFG_J-$<:%`#.OJA#VK<X!+XJ$T_
M\K%>=,"#&/\8`AK2VV#X/"(:Q`C$`MC`BWY@PARGXX\4$3&A1A0""!A@A#/V
ML0;Y3`,MR*A$.B;QQVRDP0:+:"XP+I$)1BPB'Q8Y84-"A1%$8`(3Q?@9,>A0
M`CQ0`AAV:$0_H$&.0GQWCGEPAO.$.0Q=R``F-]A`S]C@@QH08Y>:],$:GI&'
M%YRU!"#22#^J(4QBF(,0=SB!"*+U1!M,PP2:PL0=L`GGN=3S7$2P@1WP<(E=
M/);1C7;THVF(#@"S:A\"A@9/7/NNWE1Z54OD24WZP8_63K&U^AAC@'W8VO!2
MFE&MY0D5*8UI3$_V_X5&-.VM:YW:7+_*U?V`M:VMNRHN9IHG_["+J&6=;&23
M8Q'&EF(/74OL!(-ZU['N]:IZ3"6$QIK;L7)V9:>X*GWP&L&O&K==SNUK68U6
MAZF=$AYD,(2-PHJ"(>'S^I(-*V3O(]NRN@<\3'LI7>M6A[UFU*J4NJISU&0&
MBY[2.:84W=[6-KW4V,<T9!E93PM<UF/L+;8G'A+V_AK2)3?YR4L^;A])-[V(
M@$,<:N!J[Q9F!O?`Q[M"4H)EP(<PK9+BJNY!@D?T8Q+/&,(5DS)P5XUE$<"`
M=]);]8S>*'8?>.B-.\S1V5;%>1'K,,>!-7W$GP<1M;32[+4K^VOTVAHTJO]>
MZJ\/#FY6#9OMLD;[Q]MM$7X@N^T%[W;>@2[L===J&L8&O*O,`0R2_QWM2C^\
M9EV%CYN_NN^5AP\]ZAZK'"Z^LBCW_.=!'WI790`/=RA2;YQ`@D4\``:%V,4-
M2E";=6B@!6IX1@E,5H-:Y$`".:!&#>H9/6,K0@2)+H#-%L,5[2Y":GB8DCE@
M<XY(_``9SV"##"YPB4DLX`[-QL,B[C$)0MQ#!'>[`]C!:GAW.!-K[TF\.?YA
M[#W^HS;;_ZX,,L'6HJ6W'WE!1$,6@>"J009"@IY\R"XJQ89R;/"`H7#J3F*,
M`_&T[E6,"PWNRMV(#B@L0C!B)1]`1%8F@1B::8W_9F7<G@$3=NLS*,L<>@@3
M``Z'-&_@IL0?R@'RGJ$FXJ[O1"T'IV0=0&VR6NL<I(&XU$&#W@4;0"T=D"%&
MU.&FKJ08<)#57LC5]H&*6FOLEHJ"X`$'S\C5HJOOP&L*16\,R;`,744?QDT-
MGJ,?_*4?%*$.)B$-SF$&-&`-9``LI$$'W"$'6J`8GD$&A&`%\(`6M"`G9$`&
M-*`VGN$#O"$'%*$&G*@&,D$$,J(C=BD/:@(M$($/%D!QT.`"3H4']((1%@-=
M%,)(1J4C-.`]BJ4$P&(K2H`[;$`&2+$&B&`.\N`9*L(<6$D(#L0W&J"`T,(<
MQ$PK7N<2R(\1A*D$0JG\_]I@$1B`8X@`+JI!..YA-F1@$1BC;(1@+/I'%Z%#
M!H#!R/!@'1CC$GYQ`SE);G1FA":!/`AA2M3A3W3*!Q8`K.Y@OZ0I#XK`(ER"
M#L)O"%R(C;9)"-2B.:AI'5`#=82`&AAA`XAN#@R/&"!L$@P`P+#!$HHA$V)L
M$1@A_%1HFJ:!$7H#Q_C/NZ*K$O[O,HC!B8C!9M"!BJ9A`](+N]2!`8K!V-9A
MN5C0ZR!#X.YAC?YAJ=K*NK[+UT*"#>Y`!C++M4)B$0I``VR&\Y1N!FT"**;D
M;W)M&.Y@']S!'<BA'^A!':"AM=(A'6*$%[2!'(IL'0()!E^E>\;B'XC,'_"@
M&/\8H3;0X1(8P?!,2P-<!_+,<#`)$]+&30MH2IOZX1&VH`[P`!]@H`0(Z#&>
M(0?B`0=XX!FR9@A$(!.>00=80)7@S<?``@W8``BH:`B(82A"9G;:8`B<J`0>
M(T$0@0X$$AA2IH%^203@0F]>P`:><60,1KH0PBS4X01"0BRHX00T`@WJI%_Z
MP:*V`E!DI!@LI3$T('G"0@2XKQBX8A]T!@WVH0;,Y1,)`>!4A`2*X06*H3A*
M@!JX0@2$0#XW@`UJ8!$:`ER$0`-,#Q@*PF6F!!ZT@`V*;P/R8"<R0@-H@0,>
MXRA>`#:T$1$J9$6<8PA@("PX@A01:$WNLW]\0`Y$8`W_%L!FA,`.L*,X6*!.
M+@'W*F(FV>`6<>8>5(`.F!,&)F$(9@`.[J`U+R$[,08G#F-*1*D-%F0%`,$#
M1(8#9.`2/D`$K$4=A,D`2A*8`F2%J($&/J`.X&`!C@(P)=0&UH06-$`#R&,"
M+F$%[E$+RF*N)D$Q=*D$!A03RD:Z%`<U-,``L$H&[*`8%H`0B&YDM$<1IJ$Q
M4N@^L4H(&@)1*TAFB&$$'D,Y>``8]H$2-/(2R,$-AL`D+"$1#(2[[$"2H/,N
MQ)$0ZDE3<A$1U$%N%D$(BL$<(J%3&H`8B,$-..D.2/(2\(`8\$`@IP$-`N8`
M,&X.XJ@-^*\PC?58&>VD@$$#_X8@)/IK$:AA'6+B2'J#&@0A'N@@&$Q``]),
M&'9IR%R1$7IN'WS@$`UP(T#I'J)I.X:``>"B?#1#-.P`#>R`SY@"-PY"+Q@@
MWCZD."QC30C!!-#@,/PAF-C`!ACA@VK`.D,%=+!&+"3S;NX!(TI@'0[BJPI'
M4L9*.1X(#]B@#2["8E)H`S1(`W;5!DI@&E;U;J9B$>Z`$K?C#HQN'>:3$&*"
M".Y!FI+B^60`$+X*#KZ*Z)8",0+P7I`C0]C@8+=#'*.S0^X!,P;E;GS`9MB`
M&(A@'2(!F.QE38A`4!B!#;2`!?"@*;+1A<CC+-"`,.#!"OA!"YSAH-J@!;@`
M#OK@)?_ZJA_48`8*##,L8AETH`5:P+_00`L"03]T0`$P*5(V0H5R3BU*2!]4
M,Q!RP#@H@0:"03D(Q@0"4`WR(!Y:``1JP62\0096H!HV0!U\X$/X;`X<2@T.
M(A-\0Q!6(`/J8`UF8!$TP`<V`"&,C0W<1@&V0`*(0&8Q@0%\@#E]0`.FP09\
M`&3-80-Z"C4N;1@0U66`@0=LX`7N`&5YX0;60`[8H!`TEP-L((PX('B$P"`5
MP`=P;Q':P'?_83$N8#_%#!FD8DW8X#PFX1$0P0,R00W:0`1T`3`W8!&:MRDD
MA@T$$UD9N(%C:-0"K(>"+=:.L@?72+EJ[1_>LMYND(_.(2C_"8&X?&T1'F-6
M>2J\Y(:I(.@>G.,>\E?J+H$8`X6/T`!R(.-..&,.S(%\`W"=[((A)L$MU>D.
M="'\P`-A,04NYJ#I;E0#Q&,C?NDY[R&P?&T((B&`T_8N+N;/F%<\T@R22F0T
MV$"0M%'[X.,$V&`+%$$+LG'#SJ4?T(,-3V4P=*$-=J%U5*DQMFE-?.!@,\(?
MNM$FH@-*#W97:P(VE.P$YH`$&.%1^ABW2H!C#*(?X,$%]&%A[5,'@$`+PDD'
MAJ`1[N8'XD`-XB!EUV@!U(`&:J`2@&`&M"`'^B$'2"!L+B9?,$%YXT*[U`"6
M:8"-=QD(B"$-`@'0&&F:^B$.9B<%_UH`'A:6%F@@!_CL(I1L>=L@#FC@'DS@
M`GKL$&1`#58@#QIH3(IA$B#"(MK`ZC*`?_6V'X!8&WW`91HC*<B!9?"@#8SM
M#GY&#GCB!%Z@2%IF8A=A%^Z`$)SX#LB`,/8$,?[&!+Y6!)C+8L9S/A,A#9K!
M#3K3EKY/AS$!#50/#;[E'OH4<M+V!@^"VASXI%&:5]AM@<4-I35+(:]$!$C0
M5CBN58ZCD%CE'OC!"&<-;]H@E.R"&#QI'S!AC_@-T[QB[N((*X'A$>Y!'XK.
MB"*.@I*#C_8A':2+$&IB$J8EL_#@+YS(')R5PVQCMTKEB50)'80A$(H!'G0A
M5=%@C?SS&?_6H3;P@1+PX1GLP0_;H`YJ01B@`1B&@1K>0QB>`6B'8`[J0+VB
MH1:(X1LJ81$"H1;T@1*HP9@.J<U<^#W0051H`1'R01%H@0AB(`X6(1NB@088
M(")$(R0`@0'BI`[BX1DT0`1J@1'6X0RJ3@@68`5T81&T`!#@N"(6,P-H@`8H
M`1T1ZP6&@!$&$A$6NUQ+I03"Y3+P0(XN0`;(Y@6,[:>)(;@^RP2@PYS7*6R&
M8!_X@`4-HH&$(!'T&0:HUIEBH"#PX'M:1G>)`<>"``\L6B&THAB&0`NXBQ%H
M(,S,91_:X!SR0!?8(*A*(E`R88]2>L(I'%9XRC<DW"Y$.+5@[>#_>+#2THC8
M:,W@+&+<JM#7@-#6J)#OJA#R-.L+&<_Q;HV")L63;.49$NU2*"@?&`6(_NY5
M8$T?6#KS<$U7SFY5)F_P[,(*R8V**H$%?D`8,%BT<@@-#X]5>JS26LTN%F$+
MAJ`2WN7$Z\`8@>ZISXV*YF`O6JO'Y.H"S6'5D%*ZAG**0H+!IF0:>N.X:F)9
MQ=HW+J4:S$$S02.N=-S5JJL?TN$2&H$L[\)F;@ZX>"(DUH$69)(-7`@9J0$/
M?B!&+&$GS`$N\H&N_8''X8$D\\'8NB?/^Z$8)-7>:KK"87W"2R`2^H$-U-PN
M]L$$,LM6W&'H5B707B6;R"U6`GW8?]PB_\AC:M4A`*\D`(,MT\YA)]0MUZ+-
M-HHULD1\@D4KTF?PYVA-\%#\B'J+WXAMVGUNU(XZW*.-R<7.M!B%R;FH[ZQR
M\5R+R44<`ZEAZJH]!]&MUM!]VK><"HG:<W;(!WNZQ&WMS5ME&J3$YV+%QUDE
MW5AE':1=JOVQ6&=%,*8.!NT*Z"Z!%JIM5OQA&A)A`F/]Y%%^!B@A+LX*.-75
M!V@BS7%,ID'&![0H!S"!&O(6`:8A$)H@&BYA)-O`QC>,$8)!;A!!,QGAPLTA
M\;RBZ_PAQ/(`=,1FJ2[!9MA&TVJB&D#^B!J@)&*O0S2(&J22Z)SW4K+%-R*N
MIKUH57`QB3UK(_^\(X?6H0:HJ%HL@JA@!:@ASQQD"1@T\%6D8E1>W=&H(0#S
MH?ON(.=97>`@/5>,B]Y:Y1XDG*7OH1RF7>+;K=C?);W*?>UEK>DSC>3<@5%8
ML.Y.+=_\X1_ZG-PI[\K%W>)5/-D:;]?V;N\L;P-1J_91OO<=V#'Z(0TX,S[0
M@AIB8`ZB9T62SEJ`01$FX`8F0`L^(!!88!G@X)G5T*1>0+TJ2@02^P(0`3A%
MX`3X8NJ'0%$$Z$Y\MZ].8!%$@`A>@!:REQ#JQ#%P(O#[00,X3`0NX4]$P(D!
MXH2(.WE*+#I10UT_3'@(:<CSK(8-77CZX3'GXT4U8#46$.IWKP$Q1"7_$/7K
MMP]-C6F31#SK-Z<(FF?3?"`R)T/=$!N+3IKP<><9L'Z([O6;QH!(OW5#YEAL
M,ZV8NV?$%DV;<X<8,#:8%N(IMJ_?'0WW2IJ[^0_/LV>(U*W#<VE?L47F^DWJ
M>7+:(G7J+DT[^0S3NG_4P$[;ATYAOQH`^NEB4*/$)#QH)JF;1FWQRVE&W9X\
M:>Y?/W^*]QT0<E*=T7M&^XD&N8\:&Y!&:V2^IZ\?O[`HA5RRX6_T2=Z?]_%6
M5^3.R38F/W\.?M('L<_%%,A8Y_RDO[`V+AWUD=TN-2&MG_=;U*"$!FJ$BJ&$
MZ;U?L;_%^_G(\S[\\/W.B>^[%]8EZUP"G7_._QGUS"3]X*,?2L0U"&&$$DY(
M88467HAAAAINJ&%83?0T!!HV]-/&0/W80`01A$PBA'O]H(&?(!3T$4<:=4P#
MQ#(SI)"#&BSN4\-R74V"!A[`Y%$1)AST,\0=B"SBPSHEV"'"(I/X0`T:"[#A
MPSUMV.#4)0KDH4$C-@CQTF<;U&!`'E*6<$\>/'19@I-SE&04(S6(2`L>%RQ"
MBPS[^(#&3R6XY$-%^\APAP_FB/`7&RT2(4(-8<TA!")"$+H!'D+`:--)(N!!
MZ$PO1,?($--XF@<:1'S:ACEVX'$'&R*P0<@)7][)!@,G,7(",38@(H,/,K2Q
MP")%^+!(#4.<L(@(-O_48"L1FVE@@P]L'#"4.D344$,@&LB`APW3"#&4.340
M,<DD&L"(R!QH%)*)#S;@4<(E=?A`Q"/%#D6B"#(`LT$)84U2`G!DMO&,P)?D
M(0(:ZT3&AAV8U.##)`=D`J40-=G0E3H&+*(!H>J@X<,S^$8BXC27O(`')@8$
M5]9;-DW3!AOT'#S$!>1@$D26&B`R#1M$7&*.''/<0TL;!^BRU"+KM)KF`H@X
MFTD_C;"1F45#],-&#<^8,\D<6?)D3A&+/`/52>XL(,(^_PAQASG`H$&-&VTL
MI<4D]Q!"QB1M##6''/?\`Z@Z"Q2#B#0H[?+,,'0(E8D<R!3SC$WJL,(+(I3_
MW%,V-<BLHTY=')Z.>NJJK\YZZPT6@X&S-8'-B!#97N+#$).Y^,RT3>2P!1=S
MY.%."4*PH$:3S4Y\$C`V:9#S)<[?*0-)C#`R"1O33'E'$6W8R\8&WS.5<^8E
M8,)&NR*@UMH%TP#S@O,EG#N$#_[4<,<<S\RA0#5V15DBQI5`4NJH@1!JH(LV
M:``F%;E'#?+@%!L,XT3>L<$+TM2&K'R+$8BXA!MVH`Y@*.A^8B&2!A1TCR*(
MP`!LT%X_>'")>R"B#?Z(%R+R`(Q+S"%(=Q`!(_H!)Z(8``W5H(4($H@&8*2D
M2"(@2@WPX$#<L:$NB/B:O7KBCWO,80@/G(0YT(`(_S(((3B3N$#)B)$'3"R"
M#'-8`QKF4@)M/>,";-``'D[@0G^091(F>`&`%B,#!@!##1NXA"X.<`=&R(!)
M)<"#/_A`!&K8@0-H@`$P-""$!L0$#=,IRS-.,`UGB6`(,JB2[5A@K/&@003N
MZ,<E@J2#)C"`!AJ00SKZ80X-O,P.11""!L)F`T*8`!,V**8,3%`"@GF'&,7R
MP0%/<KX:+$(&B[B`#\A"%`:4<AHJL<$D7C`$-PR!2V1:0R-.PH<X``%]GT)#
M"="`!AF$@`YCJ($)V'"!0ES@@'EX@0CR<`E$H.$2)L@$'7JR#D38@0UNH,0:
M;H`&.TR##R5@!#0N8;0,3/^"`6@0@A`8@8>*N&ZD)"VI24]:H;!,8Q>MV4=P
M[':28@S%.)^I2C_4P0=SY$,A8[L#)N[!%\[4)2R8\)@YS*&0*JIC$D,8QCJF
M4;I[$(,1(*,&H(!2#0+1PAP%25`-](<Q:`P4)7FHRQTF@0E,S`%Z12$$+="@
M)W/UHT^$\`$9$&$O3'"1#9D;%B/L!;",#6%3S7/F'-1RDCRT!PULR(-O\&"'
M^N%%!'.0P:I\M9`A^,,9/FA#&X9`AQ#9H0UW(L0=T(`)2^0!."UDPQPN$!;'
MYJ4&U\N#+E8%KLK<!PTX600B-J"@8I2@&#X(53\NB0@;L`$8LP-`<TPPB8BP
M80W_C"`$8X7`AB&T85.#@Q8<K(1*D(A`AG$\R3JJMX4?U$)<.21"B$A4DGW@
M(9Q;:`$0:M`2M18#$XT$20EZUP\AE$":R;T'#7R@B#B<R@TJ.<DC:H`/Y"'`
M$7;H@"7Z08T@D0$-,V`%(EH8T3;L0\!H:,0:2M"/86)86^T"SV*(.^(VU.`2
M=Q`-'FI0'76X00.$`)(/@+$(-K2!&(D0`AU.0@(:;,"CYB"&1^W3!CM$8@-W
MX$,;T,`D<S0!!HCH\G78P`@B0(,030`),/9WY0^I@R<#0D0ZGG$'-7R`#6C8
MQQ"J001'H73/?.ZSGS?$FP?5)T*"?I"@&W1H#!$'.I]A_XU\3,>?%Y&!"-CA
M37"F(9JP&(<61J'&7^!ANFFDB1KE`9`ZBL'H:=#B/]NAS7]`1PQ_8`<3J,X+
M(R8XA[W=5#'F2*AW@'$'/+P%:9AQ"S6>L8]I5*-93>Q'Y-Y3C"$`H]?_X!(T
MQK.(>P!#JM%NRZ^2>>R3W$-2DRB&.>[1E1)D1AV("`Y#@`$,8F!B$IFPQ"1L
M,`1,@'01)<C#,FCP`;P@HE+/R$-8@&&2>&QA"[<"A@WR189]4D,&"X@9&D9`
M@T;``1%WP#<P2E"2DS1E-FRH!+CRA^X?M`"C,I#VU_H1#1I0@P%JH($:6(""
M2)RD!CQ`P2YL@(8YC!:,:UA'&__XL`/?"$$:1'!/D^>`UI<'G3Q#H$0-<G82
MRL`$1H08PHU],.]6"2$-:8`!ADT0CWCDP+$EZQ(>B$`&8/#@!T-PK#M@\`PW
MU*Y)X)E#)DX0F";P@APW70"9Y%`(<NR@"628P3GU<0$M_!,-_PB2"1:9Z#]K
M?O.<)RE-B]/J_&@Z.P;:SX-RTY_PH#X_^C$THBMT:4;\)?.=GY`YB`!I"&E[
M0IGC9.>MRWI"__$]K8$'.IPS&`=96A_[T(<YXH%+[.2#&L$IW4GT00QX+,BE
MU!#-,[H&DG4`*#CK4.(?B5&+?L1C$MA1ATL74XMT7(+YTGN/.FBA$'-0`A]`
M94UGCNO_'NEP#YRQ#^YW&.Z`';A$#'6!#OZ@%Z;C&?=`:FQA#L/P#*HQ#<00
M&(V`#"`1#-EP#O)'"#5`"/"017;P0^I`![IP#^80&_<@@'Q@!^M0%Z1S9D/`
M"T/0@0LQ!\!`#N>&#.X@!WQP?FW@1=/@#]0'=K7'A$WHA*FC:3X@&JLW:!,2
M&PZ6)KS!$B=1&%7H'/Y`%ZF7':'A',]0#&"Q#IFA:4;Q><&G?*-G:>(6>C3U
M'_SA4G-H>F[8'\$Q>B`AAFU8AWKXA:)':,41:*07>H16($O1AWDH'*/'#^\1
M%HQVB.%1B:M'AXF&>I68:)7((/V`B=KA;$.A#_H0B:/1B9$F_QPHL0[FQHK$
MD(`HP6B,IHJ?80Z,T!?Y%V[)!@SGT`_2\`BL(!\&I!#OMR'W8`=+`2"G2'K.
M086?<0E?0WM/2(W5R(27<#3/$`W94`LBD`.)H#4_<&Z!4`?Z\`QL4`U-)E7[
M,`F*@`_/D`B70`T;4!=```?$,`_NX!?`0`)'D0,S<%QU,0WTH0Z9@0@'H!`#
M"""CIQ`U`#`85@!$\`(RH%9^J`[VTP_5X!07PH<O\A+3:&BT-XF(@`G3$2',
MU2`B=!)>9%[@P@-YD`GEX1SUXAOL6!Z7T$JX1(N?T1?A,1\N8HG]D`^[D28<
MX@_5()/B1A__T%)!*7I`51]91(GY</\/VV$<Y9%Y85&5QM%\_,%\8AA\AZ9I
MZP`=I#$<BR:63GEJ87%_V.&`2`@2D"-N?3A\:=F&JFAI8EEHTVB-?>F7FW</
M##`$ME`#B@`,,T`"=6!S^X0,0B`#+0`'*2!@>#4Q=U`"$Q`'-)`#&H`)%_`2
M/]`!'B!0+U`"<U`'=X`""0!7`E,,![`WCW(K[B24I(D&;5`,U8!6$>,#(F`"
MTS$-"\"4)W`)N6D"M'`")W!8"I`),H`?G]$HE($&ZB`$1$`,EJ$5`28$<W"4
M^>9*+7(.;4`(-70'1T(-\(`(`/,/DX`(GD8/+3@$0^`=^Y`@@Q$80,410\$9
M+7@."D(+/\3_$:8C53`S#3/`DB'T&D`W#56R;=.`'>?3@@M`.O2Q%`4I`JH!
M$G\A!(F`95JIE0HA!R%3`^LPB3))BY-HB6R@&/M!7-&!%Q6RHJ.G`\K!:-0P
M6.XA!%@T(1T4'44)BOTA-J%W.(W&&XZ6'7@P>]3Q0_V0!^X1'(A5BY\!9.%Q
M!_FG<^%1-!<2%HL`E&YC!P_B#\60"4"Y#NLPI4[YEV>*IGNV#X1@`W;0!)?P
M;T$2!T(0"380"2.@!HCP`RP@%GPP!!=Y0$(0"%N@#WF*9?T`!-%`##[``_V@
M)W4P`^LP"3_P2Z4Y(D2Q-\XDHQLP!-1`!&=6+KU6`\3@*4MA`")P_P"8<$GJ
MA@9K,`0143LB``/Q>1(:P&^+\`*+L%HFD$0S9A]TU@;&HP!ZP@;ED@=$T`;(
M>0*?0DH,L$P7D`<R8`.X63&^<5,'I%P:X'5TI@'3@5^9H!*;\F'@<@$R*029
M40)<5`T2\7*=%4J+@`?)]2[V4@.8H`"3(`/X91<R(`1E1`0R\`PJ,3Q_!1+2
M2@0U\0)S\$\@<0(RH#W&@A>,\)*+0`B(P`BTH%W;4[$WN@C$T`-DP!*)4AVO
MV@-6X@/Q<1*8X`-NH`YM0`1W@`YS8`)!<@]WT")K`#U4D2G/P`,.V0\R4!*<
MP09X@31I.$U"00S$0`0-\!+FD*'G\:H@P?\`Q*`.5&L.F/$/P$`-ES$:`Q@/
MX[$+)X%O)G$5YO`]ZL`(&C!3/SL$Q7!JCU:067$2R>47_C`)OW`.)G`/S6`'
M06`7G&8W^[`.C-"*EJ"%7J0.SX!_9#FFCO$,52E^=M-CE[`9.E0,SI">]R`$
M;O!3&7@/ZS`,)IFFHTNZK:,.QM,":@`$0"`$'Y`&*(`(07`#,+`&1*`&E4`#
MS:)(EKE#/M($\_!1-J`0.1`-ES"=LJ$#<V`#CX`&/V`"C#`'RKN20K`.-G!E
M-[4(0H!'ET`(>1`ES_`"YI"]1[$`^[!=#;-(>-`&:Q!@C6";;&`#Y5$"TJD.
MA)`S:!`L&^!B0F#_#K]02G;@O5^##`O$1W@@#6S@#P=$&0K"$>O0`S9`-GEP
M!]Q)ICW@L-/F3$HZ%"R2!TAB'R*0._91&@'V$I:"!^%C.V'A`Y$!'OQ"#<1P
M90EU0[G$6_U`#!&#K_LP7!WG`W.@*4M1`_^0(A5!*-.!#H*R*0@!'M2@`'BP
M`!$A`NMP`:]%&<2T#KKP1':$,W9`1X["`D\4,08P5$0Q!QA@!R`S0#<Z(M-P
M&L#0!FFP79>`!T50!T+0`^Z1KU]"!&@`7"22!]G[`GA5`W90/4_\LR)0!\W"
M!HO4#QPP';@Z$_?P#!K@=&R(#K_92&'Q*N>3KZ4Y!]K"`.X1%M)*+1`L_P)U
M@3L*D!F+8`*;\G8FL,`C$`)H0`<#<0_$Y0].-@0P`"TW)2FEJ0$&-`1.>Q-Y
M@`A^Y'5)T5&-=`DBT&_74P,.N\)Y@#!/-+/)5+K9K,T<`F?J$`_8XP[4@`CN
MP0AVH!K1*X%Z0@UJM6V,90[(5@SK0`AU(0P2:(8/1!49AB7\]48*<JU5\@P]
M\0\/9P<W;`(!C4G"!@P_I"X@002($#-"P``=?`\#Y2P^,%R'6@/F,`3KT"S@
MU$0+D*1$<#O9.0?"PD7@I")LX`S1F0?%"A&N9"X&9`<F`-%H$+:3L`"$S`;%
MD"5"@`DPX"*50@WSDUM#0`PFD(&\(03^4P-Q(O\'8'<'W.$=(N#&0VM=;:`.
M><`'+1(M>W,)_+8GBV$[*E&L6!9*^V"]VJDM0[$.+^`/KF(0#%T$#X,3`+L!
M57%#P(`:^$H,E]!(_'H!\-0/_C1PBS`'OG@2:^`#(2`OFHM:Y4"SK]19DX`[
M`@4#=I`&0B`,_;`%EL&;C&";N*0!@?PUE$H'X%$"TW$)<+!P%5$"=0$#*(`,
M_@`#)H`,'($:-W$>Q7`)-C(#17$B"94'>$0M&+T8M&H;174',+,/XLL&1>`>
MA+`(T&`"*-`/PZ!<,#`,YK`&)C`#M;`/TF`4O^!,=H,:ZX`I&K`&>\$#D\`#
M,(`-K`!7)9#`0M`&YY7_"271!HQP#XA]O4HZ"6Z0,?<`M.IP6H*XS0O.X!22
MEG8AH588:7?9C&YHEG5H'"*:'?[0:G4H!'9P0;0A:_<00[*1&@58@"0N%5(R
M5!Y-"S?5@QCF!N(7XTBH#O3P5&!V$O_P#/0`BT(@;-1`#77A#U<&#-!`.L%0
M$]$)&--!+&>V$=UQ%;PQ;0NA;;?X`O$Q"9EQ"9@P#--@!^]$#/=P6YP++G61
M8=*F((Q`#`:45BK);OO@)G=":Y8")'5B#A;DSW?@+)-0L?%"*)?`"",F`VAP
M5OB6!P]4`H1@/(UU"3*&-[J&`DU0`H4P!]*9"34`3KBT)Z6)";N0!L:#`8DP
M_P=IL`S]H`;@!-$'E";$R-XSL`:3T`1.DQESX`8,$`@E\#TH`0,BT@2#Y0QT
MX%AL4`#^T\HSD`-UD`8,@!T0#%<UP''R`A0*D%9&H>L9`PP!4!?J0&4*X!Y8
MT>8\0`?X_>%"P`=K$`1V@`B%X`8'QP,>8[QVP0`'X0:-<`XP<`\!P`=+883#
M!0/X+263P`C.S`:5DS,GZP9`+F1&*"U:]*=)V>`1O^"9F(=<Z2`3/ARA.&BC
MEQMT^*00TN&5B(@G00SC>3IA_?$2#R%$8@.B^QSY8![9P902\AKE\0]LF7N'
M88C40!Q255/^D[A7"7[^@`G3=ZCJ(-["@2!`R1)5"?\;#^@.[O!\_>`..002
MEMT:GD$,=$`.1D$.U&P4T1#C9:,8T+`/F6`'`U@ZTT`0"R"0$CP-PB`$I^YL
MDMR*TF0.0FX316T4,*P<'_<9+,*2-*%MZQ`$>9#+%;T&ZG`.0\`#46$4ZZ"!
MGZN&M<-<71^V!RURD^!DC'`Y_W`)Q6`#4RIC5#$-Q)0)U%!N6XW4)9XY/*KR
ML;_-RT8A^C"F+J]Z$3(-.>E*K\%Z'B^)((%4[H>4%R]Z[M<?7GJ5&U\<,+_A
M&(^*K1>4QFBF)[$;>Y9%-,$A?)E2$N[]@9:(A3@<._D9I>B%TI]ZJ/>)?_@9
M]/`IRI$=FRAN$7++OX\FX='_@BCA#N?@I:E!HA4.$/T$]MM'L%^C'P3Q#:DV
MT*%!AP4'2GPH<=J]AQDU;N38T>-'D"%%CB19TN1)A^K,[0O7[Y$(8NKZ01O6
M+QXQ?-.(%<0WXE$-<_GZK9NFS^B^=?W.N>N7CZE#+=/ZZ<,W9U(@CA0'5HM!
M"%.;#9@TTGK6)IY&B8B>Y1D",>)$@=-D.EP'#Y&Y?O[@WJ$F4*M;MQ+U$BRH
MMZ!@P@+]293V;"`\8@0']R.6])Y4@_LH&IY<\)ZYP8<59]RW.*_F?O<P^@LM
M\9YIOZ/?$A:*&C;JQ(0+4RSMNG!LB/IFPX;H#Z-#PU-U5Q2-=I]P?)^3:E8-
M6+-6_]P32[-69UB=3,WK9*I;YRRTW^3GM0\\5VQG\LP#]9K6;)BWQ.PH]>_G
MW]__?P`SFD2(.F0`)H4-?)AA&1@XB&.(#QY)@04U^D&'`4$TH`$(:$CX@))^
MHF%@!C4^T`$?(#Y`8PY,ID&DCDMN($$02M1@P)PA?,!K'R%,0&,18,RAY1(;
MV-#E!5H6N8`18G#D*P\[R%&`D4O60:0-:JJ9`Y'C^@$&F`TJ&>J.2NYYAA%@
M_L'KF7\$VF"2>X(LR(8[7KC#O'R*2:H?/*99)[)[BE$GGWORV4>=9S!222!S
M9,JGG(&$D*I-Q=#)2RB!,&HC#X.J><&@ZDK0I1]JA,CKN/_))`-NRQH`VZ@Y
MNDS=2(@]0_)GCLD06>2A:=@0Z)E)/MH'C3OZ,0<>-C!["!,;?!#"G$7P$H@O
M@HHYKB!,@@UIFF('6L.9AXK1=ITVJ\D$CVN)TK:C2?H::!U:B'F&&+GBPNR>
M2Z1"1EF/S'&,HG46<7<C?Y35ZI*Y-#)'V@`;=OAAB",&R1P9,*B`!C4JG(&#
M&H3@X@9UA/!@"Q*$TZ$6'_#)88L4-NQ'&`SP>8`&&6;8(AP;:IB$&#=NL(,"
M-821H8\Z<CAA@U8O\:$8&6I@$HU)2B@"CR':8*,---#P`1$\'MFB`S16R$2+
M.6I@PP<9A*BA6(Q\P$.&R!1!XP+_/$H8PLXVICEA(!'NX.&,%V02@0\?AM"@
M&#2:30J--DK0680:%D'C$EHP<:.&(181X04@:ZBAF#:*[$>=!3`1P@9.^R&D
M!D3FH&6=3"ZI`0TV3*A!+&HN(&(.<QQ_9H@!2T!C&B)JF,8''P:CQ@<;S!&B
MA'O^68"-"WQ81!W:YR)$"&J>*48M3$QX9AT9,@D?DSFHP7R?26QPK)\73@@$
MF$OZ$>N>-88`=I]+[IE#B&*\X$<"88,(\&`._[6K!NK`0PT(X3]@]&,1NXH+
M&XKQC`,XI@1LJ$$;ZO>/.[P/#:TB@A`01HQ+[$,&/GB&.A3@O6+HI1C68L6.
MO/2,0PUE_R;J(,8":#$7/$#C'OOXQV<6T3]:8.0?/N!!)@ZE#FJ4`!B$Z,<S
M\.*OP9BI'S9X8%Z>X0]:C+!^I5E'0=3QFA-(10AXV),5C9,:8TD+$VAXS>BD
MX@]S_*,TTZ!4:HAH`YF4RH[]R(-4]O0=@]Q.8HMD9",=>1(9[``(++"%J5#@
MLT90`BAJT,$E$-$/?+3@$3QPQX;20`E%].,2*.A'!1[Q"#<`X1XZ\`$FOC*#
M1URB!#.@01T4`80A(((1_9A$&_J!AB%@HBQY`,+NQD`&1.0!#T(@PC[,`0<=
MC&!#PF"#$,0B@@NL@Q$^@*/UT(`73&PA`V@P%1X842`JZF5%Y/^$VC&5=H\[
MV`%R(G",]=+V#.85@PC`P,0B,%&#&["!#10K@53FH($\0.^8C&C5!B+C@\C5
M`!C3R-'"VH`(8)B*:>H8@C>I@8(V^&`.SS@=&DPP!QD,K`;5D%P)ZG</(60B
M!LY(6PE6J,H-:.$$I/,!,"!:@CSX@!%#0,8XA7""1>B"`4)0@$QL4,S\R:X?
MNWA`'X)1@WL,X0Z9PX0!#]>/-HB@;(SSP8K(@(82($((0]C`(A3@JX*(8`A]
MTT!2BE0#&Y3@?S;0@$-+D`D?#.@.=L-<8!&A`30LH`:16803.`"#$>!E;BK-
M@SILL`@-O(`1&NC!"Q:C-3:LXVHGJ,'_'&Q`ISOX0*\61-Y>$>$&#FI4`S:0
M@4!>4(+MO8!S<D`FUWA0OT640+2(<-PD%N`8L,#@$G8HWATXY8/8RB!8P+C`
MVCCZ.6;9@!HFL%U!@$$$(A#C`C`0`B(6P-,2X.$.H-5`)J@A@Q)0HX$*B,PC
M_?M?`#<2&,_HWC206Q46+",1Z(!'#E@0P7VH81&,B`=?8%""8E1Q"_V80PF$
MX`XA?,`$Q=B`#8#1!D64@`5U0,0E=`",&M1R*+RU`28V4()%%&]M>9CO?%N'
M-@VP@`96:P,C%N$CM9D#$6C0!5Z`]ZQ^B$`+PA/"/N9P"4(4P!T[Z4=KAQ#%
MOHAU"`S,\2+8_]AE.>BB!&O0Q1TPAP<\Y,&`/L@#(:91`B(4`Q@YH\8=ABB$
ML4:Y+U,LP=)TP0,?J*,8UKL$&OI1#!OX`YF7H-CIVH6\26`"&.1$1T%T1`S/
M[4@(DZ`GL;+5#^9>PL\*F-P++C&)/&"":_U@A`Q<-`0TB.`2<Y!)JW0EA")D
M>!I]X$$A3*7070&T'VP(UH_N40(1F$EXB9ZB#1`!/!M(Q!PB.":N]8*'8A@/
M$S((BQ27O0$(+;N6^"""#::!ASF@`=)Y`%<C>#""?LQ@5XP0@9G=<`_,17#/
M4<;+#$:0AWMT$Q.,P%J-12!.&0P!>)01`C!.4`)"ZO4?T>Y'$&:`#/\:Z+D-
MP$"##.S@9K'`F1C,,X<NB9"4-NS,FWDPP21D`"7'S8Z8IL*O$*Y&/Q,P0A<`
M'P<QR7&)(?`AX6UHPSTFX;E)L"$/YL@:$8:@!G(*H;\!YGK7O?X?X50D-L]1
MSD#N`0^_A!V!`@&&"?HQ#4L5A,`#F<8^IA'!3!TT3HY1<CK@2!WCX*$O3-H'
M.JQ%S&)UYXQ8,M9G"F*.F)N#&G:/4QO6@7%54@/4M/@5D/S1)!AW"QC$*"DU
M0C>):K36'&[(G"Z&X0],4*-XP\`#$>P@$-?=00941#6=`=J#2UQBA8LH!C6"
M]0PYL`_&-=`%2(4@`T000VT+-\=0:>TX8O#_6B#.&B8>GE[C?OQ#"'2>Q"30
M<*7V"G-8@&U#34W7++V40/[^F$01!"([$XS5!U(D@@]8C]9@$0)&,(?922FI
M8PL;8`3&60-(,P>\>X&Z*00?P(@E<[=%F"M$\`$U:HL2J(-`N`,T"`01L`%M
M<`-$<!K0<K1H(H)\"Q9$N`,&6(,T2`2SP0,[&*%U$`&9\($T$$`R:(.%<QHV
M6(`2F*,8^ZA%.)NG*X%GN`&)4P<-P`=:6P,,4(%F(#T9F`,3B#,?J!\[L`-D
MD#AB6(0A<+=CVJ@A6+,+,#T`N(>:P0.Q6(29FATT`(;B(P9$J(9U@+1S6`=D
MP(=,&(++Z,*%`0;(_ZDB\J"=.3"?2"NJKWM$2(Q$M%`,_$@-^&B.P[B.29P(
M?HD(Q(@/RH"+V0B,K'"(+O$(@"L&:\H+TNB(SB`(3%F/463%AV@3B5`'S\"(
M'!J[6JR5ZAB*N5`'7!$(1)J,7\2(:5`6'L(4U5`'8-B'ZG!`:-P'LC"6`<P+
M>!BP8_HD@3BU,W$,/%038T$[N3"3>["#1?@,?,*$>UB'R;D':EB>N.A"4BF(
M=6B7.#J>87H[J6@Y:G`1&!@"<G`':G"ZD$(#F9@&:A`XJ:B&S]H'._@!/M(:
MG:`_C("!79`#2=&39P`&BGJ=-JBX*E&;9[B#T5,:.YN$?5B$@G"#SZ(T(?_!
M`Y6RPTQPC-%K.6*(N(2KG]C[AUT3@N$QAV%2'R8TEAHH0G7HOP'#`QY8AV=X
MANOAH4E`@6`@!T8PE99SLSNXNT,AA.5APJ@I@5J11+(L2TC4(H]8ARY!#:2X
M%H,P%,+0Q8;A#93X"V@4%K$C";H$#K,4B;\P"7/P@;%\F,_P#V&H@1\(AI+X
MR[]$!A@X1>282X_(CX>`S,E4#/7(%%29B#I22^3PC;X,3=&4&'](&(PH!FZ3
M#XT`@F5X.T<;"$08&/EH@:28!AL83=+X2]RLRUEL)-VT#KX$B;UTE8ZP2XTP
MBM3PN]PL1;]@2[IL%(BH1/S`#>D,SM'(Q4K4",__A!75%+OA+`A^$,6PRPV"
M"$]1;,[?L,[=7$_V!`E_X(&;PX0+")9I,`#DF88Y(`)N)`8;R(%E^`$BJ(-:
M2`!BZ*9BT+0X$()'>`8UZ`-BV``U4`1H*(%\X)J$:4\,S5`-9:0Z:HIK&2+9
MR)2)2!62*$U4+".!R(<^VE`6;5%)+(AQZ@<9$`%?Z8=JT`!_\('?$H(-T(O(
M$88?N('L@X,:6(8\6"$\J(,."`864(0M<(*O4809T`(MT!H?(4X7S5(MW5)3
M-#NT(X@N6<N$48<5)8FUXXAV#,:"Y%(V;=-%DL,MDH%]?(;;["860@2A&`)B
M"(<<:`%T"(0MV`(BZ3\[_YB##6,!(-@"(`""$M@'.,@!+2B20L@$-ZU42[W4
M_UI+R\143NW4CKB'/-`97<`[SQJ".5B'TYD#@2"&$J`!GID!-("&&N@#/&.#
M14"$..B')FB"'`""0$`!()B!2D"#1RBI3'L?3TU695U69FU69P6)3?W0E#@.
M<S@+?-`':I@.B="'/"D*=R@&J<"(+QF*37U6<SU7W-3-WS3%<AT)(FK7YD17
M>0VP=3V)[)Q7?,U7DU#1AOD'$B4(,BW.RZA7X2R&_ND(:J`T?5W8T218AGU8
MB$6/`-G%RD2'?^65P3R)IZS78LB$3HQ8D`U9D1U9D@T)A_V'C"U9E5U9EFU9
M]O]T6)-U69F=69JM69*('O^`V7>!UY"X!VW0V8Q`!YZU6:(M6J/%5,KCCWV`
M2V.Y4(V`QZ&=3&E`!J<UV=$#VJ/-6JW=6G,%45>,VH\P!VU`"7GA6K,]6[1-
MV_V@3+4%6>QHQ74=3HX8SU=I6[O]5*Q=3ZT(T^F\6T^]V*TUSKP41;GU1%D$
MQ;[%1$P$#NH\7'=EW,%5SYR5W+QMF':D5DKAARXA#X'XASYB6_9$%'?YDZ10
M!UK(,&,IAC+U6S:=`W=B!#9@!$287=IEA#NX`SR8W2VQW=DMA$A@A$0PLO++
MA$D@WO*[!$Q`7DW+-/H)OB\AAB\!AFHH!N)SCWGQ'F+_&(;HM</GM<-J((89
MNMYGJ(9GF(;RC<=D3$9SF(:%$0_RB!YX^`XR50WZC0?Z+90A&B)"T0Q^T$36
M#<V\?:-,P8\N(9?.M93.7=W=+(ASN`1W(88F>[M)N"F"`MO_;4^`6P?6N%_C
M4`U_<(?O^`?R.*.%40=I.(=S,`>B6!CU95\79F&%)-^G'%]Y&=_1,UCNW5[D
M783B181)$*9H(H39M8,\F`,>RX,\8(,Y<(,\8)RK08,UL)H5J;-"F*])N(-,
MX&'FO80O&54N!@9=2%X[#+Y7*RA-RQ9=F038Q=T[((0Y<-W<E2;7E8,[>$$>
MSI9,H(5AT#/NO5YB((;O!61Y_QGD`0-?]WBU3,OBXDW>2=`%6IC@Y-4T+N;B
M>;D@0![?&7[*9*2&]?473E[?9`3?9Z"%T;-#/;L$@Q6&0'[*>&1E/VG?=5B'
M1HEE64YA65Z';'7?6%X83?;D>/S'3EZ81CDC$3ZC^Z7?^KB.[8#&U5@,^ET,
MXYA&ZBB,?%B,I67F(6(-9MZ'_B5<[KQ,KZN5@"6(%F(4AKE@+KV'2)-9Q/@-
M0B&48YY?=/@.69[G6UYA669?859A]A6/71[A6TYA8=[E@09E\VWE&;YD&09D
M\B6&+,%D4(;A?TS?\E5(\WU*A\9>Z-4%Y`V^3,L6'O9A8-!B*CG0.YB$"YHA
M.T0&[O]%95(F9>2EDN2MG$D@A#M@`S20+T5L8H5:D3;`K2VY$MPE!$88W@F;
MW4F8($;(8ETQLPG"73Q@NB+&`ZFS&B&8`X7"`S0HXCLH:ED[WB])7C*&:<KQ
M8>(EXCN`XSB#LY/CL=S5!3RX!&+0M`NJ!4SX8_<(ZR/*EOFR:=JEW9/VX4SS
MX3.>!.XUY#]^AF$8DDQ;A"V):C:`LRO9ZD*074:X;!X.:5U!YP4F`@O^#\;,
MS>KDQ61.#/^-C[VLW,?E[/_JC>:TYD*Q9F4^E6.N;6@V%*]]B^F$1FU>VM>H
M[6:D7WPP9F0&[OLE;O$X[C-R!W*A9[5LQC,*8?DE4WKNPUC_%FAU$&CVC6[W
M_8Y[(&%C8FW1#"O`G8@:'I^UY,P++6W#)0[KH,OLA%G5[@^"G6_F%,Y-A!7&
MK%?J+-SSS$3T$(W\>-O>_&^XF,[.T&_Q-HE[P(,%#TUXJ":/4(<:,``&V+^/
MG0D&X+S4^!%5U8AG</"/P$<&*F]CX49BY);*W4._S,M5?#M*T0H!EG'PN-=,
MK`VS8US!)<Z^_4S"C=Q9)/#HQ,OSK-OBE%PL!?*V56UUN+T'-\M[\('Z[@?]
M[+(:`()XN`0@J`3A"(0%:/!3Y0$[6`/GN82*G@9WH`1!(`8X[(=EN(-:P`=L
M*98VJ(%@4`<3:!%_*(9=.(=%>.X]_V<#?W!D&<V#79F&:CB4[AF*1#&[W^X'
M6D@TC&A'S23/TI!+@U@'&\"(9'D([VEC6C2(9T!QSG0(8MC'H6ADO$ORC`"C
M:1@F&:<U%@Q1CI@&6ND'9SB3516+_/:+N_L2$5@7A_@'>]`(*6P*2A`.BNC(
M]RE?@J#;(8_.6,]+O:!T?9#;0T%==36C@3D,SXS7'V]QOT"@>S7R`'^[[GB(
M]8W+7XP8=Q#Q)R=+=9!RD(`^^)&;.AB!)I@`O'`J)9:!-2@$P+K*MM*!&5"$
M"9B!$Y@#$4"$%I@#!FB)8<"HG/:<QZH!&="%!:":&##5;+&!N"8"#6`NU+&Q
MD9<M#;B$#?\X@6'2BS;+P)#2`!D8'N4"'9G'BW4PII/.&:%DG;"2`1/0"R9Y
M'MYK`PT80J"@A;CZE>+M&'58G?%1J46KPTD()F(X@$E02`%4LB&HG]')@V<Q
M'40HB&FX`&#8H%UH<'0AB`T`*3:(($;``W7`S_>A1D1`U;V!'R(0`4:PHFI0
M!S0Q"&"`$RN)96"0,_>`K`P;/1L-!A7Z!6+J]BHBAG/H@$HPI`A:LO!.8FJX
M]@MZEV?<!V+P5W0H9_;-T8)<NTFG!KVX1VXL&+U8%('(@UKSUU-9#VPA)X,P
M=#38NL\."3;8M=$YCG;GB+E#JTZD!@V`L'[`-4ZQ;VB%]WB/Q+#_PLL7^"09
MB`=*``(12-"6,+\:8!,;$()&X`!3P9H:^`#(<3,I]X$-,!42:`G(JP$1R(/R
MM8&V.&)SD(`YX!PA$`*`L(,&&)L2=_!,\E'CTCV%Y@CED5'C6;^*ZX38$)&'
M#9I[9'R8$&*B!+$[>?J9J]'/1QL1F"Z5P+.AC1!S+^[U$\)(QC,6.!>QN3.'
MD)`2:`P0ZS<)30U$0O)H\`',!Z%+-6#D02,"41LT/O(0JL%G2(T3BS3XZS>$
MS1H?+^YHN-1OW8MB-O+4F+/APIR*)2;E&:)A45-&)81<6->/6`E$-?!6)#+G
ML8E%<VSXZ-@/DPTT>&S4J(%82`U&=VJP_Q&":(@/.VUP_/D[!(T,<_WV]<LD
M`HBB#$!*%$/#FA&:OOWNR+`!;%$)$DGAU3":YX4,1D5*#*$EP@>C!I,VV!#2
MC]&S-B\8`=.@`5%%VCZHE3`A=YV"-28T"'FF0<2E.=,8(9*);9B(8`,>%6TP
MQ!`GU&#.'"(LPD@QS[#1#R)W`(-',9=HA0DB%RSB%3#]J,.&.6NLPX8-)>2!
MAPBW$4/$-!4YI4Y%<M30QC23](/.-+8=MXB"//9CQU;/F#.5$&C<IHXZN.T#
MSS\5^;,.;NI,8V,_]VAYCSE:5A1F1?<0(J:99Z*9IIIKLMFFFV_"&:><<]))
MYSU"X-:F$)GT4_]#.I0HLH5PZ/3S2!N($.'#&F[<0<8-=Y3PS`]Q;`'$):"I
MHP,B:O#!03K]Y,&!8&W,(4<;)4R%"!KJB%",&OY<P!-&I-G!AAT^"+%(,37X
ML`\A;`"#V3I`:B`#&AH4@^<02Q*3R0OJW,'D-"HM1!@1-0`SR1Q,RF`C&XSX
MT"=.B"""AZXU;,7&C!P*<<\DP/HPAP^*K0$,,&W4H$XF-=RQ2!XV])-($7V)
M8*,-/YK0ZQ#S267'-$.T(4,>1+9!#$<B"#%,/]JM9MLB9<9K7(M#Y!04)B7,
MD59Q_?"A0&`U3$)-&Y/<P<8<0@BASCW$H`$;&]1<4-"(%3&FPR4LK`3_C&/K
MV5Q1'L5,HP4)/GQP(#!$]'/)BRYB/02D;3R37PW_J(1)'EN]4,(TE[!GH5Z3
MH$Q1/VCH4H(Z/JRPR+0^3'.'"3#,C48>U)A0T1"+D,$S'B6P(4(;;+#!YS/+
M%H%OL1+5>H(,X?9SEP*?G<`Q&O[<HQ4CU1"SCQ`\$F.".C6@T48_P%`#Y&$U
M`(W34D1@0M`:;9SDY32X^3/-C%M.@U.22=TSS3,VJH.DFM#66;WUUV.?O?;;
MPWGWF_O@=L\]N+FC")#W$+K((ONH<XXZ_["1E#GQ?(G.,Q35K@@;"^"T#AJ$
MW&\(>?@'<1:1)*40H4S%H(8Z=$$+(;2!&I-8_P0QJ.$#GF#B'L"XA`]L<`F=
M5&02(C0@(NYQAVHH!!-L4`?-MC2$SA!&")B831O,80.)5.0.D\"3#W27ETD4
M(UHU&`).+I$5=0!C#BV!&6BD<@G#R,`$R4+#!WT`,9(5K!_R(L(=?*".(6""
M1")@!`"Y0Y9%5&1U&VC<(C*#F3NT`2=V42)QTOC"?L@!#_WBPP84,XDA$,4'
MD\!##3#QC!(`"&)SF,,B\&""&CB!#&Z(Q`L6D1]JX&:0,&!!#517$#Q<``]I
MD%T_V("(_A@(6(OQ@3E\H`'_;6XE&-I`'MIPJ7Z4P!QML$,-JK$((CR#$0=:
MQP80\8)+`.,"I/3!+__[<8,.6&):$V$#"L(%`\'9L"+,%,(Z\#`93,Q!'0O0
M0)A*8`,BK$<&F&BC._`B0AHIH`8+N)0_5L"(-F2"$3=#!#'>@XA&](,7-P"5
M:LPQA$S(I1\R$,(=^K$!&X6(#9<`#!K((+M]F,,<4#)'6DAT/DS,:!_3H`:5
MI)>F?QR(>RI=*4M;ZE(ZM?(V+VW3G7R0TCKE"4WBJTA.<4(,Q>2T'QVEDF+$
MQ(_;<!0EMKG',_I7C8[>PQ_Y(!&5J(&.>^AC2\"P#?BBNB5_/`,8-HK9/W3F
M#QG,@2(_\L<^$%$,+_6#&OBXC?I0(E(M$2-+_Z"&/_"`!YSLHZG](88_[BG_
M4B$,K1^67,<ZCO>,2<R(&LF;H5S2TD6F^@"D.F,$-=8Q#..MHP:%,(<0Y-`,
M7DCB&3)`Q#1ZU0]HP$Z"^P!&<-#`3]I6Y!DU(,(YKB:$D"Y.?2]@`RW8,T%>
M/0,102GE"=!PCA?>X1G;H8@_6()8TORB(G;@PX'H(`D4H``8SM(`,>1P@P?<
M`1'^2(H6&;&(>Q0B9H[)#1JG:@=&_K4&)FC1CT##I[CB;@CD&)L0JE$#0EI%
M*NIB1$+14(+W#$%BQ""96K[5IRD5@\&@640;#C6GH+I)'7:8*8E+;.(3SRFF
M;=H'6V\#I7UXE7C^(%V86#P^F>842A6QT8OSQ-8<_[M8J&AB\6V&"CXJ\51,
MX/MQF#K:8B4+-4]`KG&4DWPF$*<)R\68JI2I;.4OHYC$8!TR3X=JIJE>&2=?
M-=.1S:2.M,"X(E^J,:%NH^8I^T-+BC&'"8(``QV#N,56\K),QT2.0C.6S($E
M'9?V43LAL^])@75'/_XQ/"RE!;!;4K(Y%*,S-;OI'D"5DSJ,$^93HSK5++W(
M];"\&/>:V4Q-C9,YB$$,,(6IL1691IW#I`X@Q<G5_=`'EO\!XO'%&LF%5O6'
M"<UF-P45R,)^=IN9;>)@'KH?^3"'FD4=IAMO"=?-%C5[U;0/=U#:3.9PQO%8
M2@U@/&/::7+'3:UM[WOC^_],,96W8FT0B$(-81G9$"0\T!`(=RQ"#<\0!.,*
MX0QPHEL1DU!,-`[PC'4PHJC[V)`^T!$,VTPC*>`2JSI(RE2EM"LG<B%I")E$
MC:C"&3?_N'.E>9K3M"2;2D*`<]9T,0E@.SO?0A\ZT<4$:G`'>=/8"RS0=3J-
MN9II';-N*34P$8PYE;KH6M_Z3/VWXF@AX!$R2(0:6C`'-_S`!T#8@@&<0`(T
MH,`--2`#!UB@!C7D@`",Z$<V&*`($.3`!$4<`@KFD(,1S"`]0\S*0&10`HCX
MX"\:L`$BW-!&T>"F/__:PATR00A,9")11&!Y&S8P!UT4@3W/X`LC7H"(NX4'
M@,7_6(TS`C.-$FS%04/8T6S^T49?)I3KPA^^2OE==.-?STLY9],Z3D+\YT,_
M3NIP_IK0`<$.P(%)E5B!/MPQ`G008P(VB`<(]E$(-I`!#99P1P:0E@9%]",<
M3K@#UC[`HV7,@04TP!TP:O""?-R!"`B'*:&$$2V`7]W#$-B!$,03`TR)"@%#
M'DC`LDP>&@C!`IA(/^S*2EA116#""=S#`<C`!N`,-43%2Z`!&PR#B[0!'GC%
M9"1+#1!""Y*@(55#].%@#JX8\JE)/BR?G(":N=58$+X4#^Z8&^A@$B;A-#`)
MFQ"#`C`"!EQ""ZC!%K1`&OA`#@`!$#2!#/0#$:C!#*3!_P\TP25(PPTT01R`
M`!KA0PLH0@HL`PLDQ1`0`1R@@`XT`AOD0:2@@0G$#D>$C>3EP6\)@;S$`";T
M$,KQ"P,\@@F\@`;4`#&T@0GL'2V0#%,D5"9TQ`$X12%VC@\4PPZQ@0O*0(?Q
M08>QAQ#TD&70`K\HX2O"XD[AE!%FF:B)&T_!0YGY6M.YE).\28G`8C`.GRZY
MB2\1`SY`0R#DPS0@@C/@0QUDPCX(@SZL`Q\$`C7LPL6!WR(`P0-00E;502U,
M`@LD%#2@P0_`S0>XP3TL@`T00BB^GE9P&`1-P@TE5S'\2TIEV+6P`#7@02;@
M`2840PD003'<AH.52QAES4D(`?\=,B&ZP(U&*)$J'DIG!(L0X`$;K(.V6*!J
MH)$P@N3PK<,MVAF;B!H1?EA&%968,-IM_(-&;0DQ\")+B5KRN,DYF%I(ZN2]
MG4.]P4E6R0D;R,`/I!N;Z,B6)&*6.5O38=2SD0-7(4\_P,/1"54Q_(-JW=!B
M\%4N3HB-/`.E[4B>D8@&-10Q4`0M[F1:JJ69<`F:T)A%3,EMV"2)[0S+M8DY
M'`A:KN5>7L\Z-!3R=9G-'1EN9)64$1MN<!N55=NP`>4^\,.+@1E.-1F885E/
MZ1.P!9J5Z25?<N;6_6!(HJ2:X&5GDN9+F0/U:8^P3=FRH0E0*B64/1MLQN:*
M79ELUF;_T(69JW599BY;F]W<;`*GDFUF:5I/6^*@+"K=F83F7:(F<3HG]CB(
MG-B0"&#`'#3."=Q!)2`A,=P4'\#.IW21U3S";=S!3*8)7+W)DX7)H]&F<`IF
M9#YG?#(;^PSG<*J:2,4;2DQ=R>%$]*C9C_#47*+):,IG@<)47L*)EVS`'=`#
M"%S",N0#'0C`/>B"%_:#('1`ZSQ"_FG-'0`!`/3#-PA`&`7F2!';RU7$+G@A
M@/:#^]Q&MMT#I:4!,FS)D<T!B9Z)D=DF:^*@>*%$)&2")<S.)#0C&]R`#!")
M.N`!=R@%-"Q"$*A?S7A&1:062OR<)0R#09J#058$)1S/!S%"_^GX0+R@6/A,
M0O")"5!"747HPS<\FCX<IIA5SV<6W3U0@]Q,`S``U4@IST_=!C6PG`:1I)PU
MH8$:ZIN<)IVT0%)DP`BP0"TD`@20P2XT046@`"M4!#YT@&U\PPV\P0%L0R4$
M`"^<23'(``ST@2"@@!;@!!XL@#38P`P@@QM@0`A,`QF,`!_P@@EP@#.(P!#0
M`0<@83]$@B3@@`BD5#K`@`DT@QN,P"7LP@UXZ@PTPQO\0!K@@!O@PQK\@#0T
M@A.X@7V>&&[@R&*@`!H(@#HLP@]4D@CP0EY51&A0`QH4PPP4P@U8`C+<SP9$
M(FX\``_T`QT4@"6,@!P<P&9P#CX0`/_63$(E&<1`8@O2D9@ZE(`\7=1MX`.A
MJ$%2T`-AG@,/X`$M],.:BNNAZI2:50F:)>:6#)JC=5M^IHDY%*K)TBR:]`V=
ML,#5?<`CU$(\N$$?]($85L0,8&H^+(,($,HZ$,$6X,`;_$$*".E<$$&%F`,;
MS``/]$$*W$$1H8$;\``/O,$.F$,31`(BD,$,S$$C6(*MZ((%-,'0D`$/I``T
M9%$?X(`Y],$/8(,3\(`<R,$;]`$98$`K<``=\$`D40(/A$`C\$`B\&C16=)B
MV(`=0,`;4((<_,`EF$`B9$)_V@#[O-4,,$(39`)A]4G;X%('[`,/C``EI``?
M6(`=<%!%!$+_'6S!/2A'I<W(C9X:'H@'EK#6)!"'##Q"`BA"'W!`NZ1!"*A`
M("S#([``$$!#$YA`(3RNB97L>2[GC@J?S-;L]^I;F<P)"XS(!P#"(@B#&B`A
M`%"8(J"`.>1`(*C!#\"##]BN(FB`#G"!XY+((O#(&'0&^>*!`9#4)$PM(TW%
M/:2!'=C`&L"`&UQ",7#$+J@H#,Q5&V1&/VC`C+B!',R-[-"A!"'")/S`#GRA
M/T8B+I5`P#84\85(/R###:S.''"`8UP"!T3")$"/2EP"B-2`D#`83MC`7^[#
M#P0!(=`!&S`'&V!"431A<WAC#H@L^_2#+:U#"7QDB4TI;KS'#,K`_Q8L0QFB
MP#ZXP0:@03K0P!`\PB34`0G4P0Q`@PG0`XF!3_:^"7JJB?CTE/"10W.";\V:
M`^K&R3"<P^QDQ2.,U&+,"+'A`1CV0SRH`1$(`3X@@SF4;BU`PYG0@@]H@?K8
M`!M0&C40P2\D2A"Q4#VF(`4]PR*82D4-`6X<PG(U2%R]@`@0P@NUH`0M0B;\
MCC_T$B,M%`;[`UA<[]!)%S4,`1_004,!`(Y8PN<F&1J@0=4R`A$XQ5SAAD'P
ME`T00P'00ALP`L:\5P"0##'<P#/@`0M$2TXP"1-;B-R,25&]V8Z-B9;,7$EV
M%97D29=HD!>6AP]PIQOH%AAB`N`@@@*P0?\^+-0AL``AN4%?V("F%?-BRLE+
M3F8]?]OV)JA)34]<>@G,:AV!_C'XWJP=UXEKLF6>P*28Z(R5N:C-;<D]9+*+
MM1BHF0-%J,,PW-B,Q>B;>=IB\(B5^.+S3<)C+`9%+!`P[`C2W0,AR8$_Z,*[
M@=HDL%=;J:LZ3,@DP)MBC0@U",-MO-Z_S$$1P;.8')!BS0@Z[-WL?"1G2>5?
MQ57;9,)'UM`JJ44):``P<`86XTL=").*U``32L0=<`8:N"/\Q=&6O-?LM#`_
MD4C*/9;3C(@_V(&-4(/XWD'4WL&,!'(F\<@^L`%.$\*4/%'U8)1&QS25=)KP
M,>%(_S$SMIJ\#:;_CB4=2B<9D14:\<!T;E<;15\OG7K942EA8'(/B!DWFR8G
M;D*9;K=TS,79LLDBN*G9\U@$3C1/D_2#3>8#7Z6%?^8#\>SSCA65.<0E.H0/
MD##0;90#;NA:7''5K.V5G`'),TR)H^'&G;[VS+JVR08R^)JT\&VF7DY;R5("
M(?R1$!Q"H:4%+1`#(ICGT*G#)1"V%I%+SOT#D938/JQ#:")GFOS:2F5O:^WW
M]\+V?X_XB=.)(-G-.C@#`%T")FC`OJ#!#A$?(C""!LQ`/SA`&B`3%=U#'B0"
M/>B0#3SX2HGEE<5E'D\=J14#D*P#7^V8ED1/7&[XFSP,BAOJ?0LREG.Y_XGE
MQPK[Q3/,`2(4P0X1`GP`N%I,@PS$^`&TA1#PD@GP`91NP)U@.(D)J)@DVII(
M'6J?9S'0:&#I-/*PG#E@PE*9Y9M0@TIT>8$FEV3Z-IR8>*.#9`W<0U-D`DWX
M+B.P`:]$UPL0WWO80!!@@!$/P1RD@PPL0#`D@K&L1)E,^I`MIY]W>)PTSW\>
MCTB-=S&D6V<I.LG$.J4+WS.(KZ0+^['3)AKP`:C`0?0P,1->`C$,THAQ'6Y(
M%"'P`D+9@0Z=9B*@@310PH'(0+G1<5J&#;([YRH7,YK\`S`,@U(O#Y<`EIIA
M26=)63[<P\PE>9K\8+2Q"8C9-KI;FP0I]WCDXO^:2%FD0UNPG<F\KGL_?$K5
MHA@\=(GQ!7N-'?R:U+J9(+/`ER8UH)$1KOD!J*/XY;46``XC.!\1-,`%O`#<
M+$8.(`(#)(`)M!MM3@.7OF9%L&>8`)"V+=O,Z3#W-IF=RDU/W<-;(3MQ%SR+
M@0^7Y39\RLF4*?QMNB5D.IN=<A5:$AM.&0^52*Q.%7GRP>N:F,/PB*9X>'QG
M!A/#]T,.I(,^B,`ZI`40!(`Y1,(3SP&,`<.(9L,(!(P)*/P]``A3$<+0"*52
MB.PS8$)2$`,M<`F@]\,)9)`.XP;E#8]&):8/($()8`+TZ#Q*',^7*/0D:(Q&
MM241T(+E2_FQXT%9ATG_@R^&VI/(')@#2;A)*QG%CU_$':RDG/V^4*$!_@!0
M%M/4'9C9GB.\]0!WEDU#457YFOC#RK+4>L$^FYD#BJ;)N5_\VN/;[-$)"DR#
M/DQ`VA"#&OC`#RS"L/K``[#();#&T11*CK/EG.E"&VC`'#Q8RGD%'K!Y.`,$
M&Q.TSM3(@\:&#$PB\BSP@:A?/QDU2MRQ<:_$NGXVYI2H40.8CQI"]O5[5F,(
ML#8B:DQ:0(B8$!.3B`PAQB!/)FE":F2R"#%B4*%#B18U>A1I4J5+E9I[MJ_8
M-$2(]CU#5&):,4;KUA&BUF^7D'[$7JR;9$G=)40:[A$KILY<IF>T@!5;U*^D
M_PTVTX0L*I9'0XT;]S*9BRAC3K]+SR+Z`^"C7QL`Q2[M`S:MGSIB_OP1<PH,
M;[])`D"GW<B&:6K5JUFW5KKN7E*X2*F)=7T;=V[=NWGW9JJU=8EL^F3\BQAC
M4B0$=P[CB<B($+`$+/HIFA$Z:+$+J!<)T3!GDL'8>.;X&"*$T)!^1(KAD3&D
MS31&B,X\L\'^L%T9:-J@B9BGF!+N06.(!=#8(#8?-/"!#1DNN:,--NZ80P9J
M:GA!AC9N(`:-.40@<(B6?!N11*9*N@0-?X00PH8:RF/D!4PT*`$--C0P[!+4
MGA%BB!Y,R",/.XC(@\4\;!#!!!]B:)&Y:6KH9QUBIO_Q@0@BUKCPA3PB$N$0
M'H0HX:Y_-D!0!@T0(42$B8BQ00@?T&!@"`ULBFB--M13T`Z/L#-JGY)*_!/0
MW<SQ+]!"#3T44=R(N8NU(30JH45&\KAK`:!JV$`(-!!!S8<2^KGC2:+\*6FB
M&M#`PXX-#,.#P3GF8(0(?\AHHP0B1J+&#D2&*&2.E2(J85,\GA&`F(B$N&2(
M`=FX`!$T8D,C1EW)N8/5.1#Q89U,_?*A/39\N*018/(HP<]$S;WMDL3:B.\9
M!ON1`XV*YF`#DXB`$8L8']J@1I<VW%@$CQNJ46<D?^9XAA%&[NW''!L4<V@(
M(!>I`Q$1%(D(/!/Z*>9)=5[_Z'#>.8@@EXT&VI!(@\L^Q,P<!4Y8`)@G]QF"
M4:3V02>H<I/R<Q]_CM+YW*/NH28V*`WKQY]S\HG(''/\7`?HHXH1*^J@K;X:
MZ]N`861/IN[91Y]UII%F'#]'+4D=RH!1)[9[VC[:*'7LF&2=9PZ.:)VUY[C#
MJ7V@F2:/.:89>)II,)D$CS:@B>@2(4Y^1H2@@$$$F'N*,8=5H-9!0PA@@%GG
MDF(0N<.J=6K;\$Q,\JT!1<=]SAIVHXC9CP@VJ`&&C75%F,2'/)K-!&\1%JDA
M$#2FF:1&1'J=(_%8A:CFCCLFL:V&'YSY(0T?[)"0ACO68,"P.0BQ`?F3X1'A
MF0(N__'ACD[Q<8.#'\PI001@GK'HY#9\`(9S'Y[)PR!(B\@T?*8.C3",&J-Z
MAL_0\97,:"0M/ML'-4IB#J(QK&T)S`S.]C&-HL6.8<1@S#VF08RV<:4?_WC&
M)2`X#;@E91HG`^$,:5C#K1U*'T6IVL]&9`/0[)`H/./3ZXBH#KR\L(8@!`8>
MIJ$.?ZS#'.JX`RT4TX:VP*U=3>H@,:A1.'^<YQZ@J<8ZR%$X!^[C#C"8PSV>
M,8UG1*,6UEE&1*BQE2&@P3CWP(0>VT(-8E2F&,]81`F`@0EJF*-VF`&&80R'
M"1DL8A=`Z<<])N$S<Q2#<9A91QZ,2`PM]0,8EYAD&PQC#O^J]",37.L'(EB6
MA]@`8Q(1:0-H9IBV`TZ#@BE\1FSV@0Q":$2%F%G*.9R31&,>TURP[!IK@(B;
M9BY3@#H42DG\(<QI*N69R-2F;EYGL];DT)G>W)F?^!'$>\RF)/OX6D3RT2=_
M_*,:7=-9-F.GLVZZ+2CK7,HZBKE-?_Y3-\H$Z$`)FL0^#>6@T(P(T,J5SH5>
M<Z'X`)H^*#K/J#ET3P[=84,3:K/7E80,F/#9/=A@ATGVHP847!H>C!C$@HX(
M<R^5Z4R'4DB%TA2G.=4I0/?1-+Q-@PU/-(P/W-"/:0`#?8JYRS[^\<&=ZL8<
MB7GJ5(]I4ZI>%:M9/9<Z_11&*W[_A55\8$4:@'`'*;%A".X0I59O$U.VOO5<
MH;Q-GRS:&'K"%:]YW69M('<'&=Q@!!PPP1#(@(?SA`XU=]5K3!6K5\<NI21R
M;>PW#07.UDS61"Z%'4<?^E#.XD5G_!!B9V^:L\YB]K%%68,%X^,.:>QB$>:0
MTC#P0%):IA:&4L7M;G&#B7JQIAC(2QZ4V+"I260B0IB8AC#Z\0W&N,9/T(";
M.83)4(PVE+30I&8W,[J/I77THII-#4/%R\.@$%&[?!HB0M7;&-[FIH('3`HR
MVEFBJB44A;HYIV_<^E[_JF82L60-J""WO\PLH@@_H(4&UF#6.Q2@'XW80FGW
MQ-V@X.&V_U,1(#&`\@P9+H41F#2*/_#@1\H0Q2^AH06CGA'/:0I!DDG!`SF4
M@HC8J$.52IF$83Q3R0FNHQCK0(0=&!$;Q.&!B6R85%7FD(=)E*0:H,D'+4P7
MI4E:$XH1N8?"0'F)76`"M8FZQ\`0BMV<<16BI@U-1S6KSH6.ZK1QYJ93\3D4
MMQEF:`YT)C6*L32A/4.^22%'/_];Z*10(I:*+0DBQ#)+[)3@*QI8Q"74\8@$
M+*(6:DA->&K@R1H`!1&B8UTU?"(#1MQA`Q$AQ`7NT>2C*GD?S;K$-,CS#Q/`
MI`;/)48$)XT'$RR"9D>#7B&RD@>IG(`0]QB"IS)S!W)0HP`BOO_$)$A8S7,$
M]VN`>PL)U:%<RP%ZCV"BQCH6`>3G'H4!Q9HE`)@CA&+LKP2ZH+9)3,``3%0L
M9JZR@6]CTP8(FR,`DXA1`*@KLWZ80&/3H)WT2K"!-6IS&C9X@0V*Q>9,R!=M
MDYC#;8DR*`D*Q1RT(`;R+-P:-N@"OK!AI].(<@]SC%2$^GT&QXMR220>Q1S,
M,?3.CX*)M:8F-HSN!QI^WH\2,.8$_)%*(VB0!CHD94>@X=\"&#$C`5/$!_/C
M01M,P+'$120\XY*!2.Z@*3[D001L$!X1A'`'$;2!43Z8Q`&&\78A+4)?ZNF'
M>83`B-YMIP1LR%2H1O)I5:U2`VB(A`S_8BB$(LA`".9X@7G,:H,AW.`A`+`1
M>TH@@Q=,`A$VT(`-8DP4#<0S#Y<XDCD`U+DAN%"`?)!!/[HSH#R4W1Q%NX,!
MNAT`8H!$`368$AU%@CG(P(,QB-!2F`_U@KO<^R[`@(9AI\$L7:"!:WD8`AWJ
ML@@?$F,(/IA&2?"`"$Q4HQQJ(8(E$%$$8&3"!FCK#Q3K1-TU%(N'F"`"A;?Y
MS'W`(S6F0>=XC@`?RN=6@Q%Z!3520B@T(-(\:!_8@!*D00`2ZRA^CXIJ8"46
M`1.@)2)\X`+\PP9^8`[48UVD:A+(($00@1%J0!UT`3[4SG?\P09\@"YL``W(
M[P6&X`(880V4_X\1&D'9(L)1$*$&G(-S&$$=T,!W,D-C[,0VIF0([`,=M$]+
M'(<1AF!JV``/G@1:F*,&]N=),@$-[*`&S`$3F,TH-H`QY"`!+V$_BB$E9"`/
M0,-G\F#V)F$#1$`#(D,&6"DBV,`&[``-1&!])J&X?,`V[N`%1&!3"`$O?,8.
M/BR[ZDD$CD8=(B</Y&`$Z(!C,D$&VB5"&,$-F*<,:21B($,BS&$(+N$2B$#2
M;*`_&`&M?$8.;:!%"H$C-*`-%L":C.(>+D+-V`NA/LC,[&J9]"F)IL&D"K``
M2V(2J$BQ(BX':0]N]F$.C*@&-&`#T,`2AF'H&B$UPJ\$UH=&(H+T:O\`!=B@
M$?C`.9SL#$&)",)C"*YE'6C!2.Z@!)P,'9AP".8`#33`9R[A`HAA`6H#&`81
M$UCQ`S'G6N;@.Q#!'(1`\/"B!#"!?1Q&-/"`)6H`[]RD'^:@`?9!!O9!""Y@
M'33@)-AG'SA-+`@!QO:M#6S#*(!%'10",FK@`-JE`T&K)-C@!5:).<JQN-P+
MQCY$[FH`$X"@'PK`-EZ@_#YM]F*F'W(GHUJ*,RI1*TND!&()16:O!G8A$U"`
MT5*P'\9E&-2!$.P`#V#`#1(/$W1!%3-""R_A(R(C8B9!^WPF)-8`!6:@)85@
M=[!%*4*Q-=2AI9#BYO+,-=2!&A)S->K,**;_`1*9SQFU:A%H;K,6:I<R@QC2
M20,^$Q@L*O?P0ATLX\F@QF<X+(J^YA],AQC8H*7N02.^!FH6LF<.R&E<[DPR
MHJFF`<CP1@AH`2J8)E-D"PT6(>;R1C0F"#0P$A.>X2G8X`R(H5BJ83%$0`?:
M`#*)XO<^#1T@0C[,(;9H3IE.3'0N(9[\A&X0X1DFX7Z(`1+5HA^H`37.$AD8
MP09,()Y<<4_4`2@.)R+*S:AT[A)HR=@R`RB(H9@H9Y+8``"9<RR>Z^(F::U\
MBQA*@$)B9@AL8!'(``?O@`]Z!PT$KD86H0DX@`Y,H$0;YS#,H0UJ8#^>1`CP
M0`A<A22&[D-VH!#R_\0(@0T:?HL:?HL8J"B%Y&ZM&,%(=PQI[L"([H$0&.AR
M&$;`K"(B9HYMB(&6@.$KRL@UAE3`5J.#<LDHJ*'T+M/04FR@UH$14$YH>J-J
M)-,XB:!FAE&A[DN]2BXBT,"(X$R<X,N]F$*T0F,=C,-.3VJ2#/4T)VDVBZ8T
M\V%178YIC&B"WB8BT,%02[.GF(9E,$$C0"<V>"$2,B.*MF(L=N&<+.,2T"'W
M$#,B,"$Q0DP=:`P>VJ*)#D@=,C-7&8$#+B</B,:!S(&6W(AQV&`=7,Q^(F)*
M_>$2V@;,\.(?T,9(!>E**Z<J\.\2OF(=NC,UU.$9;HXI"H<VF,,RT72J2O\B
M,_FOO&Y*H_POGXJ!:-SH21<"+US.,"JU78KF'P@H,UIJ'8:@3RCUH-RL),8#
M-(QC-6.)E]@L4)'Q4-GI==S&B;"#KB+1'^KLH.Z!NSB*,S2J'P;5;31VFM+)
MG2IV9/GA;!8JH7*(KBR,O-*,8D'+M-RI7J^I8V663\PFB(ZQM(1('8`'9G$V
M*`K!1:2)O>S@N?P4HC2*B#9V*]MKKMKKNA[6J,[47'D+78LN4!J+$6#@`EQB
M`UZ`&FR@""*G'Q)A`18`$QCA!&J`#0X`,Z;!5L`C,`RC&!R@7X:@`TU`;'5E
M4F1`!##A`N3N'$UB$E9"AOPA7CSG!>;@']ID#FK_(+C8#JU6R8=HS7C6]3)U
M9AV42R0(#6^*H1A^*&@U]VG5BV%5%K(85M&J!BZRM1^@P2V"B"LP@Y[D]#86
MM6&=2C7,]&IY#LG4]5PRH4"N9>@>Z1YZ("+N(!-FYTF:A5#DA@@<D1=+J2^"
M+TWN;5+<H`C8@`C&ENA$P$-+PA*,I!IL`#.FIQKBQ4E`!1,VX",)(?#0P`?$
ML#SPP#_*];\6@1&$8!+2`0^DA!KL\U_0)U1J2']UP^<NP&$,Y!G00;E`*9Y(
MR`<,-2F&YMQN@XV>B]N0IHT*UH.8XGY^M]!*(@]`=X;,A"$@0PC^D!8XX#_@
MLW[-0<ER%!$NP`W@=Q',_X1A3D4#;-0&J($6)@(BD_,>#.(2=*&%8P-6_4,(
MON(.(((0GF0.;K1AU.$^J,%X+F$!8FDFLY50`H6B*`JK2D)RDV5/#Z<0G6S_
M\.@9^X$,S($#,``:#D`.R,`$4,((6X)H^H+_W$%*="-O,&D?'-,PX*&0>F;F
MP+4H?)>$"\U:A-=<4&3C0`->T8`(FI%+J6$2=$$O[L$'KG,,UD57T(`Q9@81
MR>!PJ2%'AH`0M&>/V(`6S"-$EF9R((*4&*9^T8"79:`8]@);%'%'CJ<\V$!3
M&.%_)!E-4XH,^(:7%Z')C/`@]HYW=ZX&T@$&>``%>"#\'-!(WG,#(&(.ZA0I
M]/^4F;95RZ`&+[KH4JFAG)8BF1/XD66J)%X%F<QYG!KCG7'W'G#&9_+A8@U#
MM/J$A."I:-P,4?L!'3"#C=3A'_[A8B'5B=C&;58(,=F&D><Y(O!@$8Y8[M:A
M)F)&"'8D7P`UJX0`_!:!"&AA'HG@&?``1F`,(N1.IZ#!:C7:L?*`:_`Y:\!+
M:-],NQ**9WKFI*[+78V6J$_77-/)9R2HJ?=AH#LKJH2V8(MF4G[ZS"H1H^3)
M:/_4O5*7:L,)$2=)G336B4J"G;_&473JI949IY^JGF_ZK9E)HYGX/J/)6#3B
MB8,"$T1'!@Z:K(<B'WQ`!"#%J:K&1F&H.]5!-FF/$9C_5*G'8JD:@U][0U*7
M@H3<VIB>X:[G^K'N@'0]6[35JUGMIW\_$Q%,8`XVA]KF0)3V(2,VXA(L`0\^
M0P&&P<.(AG*((<3D`FE@U'@$:1HX<&@`D18PP1V*@-JHS1\V.1.*IB)$XY8$
M0)0NH-/@8A&@,9ZR(E=MMQ]$H`!B@\_4X0)^T5SD&78\;+3UZB=S;+W?^Z%,
M8%!LA-$"QP?D5P,JQ0`(.;:'8`V*H`O;``_`I''_L%(V8%GP4(!8L!].X`\#
MTB7:!`^*@%M.`!ALQ088@0'P0`'88*U85%\NT:@`0`C^00-\1P[:5@[LX$AN
MN`9"8`;D@([8+EM-P`;P8`&0_^&]J6$`X?NMBA*]?=R_;.`?$B<Q:L`$.I<-
MYO>5!4@&-(((3F4]5'E%_&,F%\E1?,!C_.0.N*8L0L),(",YS0,97'D!R@,-
M(-%6C)0-W.!)1&1V&$3`;=0-[B$$(B<->2`R4N"4[(`!-(`(VH!K\G6S@OQ<
MJJ$9A3RKZCE,%5VT?2931`!_^Z%&:T`$&(&7N_Q)?$9_1$9Y-J)$68?T;GP2
MJ$'\L$5C(L(.[B+)344&RH[2K64?02+#\X`-"(&S!?,#VR"(2Z!8\LT`@.$?
MR8`/L+GK``A@Y4`DU\$?=B?.\4#C&,^!V"@B')-I'&@V3.)>BX&7BJ%@%^?*
M@'&A+/\846^FFI/H&4S*T!T=A#1%L]F=`-72,S"#'/P!]$B(#8@!^18*2M<`
M,36B<"RH'S!A"`8F]Y["A(K%9\35VT^BW!C#@OP[;=C(!V)K_-KG:#QG=@0L
M+=!0'8"!&'BA&>B!%:#!38;T;'_@+G+U58M!9*S"<YA&E58H(K2TYO$//O%"
M"!C:QJ"DF*2BY4HS48-B8J'D,;6I)(H!#N`]J]A@LID>ZJ.>*73W'_PLA;KJ
MW-']9-9=ZL][Z!J]Z^>YF<!Z[.W+JZ'V:><ILC.CIYKU*-ZI[+,J-L-^ITJ4
M[N^>`$LB)2CR(8#!'Z3!)#'Z+''F9W27-92QAC@$[V<JA^S_GNL7'_(!:AJF
MT$S:Q9A/`!&ZV-+MT[U%Y1D`\/"SS)@\Z=TC/VOTUJ`L:V15W_1;OS6\[Q[2
MA2(7(0]00`AL_00^X`Z&YZ;$M37JAEM!J!AZW/61OA^XH!)*_T_(F!B+W_F!
MBST4PB!DH`1*8$7JX`-`@$%IDKTWAER??YO4(+1CYQX>P;*`@8.H81F>(1\X
MN:NG@=RAY)8$UBB$GNBM?K2.46>O":KIJER4%B#\[>LW<&"_@P?Y&=RWT"#"
M@PX?'A0(\:'#B`@Q9I3(L:-$C1Y#BAQ)LJ3)DR@1WGNA#AB;:>J*7<)D[AFU
M2X'N"7EV$F3*GT!+$D,4M*C1HTB3_RI=>E)+):9(+PD(U,\=,1_3\A6+4VM2
MC:']J*WKIPYFOVG5^@TI=O">LWZ(T`RL0?2@NG[W"@[,8XYL/T+`$%$C>-%B
MR('^.!83LO$AFFDC^7T\.`G8P6+`\)1<E-;G6<C])O%\J$[:HL$>!T["9%(=
M(42C^ZU+#+6V;93$QHZ\9]DDQH@.S7F^_3,P\>/(DRMG6J?W<I)MT#`68J,$
MM1HRA@"K(X+1HDDO;!2+\>)Q#;IL4%-GL^C"6BT;AE#S0836$$*7B'I_QD8&
M)A%H8#(-'C)4,TP)0YB320V3''1)&T(L@A4M/62B2S7F+-(//YB<<8DN9U#3
MAB[V$(+'7?_]U."#AK^<48UDTU#CSS3EX($)AX?XHV`/K/U3PB(E3`+9)9G<
M,\Y9]@RUSAEC%///0=1,PA8T<_R#1QL'`0,,-8OTU0\P1`QQ2#7^^`,,:&=9
MED<;PO4#C7!W/4G,:-/(P`A,P-QC@W//];D40QL5I,]P'=UCSCT$&=J6.@:M
M@Z:?*!73(*&05FKII2BQ81FERKFS@`P7+$)$/VRLV4\>B.`!F`\^Q*3%$/X,
M0<P=-0@QQV#WX,%&#7.,<4\//3RCRPDOW"/"KD(,D<D=9&!"2']"9(+'$'P-
M,00B=N0A0AMLJ94'(WD0(L0O=YB`QR&+8&GE(3$@<L8)/?PRQIK_8QQ$UQQX
MQ/#N78C`UD8-)V2220DQ4,NN+OW\4\,E->!1`QIXG-'&"NK4P(809\AP1QM#
M:-:/!GC8<(<-^;9QQD%LH*'!'2(\B0D1/=1PAAUV"*$!PM,,P<8,>&B0<AYL
MO'"E.4+<,80&#4[C0[@FK/@"(YA&#16G$*W34%MMDH6BU"(5XS'78(?-]4!M
M7#)V/W@(08T0(M@P#1&(#`$-$7?,@4;<-3R#2`WU)BL#A&@,1LP%=\B`!AKK
M$"'>)"<P)@(BAU!CQP'3V&J"$)=G<L@04+]00C&(S`%,#24@.L0TDR!RR1!H
MM+'!=1I`YHX-;HP@QQG%D"''">4\8\-!_S:L0PD**#22X%^92(-&,6NLT48/
MD2#B`SZ+9()7V6C\8X,-YE!CPQ#WM&%N/Q(_DPEC_OS>AN']4&=]/V[D,6H)
M/#WHPS/#-%%#&C-8I@X;/BC!&A"1OACX@QBM>YKB;$`4<Q"!/6BP`3'R0`RQ
M6?""%AS()>9`$`QZ\(.V(9O9P"8@V6!"0H381\TP`0R]4;`:M2(&:S"!"1NT
M81)=ZH<YLM,&3,!`!IF)@1"`D8=^8*(&-AC'-&K0CSED0@1$0,,E?,`(8J@H
M#WAXQB7NX`/JD.T9F&`$,*A#A`WX@SH'F<8"VA""0I`A#VN8`1O60`.J]",[
M06C$#-;@@R=-HO\$-L@#'\B``48(80N7H`/;S.:/$A`"#0Y$A!!\@(@US.%Q
M0A!"#>H0C$L4\1XRT$D>:F`'&5S"!D]J`\?Z88+!Z,(&-X#&+H20!CZ@(2V7
M0)H,DG4^'UQB@)@(P!E;QYIID`P/C#A/&Q;Q#-V`\)G0)`XP.!C-:EK3-_UH
M`Y^X5B;#+,0C^FA+1=KB#HCD91_J0!2@S'$7O>@0,O<8"SHA,Y!\D.49B,G'
M/NYQ#W_<HR7IM,'[^F$^=OYC&H@8"R4H$4ZR3"(MU$!$7P:R"$P82@YLP0D_
M$=&@@Q!C&NNX!T_NH"%I:/,<TF,!/MP!#R\]8T8'W$EH^@*-9^#R+O?_0$0Q
MZ+$.9YB#5X@*'QKFQ`8VP$,=0YA#/NY1074(H0V(^D<QGF&..1#A&<3`H9>N
MR=6NGH06=NB@5\?*U35L$U/`Z0=M.E(8M8ZS-E3K"#6H&36-_",/X^I'0\G*
MU[Y>4Q=T]:M@,]@/LQ+FFX#J8&(K4IC%BK4QO^'(<.(:5\DJA39K#2'5$-L8
MCRBD)'MUZV10HA')#/:TU1P(,.[P6-2Z]E)H0,9KG]/6;XH54`4AB&1RFUO%
M(F8?X>0M;A/"$.#Z%B*T<6<W#TN8YKHSL<-M;F)XNQ&*1)<BBG5N9PUCV;=Z
MM[6S#2]*+O$U\9I7.6DP01K(\-0VL,&]<ZA;_Q[PA8<[W`$1BT`$(S(QB?[V
M%Q/^S02`,7&)2P!#)@8&1H&U=.`#$V.JQ`#&G";\#&?$B!K3R'"&R3$-<WC8
M'.LXASK2L0YUF/@?_+P'BONY#X'<8ZFVS>QY9TSC:U(*))'=[CB_B0G65K;&
M0":).EBXBTG,1,):PHR"=P&,7;`0P/[%X2*^DU]&](L1=R`$(>X[A_EV&6A%
M14/*5/E4,><!8D]-V1Q4B2H[F`B+<L"#G.4\ASK7>;YXF*\<V("O.C]5"&@8
M`JM8-00BU&`(@&;=X>;;AB]WF0Y8Y$-]XVO?^UJZ7_<]\QRZB(<YN*$->&7=
M4U44:`BI4I7O9<.GN__,!CG3H=-UMF]\Y\"&.Q3U#GD&-:WSP&LLXD'2];VO
ME?NE7_SZ%\I&+O"1E7V)_O(WR@1N]DQV8>!B%./!Q,CV,VQ"C6YGV!P:CI%/
MMSV-;4]UV]+PMH8_S.X/K\/=ZRBQB4W\SW3.^Y_Q+C$_U1'2>*;SGRGFIS_/
M^=R%("HC/OGQ1];:V['.*L@0CSA<?ZM/?JZ8G_%6QU'3,6][FSC?_(YWNSOL
MX1A=F!K;WC:VL:UD!C,XPL\(QIRP"F%K2SC"F+D$+72A8`)#^83]941_%\&(
M84]YP#]/72:FC,-,]&O+B,!UW>S0Z3QD*\R'`S4:YA#UN!0[#]^Q,@Z-C5__
M_!(]ZO=%.[YZ?;C61:?M[M49A/*`ZSZW.MAX"!VN2U7G/-<9U&1X.Z)]\-ZW
MMTXZ8G:OKO(@!_IVN=.=;H.NHN.#1C\UBH+V`:*MM;2LUUK6;$#$?-%NWSS;
M86.URCJU;J`B&YR'"#YP?29918;#93+K:TB9[0]7>6O]@-!#.(^*@#])06=2
MT5D_'.M8EP:W`UJ@$H^^41J[XT`5E[&]O4CVLVM;B'2?L6_5B,*E3_[E.':[
MC;5NBP.^;W>DV,3P<,?'0_KO?^_[_OR>=XC/4>)WMQO<(R<6[P83\<9_^>9A
M_@=N)/=MZH9ASQ`C-M%A$8AAWM9M%HAR*3=SUO8,_P=7?A[X@3\Q?D7A&><W
M$B18?9W55K>U@MP7*"WH3MGU6)R55@@'7C+(@CBH8R"X@SS8@S[X@T`8A+<A
M@D)8A$9XA$B8A$JXA$S8A$[XA%`8A5(XA518A59XA5C(5^<G8]=G@BJ($#*6
M%)25A618AF9X7D1XAFJXAFQ8A<201691#8A`#/DP#?LD&NI`"[UQ4/?@?C&Q
M#]/00NL@)/!087%""XCR@'B!3^K4<(XB&\UT%NIT$-V3&.K@8>UT<--P#F%A
MAU6S#^\64@91%O^T5?M$#0.!<GFA5B1F#O[48<55&/<`#Z/E6.N`#PDC'/[@
M3'Z1,(QB$0?7@7CQ$8BB#_\HUH;(F(RHY0-HX`,RP!,UD`?`\`\-0`V%8WR7
M\"1H(`)XL`AYT$6,@&C%@&@,(@(G,!9(M`B%4`(E4`UL4`)YX`;3`#'\X5&U
M,@<\0`C4L"N55PS!(`39X091)P)=-!0:4DHUD`FNAP8$@0:\0@PPD#+K0"1#
MX`:KTVID$1<B8`?#L"V9T`;^P&L&L`9W`)"+\!AX(`=\(`3J($7.2!3$<"=R
ML`C[0`B-1BJ,H`%#50(+8P.&,Q"$X)$EP"W]0`Q8T@8ET&PE@`B-8`YXL`%<
MQTQSX)/"`)!UH8Q8F95<A0:3@`;6T0\YD`?2@`D-4#TUL`P.DR?]X`,UH`%T
MX0/_>+!$D"0$HC<49*!6)]`&ZV`#(K4`;$`64G0!1+`(C-$/ER`"Q,`P6O0[
MUR$I)3!$9#`&UM@E&C`$.G0"_;`(&Y`'#/,E#%D#Q4`(YG!#;6`'/M!";E`,
M);`/[I!)Z@!'Z4$,!J`+<C`-,'!'-K`(\*`+)K`\-:``&GD)YF`VSZ``+I$'
M^^"0(I`-&U!?0G!FU%`+-0`,%R!2,I!-:&`'Y,`O"D`-,K`:):`(#\('0[`.
MRX`&H?("0@`-WV`#&**5\!F?'C000]`&S]`&@T$#DQ`/-Y`"0+`,EP`#.;`%
MR.`.^(`=B%``=@`-H;8&YK"-)7`JC*$.R(`&0;`#^P`-_P;`D.J@!G,P`1T`
M!W!`B:,C!TU`0SZ`%S:`#,#P`R9@G$)0H:R%`IKA/6["`3<@`C/$6ESY$N]U
M+3*`!Z.C`%"C#F[`D'9`!C^P"!5:`W1`#B:@)P2I(2)P)B@@!#]0`PP0#GC`
MD%=1`X5`%&B0!BV0`RR@"#?``G;``D(P"1K@E_W`""F*"&VCE_U0`@E0"<M`
M`H@`#2S@!B69",@``FK@!!.`!RB`2"T`!&<EGX[ZJ)6"!XBB!C,P"6D`!X'@
M!DVD!H$0!UN@!H(`#?W0C"*""&V`"(70!&0P"7*P#WC@#(N@&163.HMP!V@P
M1HC@!FE##<)``UK`"/L`#&C`"O]HL`:10`Q#<$1LP`=WL`9V<`YND`:C211M
M>A!HL`AN0`:GP43FX`/$,"IX8`YLL`Z6@`>GB0F90`Z6^0QH\`.'TPAK,`S%
M@`QK$`3N,`+]\`,W`!IM$",CD)H,$`=]L`@S8$3`<`-K(`>48"MS@`*ATZE;
MD`;:L`MNH`X\(!LUL#95>AE"(`PSH`BUH`-JL`Q`H`:3H`7+D`,SX`TEH`8Y
M\`W+L)Z/`JDT6[/'P44R(`,^@`()\`$H@``,0`-;T`);P``LL`4)P``B*QU=
M-@="H`"+8`,(T``\4`AL(&I8-`8*P!X8``.4H#*=!@2(H`A;``,:@`B[0`8C
M0`D[T`#_>4`+FXD,-7`#EB`'EI"M:#<)0L`&1K8()@`$C6`'E\`&EC`,XL((
MS\`(H%,,WP$PH*8+=D`-%/L#"$`'=J``#"`'C9`(;[`+.[`+A>`&E5$,A;`+
MK("JO)`&R.`$(#`)7+((E\`'?+``:Q`'=2`(CZ`&!Y`"CV`!1=`$<T`.;4`+
MZH`(%S`'Y@,31G8/<[`%%7`)=4`!?*`(E:`($\`#BF`+DZ`(*W``+4`#""`"
MY$`-PFBSYGN^09$8)P``)W`!"U`!(+`!#_`!%?``#)``"?``"I"_%X``!M``
M"5``!V``12`"1:`!(K`!&+``#;``"H"Y!]#`#6``"O```[P`_P=P``I``!FL
M``L```!@``A0``A0!`50``K0``C@P!D\``-0````PP%0``X0``$``!,,``-P
MPP$@`"<,``)@PP!@PP'@``90`#9L`#&<P0PPQ`R``#L\PSH<``-P`$1,Q"XL
M``2@PU8,PCX\Q",\`%L,`!EL`%6,``X`PC#LPP<`PT,\PS!\``EP`%6<``2P
MPQQ\``0@`%Q\`%!\`"`,`#.+OEX5AH0L<0,A`JPU&?@P$,'5#_@0#_N@3]]%
M$LD5B_Z`#_<0R?N&8NK@?O)V8OQ$#_RT#Z3<3_QD#^PG?_-7<M0P#A>H<L3@
M#+GA*")F#N3@8>2PR]*08>DV#<B`#/\I5PUS8FW$('/R.E5*-G//(,S/L`S1
M,"?#,`S(<&W5+&%*IH?1]F3!8`E&)@PUQ:O`$`W+0`W0@'+F;!//``P%@!J'
MC%9HP8$YB'`,P87>!%G)Q5WO[%4K(UK[C!SJT,[_?"G3L`$V0`1H`APRA@:T
M:(,DD2$A`49%V(?:Y4ZE7"ANY6*K:!$&(1`M1A"4W-$6P7`N.(PH>(.5C'X<
M03@./58_9EM?"!PQ[5V(U5#=IX(XW4$485T$@5TLR%GF4`"#/-#+\0RCHAI"
M0`O$,`.L85/W8&!L(`?K(`3%,`WW,`W_,`<=M0^I,PUS0`N&>2O%FQL/%4_E
M-@F'@D`,F8;_XC40=U!$(H$)'-1P';%:D%02U$`(0($&/&$.C<H1T_"5)5$3
M;-4/&P`U1(T<YN``0YW8R$$-W'@)SR`#R."3)=`7Q"`$ET`$<BT"9&`WB[`.
MF!![&&`]TZ``B7#0%W!$>>`5,(`!6*39&\.30>J06,+6X948=^`>4^4#<^!4
M=F!,BP`,&T#5F/`/V0:8-6`.5\%"W[A5Z]`ZZP`,/D`+_\`&D7L)\X&?75D7
M-<G7Q?#6ZA!1#,`3F/``ZW`'!X8'R"#:=W")@D$@H1$,^%`,C(`HPN%AU,`(
MZC"5H0$,,G8!5^G8MA'4C4W@M_$,3&1$EDD$)0#6`^$#L6-K,X`&_VMR)HA0
M'GG`&L6`)2>`W?&E0QKP>#8B`SRP""=@!VS@-L005D#HUFC`1?!X`6N``I?@
MEPL0?%&[X=H1&@;PJGDI`H%@-!-%4'B@GCXY1F=;"*PR!P]#21K0%^H`!X#$
MED0P!C[@IJZ4Y1=`#+16`VVPD6B0LZ(W7R@`(`PP!!&>U[L-0-*1,B(`UPBQ
M`7J-VPC.$>9`.7=>U`R)L1V#*FZ%"->)`FD``V@@N^>A7V=604;9#W`S!ZO3
MI=E97W^Y,I/M'4`#,=V#@]B5?7HA7)_>TZ&N5H"2S]<7B[AUZHB%ZJ>N6-/E
M?2V8&&!7#,Z8.GP@CPT0"8M09_=`/Q>`)?]G02N+,)TGE`?'DQB8@%=Y(QU$
M%.,U\`+!^EXIPA/5T`9C8`,O00M_,^W]0`O2&%:`MC28,-7:;F698`+NN@8_
MX%8^8`Z,L&FC2I<LN3;9M0'64X+8%!3?-UHZ=F,X-L^.M5B$,A"?E8.3Q5W[
MWEPHO7T,KT,%4.1'8>?FRV*)@0Z(H&*3N$^R$0G-\,E<K0LMEG=8HT.<V0_%
M,*Y9;0<'%19W09C$X`\7HPYM`#7E"X(<Q3R2Y`.DFZ]K0)<Z6>D:8I@!9$A)
MM4%H,`Q![Y6U0@A#H,@K7E2$J9,<-`0\,0G%#9?79N%M<`&B.ME3-@V/@VAS
M0#3@(C3JF+"FV4'_>^L#7+26=F/A?.;/&Z`A=#T9-*COYI?2'&%:^8X2?&]9
M"B?Q&W(6#[_GRB%^)''W*6B"'7$H80%H@(9XD!_Y;T=HDS1\*O)[731HFK=Y
MJ%8J5)=EQ49L_4)E1^=?A.`=2U<]JT]T`C,)SU9@++1@U79@UD;,U8!56#46
MI7PFP[@/5:U#;$$-EXT0UT86P@EPT\`'"#$)Q+`/YG`'?;$(+[\.NQXD!!%2
M!Z$+:`T/_<1O.E40']47)P2`@)C9Q/`/PF$'=*`H=L$&EW`/@P%2>6(KK;4`
M06_X2V$.`+!5^G]!`+&OWT"!`PT>1%@P(4*#_M2I.[=NG3J)YLQ-NSAM_QHU
M:AJI/>/XK%@Q8B.)$0-V"1,PEL"&U2K&$F7,D2TOW<24$],DE9,R(6+$B!`B
MH(CNW"&*:$Z>HW.(+F(T:=$DJE.G7EJ4:1'017>F,01KL-BDL&7-#@36!I'"
MLVW=OF7HKU\1LG#MWL6;5^]>OGW]3BM@SN]@PH4-'T:<6/%BQHWOLNVG4#)8
MR`<5RHU,\&SER@8Y6Z;,L+/`!74=GT:=6O5!:@X$KX8=6_9LVH9'B_:L>6%N
MWIXA[Q-8D*WDX`<QUT9NEV[FY,V=KY9+K<"ZY]6M7\>>7?OVQ@P6]9,K''A!
M?^$)FH\L//WZ?>B!:WZ?.7[PXO77R\</G[GZ]/_JQ<.G[[[B=!N.MP)UZVVW
MAO2BY@#JN(,P0@DGI+#"TQ:XQ$(-(9S&P0T_!#%$$4=L3H$-?""BAA2'8%$(
M(="`T<4VT&BC#2':8*-&-_)`8P@7?7PQ2!C1R+&-//*88RD\YK#C*$(.P2,H
M1*+$(P]">)011C9RW!*/.^;`P\NDG@**D:Q\0@23KIQ:A!"AMD*D33>ARBH3
M.S.A*J=),%'IDE^*^467EE)*Z1):#/WE4%UH&=2D8JIY!M)GIGEFTDJI.:E2
MD8`9::1A(OVTFI`\\L@<3`I0AT155V6U55??RL,&&V1X00892L`55Q%,$$&#
M$D0X00,.>NU5`Q%$T%7_UV.//:'8$SC08`-I-;A@@06*L#9;!AI80%H%KMV@
M66"7U:!<8\W5X(0+RI7VA`TNJ%8!!A3X=MYL%Y#@@F\WB+:((B0HHEIL&;"V
M`7H9,*"!!A*F]P`#OEW@6VPC+H*!;;_%F%YK#S#88'J_;>``C!=>`&$#'#X@
M904,>/CACU<V^&$`BCCN59MOQCEGG1'KS+K?^N%G/.#RD<N??":S#+/V_+FG
M::?O^2?J?]2)^B%X_O'GGW6:9MH>KIEN^A^HFY[H'WBHGBC5G==FNVVW'0N/
M/KG!\R\__H2V&[^>%Q+(O`#YBTQI!$,;B)_[0'L[<<479[QQQT7<.\'!'Z>\
M_W+++\<\<\TWY[QSSS\'/7311R>]=--/1SUUU5=GO;#Q"!H0\,,'S"ORUF_'
M/7?=;;Y-OX0*K'LR^V"?'.G>]I9=<MN3)WQWYY_7#IA)*N$SIYM8BFF878AY
MIB21JN&T).XSC?09:#CB2"/U+6)?(HH>@O\>=>3GVNGY\H.^=-MQD[UNP1%W
MB_``&#@""8@Y^OG/>HKV-P'*)6C$NUO^('>)1"`B$(%0A%&\Q(<^W,$.?+!#
MDHZ$!BRAP44F1.$<3@@C0K!!"(AH`YB2%*8Y$*(.89+#'.2P)#8<"4EWR,.2
M[)"''N*(2"]BPQ!HY(,M"<$'*.QACN30PS`=:0YWP/]#",&$E#L,A4Q%V<H=
MA(*(#UH0*7A@PQSHT(<^"*(0A%A$(1;1B$@L(A*1L(1**'$)2_2QCWNDA"5X
M80E)4"(2K&!%(BRQB*GTL1%TC(0C*!%(/O+I>I=H24T&Q9*;,"(F>]H)52:1
MDNJII"4E(0GWJL$]374$?>C;R"MAB9%ID`,C%V&?.=9QCO?-;WY/<QK8@/FT
M?=Q#F$W#AS^`<P^AC<=H<V->6/:GE\](T)I]V8<Z%.*.=11H?L1SQSUPHYN:
MN:X?S"Q/0>CGM*TI\WWR.Z<VX7F/K>UC:Q2YQT72MQ%^<B^5SQ@&IGA1$DX!
M0QBLN,0P@E$+2R"#%Y0(QB7_D,$*8NR"%PJ]Q"Z`P0M66*(8EJ#C)"31B$50
M`A&$Y`,C$,&'1;`T$F9:1"*D0D>HP#0HC-"*2L<$%"S.02UH7,-28)0'1`C!
MIU[*`Q^.`L0DS6%+2-*1C5!(AA@)@44F]($/AN`#,EC5!S>:$9'0X`,<L8%(
M;5B#$8>4(R&PX8D]&D(-Y%J#K-)UJT/(0QOP,`8>6)$-8?(2%HD2ID,0XHI3
M<BJ2MD0&)5IUJS%"8PRW]%<L(L4H.V5$E)C2PCO4R(E:=5%6QZK$(:4!K6&=
M$8_0L!0V=!8-51J2$TUHU15R*8I$/-)?J^0#'](!#['-DI&RV$.EW($/8>KB
MF"Q[_Q2@X`$1XKPFA8IQAQ^@P0V4Z`<*B/`,0J#A'C=``QU*,`=_K`,&KWW!
M$"Y!"#P`8PX^4$`P^H$&#0##!B4@RQTTP$1S(**ZQ:@!&@I!#3>8`P]"R$,Q
M$-'7.P@A0\70Q3-,98Y)=*08(:1.I<SQ#'5@@@UKZ0>E^M&&1:B##8OX!QXF
M<0^B_&.4]U@$,@BR#L$\A!;?_$<QU[&+<_3#'>[(ICIJ,1!XR'@?SD@5.=QA
M#FVD8R#T,`@YU.&.?IR#ROV82#_44>,>Y_,@VNR'.:Z<F_80!+H+ND<^1O0>
M9A:SF,-\VB^;EIE\_$-ROEFF,?/Q-+/)#WY_OB?\).(.JO\]9"(5D4BB::S+
M7+;/(M2@\302K<M=+IJ6&\D(-:3A2I"T4E.7RN4M^4D-:'2O4L5`!DT*2BB4
M``,DU$`&*RE%ODN9^B2/ZAXQIAG=YU"B$39P@Q,FH8\<+*,?)M"`-.1@!Z-^
M91TH<.L0VF!8$0CA#M080C\P<0=U",$&)#PG&\SA5DS4H*UN*$8>A$"$1?C`
M#M+.Q!V`,80Y4*,?B-B`O#4PB1KT,$6,$,P+A#")"UQBO&W`Q(AM,(PSV($(
M9+@#$9PH!QM@`A$:*.H)ZO(,-L@`&/UV"B+Z@8=IV"$&5(VC"#B.AAH`HQ]:
MN$`;W%"#'Y#!`H5HA`**L0->K"'_5?AP@P;L0/$:;/F)B&#1(M;-B!((P1P"
M840-/HA?;1/!'R5``R)D8`=,P%870S!'C^R`B!K<82?[T9O>@E=`X\4'[9OA
M==R=MPA,S*$?A+`!,$J`B$FT(0UV:`099A"$1M`3#95B8B:$``PBL($<1.@'
M,>IM0KT.9`[WF`8BS&$#:M2B!BK!+WYAA(=,Z((::*CPO?D@`CQ<X$8^6NTT
M]F&.!6@`1C80`DH(T8]>S>$D&A"5"-A0`T3X0!W$`.(DK#209\S(!R)H0S^`
M<8>1IV,.)>C'(DJP"!NT0023>`8C^N&#O>>A'Y,(`AD:80XRF.,!<G@#="<Q
M#$8(009#_\C')<B2X'T07QUS8#?JV`<T.#^,$PPT,`!B,*M+D#I,4`#PHP43
M\`&Z,H=+`+M[\"ZYVPODH2;EN;-Q.I[!H1W`(4'0V#4-3(Z5&(AU8`1&681B
MB(QU"(9A@(8."B<[^Z6.2+1_((:!N`1$(`;9RY!^H`;YD8@>#+LV`(D*A#1J
M6`1R>`86K`$\B+P*!`9SN#5@"`:M(@9JH`7N4H<]:2L:RX2T8`,^F`1KN\*Q
M&((XF9(\8`0[&`:)P`1BF`0RP`0W08,?!!,AV)%)`,(\D`.EB[[#ZX<YF`0E
ML@,W(`<Y:(0^0(,;F(-I((8%P(0=802!X"Y&^+!)N`,VL`,\8/\]";LW7>"1
M'G0'-(@X1,B13$"#10BO-O"!OC.!@6.Z1;B'-C@S%.3%7G2,.:LF:3H@N!/&
MYK$+^>D=L&":@T#&-DN5=;`S\!@(?Q`,&LNGIN$P^%"'KS@G@GB&=-B'9Q"G
M>WB'@2"'8FB::BB&7S((2O&'2NF':J@&?T`)D=`R"9NS932'8M`E:C"''",&
M6MB:?`*&1:`&JJ"&(?3%A61(V#"<R8'(B/S`QVB5$U0--VO(C-1(#;1(LWA(
M!7F+`P'!`<*?C33)DT3)E%3)E63)EG3)EX3)F)3)F:3)FK3)F\3)G-3)G>3)
MGO3)G[2<!!I&D!1!H#3*HT3*<0K&.QO_P;3;!WU`._N02C+S':0YD/=HNZ@\
MH&@JH(.`RJ0$R\7!!YH0!I(`AELSM5.KE&!8)6"0E$KAGE>BI49KG[1QGX<@
MIGT(FM<A'@(:RK#$G+K9C0BBG:VT#*Q$'!(T')%TN^2)H+[\2\"\BWO8B4O0
M"E$"Q*APPZ3@H31JK1J!D;!2HB8B(:/H(3(((B[ZDBVJ+$1XDLPB!$*H+"0)
MDRYQ*B,)*R*)HK*JD2S"@T)8DC$:.T:X@ZF($T;"DZJH*:GPHJ$X(Y7B@Z2`
M(S.1BJG($Y7@$V"@'F`0%$,I%&!8B470/ZH@3D`DBILZ3NJDNTNZB>MA"8T"
M!IA("?C<)$PB_RA.&89'\116<H9*49^.J"5R:+1TV#*+6!^+6+2'(+0_4X>S
M^26Q`29E.AIEZH^F<;-GLM`V"Q#)Y%#L:*9F.J:Q*30&Y:5$.P==>A^+H`@#
MQ25<4A^-*!_Q026<V!.>J%&JP!/KZ1/LO(0]"J4\P4S,?(KC\I(JPH-INZ(E
MX2G9Y"G7/(HE@=)07)(D*9(<42VKTI(L$:LU\"'6PBTBBJ(MJ1$;>3VKFJNM
MHBLB\('WHI$\>(3DZJ)`D$WC`A.B<,XO01(B6I*Q<J&Q^JJO>I$9$52S,I(T
MP@,^F"$96@HB"J$VD(.QJA&MRJH;,%-SRRK0(H.P(M0\2*N\"LT<@?^1M`*M
MNKK4%PG-3ZV1+4FK'CH2(RHK-^C-0'TBQ_*1-'*J'0*3P"(*P7(N*OJK11VJ
MI_(2-P"3H7"N\]Q5XL0#.$&$(&HA\>M0O/`;H!&@XGB@J1Q&A5C,:'T,O1P>
MN)B/9:(/HAD/8Q(:<V4F.(NSIC$T0TNTAV`T1%NT>*6T%6VT2P-0CR"UC_BT
M\IF4]+F4C^"(4B,&2$&U53J)6T.E[W&43NFT?NW73"&)5+K/8J@%72")4^-7
MD*"45X-8N$38+BS8CN36TVG*KOP9!$%,`UI9Q$P@E[4;_YC*_RC,OU%9]H!,
MOB#9DN79G@7+G25)B<Q9HJ0,H)U(GT7:I%7_VJ5EVJ9UVJ>%VJB5VJFEVJJU
MVJO%VJS5VJWEVJ[UVJ\%V[`5V[$EV[(UV[.EC<+LRYH-6HOL&:.E2;A%V[G5
MD!(T01-D3`/"GZM,$+X-P;YM"[FEVZA5AZ`@SZ!@).L4)958%$P:%&+(3TAA
MI8T]-7_*-59JI7VZI5S"2W2`T/G9,V5:V<&%G+(0R;=#70!"F@=2D+<=(,&5
M3'7(436)"L.EDYHR$_04"N<Z+B1)K,2ZD:[:*DFEJPFL`1N8*[E"WA>H@<<:
M`B*(JZXZ512*$12"/=+B@3/8JJYJ7HD+$B)@7B&8JZ\B`RMEDB#:H27)H4-M
M*J>H4S`9(CY@KZ-@_P.5"L7E>HK,Q!.K`-)(Z(D=Y5'_59-)4"FML`J=L"3P
MQ"3'W23LF=B3<$N4:#57N\^$]1Y3TUQ2<=%0,]!I0(:0R&!_I,M<NLMV!;1U
M6%`3IHBT08>F,0>H@=!_.!H+[0=R/=EA9*8`$LHU(]T-$8A=3)KVB#-?*F$:
MJX@.W@@)^S00SC1*T==:@\M;FUC'[9.=N%A08HG*O`21,(E3J@E-&A3]^U$Z
M42F<.L[Q=-Q:$&,=%6/E7(1'D`KB5"G99*\HN5^D<`JD:!/F@BFNT"DO"<4=
M8D56K=Y`[1$A6`-83:W;2J-"98,IFI%'SM/0A+VL(@(BF)47D)5:L96ZDO^!
M`',L0\[-&T&A$[(KNI(KXY4!66G>L:(\,16K(F*#'3$KLVJKV0*2'JE>(S$A
M("+6)*DLY'(NW\*1()H1-!(20V6*I=BIHM`I1K`BQ1("/)C`K$)>K/JVK0I4
MU"J2L1*YJ-U0!!*(:]5+I1&>K)3*WE';H_U:MJ!0=-J'/<LS<7HS]ICGL(%A
M>GK719M7B:`G>OJE@(;00X.(21MA%C6'%2W"%:ZT2J.T@^9@]CE179*T(XYH
M]MG<N?0(B:"4BY"PC+@(`7W1I^MARCE!YIFF<^:;M.O*U%U;PUR[_A':D"SI
MFK9IQ8%=U%C*F^;IGO;IGP;JH!;JH2;JHC;JHT;_ZJ16ZJ5FZJ9>E9QVZJAN
MR)V6ZJJ6.TQP-WC(!/0(6JOVZFL"!@;`!!N8!!,`AJ\P!V#(L&E0!UH0)V*0
MAJFMCVT5S!MVW:_>R&D0`31`QP7H@1,H!O&5`48X`#M``XE;!!$8`K7!Z\9(
M6<%\N_^A'<$A3+5S#\!576*,II0U"\X66\R;`Q%`A!X8,4;`!#0H@1-[!OP:
M`JS.`WI^6B?$BB`-I9VP;??DE)'`8'[2Z'M%T%YZ5[&A"`>=FK'AF@DU)KKQ
M&ZB&6LZ6#-9E.PB2[MDIQF)TNZVT2@(!GG#]UK<[04S`OA\9,2$H`48X`>>:
MAA(`!B`$A@OX#N;FR4L0_RL7P5);+B)2'BK5FBQ/'9+^[F_:HF\6N=3B%=_C
ME15;L942N!59L8'T@E[O93EI*R(M$508@3U#GJVORF5#K1(M"BP[((0/4BFH
M*).A2%Q&\J+B7*X0ZJ*A<),R(0JIH`0=Y21=,)1B8."8D!ZIJ-&IT.+KT:29
MD&*XO%Q;$XE*<8;\[!Z$#88CCTN/E27UL26ZQ(B/7C2.Z&"0%E!%6V$3_@="
M\[-U<AHYNP=X<!JLR5!C*@^CH=#W@,KK)IU[P(,A$+=+N`=G``8>0020Z(<[
MJ#AH>!%N;-IB:@[Q((]S8IKR"-VT85=U0(<19:85OE=U(`=+2^*/R)3<QJ17
MX_\(9T`?3H\E?L44\=%Q6E@)[-R3K*"3ZC1MQ1TE!":E\?1QQ0VEKB@*I8`#
M)Y%2`BZN19@#S;PI.%DJI4`$WUK4*A%3L\K4WR)E-`+%*TJ2'/*@/,V#(0)3
M&"&"&/DJ3)8K&>@!&ZBKV<)2+/41Z74LT<JJT(HK&U#3&M!D%5%>;C>W(&$K
M'!'4W"I4(I(JST(1'[E4$\HK29[2REJJ.28*IQBCHU"WV*)>'PHBIC`*+A*3
M.29.8E^$,#&A&K@!'K"!']"J"T^#-%B#62;60@V3-(#6P"5&K.T;=NX-M>8-
M1K"S\,O6R`M#(`8+^F/K2Q"(#@.+2;`!*L2-2UB'KGC_#:)U"\8&CP=A1K<H
M)X-@^@[4F6DZCG'&RG)5\Z?9,^/6YU]ZL[.9FODY-$O#Z"R72Q'N\A<F<U\R
M0N">:'WJB(==0G/`\HPF%7T-"8@E!FA`AE@C!F00E4GI6&@@_`SN:+=MVZF]
MAZ^BAB?R!S>P@=>&D6+P`>K;A1+8O:*Z!\IO@P8AA'UH@V'0MCFP`7&JA@NX
M@W4X:W5PN7M0`(?+`UV(O#EX#0[S1W7("A,HOD401T)(ZV)X#U%\AA<@BR`,
MLVZ3MT78@$GH06*@#KKOAQIH!")4&X5@ZW/*X7YX!O,K"&*0`>P?B,4_LSG+
M#.I8!.X_&C9#`WGJQC,;W4-__X;O[X=+\(%S6J:G[PQ$F`9"*(:$ZT9*`(AB
M_0;VV[>/($&#_>XQ6G@08<&$!#,1(W@/V,"'$2%FA*B1(\B0(D>2+&GR),J4
M*E>R;.GR)<R8,F?2K#G0G`%B/FQLP%,"49L\&RZ)J"&BT(8:DS)=*$&D30T?
M<TI,*N&CR"(9C$0<?*8!$9$AA.[X6'BA:HT+7F=HN->O#243=_@,P7.!T0L;
M,C#Q0*-!!**!(@3^VR>DAH9+)824J(%FB`A"<^[(H.I#QJ4-<X"9\#$-X:(:
M,H")$-&&F@P3>`8^\R'"L^AG@F4,N9>H1IYI)1@ADC%ID@8;D]!0`]:FGSHT
MI-&40/^#Z04A3'S@G:;MKRHB8C6$4$MZYY*-.^J(!>['2,.D9R+0J&.,YQX;
M'\4*M`F]X=DD=:1K^$,SYR$Q0\RA3AX^3.(/&T,(,1`\>/PP33%HL+$/(T(T
MA(D/SBPRS"5MT/(,`-38-.)*'WE$(D<FTN1/1P/QTP\_+\:((HTUVG@CCCE2
M4Y8&/@R!B`__+!)6/R+D\6.$_I4PAQO*7<+&'<\4<0<:;2SH@SK]%%.6#<`(
M(81L_=1`S1"&X;%!&QJ(6(P-)<B0!R%Y@%E#/W,$)<0EBZ`Q4`G5+$0-`S9\
M5=8<F-1PQQR9,'8/A(B8Y@,Q)9R`54?&73"'#_<(@<8DT]S_,9`/BU2#AA#`
M3'+</B)0(P0B#4!&V30%"+&!G-64@`<>>2S2SSHUS,&="/](D.80!N+1Y1U$
M$/$,(YGTAH8-YM@PQQQHX"'$)/U48\,SCM+2!AHF`/,"&QK,\8P-E_C`!AJ7
M<-=&&W=`)4*V_2R"B`:,7(!'#4`5.-`T=O@`[A!ML/&3#(B$9T,-F;S0A@V8
M*!!FCA5;?#%$+[J(,<<=>_PQ3>;L.4>QQ-C@0PU;]E,EGC:PH51XA*@QR2)S
MY#&'#':@08L,=VPP$#%%;-6/#2;TDT^1B`P1CP^9T%OF0`6<Q\8B\4U")[QY
MU'`)(G,,5.`T7]K`2!N8R%`G(3X@_R+$(CZ40$QH9PQ!*H9LM`',.EG>\Q-@
M@7V)B:<#M3N-W=,`L^<]=.(QQP;RWL&&.@L@XE@>]XB@S@5E(2<5(COVHP`B
M+V!BAPBZ722#$/L0(\00)A3;CP]WY+8`"2Q.4I9Z_=Q>E@^FPC#)$*W=@<CA
MTU`+/+P8]9/'RV[DT0\;0A0#WT#`1!_4)<]$=4_H;$#OVX)W,&*#BB";?S[Z
MZ:N_/OLAW7,0,`(E_-DZ!V&"D3F8K*/E)/>8HXXYIF$.6JR#$)?H!WD$@AQ&
MW.$S1+!#/UBDBT5,[Q+J4%>]^H&W84R#&L0P%4:`08MB3,(<Q#C@0*82F-:@
M81K9BA`C2/^(GV<TYW9CP,/A@-&8O1WP'FA`@P\ND:TH7:9>U&@,&VA8`]EH
MJA_$$P(1V-"A?A0K#TZSP6ILL"=>"0$/BWC&$%86O754I4ZL"Y`/A+"N-Z$.
M#<YXG@\:TH]_;$H(OQ)")GS@#R'(J2Z(2)#VS,8#-ESK#FFXVT!DL`@C>8]5
M/EI0G6K0!C+,P09#6$0)V"`<&ZQ!"&U@1!CM`!P_M:^4ICPE*E.I2I50PRTT
M6ITKT^?*?"CD??]PRR7V-Y`L^8-%![D'.A"B#G6XQ1RZ[`<\]O$^?^!M(0NY
MA%ON(1NO5&0@_[BE/_[!FF#>PY74,,<<IX=`<]SC'\2X!XN>\0+_<%J3&EWY
MC#G\@8Y]/$-$]R#&9XBA#FH40QW_>,8])E&,AY@#&,\`8#_<68U+N&,@_L"$
M!8%(C%3A0434R,,ZJ#&-BA1C'9@0T2I#*M*1DK2DJ2Q?1UA$$I2"Y",N10A+
M82J1@Y3O(RI5*4TWTJ*=ZE0CP-A52!2BD!8]9*@(81%O4M32C?%4(C+5Z5,)
M0HO/!%2E)KTJ5K.JU:URE:LFBFGZP*K4J#H5JD3M*EK3JM:ULK6M*!*K6^,J
M5QS!=:YVO2M>\ZK7O:8/IWS]*V`#*]C!$E8DHNH'.:>1I<(RUB4R@DE=.?+8
MQE*VLH"-!P%8T(\2W*$$!Z0$-/;1#&1,_V,7\.3%/<BQ#W<<T[*$G=$^?&F0
M%QV$'_Z@;4:,6A"-Z?:IC\6M:X,K7+4>!!%;H`$Z0+`%"@0B#6@8P24LT-D2
ME``8(=B!&VH`#3<T)++#_2XJ7RI3FO(VIP8Y;T=ZZ]2<)H2]0V4O5-T;$?E&
ML"#N+>I\YWO?F6XDMOPM*GPU(MZ1P!>\:/U!&B!P"34(8PN7F$$_^``$.O1C
M06AP`P=NL(-+H.$&K36P7B_!!TL@PA",<$0B^B")1"3"$(EP1",H(0E+2*(2
ME[@Q*W@Q#%8@8QC(^#$QB/&,(3^C&L5P1C*>T8QG0./'1.Y@/:FAT6\*T!Q6
M7D?>_C=,>-SR'O_#[":8[Y$/?/32E^\;")AGZET0LYFQ\*-3)5J`ACH`(1!$
M(,8/Z+"&?=!)*C!`Q!KZT8`]K;G-63W()/@0B43PH1!]H(,<6`SI/LCA#2<N
M!+7FH`A%-"(1F6`Q)1S!B$6,>M2D1@0A$$$'.ZQZ<<YC%QO8]:4O*>A+/E)0
M&H7`ACSDJ@USP`,B\&`'/-P!5\,F)+%SQ<=<D0H--[/2#TD%+F?[9PT&H];P
M[H6(8&^[V_>:@[81(3Y$&>QQ[,H#O/QC,V%/Y@[%%C<CXHV(4W<[V,5^]^+R
MD(<J_;`-UF9>4)@WAVWC(=5X*(2I%T%J>1/B7O%>A+/J;>I,2"+&E+#_!"4N
M/HD;7X(5K-C%+H+!BV($8QC.0$;(>;$+9$!#Y,,81C"040QD-(,8T*#&,YPQ
M9"EW<!H^_WD`-4J.9DB#'.2`QC2D(0UM:`,:T)#&-+1!CJ)/P^A&%R`YK&S,
M=9PC'>E0Q]>__C]VI$/J2S>Z-LR1]:QKW1SI.$?7S7$.N:NCZV!/QSN^K@XL
M=YT>Z:#'.^CACGO0H_#XZ"8^#K\/?*#WO`JA!S[J08]Z))[QCL>'?>WK>)H*
MU;R+%VI(@''`?3Q"&(K($S&`<(>"[B-;F#`'(8B`D2`HT-"V!QE*%=++?>0#
MS+T'\S_V/LQAH@/+>U_'UJ>1-^.S%LM5%J#/_W$^C2$'N?K5+P;V@:%]CG,<
M&,0HAO8_J/WQDY_\NN"X)7ZS%-YX&QB\N1<A&"'$16#B-XSXC<+AG^IM#^\.
M=N"#ON4*\^2!',C!',B!&TR:&_R:'?Q:`:X:I='!&R3@&P1!&@"!$SA!&NS`
M#_!`!TY@$UC;K]W!(M@!(D0<(O`&^^V?L$&:'#P:&:R!&[A!$S0!#Y!!$P1!
M$Z1!$PC!&^#@#LH@`LH!';@!$18@$L[@!+Y!&OP`&3@!#]S`#?#`#LP`#.#`
M#>#`#^``%`9!!CH!&?Q0!J;!$SK!&C2!$S3!%-(`#?``#L``#,S`#+CA#9!!
M!][@#8;A&J0A&CJ!#O]FH!S"H1S.0`J@0`K`P"%VX`]D(1GP(!.N01I4F@R^
MP1J001@^X1IL(0_`0".@Q(!9U4"`1Z'=WE7M0ROE5D$<DRN=F3+YDJ=DB7]9
M1#^0@S:QHN-%D)D!E#+M#WKYS_O$%BTI4VP9Q#)U7E/A8E"=R%F1(C.658O@
M%.=M7C1V'C$B'CX(WN!!WCUD8^$-'S'1PRT-WN<=7N+M`^7=P^$-WCU('I@1
M4TEP7GK%8RV-8C.2E#DLP#K`PS,H!#7<0&I1@S^PPO[0PS2X!3Q\A@G8`'+0
ME#L<Q!#HA/+L`SNAF38A4VRQ04--PPE\A#K0B5F9A(FH`_%X37UE7AM\AH#_
M$<0P/,](K(,/^(F5,<)GD(3UK,,]X(%L3,,6J81&Z,,L*@]\)(P_%)H_Z&-Y
M])1330,M=),%9=XS8$)$N,.0L1-^Y=>`Z=0]8$)%.A5"`5@_%%EZ'80YB,A[
M980TH=.,J!0Y155*>EY&K"4\9EX]SF5:48,"`(,/$(%"]L,E7,`B7`"5$$'O
M:,`0\$`Q%`4P:(#";0<T7``9#(1B^L`+E``US(%I#$2O5%=5V``U+,(TN,8"
M'`0UB(:M+(8Z#`$17`(U?,4BQ,`E0(-@+M8O$`$>[`,>$,&G](,S-$`FF``1
M0"6[Z-(02!(]"<&G>,GW04HU3$,>4`PF,,(]S`$#_[A%&_B`G$!E`543`*D#
M0%T")E"%%AT4(W#G(K@2/4$3,P&#/YA#1Q4#_:@G`BG<UV"&(HT38@'4,X#3
M/;@38A6D0#S'-`1&,8B(.E2#>1:$6YQ0#51#'!W38D3$,SP&+41$.;"(EZ'B
M0)P#/2S$,2G3\IP-@^#7KT0$BQ`#&T"4`47$.B`")I!D2!#"8M670-4`1H!B
M3)E(&U`,26@,2/"H2?BHCY(5000I4SFC2!`I77Z7.L21]\A`3N;!)"P(NIE`
M)6V6H[3!:0(#`[3!">2!T1Q$#4S#$)C#$.2!!A#"!:S)!;`!,(C;I>B:$)C#
M";@%(DB.>E0#$=`"4/0,C?_2B@F8J1WLSSW(P##PP"2(P"7(P&<<$2W@40\@
M0@F(`"01`1#9P;2\`"/<BF]<@*)J0`W(T23(`+MTUD!LBAU0UR740`EH`#AM
MR58D*AK,`":HT0LHC1#T2!CU`R:\1KOX!5[TP`:@@:H000U51KW``#CYPSW,
M30D4PYJFT=M\R=8HP..L@51L`'ETUFAL@`T0P?ZP*,EXR20,Q1#D!3AA#J+X
M`R%D`AXHQT+`@`FT4`W@!AM\9CG00204A3K`P)SJJ@R\P&%J#B)0*3$0PCXT
MW`)PYB*8P"(0@@)<0F(*B#K8C`$@0O9H@`D0S@OX@"[-&\.@T+RBP0D,`838
MP!C_1%-UXH$YW$JJ>N9CJ-$DW`$UQ-XSF.@=<$\0?622[FQ(K4.M^D`^O,"B
M#H&BW`,#(,()M`$1],,+9,(DV(`:?2<FD&`/U%<-Z$1[L('HL`=R8!(:1(6Y
M*$AY&DT_3`,A;``A+(B=^``A'`HC.,,%%`,C$,,=1$S9T@E0+.W5(E;*L(&F
MJ!&P#<00K$,U;(>]:,#(M($"X.T8E$<>0*6!""RJ&8ZP0@4[^<!EH`$A_!"9
M4$/7I!$BF(.HUH403`.WH,$"W($0_(,)W(,/^(4F18NI#,0Z%80.V0L9'(</
MM-[<K,R1O(6P#L=HUD#K-8:8[(IVB,`)-`D:>*MGW($"_PD!AD`/(_P*1JR#
M"%28"'B-#/Q`'S``&?1!"+A!"13"F/))S8J%'.W$+WC)LE:OR?B`!@`#)E0)
M\Q"""/C#"^`!&Q!"L=#"[<@`,:!!8/@#$:@1+7@D'\$`(<!+8RC`A-XC-?#`
M5%!#YER`EQ(#8,@`VV;.K@H!!F=.)O`L"9<4@IC#'&R-0^'!)`"#8:R!`>T*
M(S2J?"#".1A*<Z[&05`+)JA#(="M%MU$5,C+85S"W![&TMH+PR#"GB!"'A"!
M&YS!\/@#O9)-#V3+/=B`UA@*[,C&.I0`)K#!.G"*5!#"0-S`O-8OQ)A,?#"Q
MM>B,!@P$AMS!$&#"7KK+2=)""O\#14-I;QY4UZ&D#3%4;QHQ`@W]#R.@@3HM
M"9RJ0^M"1PU@PB*T@1/+$;J)+I`$2%"("3'83`VT!UF8`V"<@+I$R!!8SW!6
M&%3VPP(\<6IZ$IM00XX.A%+4P#J,#:9<[PGLT;3H;RTD@!T,`"^@@"7P`3#X
M8R)Y$!"`6P292@GH"3J(Q1Q\,3'@@0C@P1K\FAMT5A870AXHC6<0PPLL"+$)
M#K9TY$"P084\@[M@:G,B5@DLCW_\@V(N0KON@WQ$1?U!K0G8P1W0;U24L$"3
M5%5"A%4]A+(BQ#KX53P>S33XTBSZR3Y,@T8$$$(\`U75UY`IDUNL`S"XQ0A%
MA#IXYC[_9,E"%P0UG(,Z^,/^")$KF</&(59VE"T>*-\Y00@;@)2]M(&5A0E#
MN+#/M<9J``Q&5\-X3`,?=%0'$0/.7<1-Y"<F:$=VT((_T$+KW0,F84+BY$&,
MXL$'F/$S]$S^]`.\KD:FOMX!B>TZ;`8PH`;D[`HPL-,P4,/YK4.0(4)^O-Y`
M+,(Z9`5Q_!2!,@#;+FO/W,,8Z*265"%YJ!1X5-<B3&@_J*X/:(\DD4;P6*8,
MC&8>#`,>&(P);,`TG`&V$(,)("H>7(<<%5MY#@&+Z-"87,(<C(\,\*(&G$"I
M/(\0:%&+CK$LL\%PE$`>,,+K1L@+R`![#C1RGY)&@")!0+2*_]#C6S$CEH;$
M4$8W1*R##)AGC"($/:C(,''$6MZ#+EUH0NF-6WAH_2R$*R%?5%6W>18D@N8#
M`3F4#%!U1-S#)5#E*I8M)AQ$]I0M(\16,"4W@1?X2HT53['458I$3;E$@1UC
M0V/EC1JI,E(X4B+$?BX5@94(3S8X654W0E1305?X1E0W<QLXBJ>XBN,>^BSX
M@:\XC,>XC,\XC=>XC=\XQT"W3.@X1^B#3R+$C_^XQ_BDC_=#D!/Y0!0YCB\Y
MD].$=_5DA$,XB5LX7ZE7C?!XDV>YEK>9CZ=D1RAYD0LYD$-$F!NYDHN$F(/$
MCPO8/A!YFG/XEL<YDQO.">V"]HU0_/]@7Y!1W_<%&?9%M>@!@XUI'_@5`RWD
M.?@)F935T\^M@P!]PS>8PS=@F=8I7T;5DS?\7)6%@]9AF?$=7]X,TRT%GY=Y
M6:CG8_&%`SJL>CP,7I?=PSR,V3PD7C[H`^?YN(_/0Z[/`Z_/`SS$`Z[G>K"#
MN9GO0SP8!#'=`SR@0SRL^K*W`SQ$.SK`0Z_G@[7'PYCI0ZUK.Z_'PZ_'@Z]3
M.[7WNCZ`NZZ_N9RGNXP[I`)`10WHQ<FTB0Q4AEZX2:26!@E\P`6P``E<``AD
M0`:(@`9D0`6,@`9X0`6`P+]7P`5D``4P`,%O0`9<``5(``54O`1,P`5LO,5?
M_,-?P`9LP`3_3(`&:'P1+,`"%,$%J+S*9X#&;WP1J/P"7,#,T_P",,#&S[P'
M`/P'`/P)?(`&;(`&#+T'B,`'>,`)G(`'@(#RED;#Y[L$+/W25T#"5\#2DP`)
ME``()#S6DP`(E``+R$#89\`*E$!3F(`&E("^N[P$4+P&7,#.-_S.#[P'>(`&
M8,#!_WL&@`#"RSW"__O.9\`'\/W.?\#1,_T)9+>ZL_CB5SD5\8%*#'N8NWF;
MN_FPTQ*1YX.O>WNT+_NOKX,[H,,YI/JRYX.WUWJT][&7#1\ZA(.J<WJE3T,Y
M])S/!5``30,\K(.WDQ/R(=^559WMFT/-UJSU$4,`"<,R?,,T+`,S_WB#-TC9
MHN/<SA6_]E4#/Q&#S#$U1O=^[U]9V_T<->C<]%7#SNV<\EF9`(6#SR&?-Z#_
M6&K4)!0!EC=^3.B65^ILNL__QQS$#3S/>4<00.P3V&]?OW[Z"AH\*%!?0X/[
M&NH[J)!B05TU@%%;1U%A0W,4)1J$]\P@M6H3$;796)&C0G\).:K[:+#:1V3W
M**[#V>^?N7O$8'*\A*>CP9`M@W*LQJAE4XY'G4:5VI):D:13L6;5NI5K5Z]?
MP88-NXZ(CR'4*`*;^;"?6K%OX<:5.Y>K/X-VZ>;%6K#&'8)ZHQ*S`6R(+G/$
M@*DK1JPML6<FGMU+]^W7NDO]`LU))^S9"_^#<X3<D?'OWCIUQ-3]FV;N&;U[
MQ?8)&;8.6C]RTOJMFV,'G=T-1`$0._=1'9Y@.B\-F9/)7^1[/@NV02.DC;][
MZNY5\Z=NVC^2ZDBB@8V6N\%B)="PF4-MVK-]JZ?IC,]6:]*"5YO:);8`<'__
M_P$,L*!B-%B'$2+V0>2.>S:8HQ]&,.F'FDDN`*:8G0+,4,,-FS+'!R(F><8'
M(=;B,"Z^_,*/+HDD0H<%--91!)$7-'!#A!(FT6("0&I8`9DY:*#A#@F&$(*8
M$S)0AP>TAL#.G"&&80.-$GS`0P,[-FA#"`/F>.&,&C30!880+K'A@CG8L.L%
M(8`Q`!,3?%CD!1G_%AFB!D1J8&.2.T1@@Q`%AN"I!G_P*4:(:6H@!(8\T#"A
M44:$:+`$-FHH@9A*)^F'&`T6(::(-FPH`9@.,BA""#08*`&O#`MZAC\388U5
MUOZ`(:(??T181`@AB,BU#1$XE0&-!0Q=:=9CD?VJF#;4D:$&8M!P,-FO"K+!
M+P[OF28/'QC)`QA@:F"$F#L8.>&.2H9X1LMBYBQA"T2'\&<(6OH1PA]$>$AW
MCCOLJ*&-8JJ1080\+D6$C05*2"&$$4Q8I!A$%,*#.A_8..&%#8J9!),V3K`C
M/3Q*T`T/8H389YU`V9#!!W-$@-2'2\Q!Q`8?["!&!(V%*$$#-!9!@R!@_TQH
M`Y%GX$`!#D0">02-&1!EC,/]IHU:ZJG[H<6&?NZIX1)&3Y"!&&=]T+*?-H"Y
ME>JSI4Y("#9L6&>20%5$6Z%JKV6UG_.J\6$.1-#(8X@[1/2ARCRT0,2LO-4@
MQ`=@&.%@DL7[00-P&81@I(88T'@ACV=$&$*&.9Z1(0]>^>`A"#IX8`,/.4CR
MAY`V2KACB#;8*`$1.W;5&XUH!Y,2&#3^Z4<&6HIAP`=:-"AA#,;,.6&1=<RA
M1H-IGO,A#W^F4:<?@]71H`T66$!!C43B>$0(&H2Q@:2G7Y7;_??U>J8(/!4L
MP0T;YI"..F!>8$0#8/"@/60EQ#Y-*2!;[C,WH_\0)(%_H8\"6>+`"!*0(Q2\
M2MQ@4A`\U*`?-8B9#R080;D5)`:$B$H&,S@W_.R#'Q!,"!YR18UA"$$!;""&
M.8"Q+D1<0@B(F(0YSJ.N3##*'"_`B3I\((.,:(X1-K`#)M9AAQ+@P1(Q0P0?
M\``$<[2A!MJ2P1!_!HP=$F-VTYC9#-$PB44L0A?#T$`F@/&,2>"D,SZ@ALP(
M@0@B#(,]0B#$/30&HV\-P1SK<(LY*O4,1``!"&BXQ#`H80M%T$`#1($)5)("
ME:AHLB50@]\G02F6?3"B#9/8#B*&9HY)J",/A-@',=B`"'.L08`$68=IU)%+
M76+G'KWTY4L:^,!0#A/_&`'P`2(6<8/!#+,I>0HAAZ8A@Q<($(,&&9<U(;8J
MJ<0-*15L"H:$Z<`+FNTOV#'(=<ZYCKB%I"!SV`@GJ965@GB2F?6TIUX068,:
M[&H((]K=KDYUJG\.X9\"1<,:=H<&@@JA2$,@@UEFY@-]"JX&-M!G#<Q2I#2T
M(0]KR`,;5'<'/.1QC8A@A$E1>5)&+.*D(C5I'EU*")8B$Y4LG<0E,'%33%P"
M&),`!D\MI(MB!'42.N7I4"\!U)]BXEL6(L9BD/$,8E3C&5*M:E6G08VJ7F(1
M$;H$8];Q#&A4HQA7O:I6J9'6K$Z#K=,@ASG@6LBXFD,FM\P>]+A32/BTE:UO
M_X7>.H:3RW6@0Y?W&,C:O#F)-F`"KG=<4#^*`XWLV6$2U>#./:K*4F_D`SQX
MN`0RT!`9:LS!,9"%95G700USI$&KJ75&/ZH!.H*H<1W(M,LZ\*"6;.7C&?&H
M!![,<8[XT/5AST`&(Z:!B4Q``Q'3($@U)M$>?WQ$,ON@J_;,@8EBF&,[]X!&
M,;!3U5SVHZH*22MVL`./]T"Q']1#1S[600Q;N,,Q]XBC1.YQCGU@9QF3J<4S
MW$&+2^CW-#^]Y0]]\@UX8,T<P0!G/,#9%&)<X)X5MG`(*2C!:G:3(/[(!T%\
M&>+KZ/*6<=TK>[*J5;-*5<555>LSG.'B%3^C&L28JO^%BC%48`CX6SB=!"4P
ML<:<JE%C1;T$\7[:U*0J^:='IL4D&)$)EC)BI2:]PQT4<0=$C!01A&#$'1:A
MQB%#.<Q0SH0:";$^CL#R#E+*PT?7T`;IN&%U>4"EEN\`4Y%>><O[VO,<UH"'
M_,EA;7,@J`_0L%$V"&%?@L[#'![M!C2I)Y8OZ:"#D@*,"Y`2#VS@@!MP,@01
M%$-B>)@$>@@!C`U@`M&D)40/X@"$&]C0<#;`1!X^X@,3W$$\;1:HNH@"FB'T
MT@1$H%0F<*(E@WE(&")X!@L^M\%3`V,.&IA$#?*`"3JEK$G]((*QTW.93'"`
M<[J($!HVL`@?_&,296'#(MK_\`(BR&`2Z]#`,SZB1U[SD!HF8/40>C"-$Z##
MVDKKP#00,80\5)0Q;E@`'1@!@Q9LH1(="`07B#"#&TRC9R=@-!IJH`8A*`TM
MKY,!X"(SC4<@@K?.]68Q*'QAF<^<YC6'"S=!F<`V$*4E]QC"-.#$Q3S@A!IW
MF`0>8#"-2=C!+)A@P)G%6/0V"&D+0G@&(Y9UB4D4HQ^72/7L]M:/T>EF$?U8
MQ#WN0(U[[%P./E@0VK/[Q[T=@!%:$`(MB+`"16A!"]%8A#G6I@L;3$*6DT#&
MV/2$)X-H00*76$$.RM8&.K7!O@D@!C4`H06"B@`89.F'3\1S]6=X5@)<:,,0
M?&B`_UK)H!+?"$0AD4$Q-#@W#RA@`0WJL`5!Z,,.RW"#,!;A!FHL@AI0W)W9
M_:4%<_QCI3801!Q(`(@>R(`%E;"!TUK".9MOG_O=US`$%1B4%7JS(N)OX$!<
M.$$1.N6`WS_AAE#T3`\!@Q"TV)5;\L`'R;5A#HBNA@A\0+'00(P@30L600M(
M0%P6`1%`@Q'*YLIJ8`X0C@T*X<T8`4W.`0_P)+_V)FP2HQ_BS`?D`!%V132T
M(!#0@`O80`*$00*(`72&X!<F`0W,X=%4PN<4Y!+8(#>T@`M`(!!R(%/Z9AI6
M9A$D`!'B(`,()Q`4@/A,0*OZ85^H@Q'6@`?:H`560!!J`/\(XJ`$U$`+V.`;
MG"`8Z$]TT(`<ZF4"(($"=.`1-"`:MJ`6MD`8^N`1>H8:&($:IH,8MD`-*N$`
MGB//\,`)M(`!M.`1%N`#!"$&`DC\[D8#O"\2)7$2*?%L"D)8ODGMU&$=IN$2
M^.`CI@%P?&(1.N\]3N(9U.(?YH"J7@,/U*`8YD`'UP'7R(L0;,P<IH$8<(T:
M@&N-9H@Q_.'-1&0.Z$@(BH$:%H<D=FH?)!`>V``>:*$<+@$>2+!GLHU."((-
M?.`9IJ%LIH'KZ@`8O($DRB2/`G`9\""T#$5/;*!.KJ\?S@$-\&`:T"`3B,$?
MA"$0^@$0*J$?*F$13N,;@.$>A,#_IZ@AQS1%$=:A$AYA"!8!'Z)++8`!'="`
M*5@!AXIA"'P*'1#!'>YA#NID$>``#6@!^#+&(3.E)8`!$BNQ)5WR)6%2+T[E
MF<("_<BO+;3''Y`!_>")_2HHA<X)@0JBA3[L_6[R)A,"(3B,_<CA/AIH)WH2
M))P"DVZ2&HH2_'Q2U6)R*[FR*[V2)68R^\2#&NRB(.(CM2B"&UL"+X#!!]#P
MG-8G*+2I5;`#*(0))YZGF];!'?H!'MBC)?@A*>[AM?H!S#B"Q:P#-9Q&[3@"
M>FR#K0Z#&(H*O.[!'>A!&M*A&9Z!^/I*O]IC$5#Q>9)K+]TA&LZ!$EI!'_`!
M'>*#'#8"_Q??`:[.H1_<@1KV08UBQC'<(!CZ@1"J03Z*X0Z@ZQ`BS"!6\BN1
M,SF5T_N(H`V^;ULF@5/NH!@6(5$N`2-RB]?:`!HVQV`081_LXD;P4%R`88TJ
M:SUDJ1^0`0^&3ZI\0":<$Q,0@1KR@!K:@!)RPP"(8:7"S!.GP88L`9D@8Q&<
M@8T4R;`\:QCL8!K(P&?P0.&^Q:>*P5SN[1Y,H!@&T$)Z:D*H08Q\AF]D``\N
M``\H1VNNPQR"X!S(86V@P2=JH!!Z*3V^9E=D@`QJ(!,:00A2H`9@@`[&I@$8
M@0W*Q@W>C=XBH>M$I09F)P]X@`/60`@0"@U.@!K89EXP:@=5DO\EEW-+N;1+
MX:<@K.>9GL$-$*'8YF`!GH$'%(#^;&!F$&$!S*4`;``/!.<OVI+51$`(."!/
M/&<1;$`&2&(1!F8-VI$-9,*5H)0-1``-$*TM-L`.1,`.8.!OZ*`&&H$1Y,`$
M;,!.-FA-,J`$;@4&."`-8*`&QH`H/"@*B>`".`#D;L"#U*$&]%!PI(D(%*`$
M=`83;*`TVE0&W$`^,50CK>,"UH`-\N!F$"$8G,`)R``12D`&,*%2Z(\-R,`$
M8@?:4@`_T8`#?J`$G$L$6.`19N`';"%R-B`3L*U.["1/.`@32B`-&`$-;""/
M_L%G6.(XO31?]75?905,G;,E#$VB1L3_!PCAV_CF91@J=VS`6Q@AW;!CYVI@
M`]R.H1#!;QA0;_J!#2Z`8(9`&V_)CJ:C#4Q@"##!0=8@$6S@!U!/`^P,!A9!
M#IH`!E!@#5!@1O#`#HA``PK)!$)`$.R@`WQ@#?I!#@1M#OA``U)`F?3))V)'
M""X!#6XU#Q0`3UX`#8A@(T1'!+H,0M@$#;9#H@CJ>7P@!=[`"1)!U"9!&,(E
MC=R@`7AA%YK@`GS`L(:V!!JA`=1AAA`A!5B!`QPL3DJ@9#!A!]&`#X0@#W($
M&!B`&,8`CM"@9)\)$S:`)OFU<BWW<FO2V_*@*=:!#J*GI^YA$88+$4["'/#`
M-,@!$2ZD/#'!_[DRTFW`*[7H:A$JA+'N9AYQL6015'7G,P]6XQF:@[P0@1@N
M@1&&(1.V00Z0X1(*`1H8@;DN[QDB`0]ZB0XF0;+(B.O404^FP1UNBO`>AC%^
MAQJ@@19HP1+<H*R*(0]XC2"VJQBR"JZVBQBNXZLX;@@2`1BDP1G`)4`'K_/F
MH-.@0;@J`1/08IXFP1T&DAOWX?6D`1WN`2U`\_.<BS'P+0\N8R"#,\CFH$3^
MXA*T%'-%>(1)>)LZ:'-Q;BG#HA@809M,9/SBPC$Y)(6+8BY`N(1Q.(=S6'2:
M`AEY2D0081B22QU4%PV$1AW*<PB"X=K*YF3"C!IN"!%8Z5`4`XG58?]P^2!O
M)-,&IL$?%N&5=N$%&%`&Z(H0QD$[R@88Z'$2B*$]R"$>%R$8VN`2]($.,F%[
M#J4)Y*`MH$$:XF,8#"(3AJ`8HC%C<*UX+R^MI.$TUL$9%.09UB&6S&$.N&Z4
M,L4<M$P@;JH@.)(1X,J^)+@-<.,ZJ$$76-.YPNI6L&,8T(&!J-(GU\^;,$$$
M=+B6;7E?^<*2%(A1!3D`@4%11V8!<FH(TF4(-(`0AF!F/F(-=B@`'<D`=F&*
MWNT"U($!4"D/%B$/["!6I5@=#.`9FE,(J*$$VN`.=N$"BH$X'31H^8`%;B`.
MV-AV)F`+M@`.V(#_T``1,C4(_/0.UF`&,,'_7OM"!&"`C*+E6;5Q$1KA#BQ@
M%VR`!_"`#Q[`'/9A8#P&!L!#`W:0;[A.=N:QZVY`$5#@>6KH'C2@N:+02"Y`
M&&B@"?KA!W90".!`$48`':)2+F:9<F]YIWGZ)2]16C@"&.Y@#GA`"'IST6R@
M86TH?\CA5_I$\LJ&1&3F$BKV`OIE`70%8RHE8[1E&T<$KH2E!B"U6]Q!I$Y@
MCIFQ'T`F@DD`"##@J4X`#[0``]Q@"Q2C`(C!$GY@!&R@&$9@".A@!E#@6FJ@
M;])%&Z$URVR-%\@``=9@#3!@28RZ,"_!#?JA$9!!'?*Y'R;!&,?&N7!"&$@@
M#>[@$>[A`?Q"`\ZB_Q^&@2A\(!U&H`GJX`86=!@6H1)R8!D"9!).H*=]^[=]
M6GCLX)GXI@9&2@BLIQK6I,VH[1EVAQ"&(0_<8`#QN"Q.A0W*1`A^P09ZR`0R
M00C6J!C4@QHJASWF(&BXZ!)*8`X`[0YVAHRHM"\4X0>$@0.&`1B$%@[JH`[Z
M@`WL0$ORX`+(H!!XP`V"8,`YX.PZB'YK@`[4`W<JUHG*%.2$@`Y@X!DX2*TO
M00Z8@AZ"[%EX#1C2@?_8N.OB(!#BP+\[1],\N;T008R>80N(X`,"H0D001KL
MX!GJ@`]N^BU::!)HF8:!>\B)?)@NL6YRPI.UAQ3OX1\X$6N>8Q]&AB!DPO_4
ML"86M^<2M$<FVL)U?6(3LT5(?Z>)Z:H&\4`^5V,?J.$2AFH2U*X.'L$=_+(T
M/@(:6#,=4(FSY6`UW.%"Z&&`S8$<Z.`]"F)PH^<?'N:/O.P9"F47S@$U`%E"
M<#$1Z($<R.'=3N/=\(T-&&$3TV$U*@%2MNC*MA%KX",;U@$>@F$-2&(=D,$6
MYB`:^+(_"N+4BOS6<=W""B)V=!J6YT+(N8*=N$(P]X(K9#@K>MPH%\@_"B(3
M@CS7+PP\H?V6"T*,BWTK'-&$?9TEVB^<EA+8O2G#AOV!5.3\M-U$%@%4P7W:
MTR;\8KG7V1TY2X`I7)C(T>F<"`A#@N<N%LP@_F'_W7W=)K6I.`W([-0]WNT)
M$YQ6,;""X!$>.4T`8MA='?#B.13B'NS"'[8#Q):/P6SS+?9K+4J#('JB++-'
M*VS]X9EI%S@`&$J`I3[O&4A#M4QK'_ZOE_8!X['#NJ!<Y5VR($R`*:9]$PMB
MNC8B6\BR']`!D@UB&G1A(]3A+]\"LUP.>[3'NMSC5JBAEJ;B$F+.YT$)&6:`
M#YZA&=B`731`"$+E!)QA#O1I$0P`WM2!.H29"$J`%A:0G,`^$L-3Z*'=TOQ=
M(=2AW_<++YP\(1R^*ZRKXE?"9'9B'_I]*@:$EO<>E.@QXOOO$O)&!G"K#73!
M#BZ`%LAF;HE`(R?!`-`-_]XKO^9.@"D`?O6E9E-@_WWX(`CZP0Y^X*.0R7/\
M`30&+UB*H0;4868RYF8,U5C^`OV<4OW"*=N5??9_O1]RA=UOJ2ZX"RXV'BQ,
M0RJ0!_KEYA[6H`98YX=^A0<6P1_*$P]&QQP&$+GW92!W13XSY?6!6\B[W?D9
MJ."5'X&27\-@`O`!8E^_?@)/+!J(,*'"A0P;.GP(,:+$B10I[O-G[I[%:1HK
M,CP'K:/'?L^H-10X:</(E2Q;NGP),Z9,B).&U`!&<*`_C0()YDMX;UU"=7<0
MX3%ZQ\Z=I4N/(F+T=!*C29@F7<*$Z=(E8)=V`:,%+&PQ8,6(/2-F]FRQ9VQ+
M$O\;JQ9M6[;4V$*;AA>ON;U\S:U3!UC=.7/G[MU39V[:WG5^R4TCE]@OX;_K
M*@-.!]CPOWN;[\$SK.Y?OGT7_?DC;?C>1=6F3_?,.3.V1'_]1$R2C3NW[HC[
M%+^.:,XD3'/.\+$L^1"3AMW,FSM_CKOG3VK3$E[LQT\@:=@Y7]\+&U8K5ZU:
ML98?2^M2L6#C=='"!,Q\UDGT%TU:M`A1)JF(GO9GA`<>;N`QQQIMY#%'&VC<
MX913C,Q!R!US+(444GDP.$<>:TR8!QL^H(&&$$,,X4.)([91PQAG"`$B&@J"
MJ"`;;+C(HHMMV%1"#6@,(8,,-NA@0X]#$/&A$$:N6&/_B$:VR"23;-S(HI$^
MU%"##T*46**(,![881X7SH''A1A"Z"6-+I:)1H9HV)$''IGD=,)MOT%'9YUV
M>C0G1+^I]A`P(MP):*""#DIHH3+ER=!HANVTSSWN@!888/^H\U=0ZJ1V3SZ8
M_C-II'XQEIAB>BD6&:E[F2I97Z$&-PTU=3G3EEG(5/-,67(!4U<Q=5'7DP:W
M&0ILL,(^)%`Q?PZ+;++*MJ0=0K\]>Q)WK_4TK77=#=3L=MQAZ^QSB"X[*`>8
M@$MNN0C=HXU`]YBC#K;K:(214/VL2UL_U/6YW+?F[LMOO_[^2R>B<^K+D*_;
M`HPPG>8\X\Z\9@UD#C'M[D/6_T#K`(,.0<1D(M)"DRR7<,@BCTQRR;EM,*[)
M*L>&&$+F--R/.M/T9$[&_?BC3D_4$(,H;9@<NW+00@]-=+\:T%)TTL`"4\+!
M2C\-==12NR30!KI,C35S`ET"=-9>?PVVU!<4$_:@`@/5<;*7-$UPV6Z_#3>Y
M%R`=-W3[F///0),.M&Y',K==Z"4RU$UXX88'>P%.@!\>T^+)"H0)VXQ/3GGE
M,U5-C.6'KZUYYYY_#M'<H`.Z$TN'Y09YTZ.OSGKE&^#4ND5I4[1NNRO=\\SL
M,DUB0NR^_UZV0$1<`CQOCB]TM^X2)89Z/[P[77STTJLL4`V_3@_U)))CSWWW
M"0LD`__QWL=VO'7E>Z0]]..OS_ZP-8Q[?OLRJ>-,.KIE,KC\^N]OJ`\I[_^:
MTNFM(^ZPW4O($0P#7JX?BWB!^O@'P0C*IGK_TY]WZK6/G^A$>1ZAAP)ELP@;
M/%""P0K.O,S!+=CHBUHD?%KUQ+<_?>@C(C-<ED`8(<(6@NL9)1#!$(K!AF[I
M!"'3@%W\="@R\,'N;4?$#C_X82TH8HM:,I2'<?!A#5EPHX8(T0<XN,B2?1@P
M'?3`5CIZPJ=YB<0P#T&$`YN(Q.8@X@?]@`\FIJ$@8#"B#7>X!R+8$`Q&B,`L
M_^`*&Z@QB3OX@QCRBB/U^B&#)6;MB=HZB4"DF!!^V,-9A\'_!SKJ]8UM=",4
M?G`%*D[I"EQ@HQ_H^(,G7/'%A,Q#&7"$F#;JT0]Z-$,;`Z$'-(2R#\8,)!\9
M(<C.&@)%1(BPEHZ<8,R&(`)$`$,(-5@$$=`@`F"8(!-W0(,&,M&&`#W#!B=`
M`QMD8`(A4*.1S329#13G-4SRYHGQ8,<[SJ$-2@Z$':H(12A,(8Z!0"(4HIC%
M*&(1BU2(`J';Z$<Z-!&+7%A#'@GY1C1@D@YR#`0?T$!A/\PA#8'X8QJV2XRZ
M=!4M98ZPG7;*@TE*X`,VV&`=F;A2/](TA#R4X#Z(N`,U;+(/*K$!$2P-VCM7
MZJ]F200?X,#&8,XQIVNXXABDT8<R__S@3U3`3"#.6(5"4R&.&;8"%JE8A41S
M$0M9I.(4W>!'.J8@"UGDXAH5S<9N*JD0[SA$((2H`5*+^IQ%E`!$`,($&DQ`
M!B'THPUL.($;:G`)'TS"!C$=PCH,FP>R>/2O>E(JMZC%PA1J:SO9<A9IM$,;
MT*H0@RP<;6M?.T4AMM9:VPKM;`-(V[R"<;:RQ9,04^BT%TCR<4]$'FF*^Q!\
MW.,=@"%(3_BQ#E2$(A760$4W<J(/?)2R%_;KQS%2`8M8K((;";$&++QJBNOV
MP[RK,(4M7%&*5*1B#Y]8A2;U((KX6J.&^K`BN?#@5V8"5B;FN$3._-$?$2Q"
M(^O81S$P<?\/?P!#'?%9%TH.\HR\[>0PE*(492SS%TD=QA^:,HRF3)./T]PL
M(?4:,&Z.2B[D,F2&R'6'-5KQ"E/Z4P^E*"5!])%!@6R#NOT0ARNLX<1XH*(?
M^'B'/:!HC>FF@JZI184I4A$*3>!B(*TPA2ENT0]NC$(4G>"$)E9!FE#4MQWS
MV,<,\;&-=]RCN\,2R!V6Z6)A%0,/U\MM7A<R#1F!R$H^&,*5J$2$&B1:!E5*
M-)6&Y.@A&2E*:,@#B`P$(C:PJ`UI4%`;VD`$:D[)2C4@D9$,72/&/DD.79K#
MA,!$H?X@8A&$.$I3>IH'7!-B0GBX`R$((>O\+"(355E$5K*B%:O_D&<LQ.#*
M),)"'_*8ASQ<`0]9BE$-N<RE)&PQ2UFJ;>VQ#*-6W3Y+6UQ5DE:)BB_4*,8T
MO,T676W;+"@$7^:$]>;G.NL=KT!%CEWA!V7(8Q]2=`451#$*4&AB%*L@JRQ<
M@0]XV`\5Q]B&*T+A"G588[[7P(<[\H$*<40C'?:PAS^LL0E1B`(5K_'%*$K1
MB2ZX8B"V"(,I<#&/;*QB%=;H^3MHLX<PK&(>Z&A'/_*1#VP8W3C*`G">$38P
MZ]0KM<XE;:,P=9C.F*91.$,'ISQ,J53MA3IXV56LT(+V9HLEW,$82S&*<8E:
MQ`<\\*%/5:I2GT4P8N^%0$2$).1J`K$A_TQY@,JLJX*(^D@ED;/.#U3VKI2>
M]IH/MI[#4/&0"`#)NJ=3L<]][I.)O1N^I[M&D*ME]&DW6+I->&B#'`@!%0H-
M/D!XL,.K9Z0@4YO:!T2R`:KS<!T9/`/?XK!&+*QQC'<DQ!E96((9C!"%4XBB
MK*\XQT!<885<8%D3H#"%**1/A6WD0Q^ML((H7F&&*XQB%IO@A"?\0-%]Z&$5
M?C@&ES<Q"DZ(P@_*'P@JQEQFJ3`0VM`%H5`*\&`[EY03I:!_K^`+KA`/^H`.
MW&`-Z!!63><#G/5TWB)@_3`-M$$,'J5BZ_1G"3$7Z]!B)2@:&T@UD#1\P((/
MMW!EWO=RRH`=8?\6`4L0!=#G?IX@"E`0"M=W!"I7!5)`!>X'!E=`!<S0#_I@
M!>:7A$8(!5AP!9\P!=;7#WN@"3)W?530"5?0"9\04`+A!SZ(<*%@'-)@<ZD`
M1M?2"J+@"5(64/T0#ZW@"JL0#\A"&W,08"RH,A>@6)%T#YG3!K.6.<)!4OW0
M8`3!!@JP`#YP`B\X+PKQ$WA`-E%W,W,@$G-"&]/`"("F"Y?P*XN`A;6U$.MP
M$!;A,O7&$'/R#.P41L#5$PMF+=2`"`6$"!TA$(EA1,RR$,('+/I@#7M@"K,P
M"V06AK>0'>>0!$=@!$;0":+0!6`0!EA`!49W"T8`!F!`A53@A51@C73_-0])
M4`5Z4`55X`K=T`M54(6KX%^AX`58(`H#D0U4``9BP`E4`&90]`>AX`F:0`6?
M8!S?4("M,`]YJ!!0YGVI8`JP8`W&(0^J$`NX`%4Q\0\IV(K'@P=$X(<K(P(,
M<`_^XP,*]@(B(`3`D`<;D`>3(`(V,`U"@$*T$4[]P`$:\`+FT$!Y@!!S$#YW
M``QM(`-"H#V#Q#1",`P`,&OW@`>+D$V"E3)M4`#JH%,>E0<7P)1L,`V+8`Z(
M(`0O^`Q"T`;W$%F8H`Y"@`=;F0[AM`S@!`SD$""7<`>YDP?$,PEXL`[8!#%2
MX8D4]@_F``_$@`CJ8`)V,(E:T0_`D(LX^1;/_V`.$'8/F/`,^/`,P"`49^&!
MSU`=C5D"&G$IC+$/F(`(-2!(?&`2`C%8(G`)0C$-M$`MZY`[)$$VZL"8]V(.
MPS40P&@HX'"'H@`+I.";H``&4-`PXI`$\0@%<9B/2A@%MM`/T)`$81`&WE@&
MH;!SJQ`+[<*,5*`)4#!SM`$-4]`)\I`/\-`/H5`%5!"$_?`.GR`%46"$8`9T
MH/`)2E@&%'4.4N`)Z&`/YD!PR"40XD!0L*!RJ,`.3(8*8-67,*$.Q;!9K0@/
M'\@;_4`''(F1'8DPZC`$BS`$;6`#<]`/'W()3Y*!Q;``-G`!0>0:-Q5$(E`,
M=^`#%X`&"W"))<`&Q/^`!C60!\_@6`B"!HN0!T5`"#Y@"3[@#S)0(KJ@`#6@
M`!K!"#[`"$.0"3D4FI/`(D/`!HR@`&Q`-LZ#!X.I`39P"6U0!'PF!`@B`GB@
M`7G0H2(@IF@@`S,P`1+P"!M@`S7`!JI#!PW@331:`[9X!T7P`HA0`G<P$$-@
M`VS`E#<J!#3*`)EP`D-0:24`!Y>0IF0@J$(@6'5:#"\@!!JP-4(P!Y*E`'E@
M`HP`4R)0'?M0!&BP`5/R#%,21`Q$IVCPE2<0"290`HPF`N90`B7@H0HA`\)1
M**T0"["P"7H0"E/`?9T@!<:@#^&@!&$`"E[P!WM0"IX`!EV`!4NV#DL`"F'_
M4`K[$`]/5$-0%`U)\(5Z8!P$UP^.4`4/US"K``57X`<$%P]Z``9+4`58D`H"
MD0]_\`F><`58T`7*)P]=(`JW@`ZEF!/\0`Z],`K^)`H-UYVH(`O6@`T?=#O%
MP+`+@0_3\`P5NA![F($62C+_L)E"L`!/\J%H8%A7<@^,<`*(T*,1AA!DH).;
MR3LB<`<E,'R/24UNZJ%VJ@O`4&ESH`!X,`27,`3^8`-H,`R+8)5AV0^ZX`9L
M0#PBT"Z3,`?V00QE2@Q\^"N,X"%M@`DU,`?#$")46@/[P+5!!):30`UHL`\D
M(`%:0`.(T`;\,`1%,1!X(`3J8`/40$WJ,&ML0`3%_R`$]V8"F8,@_5`#-D`,
M4#$)#>`#+U`,,L`&/WE3-4!21#`$^[`(/H`'D*L1]Q"Y+[`F7>LG_7"2`^&D
M?F43&F`3?QM$1/`,;/`">>`#]X`&TX`&A`"C?M4MP5HH_`!RLD`*5`!QX/`%
M!P<%J*`/\+`$8A`&7@`/\Z`/XF`%4H`%4Y`I4M`)8B`+.6$/,I0=^H`*1\`)
M5?`*SC40KV`%5P`%UJ<*22`%H>"O5"`%59"$7E!&_A`*8M`%41`%74!1\N`%
MT6D-XB`.W8`-ZKA*_9`,5.`)S/L)X45P=Y@*$PP3[M`V`B01H:J!)JLL^]!'
M_^`#Y@!JC$"X<U`-H4FFB__+!N1)&X@*N?L0>SY0`D*!LFC@`VG`M400346K
M:7/``)/@`XA`)"+@!JDI`WF@6(HH`XR@([]:#!WZ;#'%"$(0E`-1`W:@(XQ%
MHWF@`4"`!C0+`G>@6"R"")&E#HP&N#5Q#V?@=/W0>M/@`U\)JC:`"`GR(;\:
M`VQP")2EQ/Y3%%Q#I<!F`GB`N1O*!QJ:@7?0!B?9.X7*J2]@HWP0I/<P!+`3
ME!F(HT.0"&CPMXBP#ZCF`Y7<#T-`#3QP"#*P"*9<O-51*/?P":G0"56`$,R@
M!&(@!9H@0U7@!5X`"C?8#Z4`!;M\1L\9!JK@$*6P!'M`!70U$%#D#%4@"E.P
M9;C_0`5Z0`4"80]>(`9>H`E7L`GAP`_^H`E8\`E5P`1A0%']<,[(ZH6;$`JS
M0`5+%F;XI0G<L`FF@`KDE0P,:<T=>"C],`=#L&(FG$2<1!"Z:#MLM">K<707
M$;((\0^Y@Q%H4*=JM!G%T&"`L0[5T&$?10MY,Q`24PV84"_WX&[ODACW8!\=
ML0Z,8&#%@`B,(4WW@$AH,`%K82^,B0X\4PS>,`>"()O]0`OF@`<"P18+ZIK3
M,`2Y.`="`+)$]5%IX@^30`3FX&YPQT`UP!9^3`R/BA-"0`;K0#;54&!"\(D"
MH6XAJ"MX,`R'Z5&3H*7.HPX:>F]L(;I&>P</5D>&&V@N_[L0)6#+A/(/H9`+
MG:`'V+%)WHN/QO$%3"`&H@!%M&$-RRP%#:4$40"NW0%%E%0*\;P)\XP0_I`.
M[Q`/QG$:VJ`']7`1>A`&7:`*4-`%8&8/72`%J/`%2^`%=M4/7B`%R<`/L>`)
MI9`.XR!=`_$.FS"MYX`*G!`+W%`/KK`)1';-'N$.,#,2^T`-&IL0*.+0)D,P
MU<(L>,`&#0HLE6`#=Z!!T>$2U)"*^Z+8AN(.>R`+8;`'3M0/?N`%H:`'!;H'
M4@`*HG!)_'`-5G`*6&"#4+`$81`*(EN>3/`):-C=R(P0]K`/X+`)[@!%!QX%
MMT`%4=`*_0`/"WP+>B`%7F#-YO^9#.OE!:8`9*G@!WP3"IPP!>"P#50@"_5`
M#ZYP4*YP7"-Q#ARQL9+X9W*0@0A]W@!CX4,$7.:S4A7:-M<1+?`K$#.$5R7H
M9R486F`.YJ35BK&U5Q'Z+>63WX5RKZ:@"5YP,P07#M?@#>\2X`BN!_R@#YID
M#E5P"E7`G%.`V56@$?50#^0`#8[0+JH0!6`@"OA`&_Z)+?S`#JO@XM\P$'JP
M!$M@#5,0!4&(#EZ@!*NP!\)M@^6)!;+@"Z$0D*LP"V:0GONP!V#P!,:0A9P@
M"<VP#:$`"]#,$N0@#2S!UK#8+;P;Y8SS&F#Q%XM-+`J!055^$;0XYC&CB56.
M[0.A#HS_P$Z#@>81NC#W\&S_4-%3+DQ_!3@]@9'_0)YX=2DJU!!M3BCX\`7Y
M%0H--1!MZ`?RN`>8%`Y5\*U(%MR=H`13``4&'`5+D`1T90Q2\`G`SN$*00]Z
M<`5F@.^&$`5*P`V<W@5>%(^M\`GQ#&;]D`I,T`G::0:C0`5FP`FH@$O^,`I=
M@([]X`IE,`I_@`VH4`K\+$\KX3C5SA!LT(?)/C68<`<<<0>,(!(\(S&NB0EV
M,%F(\"?4P`BAD15KA$+3@`[34`T$@1RRJ4!'(0/%D#'^0`TI:,:]H6$S\U'N
M32FM?`&V0PUYD`E!)!`J#>W`90Y8VZ1/>[H$(11^!SV+0*A0_\X060F:#&$#
M3.X0)>#>@#)#?L"0GZ`'V,!TW;(*4G`*7V!7`H$-!R<%O1#@2_`)46`%!CRP
M4@`%UL`/J^#.JF!`*I97UF`*4Z!>KI#Q.::OZ``.A'X+JA#:J^!_44`%4U`*
MKY`*1^8+W"!2608&[_L.H3`*4X`*>Q`*KT!1/8\GT#*R$R$00M_01`\UYC`B
M-B"F/B"L,D`,"T"V-J`!HAG%&D`,7RH$?WH"L?I1)>`/5O*H1]&K4@\0)43L
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MW5(B1A7P+ISVX+-:F!^_4)["&"J(:I0H/:)DQ:+^>/?B>]K2%:1'CB`];><*
MPIMVE3%!/`_MG^??W_]_``,4<$`""S3PP,3,">L%6H3PX9GJ%J'IA3S.,.<.
M0N;`I`U,3$#_!(\\BAFFANJF,:$?!PG91P,-^L'$!B'Z.8R@.S`IX1X\:KA`
MB`4\.@F/2W01H@@B8O2G!)HP,:D?&S"AQ@8T%JF.&#0NR0,8(630D9$E&6GC
M'F`N\.$"/(8P9X@[#J+%AR':4`>8.=C`*4<A-)BC.AJ'T(":#<R!R`<M9)BC
M2AZ$0*.&.80HIHU+:BBFNA(F86.K-DY(=!$T$&'#ATN&(8(8OX3`Y`XA;*C!
MS<1>\!/!`1]3IHI32BD%E$XX^4*5S0A:!8I3I+@%E55*D>(*U8[IIY0CPHB"
M"B6:C4*X5OYI10E-,+M*G9/ZN4<=B-"Q1HI5[%G'FDVB0.4>*J)H_P4;**)0
MYA8FQ/BM'V/TF"64ZA(+I1,P_"@(FU%DH:R;4)XR3\!SH&''*G*:H8X>9&*:
MIIK]%".H#1)9U7ACCCOV^&.0=R,(F`W0$.%#!:0D:)T":#$`$R&F80.1&EY:
MY`9&,+5$%QM*O``8$PRMI`89@,FCAI)$H&9)-O"0H1\VA(B!ECG\/&D.1#3(
MV@<=[LE#A$48(>PD'S*IQ@8B,IERB$46(6:(&AB9`YCJ$*EJD1<PP;J-?;82
MH@8LA;A3"!/R$'2.&O*8XU&H[O`AQAG[D0&13*BY0X%GA$!D$F#0\(?/DB"J
M01W!?&BCY$NFN1*-DM1!@QI@,O&!CQV.KO]AF'RA,F'5D$76QY%53#&E"UHY
M`6.5=S:[)0E00/ED6##$"`,4+Q:^Y0@Q0&&"B2B4L((*+UKI1YDEJ,_&O&Q-
MLN<ZR-)]Q:1LO)!BE'Y&P<(/9J0(8YMKI-`$WWX@8PJ@"$7%H.('3G2A%`79
M1R@FDXI8A,(C^S!@?]SA#HBD`X-6T8U,N"6R?K3A:17L70E->$(4IC!`_LA$
M(:CQC#8@HH-6><8]BO$/:NR#&N8PVR*>P8@A4(,8TW@35!91`T2@H63K,`?2
M8-</1#RE(,5@`Y<L,0Q$%&Z&EWC&$(C0AFD08@-X>(:I>%>-%YB`&I,@#$'N
MX0-$$(,<DRC&07C_MXX:O&`2-V$#,:24*:Y0@Q#/Z`$1$,>&/$QB;C!Y7744
M28A^^(!WB_#!"Y[QC!/T8Q%_*X8=GG*!23"P'R(@RB)*1H0[9((>1$`$%0_"
M"!G(8!)MP(,&_M:&9[2R,/X004Q4F!ATE.(4L@C#)TYA"E!TX0\8Y,81FB<*
M,.BO"V$`@QYTL[Q.*&L/JEB%*WRQ#7GT`QQ4$(4FDG$PQ3CB"E0`(#>\\+]^
M^.$*J7#%-,^1C2B,(A0G&6<G0E&/Q!`D%)P0Q2;VP8]]]$*?$$P%.'[)F,=$
M+7</I6A%+7I1`Y&P(.G3Z'DTU)_]I&^7$/D'`RMVCY(B9A_^L(\Y*O:/_Z?L
MHSY0L0]!U/$4=:SJ).;@UB*D"!66[L<</R6(7JI#BQ?L1P:8X-8ZVGB2FUH%
M&$]Y1GVX]0QBW$,W.2G,/43P4XPZ(CRP$$7P-K$)*'#G&JGI0B=&0;PN4&$*
MMRC(-ZS0B2F(3Y00<4<5.@$*7ZA4&]_4#2K`T*^":&,*5]##/EYA!DU\@7CA
M`$?Y0J$;?'R"%*8XQV;P5)U9F&$44^B@.<ZZBEB@`AH%0>=%YZ`?C,96MK.E
M+8$Z2M/'K)2"&KMM"J_2VP%E0A>%H1B"*I:/$GPPMOK@ABKT``9.A&(49C!#
M%=QACR>$(0R<&`4G/,&)*URV(/CPPR:\,!N$$O_$/GT817BM<AV"2.,+9>#$
M.XY%A3"@@B#O\,(5KN"/;FB"$TF@`BC>(8XEC&(/)\''*(ZY*@.&@@J>V$3Z
M4L&)6$00&Q.U*(T>4EL0AUC$*9R&G_814XCL-G<LM<H^2KI;-ZKW*O<X"8Q5
MW&(<[U7&[_VM27J\8XADZ\8T30Q'<YQBQ-0X=R2L*9*=K&..[<.KRKWHP;2!
M"BI<8114,`,4L.$/*(!A$YJH@I9%D8IVY`N!5#"62OMAB#)TX@L8/!@JRC"+
M6<2C'Z](5P'[P=].F,$?Y/`K*&:AB7>@@YSB=4=XJF":=SB#'-SPA2^XT0]4
M1.$3UH0(P6:1BE!<NK;_B./PB$U]:E3_AR"3J`8B&K11Q,0#$0@5)2+:P`@J
M%^89=6$<5%H;9,5@(I0'JBJK_M&54O<'$_DHC#H@A,(ITY:"*WT'*J3`"3WH
MH1O\6&PGH'",;:@#'R+MQQ\^T8E5)/L592"%%S9<$'O$TPRPF`6W>E$%,Y2!
M.O?X1$'3X0_1CH(49F`'/+QPS'"FHPK3I4(JS$"%[E[!#`MT!!0F0QWVS**L
MJ[A&LA]ZDDVE6N0C)WEAW,:&/7ZE`7?00`SN<(\\`H,0ZWC&(C!GDCSXP!*$
M\,$#FL&+($1B&J@DQ!"*`0<-%(,:BR""+LPA!#`6A!IMN,,^+O'R?ORC;?L`
M_P8N$7&'==AA$O\(2A@Q<0]D>-(<D\#$)1:Q#W6XS1_`D*$0V)`O=&#"([M@
M'#'`GH]BO/P94I8B-1!ACI-!R.WY,`<P:-$/=62";FO,UCKNX=)U-.E1TV!J
M,2[0CV?0[2DTAL:C[C&-&1KH'R;(-48WLQE^_&$)FJ""-?0A/S%T@;7Q=@RF
M-1$&`*I7E,T8H!A*@8^#\N,>4]A$)\J@FUY`X>$+P\<7.N$)^8SY$^8]AS\&
MN`ETF,0+!*5"^5,!"TY(AJZJ2$(YE;L/5T#P%N(`L>,\7G+\Y[^BJ^;#!DPW
MA$P0@D:AAA>(DV+P@1I`!Z[P`0Q:AS@I`3SXFV9@`/\T*((YV``X40H[&`)"
M@(,:P(13*8LV*`@?X#D\@`%DRQ(1L(,2H)D\6(0[L`,1F`0%V)2O,9PA(`JB
MV8DDL@$38`0-:`,T,)0@PPD?8`0%""5U&`(Y^0E#&8)IT!S0*P$?N`.6D(%?
M>`$;8(,TRAL;\($-6(02*)*"0(-G*`)B:`,-D`$8F`2H.YD-L`01$('74@>L
MF<.D*(().I![N!'9T@978`5\T`?86ZM/8((]Z`<O8()BF@?JV`]7$050T(-?
MLZD!`@4J>(Z"<(0I^(0K(*U^2`8HP`).2`<*FH).T`.'0H4N2`5/F(+U<*!-
MZ#A^V(,S2P51>`5\:(=2,`7_<2!$8["X3]B@@@@'5W@'>9`'SP*0=3B)>]B/
M#I*R&?N@>Z"&U".RG+L__=M&;C2A>PC"(A"<68*9>X"14%J+>\":&`$]&4B3
M-A""(4"&(H@$/A!"F#L4#)D$'Q@<&^"BUA&!?B`&'N`;@MC"F1F"?A@"-&"$
M"&Q!(;B'%T`)C,@#-#`31J"[HU%(N[F'-EB#4"HJ(H"B*C2)>TBBDL&#?FB)
M0_&312"#?GB2?B""1<A!A0R]!2B!?B@$$4($(B`(0D"#$\B4&KB'.\B4.1`!
M/L`#LH"Z_$"#26$#-C!#C;F'$V@]%7J,=)`P5=P'SYJ'\I$"+S@-)0@#+Y@'
M@EC&_WYX#%30!%!X@GMX!W8X!W8@!V>8*538@ST(@RI0!6PH!2@8A4_0A%30
MAWW(!BC02W*PBBD0!2H(!LC8!%CX!"^(!W[P`U'X!/0JA4_P!%Q<A7E@A_/C
MAMQ@ETX0!>7B!WRXAG:`A_`+$'>(B6WIH'M8AZM8!RFZ/((PATOHM<(@"#GX
ML&X,3N$\H1J@$EK`A&=`)$9`!S1`HQ\DA#3J(B4AAI)!%$18@YE$@S;(A#R@
MA@4X%$PHF_!$I+:!AJH(H3;P@47XDH(`D40:0<UAA!+8B*+LASQ`!!M`!/6T
M`S0P!SMP.UM;!#RPM7-@`UIZ!C^!R$7)`V2CA@L0##3`@_\^5`<%N).`]`$;
M(1$VJ`$>R!$PNH2P@)G\L(3S?(8#``8`P!(H(@(&0(02`"+'V2-U<(!)6(0Y
M<(F860>K=$T-X)V',H]LT`13\(1TVPQ[B(<G\`0F\`-]V(/F`(5Y6`Q5Z`)/
MH(+8J((J\(3)^(2%B9\N^(10\`(NXP13$(4OH"O>,`-2J`)K,(D]@(5-,`UH
M:#@PS0=^2(53"(4V[8=!V(3S,P4(@@4(6H5;T(=PV`196`7Y@(J;^@=F"Q!U
M2*G9K,T/DJF4XJF"N(<A8HP(U,;A_%10S2AM><9LF08(\8=G:*I5F89B<`>M
M8J*XLZJ`G`13M$:96@2MXI89N\C_?J#-3,T9W%R'?_"':B`C<_"32V`$$3"'
M:A""9_@'E,H,K=*0G/('<S#5Q2D(:!@"8,BIM!`"8CC6?2",P:B.SJ&&'#*'
M9Y@#1B@&8O@'=:4%1/@J('H\DP"&>S@[PJB&3HHA<V"$=<@/PI@$=5`'C*$%
M?$T=!%F''HVM>/"#"2N%>3!+?;B&\ED"?_D")!`#+T@SQ6@%,)!$*@"#3Z!2
M6#"%4'"H?2B%[QH-5!`>X2F%\..'=-`$QDR&M+1,3WB.<Y@"6?"$3V"V5PB%
M3<!93`L%64A:U,JP8[B&2XL'=I"'=^!*C+HM_"@)<@M5K=U:KF4,1!""\_P/
M<[C&W<"#_]`!J2%`$U3S*K+])8+P@R0(@U/P@G`@1"\(`S%(`E,H-R0@RW#@
M,(*P!C#P!$WX/9L5A?3S@FTHB';H!E##A7"X!EDP!5S@!@RRAV]`!5'P!%JT
MS%!XGSV+!5F8%V3HA55X-W`0AV[H!G1HAT'$..OX)7]H6X]"2.#J6MS-W0"Y
MW8X1ONK(EJQU,U6#BF$ELH""BM/SW=X\WHVJ&-[]#W58`!^MJ'QXAU(0!8X-
M`U/X`R^0'B2@JT'HVR]87)72!V8HIFR2'E`H4T_P@C;U!T)D!3^@/W%0A51@
M!W1(3'_(!W&(!5C`!G[P!W"X!FO(!I-X!WJX!\(\2WVX#O;QA__5\C7K>%Y6
MN;P=70R"R`/;U5T.[F`/_N`"^8<^<;U^T`=K2(7L(<ONO5LI2#-5Z-LPF%Z(
MT`=PV`/GT=(P\(0A53#Q\0=TD(=D"(55Z(9;&`1<,`=TJ#QW($RT_`]_F`9?
M<F*M^IC32RF0@IJ2H&`0WF(N[N+A5`<-`*O]$Z=5^(0PP`(L$`,QD`)PV0QC
MD`(Q^`0QAHIJ6P55<`5<P(5;X)]KV(;$3$M"%(=L8(9M8`?8W1@M-EZ/D3(`
M>8QW]%0OCF1)GF22NX<1EJV*#5,XIA4OF(Z"<`9/N`55^`8,;@=')$3"3(Q?
M,Z%$KBV"B$I(IF19GF5:QJA>HBU\<(7_4+#9DUV%-,-*<##DCO(L\R"(508J
M$WK4$"O8_A#"):EE:(YF:?XE2Y;ABRK,8UB.;GC$`*G$XE6I5E8U9O:/<`80
M=,@A$&*=:5YG=F[G*#L!:ZY:?PC>@FAB_WA&Q3AFCM%1Q9@A;&$@VNT8*.X/
M-'`#=SYHA$YH_OC&>(XM?5;HWNV'IHAEB*YHBYYD,+[@BY:V?FXR!DJ?@"8(
MI]QHDB[I6:9*C3;IBYKB%LN6;=DH?M:65=D+C9[H<E9IG,[ID?O&E-;I7[+-
M3+6\@F"B3!U;F5@5THEB(MM'GVYJI_Y4,+;BI]Z_S`AJB(C4@L@'?Y;-.4:R
M(;B3FYYJL1[K_Q-":;+F6J8.Z[->:[9&$#`.:)^FY_PC"*9N:[N^:Q52!Q&`
M:R^.1GSFPT^E:Y14:[PN;,-.#+WF:RYFY(+X![4>LL3X:XJFJ,?P@<$^;,S.
M[`)9A[W6[/RK`3N8;,\>[<Q>AQ-0;)7.!\)&$!;;*XJF:T0@;=F>[00Q@8?.
MZ=ETVZKN!Z.&O)_ZZWM8C]T@&TBR9]H^;LQ&O-5F9Y:F*;E.,646YSLJK:7I
M!_B@AZ/N#R1";NX>;<1[;IUNY942$+A+L9;JH'10KG-`;8*H@:Y8[NZ.;XA6
M;OD.L>VN;_QN:W(XD;-V,9,"(9`1:HT:Y^.U@??.;P0?:_HFZ]-S;?_&F%TJ
M/M;&4(<=8@P#3W`,GVIJX.\/#N>7WEUTT`U_*`>^9CSX1EX$;8QU\"&+24DN
M.?$,C_%(I@82N.O>@O&N$ID++DA(DG$?-VEJP$G@PO'%!O`H>[+E[0\;>/$?
M;W*+=@8.!]7]J"GEW0^T[+'WFJ@;\UTLAS51$CZ"H&>-:K(=VX>A<B-J>`IW
M.`?ACDV3N%8GF[9\T8W\%&TGO_-()HAGN)%S4(=M\7.MRE7="'1X^`=H+=B;
MTE%$1ZEG#/36-G*+DNQN9&G<'*]*_>=X(/#=D$D\[_2#)@<.$`$%6(`+N``&
M*/4+4("YN``1*/4-6(`%*`()4`!:/P`#,`#_!3"``LAU`UB`45<`!E"`!E@`
M!F``7R?V6"^""]@`$5B`#=@`5X?U#5"`(B@"6"=U:R_U4W=V:(?V4C^!#=``
M$3B!.4R(.=2`<)\+<=>`$V"1<=\`@2@!$P@)&>A"&[AW&UCW$GB!$FAW%M&`
M>9]W$3`!A6!#+=22>Z\!A4\C(AAW$]@`<+_V"R@"=*]X%MEW$YAW@1@"FGF!
MR<D#@<C/&<"`<)R$<"\!0K`!9A>!BX]WCR\!+9$!`'@\(O=TF^]&?#@'<X`&
M*'ZA2Q*B:T57:BBQ$C.''8+B:^UY=+TDIB>&2W)74"D&8)AZ8+B$ML.$JL?Z
MJ2>&J9=ZJ4?8NJ`%_UT0-F%KF[;)!$9@!$1@A#M`!$*P@[9?A+4W>T2H^[5W
M^P$EA#L84#R8`\69@S:`2K^/2B%LBHGP^\//`ZA4G#Q0_#9X_,*OR#;(00WN
M>SRP@P%%A+"I^[;?>T3P^[Z?`SR`2M8)_#M@`[_'^SI0>T1(!$0H!+?'>Z6\
M?,1O?,'/@S90'#SHZ9OO?=__?>`/_MGRZ!8O_B6+\R?K\B]79"K_+##7EJ`2
M)26;-NK'D_$6OM96,3#_K>W/,>UW_O\N\^5__N[_,?`',NU7?N%??]^7]&BT
MXGU0YIIG?_JO?_N_?_S/?_W??_[W=&]5<8"XUV\@P8(&#R),J'`APX8.'_]"
MC"AQ(L6*%B]BS*AQ(\>.'C^"#"ER),9]^PJ>;"@PXSUJ*Q6J6T=R)LV:-F_B
MS*ES)\^>/G_2O)>2H3J"^UY>7&>.X3YS,H%"C2IU*M6J5J]BS:IU*]>N7K^"
M#2MV;-6A.//YLXB4+-NV;M_"C2N7XE&=]]9"5$=M+M^^?O\"#JQS'[5_#(4B
MW/=THF*\#]=-6BIX,N7*EB\#WE>483ZS!1T_5)>6XKUGH#&C3JUZ->O6KE_#
MCBU[]L;3)%,>'7V7-N_>OG^K]GQSW<K=`]6]M`U\.?/FSJ<>%;X0N<9SB\UM
M1GYRW[3%S[^##R]^\E"SRL>C3Z]^/?OV[M_#CR__?S[]^O;OX\^O?S___O[_
M`QB@@`,2B%*!!R*8X%S2&<2@@@]"&*%-QBUTGH078IBA2`YJV*&''_9C$H@C
MDEBB0\29F***)-Z#(FFCK1BCC/;=LQE%Z^0SHXX[\MBCCS^J9B&00Q(9'F((
MY7@2A44RV>1LV`VT#SK;_9/2/>9PZ*266Z)6GE%9<AFFF&.26::99Z*9IIIK
MLMFFFV_"&:><<])9IYUWXIFGGGORV:>??P(:J*"#$EJHH8<BFJBBBS+:J*./
M0AJII)-26JFEEV*:J::;<MJIIY^"&JJHHY):JJFGHIJJJJNRVJJKK\(:JZRS
MTEJKK;?BFJNNN_+:JZ^__P(;K+##$ENLL<<BFZRRRS+;K+//0ANMM--26ZVU
MUV*;K;;;<MNMM]^"&ZZXXY);KKGGHINNNNNRVZZ[[\(;K[SSTENOO??BFZ^^
M^_+;K[__`ARPP`,37+#!!R.<L,(+,]RPPP]#'+'$$U-<L<478YRQQAMSW+''
M'X,<LL@CDURRR2>CG++**[/<LLLOPQRSS#/37+/--^.<L\X[\]RSSS\#';30
M0Q-=M-%'(YVTTDLSW;333T,=M=134UVUU5=CG;766W/=M==?@QVVV&,G;"/9
M@A)C]MEKL]VVVV_#';?<0_*S#S_\1#F0/B$.A'="V_U=D-\+#2YXWQ&!.?=[
M=_\GQ#A!=2/D=^%Z]^/X1)-?KOA\^T##"C+\9-.*,L3T@TXKK<2#CS;]N'-.
M/-$PPTT_ZL#CS3;KG(-.B/@,=`\\^22)CS[Q3(G//?&TLT_J\?2C#VYZ[^U\
M/SDV_SCFE&N^>#_DH!+/)?.XHDHVWHA3RC6NM"+.(/HLTPHXJG#C!SC&9/-,
M*-:`LPH[SA@S$#2V@&,0\_C&+<1Q"UO8`AVV@(3[;*&,5C!#'OTC!S3Z<8L+
MMB,:K;A%,*+Q#7V(`QG-V(<_D&&2;.P#',J8QCRR%Y]WO.(6U]#'+5;1BF_@
M0A4A4D<X2J$/9LCP%O)0!3AN`8Y^M"(;_6`&*EI1CX'_7,.(I6#&-YAQ#57(
M0QSZT(<JVC&/5<CC'*J(1ROZH0UH?*,5^@#'$95QC7[8XAO9L(49C5$/1W!C
M'\-8QQB_T<+Z<"X=;E,,.TH!#FL44![*J$2(\B'&?D0Q&ZFX!1:-<<16;*,?
M^$"%-?J1EFM8(QO64(8KK*&/:ZS"%D49HSY*<<%KR.,69HR&-+!1N8%,PY;(
M8`<RIJ%)5G##&LXX!S;V@0UD9&-O\!F</K#1"VRXHVWGD,0YDF@+55SC&N@8
MA#5.)P]#KD(9S"@C*L2AC$PF<2"W4"+>G,F,9.!C#[@`1S?T,8AOX&,0\IB'
M+>3Q#5O@PQ7]2$8VYM>/=.Q%_QK2Z(<QMI&,9/2#'>FSACI@X8M\N,,=MI",
M>+*TCV.<HQ_44!O9S/&,D*IC&]E@!C_0<0MFS$,?VS#&#-$1CGYPXQWL8!XS
M0KK$D.)M'=`PQ^J2L8UXJ`*"TS.&\&1Y#V3T0QF]Z.<^7&'5I6PCD\^`1E7_
M=PY\U*(?QW"%.FZ(#"&%9Q_(..(^O)&XKQ7.<HZS!][VMAU^;%%O=AM<W?#F
M#[S&M'(ID1Y!4A<B?KP#'W@3D3]RA`]PQ$,?_'B*0.*QC7`H$SSF,(=UA$./
M=&3#E_K`A^[F9I:W[@@=UK!%-MC!#"46A!W+.$=F^[$8U+IP1MDXX-[P<8QW
M$(0>RO\8+$'(@8QPR..6N1W22<@1#%NL!&_N.`8YHJ0,<$1/'^>0QS[.80QD
M,*]OUUMNC.[1BZ(0UWG:,`;]]!$-)8*#&6S<1CO400]L6(,;:,6:,DTB'+^!
M241YPYY")@<YA3QO/>:(1O40HHYZD$,8Z'"'-I"A#VBP`QN#D*$\WB$.7(3W
M:]R9\`?C\8]IY.,>T(CF[/RAE^VDQ1^C]<=V[C&/?.@#':+I!U).&R*SI`6W
M['''+4)<VX*@HQ+8$`<WN.&*T&53'"'-ABMX%S9J3",>837'_\R!#><.)!C/
M0(8Y%LJY?2R#?>A`!C0N7(MX+.,9SS`',HB1#'0L0RC-F-W_,/IACF!``QWI
MF`<ZSB&-:6C#'8@69(B<D;9^A'0?VC#-.I"A#7RX@QS4&$J+$*..9VQF'SE"
MS&[NLJ0HV6C'(1H-X/CFZ@8U1,@6.8<K#AB.;[`X(?A@+W[;C(]MW&(>V3C'
M-7!A9;`](QWZ$$8\LI&-/!M#&ECJ!R^DT0QH;,88T5A&.Y:!#BN.=G7,@`8^
M\!$,>EA2%=%`AR2Z>VYM:.,>L&/M/I+ACGNX@ZO448<TW#%,9."#'M*@!YM7
MC`]D_*,8SR!(,5Q"#7,4PQPNX3'IJ$$-8FQV&O>8QC12HHZEF(/C3IFS2SB^
MCH\_XQ_KJ,9*UN&/ZBIZ'=.8\[3O_^$/8(":QSS>>&%ZIR1_A+PH3O&O0%*R
MCDTS!1WRT,<WH-$_A>P-,2?!QBWR@0]G9*,;J[!EV(!!#7U`]1S00$8ZZI$.
M5@B$%R'=A@G-V(IPU"(;XF"O.>(!U6`8`TN6((<QV.%&%<:#&<9P!M^AH0UP
M!,.6P\@&<8[8NG[0HQC.F(;AL4&/9&B#'.MEASZ",>FEG&3._9!S4>YAF!81
M5<X#*89B0JWITD23,`N]!SZRX0Y]F,,=Z@AI=0="#8%?::0MZD<U_A'\I5#C
M&[Z<ACKRP5$T0GH=Z7CY/M*Q%'6X8^'?4$<Z\I$."V66'+Y,C('TH0S@]N,=
MUHB%*]*!C_\0*S=KY$!.,?R<#%9L@Q=C/XG:I:'YDZB#+>@#:]E".IS#,)Q#
M,,`1.+A#.D!4-ER#"@F1,BB#/#B#,Z0#YYQ#/6B#H=$#/J1#,.`#-`#7.O29
M/V##`:X#.3R1.6#7#]6#,ZS.0(C>,S"?2/G2.?!;Q$'5/BR<4PR$/\R<H?%.
M]D73^VT#.+P#A;%#N7'4"C9%.KB<RHW>R:U#,0A$.C##\JD#=S3/:-%7.X0#
M/=B64!1%EJ7#-)R#`=;%1"3>@$&=,2370%W#.R0#-I`2<`W%>$U-7=P%&:H#
M"X8(&::#-.!&3#EAY30?CJ7#EZ4#&:(#//`#/-R#/(!#$6:@G]'_7O690S.0
M0[ZMVT#<FR8)4CJX0TJ00S2D0SP($CT0QTEPG,7Y(#$`P^E%TXH!@\3YTC,\
MQ3F<8CI`PS/D&SJLF#=PF3O@PSHHT\;US3\L%#'4R%W(Q#.81$LL7SB@PX6A
MPY7HS3S@@S6(0VOYV3X$G!F=XK/)G#[\`TG%6C#D6N0,1#0\W>PP6#\X`S?$
M`S8X%*.]VG+)6OQ!7:PYCX_U3G&8@V-HQF881TK0PY6P&#ID0V0YVY2DA#^\
M!#_P3A?:G,YUX0XYQ5*D8>P5G?+D6&)I`SV@UTD8SSZX5XY]PT%2A/413HC,
MD"?A#3-`%4'X`SCL5CN`PQ]939"-%N\(_T3NZ>`ZH@,^G,-*`([=^!S?'%G\
MX98R125$$"3Y,06L$5BK/8Z!&`6"1<Y)9!8?0H]%X,-"-40535L_S--`V(,]
M$`25'8-^70W`M0(Z.(4VL`+[M`(V8(,O9,,9)0/^$(,W],,RK`,_!,/P8%(V
M?-\WE!:/@1PU\,,S9$.*"82*38-DX`,VDN,T2$-Q'$>(*(7P])=0G(1%%IWQ
M`9FI;9$[1)9)8!3UX(:``23?\(YM]N-N?N54%-.))`,T9`,^<$,[5,[@W(,Q
M=$-R^:+5F`/?N0-X8<-P#I09'0.N(0/NK%<T[`,J+*$RL`,Z8,,[*`,UL!GU
M\)@A,H,R#"<^;/_A0JF#,_3#)6Q&H?U0B\AG/TQ#6O`B\J&#TLW./I##.<38
M9OG9.JS#PNFG9MA@ZI@#,U"#V''90CF#.AC?85Y)Z7GA/0P#-%A?-*S#-UB<
M/DB?GPG2?D+:4.&#/2B&56@#1S5$/+@#.+0#1`4A/RA2.G2#\!">U=Q#,IQ#
M,F2G+0@G0_V:,JQ#/"@#-A"4/G*#,9S#.QF#BJV4.;2"-0Q%/`0#.[!7FAWF
M,OB2.O@2E@T$.N!33@X#+(8>F3X#\1"#M>FG3Y6.:"AH-:0%,:#D.33#TDW#
M-\3#-TA#-IS5/BB:9$3H,A24#LX@--"#V&W1,KA#.$P#,S!#/P3#4@S_`XV5
M'33,G(=:Q3M4D$,HDY*^7=_D`RJLPCX8PS&@`SG\X]#@PS#<)S$,9RW(E#Y,
M`S)LXS*P(I16DS8P`S#@`S9,PRD25+Y!`XW-#E0M6*"-H#14$)?M0S%L1D;I
M0_W=0WY2PYV&7#](0S1@&C>2PV*<W#V03C\0`P!:FHHQSS>\%^.%`ZB1H1H.
MA#FP@CB`@RW8'38LE"$:%VU%@S9D0SO$SM6=`SE\&82=@V/B'59@`XPPA//H
M@R7R#D:N`BY<`P1VTM9$W7&PI"8I14>2*#E^WSI$4XMD)&(<9%HPHSNL(S&8
M1GS.GS0\P[DVTD%50[+B$O-AR6:M0V0*Q,D1_\2%CI0YG*M:F1XU-H:?=4<F
MVE:N%4,^A$,TF-13">&5+(7JX$,];(,Y.*`!LL,Y))M02$,Z`*.<1@7C7*JH
M$MA`@`,NB,,\(-(<QHUP'%EF^9AN_EA"^`/$-A9!'$E_*<1&-DA&O<3?#BX)
M^<.%VIQ`B*DZ)%:(N%]WE>/._1CMS8Y5!&GBZ(,[+,.Q50X(X<(MQ,(;D5>L
M_<:KUH3F/41T9L-0^4/%A@,X?!@LG>YL\%5#6`YT;`]L,80YO$.AX0,[L,,S
M^<(V_)`XW.Z/-,,3,00_#(,=<E(GN4(O^((@W4)5+N^*"&CK[EHW=),6.90^
MB-+V]HC91H1190/;Y?9JN26#]IIOBGQ<1,1#,C@>3&[##,:OCJ@81-B59Q`>
M6>XOB5"CX4C$/=[F`*<(:&+$22KPCC2#,Z!?1.S-=#XPC_@;.>@A1"2GZE[P
MA?`=?OF",8@E@<V#*<[.,>35!^_(4<3#/=02<$6//"BE,4`#D_8#-K`5"\O(
M[MY#*UQG/\2#TSV43VT#-X2#[_+PCDBL/MSADMT#]>25.=R",BPQD5085Q($
M^B;*J5VQEGCQ%XNQ?=S-[H[Q&:-Q&JOQ&K-Q&[OQ&\-Q',OQ'--Q'=OQ'>-Q
E'NOQ'O-Q'_OQ'P-R(`OR(!-R(1OR(2-R(BOR(C-R(R]Q0```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g299211ba07i001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g299211ba07i001.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!%35),3%]'4D%02$E#4SI;0T5,3$1%
M6%]42$5205!%551)0U-=0T5,3$1%6%]42$5205!%551)0U-?0U],3T=/+D50
M4__;`$,`!P4&!@8%!P8&!@@(!PD+$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0=
M'R@@&1HE,B4H+"TO,"\=(S0X-"XW*BXO+O_;`$,!"`@("PH+%@P,%BX>&AXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN
M+BXN+O_``!$(`#\!!0,!(@`"$0$#$0'_Q``<```"`P$!`0$````````````&
M!P`$!0@#`@'_Q`!0$``!`P,!!@(%!P8*!@L````!`@,$``41!@<2$R$Q05%A
M%")Q@9$(%3)"4J'!%A<V<J*S(R0W0T1B=+'#T28G,U72\31%5&-S=8*2D[+A
M_\0`&@$``@,!`0```````````````@,!!`4`!O_$`#`1``("`0,"`P<#!0$`
M``````$"``,1!!(A,4%187$%(C*!D:&Q$R/A%#/!T?#Q_]H`#`,!``(1`Q$`
M/P#I&H3BI7-.U;7NH9]VEV-#<JTP65%M4<G==>'VED=B.@!QCQI^GT[7-M6)
MNN%2Y,<]]VB:0LBU-2[PTX^GD6HP+R@?/=R![S0_^>K1W$W=RY;N<;_HPQ[?
MI9KF;R'2I6LOLRH#DDS..OL)X$ZZL6T32%[6EJ)>66WU<@S)!943X#>P#[C1
M=7"_;!Z4U-D^O-10[Q#L*VY-V@OJ#:6,[SC`^TE1^J.X)QCPJOJ/9VU2U9^L
M?3KMQVN)TI4J5"<"LJ:$&=;ZPM>D+8)<XEQ]S*8\9!&^Z?P`[GM[>5*6-<]J
MNT`KD6I7S5:EG"%H5P48\EX*U^T<O95.WM':?M6D.S%*79X>\H-D\N`A6$I\
MMY1R?::Z):;;:;0TTA*$(2$I2D8"0.@`["KS;=,`,98^/:5!NO).<+^8B7-D
M^N'-YY>KF52"K)RZ]S/CO8Z^ZJ\NX;5]`D2KF\;I:T$;ZUGCMXZ<U8"T>T\O
M;70-?#K;;S:VG4)6VM)2I*AD*!Z@CPH!K&/#@$>D+^F4?`2#!K0NLK;K&VJE
M0P69+6$R(RSE31/]Z3V/XT44B[%IF]:/VME5IM<Q=@D+X:G4-DMI:6,X*OZB
ML>X4\7G6V&5O/.);:0DJ6M9P$@=22>@I>H1%;W#P>8=+LR^_U$^ZE)^_;9X:
M)I@:9M+UU=SNI=)*4K.?JI`*E#SY527M*VAQD"3,T(I,7F2>`\GE[>>/>*(:
M.TC)&/4R#J:\]8[:QM7OO1=*7J3&=4T^U!>6VX@X*5!!((\Z%=$[4K'J:2W;
MWFUVZY+Y(9>4%)=/@E8ZGR(!]M$VN/T,O_\`Y>_^[-!^FR6!7&(>]70E3`O8
M5>+K>=/W)^ZW"1-=1,W$K?7O%*=Q)P/>:QM!W^]S=KE]M<NZRGH#*I?#CK<R
MA&ZX`G`\A5KY.GZ,W7^W?X::PMG'\MVHOUIG[T5==%WW<=!*BL=M?,?M2J5X
MND"S6]ZXW*2B/%9&5K6?N`[D]@.9I1S=LLV?-5%TIIB1.(Z*="BI0\=Q`.![
M35*JBRSE1+;VHGQ&.FE1MYO5VLUIM+EIN,F$MR0M*U,+W2H!&0#66-JVK;4L
M.ZDT2\Q$SS<0AQK=]ZP4GXBLS;5J"UZETC8KG:9'%9,IQ*DD84VKA\TJ'8U9
MT^F=+EW#CZQ%MZM6VT\QUZ;==?T]:GWG%..N0V5K6HY*E%`))K3K)TK^B]F_
ML+'[M-".M]J=DTQ*7;F&EW&XH.%M-*"4-'P4OGS\@"?'%516UCE4&8\V*B`L
M8Q*E))&TK:)*;])A:$4J-R(5P'E9'MY9^%7[#MFA+FB!J:TOVE[.ZIS)4A!_
MK)("DCSP:8=):!D#/H8`U-9/6-ZI7B7>)&XT7<>WD;S>%^JOED<^?(^-!EKV
M@1I%[-GN=N=MK^\6]YUT*`7]D\AC/8]#R\:JE@.L-[40@,<9AS4J4,ZYU?;M
M'VH39@+K[AW6(R#A3JN_L`[G_.C52QVKUALP49,)JE">A]4SM5VU=S%C5`B%
M6ZPMZ0%<;KO$`)Z`C&>_/PJ5S(5.T]9"L&&1,;66NG['J2-!BM)>891O2T'D
M5%70`]B!S]]>VIM.:>VE6%N9%=2B6A)#$M*?7;5]A8[C/4>\4H[[.-RO,Z>?
MY]Y2QCP[?<!5C3E_GZ?GB7"7ZJL!UI7T74^!\_`]JJUZIJ[-P,Q!K\V,+.5/
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MA3XKG+93+.C]I$_3MQ/"3(*H@*C@;Z59;/\`ZAR'ZPKHVM'7C]XMV.([2']O
M'A)4J5#5.6I.5)SY0-]D1K;;]/1%*"IZBX]NG!4A)`"/85']FJDK55[OVV%B
MRV2ZOHM+#R4/(:4-Q:6QO.GIW.4_"LSY0L<C4=BDOE:8KD=3:E)[8<RK'GA0
MK0TU&RY-_<9E.^W=4VWTC2V?Z1MNDK.TRVAM5Q<0%2I!P5+7CF`>R1T`_&BW
M?1]H?&E"WL1T^XA+C=]NBD*&4D*;((/3ZM?7YC;%_ONZ_%O_`(:4ZU.Q9K#G
MT_F&IL48"?>4MN.D82('Y66M"8\QAU/I7!]7B`D`+Y?6"L<_/RHIBWMS4.QR
M9='U`R'+5(0\0,9<2A25'WD9]]#<S8SI>$SQINI)\=G(3OO.-(3D]!DC%$J+
M';M/[*[U`M5P5.AF'*<0^I:5;V\E6<%/+&::SH450<D'P[0%5P[,1@$>,P/D
MZ?HS=?[=_AIK"V<?RW:B_6F?O16[\G3]&;K_`&[_``TUA;.?Y;M1?K3/WHIK
M_'=Z12_#5ZR;7I<W4^OK9HJ&[N,MJ;"AU'%6,E9'?=1_>?&G/INP6S3EL:MU
MKCI:90!O*QZSBNZE'N324N*TVSY0S+\LCA//M[BE]!OL[B?VN5=`CI5?4DK6
MB#IC/SCZ!EW8]<XGRXVAQ"FW$A2%`A25#((\"*YHVUZ18TW<F9MK1P;9<-XF
M.CZ#3R1SP.P(.1X<QTKIFDM\HZ8R+19X&\..N0M[=SS"4H*<_%0J-`[+<`.\
MG5J#42>T*[Y?7-.[)X]R84!)%N8:8/@XM"4@^[.?=0IL/TC"-N&K+HA$B;(<
M48I=PKAI!(*^?UE*SS\!YFKNTIAQW8O;UH!(:9A+7CLG"1^(H9T#LNL>I]+0
M[NY>+@V^[OI=;:*-U"DJ(P,C/3!]].0**&).,G'\13;C:,#.!.@-]'VD_&A'
M:#I&W:LLSS*T-)N+:"J+(&-Y"P.22>Z3T(]_44(_F-L7^^[K\6_^&OQ6Q"P(
M25KOMT2D#))4V`!_[:0BU(P9;#GT_F-8V,,%/O/SY/U]?EVB?8)2R5V]86R%
M=4MJSE/L"@?C17M!T@B_1?3824IN;*?5[!Y(^H?/P/NJCLXT=I[3TZ;,L5_5
M<BZTEMU/%;<".>0?4'(\C1I>[M`L=LD7.Y/AF*PG>6H\\^``[DGD!2]4%MM.
MT<&0M0:C9;%UI/7KD6URH%X8DOSX3:BRA"<NO[O5O!^N,>\#Q',(TM8[MM4U
M.[J._E2+.TO=W4DA*@.89;\A]8^?B>7W'FW#7\R\7FW68Q782@XA;!QQ$]DJ
M.>;H`WLCJ.78$LG9GJB-<82+0\VS'G,))2EM`0EY/4J`'(*R22/?XT-=KZ4M
M4P][L?+_`'*=3;F%5IR.WG#MAEJ.RVPPVAMIM(2A"!A*0.@`["I7I4I4UIS!
M=8:K?<Y<%>=Z.ZILY.>AJI3`VM65<.\HN[2/XO-`"R!R2ZD8^\`'W&E_6<Z[
M6(GE+ZC584,8VR-[@.WASIZC(_:57QZ6/S[<?/\`U7C]BL[0;W`B7=S..;`^
M]=9OI?\`K5](S_0,?LUL^STS63Y&:VF/[">O^3"?:Z]QW+,[XMO#]I-+BC77
M[W'A61S/:0/VDT%5E:@8L(F=KO[[?+\32TVPJ5J"UL)`)7*;Y'P"@3]P-=,4
MF-D=E7*NSEY=0>!$!0V2.2G%#\`?O%.>G4+A<S4]F5E:BQ[Q7[5]G2M2[MYL
MVXW>64@*23NB0D=!GLH=C[CV(%+#M8O>FBFS:SL\EQUD!(>/J/[O]8*Y+_6!
M&?/K3[JK.M\&X-<&=#CR6OL/-A8^!%:*:@;-E@R!]1+34G=O0X,7/YZM'\/?
MX=SWOL>C#/\`]L4+7S:C?=6%=DT39Y3:W@4K?Y*="3RY8]5O]8GEY4U/R&T=
MO[_Y,VO.<_\`1DUN0H,.`UP841B,T/J,MA`^`J1;0G*ID^9D&NYN&;CR@/LL
MT"WI&$N7,4EV\2D`.J2<I:3UW$GOYGN?96AM,TBG5^G51&BE$^.KBQ5J.!O8
MP4GR(Y?`]J,:E)-[FS]3/,:*E";,<1!:2VDW+1B$Z:UG:YF(HW&G0!Q4('0$
M$X6GP4#T\:,G=L^BVVM]+D]PX^@F*0?O('WTP)]N@7%K@W"%'E-?8?:2L?`B
MLIK1FDV72\WINUI63G/HJ/\`*G-;0YW,I!\C%"NU1A6X\XG;I.U#M@N4:!;8
M#D#3L=W?6^YS&>F\3T*@"<)&>O,]Z;.HK?%M.SJZVV&@-QHUJ>:;3X`-GKYT
M3-MM,-);;0AMM`P$I``2/9VKS4[&>BK<4MIR,4G>5D*24]_+%`]^X@*,`=H2
MU8R2<DQ3?)S(.F;K@@_Q[M_X::PMG!'Y[M1`$9WIO?\`[T4\+4;:N&B1:A&]
M%>]9*XZ0$K[9Y=>E>K4*&T^J0U$80\K.\XEL!1SUR<9HSJ06<X^*"M'NISTB
MVVQ:%E:B88O5F3FZPT[I;!W5/-YR`D_:!YCVGRK#TMME;AL"VZP@RFIS'J+?
M;;YJ(^V@X*5>.,^ZG;6?<K+:+I@W*UPY9'0OLI61[R*%+U*!+!D#IXB$U+!M
MZ'!BZNFVO3#$<FWQITV21ZC9;X22?,GG\`:4^T./J2?$CZNU./1G)[I9BQ""
MGA-)3O#D>8&3T/,\R>HKI2W:7TY;'0];[';XSH.0XW'2%#V'&:TI,2++2E,J
M,R\E)R`X@*P??3:]374V:U^O6`]#V##M,2UVZ-=]"0+;,1OQI5M::6!UP6QS
M'GWI+6Z=J;9!>)$.=#7.L,AS(6GU4+/9:5=$KQR*3UQ[#712$I0A*$)"4I&`
M`,`"OEYIIYM33S:'&U#"DK`((\P:37?MR&&5/:,>G=@@X(BV9VSZ,<9#BUSV
ME8YH5&)(]X)'WT+:IVDSM8LN:;T3:IKBY0X;KZD@*W#U``)"0>ZE$<LTU'-%
MZ1<<#B]-6HJ'0^BH'X5L08$&WL\&##8C-?89;"!\`*,6T(=RJ2?,\0#7:PPS
M<>4$=!Z<@[/])N>GR6$.G,B=))W4`XZ`_92.0\>?C2GO%RN^UW5C=KM6^Q8X
MJMX*4.2$]"ZOQ4>B4_\`Z:Z(D"(]B))#+G$&>$Y@[P']4]:K,*M,*8FWL"+'
ME/(+H9;2E"EI'+>P.N*&O4[6-A&6/?PDO4"`F<+//3MCM^GK2Q:K:SPX[(ZG
MZ2U=U*/<GQH!VA:4>AR3J>PA3;K:N*^VUU2H?SB1_>/?XTTJA`(P:JV#?\4F
MZA;4V'Y>4#-(:XMUWMN;A+CQ9S.$NI6L)2OP4G)Z''3M4HH^;;=_V"-_\*?\
MJE"`P',E%M50"09\7BV1+Q;GK?-;WF71@XZI/8@]B*1%]TE/L=VCQI:5.0GG
MT-MR4#U5`J`P?LJP>GPS70M?+C:'$E#B$K2<9"AD5%E8>*U.D2_D\$1#OR[3
M;D3H%MB2&E*>"5N/20YD-J4!@;HQG-!WI7^F_'S_`$7'W4V9.RQQ^2\_\_[O
M$<4O'HN<9)./I>=9_P"9I?SCZ=^4G/<W-WT3\=^MBFS3U*0#CZQ9I<`!5X!F
M0U,M-S:MUON4.0XIMU2$.,R0WR<4,Y&Z<XJK8-(SKY=WX\9*FH##ZVW)2QR`
M"B,#[2L#I\:,8VRQQB2R_P#/^]PW$KQZ+C."#CZ7E30;;0VD(;0E*1T"1@"L
M[55TNP9/G(;1"U@SC'^94M-MB6FWLP(3?#8:3@#J3XDGN35VI4H)?``&!)4J
M5*Z3)4J5*Z=)4J5*Z=)4J5*Z=*%[;EN6N2B"^VQ(*#NN.-[Z0._+([9%!VS]
MN4C9^M;K[:XRF7>`VEO=+8]?>R<^MD\^U'SJ`XVILD@*!!QYT.Z=TY)L]GDV
MA=T,F,I*DL`LA)9!SGH?6YG-`1[V97>LFT,/`C\0%L]PU)9M#6R\LRXOS>TM
M+8B%C)6@K(*BO.<Y/0=J*M9ZDD6ZXV^U1)3,(R$%UV6ZT7>$@'``0.I)S7N[
MI$N:+8TQZ?CA;O\`&.%UPO>^CGW=:NW[3Z[C+A7&%<%P;C#!2V\&PL*0>J5)
M/44`5@,#RB%JN5-H\!W^N)F:0U#-N2+K%E.-R7(8WFIC;*FT/I(./5/0@BO/
M0<_4][88NUQEQ4P%!:`RVSA3A!QOY[<\C'E6W9K+*A(G+G79^?+EGUW%C=0@
M8P`E&<)'.O73%H^8K'%M?I''X&]_";N[O943TR?&B`;C,9779E=Q/&?SQGY0
M%ONJ[O%=N;R+Y;VG(SA#-O98,@K2#]=P?1)[^%$.K+_<8&EK?=;>&DR9+C`W
M5IWD^NG)'Q[U27H:<F'.M4;4"F;3*6IPL^C)*\DYP5YR1TKPUS`>BZ*M-ME2
MN.XB9'94\A&YD<P"!VP,?"@]X`YB3^LJN6ST^_U_UZ2]\X:BLE\M,6\38TZ)
M<EEG+3'#++F,@#GS'MJEJ#54P:AEVJ+=(UK8AH3O.NQE/J><(SC`'(#QK7B:
M7G+N\.X7J]KN*8.?16^"&\$\MY1!YFO6XZ;F*O+]WLUY7;I$EL-R$ED.I<QT
M5@D8(HL-B&4NV\9Z^/.,>OCYS(<U9<G-GLN^(;;9N,9?")*"4*(6D;P!YX(-
M:=TO4^/.TJRTIL(N+F[(RC.1N`\O#F:LG3+;FEW[!)GR9!?2>))=5O+*B<YY
M]`"!RK.8TC<C<+1,GZA5*%M5_!->C!`*<8['KTYGPKL-)*W#'?@?GG[3/OS%
MT7M)LY8FL-E4=PLE3&]PT`#?2>?,GG@\L9[ULS):T[0;=!#,<H7`<7Q%-`N`
MA70+Z@>56;WI]^?>;==X=R,.3#2I'^R#@6A1YCGT[C/G7O(LA=U1$OWI..!&
M7'X.Y]+>.<YS^%3M//K"%;@MCNP/RX@^W<=37Z7=W++-BPXT!Y4=E#C`<,A:
M>N\HGU1[*O:ANNH(&D6YS<%+=T)0E]"$\8,@GUE`#KCE\:\Y>DIHEW)RTWYR
M!'N*M^0SP`OUCR44DD;N:T)>FTKT]&L\*X2H:HNZ69#:SO[P[J^T#DY%=AN9
M`2W#=<\]_P`?\(*VS55S4M\,W^QW%D;NZJ7F&X@\\@HQ4J[,V??.TM<R^7ER
>2^4A*5,1T,@`9Z@9R>?6I0XLB@NI'0??_P!_,__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g299211ba07i002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g299211ba07i002.gif
M1TE&.#EAN``^`/<```$!`0@'!P@'"`L*"Q`/#Q`/$!,2$Q@7%Q@7&!P;&P``
M/2`?'R`?("0C)"@G)R@G*"PK*S`O,#0S,S@W-S@W.#LZ.P``1``&2@`+30`/
M4``44P`85P$<60L650D95PD=6@8A70LD7Q$A70TF8`\H8A,F8!,K9!HM91<Q
M:!PS:BDO9R0V;",Y;BHZ;R8\<2H^<BU"=3)%=S%&>#-(>3Q-?3U1?T`_/T`_
M0$!`/T1#0TA'1TA'2$Q+2U!/4%545%556EA75UE76%Q;6T!1?UI<8V!?7V!?
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MT;O`S[S"TL"_O\"_P,3#P\C'Q\C'R,C(Q\S+R\''U<3)U\;+V<G.V\W1W=#/
MS]#/T-/3T]#4W]C7U]C7V-S;V\O2X]+6X=;9X]O=Y=O?Z-_@Y]_AZ.#?W^/C
MX^'CZ>;H[NCGY^SL[.;J\>OM\>_P]/#O[_#P[_/S]/;W^??X^?CW]_[^_@``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````"X`#X```C^`'L)'-AKET!5
MCM)@N7)ES!Y/!@E*%)A+U:I5L&"IBC7QH*J/'W-UW&41H\9:O3YB5)4QXT58
M)E=JG"4PHD!>N7)V)%BK9$:6+5NBW$FTJ-&C1R=E":$A@U.G&C:\&%2TUHL/
M)4)H#2%B$D&#9CIH_1`"Q`J.$L]T*#&";`<OD-:*V$IW!-L1<\N*^.#"UL!1
M>[R\2('"+AA/'77-\)`U*UVZ)FB@@82TLN7+L+QHP+"!PP<.H$-OIH)VHID+
M'#:H[GP!3<&!NUAD2*V:@P4[KP>RB%K[@I@S%D"L'KZ!]W#0&EP(5$1EPP6G
MJ*>(`>.H(RH,H&L3+ZXZ`X8,-%#^71Y/GB"G$MA#JU]_(48NFP=3A^[\`<,5
MB;E,=%:_P83(@;!\%AH(&*B!17K9K:<@:!>D$0L5WW$@'`=VP/+51+70P-EZ
MG>VW'@8GQ`)?>202Y8AJG^T'`H>AM9:;06(@J)X&+\#62RH?>!@:!G?D-HJ.
M'&"`QPP:S&=DAPIJ0$4*&`BHP0J(Y2:13;OH<8*,"](&P@4]CECBEP*AX@&2
MV6%@YFQ`?D`+03_RIQT)0PGT"'9DIE8"2@9-4J1\&X#`"`F@K;BBAT"JEX&'
M&H0HI2J<>,*)*AW-$L:A'S1EJ7R&9@'FIE_!L">?'WB1QQU4?!I:!HSD5D63
MM''X24W^O>"!I7P7]-&++KW<@<&*R*6@R`5G>E<G:$^9R1]H'ISRFBI>Q,"!
M!M!^\,(9(J%26A\>8#`#%30,`4-MAM['*9@&V=$DH2=$*=`8&0@(&@9GW-H+
M)Z8:69\B!%V1'I`;N!!1%G0BQT(LCC1B,".,I+#G?A_DT0@C#Y.@(X^YQ?("
M:OQ9\,@N'YB@1T2;6"%1'K.IAP$94HY;GB[Z8<J!!YR\9I`J=5X0KT%5E$SL
MARA'](*I$]O:BQ4R8E!%1RX`C0)!C.@,&ISX?;M>!EZH$I6V7DVY2RT3[JB'
MRF#V@24&7J2\R[<A?("5!G@(!(G3&UQ1@H<9'&U0+7,KN%_^<@9Y.B`&N.&Z
MBT$XKJ=!#`7MDHO")H,Q92]Z8'PJ#8OLN5D8!L$'2;T?K`+VES2TB^D&ZA)4
M$2VHQ[)*YC)\NL$(M20M7W(#T9L@H>]&LLL(9&+0R(N]/%+R?O:]-HGH^Z&:
M<B_'?UB%N9]]AD$,J;R&BAXMMRC&YR72DCURREVV2-%C]+*;D=7WDL>N;IJ<
MQ2@+9U>Z0+)^V&4O,?('0FFPZJE>?54HP[Z04P+*]((&%M!1>W#%O?(HHEX8
MT-1.O+2+ULWG`^*A@M,P@*]>F"%@+IM/"*J@HPV@@!<7.L/8JF,0%NA(`RSP
M$O-TUAD-P&`(10)7:C20JDUX0#W^'L`"_QIX&33(B$!MD^'C]G`!=V$`"P+)
M'_':UHN<A:8^:!@#J[)C*@*)2R*K.E;Z:L&[['P@`U28B$'$EB/]E9"+MF+C
MLVA`Q!*I,#N=P0`+D5(+%+PP:W?<41=ZD9\.L68/JW`.!BX`K0TL$EB.',/@
M>*(?=YF0@9Y`4@V/UI'\&2D%9&*89S;PNS"D1P,TB%,=+0.&>FE`$FJLP@MD
M``,8R$`%?8B<H:8P$#W("(8I":$&(M&++8"A#YM(12Q@X0E&W*%9&OB:C3*Y
MF>3QTB!OFYK=\/,]U9`@#</:C)DPX`%/\**2'&C0*L>#!C3M:`_`^Q6T,A"5
M"^CA9[?^,\$,9#"#O(E0%Z@P550*,0$'Q,(3@[B#'>S0ATF@915O^`,I4"B0
M26``!GL`99#,\)I(N(X#:'R<\#Z$!3LT<4996(0B\B`&#YP@%XRXP(I0N<[+
MX,%ISZJ1>:(G&BIH,46B@594YM.A6(QO1R<@1``@,`<8``M8C]S`"<K0"P<`
M0``+D$`0A`"'F-4B>D(R'DXW<">9%>1\)F,$P#X4LX$\P@+WJ8$&0&##=2H1
M-A'QQ)&>105(K,(3>F#*U,CPO2PI"`.3^."[L+`+4]1!(([0@-I<IH$+#"$'
M`,BL9@-QJ]`AQRL&@44(@(0!J@Y$%U?`*8UFT;+]]&EUDYS^10@NH(A4S!4#
M(JOC'PQ0`5=41H,AI&=J-J2>"WCA-`E2#Z_P")H/M,8+&`B!T7I!AAK`RHHC
MB`'#ZFH)(1P```$`P"L>T8+A^8<@^-3A!KSP*#N4UT@@Y40LM(,<&$@$%;2!
M18PRT#/N[>((`-@!`)2PO%X``@E(>`)-+.HNPS87`R]`10E^.)^G6!A(-`(E
MC7IA!P6H(3>;2\X>).L9P,&F#@MX0\X^55=8K<^2[\ICO=+)T<A^J&P$&6D$
M5Y$M>#90"`"`0BX"@(2.)$*S"/A/&"3GX""M(!==`.$&4N"(1T#B$59^!`KJ
M59L/U&)\&OB=362``1;L06<88(3^07C!A@,<X10G#11XN%FH*RK(N`()Y(/+
MESG(L4H#G@"#!191X!(9Q`<`.$(O@@``0T@))PNX:@`P01#H%JG!S7T6!JA`
MBTYTD6(3\4(&EBLAYPXB%A[XS"ALQ`@+4*%I@M*`5S0!@2#'BL0K.F-_7\,(
M!/'KBIOAJ$'`(+K/@"`#TGS-^D9`5RMP8M!@,PB`(9"+4BSU<5"X:J(G0H@7
M>,<IJA$G!R@G$`0ZY3L7*.LD$W<'"XCS.QFPP!=Z@0)@:<!S$GE!)&CQG$66
MH!=S"$``'-V+,KA[G/&NSD0F41\[&PX#*_C=0&!P\'%>0%T&&8,%O(,!"Z"!
M`S?CE$'^LAT`2_0B"0`0!$%0>.3P-N`]:GP$&F0Y@A&\(`MV*-TD!J&(1?B<
M$.+I2"UZK@BB+V(01%A"'U0*"2^-X@=+(/H@4/&$S)I<(*L@A,^+K@A&,'`@
MHA"$)4:A!4=^1ZAF>A(>1&(31J!!#7!/`QH^)A%.O#T-:D`#*B#1UDT9)!"9
M34(O-`&`'DA)<0G0=B*00@M51GO`1GD#`"I`$"5D-A&8B,!CC6(02X07`+?H
M!2KZD`4KQ.`%5*C"'3KQGYJ6)Q0&`$`#9L$+""2`)C:JN@``(/B[4O!QB2NT
MC28Y.#8`H!3!GX@I=N^$7O#BOYF%0B\23^!UK_LK#<CL')S^S_F1#*[/WA>^
MH6>1?0``HA>67[Q$CKS[E[O>*%DERJ&M+A`D9/8!O3#^`GQ;E)%G-@?`<R'O
M1R*(!@`^`'``L'WP07[:=G4#&"D!P`8%9A"&D%D2@$)S`%X`0`J)$``)0`H"
M>"&8D%D!`((/."X&(7D`8`"[4('5-Q`HE&V[UWLG>"&"``"A4&BF\%TIUPL5
M*'`#(`'@M7B^5Q"U!@!K('XU>!D_V&@WJ&@CTG*RUWI+.!!1``"FL!.\((0`
MP`.](`L(H($`@``!8`#/-Q"`P`-M,"+&!P``6(6;`H:9Y0-UL&UJ9%6[1X1P
M^!IM@(6/,PL5D%F4IPE"&%X!\`?^GF<`N+<+EI=9G+4+;,`#F!5>"8`#!+:'
MY+$+O!"(+@<`$O@X4J!M@H>)`T%X>O@:@&B!K_`$GQ=>!,8#8XA[N;![`$``
M.<@+/#``&G@`#=``;D"*EV$0EB=PF:5RF=-GEJ"!"T"%F+@+"4!Y!!$(Y7<$
M=9!X!O!Y`.`*IA!>!?`>!I$(%:`$)B@0``8`$O`*>`4KGW-]UQ>"ZO@X-TB,
M$:`)RZ.)5B5PIPB,%>@#I.`*AM`#F=4`<P!@/%`*V1=>.]`+5YAH,C1);J"!
M.7A7$R$+N)=\^"$+7X(+KD`E(R(*NQ=>/D"%_F@)*!2*,ZB$2QAPF@4`"<`&
MB:`#`$#^!^@'7N%E":X0>SN`"[U`"I)(`6\0?'6X>R^8"$KP!/1H8%=G$+/@
M!A4@<'2P"SO0BUXX2:60!`,0@;"R"P/I:+D`!9LG$8*P`XF'`(=@"1#@``OP
M@KA0:[L7!-&8`[H(`!,`",38`+@@D7`X"W^@!'^@"8UE``:0@\FH@1-@"=?(
M!@;Q"I&F?=S7A`UPAE6G66S`:`=(@>6G`ST0`)B564DH$'.@BQ5P``*`>ZY@
M59DU"Z$8`!@Y$*6PF>:8`,18C,ZW"X&X>PD`<ZX`DP%9CAKH@,#HCKT0"@(`
M`1BY"X4(7CE``$*0@\X7B+I8!*_1@;TI$)$IA@+`!JL9BIG^I6BA0((`H`-K
MQF@,F7T@*`L-(`&7D'W2"%X1V0MT$'N[)P2]4'7$*($&`60"5W("D0AAN'LY
M0)'YR7LHN8??EPL)<'L"00<T"0!!D`M9R'T`&5X'(`LHI`GP*:#N.6!SL)G$
M.1!`MGM%U@L/*0`"AWRI&``2T`M_P)*Y,`L)T`#S"5Y(L'L'\!_:>9(NJH$2
M,$DH1XQM(!""L'N[5P$H1)\`,*&_^8X7`@0!@'R[0`I7"5X#@'P%$8,+2G`6
MJH$)@)&$)WVS`),$0(\HA&BZF`.#DPNU%EZ_*`L3H&V8D`L/`'D5@`"R<&0`
M``%MV`,&09_A)9^]8)(!(`#,>87^Q`B>!I99N^<`-.$*NAA>B^<*_)>D$Y&,
M?_`:G!A>Y]=G&4B,?FH*L4>,CK8+#4!YLW"$TH="`-9^.MD+DC>D7RB$NR<%
MO8!H$=`+0M"DO!![GOB0!`""<;"@"?F%GPH`FY>:X46GO2"=X64`#YJJ`."G
M$@"%F#@+4)`$D?H:.0"C*/20@;IM?09XQ&@`&.D*"%`!TR@002``O@4$-"D+
M!K&I`G>4KG``^3E1L/J=N8!H/+`+:]!HO0!@`=``H0`!`T!I@+"@[C>KV@:-
M)*>!CI8(C1I>!">%R&J*`[I*4"F($C$+";B?P$I1WP@`C0H`G"4+"9`#*SJ&
M&/F0*G?^"=JF:(,7H'&0.&VZ>]MWJ0'6``(@D\:G<DTH`0B@BVZPD(9(:;U0
MA\OJ6RA'AD*YD]]5GP*1H[M'<#J0H@2ZDQJ(`/!Q"0.`D9APH3X`LH<:!;IY
M@*:0`!)@LIEU?AGXD[T0B`!``33!"XFW>PEI$/:W>UX8B`6@@0.0!#11=94J
MA\3H`[/0KUBE@=L7G"0:7BH'9&T`MRE:"D^;63KP&K"HBWZ:@;ZYA`;1G08`
M`4^)0L\'!0?0"Y80EY"7&Y(7!:20603`"Z2```G`"RKHA1D8!0)QL`%6$SN0
M59E%I9L*``OP"J&I"8DW8#0A"X&H<KV0M^!U?@)A"KA0CF_^:)ZBV`LP20>$
M)W"NX*()D('@98*61Z,868&R"HR\T`!;.A%SX`!U$)<+(+T4`60_.8R6@`DH
MBI&U]G(9.(K(&UX\P`9OD'VF@&@P6X<Z"@$-H(V9Y98J.@`(H'Z'H($&<`@3
M(6#Z:0F5FP.F$`$=6XZ!8)X(X`J`!P!%A@N,UKB+=["5^9N:$(8^,`>6$`JA
M8`C9%I!NH).*XPIO`)CJ!V!/<+`[@$*S$(9T8'D2B`D`Z9TDN'A"B)']:HB6
M^Q[;V&B6((0]0!.[X*)`2(]4LF@```0*:8"I>@0#(``$!\)K$`H#X`"^58'=
MR)\#\)F)E@N,!K.2*@M*<(0K60'^0@`(_X%"`#D`08"1):F!TC<07"@`@[N=
MAN#'%6""&<@#?FR(BVP0C*:+#2"]]ZE9QCBI@1I[NDMX@NBD?\J2!O@?I0H`
M5N7!VBNR`D``BRNI!"$+EF`)EW`)UVH3I&`)%7D3;*`$1SD0KO`$4H".!>$&
M!)<+<S`'ZA<13Y``$T#%#7`)4S('3D!P!%$'1W`$]-L13!P%#YJL:Z!^L.$&
M0L#-40L%0!#-J$F-;&?+1X&7AC9!O3`+B+9[$\#%\D?/`#T2)*)$\%'08=P+
M@5"YXBI\OS>@!5UH#6DV]AS0#Y@Y.6R(^4C1&FW+!F$*@7@$Q!C.&SW2DBH(
MWY4(0`9I>1--TBSM>L8G`*_`NP?8TC0-A_YG`)J@">$E`<Q8TS[]?J$X`*&0
M"[%7`:OYTTAM5[UP@XUFG.;HSTD=U414>XVVA:LLU5A-1*5@CJ*0?9>8U6`=
7;;J9`.P<UF:]*;-`!W^PJF=M&0$!`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
